CN105189541A - 用于通过双链rna特异性抑制ckap5的方法和组合物 - Google Patents
用于通过双链rna特异性抑制ckap5的方法和组合物 Download PDFInfo
- Publication number
- CN105189541A CN105189541A CN201380070277.5A CN201380070277A CN105189541A CN 105189541 A CN105189541 A CN 105189541A CN 201380070277 A CN201380070277 A CN 201380070277A CN 105189541 A CN105189541 A CN 105189541A
- Authority
- CN
- China
- Prior art keywords
- chain
- nucleotide
- rna
- dsna
- methyl rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 1502
- 238000000034 method Methods 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 102100028624 Cytoskeleton-associated protein 5 Human genes 0.000 title claims abstract description 19
- 101000766864 Homo sapiens Cytoskeleton-associated protein 5 Proteins 0.000 title claims abstract description 19
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title abstract description 294
- 230000005764 inhibitory process Effects 0.000 title description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 73
- -1 e.g. Proteins 0.000 claims abstract description 25
- 230000000692 anti-sense effect Effects 0.000 claims description 647
- 125000003729 nucleotide group Chemical group 0.000 claims description 462
- 239000002773 nucleotide Substances 0.000 claims description 410
- 238000012986 modification Methods 0.000 claims description 187
- 230000004048 modification Effects 0.000 claims description 185
- 150000007523 nucleic acids Chemical class 0.000 claims description 155
- 210000004027 cell Anatomy 0.000 claims description 150
- 230000000694 effects Effects 0.000 claims description 134
- 102000039446 nucleic acids Human genes 0.000 claims description 134
- 108020004707 nucleic acids Proteins 0.000 claims description 134
- 108091034117 Oligonucleotide Proteins 0.000 claims description 97
- 230000000295 complement effect Effects 0.000 claims description 85
- 238000000926 separation method Methods 0.000 claims description 85
- 102000004190 Enzymes Human genes 0.000 claims description 78
- 108090000790 Enzymes Proteins 0.000 claims description 78
- 230000009467 reduction Effects 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 46
- 108020004999 messenger RNA Proteins 0.000 claims description 43
- 101150084233 ago2 gene Proteins 0.000 claims description 42
- 210000004962 mammalian cell Anatomy 0.000 claims description 42
- 108091028664 Ribonucleotide Proteins 0.000 claims description 36
- 239000002336 ribonucleotide Substances 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 33
- 230000002829 reductive effect Effects 0.000 claims description 30
- 238000005520 cutting process Methods 0.000 claims description 29
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 29
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 28
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- 108091027568 Single-stranded nucleotide Proteins 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 18
- 230000001413 cellular effect Effects 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 101150109761 CKAP5 gene Proteins 0.000 claims description 11
- 101100220774 Homo sapiens CKAP5 gene Proteins 0.000 claims description 11
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002015 acyclic group Chemical group 0.000 claims description 8
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 8
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 8
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 4
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims description 3
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 claims description 3
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000006958 oropharynx cancer Diseases 0.000 claims description 3
- JCAQMQLAHNGVPY-UUOKFMHZSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(2,2,4-trioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-7-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 JCAQMQLAHNGVPY-UUOKFMHZSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 150000003008 phosphonic acid esters Chemical class 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract description 51
- 239000003795 chemical substances by application Substances 0.000 abstract description 47
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 239000000758 substrate Substances 0.000 abstract description 13
- 108091081021 Sense strand Proteins 0.000 description 568
- 239000000178 monomer Substances 0.000 description 402
- 239000002585 base Substances 0.000 description 295
- 108020004414 DNA Proteins 0.000 description 224
- 239000003153 chemical reaction reagent Substances 0.000 description 173
- 230000000875 corresponding effect Effects 0.000 description 73
- 238000003776 cleavage reaction Methods 0.000 description 43
- 230000007017 scission Effects 0.000 description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 230000001629 suppression Effects 0.000 description 26
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 230000009368 gene silencing by RNA Effects 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 230000013011 mating Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 230000003389 potentiating effect Effects 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 101710163270 Nuclease Proteins 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 9
- 238000006073 displacement reaction Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- 229910001415 sodium ion Inorganic materials 0.000 description 9
- 239000009871 tenuigenin Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003607 modifier Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 101000836154 Homo sapiens Transforming acidic coiled-coil-containing protein 1 Proteins 0.000 description 6
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 6
- 101100220775 Mus musculus Ckap5 gene Proteins 0.000 description 6
- 102100027049 Transforming acidic coiled-coil-containing protein 1 Human genes 0.000 description 6
- 229940017687 beta-d-ribose Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 101000608672 Homo sapiens Uveal autoantigen with coiled-coil domains and ankyrin repeats Proteins 0.000 description 5
- 102100039543 Uveal autoantigen with coiled-coil domains and ankyrin repeats Human genes 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- 101000700734 Homo sapiens Serine/arginine-rich splicing factor 9 Proteins 0.000 description 4
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 4
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 102100029288 Serine/arginine-rich splicing factor 9 Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003014 phosphoric acid esters Chemical class 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001123946 Gaga Species 0.000 description 3
- 102100033969 Guanylyl cyclase-activating protein 1 Human genes 0.000 description 3
- 101001068480 Homo sapiens Guanylyl cyclase-activating protein 1 Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FEACDYATMHKJPE-JXHOJRNMSA-N xxxx-3 Chemical compound C1CC(C)CC(OC)C(O)C(C)\C=C(C)\C(OC(N)=O)C(OC)CC\C=C(C)\C(=O)NC2=CC(O)=C(O)C1=C2 FEACDYATMHKJPE-JXHOJRNMSA-N 0.000 description 3
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000023308 Acca Species 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102100030013 Endoribonuclease Human genes 0.000 description 2
- 108010093099 Endoribonucleases Proteins 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101710099377 Protein argonaute 2 Proteins 0.000 description 2
- 102100034207 Protein argonaute-2 Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108700031675 Xenopus CKAP5 Proteins 0.000 description 2
- 101000766862 Xenopus laevis Cytoskeleton-associated protein 5-A Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003793 centrosome Anatomy 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 210000002415 kinetochore Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- MPXDAIBTYWGBSL-UHFFFAOYSA-N 2,4-difluoro-1-methylbenzene Chemical compound CC1=CC=C(F)C=C1F MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 102100030786 3'-5' exoribonuclease 1 Human genes 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- 102100036962 5'-3' exoribonuclease 1 Human genes 0.000 description 1
- 102100039222 5'-3' exoribonuclease 2 Human genes 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- QCHLWIPINNRBSG-UHFFFAOYSA-N 6-thiophen-2-yl-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1C1=CC=CS1 QCHLWIPINNRBSG-UHFFFAOYSA-N 0.000 description 1
- 102100021308 60S ribosomal protein L23 Human genes 0.000 description 1
- WIPHNVWGXOHNEF-UHFFFAOYSA-N 7-thiophen-2-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CSC(C=2C=3N=CNC=3N=CC=2)=C1 WIPHNVWGXOHNEF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101100439299 Caenorhabditis elegans cgt-3 gene Proteins 0.000 description 1
- 101100172628 Caenorhabditis elegans eri-1 gene Proteins 0.000 description 1
- 101100196381 Caenorhabditis elegans rpl-23 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- CZGGKXNYNPJFAX-UHFFFAOYSA-N Dimethyldithiophosphate Chemical compound COP(S)(=S)OC CZGGKXNYNPJFAX-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100316028 Drosophila melanogaster Uggt gene Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101150016266 Eri1 gene Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000938755 Homo sapiens 3'-5' exoribonuclease 1 Proteins 0.000 description 1
- 101000804879 Homo sapiens 5'-3' exoribonuclease 1 Proteins 0.000 description 1
- 101000745788 Homo sapiens 5'-3' exoribonuclease 2 Proteins 0.000 description 1
- 101000675833 Homo sapiens 60S ribosomal protein L23 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000999373 Homo sapiens Interferon-related developmental regulator 2 Proteins 0.000 description 1
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 1
- 101000933173 Homo sapiens Pro-cathepsin H Proteins 0.000 description 1
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000841466 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 8 Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100036480 Interferon-related developmental regulator 2 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100025974 Pro-cathepsin H Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 101000639461 Rattus norvegicus Small nuclear ribonucleoprotein-associated protein B Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 1
- 101150082840 SM30 gene Proteins 0.000 description 1
- 101100298775 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP11 gene Proteins 0.000 description 1
- 101100421708 Schistosoma mansoni SM20 gene Proteins 0.000 description 1
- 101100421709 Schistosoma mansoni SM21.7 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 102100029088 Ubiquitin carboxyl-terminal hydrolase 8 Human genes 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000025085 carcinoma of parotid gland Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000004142 eccrine cell Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 108010092948 oligonucleotidase Proteins 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229940049547 paraxin Drugs 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000008933 retinal cancer Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002910 structure generation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 101150106994 yme2 gene Proteins 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及用于通过使用dsRNA例如切丁酶底物siRNA(DsiRNA)试剂来降低CKAP5靶RNA和蛋白质水平的化合物、组合物和方法。
Description
相关申请的交叉引用
本发明要求2012年12月14日提交的美国临时专利申请序列No.61/737,404的利益。本申请的全部内容在此通过引用并入本文。
技术领域
本发明涉及用于研究、诊断和治疗响应于CKAP5(细胞骨架相关蛋白5)基因表达和/或活性的调节的性状、疾病和病症的化合物、组合物和方法。
背景技术
细胞骨架相关蛋白5是在人中由CKAP5基因编码的微管相关蛋白(Nagase等人,DNARes.2:37–43;Charrasse等人EurJBiochem234:406–13;"EntrezGene:CKAP5cytoskeletonassociatedprotein5")。CKAP5也被称为ch-TOG,并且非洲爪蟾CKAP5同源物为XMAP215(Cassimeris和Morabito.MolecularBiologyoftheCell15:1580–1590)。
CKAP5蛋白在纺锤体形成中起着至少两种不同的作用:其保护动粒微管免于被MCAK(KIF2C)解聚,同时CKAP5蛋白还在中心体微管装配中起着必需的作用(一种不依赖于MCAK活性的功能)(Barr和Gergely.MolecularandCellularBiology28:7199–7211)。还已显示其与TACC1相互作用,所述TACC1是候选乳腺癌基因(Conte等人Oncogene22:8102–16;Lauffart等人Biochem.J.363:195–200;"EntrezGene:TACC1transforming,acidiccoiled-coilcontainingprotein1")。
已在某些人肝细胞瘤和结肠肿瘤中观察CKAP5的过表达发生(Charrasse等人EurJBiochem234:406–13),并且最近的报导已提出CKAP5以及其它20S蛋白酶体亚单位MCL1、RRM1和USP8为人多发性骨髓瘤细胞中的分子漏洞(molecularvulnerability)(Tiedemann等人,CancerRes.72:757-68)。
具有25至35个核苷酸链长度的双链RNA(dsRNA)试剂已被描述为在哺乳动物细胞中靶基因表达的有效抑制剂(Rossi等人,美国专利申请No.2005/0244858和US2005/0277610)。具有这样长度的dsRNA试剂被认为是由RNA干扰(RNAi)途径的切丁酶加工的,从而导致这样的试剂被称为“切丁酶底物siRNA”(“DsiRNA”)试剂。先前已描述了DsiRNA试剂的另外的修饰结构(Rossi等人,美国专利申请No.2007/0265220)。
本文中提供了靶向CKAP5的改进的dsRNA试剂。特别地,靶向CKAP5的DsiRNA已经具体地举例说明。
发明概述
本发明涉及含有抑制性核酸的组合物以及用于制备它们的方法。本发明的具体方面涉及双链核酸(“dsNA”),包括双链核糖核酸(“dsRNA”)。本发明的dsNA能够减少靶CKAP5基因在细胞(在体外或在哺乳动物受试者中)中的表达。
在一个方面,本发明提供了具有长度为15-35个核苷酸的寡核苷酸链的分离的核酸,其中所述寡核苷酸链与表11-13的靶CKAP5mRNA序列沿所述寡核苷酸链长度的至少15个核苷酸充分互补,以当所述核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
本发明的另一个方面提供了具有长度为19-35个核苷酸的寡核苷酸链的核酸,其中所述寡核苷酸链与表14-16的靶CKAP5mRNA序列沿所述寡核苷酸链长度的至少19个核苷酸充分互补,以当所述核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
本发明的另外方面提供了包含RNA的第一和第二核酸链的分离的双链核酸(dsNA),其中第一链的长度为15-35个核苷酸,并且dsNA的第二链的长度为19-35个核苷酸,其中第二寡核苷酸链与表11-13的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少15个核苷酸充分互补,以当所述dsNA被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
本发明的其它方面提供了具有第一和第二核酸链的分离的dsNA,其中第一链的长度为15-35个核苷酸并且dsNA的第二条链的长度为19-35个核苷酸,其中第二寡核苷酸链与表14-16的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少19个核苷酸充分互补,以当所述dsNA被引入哺乳动物细胞时减少CKAP5靶mRNA。
本发明的另一方面提供了具有第一和第二核酸链的分离的dsNA,其中第一链的长度为15-35个核苷酸并且dsNA的第二条链的长度为19-35个核苷酸,其中第二寡核苷酸链与表17-19的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少19个核苷酸充分互补,以当所述dsNA被引入哺乳动物细胞时减少CKAP5靶mRNA表达,并且其中,从表17-19的CKAP5mRNA序列的5'末端(位置1)开始,哺乳动物Ago2在所述序列的位置9与10之间的位点上切割所述mRNA。
本发明的另外方面提供了由有义区和反义区组成的分离的dsNA分子,其中所述有义区和反义区一起形成由25-35个碱基对组成的双链体区域,所述反义区包含为表8-10的序列的互补序列的序列,并且所述dsNA还具有0至2个3′悬突区域,其中每一个悬突区域的长度为6个或更少的核苷酸。
本发明的另一个方面提供了提供了具有第一和第二核酸链以及至少25个碱基对的双链体区域的分离的dsNA,其中第一链的长度为25-34个核苷酸,dsNA的第二链的长度为26-35个核苷酸,并且在其3′末端上包含1-5个单链核苷酸,其中所述第二寡核苷酸链与表8-10的靶CKAP5mRNA序列沿所述第二寡核苷酸长度的至少19个核苷酸充分互补,以当所述dsNA被引入哺乳动物细胞时,减少CKAP5靶基因表达。
本发明的另一个方面提供了具有第一和第二核酸链以及至少25个碱基对的双链体区域的分离的dsNA,其中第一链的长度为25-34个核苷酸,dsNA的第二链的长度为26-35个核苷酸,并且在其3′末端包含1-5个单链核苷酸,其中所述第一寡核苷酸链的3′末端与所述第二寡核苷酸链的5′末端形成平端,并且所述第二寡核苷酸链与SEQIDNO:3457-4032、2305-2880和4033-5760的靶CKAP5序列沿所述第二寡核苷酸长度的至少19个核苷酸充分互补,以当所述双链核酸被引入哺乳动物细胞时,减少CKAP5mRNA表达。
在一个实施方案中,本发明的分离的dsNA包含至少25个碱基对、19-21个碱基对或21-25个碱基对的双链体区域。在另一实施方案中,第二寡核苷酸链包括在其3′末端的1-5个单链核苷酸。
在另一个实施方案中,第一链和/或第二链的长度为25-35个核苷酸。
在一个实施方案中,第二寡核苷酸链与GenBank登录号NM_001008938.3和NM_014756.3的靶CKAP5cDNA序列沿所述第二寡核苷酸链长度的至少27个核苷酸互补。
在某些实施方案中,本发明还提供了分离的dsNA,其中所述第一链的长度为26-35个核苷酸、长度为27-35个核苷酸、长度为28-35个核苷酸、长度为29-35个核苷酸、长度为30-35个核苷酸、长度为31-35个核苷酸、长度为33-35个核苷酸、长度为34-35个核苷酸、长度为17-35个核苷酸、长度为19-35个核苷酸、长度为21-35个核苷酸、长度为23-35个核苷酸、长度为17-33个核苷酸、长度为17-31个核苷酸、长度为17-29个核苷酸、长度为17-27个核苷酸、长度为21-35个核苷酸或长度为19-33个核苷酸。
本发明还提供了分离的dsNA,其中所述第二链的长度为26-35个核苷酸、长度为27-35个核苷酸、长度为28-35个核苷酸、长度为29-35个核苷酸、长度为30-35个核苷酸、长度为31-35个核苷酸、长度为33-35个核苷酸、长度为34-35个核苷酸、长度为21-35个核苷酸、长度为23-35个核苷酸、长度为25-35个核苷酸、长度为27-35个核苷酸、长度为19-33个核苷酸、长度为19-31个核苷酸、长度为19-29个核苷酸、长度为19-27个核苷酸或长度为19-25个核苷酸。
在其它实施方案中,本发明提供了分离的dsNA,其中所述第一链和第二链中的每一个的长度为至少27个核苷酸、长度为至少28个核苷酸、长度为至少29个核苷酸、长度为至少30个核苷酸、长度为至少31个核苷酸、长度为至少32个核苷酸、长度为至少33个核苷酸、长度为至少34个核苷酸或长度为至少35个核苷酸。
任选地,所述第一和第二链的每一个的长度为至少27个和至多30个核苷酸,长度为至少28个和至多30个核苷酸,以及长度为至少29个和至多30个核苷酸。
本发明还提供了分离的dsNA,其与靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少15、16、17、18、19、20、21、22、23、24、25或更多个核苷酸充分互补,以当所述dsNA被引入哺乳动物细胞时,减少CKAP5靶mRNA表达。
在一个实施方案中,本发明的分离的核酸(任选地,dsNA)包括经修饰的核苷酸,所述经修饰的核苷酸残基任选地为2’-O-甲基、2’-甲氧基乙氧基、2’-氟、2’-烯丙基、2’-O-[2-(甲氨基)-2-氧代乙基]、4’-硫代、4’-CH2-O-2’-桥、4’-(CH2)2-O-2’-桥、2’-LNA、2’-氨基或2’-O-(N-甲基氨基甲酸酯)。
在某些实施方案中,本发明的dsNA的第一寡核苷酸链的3′末端上的第一核苷酸(位置1)开始,用经修饰的核苷酸置换位置1、2和/或3。任选地,所述第一链的3′末端的修饰核苷酸残基为脱氧核糖核苷酸、无环核苷酸或荧光分子。在相关实施方案中,所述第一寡核苷酸链的3′末端的位置1为脱氧核糖核苷酸。
在一个实施方案中,具有所述第二链的3′末端的所述1-5个单链核苷酸的本发明的dsNA的核苷酸包括经修饰的核苷酸,其任选地为为2’-O-甲基核糖核苷酸。在相实施方案中,所述第二链的3’末端的1-5个单链核苷酸的所有核苷酸是经修饰的核苷酸。
在某些实施方案中,本发明的dsNA的第一链的3’末端与第二链的5’末端形成平端。在一个实施方案中,所述第一链的长度为25个核苷酸并且所述第二链的长度为27个核苷酸。
在某些实施方案中,始于表8的CKAP5mRNA序列的5’末端(位置1),哺乳动物Ago2在序列的位置9与10之间的位点上切割所述mRNA,从而当所述dsNA被引入哺乳动物细胞时减少CKAP5靶mRNA表达。在另一个实施方案中,始于SEQIDNO:3457-4032、2305-2880和4033-5760的CKAP5mRNA序列的5’末端,哺乳动物Ago2在所述cDNA序列的位置9与10之间的位点上切割所述mRNA,从而当所述dsNA被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
在另一个实施方案中,所述第二链包含SEQIDNO:577-1152的序列。任选地,所述第一链包含SEQIDNO:1-576和1729-2304的序列。
在某些实施方案中,本发明的dsNA具有表2中显示的一对第一链和/或第二链序列。
在一个实施方案中,本发明的dsNA的第一和第二链的每一个的长度为至少26个核苷酸。
在另一实施方案中,具有所述第二链的3′末端的1-5个单链核苷酸的本发明的dsNA的核苷酸的长度为1-3个核苷酸,任选地长度为1-2个核苷酸。在相关实施方案中,所述第二链的3′末端的1-5个单链核苷酸的长度为2个核苷酸并且包含2’-O-甲基修饰的核苷酸。
在一个实施方案中,本发明的dsNA具有拥有AS-M1至AS-M52和AS-M1*至AS-M52*的修饰模式的第二寡核苷酸链。
在另一个实施方案中,本发明的核酸的第一寡核苷酸链包含SM1至SM31的修饰模式。
在一个实施方案中,本发明的dsNA的第一和第二链的每一个具有为至少26个核苷酸和至多30个核苷酸的长度。
任选地,本发明的dsNA在细胞内被切丁酶内源性切割。
在一个实施方案中,足以减少靶基因的表达的分离的核酸的量为在细胞环境中1纳摩尔或更低、200皮摩尔或更低、100皮摩尔或更低、50皮摩尔或更低、20皮摩尔或更低、10皮摩尔或更低、5皮摩尔或更低、2皮摩尔或更低或1皮摩尔或更低。
在某些实施方案中,当在细胞环境中以1纳摩尔或更低的有效浓度在哺乳动物细胞中进行体外测定时,具有25个核苷酸或更长的链长度的本发明的分离的dsNA在减少靶CKAP5mRNA表达中具有比针对相同的靶CKAP5mRNA序列的分离的21mersiRNA更大的效力。
在一个实施方案中,本发明的分离的dsNA与靶CKAP5mRNA序列充分互补,以当所述dsNA被引入哺乳动物细胞时,使CKAP5靶mRNA表达减少至少10%、至少50%、至少80-90%、至少95%、至少98%或至少99%的量(以%表示)。
在某些实施方案中,本发明的dsNA的第一链和第二链通过化学接头连接。任选地,所述第一链的3′末端和所述第二链的5′末端通过化学接头连接。
在一些实施方案中,本发明的dsNA的第二链或第一链的核苷酸被指导切丁酶切割的方向的经修饰的核苷酸置换。在一个实施方案中,本发明的分离的核酸具有经修饰的核苷酸,其为脱氧核糖核苷酸、二脱氧核糖核苷酸、无环核苷酸、3′-脱氧腺苷(虫草素)、3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-双脱氧肌苷(ddI)、2',3′-二脱氧-3′-硫代胞苷(TC)、2',3′-二脱氢-2',3′-二脱氧胸苷(dT)、3′-叠氮基-3′-脱氧胸苷(AZT)的单磷酸核苷酸、2',3′-二脱氧-3′-硫代胞苷(TC)和2',3′-二脱氢-2',3′-二脱氧胸苷(dT)的单磷酸核苷酸、4-硫尿嘧啶、5-溴尿嘧啶、5-碘尿嘧啶、5-(3-氨基烯丙基)-尿嘧啶、2’-O-烷基核糖核苷酸、2’-O-甲基核糖核苷酸、2’-氨基核糖核苷酸、2’-氟代核糖核苷酸和/或或锁核酸。在相关实施方案中,所述分离的核酸包含吗啉代核酸或肽核酸(PNA)修饰。在其它实施方案中,所述分离的核酸具有为膦酸酯、硫代磷酸酯或磷酸三酯的磷酸主链修饰。
本发明的另一个方面提供了用于减少哺乳动物细胞中靶CKAP5基因的表达的方法,其包括将哺乳动物细胞在体外与以足以减少细胞中的靶CKAP5mRNA的表达的量存在的本发明的分离的核酸接触。
在一个实施方案中,使靶CKAP5mRNA表达减少至少10%,至少50%和至少80-90%的量(以百分比表示的)。任选地,CKAP5mRNA水平在将细胞与所述核酸接触后至少8天降低至少90%的量(以%表示)。在某些实施方案中,CKAP5mRNA水平在将细胞与所述核酸接触后至少10天降低至少70%的量(以%表示)。
本发明的另外方面提供了用于减少哺乳动物中的靶CKAP5mRNA的表达的方法,其包括以足以减少哺乳动物中的靶CKAP5mRNA的表达的量向哺乳动物施用本发明的分离的核酸。
在一个实施方案中,以每天1微克至5毫克/千克哺乳动物、100微克至0.5毫克/千克、0.001至0.25毫克/千克、0.01至20微克/千克、0.01至10微克/千克、0.10至5微克/千克或0.1至2.5微克/千克的剂量施用所述分离的核酸。
在另一个实施方案中,在向哺乳动物施用所述分离的dsNA后至少3天,CKAP5mRNA水平在哺乳动物的组织中降低至少70%的量(以%表示)。
任选地,所述组织是肾、乳腺、肺、卵巢、肝脏、宫颈、食道、口咽或胰腺组织。
在一个实施方案中,施用步骤包括静脉内注射、肌内注射、腹膜内注射、输注、皮下注射、经皮、气溶胶、直肠、阴道、局部、口服或吸入递送。
本发明的其它方面提供了用于选择性抑制细胞生长的方法,其包括将所述细胞与足以抑制所述细胞生长的量的本发明的分离的核酸接触。
在一个实施方案中,所述细胞是受试者的肿瘤细胞。在某些实施方案中,所述细胞是体外肿瘤细胞。任选地,所述细胞是人细胞。
本发明的另外方面提供了包含本发明的分离的核酸的制剂,其中所述核酸以当所述核酸在体外被引入哺乳动物细胞时,有效地使靶CKAP5mRNA水平降低至少10%、至少50%和至少80-90%的量(以%表示)的量存在。在一个实施方案中,所述有效量为在细胞环境中1纳摩尔或更低、200皮摩尔或更低、100皮摩尔或更低、50皮摩尔或更低、20皮摩尔或更低、10皮摩尔或更低、5皮摩尔或更低、2皮摩尔或更低或1皮摩尔或更低。
任选地,本发明的dsNA的制剂以当所述dsNA被引入哺乳动物受试者的细胞时,有效地使靶CKAP5mRNA水平降低至少10%、至少50%和至少80-90%的量(以%表示)的量存在。在某些实施方案中,有效量为每天1微克至5毫克/千克受试者、100微克至0.5毫克/千克、0.001至0.25毫克/千克、0.01至20微克/千克、0.01至10微克/千克、0.10至5微克/千克或0.1至2.5微克/千克的剂量。
另一个方面提供了含有本发明的分离的核酸的哺乳动物细胞。其它方面提供了包含本发明的分离的核酸和药学上可接受的载体的药物组合物。另外的方面提供了含有本发明的分离的核酸和其使用说明书的试剂盒。
本发明的一个方面提供了用于治疗或预防受试者的CKAP5相关疾病或病症的方法,所述方法包括以足以治疗或预防所述受试者的CKAP5相关疾病或病症的量向所述受试者施用本发明的分离的核酸和药学上可接受的载体,从而治疗或预防所述受试者的CKAP5相关疾病或病症。
在一个实施方案中,所述CKAP5相关疾病或病症是肾癌、乳腺癌、肺癌、卵巢癌、肝癌、宫颈癌、食道癌、口咽癌和胰腺癌。
本发明的另一个方面提供了基本上由本发明的分离的核酸组成的具有CKAP5抑制活性的组合物。
本发明还涉及与性状、疾病和病况相关的化合物、组合物和方法,所述性状、疾病和病况响应参与CKAP5基因表达途径或介导这样的性状、疾病和病况的维持或发展的其它细胞过程的基因的表达和/或活性的调节。在某些方面,本发明涉及能够被切丁酶加工的小的核酸分子,诸如能够介导针对CKAP5基因表达的RNA干扰(RNAi)的切丁酶底物siRNA(DsiRNA)。本发明的抗-CKAP5dsRNA用于例如提供治疗受试者的可响应CKAP5的性状、疾病和病况(诸如癌症和/或其它增生性疾病、病症或病况)的组合物。可在一个或多个增生性疾病的动物模型(增生性疾病的示例性动物模型引述于下文中)中研究抗-CKAP5dsRNA的效率、效力、毒性和其它效应。
附图简述
图1显示靶向在本文中称为“CKAP5-6704”靶位点的CKAP5RNA中的位点的本发明的示例性DsiRNA试剂的结构。大写字母=未修饰的RNA,小写字母=DNA,粗体=错配碱基对核苷酸;箭头指示预测的切丁酶切割位点;虚线表示对应于被靶向的CKAP5序列内的预测的Argonaute2(Ago2)切割位点的有义(顶链)序列。
图2-1至2-6展示在初始步经修饰双链体筛选中获得的数据。图2-1和2-2描绘被测试的双链体的随从链和引导链的2’-O-甲基修饰模式,而图2-3至2-6显示在对于指定的DsiRNA观察到的人(图2-3和2-4)和小鼠(图2-5和2-6)CKAP5抑制效率的直方图。“P1”表示1期(初步筛选),而“1M”表示初步修饰筛选。在1期中,在人HeLa细胞的环境中以1nM测试DsiRNA。在初步修饰筛选中,在人HeLa细胞(图2-3和2-4)和小鼠(图2-5和2-6)Hepa1-6细胞的环境中以1nM和0.1nM(一式两份)测试DsiRNA。单个条块代表以一式三份观察到的平均人或小鼠CKAP5水平,显示了标准误差。将人CKAP5水平针对HPRT和SFRS9水平进行标准化,而将小鼠CKAP5水平针对HPRT和RpL23水平进行标准化。
图3-1至3-8显示显示对于指定的DsiRNA观察到人和小鼠CKAP5抑制效率的直方图。“P1”表示1期(初步筛选),而“P2”表示2期。在1期中,在人HeLa细胞(人细胞测定;图3-1至3-4)的环境中以1nM测试DsiRNA。在2期中,在人HeLa细胞(图3-1至3-4)或小鼠Hepa1-6细胞(图3-5至3-8)的环境中以1nM和0.1nM(以一式两份)测试DsiRNA。单个条块代表以一式三份观察到的平均人(图3-1至3-4)或小鼠(图3-5至3-8)CKAP5水平,显示了标准误差。将人CKAP5水平针对HPRT和SFRS9水平进行标准化,而将小鼠CKAP5水平针对HPRT和RPL23水平进行标准化。
图4-1至4-9展示了显示对于24个具有一系列引导链2’-O-甲基修饰模式(如图4-1中描绘的)的CKAP5靶向双链体序列观察到的CKAP5敲低的水平的数据。图4-2至4-9的条状图显示跨不同的指定的引导(反义)链2’-O-甲基修饰模式的24个独立CKAP5-靶向DsiRNA序列以0.1nM(一式两份)和1nM在人HeLa细胞(图4-2至4-5)和小鼠Hepa1-6细胞(图4-6至4-9)中的效率数据。
图5-1至5-6展示了在扩展的经修饰双链体的筛选中获得的数据。图5-1和5-2描绘被测试的双链体的随从链和引导链的2’-O-甲基修饰模式,而图5-3至5-6显示在人细胞中对于指定的DsiRNA观察到的人CKAP5抑制效率的直方图。“P4”表示4期(扩展的经修饰的双链体筛选)。在扩展的修饰筛选中,在人HeLa细胞的环境中以1nM和0.1nM(一式两份)测试DsiRNA。单个条块代表以一式三份观察到的平均人CKAP5水平,显示了标准误差。将人CKAP5水平针对HPRT和SFRS9水平进行标准化。
图6-1至6-20展示了2’-O-甲基修饰模式和在对CKAP5-853和CKAP5-604DsiRNA进行进一步的经修饰双链体的筛选中获得的数据。图6-1和6-2分别描绘被测试的双链体的随从链(图6-1)和引导链(图6-2)的2’-O-甲基修饰模式。图6-3至6-14显示DsiRNA的随从链和引导链的2’-O-甲基修饰模式。图6-15描绘如用于CKAP5-853双链体的随从链和引导链修饰模式。图6-16至6-19显示在人细胞中对于指定的经修饰的CKAP5-853双链体(包括具有针对靶CKAP5mRNA的错配的双链体)观察到的人CKAP5抑制效率的直方图。图6-20展示在人细胞中对于指定的经修饰的CKAP5-604双链体观察到的人CKAP5抑制效率的直方图。“P4”表示4.2期(进一步的经修饰的双链体筛选)。在该进一步的修饰筛选中,在人HeLa细胞的环境中以1nM和0.1nM(一式两份)测试DsiRNA。单个条块代表以一式三份观察到的平均人CKAP5水平,显示了标准误差。将人CKAP5水平针对HPRT和SFRS9水平进行标准化。
发明详述
本发明涉及含有双链RNA(“dsRNA”)的组合物以及用于制备它们的方法,所述组合物能够在体内或体外降低CKAP5基因的水平和/或表达。所述dsRNA的一条链含有具有范围在19至35个核苷酸的长度的核苷酸序列的区域,所述区域可指导被靶向的CKAP5转录物的破坏和/或翻译抑制。
定义
除非另外定义,否则本文中使用的所有技术和科学术语具有本发明所属领域内的普通技术人员通常理解的含义。下列参考资料为本领域普通技术人员提供了本发明中使用的许多术语的一般定义:Singleton等人,DictionaryofMicrobiologyandMolecularBiology(第2版1994);TheCambridgeDictionaryofScienceandTechnology(Walker编辑,1988);TheGlossaryofGenetics,第5版,R.Rieger等人,(编辑),SpringerVerlag(1991);和Hale&Marham,TheHarperCollinsDictionaryofBiology(1991)。如本文中所用,除非另有所指,否则下列术语在下文中具有归于它们的含义。
本发明表征了一种或多种可调节(例如,抑制)CKAP5表达的DsiRNA分子。任选地可将本发明的DsiRNA与其它基因和/或基因产物的调节剂组合使用,所述其它基因或基因产物与与CKAP5误调控相关的疾病或病症的维持或发展(例如,肿瘤形成和/或生长等)相关。本发明的DsiRNA试剂调节CKAP5RNA,诸如对应于通过GenBank登录号NM_001008938.3(人CKAP5,转录物变体1)、NM_014756.3(人CKAP5,转录变体2)和NM_001165989.1(小鼠CKAP5)提及的cDNA序列的那些CKAP5RNA,其在本文中通常称为“CKAP5”。
参考示例性CKAP5RNA(在本文中通常称为CKAP5)提供本发明的各个方面和实施方案的下列描述。然而,这样的参照意欲仅是示例性的,本发明的各个方面和实施方案还涉及替代性CKAP5RNA,诸如突变CKAP5RNA或另外的CKAP5剪接变体。某些方面和实施方案还涉及参与CKAP5途径的其它基因,包括其误调控与CKAP5的误调控协同作用(或被影响或影响CKAP5调控)以产生可被靶向治疗的表型效应(例如,肿瘤形成和/或生长等)的基因。TACC1是与CKAP5相互作用的基因的实例。与CKAP5相互作用的基因,诸如TACC1,以及还有与CKAP5协同作用的那些途径的的组分,可使用dsRNA和本文中描述的使用CKAP5-靶向dsRNA的方法来靶向。因此,可如本文中所述,进行所述其它基因的这样的抑制的抑制和效应。
术语“CKAP5”是指编码CKAP5蛋白、肽或多肽的核酸序列(例如,CKAP5转录物,诸如CKAP5Genbank登录号NM_001008938.3、NM_014756.3和NM_001165989.1的序列)。在某些实施方案中,术语“CKAP5”还意欲包括其它CKAP5编码序列,诸如其它CKAP5同种型、突变CKAP5基因、CKAP5基因的剪接变体和CKAP5基因多态型。术语“CKAP5”还用于指CKAP5基因/转录物的多肽基因产物,例如CKAP5蛋白、肽或多肽,诸如由CKAP5Genbank登录号NP_001008938.1、NP_055571.2和NP_001159461.1编码的那些那些蛋白质或多肽。
如本文中所用,“CKAP5相关疾病或病症”是指本领域中已知的与改变的CKAP5表达、水平和/或活性相关的疾病或病症。值得注意地,“CKAP5相关疾病或病症”包括癌症和/或增生性疾病、病况或病症。某些示例性“CKAP5相关疾病或病症”包括肝癌(例如肝细胞癌或HCC)、肺癌(例如,NSCLC)、结肠直肠癌、前列腺癌、胰腺癌、卵巢癌、宫颈癌、脑癌(例如,胶质母细胞瘤)、肾癌(例如,乳头状肾癌)、胃癌、食道癌、髓母细胞瘤、甲状腺癌、横纹肌肉瘤、骨肉瘤、鳞状细胞癌(例如、口腔鳞状细胞癌)、黑色素瘤、乳腺癌和造血功能障碍(例如,白血病和淋巴瘤,以及其他免疫细胞相关病症)。其它超增生性疾病或病症也可被靶向,包括例如膀胱癌、宫颈癌(子宫)、子宫内膜癌(子宫)、头颈癌和口咽癌。
如本文中所用,“增生性疾病”或“癌症”意指特征在于不受控制的细胞生长或复制(如本领域中已知的)的疾病、病况、性状、基因型或表型;包括肝细胞癌(HCC)、白血病例如急性髓性白血病(AML)、慢性髓细胞性白血病(CML)、急性淋巴细胞性白血病(ALL)和慢性淋巴细胞性白血病、AIDS相关癌症诸如卡波西肉瘤;乳腺癌;骨癌诸如骨肉瘤、软骨肉瘤、尤文氏肉瘤、纤维肉瘤、巨细胞瘤、釉质瘤和脊索瘤;脑癌诸如脑膜瘤、胶质母细胞瘤、低级别星形细胞瘤、少突胶质细胞瘤、垂体瘤、神经鞘瘤和脑转移癌;头颈癌,包括各种淋巴瘤诸如套细胞淋巴瘤、非霍奇金淋巴瘤、腺瘤、鳞状细胞癌、喉癌、胆囊和胆管癌、视网膜癌诸如视网膜母细胞瘤、食道癌、胃癌、多发性骨髓瘤、卵巢癌、子宫癌、甲状腺癌、睾丸癌、子宫内膜癌、黑色素瘤、结肠直肠癌、膀胱癌、前列腺癌、肺癌(包括非小细胞肺癌)、胰腺癌、肉瘤、肾母细胞瘤、子宫颈癌、头颈癌、皮肤癌、鼻咽癌、脂肪肉瘤、上皮癌、肾细胞癌、胆囊腺癌、腮腺癌、子宫内膜肉瘤、多药耐药癌症;和增生性疾病和病况诸如与肿瘤血管生成相关的新血管形成、黄斑变性(例如、湿/干AMD)、角膜新血管形成、糖尿病性视网膜病变、新生血管性青光眼、近视变性和其它增生性疾病和病况诸如再狭窄和多囊肾病,以及可响应单独的或与其它疗法组合的细胞或组织的疾病相关基因表达的调节的其它癌症或增生性疾病、病况、性状、基因型或表型。
在某些实施方案中,评估dsRNA介导的CKAP5靶序列的抑制。在这样的实施方案中,可通过本领域公认的方法(例如,RT-PCR、Northern印迹、表达阵列等),任选地通过在本发明的抗-CKAP5dsRNA存在的情况下相对于在这样的抗-CKAP5dsRNA不存在的情况下的CKAP5水平的比较来评估CKAP5RNA水平。在某些实施方案中,将在抗-CKAP5dsRNA存在的情况下的CKAP5水平与在单独的媒介物存在的情况下,在针对无关靶RNA的dsRNA存在的情况下,或在任何处理不存在的情况下观察到的那些CKAP5水平相比较。
还应了解,可评估CKAP5蛋白的水平,以及CKAP5蛋白水平,在不同的条件下,与CKAP5RNA水平和/或dsRNA抑制CKAP5表达所达到的程度直接或间接相关,从而还可使用本领域公认的评估CKAP5蛋白水平的方法(例如,Western印迹、免疫沉淀、其它基于抗体的方法等)来研究本发明的dsRNA的抑制作用。
如果当向系统(例如,无细胞体外系统)、细胞、组织或生物体施用本发明的抗-CKAP5dsRNA时,看到CKAP5RNA(或当评估CKAP5蛋白时,CKAP5蛋白水平)的统计学上显著的降低(如与选择的对照相比较),则本发明的抗-CKAP5dsRNA被认为具有“CKAP5抑制活性”。所进行的重复测定的实验值和数量的分布将倾向于规定什么样的CKAP5RNA的降低水平(以百分比或以绝对项表示)被认为是统计学上显著的(如通过本领域中已知的测定统计显著性的标准方法评估的)参数。然而,在某些实施方案中,“CKAP5抑制活性”是基于系统、细胞、组织或生物体中CKAP5的水平的百分比或绝对降低水平定义的。例如,在某些实施方案中,如果在本发明的dsRNA存在的情况下相较于对于适当的对照看到的CKAP5水平,观察到CKAP5RNA的至少5%的降低或至少10%的降低,则本发明的dsRNA被认为具有CKAP5抑制活性。(例如,在某些实施方案中,如果,例如相对于对照观察到CKAP5水平的5%或10%的降低,则组织和/或受试者中的体内CKAP5水平被认为被本发明的dsRNA试剂抑制)。在某些其它实施方案中,如果观察到CKAP5RNA水平相对于选择的对照降低至少15%,相对于选择的对照降低至少20%,相对于选择的对照降低至少25%,相对于选择的对照降低至少30%,相对于选择的对照降低至少35%,相对于选择的对照降低至少40%,相对于选择的对照降低至少45%,相对于选择的对照降低至少50%,相对于选择的对照降低至少55%,相对于选择的对照降低至少60%,相对于选择的对照降低至少65%,相对于选择的对照降低至少70%,相对于选择的对照降低至少75%,相对于选择的对照降低至少80%,相对于选择的对照降低至少85%,相对于选择的对照降低至少90%,相对于选择的对照降低至少95%,相对于选择的对照降低至少96%,相对于选择的对照降低至少97%,相对于选择的对照降低至少98%,相对于选择的对照降低至少99%,则本发明的dsRNA被认为具有CKAP5抑制活性。在一些实施方案中,CKAP5的完全抑制是dsRNA被认为具有CKAP5抑制活性所需的。在某些方法(例如,细胞培养)中,如果相对于适当的对照观察到CKAP5水平至少50%的降低,则dsRNA被认为具有CKAP5抑制活性。在某些其它实施方案中,如果相对于适当的对照观察到CKAP5水平至少80%的降低,则dsRNA被认为具有CKAP5抑制活性。
通过具体实例,在下面实施例2中,测试一系列DsiRNA靶向CKAP5在体外在人HeLa细胞中以这样的在细胞环境中的1nM的浓度在转染剂(LipofectamineTMRNAiMAX,Invitrogen)存在的情况下降低CKAP5mRNA水平的能力。在下面的实施例2中,CKAP5基因抑制活性归因于经观察在所述测定条件下实现CKAP5mRNA水平至少70%降低的那些DsiRNA。可预见,CKAP5抑制活性还可归因于处于比用于下面实施例2的那些条件更严格或不如其严格的条件下的dsRNA,即使在使用相同或相似的测定法和条件时。例如,在某些实施方案中,如果在细胞环境中在1nMdsRNA浓度或更低浓度下相对于适当的对照在体外在哺乳动物细胞系中观察到CKAP5mRNA水平的至少10%的降低、至少20%的降低、至少30%的降低、至少40%的降低、至少50%的降低、至少60%的降低、至少75%的降低、至少80%的降低、至少85%的降低、至少90%的降低或至少95%的降低,则本发明的测试的dsRNA被认为具有CKAP5抑制活性。
还可预见用于确定本发明的双链RNA是否具有CKAP5抑制活性的其它终点的使用。具体地,在一个实施方案中,除了评估CKAP5mRNA水平以外或作为对评估CKAP5mRNA水平的替代,还可评估测试的dsRNA降低CKAP5蛋白水平(例如,在体外或体内接触哺乳动物细胞后48小时)的能力,如果相对于适当的对照,在于体外或体内与测定的双链RNA接触的哺乳动物细胞中观察到CKAP5蛋白水平的至少10%的降低、至少20%的降低、至少30%的降低、至少40%的降低、至少50%的降低、至少60%的降低、至少70%的降低、至少75%的降低、至少80%的降低、至少85%的降低、至少90%的降低或至少95%的降低,则测试的dsRNA被认为具有CKAP5抑制活性。可预见的另外的终点包括,例如,与CKAP5水平的降低相关的表型–例如,接触的哺乳动物细胞系体外生长的减缓和/或肿瘤体内生长的减缓(例如,停止或减缓肿瘤的生长或癌细胞水平,如在本文中其它地方更详细描述的)的评估。
还可随时间过去(持续时间)和在整个浓度范围内(效力)评价CKAP5抑制活性,根据施用的浓度和施用后的持续时间调整构成具有CKAP5抑制活性的dsRNA的物质的评估。因此,在某些实施方案中,如果在向细胞或生物体施用所述dsRNA后2小时、5小时、10小时、1天、2天、3天、4天、5天、6天、7天、8天、9天、10天或更多天的持续时间中观察到至少50%的CKAP5活性的降低,则本发明的dsRNA被认为具有CKAP5抑制活性。在另外的实施方案中,如果在例如本文中描述的用于CKAP5抑制活性的体外测定中,在细胞环境中在1nM或更低、500pM或更低、200pM或更低、100pM或更低、50pM或更低、20pM或更低、10pM或更低、5pM或更低、2pM或更低或甚至1pM或更低的浓度下观察到CKAP5抑制活性(例如,在某些实施方案中,至少50%的CKAP5活性的抑制),则本发明的dsRNA被认为是强效CKAP5抑制剂。在某些实施方案中,本发明的强效CKAP5抑制性dsRNA被定义为当于有效递送媒介物(例如,有效脂质纳米颗粒制剂)中向受试者施用时,能够在10mg/kg或更低的配制浓度下具有CKAP5抑制活性(例如,在某些实施方案中,至少20%的CKAP5水平的降低)的CKAP5抑制性dsRNA。优选地,本发明的强效CKAP5抑制性dsRNA被定义为当于有效递送媒介物中向受试者施用时,能够在5mg/kg或更低的配制浓度下具有CKAP5抑制活性(例如,在某些实施方案中,至少50%的CKAP5水平的降低)的CKAP5抑制性dsRNA。更优选,本发明的强效CKAP5抑制性dsRNA被定义为当于有效递送媒介物中向受试者施用时,能够在5mg/kg或更低的配制浓度下具有CKAP5抑制活性(例如,在某些实施方案中,至少50%的CKAP5水平的降低)的CKAP5抑制性dsRNA。任选地,本发明的强效CKAP5抑制性dsRNA被定义为当于有效递送媒介物中向受试者施用时,能够在2mg/kg或更低,或甚至1mg/kg或更低的配制浓度下具有CKAP5抑制活性(例如,在某些实施方案中,至少50%的CKAP5水平的降低)的CKAP5抑制性dsRNA。
在某些实施方案中,实现特定水平的靶基因敲低所需的本发明的dsRNA的效力可参照存在于靶细胞的细胞质中的dsRNA的拷贝数来测定。例如,在某些实施方案中,强效dsRNA是当以1000或更少的拷贝数的RISC-加载的反义链每细胞存在于靶细胞的细胞质中时,能够引起50%或更多的靶mRNA敲低的dsRNA。更优选,强效dsRNA是当以500或更少的拷贝数的RISC-加载的反义链每细胞存在于靶细胞的细胞质中时,能够引起50%或更多的靶mRNA敲低的dsRNA。任选地,强效dsRNA是当以300或更少的拷贝数的RISC-加载的反义链每细胞存在于靶细胞的细胞质中时,能够引起50%或更多的靶mRNA敲低的dsRNA。
在其它实施方案中,本发明的DsiRNA的效力参照针对相同靶基因内的相同靶序列的19至23merdsRNA来确定。例如,相对于对应的19至23merdsRNA具有增强的效力的本发明的DsiRNA可以是这样的DsiRNA,所述DsiRNA当在如本文中描述的体外测定中以允许检测效力差异的足够低的浓度(例如,在本文中描述的体外测定中,在细胞环境中1nM或低于1nM、在细胞环境中100pM或低于100pM、在细胞环境中10pM或低于10pM、在细胞环境中1nM或低于1nM的转染浓度;值得注意地,应了解效力差异可通过在整个浓度范围例如0.1pM至10nM内(以生成剂量-反应曲线和确定与DsiRNA/dsRNA相关的IC50值)进行这样的测定来最好地检测)测定时,相较于对应的19至23merdsRNA使靶基因降低另外5%或更多、另外10%或更多、另外20%或更多、另外30%或更多、另外40%或更多或另外50%或更多。
CKAP5抑制水平和/或CKAP5水平还可被间接评估,例如,受试者的息肉或肿瘤的尺寸的减小、生长或扩散的数目和/或速率的测量可用于评估CKAP5水平和/或本发明的双链核酸的CKAP5抑制效率。
在某些实施方案中,短语“基本上由……组成”用于用参考本发明的抗-CKAP5dsRNA。在一些这样的实施方案中,“基本上由……组成”是指组合物,所述组合物包含具有一定水平的CKAP5抑制活性(例如,至少50%的CKAP5抑制活性)的本发明的dsRNA,并且还包含一个或多个不会显著影响dsRNA的CKAP5抑制活性的另外的组分和/或修饰。例如,在某些实施方案中,“基本上由”本发明的dsRNA组成的组合物,其中本发明的dsRNA和/或组合物的dsRNA相关组分的修饰,相较分离的本发明的dsRNA使CKAP5抑制活性(任选地包括CKAP5抑制活性的效力或持续时间)改变不超过3%、不超过5%、不超过10%、不超过15%、不超过20%、不超过25%、不超过30%、不超过35%、不超过40%、不超过45%或不超过50%。在某些实施方案中,即使CKAP5抑制活性的更急剧降低(例如,效率、持续时间和/或效力的80%的降低、90%的降低等)在另外的组分或修饰存在的情况下发生,然而其中CKAP5抑制活性在另外的组分和/或修饰存在的情况下未获得显著升高(例如,观察到的CKAP5抑制活性水平在针对分离的本发明的dsRNA观察到的CKAP5抑制活性的10%以内),组合物被认为基本上由本发明的dsRNA组成。
如本文中所用,术语“核酸”是指脱氧核糖核苷酸、核糖核苷酸或经修饰的核苷酸以及以单链或双链形式存在的其聚合物。术语包括含有已知的核苷酸类似物或经修饰的主链残基或连接的核酸,所述核酸是合成的、天然存在的和非天然存在的,其具有与参照核酸相似的结合性质,并且可以以与参照核苷酸相似的方式被代谢。这样的类似物的实例包括但不限于硫代磷酸酯、亚磷酰胺、甲基膦酸酯、手性甲基膦酸酯、2-O-甲基核糖核苷酸、肽-核酸(PNA)和解锁核酸(UNA;参见,例如,Jensen等人,NucleicAcidsSymposiumSeries52:133-4)及其衍生物。
如本文中所用,“核苷酸”如本文中所承认的,用于包括具有天然碱基(标准)和本领域中公知的经修饰的碱基的那些核苷酸。这样的碱基通常位于核苷酸糖部位的1'位置。核苷酸通常包含碱基、糖和磷酸基团。核苷酸可不被修饰或可在糖、磷酸和/或碱基部分被修饰,(也可互换地称为核苷酸类似物、经修饰的核苷酸、非天然核苷酸、非标准核苷酸等;参见,例如,Usman和McSwiggen,同上;Eckstein等人,国际PCT公开No.WO92/07065;Usman等人,国际PCT公开No.WO93/15187;Uhlman&Peyman,同上,所有文献在此通过引用并入本文)。存在几个本领域中已知的经修饰的核酸的实例,如由Limbach等人,NucleicAcidsRes.22:2183,1994概述的。可被引入核酸分子的碱基修饰的一些非限定性实例包括次黄嘌呤、嘌呤、吡啶-4-酮、吡啶-2-酮、苯基、假尿嘧啶、2,4,6-三甲氧基苯、3-甲基尿嘧啶、二氢尿苷、萘基、氨基苯基、5-烷基胞苷(例如,5-甲基胞苷)、5-烷基尿苷(例如,核糖胸苷)、5-卤代尿苷(例如,5-溴尿苷)或6-氮杂嘧啶或6-烷基嘧啶(例如6-甲基尿苷),丙炔等(Burgin,等人,Biochemistry35:14090,1996;Uhlman&Peyman,同上)。在这个方面“经修饰的碱基”意指在1'位置或它们的等同位置上除腺嘌呤、鸟嘌呤、胞嘧啶和尿嘧啶外的核苷酸碱基。
如本文中所用,“经修饰的核苷酸”是指具有一个或多个对核苷酸、核碱基、戊糖环或磷酸基团的修饰的核苷酸。例如,经修饰的核苷酸不包括含有腺苷一磷酸、鸟苷一磷酸、尿苷一磷酸以及胞苷一磷酸的核糖核苷酸和含有脱氧腺苷一磷酸、脱氧鸟苷一磷酸、脱氧胸苷一磷酸、脱氧胞苷一磷酸的脱氧核糖核苷酸。修饰包括因通过修饰核苷酸的酶诸如甲基转移酶的修饰而导致的天然发生的那些修饰。经修饰的核苷酸还包括合成或非天然存在的核苷酸。核苷酸中合成或非天然存在的修饰包括具有2’修饰的那些修饰,例如2'-甲氧基乙氧基、2'-氟、2'-烯丙基、2'-O-[2-(甲氨基)-2-氧代乙基]、4'-硫代、4'-CH2-O-2'-桥、4'-(CH2)2-O-2'-桥、2'-LNA或其它二环或“桥接的”核苷类似物,以及2'-O-(N-氨基甲酸甲酯)或包含碱基类似物的那些修饰。关于如针对本公开内容所描述的2'-修饰的核苷酸,“氨基”意指2'-NH2或2'-O-NH2,其可被修饰或不被修饰。这样的经修饰的基团描述于例如Eckstein等人,美国专利No.5,672,695和Matulic-Adamic等人,美国专利No.6,248,878中。本发明的“经修饰的核苷酸”还可包括上述核苷酸类似物。
关于本发明的核酸分子,修饰可在双链核糖核酸(dsRNA)的一条或两条链上以一定模式存在于这些试剂上。如本文中所用,“交替的位置”是指其中每隔一个核苷酸是经修饰的核苷酸或在确定长度的dsRNA的链上每一个经修饰的核苷酸之间存在未修饰的核苷酸(例如,未修饰的核糖核苷酸)的模式(例如,5′-MNMNMN-3′;3′-MNMNMN-5′;其中M是经修饰的核苷酸并且N是未修饰的核苷酸)。修饰模式始于按照位置编号惯例(例如,如本文中描述的)的5′或3′末端上的第一核苷酸位置(在某些实施方案中,在本发明的DsiRNA试剂的预测的切丁酶切割事件后参照链的末端残基指定位置1;因此,位置1并不总构成本发明的处理前试剂的3′末端或5′末端残基)。交替的位置上的经修饰的核苷酸的模式可在链的全长上延续,但在某些实施方案中包括分别含有至少2、3、4、5、6或7个经修饰的至少4、6、8、10、12、14个核苷酸。如本文中所用,“交替的位置对”是指其中两个连续的经修饰的核苷酸在确定长度的dsRNA的链上间隔以两个连续的未修饰核苷酸的模式(例如,5′-MMNNMMNNMMNN-3′;3′-MMNNMMNNMMNN-5′;其中M是经修饰的核苷酸,N是未修饰的核苷酸)。修饰模式始于按照位置编号惯例(例如,如本文中描述的那些编号惯例)的5′或3′末端上的第一核苷酸位置。交替的位置上的经修饰的核苷酸的模式可在链的全长上延续,但优选包括分别含有至少4、6、8、10、12或14个经修饰的至少8、12、16、20、24、28个核苷酸。要强调的是上述修饰模式是示例性的并且无意作为对本发明的范围的限定。
如本文中所用,“碱基类似物”是指位于可被掺入核酸双链体的经修饰的核苷酸的核苷酸糖部分的1'位置(或可被掺入核酸双链体的核苷酸糖部分置换中的等位置)的杂环部分。在本发明的dsRNA中,碱基类似物通常是不包括常用碱基鸟嘌呤(G)、胞嘧啶(C)、腺嘌呤(A)、胸腺嘧定(T)和尿嘧啶(U)的嘌呤或嘧啶碱基。碱基类似物可与dsRNA中的其它碱基或碱基类似物形成双链体。碱基类似物包括用于本发明的化合物和方法的那些碱基类似物,例如属于Benner的美国专利No.5,432,272和6,001,983和属于Manoharan的美国专利申请No.20080213891(所述专利和专利申请在此通过引用并入)中描述的那些碱基类似物。碱基的非限定性实例包括次黄嘌呤(I)、黄嘌呤(X)、3β-D-呋喃核糖苷(2,6-二氨基嘧啶)(K)、3-β-D-呋喃核糖苷(1-甲基-吡唑并[4,3-d]嘧啶-5,7(4H,6H)-二酮)(P)、异-胞嘧啶(异-C)、异-鸟嘌呤(异-G)、1-β-D-呋喃核糖苷-(5-硝基吲哚)、1-β-D-呋喃核糖苷(3-硝基吡咯)、5-溴尿嘧啶、2-氨基嘌呤、4-硫代脱氧胸苷、7-(2-噻吩基)-咪唑并[4,5-b]吡啶(Ds)和吡咯-2-甲醛(Pa)、2-氨基-6-(2-噻吩基)嘌呤(S)、2-氧代吡啶(Y)、二氟甲苯基、4-氟-6-甲基苯并咪唑、4-甲基苯并咪唑、3-甲基异羟喹啉基、5-甲基异羟喹啉基和3-甲基-7-丙炔基异羟喹啉基、7-氮杂吲哚基、6-甲基-7-氮杂吲哚基、咪唑并吡啶基、9-甲基-咪唑并吡啶基、吡咯并吡啶基、异羟喹啉基、7-丙炔异羟喹啉基、丙炔基-7-氮杂吲哚基、2,4,5-三甲基苯基,4-甲基吲哚基、4,6-二甲基吲哚基、苯基、萘基、蒽基、菲基、芘基、芪基(stilbenzyl)、并四苯基(tetracenyl)、并五苯基(pentacenyl)及其结构衍生物(Schweitzer等人,J.Org.Chem.,59:7238-7242(1994);Berger等人,NucleicAcidsResearch,28(15):2911-2914(2000);Moran等人,J.Am.Chem.Soc.,119:2056-2057(1997);Morales等人,J.Am.Chem.Soc.,121:2323-2324(1999);Guckian等人,J.Am.Chem.Soc.,118:8182-8183(1996);Morales等人,J.Am.Chem.Soc.,122(6):1001-1007(2000);McMinn等人,J.Am.Chem.Soc.,121:11585-11586(1999);Guckian等人,J.Org.Chem.,63:9652-9656(1998);Moran等人,Proc.Natl.Acad.Sci.,94:10506-10511(1997);Das等人,J.Chem.Soc.,PerkinTrans.,1:197-206(2002);Shibata等人,J.Chem.Soc.,PerkinTrans.,1:1605-1611(2001);Wu等人,J.Am.Chem.Soc.,122(32):7621-7632(2000);O'Neill等人,J.Org.Chem.,67:5869-5875(2002);Chaudhuri等人,J.Am.Chem.Soc.,117:10434-10442(1995);和美国专利No.6,218,108.)。碱基类似物还可以是通用碱基。
如本文中所用,“通用碱基”是指位于经修饰的核苷酸中的核苷酸糖部分的1'位置或核苷酸糖部分置换中的等同位置的杂环部分,所述杂环部分,当存在于核酸双链体中时,可被与超过一个类型的碱基相对地放置而不改变双螺旋结构(例如,磷酸主链的结构)。此外,通用碱基不破坏其存在于其中的单链核酸与靶核酸形成双链体的能力。含有通用碱基的单链核酸与靶核酸形成双链的能力可通过对于本领域普通技术人员来说是显然的方法(例如,紫外线吸光度、圆二色性、凝胶迁移、单链核酸酶敏感性等)来测定。此外,可改变在其下观察到双链体形成的条件以测定双链体稳定性或形成,例如温度,因为解链温度(Tm)与核酸双链体的稳定性相关。相较于与靶核酸完全互补的参照单链核酸,含有通用碱基的单链核酸与靶核酸形成双链体,所述双链体具有比与互补核酸形成的双链体更低的Tm。然而,相较于其中通用碱基已被产生单个错配的碱基替代的参照单链核酸,含有通用碱基的单链核酸与靶核酸形成双链体,所述双链体具有比与具有错配碱基的核酸形成的双链体更高的Tm。
一些通用碱基能够通过在碱基对形成条件下在所述通用碱基与所有碱基鸟嘌呤(G)、胞嘧啶(C)、腺嘌呤(A)、胸腺嘧定(T)和尿嘧啶(U)之间形成氢键来进行碱基配对。通用碱基不是仅与一个单个互补碱基形成碱基对的碱基。在双链体中,通常碱基可与双链体的相对链上与其相对的G、C、A、T和U的每一个不形成氢键、形成一个氢键或超过一个氢键。优选地,通用碱基不与双链体的相对链上与其相对的碱基相互作用。在链体中,通用碱基之间的碱基配对发生而不改变磷酸主链的双螺旋结构。通用碱基还可通过堆积相互作用与相同核酸链上的相邻核苷酸中的碱基相互作用。这样的堆积相互作用稳定双链体,尤其在其中通用碱基不与双链体的相对链上的与其相对放置的碱基形成任何氢键的情况下。通用结合核苷酸的非限定性实例包括肌苷、1-β-D-呋喃核糖苷-5-硝基吲哚和/或1-β-D-呋喃核糖苷-3-硝基吡咯(属于Quay等人的美国专利申请公开No.20070254362;VanAerschot等人,Anacyclic5-nitroindazolenucleosideanalogueasambiguousnucleoside.NucleicAcidsRes.1995年11月11日;23(21):4363-70;Loakes等人,3-Nitropyrroleand5-nitroindoleasuniversalbasesinprimersforDNAsequencingandPCR.NucleicAcidsRes.1995年7月11日;23(13):2361-6;Loakes和Brown,5-Nitroindoleasanuniversalbaseanalogue.NucleicAcidsRes.1994年10月11日;22(20):4039-43)。
如本文中所用,“环”是指由核酸的单链形成的结构,其中侧翼连接特定单链核苷酸区域的互补区以将所述互补区之间的单链核苷酸区域从双链体形成或沃森-克里克碱基配对排除的方式杂交。环是具有任意长度的单链核苷酸区域。环的实例包括存在于这样的结构如发夹、茎环或延伸环中的未配对的核苷酸。
如本文中所用,dsRNA的背景中的“延伸环”是指单链环以及此外侧翼连接该环的1、2、3、4、5、6或多至20个碱基对或双链体。在延伸环中,在5′侧上侧翼连接环的核苷酸与在3′侧上侧翼连接环的核苷酸形成双链体。延伸环可形成发夹或茎环。
如本文中所用,dsRNA的背景中的“四环”是指由形成稳定的二级结构的4个核苷酸组成的环(单链区域),所述二级结构促成相邻沃森-克里克杂交的核苷酸的稳定性。不受理论限制,四环可通过堆积相互作用稳定相邻沃森-克里克碱基对。此外,四环中的4个核苷酸间的相互作用包括但不限于非沃森-克里克碱基配对、堆积相互作用、氢键合和接触相互作用(Cheong等人,Nature1990年8月16日;346(6285):680-2;Heus和Pardi,Science1991年7月12日;12;253(5016):191-4)。四环赋予相邻双链体比从由4个随机碱基组成的简单模型环序列预期的更高的解链温度(Tm)的增加。例如,四环可在10mMNaHPO4中赋予包含长度至少2个碱基对的双链体的发夹至少55℃的解链温度。四环可含有核糖核苷酸、脱氧核糖核苷酸、经修饰的核苷酸及其组合。RNA四环的实例包括UNCG四环家族(例如,UUCG)、GNRA四环家族(例如,GAAA)和CUUG四环。(Woese等人,ProcNatlAcadSciUSA.1990年11月;87(21):8467-71;Antao等人,NucleicAcidsRes.1991年11月11日;19(21):5901-5)。DNA四环的实例包括d(GNNA)四环家族(例如,d(GTTA)、d(GNRA))、d(GNAB)四环家族、d(CNNG)四环家族、d(TNCG)四环家族(例如,d(TTCG))。(Nakano等人,Biochemistry,41(48),14281-14292,2002.;SHINJI等人,NipponKagakkaiKoenYokoshu第78卷;NO.2;第731页(2000)。)
如本文中所用,术语“siRNA”是指其中每一条链包含RNA、RNA类似物或RNA和DNA的双链核酸。siRNA包含19至23个核苷酸或包含21个核苷酸。siRNA通常在每一条链的3′末端具有2bp悬突,以便siRNA中的双链体区域包含17-21个核苷酸或19个核苷酸。通常地,siRNA的反义链与CKAP5基因/RNA的靶序列充分互补。
本发明的抗-CKAP5DsiRNA具有至少25个核苷酸的链长度。因此,在某些实施方案中,抗-CKAP5DsiRNA含有一个寡核苷酸序列(第一序列),其长度为至少25个核苷酸并且不长于35或多至50或更多个核苷酸。该RNA序列的长度可以为26至35、26至34、26至33、26至32、26至31、26至30以及26至29个核苷酸。该序列的长度可以为27或28个核苷酸或27个核苷酸。DsiRNA试剂的第二序列可以是在生物条件下,例如在真核细胞的细胞质中与所述第一序列退火的序列。一般地,第二寡核苷酸序列将具有至少19个与第一寡核苷酸序列互补的碱基对,更通常地,第二寡核苷酸序列与第一寡核苷酸序列具有21或更我个互补碱基对,或25或更多个互补碱基对。在一个实施方案中,第二序列在长度上与第一序列相同,并且DsiRNA试剂是平端。在另一个实施方案中,DsiRNA试剂的末端具有一个或多个悬突。
在某些实施方案中,DsiRNA试剂的第一和第二寡核苷酸序列存在于单独的寡核苷酸链上,所述寡核苷酸链可以是化学合成的,并且通常是化学合成的。在一些实施方案中,两条链的长度为26至35个核苷酸。在其它实施方案中,两条链的长度为26至35个核苷酸。在其它实施方案中,两条链的长度为25至30或26至30个核苷酸。在一个实施方案中,两条链的长度为27个核苷酸,完全互补并且具有平端。在本发明的某些实施方案中,抗-CKAP5DsiRNA的第一和第二序列存在于单独的RNA寡核苷酸(链)上。在一个实施方案中,一条或两条寡核苷酸链能够用作切丁酶的底物。在其它实施方案中,存在至少一个促进切丁酶以使双链RNA结构在抑制基因表达中的效率最大化的方向结合至双链RNA结构的修饰。在本发明的某些实施方案中,抗-CKAP5DsiRNA试剂由具有不同长度的两条寡核苷酸链组成,所述抗-CKAP5DsiRNA在第一链(有义链)的3′末端具有平端并且在第二链(反义链)的3′末端具有3′悬突。DsiRNA还可包含一个或多个脱氧核糖核酸(DNA)碱基置换。
可包含两个单独的寡核苷酸的适合的DsiRNA组合物可通过化学连接基团在它们的退火区域外部进行化学连接。许多适合的化学连接基团在本领域中是已知的并且可被使用。适合的基团不会阻断DsiRNA上的切丁酶活性,并且不干扰从靶基因转录的RNA定向破坏。或者,所述两个单独的寡核苷酸可通过第三寡核苷酸连接,以便在组成DsiRNA组合物的两个寡核苷酸退火后产生发夹结构。发夹结构不会阻断DsiRNA上的切丁酶活性,并且不会干扰靶RNA的定向破坏。
如本文中所用,具有与靶RNA或cDNA序列(例如,CKAP5mRNA)“充分互补”的dsRNA(例如DsiRNA或siRNA)意指,所述dsRNA具有足以触发通过RNAi机制(例如,RISC复合物)或过程进行的靶RNA(其中引述了cDNA序列,所述RNA序列对应于引述的cDNA序列)的破坏的序列。例如,为与靶RNA或cDNA序列“充分互补”以触发通过RNAi机制或过程进行靶RNA的破坏的dsRNA可被鉴定为在dsRNA活性的适当测定(例如,如下文中实施例2中描述的体外测定)中引起靶RNA的水平的可检测降低的dsRNA,或在其它实例中,与靶RNA或cDNA序列充分互补以触发通过RNAi机制或过程进行的靶RNA的破坏的dsRNA可被鉴定为这样的dsRNA,所述dsRNA在dsRNA活性的适当测定中产生靶RNA水平的至少5%、至少10%、至少15%、至少20%、至少25%、至少30%、至少35%、至少40%、至少45%、至少50%、至少55%、至少60%、至少65%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少98%或至少99%的降低。在另外的实例中,与靶RNA或cDNA序列充分互补以触发通过RNAi机制或过程进行的靶RNA的破坏的dsRNA可基于针对细胞或生物中的靶RNA或蛋白质水平的特定水平的抑制活性的持续时间的评估来鉴定。例如,与靶RNA或cDNA序列充分互补以触发通过RNAi机制或过程进行的靶RNA的破坏的dsRNA可被鉴定为能够在向细胞或生物体施用所述dsRNA后至少48小时使靶mRNA水平降低至少20%的dsRNA。优选地,与靶RNA或cDNA序列充分互补以触发通过RNAi机制或过程进行靶RNA的破坏的dsRNA可被鉴定为这样的dsRNA,所述dsRNA能够在向细胞或生物体施用所述dsRNA后至少72小时使靶mRNA水平降低至少40%,在向细胞或生物体施用所述dsRNA后至少4、5或7天使靶mRNA水平降低至少40%,在向细胞或生物体施用所述dsRNA后至少48小时使靶mRNA水平降低至少50%,在向细胞或生物体施用所述dsRNA后至少72小时使靶mRNA水平降低至少50%,在向细胞或生物体施用所述dsRNA后至少4、5或7天使靶mRNA水平降低至少50%,在向细胞或生物体施用所述dsRNA后至少48小时使靶mRNA水平降低至少80%,在向细胞或生物体施用所述dsRNA后至少752小时使靶mRNA水平降低至少80%,或在向细胞或生物体施用所述dsRNA后至少4、5或7天小时使靶mRNA水平降低至少80%。
可这样设计dsRNA分子,以便反义链的每一个残基与靶分子中的残基互补。或者,可在所述分子内产生置换以增强所述分子的稳定性和/或增强其加工活性。可在链内产生置换或可对链的末端上的残基产生置换。在某些实施方案中,在DsiRNA试剂内的特定残基上产生置换和/或修饰。这样的置换和/或修饰可包括例如位置1、2和3(当从DsiRNA试剂的有义链的3′末端位置开始编号时)的一个或多个残基上的脱氧-修饰;和2’-O-烷基(例如,2’-O-甲基)修饰在DsiRNA试剂的反义链的3′末端残基上的引入,也在反义链的3′部分的悬突位置和DsiRNA的反义链的交替的残基(所述残基包含于被加工以形成活性siRNA试剂的DsiRNA试剂的区域内)上进行这样的修饰。先前的修饰被示例性提供,并且无意以任何方式进行限定。优选DsiRNA试剂的结构的进一步考虑,包括可对本发明的抗-CKAP5DsiRNA试剂进行的修饰和置换的进一步说明可见于下文中。
当第一序列相对于本文中的第二序列被称为“大体上互补的”,所述两个序列可完全互补,或它们可在杂交后形成一个或多个,但通常不超过4、3或2个错配的碱基对,同时保留在与它们的最终应用最相关的条件下杂交的能力。然而,当两个寡核苷酸被设计用于在杂交后形成一个或多个单链悬突时,对互补性的测定,这样的悬突将不被当作错配。例如,包含一个长度为21个核苷酸的寡核苷酸和另一个长度为23个核苷酸的寡核苷酸的dsRNA(其中更长的寡核苷酸包含与更短的寡核苷酸完全互补的21个核苷酸的序列),为了本发明的目的仍然可称为“完全互补"”。
如本文中所用,术语“双链RNA”或“dsRNA”,是指具有双链体结构的核糖核酸分子的复合物,所述双链体结构包含两个反向平行且大体上互补(如上定义的)的核酸链。形成双链体结构的两条链可以是一条更大的RNA分子的不同部分,或它们具有单独的RNA分子。在单独的RNA分子的情况下,这样的dsRNA通常称为siRNA(“短干扰RNA”)或DsiRNA(“切丁酶底物siRNA”)。当两条链为一个更大的分子的部分,从而通过形成双链体结构的一条链的3′末端与各自另一条链的5'末端之间的核苷酸的连续链连接时,所述连接RNA链被称为“发夹环”、“短的发夹RNA”或“shRNA”。当两条链通过除形成双链体的一条链的3′末端与各自另一条链的5'末端之间的核苷酸的连续链外的方法共价连接时,所述连接结构被称为“接头”。RNA链可具有相同或不同数目的核苷酸。碱基对的最大数目为dsRNA的最短链中的核苷酸数目减去存在于双链体中的任何悬突。除了双链体结构以外,dsRNA还可包含一个或多个核苷酸悬突。此外,如本文中所用,“dsRNA”可包括对核糖核苷酸、核苷间连接、末端基团、帽和缀合的部分的化学修饰,包括在多个核苷酸上重大修饰和包括本文中公开的或本领域中已知的所有类型的修饰。为了本说明书和权利要求的目的,任何这样的修饰,如siRNA-或DsiRNA-型分子中使用的,由“dsRNA”包含。
短语“双链体区域”是指互补或大体上互补的寡核苷酸之间的区域,所述寡核苷酸彼此通过沃森-克里克碱基配对或其它方式(所述方式允许在互补或大体上互补的寡核苷酸链之间形成双链体)彼此形成碱基对。例如,具有21个核苷酸单位的寡核苷酸链可与具有21个核苷酸单位的另一寡核苷酸碱基配对,然而每一条链上仅19个碱基互补或大体上互补,以便“双链体区域”由19个碱基对组成。剩余的碱基对可以例如作为5'和3′悬突存在。此外,在双链体区域内,不需要100%互补,大体互补性在双链体区域内是可允许的。大体互补性是指使得它们能够在生物条件下退火的链间的互补性。凭经验确定两条链是否能够在生物条件下退火的技术在本领域是公知的。或者,可合成两条链并在生物条件下添加在一起,以确定它们是否彼此退火。
在许多碱基上碱基配对的单链核酸被认为“杂交”。通常在生理或生物相关条件(例如,细胞内:pH7.2,140mM钾离子;细胞外pH7.4,145mM钠离子)下测定杂交。杂交条件通常含有单价阳离子和生物上可接受的缓冲液,并且可含有或可以不含有二价阳离子、复合阴离子,诸如来自葡萄糖酸钾的葡萄糖酸根、不带电荷的种类诸如蔗糖,以及降低样品中水的活性的惰性聚合物例如PEG。这样的条件包括在其下碱基对可形成的条件。
杂交可通过离解形成双链体的单链核酸所需的温度,即,(解链温度;Tm)来测量。杂交条件也是在其下可形成碱基配对的条件。各种严格度的条件可用于测定杂交(参见,例如,Wahl,G.M.和S.L.Berger(1987)MethodsEnzymol.152:399;Kimmel,A.R.(1987)MethodsEnzymol.152:507)。严格温度条件通常包括至少约30℃,更优选至少约37℃和最优选至少约42℃的温度。预期长度少于50个碱基对的杂交体的杂交温度应当比杂交体的解链温度(Tm)低5-10℃,其中根据以下公式测定Tm。对于长度少于18个碱基对的杂交体,Tm(℃)=2(A+T碱基的数目)+4(G+C碱基的数目)。对于长度为18至49个碱基对的杂交体,Tm(℃)=81.5+16.6(log10[Na+])+0.41(%G+C)-(600/N),其中N为杂交体中碱基的数目,[Na+]为杂交缓冲液中的钠离子的浓度(对于1xSSC,[Na+]=0.165M)。例如,杂交测定缓冲液示于表1中。
表1.
关于杂交条件的有用变化对于本领域普通技术人员来说是显而易见的。杂交技术对于本领域普通技术人员来说是公知的,并且描述于例如Benton和Davis(Science196:180,1977);Grunstein和Hogness(Proc.Natl.Acad.Sci.,USA72:3961,1975);Ausubel等人,(CurrentProtocolsinMolecularBiology,WileyInterscience,NewYork,2001);Berger和Kimmel(AntisensetoMolecularCloningTechniques,1987,AcademicPress,NewYork);和Sambrook等人,MolecularCloning:ALaboratoryManual,ColdSpringHarborLaboratoryPress,NewYork中。
如本文中所用,“寡核苷酸链”是单链核酸分子。寡核苷酸可包含核糖核苷酸、脱氧核糖核苷酸、经修饰的核苷酸(例如,具有2’修饰的核苷酸、合成碱基类似等)或其组合。这样的经修饰的寡核苷酸因性质诸如,例如增强的细胞吸收和在核酸酶存在的情况下增强的稳定性而优于天然形式。
如本文中所用,术语“核糖核苷酸”包括天然和合成的、未修饰和修饰的核糖核苷酸。修饰包括对糖部分、对碱基部分和/或对寡核苷酸中的核糖核苷酸之间的连接的改变。如本文中所用,术语“核糖核苷酸”明确排除脱氧核糖核苷酸,所述脱氧核糖核苷酸在2’核糖环位置上具有单个质子基团。
如本文中所用,术语“脱氧核糖核苷酸”包括天然和合成的、未修饰的和经修饰的脱氧核糖核苷酸。修饰包括对糖部分、对碱基部分和/或对寡核苷酸中的脱氧核糖核苷酸之间的连接的修饰。如本文中所用,术语“脱氧核糖核苷酸”还包括不允许切丁酶切割dsRNA试剂的经修饰的核糖核苷酸,例如2’-O-甲基核糖核苷酸、不允许切丁酶切割在这样的残基的键上发生的硫代磷酸酯-修饰的核糖核苷酸残基等。
如本文中所用,术语“PS-NA”是指硫代磷酸酯修饰的核苷酸残基。术语“PS-NA”从而包括硫代磷酸酯修饰的核糖核苷酸(“PS-RNA”)和硫代磷酸酯修饰的脱氧核糖核苷酸(“PS-DNA”)。
如本文中所用,“切丁酶”是指RNA酶III家族中的内切核糖核酸酶,其将dsRNA或含dsRNA分子,例如双链RNA(dsRNA)或前microRNA(miRNA)切割成19-25个核苷酸长的双链核酸片段,通常在3′末端具有2碱基悬突。对于本发明的某些dsRNA(例如,“DsiRNA”),由本发明的试剂的dsRNA区域形成的双链体被切酶识别,并且在该双链体的至少一条链上为切丁酶底物。切丁酶催化RNA干扰途径中的第一步骤,这随后导致靶RNA的降解。在NCBI数据库中在登录号NP_085124(在此通过引用并入)下提供了人切丁酶的蛋白质序列。
切丁酶“切割”可如下进行确定(例如,参见Collingwood等人,Oligonucleotides18:187–200(2008))。在切丁酶切割测定中,将RNA双链体(100pmol)在20μL的20mMTrispH8.0、200mMNaCl、2.5mMMgCl2中与或不与1个单位的重组人切丁酶(Stratagene,LaJolla,CA)一起在37℃孵育18–24小时。使用PerformaSR96孔板(EdgeBiosystems,Gaithersburg,MD)对样品进行脱盐。使用OligoHTCS系统(Novatia,Princeton,NJ;Hail等人,2004)对利用切丁酶处理前和处理后的双链体RNA进行电喷雾-电离液相质谱(ESI-LCMS),所述系统由ThermoFinniganTSQ7000、Xcalibur数据系统、ProMass数据处理软件和ParadigmMS4HPLC(MichromBioResources,Auburn,CA)组成。在该测定中,其中至少5%、10%、20%、30%、40%、50%、60%、70%、80%、90%、95%或甚至100%的切丁酶底物dsRNA(即,25-30bpdsRNA,优选26-30bpdsRNA)被切成更短的dsRNA(例如,19-23bpdsRNA,优选地,21-23bpdsRNA)的切丁酶切割发生。
如本文中所用,“切丁酶切割位点”是指切丁酶在其上切割dsRNA的位点(例如,本发明的DsiRNA试剂的dsRNA区域)。切丁酶含有两个通常切割dsRNA的有义和反义链的RNA酶III结构域。RNaseIII结构域与PAZ结构域之间的平均距离确定其产生的短的双链核酸片段的长度,该距离可变化(Macrae等人,(2006)Science311:195–8)。如图1中所示,切丁酶经预测切割本发明的某些双链核糖核酸,所述核糖核酸具有在远离反义链的3′末端的第21个与第22个核苷酸之间的位点上,和在远离有义链的5′末端的第21个与第22个核苷酸之间的对应位点具有2个3′悬突的反义链。类似地通过本领域公认的方法鉴定不同于图1中描述的那些位点的dsRNA分子的预测的和/或普遍的切丁酶切割位点,所述方法包括Macrae等人中描述的那些方法。虽然图1中描述的切丁酶切割事件产生21个核苷酸的siRNA,但应指出dsRNA(例如,DsiRNA)的切丁酶的切割可导致在长度上具有19至23个核苷酸的切丁酶加工的siRNA长度的产生。事实上,在某些实施方案中,为了指导通常非优选的19mer或20mersiRNA而非21mer的普遍的切丁酶切除的目的,双链DNA区域可被包含在dsRNA内。
如本文中所用,“悬突”是指在于dsRNA的5′末端或3′末端上具有一个或多个游离末端的双链体的背景中的未配对的核苷酸。在某些实施方案中,所述悬突为反义链或有义链上的3′或5′悬突。在一些实施方案中,所述悬突为具有1至6个核苷酸,任选地1至5个、1至4个、1至3个、1至2个、2至6个、2至5个、2至4个、2至3个、3至6个、3至5个、3至4个、4至6个、4至5个、5至6个核苷酸或1、2、3、4、5或6个核苷酸的长度的3′悬突。“平齐的”或“平端”意指在dsRNA的该末端不存在未配对的核苷酸,即无核苷酸悬突。为清楚起见,在确定siRNA具有悬突还是为平端中不考虑缀合于siRNA的3′末端或5'末端的化学帽或非核苷酸化学部分。在某些实施方案中,本发明提供了用于抑制CKAP5靶基因在细胞或哺乳动物中表达的dsRNA分子,其中所述dsRNA包含反义链,所述反义链包含与在CKAP5靶基因的表达中形成的mRNA的至少部分互补的互补性区域,并且其中互补性区域在长度上少于35个核苷酸,任选地长度为19-24个核苷酸或长度为25-30个核苷酸,并且其中所述dsRNA,在与表达CKAP5靶基因的细胞接触后,抑制所述CKAP5靶基因的表达至少10%、25%或40%。
本发明的dsRNA包含两条充分互补以杂交形成双链体结构的包含RNA的链。dsRNA的一条链(反义链)包含与来源于在CKAP5靶基因的表达过程中形成的mRNA的序列的靶序列大体上互补,通常地完全互补的互补性区域,另一条链(有义链)包含与反义链互补的区域,以便当在适当的条件下组合时,所述两条链并形成双链体结构。通常地,双链体结构的长度为15至35个,任选地25至30个、26至30个、18至25个、19至24个或19至21个碱基对。类似地,针对靶序列的互补性区域的长度为15至35个,选地18至30个、25至30个、19至24个或19至21个核苷酸。本发明的dsRNA还可包含一个或多个单链核苷酸悬突。已鉴定包含在长度上具有15至35个碱基对的双链体结构的dsRNA在诱导RNA干扰中是有效的,包括DsiRNA(通常地,在长度上具有至少25个碱基对)和siRNA(在某些实施方案中,siRNA的双链体结构为20至23个碱基对,任选地,具体地21个碱基对(Elbashir等人,EMBO20:6877-6888))。还已鉴定具有短于20个碱基对的双链体的dsRNA可以是同样有效的(例如,15、16、17、18或19个碱基对双链体)。在某些实施方案中,本发明的dsRNA可包含至少一条具有19或更多个核苷酸的长度的链。在某些实施方案中,可合理地预期,包含与表4或表7的序列的一个互补的序列的更短的dsRNA(仅减去一个或多个末端上的少数核苷酸),相较于上文中和表2-3和5-6中所述的dsRNA,可以是类似地有效的。因此,本发明涉及包含与表4或表7的序列的一个充分互补的至少15、16、17、18、19、20或更多个连续核苷酸的部分序列,并且相异在于它们在本文中所述的测定中抑制CKAP5靶基因的表达不超过5、10、15、20、25或30%的来自包含全长序列的dsRNA的抑制的能力的dsRNA。在一个实施方案中,dsRNA的至少一个末端具有1至5个,任选地1至4个,在某些实施方案中,1或2个核苷酸的单链核苷酸悬突。某些具有至少一个核苷酸悬突的dsRNA结构相较于在dsRNA分子的两个末端上具有碱基配对的平端的对应物具有更优的抑制性质。
如本文中所用,术语“RNA加工”是指通过siRNA、miRNA或RNA酶H途径(例如,Drosha、切丁酶、Argonaute2或其它RISC内切核糖核酸酶和RNA酶H)的组分进行的加工活性,所述酶描在下文中进行了更详细地描述(参见下文中的“RNA加工”部分)。术语明确地区别于RNA的5'加帽的转录后加工和通过非-RISC-或非-RNA酶H-介导的加工对RNA的降解。RNA的这样的“降解”可采取几种形式,例如脱腺苷化(3′多聚(A)尾的除去),和/或通过几种内切-或外切-核酸酶(例如,RNA酶III、RNA酶P、RNA酶T1、RNA酶A(1、2、3、4/5)、寡核苷酸酶等)的一种或多种酶进行的部分或全部RNA主体的核酸酶降解。
“同源序列”意指由一个或多个多核苷酸序列诸如基因、基因转录物和/或非编码多核苷酸共享的核苷酸序列。例如,同源序列可以是由两个或更多个编码相关但不同的蛋白质,诸如基因家族的不同成员、不同的蛋白质表位、不同的蛋白质同种型或完全趋异进化的基因(诸如细胞因子及其对应的受体)的基因共享的核苷酸序列。同源序列可以是由两个或更多个非编码多核苷酸诸如非编码DNA或RNA、调控序列、内含子和转录控制或调控的位置共享的核苷酸序列。同源序列还可包括由超过一个多核苷酸序列共享的保守序列区域。同源性不必是完全同源性(例如,100%),因为部分同源的序列也被本发明包括(例如,99%、98%、97%、96%、95%、94%、93%、92%、91%、90%、89%、88%、87%、86%、85%、84%、83%、82%、81%、80%等)。事实上,本发明的dsRNA的设计和使用考虑使用这样的dsRNA试剂的可能性,所述dsRNA试剂不仅针对与目前描述的dsRNA试剂具有完全互补性的CKAP5的靶RNA,而且还针对具有与所述dsRNA试剂例如仅99%、98%、97%、96%、95%、94%、93%、92%、91%、90%、89%、88%、87%、86%、85%、84%、83%、82%、81%、80%等互补的序列的靶CKAP5RNA。类似地,预期目前描述的本发明的dsRNA试剂可能可由本领域普通技术人员来容易地改变,以增强所述dsRNA试剂与例如CKAP5的特定等位基因变体(例如,具有增强的治疗益处的等位基因)的靶CKAP5RNA之间的互补性程度。事实上,相对于靶CKAP5序列具有插入、缺失和单点突变的dsRNA试剂序列对于抑制也可以是有效的。或者,具有类似物置换或插入的dsRNA试剂序列对于抑制可以是有效的。
序列同一性可通过本领域已知的序列比较和比对算法来测定。为了测定两个核酸序列的(或两个氨基酸序列的)百分比同一性,为了比较目的,将序列对齐(例如,可将缺口引入第一序列或第二序列以进行最佳比对)。随后比较对应核苷酸(或氨基酸)上的核苷酸(或氨基酸残基)。当第一序列中的位置被与第二序列中对应位置相同的残基占据时,则所述分子在该益上是相同的。两个序列之间的百分比同一性是由序列共享的相同位置的数目的函数(即,百分比同源性=相同位置的数目/位置总数x100),任选地对引入的缺口的数目和/或引入的缺口的长度进行罚分。
序列的比较和两个序列之间的百分比同一性的测定可使用数学算法来实现。在一个实施方案中,在对齐的具有足够同一性的序列的某些部分但非在具有低的同一性程度的部分中产生比对(即,局部比对)。用于序列比较的局部比对算法的优选非限定性实例是Karlin和Altschul(1990)Proc.Natl.Acad.Sci.USA87:2264-68(如在Karlin和Altschul(1993)Proc.Natl.Acad.Sci.USA90:5873-77中改进的)的算法。将这样的算法整合进Altschul,等人,(1990)J.Mol.Biol.215:403-10的BLAST程序(2.0版)。
在另一个实施方案中,通过引入适当的缺口来形成带缺口的比对(所述比对被最优化),和在对齐的序列的整个长度上测定百分比同一性(即,即带缺口的比对)。为了获得带缺口的比对(用于比较目的),可如Altschul等人,(1997)NucleicAcidsRes.25(17):3389-3402中所描述的,使用带缺口的BLAST。在另一个实施方案中,通过引入合适的缺口形成比对被最优化的全局比对,并在对齐的序列的整个长度上测定百分比同一性。(即,全局比对)。用于序列的全局比较的数学算法的优选非限定性实例是Myers和Miller,CABIOS(1989)的算法。将这样的算法整合至ALIGN程序(2.0版)中,所述程序为GCG序列比对软件包的部分。当将ALIGN程序用于比较氨基酸序列时,可使用PAM120权重残基表、为12的缺口长度罚分和为4的缺口罚分。
大于80%的序列同一性,例如dsRNA反义链与CKAP5RNA序列的部分之间的80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或甚至100%的序列同一性是优选的。或者,dsRNA可在功能上被定义为这样的核苷酸序列(或寡核苷酸序列),所述核苷酸序列能够与CKAP5RNA的部分杂交(例如,在400mMNaCl,40mMPIPESpH6.4,1mMEDTA中于50℃或70℃杂交12-16小时;随后进行洗涤)。另外的优选杂交条件包括在70℃于1xSSC中或在50℃于1xSSC,50%甲酰胺中杂交,随后在70℃于0.3xSSC中洗涤,或在70℃.于4xSSC中或在50℃于4xSSC,50%甲酰胺中杂交,随后在67℃于1xSSC中洗涤。预期在长度上少于50个碱基对的杂交体的杂交温度应当比杂交体的解链温度(Tm)低5-10℃,其中按照下列公式测定Tm。对于在长度上少于18个碱基对的杂交体,Tm(℃)=2(A+T碱基的数目)+4(G+C碱基的数目)。对于长度为18至49个碱基对的杂交体,Tm(℃)=81.5+16.6(log10[Na+])+0.41(%G+C)-(600/N),其中N为杂交体中的碱基数目,[Na+]为杂交缓冲液中的钠离子浓度(对于1xSSC,[Na+]=0.165M)。在Sambrook,J.,E.F.Fritsch,和T.Maniatis,1989,MolecularCloning:ALaboratoryManual,ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.,第9和11章,和CurrentProtocolsinMolecularBiology,1995,F.M.Ausubel等人,编辑,JohnWiley&Sons,Inc.,2.10和6.3-6.4节中提供了用于多核苷酸杂交的严格度条件的另一个实例。相同的核苷酸序列的长度可以为至少10、12、15、17、20、22、25、27或30个碱基。
“保守的序列区域”意指多核苷酸中的一个或多个区域的核苷酸序列在代之间或一个生物系统、受试者或生物体与另一个生物系统、受试者或生物体之间不会显著改变。多核苷酸可包括编码和非编码DNA和RNA。
“有义区域”意指dsRNA的与该dsRNA分子的反义区具有互补性的核苷酸序列。此外,dsRNA分子的有义区域可包含与靶核酸序列具有同源性的核酸序列。
“反义区域”意指与靶核酸序列具有互补性的dsRNA分子的核苷酸序列。此外,dsRNA分子的反义区域包含与dsRNA分子的有义区域具有互补性的核酸序列。
如本文中所用,“反义链”是指具有与靶RNA的序列互补的序列的单链核酸分子。当反义链含有具有碱基类似物的经修饰的核苷酸时,其在其整个长度上不必互补,但必须至少与靶RNA杂交。
如本文中所用,“有义链”是指具有与反义链的序列互补的序列的单链核酸分子。当反义链含有具有碱基类似物的经修饰的核苷酸时,有义链不必在反义链的整个长度上是互补的,但必须至少与反义链形成双链体。
如本文中所用,“引导链”是指含有dsRNA或dsRNA的分子的单链核酸分子,其具有与靶RNA的序列充分互补的序列以导致RNA干扰。在含有dsRNA或dsRNA的分子被切丁酶切割后,引导链的片段保持与RISC结合,结合作为RISC复合物的组分的靶RNA,并且促进RISC对靶RNA的切割。如本文中所用,引导链不必指连续的单链核酸,并且可包含不连续性,优选地在被切丁酶切割的位点上。引导链是反义链。
如本文中所用,“随从链”是指含有dsRNA或dsRNA的分子的寡核苷酸链,其具有与引导链的序列互补的序列。如本文中所用,随从链不必指连续的单链核酸,并且可包含不连续性,优选在被切丁酶切割的位点上。随从链是有义链。
“靶核酸”意指其表达、水平或活性将被调节的核酸序列。靶核酸可以是DNA或RNA。对于靶向CKAP5的试剂,在某些实施方案中,所述靶核酸为CKAP5RNA,例如,在某些实施方案中,为CKAP5mRNA。CKAP5RNA靶位点还可互换地通过对应的cDNA序列引用。还可通过靶向CKAP5的上游效应子靶向CKAP5的水平,或被调节的或误调的CKAP5的效应也可通过靶向CKAP5在CKAP5信号传导途径中的下游分子来调节。
“互补性”意指核酸可与另一个核酸序列通过常规沃森-克里克或其它非常规类型形成氢键。关于本发明的核酸分子,核酸分子与其互补序列的自由能足以允许核酸的相关功能继续进行,例如,RNAi活性。核酸分子的结合自由能的测定在本领域中是公知的(参见,例如,Turner等人,1987,CSHSymp.Quant.Biol.LII第123-133页;Frier等人,1986,Proc.Nat.Acad.Sci.USA83:9373-9377;Turner等人,1987,J.Am.Chem.Soc.109:3783-3785)。百分比互补性表示核酸分子中可与第二核酸序列形成氢键(例如,沃森-克里克碱基配对)的连续残基的百分数(例如,第一寡核苷酸中总共10个核苷酸中的5、6、7、8、9或10个核苷酸与具有10个核苷酸的第二核酸序列碱基配对分别代表50%、60%、70%、80%、90%和100%的互补性)。“完全互补性”意指核酸序列的所有连续残基与第二核酸序列中的相同数目的连续残基形成氢键。在一个实施方案中,本发明的dsRNA分子包含与一个或多个靶核酸分子或其部分互补的19至30(例如,19、20、21、22、23、24、25、26、27、28、29或30或更多个)个核苷酸。
在一个实施方案中,下调或减少CKAP5基因表达的本发明的dsRNA分子用于治疗、预防或减轻受试者或生物体的CKAP5相关疾病或病症(例如,癌症)。
在本发明的实施方案中,本发明的DsiRNA分子的每一个序列在长度上独立地为25至35个核苷酸,在具体实施方案中长度为25、26、27、28、29、30、31、32、33、34或35个核苷酸。在另一个实施方案中,本发明的DsiRNA双链体独立地包含25至30个碱基对(例如,25、26、27、28、29或30个)。在另一个实施方案中,本发明的DsiRNA分子的一条或多条链独立地包含与靶(CKAP5)核酸分子互补的19至35个核苷酸(例如,19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34或35)。在某些实施方案中,本发明的DsiRNA分子具有长度为25至34个核苷酸的双链化核苷酸的长度(例如,长度为25、26、27、28、29、30、31、32、33或34个核苷酸;任选地,所有这样的核苷酸碱基与相对链的同源核苷酸碱基配对)。(本发明的示例性DsiRNA分子示于图1和下文中。
如本文中所用,“细胞”以其通常的生物学意义使用,并且不是指整个多细胞生物体,例如,明确地不是指人。细胞可存在于生物体,例如鸟类、植物和哺乳动物诸如人、牛、绵羊、猿、猴、猪、狗和猫中。细胞可以是原核生物的(例如,细菌细胞)或真核生物的(例如,哺乳动物或植物细胞)。细胞可以体细胞或生殖细胞来源的、全能或多能性的、正在分裂的或非分裂的。细胞还可来源于配子或胚胎、干细胞或完全分化的细胞或可包含配子或胚胎、干细胞或完全分化的细胞。在某些方面内,术语“细胞”明确地指包含本公开内容的一个或多个分离的dsRNA分子的哺乳动物细胞,诸如人细胞。在特定方面,细胞具有含有dsRNA或dsRNA的分子,从而导致靶核酸的RNA干扰,以及包含进行RNAi所需的蛋白质和蛋白质复合物例如切丁酶和RISC。
在某些实施方案中,本发明的dsRNA是切丁酶底物siRNA(“DsiRNA”)。DsiRNA相较于不是切丁酶底物的抑制性核酸(“非-DsiRNA”)具有某些有利方面。这样的有利方面包括但不限于DsiRNA相对于非-DsiRNA的延长的作用时间,以及DsiRNA相较于非-DsiRNA(例如,19-23mersiRNA)的增强的抑制活性(当适当地配制每一种抑制性核酸并评估其在相同浓度下在哺乳动物细胞中的抑制活性(在该后一种情形中,DsiRNA将被鉴定为比非-DsiRNA更强效)时)。通常在配制浓度(例如,dsRNA的转染浓度)上最容易地实现DsiRNA相对于非-DsiRNA的增强的效力的检测,所述浓度导致DsiRNA引发对靶RNA(例如,mRNA)约30-70%的敲低活性。对于活性DsiRNA,最常见地在适当地配制的1nM或更低的体外哺乳动物细胞DsiRNA转染浓度下实现这样的水平的敲低活性,以及在某些情况下在200pM或更低、100pM或更低、50pM或更低、20pM或更低、10pM或更低、5pM或更低或甚至1pM或更低的DsiRNA转染浓度下观察到这样的水平的敲低活性。事实上,归因于DsiRNA间在其上观察到靶RNA的30-70%的敲低的精确浓度的可变性,通过在整个有效浓度范围内评估DsiRNA和非-DsiRNA的抑制活性构建IC50曲线是用于检测DsiRNA相对于非-DsiRNA抑制剂的增强的效力的优选方法。
在某些实施方案中,DsiRNA(在于切丁酶切割前最初形成的状态下)在于哺乳动物细胞中减少CKAP5靶基因表达上比其内含有的19、20、21、22或23个碱基对序列更高效。在某些这样的实施方案中,切丁酶切割前的DsiRNA比其内含有的19-21mer更高效。任选地,切丁酶切割前的DsiRNA比其内含有的合成的具有对称dTdT悬突(从而形成具有21个核苷酸链长度的拥有dTdT悬突的siRNA)的19个碱基对的双链体更高效。在某些实施方案中,DsiRNA比靶向针对本发明的DsiRNA引用的21个核苷酸的靶序列的至少19个核苷酸的19-23mersiRNA(例如,具有dTdT悬突的19个碱基对的多链体)更高效(不希望受理论束缚,DsiRNA的这样的靶位点的鉴定是通过DsiRNA的Ago2切割位点的鉴定来鉴定的;一旦针对DsiRNA确定了DsiRNA的Ago2切割位点,就可进行任何其它抑制性dsRNA的Ago2切割位点的鉴定,可将这些Ago2切割位点对齐,从而测定多个dsRNA的预测的靶核苷酸序列的比对)。在某些相关实施方案中,DsiRNA比靶向针对本发明的DsiRNA引用的21个核苷酸的靶序列的至少20个核苷酸的19-23mersiRNA更高效。任选地,DsiRNA比靶向针对本发明的DsiRNA引用的相同的21个核苷酸的靶序列的19-23mersiRNA更高效。在某些实施方案中,DsiRNA比靶向针对本发明的DsiRNA引用的相同的21个核苷酸的靶序列的任何21mersiRNA更高效。任选地,DsiRNA比靶向针对本发明的DsiRNA引用的相同的21个核苷酸的靶序列的任何21或22mersiRNA更高效。在某些实施方案中,DsiRNA比靶向针对本发明的DsiRNA引用的相同的21个核苷酸的靶序列的任何21、22或23mersiRNA更高效。如上文中指出的,最有效地对以1nM或更低的浓度适当地配制的(例如,利用适当的转染剂配制的)dsRNA进行这样的效力评估。任选地,进行IC50评估在整个有效抑制浓度的范围内评价活性,从而允许进行所测定的dsRNA的相对效力的强大比较。
直接添加本发明的dsRNA分子,或可将其与包装在脂质体内的脂质(例如,阳离子脂质)复合,或另外地递送至靶细胞或组织。可在将核酸或核酸复合物包含在生物聚合物或未包含在生物聚合物中的情况下,将它们通过直接皮肤施用、经皮施用或注射离体地或体内局部施用至相关组织。在具体实施方案中,本发明的核酸分子包含图1中显示的序列和下文中的示例性结构。这样的核酸分子的实例基本上由这些图中定义的序列和示例性结构组成。此外,当根据DsiRNA试剂的修饰模式的下文中的描述修饰这样的试剂时,图1中描述的结构的化学修饰形式以及下文中的示例性结构可用于针对图1的DsiRNA试剂和下文中的示例性结构描述的所有用途。
在另一个方面,本发明提供了含有一种或多种本发明的dsRNA分子的哺乳动物细胞。一种或多种dsRNA分子可独立地被靶向相同或不同的位点。
“RNA”意指包含至少1个,优选至少4、8和12个核糖核苷酸残基的分子。至少4、8或12个RNA残基可以是连接的。“核糖核苷酸”意指在β-D-呋喃核糖部分的2'位置上具有羟基的核苷酸。所述术语包括双链RNA、单链RNA、分离的RNA诸如部分纯化的RNA、基本上纯的RNA、合成RNA、重组产生的RNA,以及与天然存在的RNA相异在于一个或多个核苷酸的添加、缺失、置换和/或改变的改变的RNA。这样的改变可包括非核苷酸材料诸如至dsRNA的末端或内部例如在RNA的一个或多个核苷酸上的添加。本发明的RNA分子中的核苷酸还可包含非标准分子,诸如非天然存在的核苷酸或化学合成的核苷酸或脱氧核苷酸。这些改变的RNA可被称为天然存在的RNA的类似物。
“受试者”意指作为外植细胞的供体或受体的生物体或细胞本身。“受试者”还指可向其施用本发明的dsRNA试剂的生物体。受试者可以是哺乳动物或哺乳动物细胞,包括人或人细胞。
短语“药学上可接受的载体”是指用于治疗剂的施用的载体。示例性载体包括盐水、缓冲盐水、葡萄糖、水、甘油、乙醇及其组合。对于口服施用的药物,药学上可接受的载体药学上可接受的赋形剂诸如惰性稀释剂、崩解剂、粘合剂、润滑剂、甜味剂、调味剂、着色剂和防腐剂。合适的惰性稀释剂包括碳酸钠和碳酸钙、磷酸钠和磷酸钙以及乳糖,而玉米淀粉和海藻酸是合适的崩解剂。粘合剂可包括淀粉和明胶,而润滑剂(如果存在的话)通常将是硬脂酸镁、硬脂酸或滑石粉。如果需要,片剂可以用材料诸如单硬脂酸甘油酯或二硬脂酸甘油酯进行包衣,以延迟在胃肠道中的吸收。公开的dsRNA组合物中的药学上可接受的载体可以是胶束结构,诸如脂质体、衣壳、类壳体(capsoid)、聚合纳米胶囊或聚合物微胶囊。
聚合物纳米胶囊或微胶囊促进包封或结合的dsRNA至细胞中的运输和释放。它们包括聚合物和单体材料,特别是包括聚氰基丙烯酸丁酯。材料和制造方法的概要已经公布(参见Kreuter,1991)。在聚合/纳米粒子生成步骤中从单体和/或寡聚物前体形成的聚合物材料根据现有技术本身是已知的,制造纳米颗粒的领域内的普通技术人员可按照常规技能适当地选择的聚合物材料的分子量和分子量分布同样是已知的。
本发明的各种方法包括步骤,所述步骤包括将值、水平、特性、特征、性质等与“合适的对照”(在本文中可互换地称为“适当的对照”)相比较。“合适的对照”或“适当的对照”是本领域普通技术人员熟悉用于比较目的对照或标准。在一个实施方案中,“合适的对照”或“适当的对照”是在如本文中所述进行RNAi方法之前测定的值、水平、特性、特征、性质等。例如,可在将本发明的RNA沉默剂(例如,DsiRNA)引入细胞或生物体之前,测定转录速率、mRNA水平、翻译速率、蛋白质水平、生物活性、细胞特性或属性、基因型、表型等。在另一个实施方案中,“合适的对照”或“适当的对照”是在展现例如正常性状的细胞或有机体,例如对照或正常细胞或生物体中测定的值、水平、特性、特征、性质等。在另一个实施方案中,“合适的对照”或“适当的对照”是预定的值、水平、特性、特征、性质等。
术语“体外”具有其本领域公认的含义,例如,牵涉纯化的试剂或提取物,例如细胞提取物。术语“体内”也具有其本领域公认的含义,例如牵涉活细胞,例如永生化细胞、原代细胞、细胞系和/或生物体中的细胞。
如本文中所用,“治疗(treatment/treating)”被定义为对患者应用或施用治疗剂(例如,dsRNA试剂或编码其的载体或转基因),或对来自具有病症的患者的分离的组织或细胞系应用或施用治疗剂,目的在于治愈、愈合、缓解、解除、改变、补救、减轻、改善或影响疾病或病症,或疾病或病症的症状。术语“治疗”在本文中也用于预防性施用试剂的背景。术语“有效剂量(effectivedose)”或“有效药量(effectivedosage)”被定义为足以实现或至少部分实现所需效应的量。术语“治疗有效剂量”被定义为足以治愈或至少部分阻止已患所述疾病的患者的疾病及其并发症的量。术语“患者”包括接受预防性或治疗性治疗的人和其它哺乳动物受试者。
抗-CKAP5DsiRNA试剂的结构
在某些实施方案中,本发明的抗-CKAP5DsiRNA试剂可具有下列结构:
在一个这样的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且“D”=DNA。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
本发明的DsiRNA可具有广泛的修饰模式(例如,2′-O-甲基RNA模式,例如,在延伸的DsiRNA试剂内)。本发明的DsiRNA的第二链的某些修饰模式呈现于下文中。
在一个实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体,并且“D”=DNA。顶链为有义链,底链为反义链。
在另一个这样的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且“D”=DNA。顶链为有义链,底链为反义链。
在另一个这样的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且“D”=DNA。顶链为有义链,底链为反义链。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且“D”=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M7”或“M7”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M6”或“M6”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M5”或“M5”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M4”或“M4”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M8”或“M8”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M3”或“M3”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M2”或“M2”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M1”或“M1”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M9”或“M9”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M10”或“M10”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M11”或“M11”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且”D”=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M12”或“M12”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且“D”=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M13”或“M13”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M21”或“M21”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M14”或“M14”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M15”或“M15”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M16”或“M16”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M17”或“M17”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M18”或“M18”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M19”或“M19”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M20”或“M20”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M22”或“M22”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M24”或“M24”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M25”或“M25”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M26”或“M26”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M27”或“M27”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M28”或“M28”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M29”或“M29”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M30”或“M30”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M31”或“M31”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M32”或“M32”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M34”或“M34”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M35”或“M35”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M37”或“M37”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M38”或“M38”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M40”或“M40”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M41”或“M41”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M36”或“M36”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M42”或“M42”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M43”或“M43”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RBA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M44”或“M44”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M45”或“M45”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M46”或“M46”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M47”或“M47”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M48”或“M48”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M52”或“M52”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M7*”或“M7*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M6*”或“M6*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M5*”或“M5*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M4*”或“M4*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M8*”或“M8*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M2*”或“M2*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M10*”或“M10*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M11*”或“M11*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M13*”或“M13*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M14*”或“M14*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M15*”或“M15*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M16*”或“M16*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M17*”或“M17*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M18*”或“M18*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M19*”或“M19*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M20*”或“M20*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M22*”或“M22*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M24*”或“M24*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。
在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M25*”或“M25*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M26*”或“M26*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M27*”或“M27*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M28*”或“M28*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M29*”或“M29*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M34*”或“M34*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M35*”或“M35*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M37*”或“M37*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M38*”或“M38*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M40*”或“M40*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M41*”或“M41*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M36*”或“M36*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M42*”或“M42*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M43*”或“M43*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M44*”或“M44*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M46*”或“M46*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M47*”或“M47*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M48*”或“M48*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M52*”或“M52*”修饰模式。
在更多实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M54”或“M54”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M54*”或“M54*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体。并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M55”或“M55”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=ENA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M55*”或“M55*”修饰模式。
在更多实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M56”或“M56”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M56*”或“M56*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M57”或“M57”修饰模式。
在更多实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M57*”或“M57*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M58”或“M58”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M58*”或“M58*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M59”或“M59”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M59*”或“M59*”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M60”或“M60”修饰模式。
在更多实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M60*”或“M60*”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M61”或“M61”修饰模式。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M61*”或“M61*”修饰模式。
在更多实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体。顶链为有义链,底链为反义链。在一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,″Y″为由1-4个任选地为2′-O-甲基RNA单体的RNA单体组成的悬突结构域,并且加下划线的残基为2’-O-甲基RNA单体,并且″D″=DNA。顶链为有义链,底链为反义链。在另一个相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M62”或“M62”修饰模式。
在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且“X”=2’-O-甲基RNA。顶链为有义链,底链为反义链。在其它实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA并且″X″=2′-O-甲基RNA。顶链为有义链,底链为反义链。在另一相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。顶链为有义链,底链为反义链。该修饰模式在本文中也称为“AS-M62*”或“M62*”修饰模式。
在某些实施方案中,本发明的DsiRNA的有义链是被修饰-有义链修饰的具体示例性形式示于下文中,预期这样的经修饰的有义链可替代上文中显示的任何DsiRNA的有义链以产生包含与上面描绘的反义链退火的下面描绘的有义链的DsiRNA。示例性的有义链修饰模式包括:
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM1″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM2″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM3″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM4″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM5″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM6″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM7″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM8″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM9″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM10″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM11″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM12″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM13″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM14″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM15″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM16″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM17″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM18″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM19″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM20″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM21″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM23″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM24″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM25″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM30″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM31″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM32″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM33″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM34″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM35″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM36″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM37″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM38″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM39″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM40″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM41″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM42″
5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′″SM43″
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′
5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′″SM22″
其中″X″=RNA,“X”=2’-O-甲基RNA,并且″D″=DNA。
还可将上述修饰模式掺入例如下文中描述的延伸的DsiRNA结构和错配和/或磨损的DsiRNA结构。
在另一个实施方案中,DsiRNA包含具有等同长度的、具有1-3个用于确定切丁酶切割方向的错配残基的链(具体地,当第一链与第二链彼此退火时,DsiRNA的第一链上的位置1、2或3的一个或多个(当从3′末端残基开始编号时)与第二链上的5′末端区域的对应残基错配)。显示了具有两个末端错配残基的示例性27merDsiRNA试剂:
其中“X”=RNA,“M”=当链退火时不与另外的互补链的对应的“M”残基碱基配对(氢键)的核酸残基(RNA、DNA或非天然或经修饰的核酸)。这样的试剂的任何残基可任选地是2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位,如对于上述不对称的试剂所显示的,也可用于上述“平端/磨损”DsiRNA试剂。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链。
在某些另外的实施方案中,本发明提供了用于RNA干扰(RNAi)的组合物,其在双链核酸(dsRNA)的区域内具有一个或多个碱基配对的脱氧核糖核苷酸,所述脱氧核糖核苷酸被定位在预测的有义链切丁酶切割位点的3′和预测的反义链切丁酶切割位点的对应的5′。本发明的组合物包含作为前体分子的dsRNA,即,本发明的dsRNA经历体内加工以产生活性小干扰核酸(siRNA)。dsRNA被切丁酶切工成掺入RISC的活性siRNA。
在某些实施方案中,本发明的DsiRNA试剂可具有下列示例性结构(要指出的是,在一个具体实例中可将任何下列示例性结构例如与上述结构的底链修饰模式组合,将上述结构的任何结构中显示的底链修饰模式用于下列结构的任何结构的底链的27个最3′残基;在另一个具体实例中,将上述结构的任何结构中显示的底链的23个最3′残基上的底链修饰模式用于下列结构的任何结构的底链的23个最3′残基):
在一个这样的实施方案中,DsiRNA包含下列(示例性“右延伸的”、“DNA延伸的”DsiRNA):
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*DNXX-5’
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
在相关实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-5’
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
在另外的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*DNZZ-5′
其中″X″=RNA,″X″=2′-O-甲基RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个这样的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*DNZZ-5’
其中″X″=RNA,″X″=2′-O-甲基RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个这样的实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*DNDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*DNZZ-5’
其中″X″=RNA,″X″=2′-O-甲基RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个实施方案中,DsiRNA包含:
5′-XXXXXXXXXXXXXXXXXXXXXXXXN*[X1/D1]NDD-3′
3′-YXXXXXXXXXXXXXXXXXXXXXXXXN*[X2/D2]NZZ-5’
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10,其中至少一个D1N存在于顶链中并且与存在于底链中的对应的D2N碱基配对。任选地,D1N和D1N+1与对应的D2N和D2N+1碱基配对;D1N、D1N+1和D1N+2与对应的D2N、D1N+1和D1N+2等碱基配对。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在本文中描述的结构中,有义链或反义链的5′可任选地包含磷酸基团。
在另一个实施方案中,DNA:DNA-延伸的DsiRNA包含具有等同长度的、具有1-3个用于确定切丁酶切割方向的错配残基的链(具体地,当第一链与第二链彼此退火时,DsiRNA的第一链上的位置1、2或3的一个或多个(当从3′末端残基开始编号时)与第二链上的5′末端区域的对应残基错配)。显示了具有两个末端错配残基的示例性DNA:DNA-延伸的DsiRNA试剂:
其中“X”=RNA,“M”=当链退火时不与另外的互补链的对应的“M”残基碱基配对(氢键)的核酸残基(RNA、DNA或非天然或经修饰的核酸),″D″=DNA并且“N”=1至50或更多,但任选地为1-15或,任选地,1-8。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。这样的试剂的任何残基可任选地为2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位,如对于上述不对称的试剂所显示的,也可用于上述“平端/磨损的”DsiRNA试剂。在一个实施方案中,顶链(第一链)为有义链,底链(第二链)为反义链。或者,底链为有义链,顶链为反义链。还可将平行于上文中针对不对称/悬突试剂显示的那些修饰和模式的修饰和DNA:DNA延伸模式掺入这样的“平端/磨损的”试剂。
在一个实施方案中,提供了长度延伸的DsiRNA试剂,其包含定位在被构建来通过丁酶切割的特定方向起作用的位点上的脱氧核糖核苷酸,然而这不需要碱基配对的脱氧核糖核苷酸存在于dsRNA结构中。显示了这样的分子的示例性结构:
5′-XXXXXXXXXXXXXXXXXXXDDXX-3′
3′-YXXXXXXXXXXXXXXXXXDDXXXX-5′
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且″D″=DNA。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。上述结构被构建来迫使切丁酶切割最小的21mer双链体作为其主要加工后形式。在其中上述结构的底链是反义链的实施方案中,2个脱氧核糖核苷酸残基在反义链的5′末端的最后和倒数第二个残基上的定位将帮助减小脱靶效应(因为先前的研究已显示来自反义链的5′末端的至少倒数第二位置的2’-O-甲基修饰减小脱靶效应;参见,例如,US2007/0223427)。
在一个实施方案中,DsiRNA包含下列(示例性“左延伸的”,“DNA延伸的”DsiRNA):
5′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*Y-3′
3′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*-5’
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,″D″=DNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
在相关实施方案中,DsiRNA包含:
5′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*DD-3′
3′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*XX-5’
其中″X″=RNA,任选地2′-O-甲基RNA单体″D″=DNA,“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
在另外的实施方案中,DsiRNA包含:
5′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*DD-3′
3′-DN XXXXXXXXXXXXXXXXXXXXXXXXN*ZZ-5’
其中″X″=RNA,任选地2′-O-甲基RNA单体″D″=DNA,“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。“Z”=DNA或RNA。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个这样的实施方案中,DsiRNA包含:
5′-DNXXXXXXXXXXXXXXXXXXXXXXXXN*DD-3′
3′-DN XXXXXXXXXXXXXXXXXXXXXXXXN*ZZ-5’
其中″X″=RNA,任选地2′-O-甲基RNA单体″D″=DNA,“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。“Z”=DNA或RNA。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个这样的实施方案中,DsiRNA包含:
5′-DNZZXXXXXXXXXXXXXXXXXXXXXXXXN*DD-3′
3′-DN XXXXXXXXXXXXXXXXXXXXXXXXXXN*ZZ-5’
其中″X″=RNA,″X″=2′-O-甲基RNA,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个这样的实施方案中,DsiRNA包含:
5′-DNZZXXXXXXXXXXXXXXXXXXXXXXXXN*Y-3′
3′-DN XXXXXXXXXXXXXXXXXXXXXXXXXXN*-5’
其中″X″=RNA,″X″=2′-O-甲基RNA,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个实施方案中,DsiRNA包含:
5′-[X1/D1]NXXXXXXXXXXXXXXXXXXXXXXXXN*DD-3′
3′-[X2/D2]NXXXXXXXXXXXXXXXXXXXXXXXXN*ZZ-5’
其中″X″=RNA,″D″=DNA,“Z”=DNA或RNA,并且“N”=1至50或更多,但任选地为1-8或1-10,其中至少一个D1N存在于顶链中并且与底链中的对应的D2N碱基配对。任选地,D1N和D1N+1与对应的D2N和D2N+1碱基配对;D1N、D1N+1和D1N+2与对应的D2N、D1N+1和D1N+2等碱基配对。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在相关实施方案中,DsiRNA包含:
5′-[X1/D1]NXXXXXXXXXXXXXXXXXXXXXXXXN*Y-3′
3′-[X2/D2]NXXXXXXXXXXXXXXXXXXXXXXXXN*-5’
其中″X″=RNA,″D″=DNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且“N”=1至50或更多,但任选地为1-8或1-10,其中至少一个D1N存在于顶链中并且与底链中的对应的D2N碱基配对。任选地,D1N和D1N+1与对应的D2N和D2N+1碱基配对;D1N、D1N+1和D1N+2与对应的D2N、D1N+1和D1N+2等碱基配对。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链为有义链,顶链为反义链,2’-O-甲基RNA单体位于沿上述示意图中当前描述的顶链而非底链的交替残基上。
在另一个实施方案中,DNA:DNA-延伸的DsiRNA包含具有等同长度的、具有1-3个用于确定切丁酶切割方向的错配残基的链(具体地,当第一链与第二链彼此退火时,DsiRNA的第一链上的位置1、2或3的一个或多个(当从3′末端残基开始编号时)与第二链上的5′末端区域的对应残基错配)。显示了具有两个末端错配残基的示例性DNA:DNA-延伸的DsiRNA试剂:
其中“X”=RNA,“M”=当链退火时不与另外的互补链的对应的“M”残基碱基配对(氢键)的核酸残基(RNA、DNA或非天然或经修饰的核酸),″D″=DNA并且“N”=1至50或更多,但任选地为1-8或1-10。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。这样的试剂的任何残基可任选地为2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位,如对于上述不对称的试剂所显示的,也可用于上述“平端/磨损的”DsiRNA试剂。在一个实施方案中,顶链(第一链)为有义链,底链(第二链)为反义链。或者,底链为有义链,顶链为反义链。还可将平行于上文中针对不对称/悬突试剂显示的那些修饰和模式的修饰和DNA:DNA延伸模式掺入这样的“平端/磨损的”试剂。
在另一个实施方案中,提供了长度延伸的DsiRNA试剂,其包含定位在被构建来通过丁酶切割的特定方向起作用的位点上的脱氧核糖核苷酸,然而这不需要碱基配对的脱氧核糖核苷酸存在于dsRNA结构中。显示了这样的分子的示例性结构:
5′-XXDDXXXXXXXXXXXXXXXXXXXXN*Y-3′
3′-DDXXXXXXXXXXXXXXXXXXXXXXN*-5′
或
5′-XDXDXXXXXXXXXXXXXXXXXXXXN*Y-3′
3′-DXDXXXXXXXXXXXXXXXXXXXXXN*-5′
其中″X″=RNA,″Y″为任选的由0-10个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域-在某些实施方案中,“Y”为由1-4个任选地为2’-O-甲基RNA单体的RNA单体组成的悬突结构域,并且″D″=DNA。“N*”=0至15或更多,但任选地为0、1、2、3、4、5或6。在一个实施方案中,顶链为有义链,底链为反义链。或者,底链是有义链并且顶链是反义链。
在其中上述结构的底链是反义链的上述实施方案的任何实施方案中,反义链的5′末端的最后和倒数第二残基上的两个脱氧核糖核苷酸残基的定位将帮助减小脱靶效应(因为先前的研究已显示来自反义链的5′末端的至少倒数第二位置的2’-O-甲基修饰减小脱靶效应;参见,例如,US2007/0223427)。
在某些实施方案中,上述结构的“D”残基包括至少一个PS-DNA或PS-RNA。任选地,上述结构的“D”残基包括至少一个抑制切丁酶切割的经修饰的核苷酸。
虽然上述“DNA延伸的”DsiRNA试剂可被分类为“左延伸的”或“右延伸的”,还可产生在单一试剂中包含含有左-和右-延伸的DNA的序列的DsiRNA试剂(例如,围绕核心dsRNA结构的两个侧翼序列都是dsDNA延伸),并且以与本文中针对“右延伸的”和“左延伸的”试剂描述的方式相似的方式进行使用。
在一些实施方案中,本发明的DsiRNA还包含连接DNA:DNA延伸的DsiRNA试剂的有义链与反义链的连接部分或结构域。任选地,这样的连接部分结构域连接有义链的3′末端和反义链的5′末端。连接部分可以是化学(非核苷酸)接头,诸如寡聚亚甲基二醇接头、寡聚乙二醇接头或其它本领域公认的接头部分。或者,接头可以是核苷酸接头,任选地包括延伸环和/或四环。
在一个实施方案中,DsiRNA试剂具有不对称结构,有义链具有25-碱基对长度,而反义链具有拥有1-4个碱基3′悬突(例如,1碱基3′悬突、2碱基3′悬突、3碱基3′悬突或4碱基3′悬突)的27-碱基对长度。在另一个实施方案中,该DsiRNA试剂具有还在有义链的3′末端上含有2个脱氧核苷酸的不对称结构。
在另一个实施方案中,DsiRNA试剂具有不对称结构,有义链具有25-碱基对长度,而反义链具有拥有1-4碱基3′悬突(例如,1碱基3′悬突、2碱基3′悬突、3碱基3′悬突或4碱基3′悬突)的27-碱基对长度。在另一个实施方案中,该DsiRNA试剂具有还在反义链的3′末端上含有2个脱氧核苷酸的不对称结构。
本发明的示例性CKAP5靶向DsiRNA试剂及它们的相关CKAP5靶序列包括下列试剂和序列,示于下文中的系列表中::
表编号:
(2)选择的人抗-CKAP5DsiRNA试剂(不对称的);
(3)选择的人抗-CKAP5DsiRNA,未修饰的双链体(不对称的);
(4)CKAP5mRNA中的DsiRNA靶序列(21mer);
(5)选择的人抗-CKAP5“平端/磨损”DsiRNA;
(6)选择的人抗-CKAP5“平端/平端”DsiRNA;和
(7)CKAP5mRNA中的DsiRNA组分19个核苷酸的靶序列
表2:选择的人抗-CKAP5DsiRNA试剂(不对称的)
5'-GAAGCACAAUGGGAGAUGACAGUga-3'(SEQIDNO:1)
3'-ACCUUCGUGUUACCCUCUACUGUCACU-5'(SEQIDNO:577)
CKAP5-143靶:5'-TGGAAGCACAATGGGAGATGACAGTGA-3'(SEQIDNO:1153)
5'-AGCACAAUGGGAGAUGACAGUGAgt-3'(SEQIDNO:2)
3'-CUUCGUGUUACCCUCUACUGUCACUCA-5'(SEQIDNO:578)
CKAP5-145靶:5'-GAAGCACAATGGGAGATGACAGTGAGT-3'(SEQIDNO:1154)
5'-CACAAUGGGAGAUGACAGUGAGUgg-3'(SEQIDNO:3)
3'-UCGUGUUACCCUCUACUGUCACUCACC-5'(SEQIDNO:579)
CKAP5-147靶:5'-AGCACAATGGGAGATGACAGTGAGTGG-3'(SEQIDNO:1155)
5'-CAAUGGGAGAUGACAGUGAGUGGtt-3'(SEQIDNO:4)
3'-GUGUUACCCUCUACUGUCACUCACCAA-5'(SEQIDNO:580)
CKAP5-149靶:5'-CACAATGGGAGATGACAGTGAGTGGTT-3'(SEQIDNO:1156)
5'-AUGGGAGAUGACAGUGAGUGGUUga-3'(SEQIDNO:5)
3'-GUUACCCUCUACUGUCACUCACCAACU-5'(SEQIDNO:581)
CKAP5-151靶:5'-CAATGGGAGATGACAGTGAGTGGTTGA-3'(SEQIDNO:1157)
5'-GGGAGAUGACAGUGAGUGGUUGAaa-3'(SEQIDNO:6)
3'-UACCCUCUACUGUCACUCACCAACUUU-5'(SEQIDNO:582)
CKAP5-153靶:5'-ATGGGAGATGACAGTGAGTGGTTGAAA-3'(SEQIDNO:1158)
5'-GAGAUGACAGUGAGUGGUUGAAAct-3'(SEQIDNO:7)
3'-CCCUCUACUGUCACUCACCAACUUUGA-5'(SEQIDNO:583)
CKAP5-155靶:5'-GGGAGATGACAGTGAGTGGTTGAAACT-3'(SEQIDNO:1159)
5'-GAUGACAGUGAGUGGUUGAAACUgc-3'(SEQIDNO:8)
3'-CUCUACUGUCACUCACCAACUUUGACG-5'(SEQIDNO:584)
CKAP5-157靶:5'-GAGATGACAGTGAGTGGTTGAAACTGC-3'(SEQIDNO:1160)
5'-UGACAGUGAGUGGUUGAAACUGCca-3'(SEQIDNO:9)
3'-CUACUGUCACUCACCAACUUUGACGGU-5'(SEQIDNO:585)
CKAP5-159靶:5'-GATGACAGTGAGTGGTTGAAACTGCCA-3'(SEQIDNO:1161)
5'-GAAGAUCUUCCAGAAAAUAAAGGat-3'(SEQIDNO:10)
3'-GACUUCUAGAAGGUCUUUUAUUUCCUA-5'(SEQIDNO:586)
CKAP5-246靶:5'-CTGAAGATCTTCCAGAAAATAAAGGAT-3'(SEQIDNO:1162)
5'-AGAUCUUCCAGAAAAUAAAGGAUga-3'(SEQIDNO:11)
3'-CUUCUAGAAGGUCUUUUAUUUCCUACU-5'(SEQIDNO:587)
CKAP5-248靶:5'-GAAGATCTTCCAGAAAATAAAGGATGA-3'(SEQIDNO:1163)
5'-AUCUUCCAGAAAAUAAAGGAUGAaa-3'(SEQIDNO:12)
3'-UCUAGAAGGUCUUUUAUUUCCUACUUU-5'(SEQIDNO:588)
CKAP5-250靶:5'-AGATCTTCCAGAAAATAAAGGATGAAA-3'(SEQIDNO:1164)
5'-CUUCCAGAAAAUAAAGGAUGAAAag-3'(SEQIDNO:13)
3'-UAGAAGGUCUUUUAUUUCCUACUUUUC-5'(SEQIDNO:589)
CKAP5-252靶:5'-ATCTTCCAGAAAATAAAGGATGAAAAG-3'(SEQIDNO:1165)
5'-UCCAGAAAAUAAAGGAUGAAAAGag-3'(SEQIDNO:14)
3'-GAAGGUCUUUUAUUUCCUACUUUUCUC-5'(SEQIDNO:590)
CKAP5-254靶:5'-CTTCCAGAAAATAAAGGATGAAAAGAG-3'(SEQIDNO:1166)
5'-CAGAAAAUAAAGGAUGAAAAGAGcc-3'(SEQIDNO:15)
3'-AGGUCUUUUAUUUCCUACUUUUCUCGG-5'(SEQIDNO:591)
CKAP5-256靶:5'-TCCAGAAAATAAAGGATGAAAAGAGCC-3'(SEQIDNO:1167)
5'-GAAAAUAAAGGAUGAAAAGAGCCca-3'(SEQIDNO:16)
3'-GUCUUUUAUUUCCUACUUUUCUCGGGU-5'(SEQIDNO:592)
CKAP5-258靶:5'-CAGAAAATAAAGGATGAAAAGAGCCCA-3'(SEQIDNO:1168)
5'-AAAUAAAGGAUGAAAAGAGCCCAga-3'(SEQIDNO:17)
3'-CUUUUAUUUCCUACUUUUCUCGGGUCU-5'(SEQIDNO:593)
CKAP5-260靶:5'-GAAAATAAAGGATGAAAAGAGCCCAGA-3'(SEQIDNO:1169)
5'-UCAAAAAAUUUGUCACUGAUUCCaa-3'(SEQIDNO:18)
3'-CUAGUUUUUUAAACAGUGACUAAGGUU-5'(SEQIDNO:594)
CKAP5-308靶:5'-GATCAAAAAATTTGTCACTGATTCCAA-3'(SEQIDNO:1170)
5'-AAAAAAUUUGUCACUGAUUCCAAtg-3'(SEQIDNO:19)
3'-AGUUUUUUAAACAGUGACUAAGGUUAC-5'(SEQIDNO:595)
CKAP5-310靶:5'-TCAAAAAATTTGTCACTGATTCCAATG-3'(SEQIDNO:1171)
5'-AAAAUUUGUCACUGAUUCCAAUGca-3'(SEQIDNO:20)
3'-UUUUUUAAACAGUGACUAAGGUUACGU-5'(SEQIDNO:596)
CKAP5-312靶:5'-AAAAAATTTGTCACTGATTCCAATGCA-3'(SEQIDNO:1172)
5'-AAUUUGUCACUGAUUCCAAUGCAgt-3'(SEQIDNO:21)
3'-UUUUAAACAGUGACUAAGGUUACGUCA-5'(SEQIDNO:597)
CKAP5-314靶:5'-AAAATTTGTCACTGATTCCAATGCAGT-3'(SEQIDNO:1173)
5'-UUUGUCACUGAUUCCAAUGCAGUgg-3'(SEQIDNO:22)
3'-UUAAACAGUGACUAAGGUUACGUCACC-5'(SEQIDNO:598)
CKAP5-316靶:5'-AATTTGTCACTGATTCCAATGCAGTGG-3'(SEQIDNO:1174)
5'-UGUCACUGAUUCCAAUGCAGUGGtt-3'(SEQIDNO:23)
3'-AAACAGUGACUAAGGUUACGUCACCAA-5'(SEQIDNO:599)
CKAP5-318靶:5'-TTTGTCACTGATTCCAATGCAGTGGTT-3'(SEQIDNO:1175)
5'-UCACUGAUUCCAAUGCAGUGGUUca-3'(SEQIDNO:24)
3'-ACAGUGACUAAGGUUACGUCACCAAGU-5'(SEQIDNO:600)
CKAP5-320靶:5'-TGTCACTGATTCCAATGCAGTGGTTCA-3'(SEQIDNO:1176)
5'-ACUGAUUCCAAUGCAGUGGUUCAat-3'(SEQIDNO:25)
3'-AGUGACUAAGGUUACGUCACCAAGUUA-5'(SEQIDNO:601)
CKAP5-322靶:5'-TCACTGATTCCAATGCAGTGGTTCAAT-3'(SEQIDNO:1177)
5'-UGAUUCCAAUGCAGUGGUUCAAUtg-3'(SEQIDNO:26)
3'-UGACUAAGGUUACGUCACCAAGUUAAC-5'(SEQIDNO:602)
CKAP5-324靶:5'-ACTGATTCCAATGCAGTGGTTCAATTG-3'(SEQIDNO:1178)
5'-AUUCCAAUGCAGUGGUUCAAUUGaa-3'(SEQIDNO:27)
3'-ACUAAGGUUACGUCACCAAGUUAACUU-5'(SEQIDNO:603)
CKAP5-326靶:5'-TGATTCCAATGCAGTGGTTCAATTGAA-3'(SEQIDNO:1179)
5'-UCCAAUGCAGUGGUUCAAUUGAAag-3'(SEQIDNO:28)
3'-UAAGGUUACGUCACCAAGUUAACUUUC-5'(SEQIDNO:604)
CKAP5-328靶:5'-ATTCCAATGCAGTGGTTCAATTGAAAG-3'(SEQIDNO:1180)
5'-CAAUGCAGUGGUUCAAUUGAAAGga-3'(SEQIDNO:29)
3'-AGGUUACGUCACCAAGUUAACUUUCCU-5'(SEQIDNO:605)
CKAP5-330靶:5'-TCCAATGCAGTGGTTCAATTGAAAGGA-3'(SEQIDNO:1181)
5'-AUGCAGUGGUUCAAUUGAAAGGAtt-3'(SEQIDNO:30)
3'-GUUACGUCACCAAGUUAACUUUCCUAA-5'(SEQIDNO:606)
CKAP5-332靶:5'-CAATGCAGTGGTTCAATTGAAAGGATT-3'(SEQIDNO:1182)
5'-GCAGUGGUUCAAUUGAAAGGAUUag-3'(SEQIDNO:31)
3'-UACGUCACCAAGUUAACUUUCCUAAUC-5'(SEQIDNO:607)
CKAP5-334靶:5'-ATGCAGTGGTTCAATTGAAAGGATTAG-3'(SEQIDNO:1183)
5'-AGUGGUUCAAUUGAAAGGAUUAGaa-3'(SEQIDNO:32)
3'-CGUCACCAAGUUAACUUUCCUAAUCUU-5'(SEQIDNO:608)
CKAP5-336靶:5'-GCAGTGGTTCAATTGAAAGGATTAGAA-3'(SEQIDNO:1184)
5'-AAGAUCAUAGUGGCCUGUAUAGAga-3'(SEQIDNO:33)
3'-GGUUCUAGUAUCACCGGACAUAUCUCU-5'(SEQIDNO:609)
CKAP5-565靶:5'-CCAAGATCATAGTGGCCTGTATAGAGA-3'(SEQIDNO:1185)
5'-GAUCAUAGUGGCCUGUAUAGAGAca-3'(SEQIDNO:34)
3'-UUCUAGUAUCACCGGACAUAUCUCUGU-5'(SEQIDNO:610)
CKAP5-567靶:5'-AAGATCATAGTGGCCTGTATAGAGACA-3'(SEQIDNO:1186)
5'-UCAUAGUGGCCUGUAUAGAGACAct-3'(SEQIDNO:35)
3'-CUAGUAUCACCGGACAUAUCUCUGUGA-5'(SEQIDNO:611)
CKAP5-569靶:5'-GATCATAGTGGCCTGTATAGAGACACT-3'(SEQIDNO:1187)
5'-CACUGAGGAAAGCCUUAAGUGAAtt-3'(SEQIDNO:36)
3'-CUGUGACUCCUUUCGGAAUUCACUUAA-5'(SEQIDNO:612)
CKAP5-590靶:5'-GACACTGAGGAAAGCCTTAAGTGAATT-3'(SEQIDNO:1188)
5'-CUGAGGAAAGCCUUAAGUGAAUUtg-3'(SEQIDNO:37)
3'-GUGACUCCUUUCGGAAUUCACUUAAAC-5'(SEQIDNO:613)
CKAP5-592靶:5'-CACTGAGGAAAGCCTTAAGTGAATTTG-3'(SEQIDNO:1189)
5'-GAGGAAAGCCUUAAGUGAAUUUGgt-3'(SEQIDNO:38)
3'-GACUCCUUUCGGAAUUCACUUAAACCA-5'(SEQIDNO:614)
CKAP5-594靶:5'-CTGAGGAAAGCCTTAAGTGAATTTGGT-3'(SEQIDNO:1190)
5'-GGAAAGCCUUAAGUGAAUUUGGUtc-3'(SEQIDNO:39)
3'-CUCCUUUCGGAAUUCACUUAAACCAAG-5'(SEQIDNO:615)
CKAP5-596靶:5'-GAGGAAAGCCTTAAGTGAATTTGGTTC-3'(SEQIDNO:1191)
5'-AAAGCCUUAAGUGAAUUUGGUUCca-3'(SEQIDNO:40)
3'-CCUUUCGGAAUUCACUUAAACCAAGGU-5'(SEQIDNO:616)
CKAP5-598靶:5'-GGAAAGCCTTAAGTGAATTTGGTTCCA-3'(SEQIDNO:1192)
5'-AGCCUUAAGUGAAUUUGGUUCCAaa-3'(SEQIDNO:41)
3'-UUUCGGAAUUCACUUAAACCAAGGUUU-5'(SEQIDNO:617)
CKAP5-600靶:5'-AAAGCCTTAAGTGAATTTGGTTCCAAA-3'(SEQIDNO:1193)
5'-CCUUAAGUGAAUUUGGUUCCAAAat-3'(SEQIDNO:42)
3'-UCGGAAUUCACUUAAACCAAGGUUUUA-5'(SEQIDNO:618)
CKAP5-602靶:5'-AGCCTTAAGTGAATTTGGTTCCAAAAT-3'(SEQIDNO:1194)
5'-UUAAGUGAAUUUGGUUCCAAAAUca-3'(SEQIDNO:43)
3'-GGAAUUCACUUAAACCAAGGUUUUAGU-5'(SEQIDNO:619)
CKAP5-604靶:5'-CCTTAAGTGAATTTGGTTCCAAAATCA-3'(SEQIDNO:1195)
5'-AAGUGAAUUUGGUUCCAAAAUCAtc-3'(SEQIDNO:44)
3'-AAUUCACUUAAACCAAGGUUUUAGUAG-5'(SEQIDNO:620)
CKAP5-606靶:5'-TTAAGTGAATTTGGTTCCAAAATCATC-3'(SEQIDNO:1196)
5'-GUGAAUUUGGUUCCAAAAUCAUCtt-3'(SEQIDNO:45)
3'-UUCACUUAAACCAAGGUUUUAGUAGAA-5'(SEQIDNO:621)
CKAP5-608靶:5'-AAGTGAATTTGGTTCCAAAATCATCTT-3'(SEQIDNO:1197)
5'-GAAUUUGGUUCCAAAAUCAUCUUgc-3'(SEQIDNO:46)
3'-CACUUAAACCAAGGUUUUAGUAGAACG-5'(SEQIDNO:622)
CKAP5-610靶:5'-GTGAATTTGGTTCCAAAATCATCTTGC-3'(SEQIDNO:1198)
5'-AUUUGGUUCCAAAAUCAUCUUGCtt-3'(SEQIDNO:47)
3'-CUUAAACCAAGGUUUUAGUAGAACGAA-5'(SEQIDNO:623)
CKAP5-612靶:5'-GAATTTGGTTCCAAAATCATCTTGCTT-3'(SEQIDNO:1199)
5'-CGUUCCCAACAAGAACUAGAAGCta-3'(SEQIDNO:48)
3'-AAGCAAGGGUUGUUCUUGAUCUUCGAU-5'(SEQIDNO:624)
CKAP5-847靶:5'-TTCGTTCCCAACAAGAACTAGAAGCTA-3'(SEQIDNO:1200)
5'-UUCCCAACAAGAACUAGAAGCUAaa-3'(SEQIDNO:49)
3'-GCAAGGGUUGUUCUUGAUCUUCGAUUU-5'(SEQIDNO:625)
CKAP5-849靶:5'-CGTTCCCAACAAGAACTAGAAGCTAAA-3'(SEQIDNO:1201)
5'-CCCAACAAGAACUAGAAGCUAAAtt-3'(SEQIDNO:50)
3'-AAGGGUUGUUCUUGAUCUUCGAUUUAA-5'(SEQIDNO:626)
CKAP5-851靶:5'-TTCCCAACAAGAACTAGAAGCTAAATT-3'(SEQIDNO:1202)
5'-CAACAAGAACUAGAAGCUAAAUUgg-3'(SEQIDNO:51)
3'-GGGUUGUUCUUGAUCUUCGAUUUAACC-5'(SEQIDNO:627)
CKAP5-853靶:5'-CCCAACAAGAACTAGAAGCTAAATTGG-3'(SEQIDNO:1203)
5'-ACAAGAACUAGAAGCUAAAUUGGaa-3'(SEQIDNO:52)
3'-GUUGUUCUUGAUCUUCGAUUUAACCUU-5'(SEQIDNO:628)
CKAP5-855靶:5'-CAACAAGAACTAGAAGCTAAATTGGAA-3'(SEQIDNO:1204)
5'-AACAGUCUGCUGGUGGAGAUGCUga-3'(SEQIDNO:53)
3'-UGUUGUCAGACGACCACCUCUACGACU-5'(SEQIDNO:629)
CKAP5-884靶:5'-ACAACAGTCTGCTGGTGGAGATGCTGA-3'(SEQIDNO:1205)
5'-CAGUCUGCUGGUGGAGAUGCUGAag-3'(SEQIDNO:54)
3'-UUGUCAGACGACCACCUCUACGACUUC-5'(SEQIDNO:630)
CKAP5-886靶:5'-AACAGTCTGCTGGTGGAGATGCTGAAG-3'(SEQIDNO:1206)
5'-GUGGUGAUGAUGGUGAUGAGGUGcc-3'(SEQIDNO:55)
3'-UCCACCACUACUACCACUACUCCACGG-5'(SEQIDNO:631)
CKAP5-914靶:5'-AGGTGGTGATGATGGTGATGAGGTGCC-3'(SEQIDNO:1207)
5'-GGUGAUGAUGGUGAUGAGGUGCCac-3'(SEQIDNO:56)
3'-CACCACUACUACCACUACUCCACGGUG-5'(SEQIDNO:632)
CKAP5-916靶:5'-GTGGTGATGATGGTGATGAGGTGCCAC-3'(SEQIDNO:1208)
5'-AUCCUUUCCAAACUUCCCAAAGAct-3'(SEQIDNO:57)
3'-UUUAGGAAAGGUUUGAAGGGUUUCUGA-5'(SEQIDNO:633)
CKAP5-976靶:5'-AAATCCTTTCCAAACTTCCCAAAGACT-3'(SEQIDNO:1209)
5'-CCUUUCCAAACUUCCCAAAGACUtt-3'(SEQIDNO:58)
3'-UAGGAAAGGUUUGAAGGGUUUCUGAAA-5'(SEQIDNO:634)
CKAP5-978靶:5'-ATCCTTTCCAAACTTCCCAAAGACTTT-3'(SEQIDNO:1210)
5'-UUUCCAAACUUCCCAAAGACUUUta-3'(SEQIDNO:59)
3'-GGAAAGGUUUGAAGGGUUUCUGAAAAU-5'(SEQIDNO:635)
CKAP5-980靶:5'-CCTTTCCAAACTTCCCAAAGACTTTTA-3'(SEQIDNO:1211)
5'-UCCAAACUUCCCAAAGACUUUUAtg-3'(SEQIDNO:60)
3'-AAAGGUUUGAAGGGUUUCUGAAAAUAC-5'(SEQIDNO:636)
CKAP5-982靶:5'-TTTCCAAACTTCCCAAAGACTTTTATG-3'(SEQIDNO:1212)
5'-CAAACUUCCCAAAGACUUUUAUGac-3'(SEQIDNO:61)
3'-AGGUUUGAAGGGUUUCUGAAAAUACUG-5'(SEQIDNO:637)
CKAP5-984靶:5'-TCCAAACTTCCCAAAGACTTTTATGAC-3'(SEQIDNO:1213)
5'-AACUUCCCAAAGACUUUUAUGACaa-3'(SEQIDNO:62)
3'-GUUUGAAGGGUUUCUGAAAAUACUGUU-5'(SEQIDNO:638)
CKAP5-986靶:5'-CAAACTTCCCAAAGACTTTTATGACAA-3'(SEQIDNO:1214)
5'-CUUCCCAAAGACUUUUAUGACAAaa-3'(SEQIDNO:63)
3'-UUGAAGGGUUUCUGAAAAUACUGUUUU-5'(SEQIDNO:639)
CKAP5-988靶:5'-AACTTCCCAAAGACTTTTATGACAAAA-3'(SEQIDNO:1215)
5'-UCCCAAAGACUUUUAUGACAAAAtt-3'(SEQIDNO:64)
3'-GAAGGGUUUCUGAAAAUACUGUUUUAA-5'(SEQIDNO:640)
CKAP5-990靶:5'-CTTCCCAAAGACTTTTATGACAAAATT-3'(SEQIDNO:1216)
5'-CCAAAGACUUUUAUGACAAAAUUga-3'(SEQIDNO:65)
3'-AGGGUUUCUGAAAAUACUGUUUUAACU-5'(SEQIDNO:641)
CKAP5-992靶:5'-TCCCAAAGACTTTTATGACAAAATTGA-3'(SEQIDNO:1217)
5'-AAAGACUUUUAUGACAAAAUUGAgg-3'(SEQIDNO:66)
3'-GGUUUCUGAAAAUACUGUUUUAACUCC-5'(SEQIDNO:642)
CKAP5-994靶:5'-CCAAAGACTTTTATGACAAAATTGAGG-3'(SEQIDNO:1218)
5'-AGACUUUUAUGACAAAAUUGAGGca-3'(SEQIDNO:67)
3'-UUUCUGAAAAUACUGUUUUAACUCCGU-5'(SEQIDNO:643)
CKAP5-996靶:5'-AAAGACTTTTATGACAAAATTGAGGCA-3'(SEQIDNO:1219)
5'-ACUUUUAUGACAAAAUUGAGGCAaa-3'(SEQIDNO:68)
3'-UCUGAAAAUACUGUUUUAACUCCGUUU-5'(SEQIDNO:644)
CKAP5-998靶:5'-AGACTTTTATGACAAAATTGAGGCAAA-3'(SEQIDNO:1220)
5'-UUUUAUGACAAAAUUGAGGCAAAaa-3'(SEQIDNO:69)
3'-UGAAAAUACUGUUUUAACUCCGUUUUU-5'(SEQIDNO:645)
CKAP5-1000靶:5'-ACTTTTATGACAAAATTGAGGCAAAAA-3'(SEQIDNO:1221)
5'-UUAUGACAAAAUUGAGGCAAAAAaa-3'(SEQIDNO:70)
3'-AAAAUACUGUUUUAACUCCGUUUUUUU-5'(SEQIDNO:646)
CKAP5-1002靶:5'-TTTTATGACAAAATTGAGGCAAAAAAA-3'(SEQIDNO:1222)
5'-AUGACAAAAUUGAGGCAAAAAAAtg-3'(SEQIDNO:71)
3'-AAUACUGUUUUAACUCCGUUUUUUUAC-5'(SEQIDNO:647)
CKAP5-1004靶:5'-TTATGACAAAATTGAGGCAAAAAAATG-3'(SEQIDNO:1223)
5'-AAUGGCAAGAGAGAAAAGAGGCCct-3'(SEQIDNO:72)
3'-UUUUACCGUUCUCUCUUUUCUCCGGGA-5'(SEQIDNO:648)
CKAP5-1025靶:5'-AAAATGGCAAGAGAGAAAAGAGGCCCT-3'(SEQIDNO:1224)
5'-AGGUUGUUGGAAAGGACACCAAUgt-3'(SEQIDNO:73)
3'-CUUCCAACAACCUUUCCUGUGGUUACA-5'(SEQIDNO:649)
CKAP5-1127靶:5'-GAAGGTTGTTGGAAAGGACACCAATGT-3'(SEQIDNO:1225)
5'-GUUGUUGGAAAGGACACCAAUGUca-3'(SEQIDNO:74)
3'-UCCAACAACCUUUCCUGUGGUUACAGU-5'(SEQIDNO:650)
CKAP5-1129靶:5'-AGGTTGTTGGAAAGGACACCAATGTCA-3'(SEQIDNO:1226)
5'-UGUUGGAAAGGACACCAAUGUCAtg-3'(SEQIDNO:75)
3'-CAACAACCUUUCCUGUGGUUACAGUAC-5'(SEQIDNO:651)
CKAP5-1131靶:5'-GTTGTTGGAAAGGACACCAATGTCATG-3'(SEQIDNO:1227)
5'-UUGGAAAGGACACCAAUGUCAUGtt-3'(SEQIDNO:76)
3'-ACAACCUUUCCUGUGGUUACAGUACAA-5'(SEQIDNO:652)
CKAP5-1133靶:5'-TGTTGGAAAGGACACCAATGTCATGTT-3'(SEQIDNO:1228)
5'-GGAAAGGACACCAAUGUCAUGUUgg-3'(SEQIDNO:77)
3'-AACCUUUCCUGUGGUUACAGUACAACC-5'(SEQIDNO:653)
CKAP5-1135靶:5'-TTGGAAAGGACACCAATGTCATGTTGG-3'(SEQIDNO:1229)
5'-AAAGGACACCAAUGUCAUGUUGGtg-3'(SEQIDNO:78)
3'-CCUUUCCUGUGGUUACAGUACAACCAC-5'(SEQIDNO:654)
CKAP5-1137靶:5'-GGAAAGGACACCAATGTCATGTTGGTG-3'(SEQIDNO:1230)
5'-AGGACACCAAUGUCAUGUUGGUGgc-3'(SEQIDNO:79)
3'-UUUCCUGUGGUUACAGUACAACCACCG-5'(SEQIDNO:655)
CKAP5-1139靶:5'-AAAGGACACCAATGTCATGTTGGTGGC-3'(SEQIDNO:1231)
5'-GACACCAAUGUCAUGUUGGUGGCtt-3'(SEQIDNO:80)
3'-UCCUGUGGUUACAGUACAACCACCGAA-5'(SEQIDNO:656)
CKAP5-1141靶:5'-AGGACACCAATGTCATGTTGGTGGCTT-3'(SEQIDNO:1232)
5'-GCUUUGGCAGCAAAAUGUCUUACtg-3'(SEQIDNO:81)
3'-ACCGAAACCGUCGUUUUACAGAAUGAC-5'(SEQIDNO:657)
CKAP5-1162靶:5'-TGGCTTTGGCAGCAAAATGTCTTACTG-3'(SEQIDNO:1233)
5'-UUUGGCAGCAAAAUGUCUUACUGgc-3'(SEQIDNO:82)
3'-CGAAACCGUCGUUUUACAGAAUGACCG-5'(SEQIDNO:658)
CKAP5-1164靶:5'-GCTTTGGCAGCAAAATGTCTTACTGGC-3'(SEQIDNO:1234)
5'-UGGCAGCAAAAUGUCUUACUGGCct-3'(SEQIDNO:83)
3'-AAACCGUCGUUUUACAGAAUGACCGGA-5'(SEQIDNO:659)
CKAP5-1166靶:5'-TTTGGCAGCAAAATGTCTTACTGGCCT-3'(SEQIDNO:1235)
5'-GCAGCAAAAUGUCUUACUGGCCUgg-3'(SEQIDNO:84)
3'-ACCGUCGUUUUACAGAAUGACCGGACC-5'(SEQIDNO:660)
CKAP5-1168靶:5'-TGGCAGCAAAATGTCTTACTGGCCTGG-3'(SEQIDNO:1236)
5'-AGCAAAAUGUCUUACUGGCCUGGct-3'(SEQIDNO:85)
3'-CGUCGUUUUACAGAAUGACCGGACCGA-5'(SEQIDNO:661)
CKAP5-1170靶:5'-GCAGCAAAATGTCTTACTGGCCTGGCT-3'(SEQIDNO:1237)
5'-AGAAAUUUGGACAAUAUGCAGGAca-3'(SEQIDNO:86)
3'-CUUCUUUAAACCUGUUAUACGUCCUGU-5'(SEQIDNO:662)
CKAP5-1208靶:5'-GAAGAAATTTGGACAATATGCAGGACA-3'(SEQIDNO:1238)
5'-AAAUUUGGACAAUAUGCAGGACAtg-3'(SEQIDNO:87)
3'-UCUUUAAACCUGUUAUACGUCCUGUAC-5'(SEQIDNO:663)
CKAP5-1210靶:5'-AGAAATTTGGACAATATGCAGGACATG-3'(SEQIDNO:1239)
5'-AUUUGGACAAUAUGCAGGACAUGtt-3'(SEQIDNO:88)
3'-UUUAAACCUGUUAUACGUCCUGUACAA-5'(SEQIDNO:664)
CKAP5-1212靶:5'-AAATTTGGACAATATGCAGGACATGTT-3'(SEQIDNO:1240)
5'-UUGGACAAUAUGCAGGACAUGUUgt-3'(SEQIDNO:89)
3'-UAAACCUGUUAUACGUCCUGUACAACA-5'(SEQIDNO:665)
CKAP5-1214靶:5'-ATTTGGACAATATGCAGGACATGTTGT-3'(SEQIDNO:1241)
5'-GGACAAUAUGCAGGACAUGUUGUgc-3'(SEQIDNO:90)
3'-AACCUGUUAUACGUCCUGUACAACACG-5'(SEQIDNO:666)
CKAP5-1216靶:5'-TTGGACAATATGCAGGACATGTTGTGC-3'(SEQIDNO:1242)
5'-ACAAUAUGCAGGACAUGUUGUGCca-3'(SEQIDNO:91)
3'-CCUGUUAUACGUCCUGUACAACACGGU-5'(SEQIDNO:667)
CKAP5-1218靶:5'-GGACAATATGCAGGACATGTTGTGCCA-3'(SEQIDNO:1243)
5'-AAUAUGCAGGACAUGUUGUGCCAac-3'(SEQIDNO:92)
3'-UGUUAUACGUCCUGUACAACACGGUUG-5'(SEQIDNO:668)
CKAP5-1220靶:5'-ACAATATGCAGGACATGTTGTGCCAAC-3'(SEQIDNO:1244)
5'-UAUGCAGGACAUGUUGUGCCAACca-3'(SEQIDNO:93)
3'-UUAUACGUCCUGUACAACACGGUUGGU-5'(SEQIDNO:669)
CKAP5-1222靶:5'-AATATGCAGGACATGTTGTGCCAACCA-3'(SEQIDNO:1245)
5'-UGCAGGACAUGUUGUGCCAACCAtc-3'(SEQIDNO:94)
3'-AUACGUCCUGUACAACACGGUUGGUAG-5'(SEQIDNO:670)
CKAP5-1224靶:5'-TATGCAGGACATGTTGTGCCAACCATC-3'(SEQIDNO:1246)
5'-CAGGACAUGUUGUGCCAACCAUCtt-3'(SEQIDNO:95)
3'-ACGUCCUGUACAACACGGUUGGUAGAA-5'(SEQIDNO:671)
CKAP5-1226靶:5'-TGCAGGACATGTTGTGCCAACCATCTT-3'(SEQIDNO:1247)
5'-CUCAAGUGGUACAAGCCCUGCAGga-3'(SEQIDNO:96)
3'-UGGAGUUCACCAUGUUCGGGACGUCCU-5'(SEQIDNO:672)
CKAP5-1274靶:5'-ACCTCAAGTGGTACAAGCCCTGCAGGA-3'(SEQIDNO:1248)
5'-CAAGUGGUACAAGCCCUGCAGGAgg-3'(SEQIDNO:97)
3'-GAGUUCACCAUGUUCGGGACGUCCUCC-5'(SEQIDNO:673)
CKAP5-1276靶:5'-CTCAAGTGGTACAAGCCCTGCAGGAGG-3'(SEQIDNO:1249)
5'-AGUGGUACAAGCCCUGCAGGAGGca-3'(SEQIDNO:98)
3'-GUUCACCAUGUUCGGGACGUCCUCCGU-5'(SEQIDNO:674)
CKAP5-1278靶:5'-CAAGTGGTACAAGCCCTGCAGGAGGCA-3'(SEQIDNO:1250)
5'-UGGUACAAGCCCUGCAGGAGGCAat-3'(SEQIDNO:99)
3'-UCACCAUGUUCGGGACGUCCUCCGUUA-5'(SEQIDNO:675)
CKAP5-1280靶:5'-AGTGGTACAAGCCCTGCAGGAGGCAAT-3'(SEQIDNO:1251)
5'-GUACAAGCCCUGCAGGAGGCAAUtg-3'(SEQIDNO:100)
3'-ACCAUGUUCGGGACGUCCUCCGUUAAC-5'(SEQIDNO:676)
CKAP5-1282靶:5'-TGGTACAAGCCCTGCAGGAGGCAATTG-3'(SEQIDNO:1252)
5'-ACAAGCCCUGCAGGAGGCAAUUGat-3'(SEQIDNO:101)
3'-CAUGUUCGGGACGUCCUCCGUUAACUA-5'(SEQIDNO:677)
CKAP5-1284靶:5'-GTACAAGCCCTGCAGGAGGCAATTGAT-3'(SEQIDNO:1253)
5'-AAGCCCUGCAGGAGGCAAUUGAUgc-3'(SEQIDNO:102)
3'-UGUUCGGGACGUCCUCCGUUAACUACG-5'(SEQIDNO:678)
CKAP5-1286靶:5'-ACAAGCCCTGCAGGAGGCAATTGATGC-3'(SEQIDNO:1254)
5'-GCCCUGCAGGAGGCAAUUGAUGCaa-3'(SEQIDNO:103)
3'-UUCGGGACGUCCUCCGUUAACUACGUU-5'(SEQIDNO:679)
CKAP5-1288靶:5'-AAGCCCTGCAGGAGGCAATTGATGCAA-3'(SEQIDNO:1255)
5'-CCUGCAGGAGGCAAUUGAUGCAAtc-3'(SEQIDNO:104)
3'-CGGGACGUCCUCCGUUAACUACGUUAG-5'(SEQIDNO:680)
CKAP5-1290靶:5'-GCCCTGCAGGAGGCAATTGATGCAATC-3'(SEQIDNO:1256)
5'-UGCAGGAGGCAAUUGAUGCAAUCtt-3'(SEQIDNO:105)
3'-GGACGUCCUCCGUUAACUACGUUAGAA-5'(SEQIDNO:681)
CKAP5-1292靶:5'-CCTGCAGGAGGCAATTGATGCAATCTT-3'(SEQIDNO:1257)
5'-CAGGAGGCAAUUGAUGCAAUCUUcc-3'(SEQIDNO:106)
3'-ACGUCCUCCGUUAACUACGUUAGAAGG-5'(SEQIDNO:682)
CKAP5-1294靶:5'-TGCAGGAGGCAATTGATGCAATCTTCC-3'(SEQIDNO:1258)
5'-GGAGGCAAUUGAUGCAAUCUUCCtt-3'(SEQIDNO:107)
3'-GUCCUCCGUUAACUACGUUAGAAGGAA-5'(SEQIDNO:683)
CKAP5-1296靶:5'-CAGGAGGCAATTGATGCAATCTTCCTT-3'(SEQIDNO:1259)
5'-AGGCAAUUGAUGCAAUCUUCCUUac-3'(SEQIDNO:108)
3'-CCUCCGUUAACUACGUUAGAAGGAAUG-5'(SEQIDNO:684)
CKAP5-1298靶:5'-GGAGGCAATTGATGCAATCTTCCTTAC-3'(SEQIDNO:1260)
5'-GCAAUUGAUGCAAUCUUCCUUACta-3'(SEQIDNO:109)
3'-UCCGUUAACUACGUUAGAAGGAAUGAU-5'(SEQIDNO:685)
CKAP5-1300靶:5'-AGGCAATTGATGCAATCTTCCTTACTA-3'(SEQIDNO:1261)
5'-ACUACCACACUACAGAACAUCAGtg-3'(SEQIDNO:110)
3'-AAUGAUGGUGUGAUGUCUUGUAGUCAC-5'(SEQIDNO:686)
CKAP5-1321靶:5'-TTACTACCACACTACAGAACATCAGTG-3'(SEQIDNO:1262)
5'-UACCACACUACAGAACAUCAGUGag-3'(SEQIDNO:111)
3'-UGAUGGUGUGAUGUCUUGUAGUCACUC-5'(SEQIDNO:687)
CKAP5-1323靶:5'-ACTACCACACTACAGAACATCAGTGAG-3'(SEQIDNO:1263)
5'-CCACACUACAGAACAUCAGUGAGga-3'(SEQIDNO:112)
3'-AUGGUGUGAUGUCUUGUAGUCACUCCU-5'(SEQIDNO:688)
CKAP5-1325靶:5'-TACCACACTACAGAACATCAGTGAGGA-3'(SEQIDNO:1264)
5'-ACACUACAGAACAUCAGUGAGGAtg-3'(SEQIDNO:113)
3'-GGUGUGAUGUCUUGUAGUCACUCCUAC-5'(SEQIDNO:689)
CKAP5-1327靶:5'-CCACACTACAGAACATCAGTGAGGATG-3'(SEQIDNO:1265)
5'-ACUACAGAACAUCAGUGAGGAUGtt-3'(SEQIDNO:114)
3'-UGUGAUGUCUUGUAGUCACUCCUACAA-5'(SEQIDNO:690)
CKAP5-1329靶:5'-ACACTACAGAACATCAGTGAGGATGTT-3'(SEQIDNO:1266)
5'-UACAGAACAUCAGUGAGGAUGUUtt-3'(SEQIDNO:115)
3'-UGAUGUCUUGUAGUCACUCCUACAAAA-5'(SEQIDNO:691)
CKAP5-1331靶:5'-ACTACAGAACATCAGTGAGGATGTTTT-3'(SEQIDNO:1267)
5'-CAGAACAUCAGUGAGGAUGUUUUag-3'(SEQIDNO:116)
3'-AUGUCUUGUAGUCACUCCUACAAAAUC-5'(SEQIDNO:692)
CKAP5-1333靶:5'-TACAGAACATCAGTGAGGATGTTTTAG-3'(SEQIDNO:1268)
5'-UUAGCAGUAAUGGAUAAUAAAAAtc-3'(SEQIDNO:117)
3'-AAAAUCGUCAUUACCUAUUAUUUUUAG-5'(SEQIDNO:693)
CKAP5-1354靶:5'-TTTTAGCAGTAATGGATAATAAAAATC-3'(SEQIDNO:1269)
5'-AGCAGUAAUGGAUAAUAAAAAUCca-3'(SEQIDNO:118)
3'-AAUCGUCAUUACCUAUUAUUUUUAGGU-5'(SEQIDNO:694)
CKAP5-1356靶:5'-TTAGCAGTAATGGATAATAAAAATCCA-3'(SEQIDNO:1270)
5'-CAGUAAUGGAUAAUAAAAAUCCAac-3'(SEQIDNO:119)
3'-UCGUCAUUACCUAUUAUUUUUAGGUUG-5'(SEQIDNO:695)
CKAP5-1358靶:5'-AGCAGTAATGGATAATAAAAATCCAAC-3'(SEQIDNO:1271)
5'-GUAAUGGAUAAUAAAAAUCCAACca-3'(SEQIDNO:120)
3'-GUCAUUACCUAUUAUUUUUAGGUUGGU-5'(SEQIDNO:696)
CKAP5-1360靶:5'-CAGTAATGGATAATAAAAATCCAACCA-3'(SEQIDNO:1272)
5'-ACCAUCAAGCAGCAGACAUCUCUtt-3'(SEQIDNO:121)
3'-GUUGGUAGUUCGUCGUCUGUAGAGAAA-5'(SEQIDNO:697)
CKAP5-1381靶:5'-CAACCATCAAGCAGCAGACATCTCTTT-3'(SEQIDNO:1273)
5'-CUACUUAAGCACAUCAAUGAUUCtg-3'(SEQIDNO:122)
3'-GUGAUGAAUUCGUGUAGUUACUAAGAC-5'(SEQIDNO:698)
CKAP5-1480靶:5'-CACTACTTAAGCACATCAATGATTCTG-3'(SEQIDNO:1274)
5'-ACUUAAGCACAUCAAUGAUUCUGct-3'(SEQIDNO:123)
3'-GAUGAAUUCGUGUAGUUACUAAGACGA-5'(SEQIDNO:699)
CKAP5-1482靶:5'-CTACTTAAGCACATCAATGATTCTGCT-3'(SEQIDNO:1275)
5'-UUAAGCACAUCAAUGAUUCUGCUcc-3'(SEQIDNO:124)
3'-UGAAUUCGUGUAGUUACUAAGACGAGG-5'(SEQIDNO:700)
CKAP5-1484靶:5'-ACTTAAGCACATCAATGATTCTGCTCC-3'(SEQIDNO:1276)
5'-AAGCACAUCAAUGAUUCUGCUCCtg-3'(SEQIDNO:125)
3'-AAUUCGUGUAGUUACUAAGACGAGGAC-5'(SEQIDNO:701)
CKAP5-1486靶:5'-TTAAGCACATCAATGATTCTGCTCCTG-3'(SEQIDNO:1277)
5'-GCACAUCAAUGAUUCUGCUCCUGaa-3'(SEQIDNO:126)
3'-UUCGUGUAGUUACUAAGACGAGGACUU-5'(SEQIDNO:702)
CKAP5-1488靶:5'-AAGCACATCAATGATTCTGCTCCTGAA-3'(SEQIDNO:1278)
5'-ACAUCAAUGAUUCUGCUCCUGAAgt-3'(SEQIDNO:127)
3'-CGUGUAGUUACUAAGACGAGGACUUCA-5'(SEQIDNO:703)
CKAP5-1490靶:5'-GCACATCAATGATTCTGCTCCTGAAGT-3'(SEQIDNO:1279)
5'-AUCAAUGAUUCUGCUCCUGAAGUca-3'(SEQIDNO:128)
3'-UGUAGUUACUAAGACGAGGACUUCAGU-5'(SEQIDNO:704)
CKAP5-1492靶:5'-ACATCAATGATTCTGCTCCTGAAGTCA-3'(SEQIDNO:1280)
5'-CAAUGAUUCUGCUCCUGAAGUCAga-3'(SEQIDNO:129)
3'-UAGUUACUAAGACGAGGACUUCAGUCU-5'(SEQIDNO:705)
CKAP5-1494靶:5'-ATCAATGATTCTGCTCCTGAAGTCAGA-3'(SEQIDNO:1281)
5'-AUGAUUCUGCUCCUGAAGUCAGAga-3'(SEQIDNO:130)
3'-GUUACUAAGACGAGGACUUCAGUCUCU-5'(SEQIDNO:706)
CKAP5-1496靶:5'-CAATGATTCTGCTCCTGAAGTCAGAGA-3'(SEQIDNO:1282)
5'-GAUUCUGCUCCUGAAGUCAGAGAtg-3'(SEQIDNO:131)
3'-UACUAAGACGAGGACUUCAGUCUCUAC-5'(SEQIDNO:707)
CKAP5-1498靶:5'-ATGATTCTGCTCCTGAAGTCAGAGATG-3'(SEQIDNO:1283)
5'-UUCUGCUCCUGAAGUCAGAGAUGcc-3'(SEQIDNO:132)
3'-CUAAGACGAGGACUUCAGUCUCUACGG-5'(SEQIDNO:708)
CKAP5-1500靶:5'-GATTCTGCTCCTGAAGTCAGAGATGCC-3'(SEQIDNO:1284)
5'-CUGCUCCUGAAGUCAGAGAUGCCgc-3'(SEQIDNO:133)
3'-AAGACGAGGACUUCAGUCUCUACGGCG-5'(SEQIDNO:709)
CKAP5-1502靶:5'-TTCTGCTCCTGAAGTCAGAGATGCCGC-3'(SEQIDNO:1285)
5'-GCUCCUGAAGUCAGAGAUGCCGCat-3'(SEQIDNO:134)
3'-GACGAGGACUUCAGUCUCUACGGCGUA-5'(SEQIDNO:710)
CKAP5-1504靶:5'-CTGCTCCTGAAGTCAGAGATGCCGCAT-3'(SEQIDNO:1286)
5'-GAUCAAAGAAUGUUCAGAAAAGGta-3'(SEQIDNO:135)
3'-UUCUAGUUUCUUACAAGUCUUUUCCAU-5'(SEQIDNO:711)
CKAP5-1617靶:5'-AAGATCAAAGAATGTTCAGAAAAGGTA-3'(SEQIDNO:1287)
5'-UCAAAGAAUGUUCAGAAAAGGUAga-3'(SEQIDNO:136)
3'-CUAGUUUCUUACAAGUCUUUUCCAUCU-5'(SEQIDNO:712)
CKAP5-1619靶:5'-GATCAAAGAATGTTCAGAAAAGGTAGA-3'(SEQIDNO:1288)
5'-AACCUGGAUGGAAAGAAACUAAUtt-3'(SEQIDNO:137)
3'-CUUUGGACCUACCUUUCUUUGAUUAAA-5'(SEQIDNO:713)
CKAP5-2090靶:5'-GAAACCTGGATGGAAAGAAACTAATTT-3'(SEQIDNO:1289)
5'-CCUGGAUGGAAAGAAACUAAUUUtc-3'(SEQIDNO:138)
3'-UUGGACCUACCUUUCUUUGAUUAAAAG-5'(SEQIDNO:714)
CKAP5-2092靶:5'-AACCTGGATGGAAAGAAACTAATTTTC-3'(SEQIDNO:1290)
5'-UGGAUGGAAAGAAACUAAUUUUCag-3'(SEQIDNO:139)
3'-GGACCUACCUUUCUUUGAUUAAAAGUC-5'(SEQIDNO:715)
CKAP5-2094靶:5'-CCTGGATGGAAAGAAACTAATTTTCAG-3'(SEQIDNO:1291)
5'-GAUGGAAAGAAACUAAUUUUCAGgt-3'(SEQIDNO:140)
3'-ACCUACCUUUCUUUGAUUAAAAGUCCA-5'(SEQIDNO:716)
CKAP5-2096靶:5'-TGGATGGAAAGAAACTAATTTTCAGGT-3'(SEQIDNO:1292)
5'-UGGAAAGAAACUAAUUUUCAGGUga-3'(SEQIDNO:141)
3'-CUACCUUUCUUUGAUUAAAAGUCCACU-5'(SEQIDNO:717)
CKAP5-2098靶:5'-GATGGAAAGAAACTAATTTTCAGGTGA-3'(SEQIDNO:1293)
5'-GAAAGAAACUAAUUUUCAGGUGAtg-3'(SEQIDNO:142)
3'-ACCUUUCUUUGAUUAAAAGUCCACUAC-5'(SEQIDNO:718)
CKAP5-2100靶:5'-TGGAAAGAAACTAATTTTCAGGTGATG-3'(SEQIDNO:1294)
5'-AAGAAACUAAUUUUCAGGUGAUGca-3'(SEQIDNO:143)
3'-CUUUCUUUGAUUAAAAGUCCACUACGU-5'(SEQIDNO:719)
CKAP5-2102靶:5'-GAAAGAAACTAATTTTCAGGTGATGCA-3'(SEQIDNO:1295)
5'-GAAACUAAUUUUCAGGUGAUGCAaa-3'(SEQIDNO:144)
3'-UUCUUUGAUUAAAAGUCCACUACGUUU-5'(SEQIDNO:720)
CKAP5-2104靶:5'-AAGAAACTAATTTTCAGGTGATGCAAA-3'(SEQIDNO:1296)
5'-AACUAAUUUUCAGGUGAUGCAAAtg-3'(SEQIDNO:145)
3'-CUUUGAUUAAAAGUCCACUACGUUUAC-5'(SEQIDNO:721)
CKAP5-2106靶:5'-GAAACTAATTTTCAGGTGATGCAAATG-3'(SEQIDNO:1297)
5'-CUAAUUUUCAGGUGAUGCAAAUGaa-3'(SEQIDNO:146)
3'-UUGAUUAAAAGUCCACUACGUUUACUU-5'(SEQIDNO:722)
CKAP5-2108靶:5'-AACTAATTTTCAGGTGATGCAAATGAA-3'(SEQIDNO:1298)
5'-UUGCUUUGAUUGCCCAGAAGGGAaa-3'(SEQIDNO:147)
3'-UCAACGAAACUAACGGGUCUUCCCUUU-5'(SEQIDNO:723)
CKAP5-2144靶:5'-AGTTGCTTTGATTGCCCAGAAGGGAAA-3'(SEQIDNO:1299)
5'-GCUUUGAUUGCCCAGAAGGGAAAtt-3'(SEQIDNO:148)
3'-AACGAAACUAACGGGUCUUCCCUUUAA-5'(SEQIDNO:724)
CKAP5-2146靶:5'-TTGCTTTGATTGCCCAGAAGGGAAATT-3'(SEQIDNO:1300)
5'-UUUGAUUGCCCAGAAGGGAAAUUtt-3'(SEQIDNO:149)
3'-CGAAACUAACGGGUCUUCCCUUUAAAA-5'(SEQIDNO:725)
CKAP5-2148靶:5'-GCTTTGATTGCCCAGAAGGGAAATTTT-3'(SEQIDNO:1301)
5'-UGAUUGCCCAGAAGGGAAAUUUUtc-3'(SEQIDNO:150)
3'-AAACUAACGGGUCUUCCCUUUAAAAAG-5'(SEQIDNO:726)
CKAP5-2150靶:5'-TTTGATTGCCCAGAAGGGAAATTTTTC-3'(SEQIDNO:1302)
5'-AUUGCCCAGAAGGGAAAUUUUUCca-3'(SEQIDNO:151)
3'-ACUAACGGGUCUUCCCUUUAAAAAGGU-5'(SEQIDNO:727)
CKAP5-2152靶:5'-TGATTGCCCAGAAGGGAAATTTTTCCA-3'(SEQIDNO:1303)
5'-UGCCCAGAAGGGAAAUUUUUCCAaa-3'(SEQIDNO:152)
3'-UAACGGGUCUUCCCUUUAAAAAGGUUU-5'(SEQIDNO:728)
CKAP5-2154靶:5'-ATTGCCCAGAAGGGAAATTTTTCCAAA-3'(SEQIDNO:1304)
5'-CCCAGAAGGGAAAUUUUUCCAAAac-3'(SEQIDNO:153)
3'-ACGGGUCUUCCCUUUAAAAAGGUUUUG-5'(SEQIDNO:729)
CKAP5-2156靶:5'-TGCCCAGAAGGGAAATTTTTCCAAAAC-3'(SEQIDNO:1305)
5'-GACAAGAUUGGAGAUGUGAAAUGtg-3'(SEQIDNO:154)
3'-ACCUGUUCUAACCUCUACACUUUACAC-5'(SEQIDNO:730)
CKAP5-2212靶:5'-TGGACAAGATTGGAGATGTGAAATGTG-3'(SEQIDNO:1306)
5'-CAAGAUUGGAGAUGUGAAAUGUGgg-3'(SEQIDNO:155)
3'-CUGUUCUAACCUCUACACUUUACACCC-5'(SEQIDNO:731)
CKAP5-2214靶:5'-GACAAGATTGGAGATGTGAAATGTGGG-3'(SEQIDNO:1307)
5'-AGAUUGGAGAUGUGAAAUGUGGGaa-3'(SEQIDNO:156)
3'-GUUCUAACCUCUACACUUUACACCCUU-5'(SEQIDNO:732)
CKAP5-2216靶:5'-CAAGATTGGAGATGTGAAATGTGGGAA-3'(SEQIDNO:1308)
5'-AUUGGAGAUGUGAAAUGUGGGAAca-3'(SEQIDNO:157)
3'-UCUAACCUCUACACUUUACACCCUUGU-5'(SEQIDNO:733)
CKAP5-2218靶:5'-AGATTGGAGATGTGAAATGTGGGAACA-3'(SEQIDNO:1309)
5'-UGGAGAUGUGAAAUGUGGGAACAat-3'(SEQIDNO:158)
3'-UAACCUCUACACUUUACACCCUUGUUA-5'(SEQIDNO:734)
CKAP5-2220靶:5'-ATTGGAGATGTGAAATGTGGGAACAAT-3'(SEQIDNO:1310)
5'-GAGAUGUGAAAUGUGGGAACAAUgc-3'(SEQIDNO:159)
3'-ACCUCUACACUUUACACCCUUGUUACG-5'(SEQIDNO:735)
CKAP5-2222靶:5'-TGGAGATGTGAAATGTGGGAACAATGC-3'(SEQIDNO:1311)
5'-GAUGUGAAAUGUGGGAACAAUGCaa-3'(SEQIDNO:160)
3'-CUCUACACUUUACACCCUUGUUACGUU-5'(SEQIDNO:736)
CKAP5-2224靶:5'-GAGATGTGAAATGTGGGAACAATGCAA-3'(SEQIDNO:1312)
5'-UGUGAAAUGUGGGAACAAUGCAAaa-3'(SEQIDNO:161)
3'-CUACACUUUACACCCUUGUUACGUUUU-5'(SEQIDNO:737)
CKAP5-2226靶:5'-GATGTGAAATGTGGGAACAATGCAAAA-3'(SEQIDNO:1313)
5'-UGAAAUGUGGGAACAAUGCAAAAga-3'(SEQIDNO:162)
3'-ACACUUUACACCCUUGUUACGUUUUCU-5'(SEQIDNO:738)
CKAP5-2228靶:5'-TGTGAAATGTGGGAACAATGCAAAAGA-3'(SEQIDNO:1314)
5'-AAAUGUGGGAACAAUGCAAAAGAag-3'(SEQIDNO:163)
3'-ACUUUACACCCUUGUUACGUUUUCUUC-5'(SEQIDNO:739)
CKAP5-2230靶:5'-TGAAATGTGGGAACAATGCAAAAGAAG-3'(SEQIDNO:1315)
5'-AUGUGGGAACAAUGCAAAAGAAGct-3'(SEQIDNO:164)
3'-UUUACACCCUUGUUACGUUUUCUUCGA-5'(SEQIDNO:740)
CKAP5-2232靶:5'-AAATGTGGGAACAATGCAAAAGAAGCT-3'(SEQIDNO:1316)
5'-GUGGGAACAAUGCAAAAGAAGCUat-3'(SEQIDNO:165)
3'-UACACCCUUGUUACGUUUUCUUCGAUA-5'(SEQIDNO:741)
CKAP5-2234靶:5'-ATGTGGGAACAATGCAAAAGAAGCTAT-3'(SEQIDNO:1317)
5'-GGGAACAAUGCAAAAGAAGCUAUga-3'(SEQIDNO:166)
3'-CACCCUUGUUACGUUUUCUUCGAUACU-5'(SEQIDNO:742)
CKAP5-2236靶:5'-GTGGGAACAATGCAAAAGAAGCTATGA-3'(SEQIDNO:1318)
5'-GUUGAAUGUCAAAGCUUUCAUUAgc-3'(SEQIDNO:167)
3'-CCCAACUUACAGUUUCGAAAGUAAUCG-5'(SEQIDNO:743)
CKAP5-2400靶:5'-GGGTTGAATGTCAAAGCTTTCATTAGC-3'(SEQIDNO:1319)
5'-UGAAUGUCAAAGCUUUCAUUAGCaa-3'(SEQIDNO:168)
3'-CAACUUACAGUUUCGAAAGUAAUCGUU-5'(SEQIDNO:744)
CKAP5-2402靶:5'-GTTGAATGTCAAAGCTTTCATTAGCAA-3'(SEQIDNO:1320)
5'-AAUGUCAAAGCUUUCAUUAGCAAtg-3'(SEQIDNO:169)
3'-ACUUACAGUUUCGAAAGUAAUCGUUAC-5'(SEQIDNO:745)
CKAP5-2404靶:5'-TGAATGTCAAAGCTTTCATTAGCAATG-3'(SEQIDNO:1321)
5'-UGUCAAAGCUUUCAUUAGCAAUGtg-3'(SEQIDNO:170)
3'-UUACAGUUUCGAAAGUAAUCGUUACAC-5'(SEQIDNO:746)
CKAP5-2406靶:5'-AATGTCAAAGCTTTCATTAGCAATGTG-3'(SEQIDNO:1322)
5'-UCAAAGCUUUCAUUAGCAAUGUGaa-3'(SEQIDNO:171)
3'-ACAGUUUCGAAAGUAAUCGUUACACUU-5'(SEQIDNO:747)
CKAP5-2408靶:5'-TGTCAAAGCTTTCATTAGCAATGTGAA-3'(SEQIDNO:1323)
5'-CCCUGCUUGGCGUGAUGUAUCUGta-3'(SEQIDNO:172)
3'-UUGGGACGAACCGCACUACAUAGACAU-5'(SEQIDNO:748)
CKAP5-2480靶:5'-AACCCTGCTTGGCGTGATGTATCTGTA-3'(SEQIDNO:1324)
5'-CUGCUUGGCGUGAUGUAUCUGUAtg-3'(SEQIDNO:173)
3'-GGGACGAACCGCACUACAUAGACAUAC-5'(SEQIDNO:749)
CKAP5-2482靶:5'-CCCTGCTTGGCGTGATGTATCTGTATG-3'(SEQIDNO:1325)
5'-UCUUUGAGGAUGAGAAGCCUGCCct-3'(SEQIDNO:174)
3'-CAAGAAACUCCUACUCUUCGGACGGGA-5'(SEQIDNO:750)
CKAP5-2528靶:5'-GTTCTTTGAGGATGAGAAGCCTGCCCT-3'(SEQIDNO:1326)
5'-UUUGAGGAUGAGAAGCCUGCCCUcc-3'(SEQIDNO:175)
3'-AGAAACUCCUACUCUUCGGACGGGAGG-5'(SEQIDNO:751)
CKAP5-2530靶:5'-TCTTTGAGGATGAGAAGCCTGCCCTCC-3'(SEQIDNO:1327)
5'-UGAGGAUGAGAAGCCUGCCCUCCta-3'(SEQIDNO:176)
3'-AAACUCCUACUCUUCGGACGGGAGGAU-5'(SEQIDNO:752)
CKAP5-2532靶:5'-TTTGAGGATGAGAAGCCTGCCCTCCTA-3'(SEQIDNO:1328)
5'-AGGAUGAGAAGCCUGCCCUCCUAtc-3'(SEQIDNO:177)
3'-ACUCCUACUCUUCGGACGGGAGGAUAG-5'(SEQIDNO:753)
CKAP5-2534靶:5'-TGAGGATGAGAAGCCTGCCCTCCTATC-3'(SEQIDNO:1329)
5'-GAUGAGAAGCCUGCCCUCCUAUCcc-3'(SEQIDNO:178)
3'-UCCUACUCUUCGGACGGGAGGAUAGGG-5'(SEQIDNO:754)
CKAP5-2536靶:5'-AGGATGAGAAGCCTGCCCTCCTATCCC-3'(SEQIDNO:1330)
5'-UGAGAAGCCUGCCCUCCUAUCCCag-3'(SEQIDNO:179)
3'-CUACUCUUCGGACGGGAGGAUAGGGUC-5'(SEQIDNO:755)
CKAP5-2538靶:5'-GATGAGAAGCCTGCCCTCCTATCCCAG-3'(SEQIDNO:1331)
5'-AGAAGCCUGCCCUCCUAUCCCAGat-3'(SEQIDNO:180)
3'-ACUCUUCGGACGGGAGGAUAGGGUCUA-5'(SEQIDNO:756)
CKAP5-2540靶:5'-TGAGAAGCCTGCCCTCCTATCCCAGAT-3'(SEQIDNO:1332)
5'-AAGCCUGCCCUCCUAUCCCAGAUag-3'(SEQIDNO:181)
3'-UCUUCGGACGGGAGGAUAGGGUCUAUC-5'(SEQIDNO:757)
CKAP5-2542靶:5'-AGAAGCCTGCCCTCCTATCCCAGATAG-3'(SEQIDNO:1333)
5'-GCCUGCCCUCCUAUCCCAGAUAGat-3'(SEQIDNO:182)
3'-UUCGGACGGGAGGAUAGGGUCUAUCUA-5'(SEQIDNO:758)
CKAP5-2544靶:5'-AAGCCTGCCCTCCTATCCCAGATAGAT-3'(SEQIDNO:1334)
5'-CUGCCCUCCUAUCCCAGAUAGAUgc-3'(SEQIDNO:183)
3'-CGGACGGGAGGAUAGGGUCUAUCUACG-5'(SEQIDNO:759)
CKAP5-2546靶:5'-GCCTGCCCTCCTATCCCAGATAGATGC-3'(SEQIDNO:1335)
5'-GCCCUCCUAUCCCAGAUAGAUGCag-3'(SEQIDNO:184)
3'-GACGGGAGGAUAGGGUCUAUCUACGUC-5'(SEQIDNO:760)
CKAP5-2548靶:5'-CTGCCCTCCTATCCCAGATAGATGCAG-3'(SEQIDNO:1336)
5'-CCUCCUAUCCCAGAUAGAUGCAGaa-3'(SEQIDNO:185)
3'-CGGGAGGAUAGGGUCUAUCUACGUCUU-5'(SEQIDNO:761)
CKAP5-2550靶:5'-GCCCTCCTATCCCAGATAGATGCAGAA-3'(SEQIDNO:1337)
5'-UCCUAUCCCAGAUAGAUGCAGAAtt-3'(SEQIDNO:186)
3'-GGAGGAUAGGGUCUAUCUACGUCUUAA-5'(SEQIDNO:762)
CKAP5-2552靶:5'-CCTCCTATCCCAGATAGATGCAGAATT-3'(SEQIDNO:1338)
5'-CUAUCCCAGAUAGAUGCAGAAUUtg-3'(SEQIDNO:187)
3'-AGGAUAGGGUCUAUCUACGUCUUAAAC-5'(SEQIDNO:763)
CKAP5-2554靶:5'-TCCTATCCCAGATAGATGCAGAATTTG-3'(SEQIDNO:1339)
5'-AUCCCAGAUAGAUGCAGAAUUUGag-3'(SEQIDNO:188)
3'-GAUAGGGUCUAUCUACGUCUUAAACUC-5'(SEQIDNO:764)
CKAP5-2556靶:5'-CTATCCCAGATAGATGCAGAATTTGAG-3'(SEQIDNO:1340)
5'-CCCAGAUAGAUGCAGAAUUUGAGaa-3'(SEQIDNO:189)
3'-UAGGGUCUAUCUACGUCUUAAACUCUU-5'(SEQIDNO:765)
CKAP5-2558靶:5'-ATCCCAGATAGATGCAGAATTTGAGAA-3'(SEQIDNO:1341)
5'-AAGAUGCAGGGACAAAGUCCACCtg-3'(SEQIDNO:190)
3'-UCUUCUACGUCCCUGUUUCAGGUGGAC-5'(SEQIDNO:766)
CKAP5-2581靶:5'-AGAAGATGCAGGGACAAAGTCCACCTG-3'(SEQIDNO:1342)
5'-UACAGAUGAAGGAGAAGAUGGAGat-3'(SEQIDNO:191)
3'-CCAUGUCUACUUCCUCUUCUACCUCUA-5'(SEQIDNO:767)
CKAP5-2643靶:5'-GGTACAGATGAAGGAGAAGATGGAGAT-3'(SEQIDNO:1343)
5'-CAGAUGAAGGAGAAGAUGGAGAUga-3'(SEQIDNO:192)
3'-AUGUCUACUUCCUCUUCUACCUCUACU-5'(SEQIDNO:768)
CKAP5-2645靶:5'-TACAGATGAAGGAGAAGATGGAGATGA-3'(SEQIDNO:1344)
5'-GAUGAAGGAGAAGAUGGAGAUGAac-3'(SEQIDNO:193)
3'-GUCUACUUCCUCUUCUACCUCUACUUG-5'(SEQIDNO:769)
CKAP5-2647靶:5'-CAGATGAAGGAGAAGATGGAGATGAAC-3'(SEQIDNO:1345)
5'-GUUGAUCUUUUGCCGAGGACGGAga-3'(SEQIDNO:194)
3'-AGCAACUAGAAAACGGCUCCUGCCUCU-5'(SEQIDNO:770)
CKAP5-2695靶:5'-TCGTTGATCTTTTGCCGAGGACGGAGA-3'(SEQIDNO:1346)
5'-GGAAAGAAGGCCUAGAUGAAGUGgc-3'(SEQIDNO:195)
3'-AUCCUUUCUUCCGGAUCUACUUCACCG-5'(SEQIDNO:771)
CKAP5-2780靶:5'-TAGGAAAGAAGGCCTAGATGAAGTGGC-3'(SEQIDNO:1347)
5'-AAAGAAGGCCUAGAUGAAGUGGCag-3'(SEQIDNO:196)
3'-CCUUUCUUCCGGAUCUACUUCACCGUC-5'(SEQIDNO:772)
CKAP5-2782靶:5'-GGAAAGAAGGCCTAGATGAAGTGGCAG-3'(SEQIDNO:1348)
5'-AGAAGGCCUAGAUGAAGUGGCAGgt-3'(SEQIDNO:197)
3'-UUUCUUCCGGAUCUACUUCACCGUCCA-5'(SEQIDNO:773)
CKAP5-2784靶:5'-AAAGAAGGCCTAGATGAAGTGGCAGGT-3'(SEQIDNO:1349)
5'-AAGGCCUAGAUGAAGUGGCAGGUat-3'(SEQIDNO:198)
3'-UCUUCCGGAUCUACUUCACCGUCCAUA-5'(SEQIDNO:774)
CKAP5-2786靶:5'-AGAAGGCCTAGATGAAGTGGCAGGTAT-3'(SEQIDNO:1350)
5'-GGCCUAGAUGAAGUGGCAGGUAUta-3'(SEQIDNO:199)
3'-UUCCGGAUCUACUUCACCGUCCAUAAU-5'(SEQIDNO:775)
CKAP5-2788靶:5'-AAGGCCTAGATGAAGTGGCAGGTATTA-3'(SEQIDNO:1351)
5'-CCUAGAUGAAGUGGCAGGUAUUAtt-3'(SEQIDNO:200)
3'-CCGGAUCUACUUCACCGUCCAUAAUAA-5'(SEQIDNO:776)
CKAP5-2790靶:5'-GGCCTAGATGAAGTGGCAGGTATTATT-3'(SEQIDNO:1352)
5'-UAGAUGAAGUGGCAGGUAUUAUUaa-3'(SEQIDNO:201)
3'-GGAUCUACUUCACCGUCCAUAAUAAUU-5'(SEQIDNO:777)
CKAP5-2792靶:5'-CCTAGATGAAGTGGCAGGTATTATTAA-3'(SEQIDNO:1353)
5'-GAUGAAGUGGCAGGUAUUAUUAAtg-3'(SEQIDNO:202)
3'-AUCUACUUCACCGUCCAUAAUAAUUAC-5'(SEQIDNO:778)
CKAP5-2794靶:5'-TAGATGAAGTGGCAGGTATTATTAATG-3'(SEQIDNO:1354)
5'-AAUAUAGGUGAACUUCCAACUGCct-3'(SEQIDNO:203)
3'-GCUUAUAUCCACUUGAAGGUUGACGGA-5'(SEQIDNO:779)
CKAP5-2839靶:5'-CGAATATAGGTGAACTTCCAACTGCCT-3'(SEQIDNO:1355)
5'-UAUAGGUGAACUUCCAACUGCCUtg-3'(SEQIDNO:204)
3'-UUAUAUCCACUUGAAGGUUGACGGAAC-5'(SEQIDNO:780)
CKAP5-2841靶:5'-AATATAGGTGAACTTCCAACTGCCTTG-3'(SEQIDNO:1356)
5'-UAGGUGAACUUCCAACUGCCUUGaa-3'(SEQIDNO:205)
3'-AUAUCCACUUGAAGGUUGACGGAACUU-5'(SEQIDNO:781)
CKAP5-2843靶:5'-TATAGGTGAACTTCCAACTGCCTTGAA-3'(SEQIDNO:1357)
5'-GGUGAACUUCCAACUGCCUUGAAgg-3'(SEQIDNO:206)
3'-AUCCACUUGAAGGUUGACGGAACUUCC-5'(SEQIDNO:782)
CKAP5-2845靶:5'-TAGGTGAACTTCCAACTGCCTTGAAGG-3'(SEQIDNO:1358)
5'-UGAACUUCCAACUGCCUUGAAGGgt-3'(SEQIDNO:207)
3'-CCACUUGAAGGUUGACGGAACUUCCCA-5'(SEQIDNO:783)
CKAP5-2847靶:5'-GGTGAACTTCCAACTGCCTTGAAGGGT-3'(SEQIDNO:1359)
5'-AACUUCCAACUGCCUUGAAGGGUcg-3'(SEQIDNO:208)
3'-ACUUGAAGGUUGACGGAACUUCCCAGC-5'(SEQIDNO:784)
CKAP5-2849靶:5'-TGAACTTCCAACTGCCTTGAAGGGTCG-3'(SEQIDNO:1360)
5'-CUUCCAACUGCCUUGAAGGGUCGac-3'(SEQIDNO:209)
3'-UUGAAGGUUGACGGAACUUCCCAGCUG-5'(SEQIDNO:785)
CKAP5-2851靶:5'-AACTTCCAACTGCCTTGAAGGGTCGAC-3'(SEQIDNO:1361)
5'-UCCAACUGCCUUGAAGGGUCGACtc-3'(SEQIDNO:210)
3'-GAAGGUUGACGGAACUUCCCAGCUGAG-5'(SEQIDNO:786)
CKAP5-2853靶:5'-CTTCCAACTGCCTTGAAGGGTCGACTC-3'(SEQIDNO:1362)
5'-CAACUGCCUUGAAGGGUCGACUCaa-3'(SEQIDNO:211)
3'-AGGUUGACGGAACUUCCCAGCUGAGUU-5'(SEQIDNO:787)
CKAP5-2855靶:5'-TCCAACTGCCTTGAAGGGTCGACTCAA-3'(SEQIDNO:1363)
5'-ACUGCCUUGAAGGGUCGACUCAAtg-3'(SEQIDNO:212)
3'-GUUGACGGAACUUCCCAGCUGAGUUAC-5'(SEQIDNO:788)
CKAP5-2857靶:5'-CAACTGCCTTGAAGGGTCGACTCAATG-3'(SEQIDNO:1364)
5'-CAACUGGCAGUAGCCAUGGGCCCaa-3'(SEQIDNO:213)
3'-UUGUUGACCGUCAUCGGUACCCGGGUU-5'(SEQIDNO:789)
CKAP5-2926靶:5'-AACAACTGGCAGTAGCCATGGGCCCAA-3'(SEQIDNO:1365)
5'-AGCAAGAACAAUGUUCGAGCUGCtg-3'(SEQIDNO:214)
3'-UGUCGUUCUUGUUACAAGCUCGACGAC-5'(SEQIDNO:790)
CKAP5-3007靶:5'-ACAGCAAGAACAATGTTCGAGCTGCTG-3'(SEQIDNO:1366)
5'-CAAGAACAAUGUUCGAGCUGCUGcc-3'(SEQIDNO:215)
3'-UCGUUCUUGUUACAAGCUCGACGACGG-5'(SEQIDNO:791)
CKAP5-3009靶:5'-AGCAAGAACAATGTTCGAGCTGCTGCC-3'(SEQIDNO:1367)
5'-AGAACAAUGUUCGAGCUGCUGCCct-3'(SEQIDNO:216)
3'-GUUCUUGUUACAAGCUCGACGACGGGA-5'(SEQIDNO:792)
CKAP5-3011靶:5'-CAAGAACAATGTTCGAGCTGCTGCCCT-3'(SEQIDNO:1368)
5'-AACAAUGUUCGAGCUGCUGCCCUag-3'(SEQIDNO:217)
3'-UCUUGUUACAAGCUCGACGACGGGAUC-5'(SEQIDNO:793)
CKAP5-3013靶:5'-AGAACAATGTTCGAGCTGCTGCCCTAG-3'(SEQIDNO:1369)
5'-CAAUGUUCGAGCUGCUGCCCUAGcg-3'(SEQIDNO:218)
3'-UUGUUACAAGCUCGACGACGGGAUCGC-5'(SEQIDNO:794)
CKAP5-3015靶:5'-AACAATGTTCGAGCTGCTGCCCTAGCG-3'(SEQIDNO:1370)
5'-AUGUUCGAGCUGCUGCCCUAGCGac-3'(SEQIDNO:219)
3'-GUUACAAGCUCGACGACGGGAUCGCUG-5'(SEQIDNO:795)
CKAP5-3017靶:5'-CAATGTTCGAGCTGCTGCCCTAGCGAC-3'(SEQIDNO:1371)
5'-GUUCGAGCUGCUGCCCUAGCGACtg-3'(SEQIDNO:220)
3'-UACAAGCUCGACGACGGGAUCGCUGAC-5'(SEQIDNO:796)
CKAP5-3019靶:5'-ATGTTCGAGCTGCTGCCCTAGCGACTG-3'(SEQIDNO:1372)
5'-ACUGUGAAUGCUUGGGCAGAACAga-3'(SEQIDNO:221)
3'-GCUGACACUUACGAACCCGUCUUGUCU-5'(SEQIDNO:797)
CKAP5-3040靶:5'-CGACTGTGAATGCTTGGGCAGAACAGA-3'(SEQIDNO:1373)
5'-UGUGAAUGCUUGGGCAGAACAGAct-3'(SEQIDNO:222)
3'-UGACACUUACGAACCCGUCUUGUCUGA-5'(SEQIDNO:798)
CKAP5-3042靶:5'-ACTGTGAATGCTTGGGCAGAACAGACT-3'(SEQIDNO:1374)
5'-UGAAUGCUUGGGCAGAACAGACUgg-3'(SEQIDNO:223)
3'-ACACUUACGAACCCGUCUUGUCUGACC-5'(SEQIDNO:799)
CKAP5-3044靶:5'-TGTGAATGCTTGGGCAGAACAGACTGG-3'(SEQIDNO:1375)
5'-GAGAAGAUCUUUCUGAAGAGCUCaa-3'(SEQIDNO:224)
3'-UCCUCUUCUAGAAAGACUUCUCGAGUU-5'(SEQIDNO:800)
CKAP5-3089靶:5'-AGGAGAAGATCTTTCTGAAGAGCTCAA-3'(SEQIDNO:1376)
5'-CUAGAAGAUCGAAAUGGAGAUGUgc-3'(SEQIDNO:225)
3'-CGGAUCUUCUAGCUUUACCUCUACACG-5'(SEQIDNO:801)
CKAP5-3229靶:5'-GCCTAGAAGATCGAAATGGAGATGTGC-3'(SEQIDNO:1377)
5'-AGAAGAUCGAAAUGGAGAUGUGCga-3'(SEQIDNO:226)
3'-GAUCUUCUAGCUUUACCUCUACACGCU-5'(SEQIDNO:802)
CKAP5-3231靶:5'-CTAGAAGATCGAAATGGAGATGTGCGA-3'(SEQIDNO:1378)
5'-AAGAUCGAAAUGGAGAUGUGCGAaa-3'(SEQIDNO:227)
3'-UCUUCUAGCUUUACCUCUACACGCUUU-5'(SEQIDNO:803)
CKAP5-3233靶:5'-AGAAGATCGAAATGGAGATGTGCGAAA-3'(SEQIDNO:1379)
5'-UGAUGCAUUUAGGAUAUGAAAAAat-3'(SEQIDNO:228)
3'-GUACUACGUAAAUCCUAUACUUUUUUA-5'(SEQIDNO:804)
CKAP5-3287靶:5'-CATGATGCATTTAGGATATGAAAAAAT-3'(SEQIDNO:1380)
5'-AUGCAUUUAGGAUAUGAAAAAAUgg-3'(SEQIDNO:229)
3'-ACUACGUAAAUCCUAUACUUUUUUACC-5'(SEQIDNO:805)
CKAP5-3289靶:5'-TGATGCATTTAGGATATGAAAAAATGG-3'(SEQIDNO:1381)
5'-GCAUUUAGGAUAUGAAAAAAUGGcc-3'(SEQIDNO:230)
3'-UACGUAAAUCCUAUACUUUUUUACCGG-5'(SEQIDNO:806)
CKAP5-3291靶:5'-ATGCATTTAGGATATGAAAAAATGGCC-3'(SEQIDNO:1382)
5'-AUUUAGGAUAUGAAAAAAUGGCCaa-3'(SEQIDNO:231)
3'-CGUAAAUCCUAUACUUUUUUACCGGUU-5'(SEQIDNO:807)
CKAP5-3293靶:5'-GCATTTAGGATATGAAAAAATGGCCAA-3'(SEQIDNO:1383)
5'-UUAGGAUAUGAAAAAAUGGCCAAgg-3'(SEQIDNO:232)
3'-UAAAUCCUAUACUUUUUUACCGGUUCC-5'(SEQIDNO:808)
CKAP5-3295靶:5'-ATTTAGGATATGAAAAAATGGCCAAGG-3'(SEQIDNO:1384)
5'-AAGGCUACUGGGAAACUAAAGCCaa-3'(SEQIDNO:233)
3'-GGUUCCGAUGACCCUUUGAUUUCGGUU-5'(SEQIDNO:809)
CKAP5-3316靶:5'-CCAAGGCTACTGGGAAACTAAAGCCAA-3'(SEQIDNO:1385)
5'-GGCUACUGGGAAACUAAAGCCAAct-3'(SEQIDNO:234)
3'-UUCCGAUGACCCUUUGAUUUCGGUUGA-5'(SEQIDNO:810)
CKAP5-3318靶:5'-AAGGCTACTGGGAAACTAAAGCCAACT-3'(SEQIDNO:1386)
5'-CUACUGGGAAACUAAAGCCAACUtc-3'(SEQIDNO:235)
3'-CCGAUGACCCUUUGAUUUCGGUUGAAG-5'(SEQIDNO:811)
CKAP5-3320靶:5'-GGCTACTGGGAAACTAAAGCCAACTTC-3'(SEQIDNO:1387)
5'-ACUGGGAAACUAAAGCCAACUUCta-3'(SEQIDNO:236)
3'-GAUGACCCUUUGAUUUCGGUUGAAGAU-5'(SEQIDNO:812)
CKAP5-3322靶:5'-CTACTGGGAAACTAAAGCCAACTTCTA-3'(SEQIDNO:1388)
5'-UGGGAAACUAAAGCCAACUUCUAaa-3'(SEQIDNO:237)
3'-UGACCCUUUGAUUUCGGUUGAAGAUUU-5'(SEQIDNO:813)
CKAP5-3324靶:5'-ACTGGGAAACTAAAGCCAACTTCTAAA-3'(SEQIDNO:1389)
5'-GGAAACUAAAGCCAACUUCUAAAga-3'(SEQIDNO:238)
3'-ACCCUUUGAUUUCGGUUGAAGAUUUCU-5'(SEQIDNO:814)
CKAP5-3326靶:5'-TGGGAAACTAAAGCCAACTTCTAAAGA-3'(SEQIDNO:1390)
5'-AAACUAAAGCCAACUUCUAAAGAtc-3'(SEQIDNO:239)
3'-CCUUUGAUUUCGGUUGAAGAUUUCUAG-5'(SEQIDNO:815)
CKAP5-3328靶:5'-GGAAACTAAAGCCAACTTCTAAAGATC-3'(SEQIDNO:1391)
5'-ACUAAAGCCAACUUCUAAAGAUCag-3'(SEQIDNO:240)
3'-UUUGAUUUCGGUUGAAGAUUUCUAGUC-5'(SEQIDNO:816)
CKAP5-3330靶:5'-AAACTAAAGCCAACTTCTAAAGATCAG-3'(SEQIDNO:1392)
5'-UAAAGCCAACUUCUAAAGAUCAGgt-3'(SEQIDNO:241)
3'-UGAUUUCGGUUGAAGAUUUCUAGUCCA-5'(SEQIDNO:817)
CKAP5-3332靶:5'-ACTAAAGCCAACTTCTAAAGATCAGGT-3'(SEQIDNO:1393)
5'-AAGCCAACUUCUAAAGAUCAGGUat-3'(SEQIDNO:242)
3'-AUUUCGGUUGAAGAUUUCUAGUCCAUA-5'(SEQIDNO:818)
CKAP5-3334靶:5'-TAAAGCCAACTTCTAAAGATCAGGTAT-3'(SEQIDNO:1394)
5'-CCUAUUUUUAUUGUUGUUCCAAAtg-3'(SEQIDNO:243)
3'-CCGGAUAAAAAUAACAACAAGGUUUAC-5'(SEQIDNO:819)
CKAP5-3625靶:5'-GGCCTATTTTTATTGTTGTTCCAAATG-3'(SEQIDNO:1395)
5'-UAUUUUUAUUGUUGUUCCAAAUGga-3'(SEQIDNO:244)
3'-GGAUAAAAAUAACAACAAGGUUUACCU-5'(SEQIDNO:820)
CKAP5-3627靶:5'-CCTATTTTTATTGTTGTTCCAAATGGA-3'(SEQIDNO:1396)
5'-UUUUUAUUGUUGUUCCAAAUGGAaa-3'(SEQIDNO:245)
3'-AUAAAAAUAACAACAAGGUUUACCUUU-5'(SEQIDNO:821)
CKAP5-3629靶:5'-TATTTTTATTGTTGTTCCAAATGGAAA-3'(SEQIDNO:1397)
5'-UUUAUUGUUGUUCCAAAUGGAAAag-3'(SEQIDNO:246)
3'-AAAAAUAACAACAAGGUUUACCUUUUC-5'(SEQIDNO:822)
CKAP5-3631靶:5'-TTTTTATTGTTGTTCCAAATGGAAAAG-3'(SEQIDNO:1398)
5'-UAUUGUUGUUCCAAAUGGAAAAGag-3'(SEQIDNO:247)
3'-AAAUAACAACAAGGUUUACCUUUUCUC-5'(SEQIDNO:823)
CKAP5-3633靶:5'-TTTATTGTTGTTCCAAATGGAAAAGAG-3'(SEQIDNO:1399)
5'-UUGUUGUUCCAAAUGGAAAAGAGca-3'(SEQIDNO:248)
3'-AUAACAACAAGGUUUACCUUUUCUCGU-5'(SEQIDNO:824)
CKAP5-3635靶:5'-TATTGTTGTTCCAAATGGAAAAGAGCA-3'(SEQIDNO:1400)
5'-AGGUGCUAAAGUGGAAUUUUACUac-3'(SEQIDNO:249)
3'-CUUCCACGAUUUCACCUUAAAAUGAUG-5'(SEQIDNO:825)
CKAP5-3686靶:5'-GAAGGTGCTAAAGTGGAATTTTACTAC-3'(SEQIDNO:1401)
5'-GUGCUAAAGUGGAAUUUUACUACcc-3'(SEQIDNO:250)
3'-UCCACGAUUUCACCUUAAAAUGAUGGG-5'(SEQIDNO:826)
CKAP5-3688靶:5'-AGGTGCTAAAGTGGAATTTTACTACCC-3'(SEQIDNO:1402)
5'-AUCAUCUUACUGAGAAUGAAGCAtc-3'(SEQIDNO:251)
3'-UAUAGUAGAAUGACUCUUACUUCGUAG-5'(SEQIDNO:827)
CKAP5-3989靶:5'-ATATCATCTTACTGAGAATGAAGCATC-3'(SEQIDNO:1403)
5'-CAUCUUACUGAGAAUGAAGCAUCtt-3'(SEQIDNO:252)
3'-UAGUAGAAUGACUCUUACUUCGUAGAA-5'(SEQIDNO:828)
CKAP5-3991靶:5'-ATCATCTTACTGAGAATGAAGCATCTT-3'(SEQIDNO:1404)
5'-UCUUACUGAGAAUGAAGCAUCUUcc-3'(SEQIDNO:253)
3'-GUAGAAUGACUCUUACUUCGUAGAAGG-5'(SEQIDNO:829)
CKAP5-3993靶:5'-CATCTTACTGAGAATGAAGCATCTTCC-3'(SEQIDNO:1405)
5'-UUACUGAGAAUGAAGCAUCUUCCtt-3'(SEQIDNO:254)
3'-AGAAUGACUCUUACUUCGUAGAAGGAA-5'(SEQIDNO:830)
CKAP5-3995靶:5'-TCTTACTGAGAATGAAGCATCTTCCTT-3'(SEQIDNO:1406)
5'-CAAGGUUGGAGAACCAAAGGAUGtc-3'(SEQIDNO:255)
3'-CAGUUCCAACCUCUUGGUUUCCUACAG-5'(SEQIDNO:831)
CKAP5-4038靶:5'-GTCAAGGTTGGAGAACCAAAGGATGTC-3'(SEQIDNO:1407)
5'-AGGUUGGAGAACCAAAGGAUGUCat-3'(SEQIDNO:256)
3'-GUUCCAACCUCUUGGUUUCCUACAGUA-5'(SEQIDNO:832)
CKAP5-4040靶:5'-CAAGGTTGGAGAACCAAAGGATGTCAT-3'(SEQIDNO:1408)
5'-GUUGGAGAACCAAAGGAUGUCAUtc-3'(SEQIDNO:257)
3'-UCCAACCUCUUGGUUUCCUACAGUAAG-5'(SEQIDNO:833)
CKAP5-4042靶:5'-AGGTTGGAGAACCAAAGGATGTCATTC-3'(SEQIDNO:1409)
5'-UGGAGAACCAAAGGAUGUCAUUCgt-3'(SEQIDNO:258)
3'-CAACCUCUUGGUUUCCUACAGUAAGCA-5'(SEQIDNO:834)
CKAP5-4044靶:5'-GTTGGAGAACCAAAGGATGTCATTCGT-3'(SEQIDNO:1410)
5'-GAGAACCAAAGGAUGUCAUUCGUaa-3'(SEQIDNO:259)
3'-ACCUCUUGGUUUCCUACAGUAAGCAUU-5'(SEQIDNO:835)
CKAP5-4046靶:5'-TGGAGAACCAAAGGATGTCATTCGTAA-3'(SEQIDNO:1411)
5'-GAACCAAAGGAUGUCAUUCGUAAag-3'(SEQIDNO:260)
3'-CUCUUGGUUUCCUACAGUAAGCAUUUC-5'(SEQIDNO:836)
CKAP5-4048靶:5'-GAGAACCAAAGGATGTCATTCGTAAAG-3'(SEQIDNO:1412)
5'-ACCAAAGGAUGUCAUUCGUAAAGat-3'(SEQIDNO:261)
3'-CUUGGUUUCCUACAGUAAGCAUUUCUA-5'(SEQIDNO:837)
CKAP5-4050靶:5'-GAACCAAAGGATGTCATTCGTAAAGAT-3'(SEQIDNO:1413)
5'-CAAAGGAUGUCAUUCGUAAAGAUgt-3'(SEQIDNO:262)
3'-UGGUUUCCUACAGUAAGCAUUUCUACA-5'(SEQIDNO:838)
CKAP5-4052靶:5'-ACCAAAGGATGTCATTCGTAAAGATGT-3'(SEQIDNO:1414)
5'-AAGGAUGUCAUUCGUAAAGAUGUtc-3'(SEQIDNO:263)
3'-GUUUCCUACAGUAAGCAUUUCUACAAG-5'(SEQIDNO:839)
CKAP5-4054靶:5'-CAAAGGATGTCATTCGTAAAGATGTTC-3'(SEQIDNO:1415)
5'-GGAUGUCAUUCGUAAAGAUGUUCgt-3'(SEQIDNO:264)
3'-UUCCUACAGUAAGCAUUUCUACAAGCA-5'(SEQIDNO:840)
CKAP5-4056靶:5'-AAGGATGTCATTCGTAAAGATGTTCGT-3'(SEQIDNO:1416)
5'-AUGUCAUUCGUAAAGAUGUUCGUgc-3'(SEQIDNO:265)
3'-CCUACAGUAAGCAUUUCUACAAGCACG-5'(SEQIDNO:841)
CKAP5-4058靶:5'-GGATGTCATTCGTAAAGATGTTCGTGC-3'(SEQIDNO:1417)
5'-UCCUGAACCGGAUGUGCCUUGUCta-3'(SEQIDNO:266)
3'-GUAGGACUUGGCCUACACGGAACAGAU-5'(SEQIDNO:842)
CKAP5-4085靶:5'-CATCCTGAACCGGATGTGCCTTGTCTA-3'(SEQIDNO:1418)
5'-CUGAACCGGAUGUGCCUUGUCUAcc-3'(SEQIDNO:267)
3'-AGGACUUGGCCUACACGGAACAGAUGG-5'(SEQIDNO:843)
CKAP5-4087靶:5'-TCCTGAACCGGATGTGCCTTGTCTACC-3'(SEQIDNO:1419)
5'-GAACCGGAUGUGCCUUGUCUACCca-3'(SEQIDNO:268)
3'-GACUUGGCCUACACGGAACAGAUGGGU-5'(SEQIDNO:844)
CKAP5-4089靶:5'-CTGAACCGGATGTGCCTTGTCTACCCA-3'(SEQIDNO:1420)
5'-ACCGGAUGUGCCUUGUCUACCCAgc-3'(SEQIDNO:269)
3'-CUUGGCCUACACGGAACAGAUGGGUCG-5'(SEQIDNO:845)
CKAP5-4091靶:5'-GAACCGGATGTGCCTTGTCTACCCAGC-3'(SEQIDNO:1421)
5'-CGGAUGUGCCUUGUCUACCCAGCta-3'(SEQIDNO:270)
3'-UGGCCUACACGGAACAGAUGGGUCGAU-5'(SEQIDNO:846)
CKAP5-4093靶:5'-ACCGGATGTGCCTTGTCTACCCAGCTA-3'(SEQIDNO:1422)
5'-GAUGUGCCUUGUCUACCCAGCUAgc-3'(SEQIDNO:271)
3'-GCCUACACGGAACAGAUGGGUCGAUCG-5'(SEQIDNO:847)
CKAP5-4095靶:5'-CGGATGTGCCTTGTCTACCCAGCTAGC-3'(SEQIDNO:1423)
5'-UGUGCCUUGUCUACCCAGCUAGCaa-3'(SEQIDNO:272)
3'-CUACACGGAACAGAUGGGUCGAUCGUU-5'(SEQIDNO:848)
CKAP5-4097靶:5'-GATGTGCCTTGTCTACCCAGCTAGCAA-3'(SEQIDNO:1424)
5'-CCAAAAACUCUAAGCAGAGAGCAga-3'(SEQIDNO:273)
3'-UAGGUUUUUGAGAUUCGUCUCUCGUCU-5'(SEQIDNO:849)
CKAP5-4154靶:5'-ATCCAAAAACTCTAAGCAGAGAGCAGA-3'(SEQIDNO:1425)
5'-AAAAACUCUAAGCAGAGAGCAGAgt-3'(SEQIDNO:274)
3'-GGUUUUUGAGAUUCGUCUCUCGUCUCA-5'(SEQIDNO:850)
CKAP5-4156靶:5'-CCAAAAACTCTAAGCAGAGAGCAGAGT-3'(SEQIDNO:1426)
5'-AAACUCUAAGCAGAGAGCAGAGUgc-3'(SEQIDNO:275)
3'-UUUUUGAGAUUCGUCUCUCGUCUCACG-5'(SEQIDNO:851)
CKAP5-4158靶:5'-AAAAACTCTAAGCAGAGAGCAGAGTGC-3'(SEQIDNO:1427)
5'-ACUCUAAGCAGAGAGCAGAGUGCct-3'(SEQIDNO:276)
3'-UUUGAGAUUCGUCUCUCGUCUCACGGA-5'(SEQIDNO:852)
CKAP5-4160靶:5'-AAACTCTAAGCAGAGAGCAGAGTGCCT-3'(SEQIDNO:1428)
5'-UCUAAGCAGAGAGCAGAGUGCCUgg-3'(SEQIDNO:277)
3'-UGAGAUUCGUCUCUCGUCUCACGGACC-5'(SEQIDNO:853)
CKAP5-4162靶:5'-ACTCTAAGCAGAGAGCAGAGTGCCTGG-3'(SEQIDNO:1429)
5'-UAAGCAGAGAGCAGAGUGCCUGGaa-3'(SEQIDNO:278)
3'-AGAUUCGUCUCUCGUCUCACGGACCUU-5'(SEQIDNO:854)
CKAP5-4164靶:5'-TCTAAGCAGAGAGCAGAGTGCCTGGAA-3'(SEQIDNO:1430)
5'-AGCAGAGAGCAGAGUGCCUGGAAga-3'(SEQIDNO:279)
3'-AUUCGUCUCUCGUCUCACGGACCUUCU-5'(SEQIDNO:855)
CKAP5-4166靶:5'-TAAGCAGAGAGCAGAGTGCCTGGAAGA-3'(SEQIDNO:1431)
5'-CAGAGAGCAGAGUGCCUGGAAGAgc-3'(SEQIDNO:280)
3'-UCGUCUCUCGUCUCACGGACCUUCUCG-5'(SEQIDNO:856)
CKAP5-4168靶:5'-AGCAGAGAGCAGAGTGCCTGGAAGAGC-3'(SEQIDNO:1432)
5'-GAGAGCAGAGUGCCUGGAAGAGCtg-3'(SEQIDNO:281)
3'-GUCUCUCGUCUCACGGACCUUCUCGAC-5'(SEQIDNO:857)
CKAP5-4170靶:5'-CAGAGAGCAGAGTGCCTGGAAGAGCTG-3'(SEQIDNO:1433)
5'-GAGCAGAGUGCCUGGAAGAGCUGgg-3'(SEQIDNO:282)
3'-CUCUCGUCUCACGGACCUUCUCGACCC-5'(SEQIDNO:858)
CKAP5-4172靶:5'-GAGAGCAGAGTGCCTGGAAGAGCTGGG-3'(SEQIDNO:1434)
5'-GCAGAGUGCCUGGAAGAGCUGGGat-3'(SEQIDNO:283)
3'-CUCGUCUCACGGACCUUCUCGACCCUA-5'(SEQIDNO:859)
CKAP5-4174靶:5'-GAGCAGAGTGCCTGGAAGAGCTGGGAT-3'(SEQIDNO:1435)
5'-CAGGAAAAGCCUUAAAGGAAAUAgc-3'(SEQIDNO:284)
3'-GGGUCCUUUUCGGAAUUUCCUUUAUCG-5'(SEQIDNO:860)
CKAP5-4241靶:5'-CCCAGGAAAAGCCTTAAAGGAAATAGC-3'(SEQIDNO:1436)
5'-AUCAGGUGUUCAAACUGAUUGGAaa-3'(SEQIDNO:285)
3'-CCUAGUCCACAAGUUUGACUAACCUUU-5'(SEQIDNO:861)
CKAP5-4346靶:5'-GGATCAGGTGTTCAAACTGATTGGAAA-3'(SEQIDNO:1437)
5'-CAGGUGUUCAAACUGAUUGGAAAtc-3'(SEQIDNO:286)
3'-UAGUCCACAAGUUUGACUAACCUUUAG-5'(SEQIDNO:862)
CKAP5-4348靶:5'-ATCAGGTGTTCAAACTGATTGGAAATC-3'(SEQIDNO:1438)
5'-GGUGUUCAAACUGAUUGGAAAUCtt-3'(SEQIDNO:287)
3'-GUCCACAAGUUUGACUAACCUUUAGAA-5'(SEQIDNO:863)
CKAP5-4350靶:5'-CAGGTGTTCAAACTGATTGGAAATCTT-3'(SEQIDNO:1439)
5'-UGUUCAAACUGAUUGGAAAUCUUtc-3'(SEQIDNO:288)
3'-CCACAAGUUUGACUAACCUUUAGAAAG-5'(SEQIDNO:864)
CKAP5-4352靶:5'-GGTGTTCAAACTGATTGGAAATCTTTC-3'(SEQIDNO:1440)
5'-UUCAAACUGAUUGGAAAUCUUUCtg-3'(SEQIDNO:289)
3'-ACAAGUUUGACUAACCUUUAGAAAGAC-5'(SEQIDNO:865)
CKAP5-4354靶:5'-TGTTCAAACTGATTGGAAATCTTTCTG-3'(SEQIDNO:1441)
5'-CAAACUGAUUGGAAAUCUUUCUGaa-3'(SEQIDNO:290)
3'-AAGUUUGACUAACCUUUAGAAAGACUU-5'(SEQIDNO:866)
CKAP5-4356靶:5'-TTCAAACTGATTGGAAATCTTTCTGAA-3'(SEQIDNO:1442)
5'-AACUGAUUGGAAAUCUUUCUGAAaa-3'(SEQIDNO:291)
3'-GUUUGACUAACCUUUAGAAAGACUUUU-5'(SEQIDNO:867)
CKAP5-4358靶:5'-CAAACTGATTGGAAATCTTTCTGAAAA-3'(SEQIDNO:1443)
5'-CUGAUUGGAAAUCUUUCUGAAAAgg-3'(SEQIDNO:292)
3'-UUGACUAACCUUUAGAAAGACUUUUCC-5'(SEQIDNO:868)
CKAP5-4360靶:5'-AACTGATTGGAAATCTTTCTGAAAAGG-3'(SEQIDNO:1444)
5'-AAGCGGUCAGCAAAGAGACCCUCtg-3'(SEQIDNO:293)
3'-AAUUCGCCAGUCGUUUCUCUGGGAGAC-5'(SEQIDNO:869)
CKAP5-4411靶:5'-TTAAGCGGTCAGCAAAGAGACCCTCTG-3'(SEQIDNO:1445)
5'-GCGGUCAGCAAAGAGACCCUCUGct-3'(SEQIDNO:294)
3'-UUCGCCAGUCGUUUCUCUGGGAGACGA-5'(SEQIDNO:870)
CKAP5-4413靶:5'-AAGCGGTCAGCAAAGAGACCCTCTGCT-3'(SEQIDNO:1446)
5'-GGUCAGCAAAGAGACCCUCUGCUgc-3'(SEQIDNO:295)
3'-CGCCAGUCGUUUCUCUGGGAGACGACG-5'(SEQIDNO:871)
CKAP5-4415靶:5'-GCGGTCAGCAAAGAGACCCTCTGCTGC-3'(SEQIDNO:1447)
5'-UCAGCAAAGAGACCCUCUGCUGCac-3'(SEQIDNO:296)
3'-CCAGUCGUUUCUCUGGGAGACGACGUG-5'(SEQIDNO:872)
CKAP5-4417靶:5'-GGTCAGCAAAGAGACCCTCTGCTGCAC-3'(SEQIDNO:1448)
5'-AGCAAAGAGACCCUCUGCUGCACca-3'(SEQIDNO:297)
3'-AGUCGUUUCUCUGGGAGACGACGUGGU-5'(SEQIDNO:873)
CKAP5-4419靶:5'-TCAGCAAAGAGACCCTCTGCTGCACCA-3'(SEQIDNO:1449)
5'-CAAAGAGACCCUCUGCUGCACCAat-3'(SEQIDNO:298)
3'-UCGUUUCUCUGGGAGACGACGUGGUUA-5'(SEQIDNO:874)
CKAP5-4421靶:5'-AGCAAAGAGACCCTCTGCTGCACCAAT-3'(SEQIDNO:1450)
5'-AAGAGACCCUCUGCUGCACCAAUaa-3'(SEQIDNO:299)
3'-GUUUCUCUGGGAGACGACGUGGUUAUU-5'(SEQIDNO:875)
CKAP5-4423靶:5'-CAAAGAGACCCTCTGCTGCACCAATAA-3'(SEQIDNO:1451)
5'-UACGCAAGGGACCAGCUGAGGACat-3'(SEQIDNO:300)
3'-CAAUGCGUUCCCUGGUCGACUCCUGUA-5'(SEQIDNO:876)
CKAP5-4505靶:5'-GTTACGCAAGGGACCAGCTGAGGACAT-3'(SEQIDNO:1452)
5'-CGCAAGGGACCAGCUGAGGACAUgt-3'(SEQIDNO:301)
3'-AUGCGUUCCCUGGUCGACUCCUGUACA-5'(SEQIDNO:877)
CKAP5-4507靶:5'-TACGCAAGGGACCAGCTGAGGACATGT-3'(SEQIDNO:1453)
5'-CGCCGAGAAUUCCAGCUGGAUCUag-3'(SEQIDNO:302)
3'-AGGCGGCUCUUAAGGUCGACCUAGAUC-5'(SEQIDNO:878)
CKAP5-4591靶:5'-TCCGCCGAGAATTCCAGCTGGATCTAG-3'(SEQIDNO:1454)
5'-CCGAGAAUUCCAGCUGGAUCUAGat-3'(SEQIDNO:303)
3'-GCGGCUCUUAAGGUCGACCUAGAUCUA-5'(SEQIDNO:879)
CKAP5-4593靶:5'-CGCCGAGAATTCCAGCTGGATCTAGAT-3'(SEQIDNO:1455)
5'-AGAUCCGGGCUGUUUCUCCACACtt-3'(SEQIDNO:304)
3'-GUUCUAGGCCCGACAAAGAGGUGUGAA-5'(SEQIDNO:880)
CKAP5-4718靶:5'-CAAGATCCGGGCTGTTTCTCCACACTT-3'(SEQIDNO:1456)
5'-AUCCGGGCUGUUUCUCCACACUUcg-3'(SEQIDNO:305)
3'-UCUAGGCCCGACAAAGAGGUGUGAAGC-5'(SEQIDNO:881)
CKAP5-4720靶:5'-AGATCCGGGCTGTTTCTCCACACTTCG-3'(SEQIDNO:1457)
5'-GAUGACAUGCACAGUAAUACAGCat-3'(SEQIDNO:306)
3'-AGCUACUGUACGUGUCAUUAUGUCGUA-5'(SEQIDNO:882)
CKAP5-4744靶:5'-TCGATGACATGCACAGTAATACAGCAT-3'(SEQIDNO:1458)
5'-UGACAUGCACAGUAAUACAGCAUcc-3'(SEQIDNO:307)
3'-CUACUGUACGUGUCAUUAUGUCGUAGG-5'(SEQIDNO:883)
CKAP5-4746靶:5'-GATGACATGCACAGTAATACAGCATCC-3'(SEQIDNO:1459)
5'-ACAUGCACAGUAAUACAGCAUCCac-3'(SEQIDNO:308)
3'-ACUGUACGUGUCAUUAUGUCGUAGGUG-5'(SEQIDNO:884)
CKAP5-4748靶:5'-TGACATGCACAGTAATACAGCATCCAC-3'(SEQIDNO:1460)
5'-AUGCACAGUAAUACAGCAUCCACaa-3'(SEQIDNO:309)
3'-UGUACGUGUCAUUAUGUCGUAGGUGUU-5'(SEQIDNO:885)
CKAP5-4750靶:5'-ACATGCACAGTAATACAGCATCCACAA-3'(SEQIDNO:1461)
5'-GCACAGUAAUACAGCAUCCACAAtc-3'(SEQIDNO:310)
3'-UACGUGUCAUUAUGUCGUAGGUGUUAG-5'(SEQIDNO:886)
CKAP5-4752靶:5'-ATGCACAGTAATACAGCATCCACAATC-3'(SEQIDNO:1462)
5'-ACAGUAAUACAGCAUCCACAAUCaa-3'(SEQIDNO:311)
3'-CGUGUCAUUAUGUCGUAGGUGUUAGUU-5'(SEQIDNO:887)
CKAP5-4754靶:5'-GCACAGTAATACAGCATCCACAATCAA-3'(SEQIDNO:1463)
5'-AGUAAUACAGCAUCCACAAUCAAtt-3'(SEQIDNO:312)
3'-UGUCAUUAUGUCGUAGGUGUUAGUUAA-5'(SEQIDNO:888)
CKAP5-4756靶:5'-ACAGTAATACAGCATCCACAATCAATT-3'(SEQIDNO:1464)
5'-UAAUACAGCAUCCACAAUCAAUUtc-3'(SEQIDNO:313)
3'-UCAUUAUGUCGUAGGUGUUAGUUAAAG-5'(SEQIDNO:889)
CKAP5-4758靶:5'-AGTAATACAGCATCCACAATCAATTTC-3'(SEQIDNO:1465)
5'-AUACAGCAUCCACAAUCAAUUUCat-3'(SEQIDNO:314)
3'-AUUAUGUCGUAGGUGUUAGUUAAAGUA-5'(SEQIDNO:890)
CKAP5-4760靶:5'-TAATACAGCATCCACAATCAATTTCAT-3'(SEQIDNO:1466)
5'-ACAGCAUCCACAAUCAAUUUCAUta-3'(SEQIDNO:315)
3'-UAUGUCGUAGGUGUUAGUUAAAGUAAU-5'(SEQIDNO:891)
CKAP5-4762靶:5'-ATACAGCATCCACAATCAATTTCATTA-3'(SEQIDNO:1467)
5'-AGCAUCCACAAUCAAUUUCAUUAtc-3'(SEQIDNO:316)
3'-UGUCGUAGGUGUUAGUUAAAGUAAUAG-5'(SEQIDNO:892)
CKAP5-4764靶:5'-ACAGCATCCACAATCAATTTCATTATC-3'(SEQIDNO:1468)
5'-CAUCCACAAUCAAUUUCAUUAUCtc-3'(SEQIDNO:317)
3'-UCGUAGGUGUUAGUUAAAGUAAUAGAG-5'(SEQIDNO:893)
CKAP5-4766靶:5'-AGCATCCACAATCAATTTCATTATCTC-3'(SEQIDNO:1469)
5'-UCCACAAUCAAUUUCAUUAUCUCcc-3'(SEQIDNO:318)
3'-GUAGGUGUUAGUUAAAGUAAUAGAGGG-5'(SEQIDNO:894)
CKAP5-4768靶:5'-CATCCACAATCAATTTCATTATCTCCC-3'(SEQIDNO:1470)
5'-CACAAUCAAUUUCAUUAUCUCCCaa-3'(SEQIDNO:319)
3'-AGGUGUUAGUUAAAGUAAUAGAGGGUU-5'(SEQIDNO:895)
CKAP5-4770靶:5'-TCCACAATCAATTTCATTATCTCCCAA-3'(SEQIDNO:1471)
5'-CAAUCAAUUUCAUUAUCUCCCAAgt-3'(SEQIDNO:320)
3'-GUGUUAGUUAAAGUAAUAGAGGGUUCA-5'(SEQIDNO:896)
CKAP5-4772靶:5'-CACAATCAATTTCATTATCTCCCAAGT-3'(SEQIDNO:1472)
5'-AUCAAUUUCAUUAUCUCCCAAGUag-3'(SEQIDNO:321)
3'-GUUAGUUAAAGUAAUAGAGGGUUCAUC-5'(SEQIDNO:897)
CKAP5-4774靶:5'-CAATCAATTTCATTATCTCCCAAGTAG-3'(SEQIDNO:1473)
5'-CAAUUUCAUUAUCUCCCAAGUAGcc-3'(SEQIDNO:322)
3'-UAGUUAAAGUAAUAGAGGGUUCAUCGG-5'(SEQIDNO:898)
CKAP5-4776靶:5'-ATCAATTTCATTATCTCCCAAGTAGCC-3'(SEQIDNO:1474)
5'-AUUUCAUUAUCUCCCAAGUAGCCag-3'(SEQIDNO:323)
3'-GUUAAAGUAAUAGAGGGUUCAUCGGUC-5'(SEQIDNO:899)
CKAP5-4778靶:5'-CAATTTCATTATCTCCCAAGTAGCCAG-3'(SEQIDNO:1475)
5'-UUCAUUAUCUCCCAAGUAGCCAGtg-3'(SEQIDNO:324)
3'-UAAAGUAAUAGAGGGUUCAUCGGUCAC-5'(SEQIDNO:900)
CKAP5-4780靶:5'-ATTTCATTATCTCCCAAGTAGCCAGTG-3'(SEQIDNO:1476)
5'-CAUUAUCUCCCAAGUAGCCAGUGgt-3'(SEQIDNO:325)
3'-AAGUAAUAGAGGGUUCAUCGGUCACCA-5'(SEQIDNO:901)
CKAP5-4782靶:5'-TTCATTATCTCCCAAGTAGCCAGTGGT-3'(SEQIDNO:1477)
5'-UUAUCUCCCAAGUAGCCAGUGGUga-3'(SEQIDNO:326)
3'-GUAAUAGAGGGUUCAUCGGUCACCACU-5'(SEQIDNO:902)
CKAP5-4784靶:5'-CATTATCTCCCAAGTAGCCAGTGGTGA-3'(SEQIDNO:1478)
5'-AUCUCCCAAGUAGCCAGUGGUGAca-3'(SEQIDNO:327)
3'-AAUAGAGGGUUCAUCGGUCACCACUGU-5'(SEQIDNO:903)
CKAP5-4786靶:5'-TTATCTCCCAAGTAGCCAGTGGTGACA-3'(SEQIDNO:1479)
5'-CUCCCAAGUAGCCAGUGGUGACAtc-3'(SEQIDNO:328)
3'-UAGAGGGUUCAUCGGUCACCACUGUAG-5'(SEQIDNO:904)
CKAP5-4788靶:5'-ATCTCCCAAGTAGCCAGTGGTGACATC-3'(SEQIDNO:1480)
5'-CCCAAGUAGCCAGUGGUGACAUCaa-3'(SEQIDNO:329)
3'-GAGGGUUCAUCGGUCACCACUGUAGUU-5'(SEQIDNO:905)
CKAP5-4790靶:5'-CTCCCAAGTAGCCAGTGGTGACATCAA-3'(SEQIDNO:1481)
5'-CAAGUAGCCAGUGGUGACAUCAAca-3'(SEQIDNO:330)
3'-GGGUUCAUCGGUCACCACUGUAGUUGU-5'(SEQIDNO:906)
CKAP5-4792靶:5'-CCCAAGTAGCCAGTGGTGACATCAACA-3'(SEQIDNO:1482)
5'-GCCCGGGAGGCCUCCACUGGAGUac-3'(SEQIDNO:331)
3'-AACGGGCCCUCCGGAGGUGACCUCAUG-5'(SEQIDNO:907)
CKAP5-5041靶:5'-TTGCCCGGGAGGCCTCCACTGGAGTAC-3'(SEQIDNO:1483)
5'-CCGGGAGGCCUCCACUGGAGUACta-3'(SEQIDNO:332)
3'-CGGGCCCUCCGGAGGUGACCUCAUGAU-5'(SEQIDNO:908)
CKAP5-5043靶:5'-GCCCGGGAGGCCTCCACTGGAGTACTA-3'(SEQIDNO:1484)
5'-GGGAGGCCUCCACUGGAGUACUAaa-3'(SEQIDNO:333)
3'-GGCCCUCCGGAGGUGACCUCAUGAUUU-5'(SEQIDNO:909)
CKAP5-5045靶:5'-CCGGGAGGCCTCCACTGGAGTACTAAA-3'(SEQIDNO:1485)
5'-GAGGCCUCCACUGGAGUACUAAAag-3'(SEQIDNO:334)
3'-CCCUCCGGAGGUGACCUCAUGAUUUUC-5'(SEQIDNO:910)
CKAP5-5047靶:5'-GGGAGGCCTCCACTGGAGTACTAAAAG-3'(SEQIDNO:1486)
5'-AUCACCUUAAUGCUGGAUUCUCGga-3'(SEQIDNO:335)
3'-AGUAGUGGAAUUACGACCUAAGAGCCU-5'(SEQIDNO:911)
CKAP5-5089靶:5'-TCATCACCTTAATGCTGGATTCTCGGA-3'(SEQIDNO:1487)
5'-CACCUUAAUGCUGGAUUCUCGGAtt-3'(SEQIDNO:336)
3'-UAGUGGAAUUACGACCUAAGAGCCUAA-5'(SEQIDNO:912)
CKAP5-5091靶:5'-ATCACCTTAATGCTGGATTCTCGGATT-3'(SEQIDNO:1488)
5'-CCUUAAUGCUGGAUUCUCGGAUUga-3'(SEQIDNO:337)
3'-GUGGAAUUACGACCUAAGAGCCUAACU-5'(SEQIDNO:913)
CKAP5-5093靶:5'-CACCTTAATGCTGGATTCTCGGATTGA-3'(SEQIDNO:1489)
5'-UUAAUGCUGGAUUCUCGGAUUGAag-3'(SEQIDNO:338)
3'-GGAAUUACGACCUAAGAGCCUAACUUC-5'(SEQIDNO:914)
CKAP5-5095靶:5'-CCTTAATGCTGGATTCTCGGATTGAAG-3'(SEQIDNO:1490)
5'-AAUGCUGGAUUCUCGGAUUGAAGat-3'(SEQIDNO:339)
3'-AAUUACGACCUAAGAGCCUAACUUCUA-5'(SEQIDNO:915)
CKAP5-5097靶:5'-TTAATGCTGGATTCTCGGATTGAAGAT-3'(SEQIDNO:1491)
5'-UGCUGGAUUCUCGGAUUGAAGAUct-3'(SEQIDNO:340)
3'-UUACGACCUAAGAGCCUAACUUCUAGA-5'(SEQIDNO:916)
CKAP5-5099靶:5'-AATGCTGGATTCTCGGATTGAAGATCT-3'(SEQIDNO:1492)
5'-CUGGAUUCUCGGAUUGAAGAUCUtg-3'(SEQIDNO:341)
3'-ACGACCUAAGAGCCUAACUUCUAGAAC-5'(SEQIDNO:917)
CKAP5-5101靶:5'-TGCTGGATTCTCGGATTGAAGATCTTG-3'(SEQIDNO:1493)
5'-GGAUUCUCGGAUUGAAGAUCUUGag-3'(SEQIDNO:342)
3'-GACCUAAGAGCCUAACUUCUAGAACUC-5'(SEQIDNO:918)
CKAP5-5103靶:5'-CTGGATTCTCGGATTGAAGATCTTGAG-3'(SEQIDNO:1494)
5'-AUUCUCGGAUUGAAGAUCUUGAGga-3'(SEQIDNO:343)
3'-CCUAAGAGCCUAACUUCUAGAACUCCU-5'(SEQIDNO:919)
CKAP5-5105靶:5'-GGATTCTCGGATTGAAGATCTTGAGGA-3'(SEQIDNO:1495)
5'-CUGUGAACCUCUUGGUGGUGAAGgt-3'(SEQIDNO:344)
3'-GAGACACUUGGAGAACCACCACUUCCA-5'(SEQIDNO:920)
CKAP5-5150靶:5'-CTCTGTGAACCTCTTGGTGGTGAAGGT-3'(SEQIDNO:1496)
5'-GUGAACCUCUUGGUGGUGAAGGUtc-3'(SEQIDNO:345)
3'-GACACUUGGAGAACCACCACUUCCAAG-5'(SEQIDNO:921)
CKAP5-5152靶:5'-CTGTGAACCTCTTGGTGGTGAAGGTTC-3'(SEQIDNO:1497)
5'-GAACCUCUUGGUGGUGAAGGUUCtg-3'(SEQIDNO:346)
3'-CACUUGGAGAACCACCACUUCCAAGAC-5'(SEQIDNO:922)
CKAP5-5154靶:5'-GTGAACCTCTTGGTGGTGAAGGTTCTG-3'(SEQIDNO:1498)
5'-ACCUCUUGGUGGUGAAGGUUCUGga-3'(SEQIDNO:347)
3'-CUUGGAGAACCACCACUUCCAAGACCU-5'(SEQIDNO:923)
CKAP5-5156靶:5'-GAACCTCTTGGTGGTGAAGGTTCTGGA-3'(SEQIDNO:1499)
5'-GACAGCCUGCUAGCAACAGCCAGtt-3'(SEQIDNO:348)
3'-UUCUGUCGGACGAUCGUUGUCGGUCAA-5'(SEQIDNO:924)
CKAP5-5230靶:5'-AAGACAGCCTGCTAGCAACAGCCAGTT-3'(SEQIDNO:1500)
5'-AGUUCUCCCAAAUUCUCAGAGCUtg-3'(SEQIDNO:349)
3'-GGUCAAGAGGGUUUAAGAGUCUCGAAC-5'(SEQIDNO:925)
CKAP5-5251靶:5'-CCAGTTCTCCCAAATTCTCAGAGCTTG-3'(SEQIDNO:1501)
5'-UUCUCCCAAAUUCUCAGAGCUUGtt-3'(SEQIDNO:350)
3'-UCAAGAGGGUUUAAGAGUCUCGAACAA-5'(SEQIDNO:926)
CKAP5-5253靶:5'-AGTTCTCCCAAATTCTCAGAGCTTGTT-3'(SEQIDNO:1502)
5'-CUCCCAAAUUCUCAGAGCUUGUUat-3'(SEQIDNO:351)
3'-AAGAGGGUUUAAGAGUCUCGAACAAUA-5'(SEQIDNO:927)
CKAP5-5255靶:5'-TTCTCCCAAATTCTCAGAGCTTGTTAT-3'(SEQIDNO:1503)
5'-CCCAAAUUCUCAGAGCUUGUUAUga-3'(SEQIDNO:352)
3'-GAGGGUUUAAGAGUCUCGAACAAUACU-5'(SEQIDNO:928)
CKAP5-5257靶:5'-CTCCCAAATTCTCAGAGCTTGTTATGA-3'(SEQIDNO:1504)
5'-CAAAUUCUCAGAGCUUGUUAUGAag-3'(SEQIDNO:353)
3'-GGGUUUAAGAGUCUCGAACAAUACUUC-5'(SEQIDNO:929)
CKAP5-5259靶:5'-CCCAAATTCTCAGAGCTTGTTATGAAG-3'(SEQIDNO:1505)
5'-AAUUCUCAGAGCUUGUUAUGAAGtg-3'(SEQIDNO:354)
3'-GUUUAAGAGUCUCGAACAAUACUUCAC-5'(SEQIDNO:930)
CKAP5-5261靶:5'-CAAATTCTCAGAGCTTGTTATGAAGTG-3'(SEQIDNO:1506)
5'-UUCUCAGAGCUUGUUAUGAAGUGtc-3'(SEQIDNO:355)
3'-UUAAGAGUCUCGAACAAUACUUCACAG-5'(SEQIDNO:931)
CKAP5-5263靶:5'-AATTCTCAGAGCTTGTTATGAAGTGTC-3'(SEQIDNO:1507)
5'-CUCAGAGCUUGUUAUGAAGUGUCtc-3'(SEQIDNO:356)
3'-AAGAGUCUCGAACAAUACUUCACAGAG-5'(SEQIDNO:932)
CKAP5-5265靶:5'-TTCTCAGAGCTTGTTATGAAGTGTCTC-3'(SEQIDNO:1508)
5'-CAGAGCUUGUUAUGAAGUGUCUCtg-3'(SEQIDNO:357)
3'-GAGUCUCGAACAAUACUUCACAGAGAC-5'(SEQIDNO:933)
CKAP5-5267靶:5'-CTCAGAGCTTGTTATGAAGTGTCTCTG-3'(SEQIDNO:1509)
5'-GAGCUUGUUAUGAAGUGUCUCUGga-3'(SEQIDNO:358)
3'-GUCUCGAACAAUACUUCACAGAGACCU-5'(SEQIDNO:934)
CKAP5-5269靶:5'-CAGAGCTTGTTATGAAGTGTCTCTGGA-3'(SEQIDNO:1510)
5'-AGCAUUAACCUAGACAGAAUUCUtc-3'(SEQIDNO:359)
3'-UAUCGUAAUUGGAUCUGUCUUAAGAAG-5'(SEQIDNO:935)
CKAP5-5326靶:5'-ATAGCATTAACCTAGACAGAATTCTTC-3'(SEQIDNO:1511)
5'-CAUUAACCUAGACAGAAUUCUUCtg-3'(SEQIDNO:360)
3'-UCGUAAUUGGAUCUGUCUUAAGAAGAC-5'(SEQIDNO:936)
CKAP5-5328靶:5'-AGCATTAACCTAGACAGAATTCTTCTG-3'(SEQIDNO:1512)
5'-UUAACCUAGACAGAAUUCUUCUGga-3'(SEQIDNO:361)
3'-GUAAUUGGAUCUGUCUUAAGAAGACCU-5'(SEQIDNO:937)
CKAP5-5330靶:5'-CATTAACCTAGACAGAATTCTTCTGGA-3'(SEQIDNO:1513)
5'-AACCUAGACAGAAUUCUUCUGGAta-3'(SEQIDNO:362)
3'-AAUUGGAUCUGUCUUAAGAAGACCUAU-5'(SEQIDNO:938)
CKAP5-5332靶:5'-TTAACCTAGACAGAATTCTTCTGGATA-3'(SEQIDNO:1514)
5'-CCUAGACAGAAUUCUUCUGGAUAtc-3'(SEQIDNO:363)
3'-UUGGAUCUGUCUUAAGAAGACCUAUAG-5'(SEQIDNO:939)
CKAP5-5334靶:5'-AACCTAGACAGAATTCTTCTGGATATC-3'(SEQIDNO:1515)
5'-UAGACAGAAUUCUUCUGGAUAUCca-3'(SEQIDNO:364)
3'-GGAUCUGUCUUAAGAAGACCUAUAGGU-5'(SEQIDNO:940)
CKAP5-5336靶:5'-CCTAGACAGAATTCTTCTGGATATCCA-3'(SEQIDNO:1516)
5'-UCCACAUUUUCAUGAAGGUCUUCcc-3'(SEQIDNO:365)
3'-AUAGGUGUAAAAGUACUUCCAGAAGGG-5'(SEQIDNO:941)
CKAP5-5357靶:5'-TATCCACATTTTCATGAAGGTCTTCCC-3'(SEQIDNO:1517)
5'-GAAGCAAUGCAAAAGUGAAUUUCcc-3'(SEQIDNO:366)
3'-GACUUCGUUACGUUUUCACUUAAAGGG-5'(SEQIDNO:942)
CKAP5-5394靶:5'-CTGAAGCAATGCAAAAGTGAATTTCCC-3'(SEQIDNO:1518)
5'-AGCAAUGCAAAAGUGAAUUUCCCat-3'(SEQIDNO:367)
3'-CUUCGUUACGUUUUCACUUAAAGGGUA-5'(SEQIDNO:943)
CKAP5-5396靶:5'-GAAGCAATGCAAAAGTGAATTTCCCAT-3'(SEQIDNO:1519)
5'-CAAUGCAAAAGUGAAUUUCCCAUaa-3'(SEQIDNO:368)
3'-UCGUUACGUUUUCACUUAAAGGGUAUU-5'(SEQIDNO:944)
CKAP5-5398靶:5'-AGCAATGCAAAAGTGAATTTCCCATAA-3'(SEQIDNO:1520)
5'-AGUAUGGACCAGACUGGGAGCAAgt-3'(SEQIDNO:369)
3'-UGUCAUACCUGGUCUGACCCUCGUUCA-5'(SEQIDNO:945)
CKAP5-5551靶:5'-ACAGTATGGACCAGACTGGGAGCAAGT-3'(SEQIDNO:1521)
5'-UAUGGACCAGACUGGGAGCAAGUct-3'(SEQIDNO:370)
3'-UCAUACCUGGUCUGACCCUCGUUCAGA-5'(SEQIDNO:946)
CKAP5-5553靶:5'-AGTATGGACCAGACTGGGAGCAAGTCT-3'(SEQIDNO:1522)
5'-UGGACCAGACUGGGAGCAAGUCUga-3'(SEQIDNO:371)
3'-AUACCUGGUCUGACCCUCGUUCAGACU-5'(SEQIDNO:947)
CKAP5-5555靶:5'-TATGGACCAGACTGGGAGCAAGTCTGA-3'(SEQIDNO:1523)
5'-GACCAGACUGGGAGCAAGUCUGAta-3'(SEQIDNO:372)
3'-ACCUGGUCUGACCCUCGUUCAGACUAU-5'(SEQIDNO:948)
CKAP5-5557靶:5'-TGGACCAGACTGGGAGCAAGTCTGATA-3'(SEQIDNO:1524)
5'-CCAGACUGGGAGCAAGUCUGAUAag-3'(SEQIDNO:373)
3'-CUGGUCUGACCCUCGUUCAGACUAUUC-5'(SEQIDNO:949)
CKAP5-5559靶:5'-GACCAGACTGGGAGCAAGTCTGATAAG-3'(SEQIDNO:1525)
5'-AGACUGGGAGCAAGUCUGAUAAGga-3'(SEQIDNO:374)
3'-GGUCUGACCCUCGUUCAGACUAUUCCU-5'(SEQIDNO:950)
CKAP5-5561靶:5'-CCAGACTGGGAGCAAGTCTGATAAGGA-3'(SEQIDNO:1526)
5'-ACUGGGAGCAAGUCUGAUAAGGAaa-3'(SEQIDNO:375)
3'-UCUGACCCUCGUUCAGACUAUUCCUUU-5'(SEQIDNO:951)
CKAP5-5563靶:5'-AGACTGGGAGCAAGTCTGATAAGGAAA-3'(SEQIDNO:1527)
5'-UGGGAGCAAGUCUGAUAAGGAAAca-3'(SEQIDNO:376)
3'-UGACCCUCGUUCAGACUAUUCCUUUGU-5'(SEQIDNO:952)
CKAP5-5565靶:5'-ACTGGGAGCAAGTCTGATAAGGAAACA-3'(SEQIDNO:1528)
5'-GGAGCAAGUCUGAUAAGGAAACAga-3'(SEQIDNO:377)
3'-ACCCUCGUUCAGACUAUUCCUUUGUCU-5'(SEQIDNO:953)
CKAP5-5567靶:5'-TGGGAGCAAGTCTGATAAGGAAACAGA-3'(SEQIDNO:1529)
5'-AGCAAGUCUGAUAAGGAAACAGAaa-3'(SEQIDNO:378)
3'-CCUCGUUCAGACUAUUCCUUUGUCUUU-5'(SEQIDNO:954)
CKAP5-5569靶:5'-GGAGCAAGTCTGATAAGGAAACAGAAA-3'(SEQIDNO:1530)
5'-CAAGUCUGAUAAGGAAACAGAAAag-3'(SEQIDNO:379)
3'-UCGUUCAGACUAUUCCUUUGUCUUUUC-5'(SEQIDNO:955)
CKAP5-5571靶:5'-AGCAAGTCTGATAAGGAAACAGAAAAG-3'(SEQIDNO:1531)
5'-AGUCUGAUAAGGAAACAGAAAAGgg-3'(SEQIDNO:380)
3'-GUUCAGACUAUUCCUUUGUCUUUUCCC-5'(SEQIDNO:956)
CKAP5-5573靶:5'-CAAGTCTGATAAGGAAACAGAAAAGGG-3'(SEQIDNO:1532)
5'-UCUGAUAAGGAAACAGAAAAGGGag-3'(SEQIDNO:381)
3'-UCAGACUAUUCCUUUGUCUUUUCCCUC-5'(SEQIDNO:957)
CKAP5-5575靶:5'-AGTCTGATAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:1533)
5'-UGAUAAGGAAACAGAAAAGGGAGca-3'(SEQIDNO:382)
3'-AGACUAUUCCUUUGUCUUUUCCCUCGU-5'(SEQIDNO:958)
CKAP5-5577靶:5'-TCTGATAAGGAAACAGAAAAGGGAGCA-3'(SEQIDNO:1534)
5'-AUAAGGAAACAGAAAAGGGAGCAtc-3'(SEQIDNO:383)
3'-ACUAUUCCUUUGUCUUUUCCCUCGUAG-5'(SEQIDNO:959)
CKAP5-5579靶:5'-TGATAAGGAAACAGAAAAGGGAGCATC-3'(SEQIDNO:1535)
5'-AAGGAAACAGAAAAGGGAGCAUCtc-3'(SEQIDNO:384)
3'-UAUUCCUUUGUCUUUUCCCUCGUAGAG-5'(SEQIDNO:960)
CKAP5-5581靶:5'-ATAAGGAAACAGAAAAGGGAGCATCTC-3'(SEQIDNO:1536)
5'-UCUCGAAUAGAUGAAAAAUCAUCaa-3'(SEQIDNO:385)
3'-GUAGAGCUUAUCUACUUUUUAGUAGUU-5'(SEQIDNO:961)
CKAP5-5602靶:5'-CATCTCGAATAGATGAAAAATCATCAA-3'(SEQIDNO:1537)
5'-UCGAAUAGAUGAAAAAUCAUCAAag-3'(SEQIDNO:386)
3'-AGAGCUUAUCUACUUUUUAGUAGUUUC-5'(SEQIDNO:962)
CKAP5-5604靶:5'-TCTCGAATAGATGAAAAATCATCAAAG-3'(SEQIDNO:1538)
5'-GAAUAGAUGAAAAAUCAUCAAAGgc-3'(SEQIDNO:387)
3'-AGCUUAUCUACUUUUUAGUAGUUUCCG-5'(SEQIDNO:963)
CKAP5-5606靶:5'-TCGAATAGATGAAAAATCATCAAAGGC-3'(SEQIDNO:1539)
5'-AUAGAUGAAAAAUCAUCAAAGGCca-3'(SEQIDNO:388)
3'-CUUAUCUACUUUUUAGUAGUUUCCGGU-5'(SEQIDNO:964)
CKAP5-5608靶:5'-GAATAGATGAAAAATCATCAAAGGCCA-3'(SEQIDNO:1540)
5'-AGAUGAAAAAUCAUCAAAGGCCAaa-3'(SEQIDNO:389)
3'-UAUCUACUUUUUAGUAGUUUCCGGUUU-5'(SEQIDNO:965)
CKAP5-5610靶:5'-ATAGATGAAAAATCATCAAAGGCCAAA-3'(SEQIDNO:1541)
5'-AUGAAAAAUCAUCAAAGGCCAAAgt-3'(SEQIDNO:390)
3'-UCUACUUUUUAGUAGUUUCCGGUUUCA-5'(SEQIDNO:966)
CKAP5-5612靶:5'-AGATGAAAAATCATCAAAGGCCAAAGT-3'(SEQIDNO:1542)
5'-GAAAAAUCAUCAAAGGCCAAAGUga-3'(SEQIDNO:391)
3'-UACUUUUUAGUAGUUUCCGGUUUCACU-5'(SEQIDNO:967)
CKAP5-5614靶:5'-ATGAAAAATCATCAAAGGCCAAAGTGA-3'(SEQIDNO:1543)
5'-AAAAUCAUCAAAGGCCAAAGUGAat-3'(SEQIDNO:392)
3'-CUUUUUAGUAGUUUCCGGUUUCACUUA-5'(SEQIDNO:968)
CKAP5-5616靶:5'-GAAAAATCATCAAAGGCCAAAGTGAAT-3'(SEQIDNO:1544)
5'-AAUCAUCAAAGGCCAAAGUGAAUga-3'(SEQIDNO:393)
3'-UUUUAGUAGUUUCCGGUUUCACUUACU-5'(SEQIDNO:969)
CKAP5-5618靶:5'-AAAATCATCAAAGGCCAAAGTGAATGA-3'(SEQIDNO:1545)
5'-AUGAUUUCUUAGCUGAGAUUUUUaa-3'(SEQIDNO:394)
3'-CUUACUAAAGAAUCGACUCUAAAAAUU-5'(SEQIDNO:970)
CKAP5-5639靶:5'-GAATGATTTCTTAGCTGAGATTTTTAA-3'(SEQIDNO:1546)
5'-GAUUUCUUAGCUGAGAUUUUUAAga-3'(SEQIDNO:395)
3'-UACUAAAGAAUCGACUCUAAAAAUUCU-5'(SEQIDNO:971)
CKAP5-5641靶:5'-ATGATTTCTTAGCTGAGATTTTTAAGA-3'(SEQIDNO:1547)
5'-UUUCUUAGCUGAGAUUUUUAAGAag-3'(SEQIDNO:396)
3'-CUAAAGAAUCGACUCUAAAAAUUCUUC-5'(SEQIDNO:972)
CKAP5-5643靶:5'-GATTTCTTAGCTGAGATTTTTAAGAAG-3'(SEQIDNO:1548)
5'-UCUUAGCUGAGAUUUUUAAGAAGat-3'(SEQIDNO:397)
3'-AAAGAAUCGACUCUAAAAAUUCUUCUA-5'(SEQIDNO:973)
CKAP5-5645靶:5'-TTTCTTAGCTGAGATTTTTAAGAAGAT-3'(SEQIDNO:1549)
5'-UUAGCUGAGAUUUUUAAGAAGAUtg-3'(SEQIDNO:398)
3'-AGAAUCGACUCUAAAAAUUCUUCUAAC-5'(SEQIDNO:974)
CKAP5-5647靶:5'-TCTTAGCTGAGATTTTTAAGAAGATTG-3'(SEQIDNO:1550)
5'-AGCUGAGAUUUUUAAGAAGAUUGgc-3'(SEQIDNO:399)
3'-AAUCGACUCUAAAAAUUCUUCUAACCG-5'(SEQIDNO:975)
CKAP5-5649靶:5'-TTAGCTGAGATTTTTAAGAAGATTGGC-3'(SEQIDNO:1551)
5'-CUGAGAUUUUUAAGAAGAUUGGCtc-3'(SEQIDNO:400)
3'-UCGACUCUAAAAAUUCUUCUAACCGAG-5'(SEQIDNO:976)
CKAP5-5651靶:5'-AGCTGAGATTTTTAAGAAGATTGGCTC-3'(SEQIDNO:1552)
5'-GAGAUUUUUAAGAAGAUUGGCUCta-3'(SEQIDNO:401)
3'-GACUCUAAAAAUUCUUCUAACCGAGAU-5'(SEQIDNO:977)
CKAP5-5653靶:5'-CTGAGATTTTTAAGAAGATTGGCTCTA-3'(SEQIDNO:1553)
5'-GAUUUUUAAGAAGAUUGGCUCUAaa-3'(SEQIDNO:402)
3'-CUCUAAAAAUUCUUCUAACCGAGAUUU-5'(SEQIDNO:978)
CKAP5-5655靶:5'-GAGATTTTTAAGAAGATTGGCTCTAAA-3'(SEQIDNO:1554)
5'-UUUUUAAGAAGAUUGGCUCUAAAga-3'(SEQIDNO:403)
3'-CUAAAAAUUCUUCUAACCGAGAUUUCU-5'(SEQIDNO:979)
CKAP5-5657靶:5'-GATTTTTAAGAAGATTGGCTCTAAAGA-3'(SEQIDNO:1555)
5'-UAGCAGAGUUAUAUGAAUAUAAGaa-3'(SEQIDNO:404)
3'-UGAUCGUCUCAAUAUACUUAUAUUCUU-5'(SEQIDNO:980)
CKAP5-5699靶:5'-ACTAGCAGAGTTATATGAATATAAGAA-3'(SEQIDNO:1556)
5'-GCAGAGUUAUAUGAAUAUAAGAAga-3'(SEQIDNO:405)
3'-AUCGUCUCAAUAUACUUAUAUUCUUCU-5'(SEQIDNO:981)
CKAP5-5701靶:5'-TAGCAGAGTTATATGAATATAAGAAGA-3'(SEQIDNO:1557)
5'-AGAGUUAUAUGAAUAUAAGAAGAaa-3'(SEQIDNO:406)
3'-CGUCUCAAUAUACUUAUAUUCUUCUUU-5'(SEQIDNO:982)
CKAP5-5703靶:5'-GCAGAGTTATATGAATATAAGAAGAAA-3'(SEQIDNO:1558)
5'-AGUUAUAUGAAUAUAAGAAGAAAta-3'(SEQIDNO:407)
3'-UCUCAAUAUACUUAUAUUCUUCUUUAU-5'(SEQIDNO:983)
CKAP5-5705靶:5'-AGAGTTATATGAATATAAGAAGAAATA-3'(SEQIDNO:1559)
5'-UUAUAUGAAUAUAAGAAGAAAUAct-3'(SEQIDNO:408)
3'-UCAAUAUACUUAUAUUCUUCUUUAUGA-5'(SEQIDNO:984)
CKAP5-5707靶:5'-AGTTATATGAATATAAGAAGAAATACT-3'(SEQIDNO:1560)
5'-AUAUGAAUAUAAGAAGAAAUACUca-3'(SEQIDNO:409)
3'-AAUAUACUUAUAUUCUUCUUUAUGAGU-5'(SEQIDNO:985)
CKAP5-5709靶:5'-TTATATGAATATAAGAAGAAATACTCA-3'(SEQIDNO:1561)
5'-AUGAAUAUAAGAAGAAAUACUCAga-3'(SEQIDNO:410)
3'-UAUACUUAUAUUCUUCUUUAUGAGUCU-5'(SEQIDNO:986)
CKAP5-5711靶:5'-ATATGAATATAAGAAGAAATACTCAGA-3'(SEQIDNO:1562)
5'-UGACAUUGAACCAUUUCUGAAAAat-3'(SEQIDNO:411)
3'-CGACUGUAACUUGGUAAAGACUUUUUA-5'(SEQIDNO:987)
CKAP5-5739靶:5'-GCTGACATTGAACCATTTCTGAAAAAT-3'(SEQIDNO:1563)
5'-ACAUUGAACCAUUUCUGAAAAAUtc-3'(SEQIDNO:412)
3'-ACUGUAACUUGGUAAAGACUUUUUAAG-5'(SEQIDNO:988)
CKAP5-5741靶:5'-TGACATTGAACCATTTCTGAAAAATTC-3'(SEQIDNO:1564)
5'-AUUGAACCAUUUCUGAAAAAUUCct-3'(SEQIDNO:413)
3'-UGUAACUUGGUAAAGACUUUUUAAGGA-5'(SEQIDNO:989)
CKAP5-5743靶:5'-ACATTGAACCATTTCTGAAAAATTCCT-3'(SEQIDNO:1565)
5'-UGAACCAUUUCUGAAAAAUUCCUca-3'(SEQIDNO:414)
3'-UAACUUGGUAAAGACUUUUUAAGGAGU-5'(SEQIDNO:990)
CKAP5-5745靶:5'-ATTGAACCATTTCTGAAAAATTCCTCA-3'(SEQIDNO:1566)
5'-AACCAUUUCUGAAAAAUUCCUCAca-3'(SEQIDNO:415)
3'-ACUUGGUAAAGACUUUUUAAGGAGUGU-5'(SEQIDNO:991)
CKAP5-5747靶:5'-TGAACCATTTCTGAAAAATTCCTCACA-3'(SEQIDNO:1567)
5'-CCAUUUCUGAAAAAUUCCUCACAgt-3'(SEQIDNO:416)
3'-UUGGUAAAGACUUUUUAAGGAGUGUCA-5'(SEQIDNO:992)
CKAP5-5749靶:5'-AACCATTTCTGAAAAATTCCTCACAGT-3'(SEQIDNO:1568)
5'-AGAGGCCUUCGGGUGAUUGAGAUgg-3'(SEQIDNO:417)
3'-UUUCUCCGGAAGCCCACUAACUCUACC-5'(SEQIDNO:993)
CKAP5-5794靶:5'-AAAGAGGCCTTCGGGTGATTGAGATGG-3'(SEQIDNO:1569)
5'-AGGCCUUCGGGUGAUUGAGAUGGag-3'(SEQIDNO:418)
3'-UCUCCGGAAGCCCACUAACUCUACCUC-5'(SEQIDNO:994)
CKAP5-5796靶:5'-AGAGGCCTTCGGGTGATTGAGATGGAG-3'(SEQIDNO:1570)
5'-GCCUUCGGGUGAUUGAGAUGGAGag-3'(SEQIDNO:419)
3'-UCCGGAAGCCCACUAACUCUACCUCUC-5'(SEQIDNO:995)
CKAP5-5798靶:5'-AGGCCTTCGGGTGATTGAGATGGAGAG-3'(SEQIDNO:1571)
5'-CUUCGGGUGAUUGAGAUGGAGAGgg-3'(SEQIDNO:420)
3'-CGGAAGCCCACUAACUCUACCUCUCCC-5'(SEQIDNO:996)
CKAP5-5800靶:5'-GCCTTCGGGTGATTGAGATGGAGAGGG-3'(SEQIDNO:1572)
5'-UCGGGUGAUUGAGAUGGAGAGGGag-3'(SEQIDNO:421)
3'-GAAGCCCACUAACUCUACCUCUCCCUC-5'(SEQIDNO:997)
CKAP5-5802靶:5'-CTTCGGGTGATTGAGATGGAGAGGGAG-3'(SEQIDNO:1573)
5'-GGGUGAUUGAGAUGGAGAGGGAGgg-3'(SEQIDNO:422)
3'-AGCCCACUAACUCUACCUCUCCCUCCC-5'(SEQIDNO:998)
CKAP5-5804靶:5'-TCGGGTGATTGAGATGGAGAGGGAGGG-3'(SEQIDNO:1574)
5'-CCAUCUGUCUACUUGGAAAGGCUaa-3'(SEQIDNO:423)
3'-CCGGUAGACAGAUGAACCUUUCCGAUU-5'(SEQIDNO:999)
CKAP5-5944靶:5'-GGCCATCTGTCTACTTGGAAAGGCTAA-3'(SEQIDNO:1575)
5'-AUCUGUCUACUUGGAAAGGCUAAag-3'(SEQIDNO:424)
3'-GGUAGACAGAUGAACCUUUCCGAUUUC-5'(SEQIDNO:1000)
CKAP5-5946靶:5'-CCATCTGTCTACTTGGAAAGGCTAAAG-3'(SEQIDNO:1576)
5'-CUGUCUACUUGGAAAGGCUAAAGat-3'(SEQIDNO:425)
3'-UAGACAGAUGAACCUUUCCGAUUUCUA-5'(SEQIDNO:1001)
CKAP5-5948靶:5'-ATCTGTCTACTTGGAAAGGCTAAAGAT-3'(SEQIDNO:1577)
5'-GUCUACUUGGAAAGGCUAAAGAUcc-3'(SEQIDNO:426)
3'-GACAGAUGAACCUUUCCGAUUUCUAGG-5'(SEQIDNO:1002)
CKAP5-5950靶:5'-CTGTCTACTTGGAAAGGCTAAAGATCC-3'(SEQIDNO:1578)
5'-UGACCUCUUUGCUCUCCAAACCAgc-3'(SEQIDNO:427)
3'-AAACUGGAGAAACGAGAGGUUUGGUCG-5'(SEQIDNO:1003)
CKAP5-6026靶:5'-TTTGACCTCTTTGCTCTCCAAACCAGC-3'(SEQIDNO:1579)
5'-ACCUCUUUGCUCUCCAAACCAGCag-3'(SEQIDNO:428)
3'-ACUGGAGAAACGAGAGGUUUGGUCGUC-5'(SEQIDNO:1004)
CKAP5-6028靶:5'-TGACCTCTTTGCTCTCCAAACCAGCAG-3'(SEQIDNO:1580)
5'-CUCUUUGCUCUCCAAACCAGCAGtt-3'(SEQIDNO:429)
3'-UGGAGAAACGAGAGGUUUGGUCGUCAA-5'(SEQIDNO:1005)
CKAP5-6030靶:5'-ACCTCTTTGCTCTCCAAACCAGCAGTT-3'(SEQIDNO:1581)
5'-CUUUGCUCUCCAAACCAGCAGUUcc-3'(SEQIDNO:430)
3'-GAGAAACGAGAGGUUUGGUCGUCAAGG-5'(SEQIDNO:1006)
CKAP5-6032靶:5'-CTCTTTGCTCTCCAAACCAGCAGTTCC-3'(SEQIDNO:1582)
5'-UGACCUCCUCCUCCUCCACAGCUaa-3'(SEQIDNO:431)
3'-ACACUGGAGGAGGAGGAGGUGUCGAUU-5'(SEQIDNO:1007)
CKAP5-6173靶:5'-TGTGACCTCCTCCTCCTCCACAGCTAA-3'(SEQIDNO:1583)
5'-AGACUGGAGAGAAUAAAGAGCAGtc-3'(SEQIDNO:432)
3'-UUUCUGACCUCUCUUAUUUCUCGUCAG-5'(SEQIDNO:1008)
CKAP5-6217靶:5'-AAAGACTGGAGAGAATAAAGAGCAGTC-3'(SEQIDNO:1584)
5'-ACUGGAGAGAAUAAAGAGCAGUCgc-3'(SEQIDNO:433)
3'-UCUGACCUCUCUUAUUUCUCGUCAGCG-5'(SEQIDNO:1009)
CKAP5-6219靶:5'-AGACTGGAGAGAATAAAGAGCAGTCGC-3'(SEQIDNO:1585)
5'-UGGAGAGAAUAAAGAGCAGUCGCaa-3'(SEQIDNO:434)
3'-UGACCUCUCUUAUUUCUCGUCAGCGUU-5'(SEQIDNO:1010)
CKAP5-6221靶:5'-ACTGGAGAGAATAAAGAGCAGTCGCAA-3'(SEQIDNO:1586)
5'-GAGAGAAUAAAGAGCAGUCGCAAat-3'(SEQIDNO:435)
3'-ACCUCUCUUAUUUCUCGUCAGCGUUUA-5'(SEQIDNO:1011)
CKAP5-6223靶:5'-TGGAGAGAATAAAGAGCAGTCGCAAAT-3'(SEQIDNO:1587)
5'-GAGAAUAAAGAGCAGUCGCAAAUga-3'(SEQIDNO:436)
3'-CUCUCUUAUUUCUCGUCAGCGUUUACU-5'(SEQIDNO:1012)
CKAP5-6225靶:5'-GAGAGAATAAAGAGCAGTCGCAAATGA-3'(SEQIDNO:1588)
5'-GAAUAAAGAGCAGUCGCAAAUGAag-3'(SEQIDNO:437)
3'-CUCUUAUUUCUCGUCAGCGUUUACUUC-5'(SEQIDNO:1013)
CKAP5-6227靶:5'-GAGAATAAAGAGCAGTCGCAAATGAAG-3'(SEQIDNO:1589)
5'-AUAAAGAGCAGUCGCAAAUGAAGct-3'(SEQIDNO:438)
3'-CUUAUUUCUCGUCAGCGUUUACUUCGA-5'(SEQIDNO:1014)
CKAP5-6229靶:5'-GAATAAAGAGCAGTCGCAAATGAAGCT-3'(SEQIDNO:1590)
5'-AAAGAGCAGUCGCAAAUGAAGCUgc-3'(SEQIDNO:439)
3'-UAUUUCUCGUCAGCGUUUACUUCGACG-5'(SEQIDNO:1015)
CKAP5-6231靶:5'-ATAAAGAGCAGTCGCAAATGAAGCTGC-3'(SEQIDNO:1591)
5'-AGAGCAGUCGCAAAUGAAGCUGCcc-3'(SEQIDNO:440)
3'-UUUCUCGUCAGCGUUUACUUCGACGGG-5'(SEQIDNO:1016)
CKAP5-6233靶:5'-AAAGAGCAGTCGCAAATGAAGCTGCCC-3'(SEQIDNO:1592)
5'-AAACUGGUUGUAUGUAUCAUGCCgt-3'(SEQIDNO:441)
3'-UGUUUGACCAACAUACAUAGUACGGCA-5'(SEQIDNO:1017)
CKAP5-6342靶:5'-ACAAACTGGTTGTATGTATCATGCCGT-3'(SEQIDNO:1593)
5'-CUCAUUUGUAAAAUUGUCCUAAUct-3'(SEQIDNO:442)
3'-ACGAGUAAACAUUUUAACAGGAUUAGA-5'(SEQIDNO:1018)
CKAP5-6544靶:5'-TGCTCATTTGTAAAATTGTCCTAATCT-3'(SEQIDNO:1594)
5'-CAUUUGUAAAAUUGUCCUAAUCUtt-3'(SEQIDNO:443)
3'-GAGUAAACAUUUUAACAGGAUUAGAAA-5'(SEQIDNO:1019)
CKAP5-6546靶:5'-CTCATTTGTAAAATTGTCCTAATCTTT-3'(SEQIDNO:1595)
5'-UUUGUAAAAUUGUCCUAAUCUUUcc-3'(SEQIDNO:444)
3'-GUAAACAUUUUAACAGGAUUAGAAAGG-5'(SEQIDNO:1020)
CKAP5-6548靶:5'-CATTTGTAAAATTGTCCTAATCTTTCC-3'(SEQIDNO:1596)
5'-ACUGUAUUCUGUAUGAAUGCAUGgc-3'(SEQIDNO:445)
3'-AGUGACAUAAGACAUACUUACGUACCG-5'(SEQIDNO:1021)
CKAP5-6656靶:5'-TCACTGTATTCTGTATGAATGCATGGC-3'(SEQIDNO:1597)
5'-UGUAUUCUGUAUGAAUGCAUGGCat-3'(SEQIDNO:446)
3'-UGACAUAAGACAUACUUACGUACCGUA-5'(SEQIDNO:1022)
CKAP5-6658靶:5'-ACTGTATTCTGTATGAATGCATGGCAT-3'(SEQIDNO:1598)
5'-UAUUCUGUAUGAAUGCAUGGCAUga-3'(SEQIDNO:447)
3'-ACAUAAGACAUACUUACGUACCGUACU-5'(SEQIDNO:1023)
CKAP5-6660靶:5'-TGTATTCTGTATGAATGCATGGCATGA-3'(SEQIDNO:1599)
5'-UUCUGUAUGAAUGCAUGGCAUGAta-3'(SEQIDNO:448)
3'-AUAAGACAUACUUACGUACCGUACUAU-5'(SEQIDNO:1024)
CKAP5-6662靶:5'-TATTCTGTATGAATGCATGGCATGATA-3'(SEQIDNO:1600)
5'-CUGUAUGAAUGCAUGGCAUGAUAca-3'(SEQIDNO:449)
3'-AAGACAUACUUACGUACCGUACUAUGU-5'(SEQIDNO:1025)
CKAP5-6664靶:5'-TTCTGTATGAATGCATGGCATGATACA-3'(SEQIDNO:1601)
5'-GUAUGAAUGCAUGGCAUGAUACAac-3'(SEQIDNO:450)
3'-GACAUACUUACGUACCGUACUAUGUUG-5'(SEQIDNO:1026)
CKAP5-6666靶:5'-CTGTATGAATGCATGGCATGATACAAC-3'(SEQIDNO:1602)
5'-UUUUAUAAAUAAAGUUUGCAUUAac-3'(SEQIDNO:451)
3'-AGAAAAUAUUUAUUUCAAACGUAAUUG-5'(SEQIDNO:1027)
CKAP5-6704靶:5'-TCTTTTATAAATAAAGTTTGCATTAAC-3'(SEQIDNO:1603)
5'-UUAUAAAUAAAGUUUGCAUUAACta-3'(SEQIDNO:452)
3'-AAAAUAUUUAUUUCAAACGUAAUUGAU-5'(SEQIDNO:1028)
CKAP5-6706靶:5'-TTTTATAAATAAAGTTTGCATTAACTA-3'(SEQIDNO:1604)
5'-AUAAAUAAAGUUUGCAUUAACUAta-3'(SEQIDNO:453)
3'-AAUAUUUAUUUCAAACGUAAUUGAUAU-5'(SEQIDNO:1029)
CKAP5-6708靶:5'-TTATAAATAAAGTTTGCATTAACTATA-3'(SEQIDNO:1605)
5'-AAAUAAAGUUUGCAUUAACUAUAcc-3'(SEQIDNO:454)
3'-UAUUUAUUUCAAACGUAAUUGAUAUGG-5'(SEQIDNO:1030)
CKAP5-6710靶:5'-ATAAATAAAGTTTGCATTAACTATACC-3'(SEQIDNO:1606)
5'-AUAAAGUUUGCAUUAACUAUACCtg-3'(SEQIDNO:455)
3'-UUUAUUUCAAACGUAAUUGAUAUGGAC-5'(SEQIDNO:1031)
CKAP5-6712靶:5'-AAATAAAGTTTGCATTAACTATACCTG-3'(SEQIDNO:1607)
5'-AAAGUUUGCAUUAACUAUACCUGac-3'(SEQIDNO:456)
3'-UAUUUCAAACGUAAUUGAUAUGGACUG-5'(SEQIDNO:1032)
CKAP5-6714靶:5'-ATAAAGTTTGCATTAACTATACCTGAC-3'(SEQIDNO:1608)
5'-CAGCUGAGGAAAUACUCUUAAUUct-3'(SEQIDNO:457)
3'-GGGUCGACUCCUUUAUGAGAAUUAAGA-5'(SEQIDNO:1033)
CKAP5-106靶:5'-CCCAGCTGAGGAAATACTCTTAATTCT-3'(SEQIDNO:1609)
5'-UUGAAACUGCCAGUUGAUCAGAAat-3'(SEQIDNO:458)
3'-CCAACUUUGACGGUCAACUAGUCUUUA-5'(SEQIDNO:1034)
CKAP5-172靶:5'-GGTTGAAACTGCCAGTTGATCAGAAAT-3'(SEQIDNO:1610)
5'-GCCAGUUGAUCAGAAAUGUGAACac-3'(SEQIDNO:459)
3'-GACGGUCAACUAGUCUUUACACUUGUG-5'(SEQIDNO:1035)
CKAP5-180靶:5'-CTGCCAGTTGATCAGAAATGTGAACAC-3'(SEQIDNO:1611)
5'-GAAAGCAAGGUUAAGUGGGUAUGaa-3'(SEQIDNO:460)
3'-ACCUUUCGUUCCAAUUCACCCAUACUU-5'(SEQIDNO:1036)
CKAP5-213靶:5'-TGGAAAGCAAGGTTAAGTGGGTATGAA-3'(SEQIDNO:1612)
5'-CAGAGUGGUCCAAAUUUUUAGGAtt-3'(SEQIDNO:461)
3'-GGGUCUCACCAGGUUUAAAAAUCCUAA-5'(SEQIDNO:1037)
CKAP5-281靶:5'-CCCAGAGTGGTCCAAATTTTTAGGATT-3'(SEQIDNO:1613)
5'-GUGGUUCAAUUGAAAGGAUUAGAag-3'(SEQIDNO:462)
3'-GUCACCAAGUUAACUUUCCUAAUCUUC-5'(SEQIDNO:1038)
CKAP5-337靶:5'-CAGTGGTTCAATTGAAAGGATTAGAAG-3'(SEQIDNO:1614)
5'-GAUUAGAAGCUGCACUUGUUUAUgt-3'(SEQIDNO:463)
3'-UCCUAAUCUUCGACGUGAACAAAUACA-5'(SEQIDNO:1039)
CKAP5-353靶:5'-AGGATTAGAAGCTGCACTTGTTTATGT-3'(SEQIDNO:1615)
5'-CUGCACUUGUUUAUGUUGAAAAUgc-3'(SEQIDNO:464)
3'-UCGACGUGAACAAAUACAACUUUUACG-5'(SEQIDNO:1040)
CKAP5-362靶:5'-AGCTGCACTTGTTTATGTTGAAAATGC-3'(SEQIDNO:1616)
5'-CAGGAAAAACCACAGGAGAAGUUgt-3'(SEQIDNO:465)
3'-UCGUCCUUUUUGGUGUCCUCUUCAACA-5'(SEQIDNO:1041)
CKAP5-395靶:5'-AGCAGGAAAAACCACAGGAGAAGTTGT-3'(SEQIDNO:1617)
5'-CAGGUGUUGUAAGUAAGGUGUUCaa-3'(SEQIDNO:466)
3'-CAGUCCACAACAUUCAUUCCACAAGUU-5'(SEQIDNO:1042)
CKAP5-422靶:5'-GTCAGGTGTTGTAAGTAAGGTGTTCAA-3'(SEQIDNO:1618)
5'-GUUGUAAGUAAGGUGUUCAAUCAac-3'(SEQIDNO:467)
3'-CACAACAUUCAUUCCACAAGUUAGUUG-5'(SEQIDNO:1043)
CKAP5-427靶:5'-GTGTTGTAAGTAAGGTGTTCAATCAAC-3'(SEQIDNO:1619)
5'-UCAAUCAACCUAAAGCUAAAGCCaa-3'(SEQIDNO:468)
3'-CAAGUUAGUUGGAUUUCGAUUUCGGUU-5'(SEQIDNO:1044)
CKAP5-443靶:5'-GTTCAATCAACCTAAAGCTAAAGCCAA-3'(SEQIDNO:1620)
5'-CCUGAAAGGCUUGGACAAUAAGAat-3'(SEQIDNO:469)
3'-GAGGACUUUCCGAACCUGUUAUUCUUA-5'(SEQIDNO:1045)
CKAP5-537靶:5'-CTCCTGAAAGGCTTGGACAATAAGAAT-3'(SEQIDNO:1621)
5'-AAGCCAAUUAUCAAAGUGUUGCCaa-3'(SEQIDNO:470)
3'-AAUUCGGUUAAUAGUUUCACAACGGUU-5'(SEQIDNO:1046)
CKAP5-637靶:5'-TTAAGCCAATTATCAAAGTGTTGCCAA-3'(SEQIDNO:1622)
5'-AAAGUGUUGCCAAAACUCUUUGAgt-3'(SEQIDNO:471)
3'-AGUUUCACAACGGUUUUGAGAAACUCA-5'(SEQIDNO:1047)
CKAP5-649靶:5'-TCAAAGTGTTGCCAAAACTCTTTGAGT-3'(SEQIDNO:1623)
5'-CAAAACUCUUUGAGUCUCGAGAGaa-3'(SEQIDNO:472)
3'-CGGUUUUGAGAAACUCAGAGCUCUCUU-5'(SEQIDNO:1048)
CKAP5-659靶:5'-GCCAAAACTCTTTGAGTCTCGAGAGAA-3'(SEQIDNO:1624)
5'-CUGUUCGAGAUGAAGCCAAACUAat-3'(SEQIDNO:473)
3'-CCGACAAGCUCUACUUCGGUUUGAUUA-5'(SEQIDNO:1049)
CKAP5-686靶:5'-GGCTGTTCGAGATGAAGCCAAACTAAT-3'(SEQIDNO:1625)
5'-CAUUACAAAAUAUAAACUCUGUUca-3'(SEQIDNO:474)
3'-GGGUAAUGUUUUAUAUUUGAGACAAGU-5'(SEQIDNO:1050)
CKAP5-755靶:5'-CCCATTACAAAATATAAACTCTGTTCA-3'(SEQIDNO:1626)
5'-AAAAUAUAAACUCUGUUCAGUUGaa-3'(SEQIDNO:475)
3'-UGUUUUAUAUUUGAGACAAGUCAACUU-5'(SEQIDNO:1051)
CKAP5-761靶:5'-ACAAAATATAAACTCTGTTCAGTTGAA-3'(SEQIDNO:1627)
5'-AUAAACUCUGUUCAGUUGAAAGAac-3'(SEQIDNO:476)
3'-UAUAUUUGAGACAAGUCAACUUUCUUG-5'(SEQIDNO:1052)
CKAP5-766靶:5'-ATATAAACTCTGTTCAGTTGAAAGAAC-3'(SEQIDNO:1628)
5'-CUGUUCAGUUGAAAGAACUAGAAga-3'(SEQIDNO:477)
3'-GAGACAAGUCAACUUUCUUGAUCUUCU-5'(SEQIDNO:1053)
CKAP5-773靶:5'-CTCTGTTCAGTTGAAAGAACTAGAAGA-3'(SEQIDNO:1629)
5'-GAUGAGGUGCCACAAAUAGAUGCtt-3'(SEQIDNO:478)
3'-CACUACUCCACGGUGUUUAUCUACGAA-5'(SEQIDNO:1054)
CKAP5-928靶:5'-GTGATGAGGTGCCACAAATAGATGCTT-3'(SEQIDNO:1630)
5'-AAAUAGAUGCUUAUGAGCUUUUAga-3'(SEQIDNO:479)
3'-UGUUUAUCUACGAAUACUCGAAAAUCU-5'(SEQIDNO:1055)
CKAP5-941靶:5'-ACAAATAGATGCTTATGAGCTTTTAGA-3'(SEQIDNO:1631)
5'-AUGAGCUUUUAGAAGCUGUAGAAat-3'(SEQIDNO:480)
3'-AAUACUCGAAAAUCUUCGACAUCUUUA-5'(SEQIDNO:1056)
CKAP5-953靶:5'-TTATGAGCTTTTAGAAGCTGTAGAAAT-3'(SEQIDNO:1632)
5'-CCCUGGAGUCUGUAGAAGUACUAat-3'(SEQIDNO:481)
3'-CCGGGACCUCAGACAUCUUCAUGAUUA-5'(SEQIDNO:1057)
CKAP5-1046靶:5'-GGCCCTGGAGTCTGTAGAAGTACTAAT-3'(SEQIDNO:1633)
5'-GAGUCUGUAGAAGUACUAAUAAAaa-3'(SEQIDNO:482)
3'-ACCUCAGACAUCUUCAUGAUUAUUUUU-5'(SEQIDNO:1058)
CKAP5-1051靶:5'-TGGAGTCTGTAGAAGTACTAATAAAAA-3'(SEQIDNO:1634)
5'-CAGAUUUAGUAAAAGCAUUAAAGaa-3'(SEQIDNO:483)
3'-ACGUCUAAAUCAUUUUCGUAAUUUCUU-5'(SEQIDNO:1059)
CKAP5-1103靶:5'-TGCAGATTTAGTAAAAGCATTAAAGAA-3'(SEQIDNO:1635)
5'-AAAAGCAUUAAAGAAGGUUGUUGga-3'(SEQIDNO:484)
3'-CAUUUUCGUAAUUUCUUCCAACAACCU-5'(SEQIDNO:1060)
CKAP5-1113靶:5'-GTAAAAGCATTAAAGAAGGTTGTTGGA-3'(SEQIDNO:1636)
5'-CAUUAAAGAAGGUUGUUGGAAAGga-3'(SEQIDNO:485)
3'-UCGUAAUUUCUUCCAACAACCUUUCCU-5'(SEQIDNO:1061)
CKAP5-1118靶:5'-AGCATTAAAGAAGGTTGTTGGAAAGGA-3'(SEQIDNO:1637)
5'-GAAGGUUGUUGGAAAGGACACCAat-3'(SEQIDNO:486)
3'-UUCUUCCAACAACCUUUCCUGUGGUUA-5'(SEQIDNO:1062)
CKAP5-1125靶:5'-AAGAAGGTTGTTGGAAAGGACACCAAT-3'(SEQIDNO:1638)
5'-GGAAGAAAUUUGGACAAUAUGCAgg-3'(SEQIDNO:487)
3'-UUCCUUCUUUAAACCUGUUAUACGUCC-5'(SEQIDNO:1063)
CKAP5-1205靶:5'-AAGGAAGAAATTTGGACAATATGCAGG-3'(SEQIDNO:1639)
5'-GUGAGGAUGUUUUAGCAGUAAUGga-3'(SEQIDNO:488)
3'-GUCACUCCUACAAAAUCGUCAUUACCU-5'(SEQIDNO:1064)
CKAP5-1343靶:5'-CAGTGAGGATGTTTTAGCAGTAATGGA-3'(SEQIDNO:1640)
5'-GUUUUAGCAGUAAUGGAUAAUAAaa-3'(SEQIDNO:489)
3'-UACAAAAUCGUCAUUACCUAUUAUUUU-5'(SEQIDNO:1065)
CKAP5-1351靶:5'-ATGTTTTAGCAGTAATGGATAATAAAA-3'(SEQIDNO:1641)
5'-CAAGCAGCAGACAUCUCUUUUUAtt-3'(SEQIDNO:490)
3'-UAGUUCGUCGUCUGUAGAGAAAAAUAA-5'(SEQIDNO:1066)
CKAP5-1386靶:5'-ATCAAGCAGCAGACATCTCTTTTTATT-3'(SEQIDNO:1642)
5'-GACAUCUCUUUUUAUUGCAAGAAgt-3'(SEQIDNO:491)
3'-GUCUGUAGAGAAAAAUAACGUUCUUCA-5'(SEQIDNO:1067)
CKAP5-1395靶:5'-CAGACATCTCTTTTTATTGCAAGAAGT-3'(SEQIDNO:1643)
5'-UCAGAGAUGCCGCAUUUGAAGCAtt-3'(SEQIDNO:492)
3'-UCAGUCUCUACGGCGUAAACUUCGUAA-5'(SEQIDNO:1068)
CKAP5-1514靶:5'-AGTCAGAGATGCCGCATTTGAAGCATT-3'(SEQIDNO:1644)
5'-CAUUGGGUACUGCUUUGAAGGUGgt-3'(SEQIDNO:493)
3'-UCGUAACCCAUGACGAAACUUCCACCA-5'(SEQIDNO:1069)
CKAP5-1535靶:5'-AGCATTGGGTACTGCTTTGAAGGTGGT-3'(SEQIDNO:1645)
5'-GUGGACAAACUCAAGCUUGAUAAga-3'(SEQIDNO:494)
3'-UACACCUGUUUGAGUUCGAACUAUUCU-5'(SEQIDNO:1070)
CKAP5-1594靶:5'-ATGTGGACAAACTCAAGCTTGATAAGA-3'(SEQIDNO:1646)
5'-AAGAAUGUUCAGAAAAGGUAGAAct-3'(SEQIDNO:495)
3'-GUUUCUUACAAGUCUUUUCCAUCUUGA-5'(SEQIDNO:1071)
CKAP5-1622靶:5'-CAAAGAATGTTCAGAAAAGGTAGAACT-3'(SEQIDNO:1647)
5'-UCAGAAAAGGUAGAACUGAUACAtg-3'(SEQIDNO:496)
3'-CAAGUCUUUUCCAUCUUGACUAUGUAC-5'(SEQIDNO:1072)
CKAP5-1630靶:5'-GTTCAGAAAAGGTAGAACTGATACATG-3'(SEQIDNO:1648)
5'-GGUAGAACUGAUACAUGGUAAGAaa-3'(SEQIDNO:497)
3'-UUCCAUCUUGACUAUGUACCAUUCUUU-5'(SEQIDNO:1073)
CKAP5-1638靶:5'-AAGGTAGAACTGATACATGGTAAGAAA-3'(SEQIDNO:1649)
5'-CAGGGAAUACUGGAACCAAGAACaa-3'(SEQIDNO:498)
3'-GCGUCCCUUAUGACCUUGGUUCUUGUU-5'(SEQIDNO:1074)
CKAP5-1847靶:5'-CGCAGGGAATACTGGAACCAAGAACAA-3'(SEQIDNO:1650)
5'-CCUGAGCUCUCGAUAGAAGUAUGtg-3'(SEQIDNO:499)
3'-UCGGACUCGAGAGCUAUCUUCAUACAC-5'(SEQIDNO:1075)
CKAP5-1903靶:5'-AGCCTGAGCTCTCGATAGAAGTATGTG-3'(SEQIDNO:1651)
5'-CGAUAGAAGUAUGUGAAGAAAAAgc-3'(SEQIDNO:500)
3'-GAGCUAUCUUCAUACACUUCUUUUUCG-5'(SEQIDNO:1076)
CKAP5-1913靶:5'-CTCGATAGAAGTATGTGAAGAAAAAGC-3'(SEQIDNO:1652)
5'-CUUGACAGCAGUAACUGGAAAGAaa-3'(SEQIDNO:501)
3'-AAGAACUGUCGUCAUUGACCUUUCUUU-5'(SEQIDNO:1077)
CKAP5-1972靶:5'-TTCTTGACAGCAGTAACTGGAAAGAAA-3'(SEQIDNO:1653)
5'-GCUAAUGGACCGAACUGAAAUGCca-3'(SEQIDNO:502)
3'-CUCGAUUACCUGGCUUGACUUUACGGU-5'(SEQIDNO:1078)
CKAP5-2034靶:5'-GAGCTAATGGACCGAACTGAAATGCCA-3'(SEQIDNO:1654)
5'-UUAGUGAGGAUGCUAGCCAAGAAac-3'(SEQIDNO:503)
3'-GUAAUCACUCCUACGAUCGGUUCUUUG-5'(SEQIDNO:1079)
CKAP5-2068靶:5'-CATTAGTGAGGATGCTAGCCAAGAAAC-3'(SEQIDNO:1655)
5'-GCCAAGAAACCUGGAUGGAAAGAaa-3'(SEQIDNO:504)
3'-AUCGGUUCUUUGGACCUACCUUUCUUU-5'(SEQIDNO:1080)
CKAP5-2083靶:5'-TAGCCAAGAAACCTGGATGGAAAGAAA-3'(SEQIDNO:1656)
5'-GAAACCUGGAUGGAAAGAAACUAat-3'(SEQIDNO:505)
3'-UUCUUUGGACCUACCUUUCUUUGAUUA-5'(SEQIDNO:1081)
CKAP5-2088靶:5'-AAGAAACCTGGATGGAAAGAAACTAAT-3'(SEQIDNO:1657)
5'-GUGAUGCAAAUGAAGCUUCAUAUag-3'(SEQIDNO:506)
3'-UCCACUACGUUUACUUCGAAGUAUAUC-5'(SEQIDNO:1082)
CKAP5-2119靶:5'-AGGTGATGCAAATGAAGCTTCATATAG-3'(SEQIDNO:1658)
5'-AAACGUCAGCUCAGGUUGUAUUAga-3'(SEQIDNO:507)
3'-GUUUUGCAGUCGAGUCCAACAUAAUCU-5'(SEQIDNO:1083)
CKAP5-2177靶:5'-CAAAACGTCAGCTCAGGTTGTATTAGA-3'(SEQIDNO:1659)
5'-CAAAAGAAGCUAUGACAGCAAUAgc-3'(SEQIDNO:508)
3'-ACGUUUUCUUCGAUACUGUCGUUAUCG-5'(SEQIDNO:1084)
CKAP5-2246靶:5'-TGCAAAAGAAGCTATGACAGCAATAGC-3'(SEQIDNO:1660)
5'-CAGCAAUAGCCGAAGCCUGUAUGtt-3'(SEQIDNO:509)
3'-CUGUCGUUAUCGGCUUCGGACAUACAA-5'(SEQIDNO:1085)
CKAP5-2261靶:5'-GACAGCAATAGCCGAAGCCTGTATGTT-3'(SEQIDNO:1661)
5'-GAAGCCUGUAUGUUACCAUGGACtg-3'(SEQIDNO:510)
3'-GGCUUCGGACAUACAAUGGUACCUGAC-5'(SEQIDNO:1086)
CKAP5-2272靶:5'-CCGAAGCCTGTATGTTACCATGGACTG-3'(SEQIDNO:1662)
5'-AAAAUCAGUCAGAAACUCUGAAUtg-3'(SEQIDNO:511)
3'-GUUUUUAGUCAGUCUUUGAGACUUAAC-5'(SEQIDNO:1087)
CKAP5-2339靶:5'-CAAAAATCAGTCAGAAACTCTGAATTG-3'(SEQIDNO:1663)
5'-AGCUUUCAUUAGCAAUGUGAAGAca-3'(SEQIDNO:512)
3'-UUUCGAAAGUAAUCGUUACACUUCUGU-5'(SEQIDNO:1088)
CKAP5-2412靶:5'-AAAGCTTTCATTAGCAATGTGAAGACA-3'(SEQIDNO:1664)
5'-GAGAAGAUGCAGGGACAAAGUCCac-3'(SEQIDNO:513)
3'-AACUCUUCUACGUCCCUGUUUCAGGUG-5'(SEQIDNO:1089)
CKAP5-2578靶:5'-TTGAGAAGATGCAGGGACAAAGTCCAC-3'(SEQIDNO:1665)
5'-GCAAUGAUGUCGUUGAUCUUUUGcc-3'(SEQIDNO:514)
3'-CUCGUUACUACAGCAACUAGAAAACGG-5'(SEQIDNO:1090)
CKAP5-2684靶:5'-GAGCAATGATGTCGTTGATCTTTTGCC-3'(SEQIDNO:1666)
5'-GAAGUGGCAGGUAUUAUUAAUGAcg-3'(SEQIDNO:515)
3'-UACUUCACCGUCCAUAAUAAUUACUGC-5'(SEQIDNO:1091)
CKAP5-2797靶:5'-ATGAAGTGGCAGGTATTATTAATGACG-3'(SEQIDNO:1667)
5'-GCCUUGAAGGGUCGACUCAAUGAtt-3'(SEQIDNO:516)
3'-GACGGAACUUCCCAGCUGAGUUACUAA-5'(SEQIDNO:1092)
CKAP5-2860靶:5'-CTGCCTTGAAGGGTCGACTCAATGATT-3'(SEQIDNO:1668)
5'-GAAGGGUCGACUCAAUGAUUCAAat-3'(SEQIDNO:517)
3'-AACUUCCCAGCUGAGUUACUAAGUUUA-5'(SEQIDNO:1093)
CKAP5-2865靶:5'-TTGAAGGGTCGACTCAATGATTCAAAT-3'(SEQIDNO:1669)
5'-GACUCAAUGAUUCAAAUAAAAUCtt-3'(SEQIDNO:518)
3'-AGCUGAGUUACUAAGUUUAUUUUAGAA-5'(SEQIDNO:1094)
CKAP5-2873靶:5'-TCGACTCAATGATTCAAATAAAATCTT-3'(SEQIDNO:1670)
5'-AUGAUUCAAAUAAAAUCUUGGUAca-3'(SEQIDNO:519)
3'-GUUACUAAGUUUAUUUUAGAACCAUGU-5'(SEQIDNO:1095)
CKAP5-2879靶:5'-CAATGATTCAAATAAAATCTTGGTACA-3'(SEQIDNO:1671)
5'-AGCCAUGGGCCCAAAUAUUAAGCaa-3'(SEQIDNO:520)
3'-CAUCGGUACCCGGGUUUAUAAUUCGUU-5'(SEQIDNO:1096)
CKAP5-2937靶:5'-GTAGCCATGGGCCCAAATATTAAGCAA-3'(SEQIDNO:1672)
5'-AAAUAUUAAGCAACAUGUAAAAAat-3'(SEQIDNO:521)
3'-GGUUUAUAAUUCGUUGUACAUUUUUUA-5'(SEQIDNO:1097)
CKAP5-2949靶:5'-CCAAATATTAAGCAACATGTAAAAAAT-3'(SEQIDNO:1673)
5'-CCUUGGAGACAGCAAGAACAAUGtt-3'(SEQIDNO:522)
3'-CAGGAACCUCUGUCGUUCUUGUUACAA-5'(SEQIDNO:1098)
CKAP5-2997靶:5'-GTCCTTGGAGACAGCAAGAACAATGTT-3'(SEQIDNO:1674)
5'-GAGACAGCAAGAACAAUGUUCGAgc-3'(SEQIDNO:523)
3'-ACCUCUGUCGUUCUUGUUACAAGCUCG-5'(SEQIDNO:1099)
CKAP5-3002靶:5'-TGGAGACAGCAAGAACAATGTTCGAGC-3'(SEQIDNO:1675)
5'-CAUGAUGCAUUUAGGAUAUGAAAaa-3'(SEQIDNO:524)
3'-AAGUACUACGUAAAUCCUAUACUUUUU-5'(SEQIDNO:1100)
CKAP5-3285靶:5'-TTCATGATGCATTTAGGATATGAAAAA-3'(SEQIDNO:1676)
5'-CUAGAGAAAGCCAAAGUUAACAUgc-3'(SEQIDNO:525)
3'-ACGAUCUCUUUCGGUUUCAAUUGUACG-5'(SEQIDNO:1101)
CKAP5-3367靶:5'-TGCTAGAGAAAGCCAAAGTTAACATGC-3'(SEQIDNO:1677)
5'-GGGAAGAAGAUGCCAAGCAAAACca-3'(SEQIDNO:526)
3'-UUCCCUUCUUCUACGGUUCGUUUUGGU-5'(SEQIDNO:1102)
CKAP5-3571靶:5'-AAGGGAAGAAGATGCCAAGCAAAACCA-3'(SEQIDNO:1678)
5'-GAAAAGAGCAAAGGAUGAAAGAUga-3'(SEQIDNO:527)
3'-ACCUUUUCUCGUUUCCUACUUUCUACU-5'(SEQIDNO:1103)
CKAP5-3650靶:5'-TGGAAAAGAGCAAAGGATGAAAGATGA-3'(SEQIDNO:1679)
5'-GAGCAAAGGAUGAAAGAUGAAAAag-3'(SEQIDNO:528)
3'-UUCUCGUUUCCUACUUUCUACUUUUUC-5'(SEQIDNO:1104)
CKAP5-3655靶:5'-AAGAGCAAAGGATGAAAGATGAAAAAG-3'(SEQIDNO:1680)
5'-GGGAUGAAUACAUUGAGCAACUAaa-3'(SEQIDNO:529)
3'-UGCCCUACUUAUGUAACUCGUUGAUUU-5'(SEQIDNO:1105)
CKAP5-3716靶:5'-ACGGGATGAATACATTGAGCAACTAAA-3'(SEQIDNO:1681)
5'-GAAUACAUUGAGCAACUAAAGACtc-3'(SEQIDNO:530)
3'-UACUUAUGUAACUCGUUGAUUUCUGAG-5'(SEQIDNO:1106)
CKAP5-3721靶:5'-ATGAATACATTGAGCAACTAAAGACTC-3'(SEQIDNO:1682)
5'-AGUGGCUUACCCUGAGGUUUUUUga-3'(SEQIDNO:531)
3'-UUUCACCGAAUGGGACUCCAAAAAACU-5'(SEQIDNO:1107)
CKAP5-3890靶:5'-AAAGTGGCTTACCCTGAGGTTTTTTGA-3'(SEQIDNO:1683)
5'-CCUGAGGUUUUUUGACACCAAUAca-3'(SEQIDNO:532)
3'-UGGGACUCCAAAAAACUGUGGUUAUGU-5'(SEQIDNO:1108)
CKAP5-3900靶:5'-ACCCTGAGGTTTTTTGACACCAATACA-3'(SEQIDNO:1684)
5'-CAAUACAAGCGUCCUGAUGAAAGca-3'(SEQIDNO:533)
3'-UGGUUAUGUUCGCAGGACUACUUUCGU-5'(SEQIDNO:1109)
CKAP5-3918靶:5'-ACCAATACAAGCGTCCTGATGAAAGCA-3'(SEQIDNO:1685)
5'-GUCCUGAUGAAAGCACUAGAAUAtt-3'(SEQIDNO:534)
3'-CGCAGGACUACUUUCGUGAUCUUAUAA-5'(SEQIDNO:1110)
CKAP5-3928靶:5'-GCGTCCTGATGAAAGCACTAGAATATT-3'(SEQIDNO:1686)
5'-AUGAAAGCACUAGAAUAUUUAAAat-3'(SEQIDNO:535)
3'-ACUACUUUCGUGAUCUUAUAAAUUUUA-5'(SEQIDNO:1111)
CKAP5-3934靶:5'-TGATGAAAGCACTAGAATATTTAAAAT-3'(SEQIDNO:1687)
5'-GAAAUCUUUCUGAAAAGGAUAUGag-3'(SEQIDNO:536)
3'-ACCUUUAGAAAGACUUUUCCUAUACUC-5'(SEQIDNO:1112)
CKAP5-4367靶:5'-TGGAAATCTTTCTGAAAAGGATATGAG-3'(SEQIDNO:1688)
5'-GAAAAGGAUAUGAGCAUGCUCGAgg-3'(SEQIDNO:537)
3'-GACUUUUCCUAUACUCGUACGAGCUCC-5'(SEQIDNO:1113)
CKAP5-4378靶:5'-CTGAAAAGGATATGAGCATGCTCGAGG-3'(SEQIDNO:1689)
5'-GCUCCAAUGCCAACAUGUUACGCaa-3'(SEQIDNO:538)
3'-UUCGAGGUUACGGUUGUACAAUGCGUU-5'(SEQIDNO:1114)
CKAP5-4487靶:5'-AAGCTCCAATGCCAACATGTTACGCAA-3'(SEQIDNO:1690)
5'-AAUGCCAACAUGUUACGCAAGGGac-3'(SEQIDNO:539)
3'-GGUUACGGUUGUACAAUGCGUUCCCUG-5'(SEQIDNO:1115)
CKAP5-4492靶:5'-CCAATGCCAACATGTTACGCAAGGGAC-3'(SEQIDNO:1691)
5'-GUGAAAUGCCAGAACUUGUUCAGca-3'(SEQIDNO:540)
3'-UACACUUUACGGUCUUGAACAAGUCGU-5'(SEQIDNO:1116)
CKAP5-4649靶:5'-ATGTGAAATGCCAGAACTTGTTCAGCA-3'(SEQIDNO:1692)
5'-CAGAACUUGUUCAGCACAAACUGga-3'(SEQIDNO:541)
3'-CGGUCUUGAACAAGUCGUGUUUGACCU-5'(SEQIDNO:1117)
CKAP5-4658靶:5'-GCCAGAACTTGTTCAGCACAAACTGGA-3'(SEQIDNO:1693)
5'-ACAAACUGGAUGACAUUUUUGAGcc-3'(SEQIDNO:542)
3'-CGUGUUUGACCUACUGUAAAAACUCGG-5'(SEQIDNO:1118)
CKAP5-4673靶:5'-GCACAAACTGGATGACATTTTTGAGCC-3'(SEQIDNO:1694)
5'-GAUGACAUUUUUGAGCCAGUCCUta-3'(SEQIDNO:543)
3'-ACCUACUGUAAAAACUCGGUCAGGAAU-5'(SEQIDNO:1119)
CKAP5-4681靶:5'-TGGATGACATTTTTGAGCCAGTCCTTA-3'(SEQIDNO:1695)
5'-CAUUUUUGAGCCAGUCCUUAUUCct-3'(SEQIDNO:544)
3'-CUGUAAAAACUCGGUCAGGAAUAAGGA-5'(SEQIDNO:1120)
CKAP5-4686靶:5'-GACATTTTTGAGCCAGTCCTTATTCCT-3'(SEQIDNO:1696)
5'-GAGCCAGUCCUUAUUCCUGAACCca-3'(SEQIDNO:545)
3'-AACUCGGUCAGGAAUAAGGACUUGGGU-5'(SEQIDNO:1121)
CKAP5-4693靶:5'-TTGAGCCAGTCCTTATTCCTGAACCCA-3'(SEQIDNO:1697)
5'-CUGGAGUACUAAAAGACCUAAUGca-3'(SEQIDNO:546)
3'-GUGACCUCAUGAUUUUCUGGAUUACGU-5'(SEQIDNO:1122)
CKAP5-5057靶:5'-CACTGGAGTACTAAAAGACCTAATGCA-3'(SEQIDNO:1698)
5'-GUGAAGGUUCUGGAGAAGUCAGAcc-3'(SEQIDNO:547)
3'-ACCACUUCCAAGACCUCUUCAGUCUGG-5'(SEQIDNO:1123)
CKAP5-5167靶:5'-TGGTGAAGGTTCTGGAGAAGTCAGACC-3'(SEQIDNO:1699)
5'-CCUGAGUGCCCUACUUGUUUUGCtc-3'(SEQIDNO:548)
3'-UAGGACUCACGGGAUGAACAAAACGAG-5'(SEQIDNO:1124)
CKAP5-5202靶:5'-ATCCTGAGTGCCCTACTTGTTTTGCTC-3'(SEQIDNO:1700)
5'-CAGCCAGUUCUCCCAAAUUCUCAga-3'(SEQIDNO:549)
3'-UUGUCGGUCAAGAGGGUUUAAGAGUCU-5'(SEQIDNO:1125)
CKAP5-5246靶:5'-AACAGCCAGTTCTCCCAAATTCTCAGA-3'(SEQIDNO:1701)
5'-GCUUGUUAUGAAGUGUCUCUGGAga-3'(SEQIDNO:550)
3'-CUCGAACAAUACUUCACAGAGACCUCU-5'(SEQIDNO:1126)
CKAP5-5271靶:5'-GAGCTTGTTATGAAGTGTCTCTGGAGA-3'(SEQIDNO:1702)
5'-CGACUGUUGCCUGAUACCAUCAAta-3'(SEQIDNO:551)
3'-AAGCUGACAACGGACUAUGGUAGUUAU-5'(SEQIDNO:1127)
CKAP5-5302靶:5'-TTCGACTGTTGCCTGATACCATCAATA-3'(SEQIDNO:1703)
5'-GUUGCCUGAUACCAUCAAUAGCAtt-3'(SEQIDNO:552)
3'-GACAACGGACUAUGGUAGUUAUCGUAA-5'(SEQIDNO:1128)
CKAP5-5307靶:5'-CTGTTGCCTGATACCATCAATAGCATT-3'(SEQIDNO:1704)
5'-CUGAUACCAUCAAUAGCAUUAACct-3'(SEQIDNO:553)
3'-CGGACUAUGGUAGUUAUCGUAAUUGGA-5'(SEQIDNO:1129)
CKAP5-5312靶:5'-GCCTGATACCATCAATAGCATTAACCT-3'(SEQIDNO:1705)
5'-AUCAAUAGCAUUAACCUAGACAGaa-3'(SEQIDNO:554)
3'-GGUAGUUAUCGUAAUUGGAUCUGUCUU-5'(SEQIDNO:1130)
CKAP5-5320靶:5'-CCATCAATAGCATTAACCTAGACAGAA-3'(SEQIDNO:1706)
5'-UAGCAUUAACCUAGACAGAAUUCtt-3'(SEQIDNO:555)
3'-UUAUCGUAAUUGGAUCUGUCUUAAGAA-5'(SEQIDNO:1131)
CKAP5-5325靶:5'-AATAGCATTAACCTAGACAGAATTCTT-3'(SEQIDNO:1707)
5'-GAAUUCUUCUGGAUAUCCACAUUtt-3'(SEQIDNO:556)
3'-GUCUUAAGAAGACCUAUAGGUGUAAAA-5'(SEQIDNO:1132)
CKAP5-5342靶:5'-CAGAATTCTTCTGGATATCCACATTTT-3'(SEQIDNO:1708)
5'-CUGGAUAUCCACAUUUUCAUGAAgg-3'(SEQIDNO:557)
3'-AAGACCUAUAGGUGUAAAAGUACUUCC-5'(SEQIDNO:1133)
CKAP5-5350靶:5'-TTCTGGATATCCACATTTTCATGAAGG-3'(SEQIDNO:1709)
5'-AAAGAGAAACUGAAGCAAUGCAAaa-3'(SEQIDNO:558)
3'-GGUUUCUCUUUGACUUCGUUACGUUUU-5'(SEQIDNO:1134)
CKAP5-5383靶:5'-CCAAAGAGAAACTGAAGCAATGCAAAA-3'(SEQIDNO:1710)
5'-GAAACUGAAGCAAUGCAAAAGUGaa-3'(SEQIDNO:559)
3'-CUCUUUGACUUCGUUACGUUUUCACUU-5'(SEQIDNO:1135)
CKAP5-5388靶:5'-GAGAAACTGAAGCAATGCAAAAGTGAA-3'(SEQIDNO:1711)
5'-CGGAUGAUGAAGCACAGUAUGGAcc-3'(SEQIDNO:560)
3'-CGGCCUACUACUUCGUGUCAUACCUGG-5'(SEQIDNO:1136)
CKAP5-5536靶:5'-GCCGGATGATGAAGCACAGTATGGACC-3'(SEQIDNO:1712)
5'-CAGAAAAGGGAGCAUCUCGAAUAga-3'(SEQIDNO:561)
3'-UUGUCUUUUCCCUCGUAGAGCUUAUCU-5'(SEQIDNO:1137)
CKAP5-5588靶:5'-AACAGAAAAGGGAGCATCTCGAATAGA-3'(SEQIDNO:1713)
5'-AGGGAGCAUCUCGAAUAGAUGAAaa-3'(SEQIDNO:562)
3'-UUUCCCUCGUAGAGCUUAUCUACUUUU-5'(SEQIDNO:1138)
CKAP5-5594靶:5'-AAAGGGAGCATCTCGAATAGATGAAAA-3'(SEQIDNO:1714)
5'-GCAUCUCGAAUAGAUGAAAAAUCat-3'(SEQIDNO:563)
3'-CUCGUAGAGCUUAUCUACUUUUUAGUA-5'(SEQIDNO:1139)
CKAP5-5599靶:5'-GAGCATCTCGAATAGATGAAAAATCAT-3'(SEQIDNO:1715)
5'-GAGGGACUAGCAGAGUUAUAUGAat-3'(SEQIDNO:564)
3'-UUCUCCCUGAUCGUCUCAAUAUACUUA-5'(SEQIDNO:1140)
CKAP5-5692靶:5'-AAGAGGGACTAGCAGAGTTATATGAAT-3'(SEQIDNO:1716)
5'-ACUCAGAUGCUGACAUUGAACCAtt-3'(SEQIDNO:565)
3'-UAUGAGUCUACGACUGUAACUUGGUAA-5'(SEQIDNO:1141)
CKAP5-5729靶:5'-ATACTCAGATGCTGACATTGAACCATT-3'(SEQIDNO:1717)
5'-CAUUCAGACCUGGAUUCUAACCAga-3'(SEQIDNO:566)
3'-UCGUAAGUCUGGACCUAAGAUUGGUCU-5'(SEQIDNO:1142)
CKAP5-6130靶:5'-AGCATTCAGACCTGGATTCTAACCAGA-3'(SEQIDNO:1718)
5'-GACCUGGAUUCUAACCAGACUCAct-3'(SEQIDNO:567)
3'-GUCUGGACCUAAGAUUGGUCUGAGUGA-5'(SEQIDNO:1143)
CKAP5-6136靶:5'-CAGACCTGGATTCTAACCAGACTCACT-3'(SEQIDNO:1719)
5'-GGAUUCUAACCAGACUCACUCUUca-3'(SEQIDNO:568)
3'-GACCUAAGAUUGGUCUGAGUGAGAAGU-5'(SEQIDNO:1144)
CKAP5-6141靶:5'-CTGGATTCTAACCAGACTCACTCTTCA-3'(SEQIDNO:1720)
5'-GCUAACAUAGACGACUUGAAAAAaa-3'(SEQIDNO:569)
3'-GUCGAUUGUAUCUGCUGAACUUUUUUU-5'(SEQIDNO:1145)
CKAP5-6193靶:5'-CAGCTAACATAGACGACTTGAAAAAAA-3'(SEQIDNO:1721)
5'-CAUAGACGACUUGAAAAAAAGACtg-3'(SEQIDNO:570)
3'-UUGUAUCUGCUGAACUUUUUUUCUGAC-5'(SEQIDNO:1146)
CKAP5-6198靶:5'-AACATAGACGACTTGAAAAAAAGACTG-3'(SEQIDNO:1722)
5'-CUAGAAGUCCUCAUAGUUUAAAAtg-3'(SEQIDNO:571)
3'-UUGAUCUUCAGGAGUAUCAAAUUUUAC-5'(SEQIDNO:1147)
CKAP5-6294靶:5'-AACTAGAAGTCCTCATAGTTTAAAATG-3'(SEQIDNO:1723)
5'-GAUGAGUUUAGUGUACAGACUUGta-3'(SEQIDNO:572)
3'-ACCUACUCAAAUCACAUGUCUGAACAU-5'(SEQIDNO:1148)
CKAP5-6459靶:5'-TGGATGAGTTTAGTGTACAGACTTGTA-3'(SEQIDNO:1724)
5'-CAGAUCCUUUUCUUUUCUUUUUAat-3'(SEQIDNO:573)
3'-GGGUCUAGGAAAAGAAAAGAAAAAUUA-5'(SEQIDNO:1149)
CKAP5-6517靶:5'-CCCAGATCCTTTTCTTTTCTTTTTAAT-3'(SEQIDNO:1725)
5'-UGCUCAUUUGUAAAAUUGUCCUAat-3'(SEQIDNO:574)
3'-UAACGAGUAAACAUUUUAACAGGAUUA-5'(SEQIDNO:1150)
CKAP5-6542靶:5'-ATTGCTCATTTGTAAAATTGTCCTAAT-3'(SEQIDNO:1726)
5'-GAAGGGUCACUGUAUUCUGUAUGaa-3'(SEQIDNO:575)
3'-GACUUCCCAGUGACAUAAGACAUACUU-5'(SEQIDNO:1151)
CKAP5-6648靶:5'-CTGAAGGGTCACTGTATTCTGTATGAA-3'(SEQIDNO:1727)
5'-GUCACUGUAUUCUGUAUGAAUGCat-3'(SEQIDNO:576)
3'-CCCAGUGACAUAAGACAUACUUACGUA-5'(SEQIDNO:1152)
CKAP5-6653靶:5'-GGGTCACTGTATTCTGTATGAATGCAT-3'(SEQIDNO:1728)
表3:选择的人抗-CKAP5DsiRNA,未修饰的双链体(不对称的)
5'-GAAGCACAAUGGGAGAUGACAGUGA-3'(SEQIDNO:1729)
3'-ACCUUCGUGUUACCCUCUACUGUCACU-5'(SEQIDNO:577)
CKAP5-143靶:5'-TGGAAGCACAATGGGAGATGACAGTGA-3'(SEQIDNO:1153)
5'-AGCACAAUGGGAGAUGACAGUGAGU-3'(SEQIDNO:1730)
3'-CUUCGUGUUACCCUCUACUGUCACUCA-5'(SEQIDNO:578)
CKAP5-145靶:5'-GAAGCACAATGGGAGATGACAGTGAGT-3'(SEQIDNO:1154)
5'-CACAAUGGGAGAUGACAGUGAGUGG-3'(SEQIDNO:1731)
3'-UCGUGUUACCCUCUACUGUCACUCACC-5'(SEQIDNO:579)
CKAP5-147靶:5'-AGCACAATGGGAGATGACAGTGAGTGG-3'(SEQIDNO:1155)
5'-CAAUGGGAGAUGACAGUGAGUGGUU-3'(SEQIDNO:1732)
3'-GUGUUACCCUCUACUGUCACUCACCAA-5'(SEQIDNO:580)
CKAP5-149靶:5'-CACAATGGGAGATGACAGTGAGTGGTT-3'(SEQIDNO:1156)
5'-AUGGGAGAUGACAGUGAGUGGUUGA-3'(SEQIDNO:1733)
3'-GUUACCCUCUACUGUCACUCACCAACU-5'(SEQIDNO:581)
CKAP5-151靶:5'-CAATGGGAGATGACAGTGAGTGGTTGA-3'(SEQIDNO:1157)
5'-GGGAGAUGACAGUGAGUGGUUGAAA-3'(SEQIDNO:1734)
3'-UACCCUCUACUGUCACUCACCAACUUU-5'(SEQIDNO:582)
CKAP5-153靶:5'-ATGGGAGATGACAGTGAGTGGTTGAAA-3'(SEQIDNO:1158)
5'-GAGAUGACAGUGAGUGGUUGAAACU-3'(SEQIDNO:1735)
3'-CCCUCUACUGUCACUCACCAACUUUGA-5'(SEQIDNO:583)
CKAP5-155靶:5'-GGGAGATGACAGTGAGTGGTTGAAACT-3'(SEQIDNO:1159)
5'-GAUGACAGUGAGUGGUUGAAACUGC-3'(SEQIDNO:1736)
3'-CUCUACUGUCACUCACCAACUUUGACG-5'(SEQIDNO:584)
CKAP5-157靶:5'-GAGATGACAGTGAGTGGTTGAAACTGC-3'(SEQIDNO:1160)
5'-UGACAGUGAGUGGUUGAAACUGCCA-3'(SEQIDNO:1737)
3'-CUACUGUCACUCACCAACUUUGACGGU-5'(SEQIDNO:585)
CKAP5-159靶:5'-GATGACAGTGAGTGGTTGAAACTGCCA-3'(SEQIDNO:1161)
5'-GAAGAUCUUCCAGAAAAUAAAGGAU-3'(SEQIDNO:1738)
3'-GACUUCUAGAAGGUCUUUUAUUUCCUA-5'(SEQIDNO:586)
CKAP5-246靶:5'-CTGAAGATCTTCCAGAAAATAAAGGAT-3'(SEQIDNO:1162)
5'-AGAUCUUCCAGAAAAUAAAGGAUGA-3'(SEQIDNO:1739)
3'-CUUCUAGAAGGUCUUUUAUUUCCUACU-5'(SEQIDNO:587)
CKAP5-248靶:5'-GAAGATCTTCCAGAAAATAAAGGATGA-3'(SEQIDNO:1163)
5'-AUCUUCCAGAAAAUAAAGGAUGAAA-3'(SEQIDNO:1740)
3'-UCUAGAAGGUCUUUUAUUUCCUACUUU-5'(SEQIDNO:588)
CKAP5-250靶:5'-AGATCTTCCAGAAAATAAAGGATGAAA-3'(SEQIDNO:1164)
5'-CUUCCAGAAAAUAAAGGAUGAAAAG-3'(SEQIDNO:1741)
3'-UAGAAGGUCUUUUAUUUCCUACUUUUC-5'(SEQIDNO:589)
CKAP5-252靶:5'-ATCTTCCAGAAAATAAAGGATGAAAAG-3'(SEQIDNO:1165)
5'-UCCAGAAAAUAAAGGAUGAAAAGAG-3'(SEQIDNO:1742)
3'-GAAGGUCUUUUAUUUCCUACUUUUCUC-5'(SEQIDNO:590)
CKAP5-254靶:5'-CTTCCAGAAAATAAAGGATGAAAAGAG-3'(SEQIDNO:1166)
5'-CAGAAAAUAAAGGAUGAAAAGAGCC-3'(SEQIDNO:1743)
3'-AGGUCUUUUAUUUCCUACUUUUCUCGG-5'(SEQIDNO:591)
CKAP5-256靶:5'-TCCAGAAAATAAAGGATGAAAAGAGCC-3'(SEQIDNO:1167)
5'-GAAAAUAAAGGAUGAAAAGAGCCCA-3'(SEQIDNO:1744)
3'-GUCUUUUAUUUCCUACUUUUCUCGGGU-5'(SEQIDNO:592)
CKAP5-258靶:5'-CAGAAAATAAAGGATGAAAAGAGCCCA-3'(SEQIDNO:1168)
5'-AAAUAAAGGAUGAAAAGAGCCCAGA-3'(SEQIDNO:1745)
3'-CUUUUAUUUCCUACUUUUCUCGGGUCU-5'(SEQIDNO:593)
CKAP5-260靶:5'-GAAAATAAAGGATGAAAAGAGCCCAGA-3'(SEQIDNO:1169)
5'-UCAAAAAAUUUGUCACUGAUUCCAA-3'(SEQIDNO:1746)
3'-CUAGUUUUUUAAACAGUGACUAAGGUU-5'(SEQIDNO:594)
CKAP5-308靶:5'-GATCAAAAAATTTGTCACTGATTCCAA-3'(SEQIDNO:1170)
5'-AAAAAAUUUGUCACUGAUUCCAAUG-3'(SEQIDNO:1747)
3'-AGUUUUUUAAACAGUGACUAAGGUUAC-5'(SEQIDNO:595)
CKAP5-310靶:5'-TCAAAAAATTTGTCACTGATTCCAATG-3'(SEQIDNO:1171)
5'-AAAAUUUGUCACUGAUUCCAAUGCA-3'(SEQIDNO:1748)
3'-UUUUUUAAACAGUGACUAAGGUUACGU-5'(SEQIDNO:596)
CKAP5-312靶:5'-AAAAAATTTGTCACTGATTCCAATGCA-3'(SEQIDNO:1172)
5'-AAUUUGUCACUGAUUCCAAUGCAGU-3'(SEQIDNO:1749)
3'-UUUUAAACAGUGACUAAGGUUACGUCA-5'(SEQIDNO:597)
CKAP5-314靶:5'-AAAATTTGTCACTGATTCCAATGCAGT-3'(SEQIDNO:1173)
5'-UUUGUCACUGAUUCCAAUGCAGUGG-3'(SEQIDNO:1750)
3'-UUAAACAGUGACUAAGGUUACGUCACC-5'(SEQIDNO:598)
CKAP5-316靶:5'-AATTTGTCACTGATTCCAATGCAGTGG-3'(SEQIDNO:1174)
5'-UGUCACUGAUUCCAAUGCAGUGGUU-3'(SEQIDNO:1751)
3'-AAACAGUGACUAAGGUUACGUCACCAA-5'(SEQIDNO:599)
CKAP5-318靶:5'-TTTGTCACTGATTCCAATGCAGTGGTT-3'(SEQIDNO:1175)
5'-UCACUGAUUCCAAUGCAGUGGUUCA-3'(SEQIDNO:1752)
3'-ACAGUGACUAAGGUUACGUCACCAAGU-5'(SEQIDNO:600)
CKAP5-320靶:5'-TGTCACTGATTCCAATGCAGTGGTTCA-3'(SEQIDNO:1176)
5'-ACUGAUUCCAAUGCAGUGGUUCAAU-3'(SEQIDNO:1753)
3'-AGUGACUAAGGUUACGUCACCAAGUUA-5'(SEQIDNO:601)
CKAP5-322靶:5'-TCACTGATTCCAATGCAGTGGTTCAAT-3'(SEQIDNO:1177)
5'-UGAUUCCAAUGCAGUGGUUCAAUUG-3'(SEQIDNO:1754)
3'-UGACUAAGGUUACGUCACCAAGUUAAC-5'(SEQIDNO:602)
CKAP5-324靶:5'-ACTGATTCCAATGCAGTGGTTCAATTG-3'(SEQIDNO:1178)
5'-AUUCCAAUGCAGUGGUUCAAUUGAA-3'(SEQIDNO:1755)
3'-ACUAAGGUUACGUCACCAAGUUAACUU-5'(SEQIDNO:603)
CKAP5-326靶:5'-TGATTCCAATGCAGTGGTTCAATTGAA-3'(SEQIDNO:1179)
5'-UCCAAUGCAGUGGUUCAAUUGAAAG-3'(SEQIDNO:1756)
3'-UAAGGUUACGUCACCAAGUUAACUUUC-5'(SEQIDNO:604)
CKAP5-328靶:5'-ATTCCAATGCAGTGGTTCAATTGAAAG-3'(SEQIDNO:1180)
5'-CAAUGCAGUGGUUCAAUUGAAAGGA-3'(SEQIDNO:1757)
3'-AGGUUACGUCACCAAGUUAACUUUCCU-5'(SEQIDNO:605)
CKAP5-330靶:5'-TCCAATGCAGTGGTTCAATTGAAAGGA-3'(SEQIDNO:1181)
5'-AUGCAGUGGUUCAAUUGAAAGGAUU-3'(SEQIDNO:1758)
3'-GUUACGUCACCAAGUUAACUUUCCUAA-5'(SEQIDNO:606)
CKAP5-332靶:5'-CAATGCAGTGGTTCAATTGAAAGGATT-3'(SEQIDNO:1182)
5'-GCAGUGGUUCAAUUGAAAGGAUUAG-3'(SEQIDNO:1759)
3'-UACGUCACCAAGUUAACUUUCCUAAUC-5'(SEQIDNO:607)
CKAP5-334靶:5'-ATGCAGTGGTTCAATTGAAAGGATTAG-3'(SEQIDNO:1183)
5'-AGUGGUUCAAUUGAAAGGAUUAGAA-3'(SEQIDNO:1760)
3'-CGUCACCAAGUUAACUUUCCUAAUCUU-5'(SEQIDNO:608)
CKAP5-336靶:5'-GCAGTGGTTCAATTGAAAGGATTAGAA-3'(SEQIDNO:1184)
5'-AAGAUCAUAGUGGCCUGUAUAGAGA-3'(SEQIDNO:1761)
3'-GGUUCUAGUAUCACCGGACAUAUCUCU-5'(SEQIDNO:609)
CKAP5-565靶:5'-CCAAGATCATAGTGGCCTGTATAGAGA-3'(SEQIDNO:1185)
5'-GAUCAUAGUGGCCUGUAUAGAGACA-3'(SEQIDNO:1762)
3'-UUCUAGUAUCACCGGACAUAUCUCUGU-5'(SEQIDNO:610)
CKAP5-567靶:5'-AAGATCATAGTGGCCTGTATAGAGACA-3'(SEQIDNO:1186)
5'-UCAUAGUGGCCUGUAUAGAGACACU-3'(SEQIDNO:1763)
3'-CUAGUAUCACCGGACAUAUCUCUGUGA-5'(SEQIDNO:611)
CKAP5-569靶:5'-GATCATAGTGGCCTGTATAGAGACACT-3'(SEQIDNO:1187)
5'-CACUGAGGAAAGCCUUAAGUGAAUU-3'(SEQIDNO:1764)
3'-CUGUGACUCCUUUCGGAAUUCACUUAA-5'(SEQIDNO:612)
CKAP5-590靶:5'-GACACTGAGGAAAGCCTTAAGTGAATT-3'(SEQIDNO:1188)
5'-CUGAGGAAAGCCUUAAGUGAAUUUG-3'(SEQIDNO:1765)
3'-GUGACUCCUUUCGGAAUUCACUUAAAC-5'(SEQIDNO:613)
CKAP5-592靶:5'-CACTGAGGAAAGCCTTAAGTGAATTTG-3'(SEQIDNO:1189)
5'-GAGGAAAGCCUUAAGUGAAUUUGGU-3'(SEQIDNO:1766)
3'-GACUCCUUUCGGAAUUCACUUAAACCA-5'(SEQIDNO:614)
CKAP5-594靶:5'-CTGAGGAAAGCCTTAAGTGAATTTGGT-3'(SEQIDNO:1190)
5'-GGAAAGCCUUAAGUGAAUUUGGUUC-3'(SEQIDNO:1767)
3'-CUCCUUUCGGAAUUCACUUAAACCAAG-5'(SEQIDNO:615)
CKAP5-596靶:5'-GAGGAAAGCCTTAAGTGAATTTGGTTC-3'(SEQIDNO:1191)
5'-AAAGCCUUAAGUGAAUUUGGUUCCA-3'(SEQIDNO:1768)
3'-CCUUUCGGAAUUCACUUAAACCAAGGU-5'(SEQIDNO:616)
CKAP5-598靶:5'-GGAAAGCCTTAAGTGAATTTGGTTCCA-3'(SEQIDNO:1192)
5'-AGCCUUAAGUGAAUUUGGUUCCAAA-3'(SEQIDNO:1769)
3'-UUUCGGAAUUCACUUAAACCAAGGUUU-5'(SEQIDNO:617)
CKAP5-600靶:5'-AAAGCCTTAAGTGAATTTGGTTCCAAA-3'(SEQIDNO:1193)
5'-CCUUAAGUGAAUUUGGUUCCAAAAU-3'(SEQIDNO:1770)
3'-UCGGAAUUCACUUAAACCAAGGUUUUA-5'(SEQIDNO:618)
CKAP5-602靶:5'-AGCCTTAAGTGAATTTGGTTCCAAAAT-3'(SEQIDNO:1194)
5'-UUAAGUGAAUUUGGUUCCAAAAUCA-3'(SEQIDNO:1771)
3'-GGAAUUCACUUAAACCAAGGUUUUAGU-5'(SEQIDNO:619)
CKAP5-604靶:5'-CCTTAAGTGAATTTGGTTCCAAAATCA-3'(SEQIDNO:1195)
5'-AAGUGAAUUUGGUUCCAAAAUCAUC-3'(SEQIDNO:1772)
3'-AAUUCACUUAAACCAAGGUUUUAGUAG-5'(SEQIDNO:620)
CKAP5-606靶:5'-TTAAGTGAATTTGGTTCCAAAATCATC-3'(SEQIDNO:1196)
5'-GUGAAUUUGGUUCCAAAAUCAUCUU-3'(SEQIDNO:1773)
3'-UUCACUUAAACCAAGGUUUUAGUAGAA-5'(SEQIDNO:621)
CKAP5-608靶:5'-AAGTGAATTTGGTTCCAAAATCATCTT-3'(SEQIDNO:1197)
5'-GAAUUUGGUUCCAAAAUCAUCUUGC-3'(SEQIDNO:1774)
3'-CACUUAAACCAAGGUUUUAGUAGAACG-5'(SEQIDNO:622)
CKAP5-610靶:5'-GTGAATTTGGTTCCAAAATCATCTTGC-3'(SEQIDNO:1198)
5'-AUUUGGUUCCAAAAUCAUCUUGCUU-3'(SEQIDNO:1775)
3'-CUUAAACCAAGGUUUUAGUAGAACGAA-5'(SEQIDNO:623)
CKAP5-612靶:5'-GAATTTGGTTCCAAAATCATCTTGCTT-3'(SEQIDNO:1199)
5'-CGUUCCCAACAAGAACUAGAAGCUA-3'(SEQIDNO:1776)
3'-AAGCAAGGGUUGUUCUUGAUCUUCGAU-5'(SEQIDNO:624)
CKAP5-847靶:5'-TTCGTTCCCAACAAGAACTAGAAGCTA-3'(SEQIDNO:1200)
5'-UUCCCAACAAGAACUAGAAGCUAAA-3'(SEQIDNO:1777)
3'-GCAAGGGUUGUUCUUGAUCUUCGAUUU-5'(SEQIDNO:625)
CKAP5-849靶:5'-CGTTCCCAACAAGAACTAGAAGCTAAA-3'(SEQIDNO:1201)
5'-CCCAACAAGAACUAGAAGCUAAAUU-3'(SEQIDNO:1778)
3'-AAGGGUUGUUCUUGAUCUUCGAUUUAA-5'(SEQIDNO:626)
CKAP5-851靶:5'-TTCCCAACAAGAACTAGAAGCTAAATT-3'(SEQIDNO:1202)
5'-CAACAAGAACUAGAAGCUAAAUUGG-3'(SEQIDNO:1779)
3'-GGGUUGUUCUUGAUCUUCGAUUUAACC-5'(SEQIDNO:627)
CKAP5-853靶:5'-CCCAACAAGAACTAGAAGCTAAATTGG-3'(SEQIDNO:1203)
5'-ACAAGAACUAGAAGCUAAAUUGGAA-3'(SEQIDNO:1780)
3'-GUUGUUCUUGAUCUUCGAUUUAACCUU-5'(SEQIDNO:628)
CKAP5-855靶:5'-CAACAAGAACTAGAAGCTAAATTGGAA-3'(SEQIDNO:1204)
5'-AACAGUCUGCUGGUGGAGAUGCUGA-3'(SEQIDNO:1781)
3'-UGUUGUCAGACGACCACCUCUACGACU-5'(SEQIDNO:629)
CKAP5-884靶:5'-ACAACAGTCTGCTGGTGGAGATGCTGA-3'(SEQIDNO:1205)
5'-CAGUCUGCUGGUGGAGAUGCUGAAG-3'(SEQIDNO:1782)
3'-UUGUCAGACGACCACCUCUACGACUUC-5'(SEQIDNO:630)
CKAP5-886靶:5'-AACAGTCTGCTGGTGGAGATGCTGAAG-3'(SEQIDNO:1206)
5'-GUGGUGAUGAUGGUGAUGAGGUGCC-3'(SEQIDNO:1783)
3'-UCCACCACUACUACCACUACUCCACGG-5'(SEQIDNO:631)
CKAP5-914靶:5'-AGGTGGTGATGATGGTGATGAGGTGCC-3'(SEQIDNO:1207)
5'-GGUGAUGAUGGUGAUGAGGUGCCAC-3'(SEQIDNO:1784)
3'-CACCACUACUACCACUACUCCACGGUG-5'(SEQIDNO:632)
CKAP5-916靶:5'-GTGGTGATGATGGTGATGAGGTGCCAC-3'(SEQIDNO:1208)
5'-AUCCUUUCCAAACUUCCCAAAGACU-3'(SEQIDNO:1785)
3'-UUUAGGAAAGGUUUGAAGGGUUUCUGA-5'(SEQIDNO:633)
CKAP5-976靶:5'-AAATCCTTTCCAAACTTCCCAAAGACT-3'(SEQIDNO:1209)
5'-CCUUUCCAAACUUCCCAAAGACUUU-3'(SEQIDNO:1786)
3'-UAGGAAAGGUUUGAAGGGUUUCUGAAA-5'(SEQIDNO:634)
CKAP5-978靶:5'-ATCCTTTCCAAACTTCCCAAAGACTTT-3'(SEQIDNO:1210)
5'-UUUCCAAACUUCCCAAAGACUUUUA-3'(SEQIDNO:1787)
3'-GGAAAGGUUUGAAGGGUUUCUGAAAAU-5'(SEQIDNO:635)
CKAP5-980靶:5'-CCTTTCCAAACTTCCCAAAGACTTTTA-3'(SEQIDNO:1211)
5'-UCCAAACUUCCCAAAGACUUUUAUG-3'(SEQIDNO:1788)
3'-AAAGGUUUGAAGGGUUUCUGAAAAUAC-5'(SEQIDNO:636)
CKAP5-982靶:5'-TTTCCAAACTTCCCAAAGACTTTTATG-3'(SEQIDNO:1212)
5'-CAAACUUCCCAAAGACUUUUAUGAC-3'(SEQIDNO:1789)
3'-AGGUUUGAAGGGUUUCUGAAAAUACUG-5'(SEQIDNO:637)
CKAP5-984靶:5'-TCCAAACTTCCCAAAGACTTTTATGAC-3'(SEQIDNO:1213)
5'-AACUUCCCAAAGACUUUUAUGACAA-3'(SEQIDNO:1790)
3'-GUUUGAAGGGUUUCUGAAAAUACUGUU-5'(SEQIDNO:638)
CKAP5-986靶:5'-CAAACTTCCCAAAGACTTTTATGACAA-3'(SEQIDNO:1214)
5'-CUUCCCAAAGACUUUUAUGACAAAA-3'(SEQIDNO:1791)
3'-UUGAAGGGUUUCUGAAAAUACUGUUUU-5'(SEQIDNO:639)
CKAP5-988靶:5'-AACTTCCCAAAGACTTTTATGACAAAA-3'(SEQIDNO:1215)
5'-UCCCAAAGACUUUUAUGACAAAAUU-3'(SEQIDNO:1792)
3'-GAAGGGUUUCUGAAAAUACUGUUUUAA-5'(SEQIDNO:640)
CKAP5-990靶:5'-CTTCCCAAAGACTTTTATGACAAAATT-3'(SEQIDNO:1216)
5'-CCAAAGACUUUUAUGACAAAAUUGA-3'(SEQIDNO:1793)
3'-AGGGUUUCUGAAAAUACUGUUUUAACU-5'(SEQIDNO:641)
CKAP5-992靶:5'-TCCCAAAGACTTTTATGACAAAATTGA-3'(SEQIDNO:1217)
5'-AAAGACUUUUAUGACAAAAUUGAGG-3'(SEQIDNO:1794)
3'-GGUUUCUGAAAAUACUGUUUUAACUCC-5'(SEQIDNO:642)
CKAP5-994靶:5'-CCAAAGACTTTTATGACAAAATTGAGG-3'(SEQIDNO:1218)
5'-AGACUUUUAUGACAAAAUUGAGGCA-3'(SEQIDNO:1795)
3'-UUUCUGAAAAUACUGUUUUAACUCCGU-5'(SEQIDNO:643)
CKAP5-996靶:5'-AAAGACTTTTATGACAAAATTGAGGCA-3'(SEQIDNO:1219)
5'-ACUUUUAUGACAAAAUUGAGGCAAA-3'(SEQIDNO:1796)
3'-UCUGAAAAUACUGUUUUAACUCCGUUU-5'(SEQIDNO:644)
CKAP5-998靶:5'-AGACTTTTATGACAAAATTGAGGCAAA-3'(SEQIDNO:1220)
5'-UUUUAUGACAAAAUUGAGGCAAAAA-3'(SEQIDNO:1797)
3'-UGAAAAUACUGUUUUAACUCCGUUUUU-5'(SEQIDNO:645)
CKAP5-1000靶:5'-ACTTTTATGACAAAATTGAGGCAAAAA-3'(SEQIDNO:1221)
5'-UUAUGACAAAAUUGAGGCAAAAAAA-3'(SEQIDNO:1798)
3'-AAAAUACUGUUUUAACUCCGUUUUUUU-5'(SEQIDNO:646)
CKAP5-1002靶:5'-TTTTATGACAAAATTGAGGCAAAAAAA-3'(SEQIDNO:1222)
5'-AUGACAAAAUUGAGGCAAAAAAAUG-3'(SEQIDNO:1799)
3'-AAUACUGUUUUAACUCCGUUUUUUUAC-5'(SEQIDNO:647)
CKAP5-1004靶:5'-TTATGACAAAATTGAGGCAAAAAAATG-3'(SEQIDNO:1223)
5'-AAUGGCAAGAGAGAAAAGAGGCCCU-3'(SEQIDNO:1800)
3'-UUUUACCGUUCUCUCUUUUCUCCGGGA-5'(SEQIDNO:648)
CKAP5-1025靶:5'-AAAATGGCAAGAGAGAAAAGAGGCCCT-3'(SEQIDNO:1224)
5'-AGGUUGUUGGAAAGGACACCAAUGU-3'(SEQIDNO:1801)
3'-CUUCCAACAACCUUUCCUGUGGUUACA-5'(SEQIDNO:649)
CKAP5-1127靶:5'-GAAGGTTGTTGGAAAGGACACCAATGT-3'(SEQIDNO:1225)
5'-GUUGUUGGAAAGGACACCAAUGUCA-3'(SEQIDNO:1802)
3'-UCCAACAACCUUUCCUGUGGUUACAGU-5'(SEQIDNO:650)
CKAP5-1129靶:5'-AGGTTGTTGGAAAGGACACCAATGTCA-3'(SEQIDNO:1226)
5'-UGUUGGAAAGGACACCAAUGUCAUG-3'(SEQIDNO:1803)
3'-CAACAACCUUUCCUGUGGUUACAGUAC-5'(SEQIDNO:651)
CKAP5-1131靶:5'-GTTGTTGGAAAGGACACCAATGTCATG-3'(SEQIDNO:1227)
5'-UUGGAAAGGACACCAAUGUCAUGUU-3'(SEQIDNO:1804)
3'-ACAACCUUUCCUGUGGUUACAGUACAA-5'(SEQIDNO:652)
CKAP5-1133靶:5'-TGTTGGAAAGGACACCAATGTCATGTT-3'(SEQIDNO:1228)
5'-GGAAAGGACACCAAUGUCAUGUUGG-3'(SEQIDNO:1805)
3'-AACCUUUCCUGUGGUUACAGUACAACC-5'(SEQIDNO:653)
CKAP5-1135靶:5'-TTGGAAAGGACACCAATGTCATGTTGG-3'(SEQIDNO:1229)
5'-AAAGGACACCAAUGUCAUGUUGGUG-3'(SEQIDNO:1806)
3'-CCUUUCCUGUGGUUACAGUACAACCAC-5'(SEQIDNO:654)
CKAP5-1137靶:5'-GGAAAGGACACCAATGTCATGTTGGTG-3'(SEQIDNO:1230)
5'-AGGACACCAAUGUCAUGUUGGUGGC-3'(SEQIDNO:1807)
3'-UUUCCUGUGGUUACAGUACAACCACCG-5'(SEQIDNO:655)
CKAP5-1139靶:5'-AAAGGACACCAATGTCATGTTGGTGGC-3'(SEQIDNO:1231)
5'-GACACCAAUGUCAUGUUGGUGGCUU-3'(SEQIDNO:1808)
3'-UCCUGUGGUUACAGUACAACCACCGAA-5'(SEQIDNO:656)
CKAP5-1141靶:5'-AGGACACCAATGTCATGTTGGTGGCTT-3'(SEQIDNO:1232)
5'-GCUUUGGCAGCAAAAUGUCUUACUG-3'(SEQIDNO:1809)
3'-ACCGAAACCGUCGUUUUACAGAAUGAC-5'(SEQIDNO:657)
CKAP5-1162靶:5'-TGGCTTTGGCAGCAAAATGTCTTACTG-3'(SEQIDNO:1233)
5'-UUUGGCAGCAAAAUGUCUUACUGGC-3'(SEQIDNO:1810)
3'-CGAAACCGUCGUUUUACAGAAUGACCG-5'(SEQIDNO:658)
CKAP5-1164靶:5'-GCTTTGGCAGCAAAATGTCTTACTGGC-3'(SEQIDNO:1234)
5'-UGGCAGCAAAAUGUCUUACUGGCCU-3'(SEQIDNO:1811)
3'-AAACCGUCGUUUUACAGAAUGACCGGA-5'(SEQIDNO:659)
CKAP5-1166靶:5'-TTTGGCAGCAAAATGTCTTACTGGCCT-3'(SEQIDNO:1235)
5'-GCAGCAAAAUGUCUUACUGGCCUGG-3'(SEQIDNO:1812)
3'-ACCGUCGUUUUACAGAAUGACCGGACC-5'(SEQIDNO:660)
CKAP5-1168靶:5'-TGGCAGCAAAATGTCTTACTGGCCTGG-3'(SEQIDNO:1236)
5'-AGCAAAAUGUCUUACUGGCCUGGCU-3'(SEQIDNO:1813)
3'-CGUCGUUUUACAGAAUGACCGGACCGA-5'(SEQIDNO:661)
CKAP5-1170靶:5'-GCAGCAAAATGTCTTACTGGCCTGGCT-3'(SEQIDNO:1237)
5'-AGAAAUUUGGACAAUAUGCAGGACA-3'(SEQIDNO:1814)
3'-CUUCUUUAAACCUGUUAUACGUCCUGU-5'(SEQIDNO:662)
CKAP5-1208靶:5'-GAAGAAATTTGGACAATATGCAGGACA-3'(SEQIDNO:1238)
5'-AAAUUUGGACAAUAUGCAGGACAUG-3'(SEQIDNO:1815)
3'-UCUUUAAACCUGUUAUACGUCCUGUAC-5'(SEQIDNO:663)
CKAP5-1210靶:5'-AGAAATTTGGACAATATGCAGGACATG-3'(SEQIDNO:1239)
5'-AUUUGGACAAUAUGCAGGACAUGUU-3'(SEQIDNO:1816)
3'-UUUAAACCUGUUAUACGUCCUGUACAA-5'(SEQIDNO:664)
CKAP5-1212靶:5'-AAATTTGGACAATATGCAGGACATGTT-3'(SEQIDNO:1240)
5'-UUGGACAAUAUGCAGGACAUGUUGU-3'(SEQIDNO:1817)
3'-UAAACCUGUUAUACGUCCUGUACAACA-5'(SEQIDNO:665)
CKAP5-1214靶:5'-ATTTGGACAATATGCAGGACATGTTGT-3'(SEQIDNO:1241)
5'-GGACAAUAUGCAGGACAUGUUGUGC-3'(SEQIDNO:1818)
3'-AACCUGUUAUACGUCCUGUACAACACG-5'(SEQIDNO:666)
CKAP5-1216靶:5'-TTGGACAATATGCAGGACATGTTGTGC-3'(SEQIDNO:1242)
5'-ACAAUAUGCAGGACAUGUUGUGCCA-3'(SEQIDNO:1819)
3'-CCUGUUAUACGUCCUGUACAACACGGU-5'(SEQIDNO:667)
CKAP5-1218靶:5'-GGACAATATGCAGGACATGTTGTGCCA-3'(SEQIDNO:1243)
5'-AAUAUGCAGGACAUGUUGUGCCAAC-3'(SEQIDNO:1820)
3'-UGUUAUACGUCCUGUACAACACGGUUG-5'(SEQIDNO:668)
CKAP5-1220靶:5'-ACAATATGCAGGACATGTTGTGCCAAC-3'(SEQIDNO:1244)
5'-UAUGCAGGACAUGUUGUGCCAACCA-3'(SEQIDNO:1821)
3'-UUAUACGUCCUGUACAACACGGUUGGU-5'(SEQIDNO:669)
CKAP5-1222靶:5'-AATATGCAGGACATGTTGTGCCAACCA-3'(SEQIDNO:1245)
5'-UGCAGGACAUGUUGUGCCAACCAUC-3'(SEQIDNO:1822)
3'-AUACGUCCUGUACAACACGGUUGGUAG-5'(SEQIDNO:670)
CKAP5-1224靶:5'-TATGCAGGACATGTTGTGCCAACCATC-3'(SEQIDNO:1246)
5'-CAGGACAUGUUGUGCCAACCAUCUU-3'(SEQIDNO:1823)
3'-ACGUCCUGUACAACACGGUUGGUAGAA-5'(SEQIDNO:671)
CKAP5-1226靶:5'-TGCAGGACATGTTGTGCCAACCATCTT-3'(SEQIDNO:1247)
5'-CUCAAGUGGUACAAGCCCUGCAGGA-3'(SEQIDNO:1824)
3'-UGGAGUUCACCAUGUUCGGGACGUCCU-5'(SEQIDNO:672)
CKAP5-1274靶:5'-ACCTCAAGTGGTACAAGCCCTGCAGGA-3'(SEQIDNO:1248)
5'-CAAGUGGUACAAGCCCUGCAGGAGG-3'(SEQIDNO:1825)
3'-GAGUUCACCAUGUUCGGGACGUCCUCC-5'(SEQIDNO:673)
CKAP5-1276靶:5'-CTCAAGTGGTACAAGCCCTGCAGGAGG-3'(SEQIDNO:1249)
5'-AGUGGUACAAGCCCUGCAGGAGGCA-3'(SEQIDNO:1826)
3'-GUUCACCAUGUUCGGGACGUCCUCCGU-5'(SEQIDNO:674)
CKAP5-1278靶:5'-CAAGTGGTACAAGCCCTGCAGGAGGCA-3'(SEQIDNO:1250)
5'-UGGUACAAGCCCUGCAGGAGGCAAU-3'(SEQIDNO:1827)
3'-UCACCAUGUUCGGGACGUCCUCCGUUA-5'(SEQIDNO:675)
CKAP5-1280靶:5'-AGTGGTACAAGCCCTGCAGGAGGCAAT-3'(SEQIDNO:1251)
5'-GUACAAGCCCUGCAGGAGGCAAUUG-3'(SEQIDNO:1828)
3'-ACCAUGUUCGGGACGUCCUCCGUUAAC-5'(SEQIDNO:676)
CKAP5-1282靶:5'-TGGTACAAGCCCTGCAGGAGGCAATTG-3'(SEQIDNO:1252)
5'-ACAAGCCCUGCAGGAGGCAAUUGAU-3'(SEQIDNO:1829)
3'-CAUGUUCGGGACGUCCUCCGUUAACUA-5'(SEQIDNO:677)
CKAP5-1284靶:5'-GTACAAGCCCTGCAGGAGGCAATTGAT-3'(SEQIDNO:1253)
5'-AAGCCCUGCAGGAGGCAAUUGAUGC-3'(SEQIDNO:1830)
3'-UGUUCGGGACGUCCUCCGUUAACUACG-5'(SEQIDNO:678)
CKAP5-1286靶:5'-ACAAGCCCTGCAGGAGGCAATTGATGC-3'(SEQIDNO:1254)
5'-GCCCUGCAGGAGGCAAUUGAUGCAA-3'(SEQIDNO:1831)
3'-UUCGGGACGUCCUCCGUUAACUACGUU-5'(SEQIDNO:679)
CKAP5-1288靶:5'-AAGCCCTGCAGGAGGCAATTGATGCAA-3'(SEQIDNO:1255)
5'-CCUGCAGGAGGCAAUUGAUGCAAUC-3'(SEQIDNO:1832)
3'-CGGGACGUCCUCCGUUAACUACGUUAG-5'(SEQIDNO:680)
CKAP5-1290靶:5'-GCCCTGCAGGAGGCAATTGATGCAATC-3'(SEQIDNO:1256)
5'-UGCAGGAGGCAAUUGAUGCAAUCUU-3'(SEQIDNO:1833)
3'-GGACGUCCUCCGUUAACUACGUUAGAA-5'(SEQIDNO:681)
CKAP5-1292靶:5'-CCTGCAGGAGGCAATTGATGCAATCTT-3'(SEQIDNO:1257)
5'-CAGGAGGCAAUUGAUGCAAUCUUCC-3'(SEQIDNO:1834)
3'-ACGUCCUCCGUUAACUACGUUAGAAGG-5'(SEQIDNO:682)
CKAP5-1294靶:5'-TGCAGGAGGCAATTGATGCAATCTTCC-3'(SEQIDNO:1258)
5'-GGAGGCAAUUGAUGCAAUCUUCCUU-3'(SEQIDNO:1835)
3'-GUCCUCCGUUAACUACGUUAGAAGGAA-5'(SEQIDNO:683)
CKAP5-1296靶:5'-CAGGAGGCAATTGATGCAATCTTCCTT-3'(SEQIDNO:1259)
5'-AGGCAAUUGAUGCAAUCUUCCUUAC-3'(SEQIDNO:1836)
3'-CCUCCGUUAACUACGUUAGAAGGAAUG-5'(SEQIDNO:684)
CKAP5-1298靶:5'-GGAGGCAATTGATGCAATCTTCCTTAC-3'(SEQIDNO:1260)
5'-GCAAUUGAUGCAAUCUUCCUUACUA-3'(SEQIDNO:1837)
3'-UCCGUUAACUACGUUAGAAGGAAUGAU-5'(SEQIDNO:685)
CKAP5-1300靶:5'-AGGCAATTGATGCAATCTTCCTTACTA-3'(SEQIDNO:1261)
5'-ACUACCACACUACAGAACAUCAGUG-3'(SEQIDNO:1838)
3'-AAUGAUGGUGUGAUGUCUUGUAGUCAC-5'(SEQIDNO:686)
CKAP5-1321靶:5'-TTACTACCACACTACAGAACATCAGTG-3'(SEQIDNO:1262)
5'-UACCACACUACAGAACAUCAGUGAG-3'(SEQIDNO:1839)
3'-UGAUGGUGUGAUGUCUUGUAGUCACUC-5'(SEQIDNO:687)
CKAP5-1323靶:5'-ACTACCACACTACAGAACATCAGTGAG-3'(SEQIDNO:1263)
5'-CCACACUACAGAACAUCAGUGAGGA-3'(SEQIDNO:1840)
3'-AUGGUGUGAUGUCUUGUAGUCACUCCU-5'(SEQIDNO:688)
CKAP5-1325靶:5'-TACCACACTACAGAACATCAGTGAGGA-3'(SEQIDNO:1264)
5'-ACACUACAGAACAUCAGUGAGGAUG-3'(SEQIDNO:1841)
3'-GGUGUGAUGUCUUGUAGUCACUCCUAC-5'(SEQIDNO:689)
CKAP5-1327靶:5'-CCACACTACAGAACATCAGTGAGGATG-3'(SEQIDNO:1265)
5'-ACUACAGAACAUCAGUGAGGAUGUU-3'(SEQIDNO:1842)
3'-UGUGAUGUCUUGUAGUCACUCCUACAA-5'(SEQIDNO:690)
CKAP5-1329靶:5'-ACACTACAGAACATCAGTGAGGATGTT-3'(SEQIDNO:1266)
5'-UACAGAACAUCAGUGAGGAUGUUUU-3'(SEQIDNO:1843)
3'-UGAUGUCUUGUAGUCACUCCUACAAAA-5'(SEQIDNO:691)
CKAP5-1331靶:5'-ACTACAGAACATCAGTGAGGATGTTTT-3'(SEQIDNO:1267)
5'-CAGAACAUCAGUGAGGAUGUUUUAG-3'(SEQIDNO:1844)
3'-AUGUCUUGUAGUCACUCCUACAAAAUC-5'(SEQIDNO:692)
CKAP5-1333靶:5'-TACAGAACATCAGTGAGGATGTTTTAG-3'(SEQIDNO:1268)
5'-UUAGCAGUAAUGGAUAAUAAAAAUC-3'(SEQIDNO:1845)
3'-AAAAUCGUCAUUACCUAUUAUUUUUAG-5'(SEQIDNO:693)
CKAP5-1354靶:5'-TTTTAGCAGTAATGGATAATAAAAATC-3'(SEQIDNO:1269)
5'-AGCAGUAAUGGAUAAUAAAAAUCCA-3'(SEQIDNO:1846)
3'-AAUCGUCAUUACCUAUUAUUUUUAGGU-5'(SEQIDNO:694)
CKAP5-1356靶:5'-TTAGCAGTAATGGATAATAAAAATCCA-3'(SEQIDNO:1270)
5'-CAGUAAUGGAUAAUAAAAAUCCAAC-3'(SEQIDNO:1847)
3'-UCGUCAUUACCUAUUAUUUUUAGGUUG-5'(SEQIDNO:695)
CKAP5-1358靶:5'-AGCAGTAATGGATAATAAAAATCCAAC-3'(SEQIDNO:1271)
5'-GUAAUGGAUAAUAAAAAUCCAACCA-3'(SEQIDNO:1848)
3'-GUCAUUACCUAUUAUUUUUAGGUUGGU-5'(SEQIDNO:696)
CKAP5-1360靶:5'-CAGTAATGGATAATAAAAATCCAACCA-3'(SEQIDNO:1272)
5'-ACCAUCAAGCAGCAGACAUCUCUUU-3'(SEQIDNO:1849)
3'-GUUGGUAGUUCGUCGUCUGUAGAGAAA-5'(SEQIDNO:697)
CKAP5-1381靶:5'-CAACCATCAAGCAGCAGACATCTCTTT-3'(SEQIDNO:1273)
5'-CUACUUAAGCACAUCAAUGAUUCUG-3'(SEQIDNO:1850)
3'-GUGAUGAAUUCGUGUAGUUACUAAGAC-5'(SEQIDNO:698)
CKAP5-1480靶:5'-CACTACTTAAGCACATCAATGATTCTG-3'(SEQIDNO:1274)
5'-ACUUAAGCACAUCAAUGAUUCUGCU-3'(SEQIDNO:1851)
3'-GAUGAAUUCGUGUAGUUACUAAGACGA-5'(SEQIDNO:699)
CKAP5-1482靶:5'-CTACTTAAGCACATCAATGATTCTGCT-3'(SEQIDNO:1275)
5'-UUAAGCACAUCAAUGAUUCUGCUCC-3'(SEQIDNO:1852)
3'-UGAAUUCGUGUAGUUACUAAGACGAGG-5'(SEQIDNO:700)
CKAP5-1484靶:5'-ACTTAAGCACATCAATGATTCTGCTCC-3'(SEQIDNO:1276)
5'-AAGCACAUCAAUGAUUCUGCUCCUG-3'(SEQIDNO:1853)
3'-AAUUCGUGUAGUUACUAAGACGAGGAC-5'(SEQIDNO:701)
CKAP5-1486靶:5'-TTAAGCACATCAATGATTCTGCTCCTG-3'(SEQIDNO:1277)
5'-GCACAUCAAUGAUUCUGCUCCUGAA-3'(SEQIDNO:1854)
3'-UUCGUGUAGUUACUAAGACGAGGACUU-5'(SEQIDNO:702)
CKAP5-1488靶:5'-AAGCACATCAATGATTCTGCTCCTGAA-3'(SEQIDNO:1278)
5'-ACAUCAAUGAUUCUGCUCCUGAAGU-3'(SEQIDNO:1855)
3'-CGUGUAGUUACUAAGACGAGGACUUCA-5'(SEQIDNO:703)
CKAP5-1490靶:5'-GCACATCAATGATTCTGCTCCTGAAGT-3'(SEQIDNO:1279)
5'-AUCAAUGAUUCUGCUCCUGAAGUCA-3'(SEQIDNO:1856)
3'-UGUAGUUACUAAGACGAGGACUUCAGU-5'(SEQIDNO:704)
CKAP5-1492靶:5'-ACATCAATGATTCTGCTCCTGAAGTCA-3'(SEQIDNO:1280)
5'-CAAUGAUUCUGCUCCUGAAGUCAGA-3'(SEQIDNO:1857)
3'-UAGUUACUAAGACGAGGACUUCAGUCU-5'(SEQIDNO:705)
CKAP5-1494靶:5'-ATCAATGATTCTGCTCCTGAAGTCAGA-3'(SEQIDNO:1281)
5'-AUGAUUCUGCUCCUGAAGUCAGAGA-3'(SEQIDNO:1858)
3'-GUUACUAAGACGAGGACUUCAGUCUCU-5'(SEQIDNO:706)
CKAP5-1496靶:5'-CAATGATTCTGCTCCTGAAGTCAGAGA-3'(SEQIDNO:1282)
5'-GAUUCUGCUCCUGAAGUCAGAGAUG-3'(SEQIDNO:1859)
3'-UACUAAGACGAGGACUUCAGUCUCUAC-5'(SEQIDNO:707)
CKAP5-1498靶:5'-ATGATTCTGCTCCTGAAGTCAGAGATG-3'(SEQIDNO:1283)
5'-UUCUGCUCCUGAAGUCAGAGAUGCC-3'(SEQIDNO:1860)
3'-CUAAGACGAGGACUUCAGUCUCUACGG-5'(SEQIDNO:708)
CKAP5-1500靶:5'-GATTCTGCTCCTGAAGTCAGAGATGCC-3'(SEQIDNO:1284)
5'-CUGCUCCUGAAGUCAGAGAUGCCGC-3'(SEQIDNO:1861)
3'-AAGACGAGGACUUCAGUCUCUACGGCG-5'(SEQIDNO:709)
CKAP5-1502靶:5'-TTCTGCTCCTGAAGTCAGAGATGCCGC-3'(SEQIDNO:1285)
5'-GCUCCUGAAGUCAGAGAUGCCGCAU-3'(SEQIDNO:1862)
3'-GACGAGGACUUCAGUCUCUACGGCGUA-5'(SEQIDNO:710)
CKAP5-1504靶:5'-CTGCTCCTGAAGTCAGAGATGCCGCAT-3'(SEQIDNO:1286)
5'-GAUCAAAGAAUGUUCAGAAAAGGUA-3'(SEQIDNO:1863)
3'-UUCUAGUUUCUUACAAGUCUUUUCCAU-5'(SEQIDNO:711)
CKAP5-1617靶:5'-AAGATCAAAGAATGTTCAGAAAAGGTA-3'(SEQIDNO:1287)
5'-UCAAAGAAUGUUCAGAAAAGGUAGA-3'(SEQIDNO:1864)
3'-CUAGUUUCUUACAAGUCUUUUCCAUCU-5'(SEQIDNO:712)
CKAP5-1619靶:5'-GATCAAAGAATGTTCAGAAAAGGTAGA-3'(SEQIDNO:1288)
5'-AACCUGGAUGGAAAGAAACUAAUUU-3'(SEQIDNO:1865)
3'-CUUUGGACCUACCUUUCUUUGAUUAAA-5'(SEQIDNO:713)
CKAP5-2090靶:5'-GAAACCTGGATGGAAAGAAACTAATTT-3'(SEQIDNO:1289)
5'-CCUGGAUGGAAAGAAACUAAUUUUC-3'(SEQIDNO:1866)
3'-UUGGACCUACCUUUCUUUGAUUAAAAG-5'(SEQIDNO:714)
CKAP5-2092靶:5'-AACCTGGATGGAAAGAAACTAATTTTC-3'(SEQIDNO:1290)
5'-UGGAUGGAAAGAAACUAAUUUUCAG-3'(SEQIDNO:1867)
3'-GGACCUACCUUUCUUUGAUUAAAAGUC-5'(SEQIDNO:715)
CKAP5-2094靶:5'-CCTGGATGGAAAGAAACTAATTTTCAG-3'(SEQIDNO:1291)
5'-GAUGGAAAGAAACUAAUUUUCAGGU-3'(SEQIDNO:1868)
3'-ACCUACCUUUCUUUGAUUAAAAGUCCA-5'(SEQIDNO:716)
CKAP5-2096靶:5'-TGGATGGAAAGAAACTAATTTTCAGGT-3'(SEQIDNO:1292)
5'-UGGAAAGAAACUAAUUUUCAGGUGA-3'(SEQIDNO:1869)
3'-CUACCUUUCUUUGAUUAAAAGUCCACU-5'(SEQIDNO:717)
CKAP5-2098靶:5'-GATGGAAAGAAACTAATTTTCAGGTGA-3'(SEQIDNO:1293)
5'-GAAAGAAACUAAUUUUCAGGUGAUG-3'(SEQIDNO:1870)
3'-ACCUUUCUUUGAUUAAAAGUCCACUAC-5'(SEQIDNO:718)
CKAP5-2100靶:5'-TGGAAAGAAACTAATTTTCAGGTGATG-3'(SEQIDNO:1294)
5'-AAGAAACUAAUUUUCAGGUGAUGCA-3'(SEQIDNO:1871)
3'-CUUUCUUUGAUUAAAAGUCCACUACGU-5'(SEQIDNO:719)
CKAP5-2102靶:5'-GAAAGAAACTAATTTTCAGGTGATGCA-3'(SEQIDNO:1295)
5'-GAAACUAAUUUUCAGGUGAUGCAAA-3'(SEQIDNO:1872)
3'-UUCUUUGAUUAAAAGUCCACUACGUUU-5'(SEQIDNO:720)
CKAP5-2104靶:5'-AAGAAACTAATTTTCAGGTGATGCAAA-3'(SEQIDNO:1296)
5'-AACUAAUUUUCAGGUGAUGCAAAUG-3'(SEQIDNO:1873)
3'-CUUUGAUUAAAAGUCCACUACGUUUAC-5'(SEQIDNO:721)
CKAP5-2106靶:5'-GAAACTAATTTTCAGGTGATGCAAATG-3'(SEQIDNO:1297)
5'-CUAAUUUUCAGGUGAUGCAAAUGAA-3'(SEQIDNO:1874)
3'-UUGAUUAAAAGUCCACUACGUUUACUU-5'(SEQIDNO:722)
CKAP5-2108靶:5'-AACTAATTTTCAGGTGATGCAAATGAA-3'(SEQIDNO:1298)
5'-UUGCUUUGAUUGCCCAGAAGGGAAA-3'(SEQIDNO:1875)
3'-UCAACGAAACUAACGGGUCUUCCCUUU-5'(SEQIDNO:723)
CKAP5-2144靶:5'-AGTTGCTTTGATTGCCCAGAAGGGAAA-3'(SEQIDNO:1299)
5'-GCUUUGAUUGCCCAGAAGGGAAAUU-3'(SEQIDNO:1876)
3'-AACGAAACUAACGGGUCUUCCCUUUAA-5'(SEQIDNO:724)
CKAP5-2146靶:5'-TTGCTTTGATTGCCCAGAAGGGAAATT-3'(SEQIDNO:1300)
5'-UUUGAUUGCCCAGAAGGGAAAUUUU-3'(SEQIDNO:1877)
3'-CGAAACUAACGGGUCUUCCCUUUAAAA-5'(SEQIDNO:725)
CKAP5-2148靶:5'-GCTTTGATTGCCCAGAAGGGAAATTTT-3'(SEQIDNO:1301)
5'-UGAUUGCCCAGAAGGGAAAUUUUUC-3'(SEQIDNO:1878)
3'-AAACUAACGGGUCUUCCCUUUAAAAAG-5'(SEQIDNO:726)
CKAP5-2150靶:5'-TTTGATTGCCCAGAAGGGAAATTTTTC-3'(SEQIDNO:1302)
5'-AUUGCCCAGAAGGGAAAUUUUUCCA-3'(SEQIDNO:1879)
3'-ACUAACGGGUCUUCCCUUUAAAAAGGU-5'(SEQIDNO:727)
CKAP5-2152靶:5'-TGATTGCCCAGAAGGGAAATTTTTCCA-3'(SEQIDNO:1303)
5'-UGCCCAGAAGGGAAAUUUUUCCAAA-3'(SEQIDNO:1880)
3'-UAACGGGUCUUCCCUUUAAAAAGGUUU-5'(SEQIDNO:728)
CKAP5-2154靶:5'-ATTGCCCAGAAGGGAAATTTTTCCAAA-3'(SEQIDNO:1304)
5'-CCCAGAAGGGAAAUUUUUCCAAAAC-3'(SEQIDNO:1881)
3'-ACGGGUCUUCCCUUUAAAAAGGUUUUG-5'(SEQIDNO:729)
CKAP5-2156靶:5'-TGCCCAGAAGGGAAATTTTTCCAAAAC-3'(SEQIDNO:1305)
5'-GACAAGAUUGGAGAUGUGAAAUGUG-3'(SEQIDNO:1882)
3'-ACCUGUUCUAACCUCUACACUUUACAC-5'(SEQIDNO:730)
CKAP5-2212靶:5'-TGGACAAGATTGGAGATGTGAAATGTG-3'(SEQIDNO:1306)
5'-CAAGAUUGGAGAUGUGAAAUGUGGG-3'(SEQIDNO:1883)
3'-CUGUUCUAACCUCUACACUUUACACCC-5'(SEQIDNO:731)
CKAP5-2214靶:5'-GACAAGATTGGAGATGTGAAATGTGGG-3'(SEQIDNO:1307)
5'-AGAUUGGAGAUGUGAAAUGUGGGAA-3'(SEQIDNO:1884)
3'-GUUCUAACCUCUACACUUUACACCCUU-5'(SEQIDNO:732)
CKAP5-2216靶:5'-CAAGATTGGAGATGTGAAATGTGGGAA-3'(SEQIDNO:1308)
5'-AUUGGAGAUGUGAAAUGUGGGAACA-3'(SEQIDNO:1885)
3'-UCUAACCUCUACACUUUACACCCUUGU-5'(SEQIDNO:733)
CKAP5-2218靶:5'-AGATTGGAGATGTGAAATGTGGGAACA-3'(SEQIDNO:1309)
5'-UGGAGAUGUGAAAUGUGGGAACAAU-3'(SEQIDNO:1886)
3'-UAACCUCUACACUUUACACCCUUGUUA-5'(SEQIDNO:734)
CKAP5-2220靶:5'-ATTGGAGATGTGAAATGTGGGAACAAT-3'(SEQIDNO:1310)
5'-GAGAUGUGAAAUGUGGGAACAAUGC-3'(SEQIDNO:1887)
3'-ACCUCUACACUUUACACCCUUGUUACG-5'(SEQIDNO:735)
CKAP5-2222靶:5'-TGGAGATGTGAAATGTGGGAACAATGC-3'(SEQIDNO:1311)
5'-GAUGUGAAAUGUGGGAACAAUGCAA-3'(SEQIDNO:1888)
3'-CUCUACACUUUACACCCUUGUUACGUU-5'(SEQIDNO:736)
CKAP5-2224靶:5'-GAGATGTGAAATGTGGGAACAATGCAA-3'(SEQIDNO:1312)
5'-UGUGAAAUGUGGGAACAAUGCAAAA-3'(SEQIDNO:1889)
3'-CUACACUUUACACCCUUGUUACGUUUU-5'(SEQIDNO:737)
CKAP5-2226靶:5'-GATGTGAAATGTGGGAACAATGCAAAA-3'(SEQIDNO:1313)
5'-UGAAAUGUGGGAACAAUGCAAAAGA-3'(SEQIDNO:1890)
3'-ACACUUUACACCCUUGUUACGUUUUCU-5'(SEQIDNO:738)
CKAP5-2228靶:5'-TGTGAAATGTGGGAACAATGCAAAAGA-3'(SEQIDNO:1314)
5'-AAAUGUGGGAACAAUGCAAAAGAAG-3'(SEQIDNO:1891)
3'-ACUUUACACCCUUGUUACGUUUUCUUC-5'(SEQIDNO:739)
CKAP5-2230靶:5'-TGAAATGTGGGAACAATGCAAAAGAAG-3'(SEQIDNO:1315)
5'-AUGUGGGAACAAUGCAAAAGAAGCU-3'(SEQIDNO:1892)
3'-UUUACACCCUUGUUACGUUUUCUUCGA-5'(SEQIDNO:740)
CKAP5-2232靶:5'-AAATGTGGGAACAATGCAAAAGAAGCT-3'(SEQIDNO:1316)
5'-GUGGGAACAAUGCAAAAGAAGCUAU-3'(SEQIDNO:1893)
3'-UACACCCUUGUUACGUUUUCUUCGAUA-5'(SEQIDNO:741)
CKAP5-2234靶:5'-ATGTGGGAACAATGCAAAAGAAGCTAT-3'(SEQIDNO:1317)
5'-GGGAACAAUGCAAAAGAAGCUAUGA-3'(SEQIDNO:1894)
3'-CACCCUUGUUACGUUUUCUUCGAUACU-5'(SEQIDNO:742)
CKAP5-2236靶:5'-GTGGGAACAATGCAAAAGAAGCTATGA-3'(SEQIDNO:1318)
5'-GUUGAAUGUCAAAGCUUUCAUUAGC-3'(SEQIDNO:1895)
3'-CCCAACUUACAGUUUCGAAAGUAAUCG-5'(SEQIDNO:743)
CKAP5-2400靶:5'-GGGTTGAATGTCAAAGCTTTCATTAGC-3'(SEQIDNO:1319)
5'-UGAAUGUCAAAGCUUUCAUUAGCAA-3'(SEQIDNO:1896)
3'-CAACUUACAGUUUCGAAAGUAAUCGUU-5'(SEQIDNO:744)
CKAP5-2402靶:5'-GTTGAATGTCAAAGCTTTCATTAGCAA-3'(SEQIDNO:1320)
5'-AAUGUCAAAGCUUUCAUUAGCAAUG-3'(SEQIDNO:1897)
3'-ACUUACAGUUUCGAAAGUAAUCGUUAC-5'(SEQIDNO:745)
CKAP5-2404靶:5'-TGAATGTCAAAGCTTTCATTAGCAATG-3'(SEQIDNO:1321)
5'-UGUCAAAGCUUUCAUUAGCAAUGUG-3'(SEQIDNO:1898)
3'-UUACAGUUUCGAAAGUAAUCGUUACAC-5'(SEQIDNO:746)
CKAP5-2406靶:5'-AATGTCAAAGCTTTCATTAGCAATGTG-3'(SEQIDNO:1322)
5'-UCAAAGCUUUCAUUAGCAAUGUGAA-3'(SEQIDNO:1899)
3'-ACAGUUUCGAAAGUAAUCGUUACACUU-5'(SEQIDNO:747)
CKAP5-2408靶:5'-TGTCAAAGCTTTCATTAGCAATGTGAA-3'(SEQIDNO:1323)
5'-CCCUGCUUGGCGUGAUGUAUCUGUA-3'(SEQIDNO:1900)
3'-UUGGGACGAACCGCACUACAUAGACAU-5'(SEQIDNO:748)
CKAP5-2480靶:5'-AACCCTGCTTGGCGTGATGTATCTGTA-3'(SEQIDNO:1324)
5'-CUGCUUGGCGUGAUGUAUCUGUAUG-3'(SEQIDNO:1901)
3'-GGGACGAACCGCACUACAUAGACAUAC-5'(SEQIDNO:749)
CKAP5-2482靶:5'-CCCTGCTTGGCGTGATGTATCTGTATG-3'(SEQIDNO:1325)
5'-UCUUUGAGGAUGAGAAGCCUGCCCU-3'(SEQIDNO:1902)
3'-CAAGAAACUCCUACUCUUCGGACGGGA-5'(SEQIDNO:750)
CKAP5-2528靶:5'-GTTCTTTGAGGATGAGAAGCCTGCCCT-3'(SEQIDNO:1326)
5'-UUUGAGGAUGAGAAGCCUGCCCUCC-3'(SEQIDNO:1903)
3'-AGAAACUCCUACUCUUCGGACGGGAGG-5'(SEQIDNO:751)
CKAP5-2530靶:5'-TCTTTGAGGATGAGAAGCCTGCCCTCC-3'(SEQIDNO:1327)
5'-UGAGGAUGAGAAGCCUGCCCUCCUA-3'(SEQIDNO:1904)
3'-AAACUCCUACUCUUCGGACGGGAGGAU-5'(SEQIDNO:752)
CKAP5-2532靶:5'-TTTGAGGATGAGAAGCCTGCCCTCCTA-3'(SEQIDNO:1328)
5'-AGGAUGAGAAGCCUGCCCUCCUAUC-3'(SEQIDNO:1905)
3'-ACUCCUACUCUUCGGACGGGAGGAUAG-5'(SEQIDNO:753)
CKAP5-2534靶:5'-TGAGGATGAGAAGCCTGCCCTCCTATC-3'(SEQIDNO:1329)
5'-GAUGAGAAGCCUGCCCUCCUAUCCC-3'(SEQIDNO:1906)
3'-UCCUACUCUUCGGACGGGAGGAUAGGG-5'(SEQIDNO:754)
CKAP5-2536靶:5'-AGGATGAGAAGCCTGCCCTCCTATCCC-3'(SEQIDNO:1330)
5'-UGAGAAGCCUGCCCUCCUAUCCCAG-3'(SEQIDNO:1907)
3'-CUACUCUUCGGACGGGAGGAUAGGGUC-5'(SEQIDNO:755)
CKAP5-2538靶:5'-GATGAGAAGCCTGCCCTCCTATCCCAG-3'(SEQIDNO:1331)
5'-AGAAGCCUGCCCUCCUAUCCCAGAU-3'(SEQIDNO:1908)
3'-ACUCUUCGGACGGGAGGAUAGGGUCUA-5'(SEQIDNO:756)
CKAP5-2540靶:5'-TGAGAAGCCTGCCCTCCTATCCCAGAT-3'(SEQIDNO:1332)
5'-AAGCCUGCCCUCCUAUCCCAGAUAG-3'(SEQIDNO:1909)
3'-UCUUCGGACGGGAGGAUAGGGUCUAUC-5'(SEQIDNO:757)
CKAP5-2542靶:5'-AGAAGCCTGCCCTCCTATCCCAGATAG-3'(SEQIDNO:1333)
5'-GCCUGCCCUCCUAUCCCAGAUAGAU-3'(SEQIDNO:1910)
3'-UUCGGACGGGAGGAUAGGGUCUAUCUA-5'(SEQIDNO:758)
CKAP5-2544靶:5'-AAGCCTGCCCTCCTATCCCAGATAGAT-3'(SEQIDNO:1334)
5'-CUGCCCUCCUAUCCCAGAUAGAUGC-3'(SEQIDNO:1911)
3'-CGGACGGGAGGAUAGGGUCUAUCUACG-5'(SEQIDNO:759)
CKAP5-2546靶:5'-GCCTGCCCTCCTATCCCAGATAGATGC-3'(SEQIDNO:1335)
5'-GCCCUCCUAUCCCAGAUAGAUGCAG-3'(SEQIDNO:1912)
3'-GACGGGAGGAUAGGGUCUAUCUACGUC-5'(SEQIDNO:760)
CKAP5-2548靶:5'-CTGCCCTCCTATCCCAGATAGATGCAG-3'(SEQIDNO:1336)
5'-CCUCCUAUCCCAGAUAGAUGCAGAA-3'(SEQIDNO:1913)
3'-CGGGAGGAUAGGGUCUAUCUACGUCUU-5'(SEQIDNO:761)
CKAP5-2550靶:5'-GCCCTCCTATCCCAGATAGATGCAGAA-3'(SEQIDNO:1337)
5'-UCCUAUCCCAGAUAGAUGCAGAAUU-3'(SEQIDNO:1914)
3'-GGAGGAUAGGGUCUAUCUACGUCUUAA-5'(SEQIDNO:762)
CKAP5-2552靶:5'-CCTCCTATCCCAGATAGATGCAGAATT-3'(SEQIDNO:1338)
5'-CUAUCCCAGAUAGAUGCAGAAUUUG-3'(SEQIDNO:1915)
3'-AGGAUAGGGUCUAUCUACGUCUUAAAC-5'(SEQIDNO:763)
CKAP5-2554靶:5'-TCCTATCCCAGATAGATGCAGAATTTG-3'(SEQIDNO:1339)
5'-AUCCCAGAUAGAUGCAGAAUUUGAG-3'(SEQIDNO:1916)
3'-GAUAGGGUCUAUCUACGUCUUAAACUC-5'(SEQIDNO:764)
CKAP5-2556靶:5'-CTATCCCAGATAGATGCAGAATTTGAG-3'(SEQIDNO:1340)
5'-CCCAGAUAGAUGCAGAAUUUGAGAA-3'(SEQIDNO:1917)
3'-UAGGGUCUAUCUACGUCUUAAACUCUU-5'(SEQIDNO:765)
CKAP5-2558靶:5'-ATCCCAGATAGATGCAGAATTTGAGAA-3'(SEQIDNO:1341)
5'-AAGAUGCAGGGACAAAGUCCACCUG-3'(SEQIDNO:1918)
3'-UCUUCUACGUCCCUGUUUCAGGUGGAC-5'(SEQIDNO:766)
CKAP5-2581靶:5'-AGAAGATGCAGGGACAAAGTCCACCTG-3'(SEQIDNO:1342)
5'-UACAGAUGAAGGAGAAGAUGGAGAU-3'(SEQIDNO:1919)
3'-CCAUGUCUACUUCCUCUUCUACCUCUA-5'(SEQIDNO:767)
CKAP5-2643靶:5'-GGTACAGATGAAGGAGAAGATGGAGAT-3'(SEQIDNO:1343)
5'-CAGAUGAAGGAGAAGAUGGAGAUGA-3'(SEQIDNO:1920)
3'-AUGUCUACUUCCUCUUCUACCUCUACU-5'(SEQIDNO:768)
CKAP5-2645靶:5'-TACAGATGAAGGAGAAGATGGAGATGA-3'(SEQIDNO:1344)
5'-GAUGAAGGAGAAGAUGGAGAUGAAC-3'(SEQIDNO:1921)
3'-GUCUACUUCCUCUUCUACCUCUACUUG-5'(SEQIDNO:769)
CKAP5-2647靶:5'-CAGATGAAGGAGAAGATGGAGATGAAC-3'(SEQIDNO:1345)
5'-GUUGAUCUUUUGCCGAGGACGGAGA-3'(SEQIDNO:1922)
3'-AGCAACUAGAAAACGGCUCCUGCCUCU-5'(SEQIDNO:770)
CKAP5-2695靶:5'-TCGTTGATCTTTTGCCGAGGACGGAGA-3'(SEQIDNO:1346)
5'-GGAAAGAAGGCCUAGAUGAAGUGGC-3'(SEQIDNO:1923)
3'-AUCCUUUCUUCCGGAUCUACUUCACCG-5'(SEQIDNO:771)
CKAP5-2780靶:5'-TAGGAAAGAAGGCCTAGATGAAGTGGC-3'(SEQIDNO:1347)
5'-AAAGAAGGCCUAGAUGAAGUGGCAG-3'(SEQIDNO:1924)
3'-CCUUUCUUCCGGAUCUACUUCACCGUC-5'(SEQIDNO:772)
CKAP5-2782靶:5'-GGAAAGAAGGCCTAGATGAAGTGGCAG-3'(SEQIDNO:1348)
5'-AGAAGGCCUAGAUGAAGUGGCAGGU-3'(SEQIDNO:1925)
3'-UUUCUUCCGGAUCUACUUCACCGUCCA-5'(SEQIDNO:773)
CKAP5-2784靶:5'-AAAGAAGGCCTAGATGAAGTGGCAGGT-3'(SEQIDNO:1349)
5'-AAGGCCUAGAUGAAGUGGCAGGUAU-3'(SEQIDNO:1926)
3'-UCUUCCGGAUCUACUUCACCGUCCAUA-5'(SEQIDNO:774)
CKAP5-2786靶:5'-AGAAGGCCTAGATGAAGTGGCAGGTAT-3'(SEQIDNO:1350)
5'-GGCCUAGAUGAAGUGGCAGGUAUUA-3'(SEQIDNO:1927)
3'-UUCCGGAUCUACUUCACCGUCCAUAAU-5'(SEQIDNO:775)
CKAP5-2788靶:5'-AAGGCCTAGATGAAGTGGCAGGTATTA-3'(SEQIDNO:1351)
5'-CCUAGAUGAAGUGGCAGGUAUUAUU-3'(SEQIDNO:1928)
3'-CCGGAUCUACUUCACCGUCCAUAAUAA-5'(SEQIDNO:776)
CKAP5-2790靶:5'-GGCCTAGATGAAGTGGCAGGTATTATT-3'(SEQIDNO:1352)
5'-UAGAUGAAGUGGCAGGUAUUAUUAA-3'(SEQIDNO:1929)
3'-GGAUCUACUUCACCGUCCAUAAUAAUU-5'(SEQIDNO:777)
CKAP5-2792靶:5'-CCTAGATGAAGTGGCAGGTATTATTAA-3'(SEQIDNO:1353)
5'-GAUGAAGUGGCAGGUAUUAUUAAUG-3'(SEQIDNO:1930)
3'-AUCUACUUCACCGUCCAUAAUAAUUAC-5'(SEQIDNO:778)
CKAP5-2794靶:5'-TAGATGAAGTGGCAGGTATTATTAATG-3'(SEQIDNO:1354)
5'-AAUAUAGGUGAACUUCCAACUGCCU-3'(SEQIDNO:1931)
3'-GCUUAUAUCCACUUGAAGGUUGACGGA-5'(SEQIDNO:779)
CKAP5-2839靶:5'-CGAATATAGGTGAACTTCCAACTGCCT-3'(SEQIDNO:1355)
5'-UAUAGGUGAACUUCCAACUGCCUUG-3'(SEQIDNO:1932)
3'-UUAUAUCCACUUGAAGGUUGACGGAAC-5'(SEQIDNO:780)
CKAP5-2841靶:5'-AATATAGGTGAACTTCCAACTGCCTTG-3'(SEQIDNO:1356)
5'-UAGGUGAACUUCCAACUGCCUUGAA-3'(SEQIDNO:1933)
3'-AUAUCCACUUGAAGGUUGACGGAACUU-5'(SEQIDNO:781)
CKAP5-2843靶:5'-TATAGGTGAACTTCCAACTGCCTTGAA-3'(SEQIDNO:1357)
5'-GGUGAACUUCCAACUGCCUUGAAGG-3'(SEQIDNO:1934)
3'-AUCCACUUGAAGGUUGACGGAACUUCC-5'(SEQIDNO:782)
CKAP5-2845靶:5'-TAGGTGAACTTCCAACTGCCTTGAAGG-3'(SEQIDNO:1358)
5'-UGAACUUCCAACUGCCUUGAAGGGU-3'(SEQIDNO:1935)
3'-CCACUUGAAGGUUGACGGAACUUCCCA-5'(SEQIDNO:783)
CKAP5-2847靶:5'-GGTGAACTTCCAACTGCCTTGAAGGGT-3'(SEQIDNO:1359)
5'-AACUUCCAACUGCCUUGAAGGGUCG-3'(SEQIDNO:1936)
3'-ACUUGAAGGUUGACGGAACUUCCCAGC-5'(SEQIDNO:784)
CKAP5-2849靶:5'-TGAACTTCCAACTGCCTTGAAGGGTCG-3'(SEQIDNO:1360)
5'-CUUCCAACUGCCUUGAAGGGUCGAC-3'(SEQIDNO:1937)
3'-UUGAAGGUUGACGGAACUUCCCAGCUG-5'(SEQIDNO:785)
CKAP5-2851靶:5'-AACTTCCAACTGCCTTGAAGGGTCGAC-3'(SEQIDNO:1361)
5'-UCCAACUGCCUUGAAGGGUCGACUC-3'(SEQIDNO:1938)
3'-GAAGGUUGACGGAACUUCCCAGCUGAG-5'(SEQIDNO:786)
CKAP5-2853靶:5'-CTTCCAACTGCCTTGAAGGGTCGACTC-3'(SEQIDNO:1362)
5'-CAACUGCCUUGAAGGGUCGACUCAA-3'(SEQIDNO:1939)
3'-AGGUUGACGGAACUUCCCAGCUGAGUU-5'(SEQIDNO:787)
CKAP5-2855靶:5'-TCCAACTGCCTTGAAGGGTCGACTCAA-3'(SEQIDNO:1363)
5'-ACUGCCUUGAAGGGUCGACUCAAUG-3'(SEQIDNO:1940)
3'-GUUGACGGAACUUCCCAGCUGAGUUAC-5'(SEQIDNO:788)
CKAP5-2857靶:5'-CAACTGCCTTGAAGGGTCGACTCAATG-3'(SEQIDNO:1364)
5'-CAACUGGCAGUAGCCAUGGGCCCAA-3'(SEQIDNO:1941)
3'-UUGUUGACCGUCAUCGGUACCCGGGUU-5'(SEQIDNO:789)
CKAP5-2926靶:5'-AACAACTGGCAGTAGCCATGGGCCCAA-3'(SEQIDNO:1365)
5'-AGCAAGAACAAUGUUCGAGCUGCUG-3'(SEQIDNO:1942)
3'-UGUCGUUCUUGUUACAAGCUCGACGAC-5'(SEQIDNO:790)
CKAP5-3007靶:5'-ACAGCAAGAACAATGTTCGAGCTGCTG-3'(SEQIDNO:1366)
5'-CAAGAACAAUGUUCGAGCUGCUGCC-3'(SEQIDNO:1943)
3'-UCGUUCUUGUUACAAGCUCGACGACGG-5'(SEQIDNO:791)
CKAP5-3009靶:5'-AGCAAGAACAATGTTCGAGCTGCTGCC-3'(SEQIDNO:1367)
5'-AGAACAAUGUUCGAGCUGCUGCCCU-3'(SEQIDNO:1944)
3'-GUUCUUGUUACAAGCUCGACGACGGGA-5'(SEQIDNO:792)
CKAP5-3011靶:5'-CAAGAACAATGTTCGAGCTGCTGCCCT-3'(SEQIDNO:1368)
5'-AACAAUGUUCGAGCUGCUGCCCUAG-3'(SEQIDNO:1945)
3'-UCUUGUUACAAGCUCGACGACGGGAUC-5'(SEQIDNO:793)
CKAP5-3013靶:5'-AGAACAATGTTCGAGCTGCTGCCCTAG-3'(SEQIDNO:1369)
5'-CAAUGUUCGAGCUGCUGCCCUAGCG-3'(SEQIDNO:1946)
3'-UUGUUACAAGCUCGACGACGGGAUCGC-5'(SEQIDNO:794)
CKAP5-3015靶:5'-AACAATGTTCGAGCTGCTGCCCTAGCG-3'(SEQIDNO:1370)
5'-AUGUUCGAGCUGCUGCCCUAGCGAC-3'(SEQIDNO:1947)
3'-GUUACAAGCUCGACGACGGGAUCGCUG-5'(SEQIDNO:795)
CKAP5-3017靶:5'-CAATGTTCGAGCTGCTGCCCTAGCGAC-3'(SEQIDNO:1371)
5'-GUUCGAGCUGCUGCCCUAGCGACUG-3'(SEQIDNO:1948)
3'-UACAAGCUCGACGACGGGAUCGCUGAC-5'(SEQIDNO:796)
CKAP5-3019靶:5'-ATGTTCGAGCTGCTGCCCTAGCGACTG-3'(SEQIDNO:1372)
5'-ACUGUGAAUGCUUGGGCAGAACAGA-3'(SEQIDNO:1949)
3'-GCUGACACUUACGAACCCGUCUUGUCU-5'(SEQIDNO:797)
CKAP5-3040靶:5'-CGACTGTGAATGCTTGGGCAGAACAGA-3'(SEQIDNO:1373)
5'-UGUGAAUGCUUGGGCAGAACAGACU-3'(SEQIDNO:1950)
3'-UGACACUUACGAACCCGUCUUGUCUGA-5'(SEQIDNO:798)
CKAP5-3042靶:5'-ACTGTGAATGCTTGGGCAGAACAGACT-3'(SEQIDNO:1374)
5'-UGAAUGCUUGGGCAGAACAGACUGG-3'(SEQIDNO:1951)
3'-ACACUUACGAACCCGUCUUGUCUGACC-5'(SEQIDNO:799)
CKAP5-3044靶:5'-TGTGAATGCTTGGGCAGAACAGACTGG-3'(SEQIDNO:1375)
5'-GAGAAGAUCUUUCUGAAGAGCUCAA-3'(SEQIDNO:1952)
3'-UCCUCUUCUAGAAAGACUUCUCGAGUU-5'(SEQIDNO:800)
CKAP5-3089靶:5'-AGGAGAAGATCTTTCTGAAGAGCTCAA-3'(SEQIDNO:1376)
5'-CUAGAAGAUCGAAAUGGAGAUGUGC-3'(SEQIDNO:1953)
3'-CGGAUCUUCUAGCUUUACCUCUACACG-5'(SEQIDNO:801)
CKAP5-3229靶:5'-GCCTAGAAGATCGAAATGGAGATGTGC-3'(SEQIDNO:1377)
5'-AGAAGAUCGAAAUGGAGAUGUGCGA-3'(SEQIDNO:1954)
3'-GAUCUUCUAGCUUUACCUCUACACGCU-5'(SEQIDNO:802)
CKAP5-3231靶:5'-CTAGAAGATCGAAATGGAGATGTGCGA-3'(SEQIDNO:1378)
5'-AAGAUCGAAAUGGAGAUGUGCGAAA-3'(SEQIDNO:1955)
3'-UCUUCUAGCUUUACCUCUACACGCUUU-5'(SEQIDNO:803)
CKAP5-3233靶:5'-AGAAGATCGAAATGGAGATGTGCGAAA-3'(SEQIDNO:1379)
5'-UGAUGCAUUUAGGAUAUGAAAAAAU-3'(SEQIDNO:1956)
3'-GUACUACGUAAAUCCUAUACUUUUUUA-5'(SEQIDNO:804)
CKAP5-3287靶:5'-CATGATGCATTTAGGATATGAAAAAAT-3'(SEQIDNO:1380)
5'-AUGCAUUUAGGAUAUGAAAAAAUGG-3'(SEQIDNO:1957)
3'-ACUACGUAAAUCCUAUACUUUUUUACC-5'(SEQIDNO:805)
CKAP5-3289靶:5'-TGATGCATTTAGGATATGAAAAAATGG-3'(SEQIDNO:1381)
5'-GCAUUUAGGAUAUGAAAAAAUGGCC-3'(SEQIDNO:1958)
3'-UACGUAAAUCCUAUACUUUUUUACCGG-5'(SEQIDNO:806)
CKAP5-3291靶:5'-ATGCATTTAGGATATGAAAAAATGGCC-3'(SEQIDNO:1382)
5'-AUUUAGGAUAUGAAAAAAUGGCCAA-3'(SEQIDNO:1959)
3'-CGUAAAUCCUAUACUUUUUUACCGGUU-5'(SEQIDNO:807)
CKAP5-3293靶:5'-GCATTTAGGATATGAAAAAATGGCCAA-3'(SEQIDNO:1383)
5'-UUAGGAUAUGAAAAAAUGGCCAAGG-3'(SEQIDNO:1960)
3'-UAAAUCCUAUACUUUUUUACCGGUUCC-5'(SEQIDNO:808)
CKAP5-3295靶:5'-ATTTAGGATATGAAAAAATGGCCAAGG-3'(SEQIDNO:1384)
5'-AAGGCUACUGGGAAACUAAAGCCAA-3'(SEQIDNO:1961)
3'-GGUUCCGAUGACCCUUUGAUUUCGGUU-5'(SEQIDNO:809)
CKAP5-3316靶:5'-CCAAGGCTACTGGGAAACTAAAGCCAA-3'(SEQIDNO:1385)
5'-GGCUACUGGGAAACUAAAGCCAACU-3'(SEQIDNO:1962)
3'-UUCCGAUGACCCUUUGAUUUCGGUUGA-5'(SEQIDNO:810)
CKAP5-3318靶:5'-AAGGCTACTGGGAAACTAAAGCCAACT-3'(SEQIDNO:1386)
5'-CUACUGGGAAACUAAAGCCAACUUC-3'(SEQIDNO:1963)
3'-CCGAUGACCCUUUGAUUUCGGUUGAAG-5'(SEQIDNO:811)
CKAP5-3320靶:5'-GGCTACTGGGAAACTAAAGCCAACTTC-3'(SEQIDNO:1387)
5'-ACUGGGAAACUAAAGCCAACUUCUA-3'(SEQIDNO:1964)
3'-GAUGACCCUUUGAUUUCGGUUGAAGAU-5'(SEQIDNO:812)
CKAP5-3322靶:5'-CTACTGGGAAACTAAAGCCAACTTCTA-3'(SEQIDNO:1388)
5'-UGGGAAACUAAAGCCAACUUCUAAA-3'(SEQIDNO:1965)
3'-UGACCCUUUGAUUUCGGUUGAAGAUUU-5'(SEQIDNO:813)
CKAP5-3324靶:5'-ACTGGGAAACTAAAGCCAACTTCTAAA-3'(SEQIDNO:1389)
5'-GGAAACUAAAGCCAACUUCUAAAGA-3'(SEQIDNO:1966)
3'-ACCCUUUGAUUUCGGUUGAAGAUUUCU-5'(SEQIDNO:814)
CKAP5-3326靶:5'-TGGGAAACTAAAGCCAACTTCTAAAGA-3'(SEQIDNO:1390)
5'-AAACUAAAGCCAACUUCUAAAGAUC-3'(SEQIDNO:1967)
3'-CCUUUGAUUUCGGUUGAAGAUUUCUAG-5'(SEQIDNO:815)
CKAP5-3328靶:5'-GGAAACTAAAGCCAACTTCTAAAGATC-3'(SEQIDNO:1391)
5'-ACUAAAGCCAACUUCUAAAGAUCAG-3'(SEQIDNO:1968)
3'-UUUGAUUUCGGUUGAAGAUUUCUAGUC-5'(SEQIDNO:816)
CKAP5-3330靶:5'-AAACTAAAGCCAACTTCTAAAGATCAG-3'(SEQIDNO:1392)
5'-UAAAGCCAACUUCUAAAGAUCAGGU-3'(SEQIDNO:1969)
3'-UGAUUUCGGUUGAAGAUUUCUAGUCCA-5'(SEQIDNO:817)
CKAP5-3332靶:5'-ACTAAAGCCAACTTCTAAAGATCAGGT-3'(SEQIDNO:1393)
5'-AAGCCAACUUCUAAAGAUCAGGUAU-3'(SEQIDNO:1970)
3'-AUUUCGGUUGAAGAUUUCUAGUCCAUA-5'(SEQIDNO:818)
CKAP5-3334靶:5'-TAAAGCCAACTTCTAAAGATCAGGTAT-3'(SEQIDNO:1394)
5'-CCUAUUUUUAUUGUUGUUCCAAAUG-3'(SEQIDNO:1971)
3'-CCGGAUAAAAAUAACAACAAGGUUUAC-5'(SEQIDNO:819)
CKAP5-3625靶:5'-GGCCTATTTTTATTGTTGTTCCAAATG-3'(SEQIDNO:1395)
5'-UAUUUUUAUUGUUGUUCCAAAUGGA-3'(SEQIDNO:1972)
3'-GGAUAAAAAUAACAACAAGGUUUACCU-5'(SEQIDNO:820)
CKAP5-3627靶:5'-CCTATTTTTATTGTTGTTCCAAATGGA-3'(SEQIDNO:1396)
5'-UUUUUAUUGUUGUUCCAAAUGGAAA-3'(SEQIDNO:1973)
3'-AUAAAAAUAACAACAAGGUUUACCUUU-5'(SEQIDNO:821)
CKAP5-3629靶:5'-TATTTTTATTGTTGTTCCAAATGGAAA-3'(SEQIDNO:1397)
5'-UUUAUUGUUGUUCCAAAUGGAAAAG-3'(SEQIDNO:1974)
3'-AAAAAUAACAACAAGGUUUACCUUUUC-5'(SEQIDNO:822)
CKAP5-3631靶:5'-TTTTTATTGTTGTTCCAAATGGAAAAG-3'(SEQIDNO:1398)
5'-UAUUGUUGUUCCAAAUGGAAAAGAG-3'(SEQIDNO:1975)
3'-AAAUAACAACAAGGUUUACCUUUUCUC-5'(SEQIDNO:823)
CKAP5-3633靶:5'-TTTATTGTTGTTCCAAATGGAAAAGAG-3'(SEQIDNO:1399)
5'-UUGUUGUUCCAAAUGGAAAAGAGCA-3'(SEQIDNO:1976)
3'-AUAACAACAAGGUUUACCUUUUCUCGU-5'(SEQIDNO:824)
CKAP5-3635靶:5'-TATTGTTGTTCCAAATGGAAAAGAGCA-3'(SEQIDNO:1400)
5'-AGGUGCUAAAGUGGAAUUUUACUAC-3'(SEQIDNO:1977)
3'-CUUCCACGAUUUCACCUUAAAAUGAUG-5'(SEQIDNO:825)
CKAP5-3686靶:5'-GAAGGTGCTAAAGTGGAATTTTACTAC-3'(SEQIDNO:1401)
5'-GUGCUAAAGUGGAAUUUUACUACCC-3'(SEQIDNO:1978)
3'-UCCACGAUUUCACCUUAAAAUGAUGGG-5'(SEQIDNO:826)
CKAP5-3688靶:5'-AGGTGCTAAAGTGGAATTTTACTACCC-3'(SEQIDNO:1402)
5'-AUCAUCUUACUGAGAAUGAAGCAUC-3'(SEQIDNO:1979)
3'-UAUAGUAGAAUGACUCUUACUUCGUAG-5'(SEQIDNO:827)
CKAP5-3989靶:5'-ATATCATCTTACTGAGAATGAAGCATC-3'(SEQIDNO:1403)
5'-CAUCUUACUGAGAAUGAAGCAUCUU-3'(SEQIDNO:1980)
3'-UAGUAGAAUGACUCUUACUUCGUAGAA-5'(SEQIDNO:828)
CKAP5-3991靶:5'-ATCATCTTACTGAGAATGAAGCATCTT-3'(SEQIDNO:1404)
5'-UCUUACUGAGAAUGAAGCAUCUUCC-3'(SEQIDNO:1981)
3'-GUAGAAUGACUCUUACUUCGUAGAAGG-5'(SEQIDNO:829)
CKAP5-3993靶:5'-CATCTTACTGAGAATGAAGCATCTTCC-3'(SEQIDNO:1405)
5'-UUACUGAGAAUGAAGCAUCUUCCUU-3'(SEQIDNO:1982)
3'-AGAAUGACUCUUACUUCGUAGAAGGAA-5'(SEQIDNO:830)
CKAP5-3995靶:5'-TCTTACTGAGAATGAAGCATCTTCCTT-3'(SEQIDNO:1406)
5'-CAAGGUUGGAGAACCAAAGGAUGUC-3'(SEQIDNO:1983)
3'-CAGUUCCAACCUCUUGGUUUCCUACAG-5'(SEQIDNO:831)
CKAP5-4038靶:5'-GTCAAGGTTGGAGAACCAAAGGATGTC-3'(SEQIDNO:1407)
5'-AGGUUGGAGAACCAAAGGAUGUCAU-3'(SEQIDNO:1984)
3'-GUUCCAACCUCUUGGUUUCCUACAGUA-5'(SEQIDNO:832)
CKAP5-4040靶:5'-CAAGGTTGGAGAACCAAAGGATGTCAT-3'(SEQIDNO:1408)
5'-GUUGGAGAACCAAAGGAUGUCAUUC-3'(SEQIDNO:1985)
3'-UCCAACCUCUUGGUUUCCUACAGUAAG-5'(SEQIDNO:833)
CKAP5-4042靶:5'-AGGTTGGAGAACCAAAGGATGTCATTC-3'(SEQIDNO:1409)
5'-UGGAGAACCAAAGGAUGUCAUUCGU-3'(SEQIDNO:1986)
3'-CAACCUCUUGGUUUCCUACAGUAAGCA-5'(SEQIDNO:834)
CKAP5-4044靶:5'-GTTGGAGAACCAAAGGATGTCATTCGT-3'(SEQIDNO:1410)
5'-GAGAACCAAAGGAUGUCAUUCGUAA-3'(SEQIDNO:1987)
3'-ACCUCUUGGUUUCCUACAGUAAGCAUU-5'(SEQIDNO:835)
CKAP5-4046靶:5'-TGGAGAACCAAAGGATGTCATTCGTAA-3'(SEQIDNO:1411)
5'-GAACCAAAGGAUGUCAUUCGUAAAG-3'(SEQIDNO:1988)
3'-CUCUUGGUUUCCUACAGUAAGCAUUUC-5'(SEQIDNO:836)
CKAP5-4048靶:5'-GAGAACCAAAGGATGTCATTCGTAAAG-3'(SEQIDNO:1412)
5'-ACCAAAGGAUGUCAUUCGUAAAGAU-3'(SEQIDNO:1989)
3'-CUUGGUUUCCUACAGUAAGCAUUUCUA-5'(SEQIDNO:837)
CKAP5-4050靶:5'-GAACCAAAGGATGTCATTCGTAAAGAT-3'(SEQIDNO:1413)
5'-CAAAGGAUGUCAUUCGUAAAGAUGU-3'(SEQIDNO:1990)
3'-UGGUUUCCUACAGUAAGCAUUUCUACA-5'(SEQIDNO:838)
CKAP5-4052靶:5'-ACCAAAGGATGTCATTCGTAAAGATGT-3'(SEQIDNO:1414)
5'-AAGGAUGUCAUUCGUAAAGAUGUUC-3'(SEQIDNO:1991)
3'-GUUUCCUACAGUAAGCAUUUCUACAAG-5'(SEQIDNO:839)
CKAP5-4054靶:5'-CAAAGGATGTCATTCGTAAAGATGTTC-3'(SEQIDNO:1415)
5'-GGAUGUCAUUCGUAAAGAUGUUCGU-3'(SEQIDNO:1992)
3'-UUCCUACAGUAAGCAUUUCUACAAGCA-5'(SEQIDNO:840)
CKAP5-4056靶:5'-AAGGATGTCATTCGTAAAGATGTTCGT-3'(SEQIDNO:1416)
5'-AUGUCAUUCGUAAAGAUGUUCGUGC-3'(SEQIDNO:1993)
3'-CCUACAGUAAGCAUUUCUACAAGCACG-5'(SEQIDNO:841)
CKAP5-4058靶:5'-GGATGTCATTCGTAAAGATGTTCGTGC-3'(SEQIDNO:1417)
5'-UCCUGAACCGGAUGUGCCUUGUCUA-3'(SEQIDNO:1994)
3'-GUAGGACUUGGCCUACACGGAACAGAU-5'(SEQIDNO:842)
CKAP5-4085靶:5'-CATCCTGAACCGGATGTGCCTTGTCTA-3'(SEQIDNO:1418)
5'-CUGAACCGGAUGUGCCUUGUCUACC-3'(SEQIDNO:1995)
3'-AGGACUUGGCCUACACGGAACAGAUGG-5'(SEQIDNO:843)
CKAP5-4087靶:5'-TCCTGAACCGGATGTGCCTTGTCTACC-3'(SEQIDNO:1419)
5'-GAACCGGAUGUGCCUUGUCUACCCA-3'(SEQIDNO:1996)
3'-GACUUGGCCUACACGGAACAGAUGGGU-5'(SEQIDNO:844)
CKAP5-4089靶:5'-CTGAACCGGATGTGCCTTGTCTACCCA-3'(SEQIDNO:1420)
5'-ACCGGAUGUGCCUUGUCUACCCAGC-3'(SEQIDNO:1997)
3'-CUUGGCCUACACGGAACAGAUGGGUCG-5'(SEQIDNO:845)
CKAP5-4091靶:5'-GAACCGGATGTGCCTTGTCTACCCAGC-3'(SEQIDNO:1421)
5'-CGGAUGUGCCUUGUCUACCCAGCUA-3'(SEQIDNO:1998)
3'-UGGCCUACACGGAACAGAUGGGUCGAU-5'(SEQIDNO:846)
CKAP5-4093靶:5'-ACCGGATGTGCCTTGTCTACCCAGCTA-3'(SEQIDNO:1422)
5'-GAUGUGCCUUGUCUACCCAGCUAGC-3'(SEQIDNO:1999)
3'-GCCUACACGGAACAGAUGGGUCGAUCG-5'(SEQIDNO:847)
CKAP5-4095靶:5'-CGGATGTGCCTTGTCTACCCAGCTAGC-3'(SEQIDNO:1423)
5'-UGUGCCUUGUCUACCCAGCUAGCAA-3'(SEQIDNO:2000)
3'-CUACACGGAACAGAUGGGUCGAUCGUU-5'(SEQIDNO:848)
CKAP5-4097靶:5'-GATGTGCCTTGTCTACCCAGCTAGCAA-3'(SEQIDNO:1424)
5'-CCAAAAACUCUAAGCAGAGAGCAGA-3'(SEQIDNO:2001)
3'-UAGGUUUUUGAGAUUCGUCUCUCGUCU-5'(SEQIDNO:849)
CKAP5-4154靶:5'-ATCCAAAAACTCTAAGCAGAGAGCAGA-3'(SEQIDNO:1425)
5'-AAAAACUCUAAGCAGAGAGCAGAGU-3'(SEQIDNO:2002)
3'-GGUUUUUGAGAUUCGUCUCUCGUCUCA-5'(SEQIDNO:850)
CKAP5-4156靶:5'-CCAAAAACTCTAAGCAGAGAGCAGAGT-3'(SEQIDNO:1426)
5'-AAACUCUAAGCAGAGAGCAGAGUGC-3'(SEQIDNO:2003)
3'-UUUUUGAGAUUCGUCUCUCGUCUCACG-5'(SEQIDNO:851)
CKAP5-4158靶:5'-AAAAACTCTAAGCAGAGAGCAGAGTGC-3'(SEQIDNO:1427)
5'-ACUCUAAGCAGAGAGCAGAGUGCCU-3'(SEQIDNO:2004)
3'-UUUGAGAUUCGUCUCUCGUCUCACGGA-5'(SEQIDNO:852)
CKAP5-4160靶:5'-AAACTCTAAGCAGAGAGCAGAGTGCCT-3'(SEQIDNO:1428)
5'-UCUAAGCAGAGAGCAGAGUGCCUGG-3'(SEQIDNO:2005)
3'-UGAGAUUCGUCUCUCGUCUCACGGACC-5'(SEQIDNO:853)
CKAP5-4162靶:5'-ACTCTAAGCAGAGAGCAGAGTGCCTGG-3'(SEQIDNO:1429)
5'-UAAGCAGAGAGCAGAGUGCCUGGAA-3'(SEQIDNO:2006)
3'-AGAUUCGUCUCUCGUCUCACGGACCUU-5'(SEQIDNO:854)
CKAP5-4164靶:5'-TCTAAGCAGAGAGCAGAGTGCCTGGAA-3'(SEQIDNO:1430)
5'-AGCAGAGAGCAGAGUGCCUGGAAGA-3'(SEQIDNO:2007)
3'-AUUCGUCUCUCGUCUCACGGACCUUCU-5'(SEQIDNO:855)
CKAP5-4166靶:5'-TAAGCAGAGAGCAGAGTGCCTGGAAGA-3'(SEQIDNO:1431)
5'-CAGAGAGCAGAGUGCCUGGAAGAGC-3'(SEQIDNO:2008)
3'-UCGUCUCUCGUCUCACGGACCUUCUCG-5'(SEQIDNO:856)
CKAP5-4168靶:5'-AGCAGAGAGCAGAGTGCCTGGAAGAGC-3'(SEQIDNO:1432)
5'-GAGAGCAGAGUGCCUGGAAGAGCUG-3'(SEQIDNO:2009)
3'-GUCUCUCGUCUCACGGACCUUCUCGAC-5'(SEQIDNO:857)
CKAP5-4170靶:5'-CAGAGAGCAGAGTGCCTGGAAGAGCTG-3'(SEQIDNO:1433)
5'-GAGCAGAGUGCCUGGAAGAGCUGGG-3'(SEQIDNO:2010)
3'-CUCUCGUCUCACGGACCUUCUCGACCC-5'(SEQIDNO:858)
CKAP5-4172靶:5'-GAGAGCAGAGTGCCTGGAAGAGCTGGG-3'(SEQIDNO:1434)
5'-GCAGAGUGCCUGGAAGAGCUGGGAU-3'(SEQIDNO:2011)
3'-CUCGUCUCACGGACCUUCUCGACCCUA-5'(SEQIDNO:859)
CKAP5-4174靶:5'-GAGCAGAGTGCCTGGAAGAGCTGGGAT-3'(SEQIDNO:1435)
5'-CAGGAAAAGCCUUAAAGGAAAUAGC-3'(SEQIDNO:2012)
3'-GGGUCCUUUUCGGAAUUUCCUUUAUCG-5'(SEQIDNO:860)
CKAP5-4241靶:5'-CCCAGGAAAAGCCTTAAAGGAAATAGC-3'(SEQIDNO:1436)
5'-AUCAGGUGUUCAAACUGAUUGGAAA-3'(SEQIDNO:2013)
3'-CCUAGUCCACAAGUUUGACUAACCUUU-5'(SEQIDNO:861)
CKAP5-4346靶:5'-GGATCAGGTGTTCAAACTGATTGGAAA-3'(SEQIDNO:1437)
5'-CAGGUGUUCAAACUGAUUGGAAAUC-3'(SEQIDNO:2014)
3'-UAGUCCACAAGUUUGACUAACCUUUAG-5'(SEQIDNO:862)
CKAP5-4348靶:5'-ATCAGGTGTTCAAACTGATTGGAAATC-3'(SEQIDNO:1438)
5'-GGUGUUCAAACUGAUUGGAAAUCUU-3'(SEQIDNO:2015)
3'-GUCCACAAGUUUGACUAACCUUUAGAA-5'(SEQIDNO:863)
CKAP5-4350靶:5'-CAGGTGTTCAAACTGATTGGAAATCTT-3'(SEQIDNO:1439)
5'-UGUUCAAACUGAUUGGAAAUCUUUC-3'(SEQIDNO:2016)
3'-CCACAAGUUUGACUAACCUUUAGAAAG-5'(SEQIDNO:864)
CKAP5-4352靶:5'-GGTGTTCAAACTGATTGGAAATCTTTC-3'(SEQIDNO:1440)
5'-UUCAAACUGAUUGGAAAUCUUUCUG-3'(SEQIDNO:2017)
3'-ACAAGUUUGACUAACCUUUAGAAAGAC-5'(SEQIDNO:865)
CKAP5-4354靶:5'-TGTTCAAACTGATTGGAAATCTTTCTG-3'(SEQIDNO:1441)
5'-CAAACUGAUUGGAAAUCUUUCUGAA-3'(SEQIDNO:2018)
3'-AAGUUUGACUAACCUUUAGAAAGACUU-5'(SEQIDNO:866)
CKAP5-4356靶:5'-TTCAAACTGATTGGAAATCTTTCTGAA-3'(SEQIDNO:1442)
5'-AACUGAUUGGAAAUCUUUCUGAAAA-3'(SEQIDNO:2019)
3'-GUUUGACUAACCUUUAGAAAGACUUUU-5'(SEQIDNO:867)
CKAP5-4358靶:5'-CAAACTGATTGGAAATCTTTCTGAAAA-3'(SEQIDNO:1443)
5'-CUGAUUGGAAAUCUUUCUGAAAAGG-3'(SEQIDNO:2020)
3'-UUGACUAACCUUUAGAAAGACUUUUCC-5'(SEQIDNO:868)
CKAP5-4360靶:5'-AACTGATTGGAAATCTTTCTGAAAAGG-3'(SEQIDNO:1444)
5'-AAGCGGUCAGCAAAGAGACCCUCUG-3'(SEQIDNO:2021)
3'-AAUUCGCCAGUCGUUUCUCUGGGAGAC-5'(SEQIDNO:869)
CKAP5-4411靶:5'-TTAAGCGGTCAGCAAAGAGACCCTCTG-3'(SEQIDNO:1445)
5'-GCGGUCAGCAAAGAGACCCUCUGCU-3'(SEQIDNO:2022)
3'-UUCGCCAGUCGUUUCUCUGGGAGACGA-5'(SEQIDNO:870)
CKAP5-4413靶:5'-AAGCGGTCAGCAAAGAGACCCTCTGCT-3'(SEQIDNO:1446)
5'-GGUCAGCAAAGAGACCCUCUGCUGC-3'(SEQIDNO:2023)
3'-CGCCAGUCGUUUCUCUGGGAGACGACG-5'(SEQIDNO:871)
CKAP5-4415靶:5'-GCGGTCAGCAAAGAGACCCTCTGCTGC-3'(SEQIDNO:1447)
5'-UCAGCAAAGAGACCCUCUGCUGCAC-3'(SEQIDNO:2024)
3'-CCAGUCGUUUCUCUGGGAGACGACGUG-5'(SEQIDNO:872)
CKAP5-4417靶:5'-GGTCAGCAAAGAGACCCTCTGCTGCAC-3'(SEQIDNO:1448)
5'-AGCAAAGAGACCCUCUGCUGCACCA-3'(SEQIDNO:2025)
3'-AGUCGUUUCUCUGGGAGACGACGUGGU-5'(SEQIDNO:873)
CKAP5-4419靶:5'-TCAGCAAAGAGACCCTCTGCTGCACCA-3'(SEQIDNO:1449)
5'-CAAAGAGACCCUCUGCUGCACCAAU-3'(SEQIDNO:2026)
3'-UCGUUUCUCUGGGAGACGACGUGGUUA-5'(SEQIDNO:874)
CKAP5-4421靶:5'-AGCAAAGAGACCCTCTGCTGCACCAAT-3'(SEQIDNO:1450)
5'-AAGAGACCCUCUGCUGCACCAAUAA-3'(SEQIDNO:2027)
3'-GUUUCUCUGGGAGACGACGUGGUUAUU-5'(SEQIDNO:875)
CKAP5-4423靶:5'-CAAAGAGACCCTCTGCTGCACCAATAA-3'(SEQIDNO:1451)
5'-UACGCAAGGGACCAGCUGAGGACAU-3'(SEQIDNO:2028)
3'-CAAUGCGUUCCCUGGUCGACUCCUGUA-5'(SEQIDNO:876)
CKAP5-4505靶:5'-GTTACGCAAGGGACCAGCTGAGGACAT-3'(SEQIDNO:1452)
5'-CGCAAGGGACCAGCUGAGGACAUGU-3'(SEQIDNO:2029)
3'-AUGCGUUCCCUGGUCGACUCCUGUACA-5'(SEQIDNO:877)
CKAP5-4507靶:5'-TACGCAAGGGACCAGCTGAGGACATGT-3'(SEQIDNO:1453)
5'-CGCCGAGAAUUCCAGCUGGAUCUAG-3'(SEQIDNO:2030)
3'-AGGCGGCUCUUAAGGUCGACCUAGAUC-5'(SEQIDNO:878)
CKAP5-4591靶:5'-TCCGCCGAGAATTCCAGCTGGATCTAG-3'(SEQIDNO:1454)
5'-CCGAGAAUUCCAGCUGGAUCUAGAU-3'(SEQIDNO:2031)
3'-GCGGCUCUUAAGGUCGACCUAGAUCUA-5'(SEQIDNO:879)
CKAP5-4593靶:5'-CGCCGAGAATTCCAGCTGGATCTAGAT-3'(SEQIDNO:1455)
5'-AGAUCCGGGCUGUUUCUCCACACUU-3'(SEQIDNO:2032)
3'-GUUCUAGGCCCGACAAAGAGGUGUGAA-5'(SEQIDNO:880)
CKAP5-4718靶:5'-CAAGATCCGGGCTGTTTCTCCACACTT-3'(SEQIDNO:1456)
5'-AUCCGGGCUGUUUCUCCACACUUCG-3'(SEQIDNO:2033)
3'-UCUAGGCCCGACAAAGAGGUGUGAAGC-5'(SEQIDNO:881)
CKAP5-4720靶:5'-AGATCCGGGCTGTTTCTCCACACTTCG-3'(SEQIDNO:1457)
5'-GAUGACAUGCACAGUAAUACAGCAU-3'(SEQIDNO:2034)
3'-AGCUACUGUACGUGUCAUUAUGUCGUA-5'(SEQIDNO:882)
CKAP5-4744靶:5'-TCGATGACATGCACAGTAATACAGCAT-3'(SEQIDNO:1458)
5'-UGACAUGCACAGUAAUACAGCAUCC-3'(SEQIDNO:2035)
3'-CUACUGUACGUGUCAUUAUGUCGUAGG-5'(SEQIDNO:883)
CKAP5-4746靶:5'-GATGACATGCACAGTAATACAGCATCC-3'(SEQIDNO:1459)
5'-ACAUGCACAGUAAUACAGCAUCCAC-3'(SEQIDNO:2036)
3'-ACUGUACGUGUCAUUAUGUCGUAGGUG-5'(SEQIDNO:884)
CKAP5-4748靶:5'-TGACATGCACAGTAATACAGCATCCAC-3'(SEQIDNO:1460)
5'-AUGCACAGUAAUACAGCAUCCACAA-3'(SEQIDNO:2037)
3'-UGUACGUGUCAUUAUGUCGUAGGUGUU-5'(SEQIDNO:885)
CKAP5-4750靶:5'-ACATGCACAGTAATACAGCATCCACAA-3'(SEQIDNO:1461)
5'-GCACAGUAAUACAGCAUCCACAAUC-3'(SEQIDNO:2038)
3'-UACGUGUCAUUAUGUCGUAGGUGUUAG-5'(SEQIDNO:886)
CKAP5-4752靶:5'-ATGCACAGTAATACAGCATCCACAATC-3'(SEQIDNO:1462)
5'-ACAGUAAUACAGCAUCCACAAUCAA-3'(SEQIDNO:2039)
3'-CGUGUCAUUAUGUCGUAGGUGUUAGUU-5'(SEQIDNO:887)
CKAP5-4754靶:5'-GCACAGTAATACAGCATCCACAATCAA-3'(SEQIDNO:1463)
5'-AGUAAUACAGCAUCCACAAUCAAUU-3'(SEQIDNO:2040)
3'-UGUCAUUAUGUCGUAGGUGUUAGUUAA-5'(SEQIDNO:888)
CKAP5-4756靶:5'-ACAGTAATACAGCATCCACAATCAATT-3'(SEQIDNO:1464)
5'-UAAUACAGCAUCCACAAUCAAUUUC-3'(SEQIDNO:2041)
3'-UCAUUAUGUCGUAGGUGUUAGUUAAAG-5'(SEQIDNO:889)
CKAP5-4758靶:5'-AGTAATACAGCATCCACAATCAATTTC-3'(SEQIDNO:1465)
5'-AUACAGCAUCCACAAUCAAUUUCAU-3'(SEQIDNO:2042)
3'-AUUAUGUCGUAGGUGUUAGUUAAAGUA-5'(SEQIDNO:890)
CKAP5-4760靶:5'-TAATACAGCATCCACAATCAATTTCAT-3'(SEQIDNO:1466)
5'-ACAGCAUCCACAAUCAAUUUCAUUA-3'(SEQIDNO:2043)
3'-UAUGUCGUAGGUGUUAGUUAAAGUAAU-5'(SEQIDNO:891)
CKAP5-4762靶:5'-ATACAGCATCCACAATCAATTTCATTA-3'(SEQIDNO:1467)
5'-AGCAUCCACAAUCAAUUUCAUUAUC-3'(SEQIDNO:2044)
3'-UGUCGUAGGUGUUAGUUAAAGUAAUAG-5'(SEQIDNO:892)
CKAP5-4764靶:5'-ACAGCATCCACAATCAATTTCATTATC-3'(SEQIDNO:1468)
5'-CAUCCACAAUCAAUUUCAUUAUCUC-3'(SEQIDNO:2045)
3'-UCGUAGGUGUUAGUUAAAGUAAUAGAG-5'(SEQIDNO:893)
CKAP5-4766靶:5'-AGCATCCACAATCAATTTCATTATCTC-3'(SEQIDNO:1469)
5'-UCCACAAUCAAUUUCAUUAUCUCCC-3'(SEQIDNO:2046)
3'-GUAGGUGUUAGUUAAAGUAAUAGAGGG-5'(SEQIDNO:894)
CKAP5-4768靶:5'-CATCCACAATCAATTTCATTATCTCCC-3'(SEQIDNO:1470)
5'-CACAAUCAAUUUCAUUAUCUCCCAA-3'(SEQIDNO:2047)
3'-AGGUGUUAGUUAAAGUAAUAGAGGGUU-5'(SEQIDNO:895)
CKAP5-4770靶:5'-TCCACAATCAATTTCATTATCTCCCAA-3'(SEQIDNO:1471)
5'-CAAUCAAUUUCAUUAUCUCCCAAGU-3'(SEQIDNO:2048)
3'-GUGUUAGUUAAAGUAAUAGAGGGUUCA-5'(SEQIDNO:896)
CKAP5-4772靶:5'-CACAATCAATTTCATTATCTCCCAAGT-3'(SEQIDNO:1472)
5'-AUCAAUUUCAUUAUCUCCCAAGUAG-3'(SEQIDNO:2049)
3'-GUUAGUUAAAGUAAUAGAGGGUUCAUC-5'(SEQIDNO:897)
CKAP5-4774靶:5'-CAATCAATTTCATTATCTCCCAAGTAG-3'(SEQIDNO:1473)
5'-CAAUUUCAUUAUCUCCCAAGUAGCC-3'(SEQIDNO:2050)
3'-UAGUUAAAGUAAUAGAGGGUUCAUCGG-5'(SEQIDNO:898)
CKAP5-4776靶:5'-ATCAATTTCATTATCTCCCAAGTAGCC-3'(SEQIDNO:1474)
5'-AUUUCAUUAUCUCCCAAGUAGCCAG-3'(SEQIDNO:2051)
3'-GUUAAAGUAAUAGAGGGUUCAUCGGUC-5'(SEQIDNO:899)
CKAP5-4778靶:5'-CAATTTCATTATCTCCCAAGTAGCCAG-3'(SEQIDNO:1475)
5'-UUCAUUAUCUCCCAAGUAGCCAGUG-3'(SEQIDNO:2052)
3'-UAAAGUAAUAGAGGGUUCAUCGGUCAC-5'(SEQIDNO:900)
CKAP5-4780靶:5'-ATTTCATTATCTCCCAAGTAGCCAGTG-3'(SEQIDNO:1476)
5'-CAUUAUCUCCCAAGUAGCCAGUGGU-3'(SEQIDNO:2053)
3'-AAGUAAUAGAGGGUUCAUCGGUCACCA-5'(SEQIDNO:901)
CKAP5-4782靶:5'-TTCATTATCTCCCAAGTAGCCAGTGGT-3'(SEQIDNO:1477)
5'-UUAUCUCCCAAGUAGCCAGUGGUGA-3'(SEQIDNO:2054)
3'-GUAAUAGAGGGUUCAUCGGUCACCACU-5'(SEQIDNO:902)
CKAP5-4784靶:5'-CATTATCTCCCAAGTAGCCAGTGGTGA-3'(SEQIDNO:1478)
5'-AUCUCCCAAGUAGCCAGUGGUGACA-3'(SEQIDNO:2055)
3'-AAUAGAGGGUUCAUCGGUCACCACUGU-5'(SEQIDNO:903)
CKAP5-4786靶:5'-TTATCTCCCAAGTAGCCAGTGGTGACA-3'(SEQIDNO:1479)
5'-CUCCCAAGUAGCCAGUGGUGACAUC-3'(SEQIDNO:2056)
3'-UAGAGGGUUCAUCGGUCACCACUGUAG-5'(SEQIDNO:904)
CKAP5-4788靶:5'-ATCTCCCAAGTAGCCAGTGGTGACATC-3'(SEQIDNO:1480)
5'-CCCAAGUAGCCAGUGGUGACAUCAA-3'(SEQIDNO:2057)
3'-GAGGGUUCAUCGGUCACCACUGUAGUU-5'(SEQIDNO:905)
CKAP5-4790靶:5'-CTCCCAAGTAGCCAGTGGTGACATCAA-3'(SEQIDNO:1481)
5'-CAAGUAGCCAGUGGUGACAUCAACA-3'(SEQIDNO:2058)
3'-GGGUUCAUCGGUCACCACUGUAGUUGU-5'(SEQIDNO:906)
CKAP5-4792靶:5'-CCCAAGTAGCCAGTGGTGACATCAACA-3'(SEQIDNO:1482)
5'-GCCCGGGAGGCCUCCACUGGAGUAC-3'(SEQIDNO:2059)
3'-AACGGGCCCUCCGGAGGUGACCUCAUG-5'(SEQIDNO:907)
CKAP5-5041靶:5'-TTGCCCGGGAGGCCTCCACTGGAGTAC-3'(SEQIDNO:1483)
5'-CCGGGAGGCCUCCACUGGAGUACUA-3'(SEQIDNO:2060)
3'-CGGGCCCUCCGGAGGUGACCUCAUGAU-5'(SEQIDNO:908)
CKAP5-5043靶:5'-GCCCGGGAGGCCTCCACTGGAGTACTA-3'(SEQIDNO:1484)
5'-GGGAGGCCUCCACUGGAGUACUAAA-3'(SEQIDNO:2061)
3'-GGCCCUCCGGAGGUGACCUCAUGAUUU-5'(SEQIDNO:909)
CKAP5-5045靶:5'-CCGGGAGGCCTCCACTGGAGTACTAAA-3'(SEQIDNO:1485)
5'-GAGGCCUCCACUGGAGUACUAAAAG-3'(SEQIDNO:2062)
3'-CCCUCCGGAGGUGACCUCAUGAUUUUC-5'(SEQIDNO:910)
CKAP5-5047靶:5'-GGGAGGCCTCCACTGGAGTACTAAAAG-3'(SEQIDNO:1486)
5'-AUCACCUUAAUGCUGGAUUCUCGGA-3'(SEQIDNO:2063)
3'-AGUAGUGGAAUUACGACCUAAGAGCCU-5'(SEQIDNO:911)
CKAP5-5089靶:5'-TCATCACCTTAATGCTGGATTCTCGGA-3'(SEQIDNO:1487)
5'-CACCUUAAUGCUGGAUUCUCGGAUU-3'(SEQIDNO:2064)
3'-UAGUGGAAUUACGACCUAAGAGCCUAA-5'(SEQIDNO:912)
CKAP5-5091靶:5'-ATCACCTTAATGCTGGATTCTCGGATT-3'(SEQIDNO:1488)
5'-CCUUAAUGCUGGAUUCUCGGAUUGA-3'(SEQIDNO:2065)
3'-GUGGAAUUACGACCUAAGAGCCUAACU-5'(SEQIDNO:913)
CKAP5-5093靶:5'-CACCTTAATGCTGGATTCTCGGATTGA-3'(SEQIDNO:1489)
5'-UUAAUGCUGGAUUCUCGGAUUGAAG-3'(SEQIDNO:2066)
3'-GGAAUUACGACCUAAGAGCCUAACUUC-5'(SEQIDNO:914)
CKAP5-5095靶:5'-CCTTAATGCTGGATTCTCGGATTGAAG-3'(SEQIDNO:1490)
5'-AAUGCUGGAUUCUCGGAUUGAAGAU-3'(SEQIDNO:2067)
3'-AAUUACGACCUAAGAGCCUAACUUCUA-5'(SEQIDNO:915)
CKAP5-5097靶:5'-TTAATGCTGGATTCTCGGATTGAAGAT-3'(SEQIDNO:1491)
5'-UGCUGGAUUCUCGGAUUGAAGAUCU-3'(SEQIDNO:2068)
3'-UUACGACCUAAGAGCCUAACUUCUAGA-5'(SEQIDNO:916)
CKAP5-5099靶:5'-AATGCTGGATTCTCGGATTGAAGATCT-3'(SEQIDNO:1492)
5'-CUGGAUUCUCGGAUUGAAGAUCUUG-3'(SEQIDNO:2069)
3'-ACGACCUAAGAGCCUAACUUCUAGAAC-5'(SEQIDNO:917)
CKAP5-5101靶:5'-TGCTGGATTCTCGGATTGAAGATCTTG-3'(SEQIDNO:1493)
5'-GGAUUCUCGGAUUGAAGAUCUUGAG-3'(SEQIDNO:2070)
3'-GACCUAAGAGCCUAACUUCUAGAACUC-5'(SEQIDNO:918)
CKAP5-5103靶:5'-CTGGATTCTCGGATTGAAGATCTTGAG-3'(SEQIDNO:1494)
5'-AUUCUCGGAUUGAAGAUCUUGAGGA-3'(SEQIDNO:2071)
3'-CCUAAGAGCCUAACUUCUAGAACUCCU-5'(SEQIDNO:919)
CKAP5-5105靶:5'-GGATTCTCGGATTGAAGATCTTGAGGA-3'(SEQIDNO:1495)
5'-CUGUGAACCUCUUGGUGGUGAAGGU-3'(SEQIDNO:2072)
3'-GAGACACUUGGAGAACCACCACUUCCA-5'(SEQIDNO:920)
CKAP5-5150靶:5'-CTCTGTGAACCTCTTGGTGGTGAAGGT-3'(SEQIDNO:1496)
5'-GUGAACCUCUUGGUGGUGAAGGUUC-3'(SEQIDNO:2073)
3'-GACACUUGGAGAACCACCACUUCCAAG-5'(SEQIDNO:921)
CKAP5-5152靶:5'-CTGTGAACCTCTTGGTGGTGAAGGTTC-3'(SEQIDNO:1497)
5'-GAACCUCUUGGUGGUGAAGGUUCUG-3'(SEQIDNO:2074)
3'-CACUUGGAGAACCACCACUUCCAAGAC-5'(SEQIDNO:922)
CKAP5-5154靶:5'-GTGAACCTCTTGGTGGTGAAGGTTCTG-3'(SEQIDNO:1498)
5'-ACCUCUUGGUGGUGAAGGUUCUGGA-3'(SEQIDNO:2075)
3'-CUUGGAGAACCACCACUUCCAAGACCU-5'(SEQIDNO:923)
CKAP5-5156靶:5'-GAACCTCTTGGTGGTGAAGGTTCTGGA-3'(SEQIDNO:1499)
5'-GACAGCCUGCUAGCAACAGCCAGUU-3'(SEQIDNO:2076)
3'-UUCUGUCGGACGAUCGUUGUCGGUCAA-5'(SEQIDNO:924)
CKAP5-5230靶:5'-AAGACAGCCTGCTAGCAACAGCCAGTT-3'(SEQIDNO:1500)
5'-AGUUCUCCCAAAUUCUCAGAGCUUG-3'(SEQIDNO:2077)
3'-GGUCAAGAGGGUUUAAGAGUCUCGAAC-5'(SEQIDNO:925)
CKAP5-5251靶:5'-CCAGTTCTCCCAAATTCTCAGAGCTTG-3'(SEQIDNO:1501)
5'-UUCUCCCAAAUUCUCAGAGCUUGUU-3'(SEQIDNO:2078)
3'-UCAAGAGGGUUUAAGAGUCUCGAACAA-5'(SEQIDNO:926)
CKAP5-5253靶:5'-AGTTCTCCCAAATTCTCAGAGCTTGTT-3'(SEQIDNO:1502)
5'-CUCCCAAAUUCUCAGAGCUUGUUAU-3'(SEQIDNO:2079)
3'-AAGAGGGUUUAAGAGUCUCGAACAAUA-5'(SEQIDNO:927)
CKAP5-5255靶:5'-TTCTCCCAAATTCTCAGAGCTTGTTAT-3'(SEQIDNO:1503)
5'-CCCAAAUUCUCAGAGCUUGUUAUGA-3'(SEQIDNO:2080)
3'-GAGGGUUUAAGAGUCUCGAACAAUACU-5'(SEQIDNO:928)
CKAP5-5257靶:5'-CTCCCAAATTCTCAGAGCTTGTTATGA-3'(SEQIDNO:1504)
5'-CAAAUUCUCAGAGCUUGUUAUGAAG-3'(SEQIDNO:2081)
3'-GGGUUUAAGAGUCUCGAACAAUACUUC-5'(SEQIDNO:929)
CKAP5-5259靶:5'-CCCAAATTCTCAGAGCTTGTTATGAAG-3'(SEQIDNO:1505)
5'-AAUUCUCAGAGCUUGUUAUGAAGUG-3'(SEQIDNO:2082)
3'-GUUUAAGAGUCUCGAACAAUACUUCAC-5'(SEQIDNO:930)
CKAP5-5261靶:5'-CAAATTCTCAGAGCTTGTTATGAAGTG-3'(SEQIDNO:1506)
5'-UUCUCAGAGCUUGUUAUGAAGUGUC-3'(SEQIDNO:2083)
3'-UUAAGAGUCUCGAACAAUACUUCACAG-5'(SEQIDNO:931)
CKAP5-5263靶:5'-AATTCTCAGAGCTTGTTATGAAGTGTC-3'(SEQIDNO:1507)
5'-CUCAGAGCUUGUUAUGAAGUGUCUC-3'(SEQIDNO:2084)
3'-AAGAGUCUCGAACAAUACUUCACAGAG-5'(SEQIDNO:932)
CKAP5-5265靶:5'-TTCTCAGAGCTTGTTATGAAGTGTCTC-3'(SEQIDNO:1508)
5'-CAGAGCUUGUUAUGAAGUGUCUCUG-3'(SEQIDNO:2085)
3'-GAGUCUCGAACAAUACUUCACAGAGAC-5'(SEQIDNO:933)
CKAP5-5267靶:5'-CTCAGAGCTTGTTATGAAGTGTCTCTG-3'(SEQIDNO:1509)
5'-GAGCUUGUUAUGAAGUGUCUCUGGA-3'(SEQIDNO:2086)
3'-GUCUCGAACAAUACUUCACAGAGACCU-5'(SEQIDNO:934)
CKAP5-5269靶:5'-CAGAGCTTGTTATGAAGTGTCTCTGGA-3'(SEQIDNO:1510)
5'-AGCAUUAACCUAGACAGAAUUCUUC-3'(SEQIDNO:2087)
3'-UAUCGUAAUUGGAUCUGUCUUAAGAAG-5'(SEQIDNO:935)
CKAP5-5326靶:5'-ATAGCATTAACCTAGACAGAATTCTTC-3'(SEQIDNO:1511)
5'-CAUUAACCUAGACAGAAUUCUUCUG-3'(SEQIDNO:2088)
3'-UCGUAAUUGGAUCUGUCUUAAGAAGAC-5'(SEQIDNO:936)
CKAP5-5328靶:5'-AGCATTAACCTAGACAGAATTCTTCTG-3'(SEQIDNO:1512)
5'-UUAACCUAGACAGAAUUCUUCUGGA-3'(SEQIDNO:2089)
3'-GUAAUUGGAUCUGUCUUAAGAAGACCU-5'(SEQIDNO:937)
CKAP5-5330靶:5'-CATTAACCTAGACAGAATTCTTCTGGA-3'(SEQIDNO:1513)
5'-AACCUAGACAGAAUUCUUCUGGAUA-3'(SEQIDNO:2090)
3'-AAUUGGAUCUGUCUUAAGAAGACCUAU-5'(SEQIDNO:938)
CKAP5-5332靶:5'-TTAACCTAGACAGAATTCTTCTGGATA-3'(SEQIDNO:1514)
5'-CCUAGACAGAAUUCUUCUGGAUAUC-3'(SEQIDNO:2091)
3'-UUGGAUCUGUCUUAAGAAGACCUAUAG-5'(SEQIDNO:939)
CKAP5-5334靶:5'-AACCTAGACAGAATTCTTCTGGATATC-3'(SEQIDNO:1515)
5'-UAGACAGAAUUCUUCUGGAUAUCCA-3'(SEQIDNO:2092)
3'-GGAUCUGUCUUAAGAAGACCUAUAGGU-5'(SEQIDNO:940)
CKAP5-5336靶:5'-CCTAGACAGAATTCTTCTGGATATCCA-3'(SEQIDNO:1516)
5'-UCCACAUUUUCAUGAAGGUCUUCCC-3'(SEQIDNO:2093)
3'-AUAGGUGUAAAAGUACUUCCAGAAGGG-5'(SEQIDNO:941)
CKAP5-5357靶:5'-TATCCACATTTTCATGAAGGTCTTCCC-3'(SEQIDNO:1517)
5'-GAAGCAAUGCAAAAGUGAAUUUCCC-3'(SEQIDNO:2094)
3'-GACUUCGUUACGUUUUCACUUAAAGGG-5'(SEQIDNO:942)
CKAP5-5394靶:5'-CTGAAGCAATGCAAAAGTGAATTTCCC-3'(SEQIDNO:1518)
5'-AGCAAUGCAAAAGUGAAUUUCCCAU-3'(SEQIDNO:2095)
3'-CUUCGUUACGUUUUCACUUAAAGGGUA-5'(SEQIDNO:943)
CKAP5-5396靶:5'-GAAGCAATGCAAAAGTGAATTTCCCAT-3'(SEQIDNO:1519)
5'-CAAUGCAAAAGUGAAUUUCCCAUAA-3'(SEQIDNO:2096)
3'-UCGUUACGUUUUCACUUAAAGGGUAUU-5'(SEQIDNO:944)
CKAP5-5398靶:5'-AGCAATGCAAAAGTGAATTTCCCATAA-3'(SEQIDNO:1520)
5'-AGUAUGGACCAGACUGGGAGCAAGU-3'(SEQIDNO:2097)
3'-UGUCAUACCUGGUCUGACCCUCGUUCA-5'(SEQIDNO:945)
CKAP5-5551靶:5'-ACAGTATGGACCAGACTGGGAGCAAGT-3'(SEQIDNO:1521)
5'-UAUGGACCAGACUGGGAGCAAGUCU-3'(SEQIDNO:2098)
3'-UCAUACCUGGUCUGACCCUCGUUCAGA-5'(SEQIDNO:946)
CKAP5-5553靶:5'-AGTATGGACCAGACTGGGAGCAAGTCT-3'(SEQIDNO:1522)
5'-UGGACCAGACUGGGAGCAAGUCUGA-3'(SEQIDNO:2099)
3'-AUACCUGGUCUGACCCUCGUUCAGACU-5'(SEQIDNO:947)
CKAP5-5555靶:5'-TATGGACCAGACTGGGAGCAAGTCTGA-3'(SEQIDNO:1523)
5'-GACCAGACUGGGAGCAAGUCUGAUA-3'(SEQIDNO:2100)
3'-ACCUGGUCUGACCCUCGUUCAGACUAU-5'(SEQIDNO:948)
CKAP5-5557靶:5'-TGGACCAGACTGGGAGCAAGTCTGATA-3'(SEQIDNO:1524)
5'-CCAGACUGGGAGCAAGUCUGAUAAG-3'(SEQIDNO:2101)
3'-CUGGUCUGACCCUCGUUCAGACUAUUC-5'(SEQIDNO:949)
CKAP5-5559靶:5'-GACCAGACTGGGAGCAAGTCTGATAAG-3'(SEQIDNO:1525)
5'-AGACUGGGAGCAAGUCUGAUAAGGA-3'(SEQIDNO:2102)
3'-GGUCUGACCCUCGUUCAGACUAUUCCU-5'(SEQIDNO:950)
CKAP5-5561靶:5'-CCAGACTGGGAGCAAGTCTGATAAGGA-3'(SEQIDNO:1526)
5'-ACUGGGAGCAAGUCUGAUAAGGAAA-3'(SEQIDNO:2103)
3'-UCUGACCCUCGUUCAGACUAUUCCUUU-5'(SEQIDNO:951)
CKAP5-5563靶:5'-AGACTGGGAGCAAGTCTGATAAGGAAA-3'(SEQIDNO:1527)
5'-UGGGAGCAAGUCUGAUAAGGAAACA-3'(SEQIDNO:2104)
3'-UGACCCUCGUUCAGACUAUUCCUUUGU-5'(SEQIDNO:952)
CKAP5-5565靶:5'-ACTGGGAGCAAGTCTGATAAGGAAACA-3'(SEQIDNO:1528)
5'-GGAGCAAGUCUGAUAAGGAAACAGA-3'(SEQIDNO:2105)
3'-ACCCUCGUUCAGACUAUUCCUUUGUCU-5'(SEQIDNO:953)
CKAP5-5567靶:5'-TGGGAGCAAGTCTGATAAGGAAACAGA-3'(SEQIDNO:1529)
5'-AGCAAGUCUGAUAAGGAAACAGAAA-3'(SEQIDNO:2106)
3'-CCUCGUUCAGACUAUUCCUUUGUCUUU-5'(SEQIDNO:954)
CKAP5-5569靶:5'-GGAGCAAGTCTGATAAGGAAACAGAAA-3'(SEQIDNO:1530)
5'-CAAGUCUGAUAAGGAAACAGAAAAG-3'(SEQIDNO:2107)
3'-UCGUUCAGACUAUUCCUUUGUCUUUUC-5'(SEQIDNO:955)
CKAP5-5571靶:5'-AGCAAGTCTGATAAGGAAACAGAAAAG-3'(SEQIDNO:1531)
5'-AGUCUGAUAAGGAAACAGAAAAGGG-3'(SEQIDNO:2108)
3'-GUUCAGACUAUUCCUUUGUCUUUUCCC-5'(SEQIDNO:956)
CKAP5-5573靶:5'-CAAGTCTGATAAGGAAACAGAAAAGGG-3'(SEQIDNO:1532)
5'-UCUGAUAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:2109)
3'-UCAGACUAUUCCUUUGUCUUUUCCCUC-5'(SEQIDNO:957)
CKAP5-5575靶:5'-AGTCTGATAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:1533)
5'-UGAUAAGGAAACAGAAAAGGGAGCA-3'(SEQIDNO:2110)
3'-AGACUAUUCCUUUGUCUUUUCCCUCGU-5'(SEQIDNO:958)
CKAP5-5577靶:5'-TCTGATAAGGAAACAGAAAAGGGAGCA-3'(SEQIDNO:1534)
5'-AUAAGGAAACAGAAAAGGGAGCAUC-3'(SEQIDNO:2111)
3'-ACUAUUCCUUUGUCUUUUCCCUCGUAG-5'(SEQIDNO:959)
CKAP5-5579靶:5'-TGATAAGGAAACAGAAAAGGGAGCATC-3'(SEQIDNO:1535)
5'-AAGGAAACAGAAAAGGGAGCAUCUC-3'(SEQIDNO:2112)
3'-UAUUCCUUUGUCUUUUCCCUCGUAGAG-5'(SEQIDNO:960)
CKAP5-5581靶:5'-ATAAGGAAACAGAAAAGGGAGCATCTC-3'(SEQIDNO:1536)
5'-UCUCGAAUAGAUGAAAAAUCAUCAA-3'(SEQIDNO:2113)
3'-GUAGAGCUUAUCUACUUUUUAGUAGUU-5'(SEQIDNO:961)
CKAP5-5602靶:5'-CATCTCGAATAGATGAAAAATCATCAA-3'(SEQIDNO:1537)
5'-UCGAAUAGAUGAAAAAUCAUCAAAG-3'(SEQIDNO:2114)
3'-AGAGCUUAUCUACUUUUUAGUAGUUUC-5'(SEQIDNO:962)
CKAP5-5604靶:5'-TCTCGAATAGATGAAAAATCATCAAAG-3'(SEQIDNO:1538)
5'-GAAUAGAUGAAAAAUCAUCAAAGGC-3'(SEQIDNO:2115)
3'-AGCUUAUCUACUUUUUAGUAGUUUCCG-5'(SEQIDNO:963)
CKAP5-5606靶:5'-TCGAATAGATGAAAAATCATCAAAGGC-3'(SEQIDNO:1539)
5'-AUAGAUGAAAAAUCAUCAAAGGCCA-3'(SEQIDNO:2116)
3'-CUUAUCUACUUUUUAGUAGUUUCCGGU-5'(SEQIDNO:964)
CKAP5-5608靶:5'-GAATAGATGAAAAATCATCAAAGGCCA-3'(SEQIDNO:1540)
5'-AGAUGAAAAAUCAUCAAAGGCCAAA-3'(SEQIDNO:2117)
3'-UAUCUACUUUUUAGUAGUUUCCGGUUU-5'(SEQIDNO:965)
CKAP5-5610靶:5'-ATAGATGAAAAATCATCAAAGGCCAAA-3'(SEQIDNO:1541)
5'-AUGAAAAAUCAUCAAAGGCCAAAGU-3'(SEQIDNO:2118)
3'-UCUACUUUUUAGUAGUUUCCGGUUUCA-5'(SEQIDNO:966)
CKAP5-5612靶:5'-AGATGAAAAATCATCAAAGGCCAAAGT-3'(SEQIDNO:1542)
5'-GAAAAAUCAUCAAAGGCCAAAGUGA-3'(SEQIDNO:2119)
3'-UACUUUUUAGUAGUUUCCGGUUUCACU-5'(SEQIDNO:967)
CKAP5-5614靶:5'-ATGAAAAATCATCAAAGGCCAAAGTGA-3'(SEQIDNO:1543)
5'-AAAAUCAUCAAAGGCCAAAGUGAAU-3'(SEQIDNO:2120)
3'-CUUUUUAGUAGUUUCCGGUUUCACUUA-5'(SEQIDNO:968)
CKAP5-5616靶:5'-GAAAAATCATCAAAGGCCAAAGTGAAT-3'(SEQIDNO:1544)
5'-AAUCAUCAAAGGCCAAAGUGAAUGA-3'(SEQIDNO:2121)
3'-UUUUAGUAGUUUCCGGUUUCACUUACU-5'(SEQIDNO:969)
CKAP5-5618靶:5'-AAAATCATCAAAGGCCAAAGTGAATGA-3'(SEQIDNO:1545)
5'-AUGAUUUCUUAGCUGAGAUUUUUAA-3'(SEQIDNO:2122)
3'-CUUACUAAAGAAUCGACUCUAAAAAUU-5'(SEQIDNO:970)
CKAP5-5639靶:5'-GAATGATTTCTTAGCTGAGATTTTTAA-3'(SEQIDNO:1546)
5'-GAUUUCUUAGCUGAGAUUUUUAAGA-3'(SEQIDNO:2123)
3'-UACUAAAGAAUCGACUCUAAAAAUUCU-5'(SEQIDNO:971)
CKAP5-5641靶:5'-ATGATTTCTTAGCTGAGATTTTTAAGA-3'(SEQIDNO:1547)
5'-UUUCUUAGCUGAGAUUUUUAAGAAG-3'(SEQIDNO:2124)
3'-CUAAAGAAUCGACUCUAAAAAUUCUUC-5'(SEQIDNO:972)
CKAP5-5643靶:5'-GATTTCTTAGCTGAGATTTTTAAGAAG-3'(SEQIDNO:1548)
5'-UCUUAGCUGAGAUUUUUAAGAAGAU-3'(SEQIDNO:2125)
3'-AAAGAAUCGACUCUAAAAAUUCUUCUA-5'(SEQIDNO:973)
CKAP5-5645靶:5'-TTTCTTAGCTGAGATTTTTAAGAAGAT-3'(SEQIDNO:1549)
5'-UUAGCUGAGAUUUUUAAGAAGAUUG-3'(SEQIDNO:2126)
3'-AGAAUCGACUCUAAAAAUUCUUCUAAC-5'(SEQIDNO:974)
CKAP5-5647靶:5'-TCTTAGCTGAGATTTTTAAGAAGATTG-3'(SEQIDNO:1550)
5'-AGCUGAGAUUUUUAAGAAGAUUGGC-3'(SEQIDNO:2127)
3'-AAUCGACUCUAAAAAUUCUUCUAACCG-5'(SEQIDNO:975)
CKAP5-5649靶:5'-TTAGCTGAGATTTTTAAGAAGATTGGC-3'(SEQIDNO:1551)
5'-CUGAGAUUUUUAAGAAGAUUGGCUC-3'(SEQIDNO:2128)
3'-UCGACUCUAAAAAUUCUUCUAACCGAG-5'(SEQIDNO:976)
CKAP5-5651靶:5'-AGCTGAGATTTTTAAGAAGATTGGCTC-3'(SEQIDNO:1552)
5'-GAGAUUUUUAAGAAGAUUGGCUCUA-3'(SEQIDNO:2129)
3'-GACUCUAAAAAUUCUUCUAACCGAGAU-5'(SEQIDNO:977)
CKAP5-5653靶:5'-CTGAGATTTTTAAGAAGATTGGCTCTA-3'(SEQIDNO:1553)
5'-GAUUUUUAAGAAGAUUGGCUCUAAA-3'(SEQIDNO:2130)
3'-CUCUAAAAAUUCUUCUAACCGAGAUUU-5'(SEQIDNO:978)
CKAP5-5655靶:5'-GAGATTTTTAAGAAGATTGGCTCTAAA-3'(SEQIDNO:1554)
5'-UUUUUAAGAAGAUUGGCUCUAAAGA-3'(SEQIDNO:2131)
3'-CUAAAAAUUCUUCUAACCGAGAUUUCU-5'(SEQIDNO:979)
CKAP5-5657靶:5'-GATTTTTAAGAAGATTGGCTCTAAAGA-3'(SEQIDNO:1555)
5'-UAGCAGAGUUAUAUGAAUAUAAGAA-3'(SEQIDNO:2132)
3'-UGAUCGUCUCAAUAUACUUAUAUUCUU-5'(SEQIDNO:980)
CKAP5-5699靶:5'-ACTAGCAGAGTTATATGAATATAAGAA-3'(SEQIDNO:1556)
5'-GCAGAGUUAUAUGAAUAUAAGAAGA-3'(SEQIDNO:2133)
3'-AUCGUCUCAAUAUACUUAUAUUCUUCU-5'(SEQIDNO:981)
CKAP5-5701靶:5'-TAGCAGAGTTATATGAATATAAGAAGA-3'(SEQIDNO:1557)
5'-AGAGUUAUAUGAAUAUAAGAAGAAA-3'(SEQIDNO:2134)
3'-CGUCUCAAUAUACUUAUAUUCUUCUUU-5'(SEQIDNO:982)
CKAP5-5703靶:5'-GCAGAGTTATATGAATATAAGAAGAAA-3'(SEQIDNO:1558)
5'-AGUUAUAUGAAUAUAAGAAGAAAUA-3'(SEQIDNO:2135)
3'-UCUCAAUAUACUUAUAUUCUUCUUUAU-5'(SEQIDNO:983)
CKAP5-5705靶:5'-AGAGTTATATGAATATAAGAAGAAATA-3'(SEQIDNO:1559)
5'-UUAUAUGAAUAUAAGAAGAAAUACU-3'(SEQIDNO:2136)
3'-UCAAUAUACUUAUAUUCUUCUUUAUGA-5'(SEQIDNO:984)
CKAP5-5707靶:5'-AGTTATATGAATATAAGAAGAAATACT-3'(SEQIDNO:1560)
5'-AUAUGAAUAUAAGAAGAAAUACUCA-3'(SEQIDNO:2137)
3'-AAUAUACUUAUAUUCUUCUUUAUGAGU-5'(SEQIDNO:985)
CKAP5-5709靶:5'-TTATATGAATATAAGAAGAAATACTCA-3'(SEQIDNO:1561)
5'-AUGAAUAUAAGAAGAAAUACUCAGA-3'(SEQIDNO:2138)
3'-UAUACUUAUAUUCUUCUUUAUGAGUCU-5'(SEQIDNO:986)
CKAP5-5711靶:5'-ATATGAATATAAGAAGAAATACTCAGA-3'(SEQIDNO:1562)
5'-UGACAUUGAACCAUUUCUGAAAAAU-3'(SEQIDNO:2139)
3'-CGACUGUAACUUGGUAAAGACUUUUUA-5'(SEQIDNO:987)
CKAP5-5739靶:5'-GCTGACATTGAACCATTTCTGAAAAAT-3'(SEQIDNO:1563)
5'-ACAUUGAACCAUUUCUGAAAAAUUC-3'(SEQIDNO:2140)
3'-ACUGUAACUUGGUAAAGACUUUUUAAG-5'(SEQIDNO:988)
CKAP5-5741靶:5'-TGACATTGAACCATTTCTGAAAAATTC-3'(SEQIDNO:1564)
5'-AUUGAACCAUUUCUGAAAAAUUCCU-3'(SEQIDNO:2141)
3'-UGUAACUUGGUAAAGACUUUUUAAGGA-5'(SEQIDNO:989)
CKAP5-5743靶:5'-ACATTGAACCATTTCTGAAAAATTCCT-3'(SEQIDNO:1565)
5'-UGAACCAUUUCUGAAAAAUUCCUCA-3'(SEQIDNO:2142)
3'-UAACUUGGUAAAGACUUUUUAAGGAGU-5'(SEQIDNO:990)
CKAP5-5745靶:5'-ATTGAACCATTTCTGAAAAATTCCTCA-3'(SEQIDNO:1566)
5'-AACCAUUUCUGAAAAAUUCCUCACA-3'(SEQIDNO:2143)
3'-ACUUGGUAAAGACUUUUUAAGGAGUGU-5'(SEQIDNO:991)
CKAP5-5747靶:5'-TGAACCATTTCTGAAAAATTCCTCACA-3'(SEQIDNO:1567)
5'-CCAUUUCUGAAAAAUUCCUCACAGU-3'(SEQIDNO:2144)
3'-UUGGUAAAGACUUUUUAAGGAGUGUCA-5'(SEQIDNO:992)
CKAP5-5749靶:5'-AACCATTTCTGAAAAATTCCTCACAGT-3'(SEQIDNO:1568)
5'-AGAGGCCUUCGGGUGAUUGAGAUGG-3'(SEQIDNO:2145)
3'-UUUCUCCGGAAGCCCACUAACUCUACC-5'(SEQIDNO:993)
CKAP5-5794靶:5'-AAAGAGGCCTTCGGGTGATTGAGATGG-3'(SEQIDNO:1569)
5'-AGGCCUUCGGGUGAUUGAGAUGGAG-3'(SEQIDNO:2146)
3'-UCUCCGGAAGCCCACUAACUCUACCUC-5'(SEQIDNO:994)
CKAP5-5796靶:5'-AGAGGCCTTCGGGTGATTGAGATGGAG-3'(SEQIDNO:1570)
5'-GCCUUCGGGUGAUUGAGAUGGAGAG-3'(SEQIDNO:2147)
3'-UCCGGAAGCCCACUAACUCUACCUCUC-5'(SEQIDNO:995)
CKAP5-5798靶:5'-AGGCCTTCGGGTGATTGAGATGGAGAG-3'(SEQIDNO:1571)
5'-CUUCGGGUGAUUGAGAUGGAGAGGG-3'(SEQIDNO:2148)
3'-CGGAAGCCCACUAACUCUACCUCUCCC-5'(SEQIDNO:996)
CKAP5-5800靶:5'-GCCTTCGGGTGATTGAGATGGAGAGGG-3'(SEQIDNO:1572)
5'-UCGGGUGAUUGAGAUGGAGAGGGAG-3'(SEQIDNO:2149)
3'-GAAGCCCACUAACUCUACCUCUCCCUC-5'(SEQIDNO:997)
CKAP5-5802靶:5'-CTTCGGGTGATTGAGATGGAGAGGGAG-3'(SEQIDNO:1573)
5'-GGGUGAUUGAGAUGGAGAGGGAGGG-3'(SEQIDNO:2150)
3'-AGCCCACUAACUCUACCUCUCCCUCCC-5'(SEQIDNO:998)
CKAP5-5804靶:5'-TCGGGTGATTGAGATGGAGAGGGAGGG-3'(SEQIDNO:1574)
5'-CCAUCUGUCUACUUGGAAAGGCUAA-3'(SEQIDNO:2151)
3'-CCGGUAGACAGAUGAACCUUUCCGAUU-5'(SEQIDNO:999)
CKAP5-5944靶:5'-GGCCATCTGTCTACTTGGAAAGGCTAA-3'(SEQIDNO:1575)
5'-AUCUGUCUACUUGGAAAGGCUAAAG-3'(SEQIDNO:2152)
3'-GGUAGACAGAUGAACCUUUCCGAUUUC-5'(SEQIDNO:1000)
CKAP5-5946靶:5'-CCATCTGTCTACTTGGAAAGGCTAAAG-3'(SEQIDNO:1576)
5'-CUGUCUACUUGGAAAGGCUAAAGAU-3'(SEQIDNO:2153)
3'-UAGACAGAUGAACCUUUCCGAUUUCUA-5'(SEQIDNO:1001)
CKAP5-5948靶:5'-ATCTGTCTACTTGGAAAGGCTAAAGAT-3'(SEQIDNO:1577)
5'-GUCUACUUGGAAAGGCUAAAGAUCC-3'(SEQIDNO:2154)
3'-GACAGAUGAACCUUUCCGAUUUCUAGG-5'(SEQIDNO:1002)
CKAP5-5950靶:5'-CTGTCTACTTGGAAAGGCTAAAGATCC-3'(SEQIDNO:1578)
5'-UGACCUCUUUGCUCUCCAAACCAGC-3'(SEQIDNO:2155)
3'-AAACUGGAGAAACGAGAGGUUUGGUCG-5'(SEQIDNO:1003)
CKAP5-6026靶:5'-TTTGACCTCTTTGCTCTCCAAACCAGC-3'(SEQIDNO:1579)
5'-ACCUCUUUGCUCUCCAAACCAGCAG-3'(SEQIDNO:2156)
3'-ACUGGAGAAACGAGAGGUUUGGUCGUC-5'(SEQIDNO:1004)
CKAP5-6028靶:5'-TGACCTCTTTGCTCTCCAAACCAGCAG-3'(SEQIDNO:1580)
5'-CUCUUUGCUCUCCAAACCAGCAGUU-3'(SEQIDNO:2157)
3'-UGGAGAAACGAGAGGUUUGGUCGUCAA-5'(SEQIDNO:1005)
CKAP5-6030靶:5'-ACCTCTTTGCTCTCCAAACCAGCAGTT-3'(SEQIDNO:1581)
5'-CUUUGCUCUCCAAACCAGCAGUUCC-3'(SEQIDNO:2158)
3'-GAGAAACGAGAGGUUUGGUCGUCAAGG-5'(SEQIDNO:1006)
CKAP5-6032靶:5'-CTCTTTGCTCTCCAAACCAGCAGTTCC-3'(SEQIDNO:1582)
5'-UGACCUCCUCCUCCUCCACAGCUAA-3'(SEQIDNO:2159)
3'-ACACUGGAGGAGGAGGAGGUGUCGAUU-5'(SEQIDNO:1007)
CKAP5-6173靶:5'-TGTGACCTCCTCCTCCTCCACAGCTAA-3'(SEQIDNO:1583)
5'-AGACUGGAGAGAAUAAAGAGCAGUC-3'(SEQIDNO:2160)
3'-UUUCUGACCUCUCUUAUUUCUCGUCAG-5'(SEQIDNO:1008)
CKAP5-6217靶:5'-AAAGACTGGAGAGAATAAAGAGCAGTC-3'(SEQIDNO:1584)
5'-ACUGGAGAGAAUAAAGAGCAGUCGC-3'(SEQIDNO:2161)
3'-UCUGACCUCUCUUAUUUCUCGUCAGCG-5'(SEQIDNO:1009)
CKAP5-6219靶:5'-AGACTGGAGAGAATAAAGAGCAGTCGC-3'(SEQIDNO:1585)
5'-UGGAGAGAAUAAAGAGCAGUCGCAA-3'(SEQIDNO:2162)
3'-UGACCUCUCUUAUUUCUCGUCAGCGUU-5'(SEQIDNO:1010)
CKAP5-6221靶:5'-ACTGGAGAGAATAAAGAGCAGTCGCAA-3'(SEQIDNO:1586)
5'-GAGAGAAUAAAGAGCAGUCGCAAAU-3'(SEQIDNO:2163)
3'-ACCUCUCUUAUUUCUCGUCAGCGUUUA-5'(SEQIDNO:1011)
CKAP5-6223靶:5'-TGGAGAGAATAAAGAGCAGTCGCAAAT-3'(SEQIDNO:1587)
5'-GAGAAUAAAGAGCAGUCGCAAAUGA-3'(SEQIDNO:2164)
3'-CUCUCUUAUUUCUCGUCAGCGUUUACU-5'(SEQIDNO:1012)
CKAP5-6225靶:5'-GAGAGAATAAAGAGCAGTCGCAAATGA-3'(SEQIDNO:1588)
5'-GAAUAAAGAGCAGUCGCAAAUGAAG-3'(SEQIDNO:2165)
3'-CUCUUAUUUCUCGUCAGCGUUUACUUC-5'(SEQIDNO:1013)
CKAP5-6227靶:5'-GAGAATAAAGAGCAGTCGCAAATGAAG-3'(SEQIDNO:1589)
5'-AUAAAGAGCAGUCGCAAAUGAAGCU-3'(SEQIDNO:2166)
3'-CUUAUUUCUCGUCAGCGUUUACUUCGA-5'(SEQIDNO:1014)
CKAP5-6229靶:5'-GAATAAAGAGCAGTCGCAAATGAAGCT-3'(SEQIDNO:1590)
5'-AAAGAGCAGUCGCAAAUGAAGCUGC-3'(SEQIDNO:2167)
3'-UAUUUCUCGUCAGCGUUUACUUCGACG-5'(SEQIDNO:1015)
CKAP5-6231靶:5'-ATAAAGAGCAGTCGCAAATGAAGCTGC-3'(SEQIDNO:1591)
5'-AGAGCAGUCGCAAAUGAAGCUGCCC-3'(SEQIDNO:2168)
3'-UUUCUCGUCAGCGUUUACUUCGACGGG-5'(SEQIDNO:1016)
CKAP5-6233靶:5'-AAAGAGCAGTCGCAAATGAAGCTGCCC-3'(SEQIDNO:1592)
5'-AAACUGGUUGUAUGUAUCAUGCCGU-3'(SEQIDNO:2169)
3'-UGUUUGACCAACAUACAUAGUACGGCA-5'(SEQIDNO:1017)
CKAP5-6342靶:5'-ACAAACTGGTTGTATGTATCATGCCGT-3'(SEQIDNO:1593)
5'-CUCAUUUGUAAAAUUGUCCUAAUCU-3'(SEQIDNO:2170)
3'-ACGAGUAAACAUUUUAACAGGAUUAGA-5'(SEQIDNO:1018)
CKAP5-6544靶:5'-TGCTCATTTGTAAAATTGTCCTAATCT-3'(SEQIDNO:1594)
5'-CAUUUGUAAAAUUGUCCUAAUCUUU-3'(SEQIDNO:2171)
3'-GAGUAAACAUUUUAACAGGAUUAGAAA-5'(SEQIDNO:1019)
CKAP5-6546靶:5'-CTCATTTGTAAAATTGTCCTAATCTTT-3'(SEQIDNO:1595)
5'-UUUGUAAAAUUGUCCUAAUCUUUCC-3'(SEQIDNO:2172)
3'-GUAAACAUUUUAACAGGAUUAGAAAGG-5'(SEQIDNO:1020)
CKAP5-6548靶:5'-CATTTGTAAAATTGTCCTAATCTTTCC-3'(SEQIDNO:1596)
5'-ACUGUAUUCUGUAUGAAUGCAUGGC-3'(SEQIDNO:2173)
3'-AGUGACAUAAGACAUACUUACGUACCG-5'(SEQIDNO:1021)
CKAP5-6656靶:5'-TCACTGTATTCTGTATGAATGCATGGC-3'(SEQIDNO:1597)
5'-UGUAUUCUGUAUGAAUGCAUGGCAU-3'(SEQIDNO:2174)
3'-UGACAUAAGACAUACUUACGUACCGUA-5'(SEQIDNO:1022)
CKAP5-6658靶:5'-ACTGTATTCTGTATGAATGCATGGCAT-3'(SEQIDNO:1598)
5'-UAUUCUGUAUGAAUGCAUGGCAUGA-3'(SEQIDNO:2175)
3'-ACAUAAGACAUACUUACGUACCGUACU-5'(SEQIDNO:1023)
CKAP5-6660靶:5'-TGTATTCTGTATGAATGCATGGCATGA-3'(SEQIDNO:1599)
5'-UUCUGUAUGAAUGCAUGGCAUGAUA-3'(SEQIDNO:2176)
3'-AUAAGACAUACUUACGUACCGUACUAU-5'(SEQIDNO:1024)
CKAP5-6662靶:5'-TATTCTGTATGAATGCATGGCATGATA-3'(SEQIDNO:1600)
5'-CUGUAUGAAUGCAUGGCAUGAUACA-3'(SEQIDNO:2177)
3'-AAGACAUACUUACGUACCGUACUAUGU-5'(SEQIDNO:1025)
CKAP5-6664靶:5'-TTCTGTATGAATGCATGGCATGATACA-3'(SEQIDNO:1601)
5'-GUAUGAAUGCAUGGCAUGAUACAAC-3'(SEQIDNO:2178)
3'-GACAUACUUACGUACCGUACUAUGUUG-5'(SEQIDNO:1026)
CKAP5-6666靶:5'-CTGTATGAATGCATGGCATGATACAAC-3'(SEQIDNO:1602)
5'-UUUUAUAAAUAAAGUUUGCAUUAAC-3'(SEQIDNO:2179)
3'-AGAAAAUAUUUAUUUCAAACGUAAUUG-5'(SEQIDNO:1027)
CKAP5-6704靶:5'-TCTTTTATAAATAAAGTTTGCATTAAC-3'(SEQIDNO:1603)
5'-UUAUAAAUAAAGUUUGCAUUAACUA-3'(SEQIDNO:2180)
3'-AAAAUAUUUAUUUCAAACGUAAUUGAU-5'(SEQIDNO:1028)
CKAP5-6706靶:5'-TTTTATAAATAAAGTTTGCATTAACTA-3'(SEQIDNO:1604)
5'-AUAAAUAAAGUUUGCAUUAACUAUA-3'(SEQIDNO:2181)
3'-AAUAUUUAUUUCAAACGUAAUUGAUAU-5'(SEQIDNO:1029)
CKAP5-6708靶:5'-TTATAAATAAAGTTTGCATTAACTATA-3'(SEQIDNO:1605)
5'-AAAUAAAGUUUGCAUUAACUAUACC-3'(SEQIDNO:2182)
3'-UAUUUAUUUCAAACGUAAUUGAUAUGG-5'(SEQIDNO:1030)
CKAP5-6710靶:5'-ATAAATAAAGTTTGCATTAACTATACC-3'(SEQIDNO:1606)
5'-AUAAAGUUUGCAUUAACUAUACCUG-3'(SEQIDNO:2183)
3'-UUUAUUUCAAACGUAAUUGAUAUGGAC-5'(SEQIDNO:1031)
CKAP5-6712靶:5'-AAATAAAGTTTGCATTAACTATACCTG-3'(SEQIDNO:1607)
5'-AAAGUUUGCAUUAACUAUACCUGAC-3'(SEQIDNO:2184)
3'-UAUUUCAAACGUAAUUGAUAUGGACUG-5'(SEQIDNO:1032)
CKAP5-6714靶:5'-ATAAAGTTTGCATTAACTATACCTGAC-3'(SEQIDNO:1608)
5'-CAGCUGAGGAAAUACUCUUAAUUCU-3'(SEQIDNO:2185)
3'-GGGUCGACUCCUUUAUGAGAAUUAAGA-5'(SEQIDNO:1033)
CKAP5-106靶:5'-CCCAGCTGAGGAAATACTCTTAATTCT-3'(SEQIDNO:1609)
5'-UUGAAACUGCCAGUUGAUCAGAAAU-3'(SEQIDNO:2186)
3'-CCAACUUUGACGGUCAACUAGUCUUUA-5'(SEQIDNO:1034)
CKAP5-172靶:5'-GGTTGAAACTGCCAGTTGATCAGAAAT-3'(SEQIDNO:1610)
5'-GCCAGUUGAUCAGAAAUGUGAACAC-3'(SEQIDNO:2187)
3'-GACGGUCAACUAGUCUUUACACUUGUG-5'(SEQIDNO:1035)
CKAP5-180靶:5'-CTGCCAGTTGATCAGAAATGTGAACAC-3'(SEQIDNO:1611)
5'-GAAAGCAAGGUUAAGUGGGUAUGAA-3'(SEQIDNO:2188)
3'-ACCUUUCGUUCCAAUUCACCCAUACUU-5'(SEQIDNO:1036)
CKAP5-213靶:5'-TGGAAAGCAAGGTTAAGTGGGTATGAA-3'(SEQIDNO:1612)
5'-CAGAGUGGUCCAAAUUUUUAGGAUU-3'(SEQIDNO:2189)
3'-GGGUCUCACCAGGUUUAAAAAUCCUAA-5'(SEQIDNO:1037)
CKAP5-281靶:5'-CCCAGAGTGGTCCAAATTTTTAGGATT-3'(SEQIDNO:1613)
5'-GUGGUUCAAUUGAAAGGAUUAGAAG-3'(SEQIDNO:2190)
3'-GUCACCAAGUUAACUUUCCUAAUCUUC-5'(SEQIDNO:1038)
CKAP5-337靶:5'-CAGTGGTTCAATTGAAAGGATTAGAAG-3'(SEQIDNO:1614)
5'-GAUUAGAAGCUGCACUUGUUUAUGU-3'(SEQIDNO:2191)
3'-UCCUAAUCUUCGACGUGAACAAAUACA-5'(SEQIDNO:1039)
CKAP5-353靶:5'-AGGATTAGAAGCTGCACTTGTTTATGT-3'(SEQIDNO:1615)
5'-CUGCACUUGUUUAUGUUGAAAAUGC-3'(SEQIDNO:2192)
3'-UCGACGUGAACAAAUACAACUUUUACG-5'(SEQIDNO:1040)
CKAP5-362靶:5'-AGCTGCACTTGTTTATGTTGAAAATGC-3'(SEQIDNO:1616)
5'-CAGGAAAAACCACAGGAGAAGUUGU-3'(SEQIDNO:2193)
3'-UCGUCCUUUUUGGUGUCCUCUUCAACA-5'(SEQIDNO:1041)
CKAP5-395靶:5'-AGCAGGAAAAACCACAGGAGAAGTTGT-3'(SEQIDNO:1617)
5'-CAGGUGUUGUAAGUAAGGUGUUCAA-3'(SEQIDNO:2194)
3'-CAGUCCACAACAUUCAUUCCACAAGUU-5'(SEQIDNO:1042)
CKAP5-422靶:5'-GTCAGGTGTTGTAAGTAAGGTGTTCAA-3'(SEQIDNO:1618)
5'-GUUGUAAGUAAGGUGUUCAAUCAAC-3'(SEQIDNO:2195)
3'-CACAACAUUCAUUCCACAAGUUAGUUG-5'(SEQIDNO:1043)
CKAP5-427靶:5'-GTGTTGTAAGTAAGGTGTTCAATCAAC-3'(SEQIDNO:1619)
5'-UCAAUCAACCUAAAGCUAAAGCCAA-3'(SEQIDNO:2196)
3'-CAAGUUAGUUGGAUUUCGAUUUCGGUU-5'(SEQIDNO:1044)
CKAP5-443靶:5'-GTTCAATCAACCTAAAGCTAAAGCCAA-3'(SEQIDNO:1620)
5'-CCUGAAAGGCUUGGACAAUAAGAAU-3'(SEQIDNO:2197)
3'-GAGGACUUUCCGAACCUGUUAUUCUUA-5'(SEQIDNO:1045)
CKAP5-537靶:5'-CTCCTGAAAGGCTTGGACAATAAGAAT-3'(SEQIDNO:1621)
5'-AAGCCAAUUAUCAAAGUGUUGCCAA-3'(SEQIDNO:2198)
3'-AAUUCGGUUAAUAGUUUCACAACGGUU-5'(SEQIDNO:1046)
CKAP5-637靶:5'-TTAAGCCAATTATCAAAGTGTTGCCAA-3'(SEQIDNO:1622)
5'-AAAGUGUUGCCAAAACUCUUUGAGU-3'(SEQIDNO:2199)
3'-AGUUUCACAACGGUUUUGAGAAACUCA-5'(SEQIDNO:1047)
CKAP5-649靶:5'-TCAAAGTGTTGCCAAAACTCTTTGAGT-3'(SEQIDNO:1623)
5'-CAAAACUCUUUGAGUCUCGAGAGAA-3'(SEQIDNO:2200)
3'-CGGUUUUGAGAAACUCAGAGCUCUCUU-5'(SEQIDNO:1048)
CKAP5-659靶:5'-GCCAAAACTCTTTGAGTCTCGAGAGAA-3'(SEQIDNO:1624)
5'-CUGUUCGAGAUGAAGCCAAACUAAU-3'(SEQIDNO:2201)
3'-CCGACAAGCUCUACUUCGGUUUGAUUA-5'(SEQIDNO:1049)
CKAP5-686靶:5'-GGCTGTTCGAGATGAAGCCAAACTAAT-3'(SEQIDNO:1625)
5'-CAUUACAAAAUAUAAACUCUGUUCA-3'(SEQIDNO:2202)
3'-GGGUAAUGUUUUAUAUUUGAGACAAGU-5'(SEQIDNO:1050)
CKAP5-755靶:5'-CCCATTACAAAATATAAACTCTGTTCA-3'(SEQIDNO:1626)
5'-AAAAUAUAAACUCUGUUCAGUUGAA-3'(SEQIDNO:2203)
3'-UGUUUUAUAUUUGAGACAAGUCAACUU-5'(SEQIDNO:1051)
CKAP5-761靶:5'-ACAAAATATAAACTCTGTTCAGTTGAA-3'(SEQIDNO:1627)
5'-AUAAACUCUGUUCAGUUGAAAGAAC-3'(SEQIDNO:2204)
3'-UAUAUUUGAGACAAGUCAACUUUCUUG-5'(SEQIDNO:1052)
CKAP5-766靶:5'-ATATAAACTCTGTTCAGTTGAAAGAAC-3'(SEQIDNO:1628)
5'-CUGUUCAGUUGAAAGAACUAGAAGA-3'(SEQIDNO:2205)
3'-GAGACAAGUCAACUUUCUUGAUCUUCU-5'(SEQIDNO:1053)
CKAP5-773靶:5'-CTCTGTTCAGTTGAAAGAACTAGAAGA-3'(SEQIDNO:1629)
5'-GAUGAGGUGCCACAAAUAGAUGCUU-3'(SEQIDNO:2206)
3'-CACUACUCCACGGUGUUUAUCUACGAA-5'(SEQIDNO:1054)
CKAP5-928靶:5'-GTGATGAGGTGCCACAAATAGATGCTT-3'(SEQIDNO:1630)
5'-AAAUAGAUGCUUAUGAGCUUUUAGA-3'(SEQIDNO:2207)
3'-UGUUUAUCUACGAAUACUCGAAAAUCU-5'(SEQIDNO:1055)
CKAP5-941靶:5'-ACAAATAGATGCTTATGAGCTTTTAGA-3'(SEQIDNO:1631)
5'-AUGAGCUUUUAGAAGCUGUAGAAAU-3'(SEQIDNO:2208)
3'-AAUACUCGAAAAUCUUCGACAUCUUUA-5'(SEQIDNO:1056)
CKAP5-953靶:5'-TTATGAGCTTTTAGAAGCTGTAGAAAT-3'(SEQIDNO:1632)
5'-CCCUGGAGUCUGUAGAAGUACUAAU-3'(SEQIDNO:2209)
3'-CCGGGACCUCAGACAUCUUCAUGAUUA-5'(SEQIDNO:1057)
CKAP5-1046靶:5'-GGCCCTGGAGTCTGTAGAAGTACTAAT-3'(SEQIDNO:1633)
5'-GAGUCUGUAGAAGUACUAAUAAAAA-3'(SEQIDNO:2210)
3'-ACCUCAGACAUCUUCAUGAUUAUUUUU-5'(SEQIDNO:1058)
CKAP5-1051靶:5'-TGGAGTCTGTAGAAGTACTAATAAAAA-3'(SEQIDNO:1634)
5'-CAGAUUUAGUAAAAGCAUUAAAGAA-3'(SEQIDNO:2211)
3'-ACGUCUAAAUCAUUUUCGUAAUUUCUU-5'(SEQIDNO:1059)
CKAP5-1103靶:5'-TGCAGATTTAGTAAAAGCATTAAAGAA-3'(SEQIDNO:1635)
5'-AAAAGCAUUAAAGAAGGUUGUUGGA-3'(SEQIDNO:2212)
3'-CAUUUUCGUAAUUUCUUCCAACAACCU-5'(SEQIDNO:1060)
CKAP5-1113靶:5'-GTAAAAGCATTAAAGAAGGTTGTTGGA-3'(SEQIDNO:1636)
5'-CAUUAAAGAAGGUUGUUGGAAAGGA-3'(SEQIDNO:2213)
3'-UCGUAAUUUCUUCCAACAACCUUUCCU-5'(SEQIDNO:1061)
CKAP5-1118靶:5'-AGCATTAAAGAAGGTTGTTGGAAAGGA-3'(SEQIDNO:1637)
5'-GAAGGUUGUUGGAAAGGACACCAAU-3'(SEQIDNO:2214)
3'-UUCUUCCAACAACCUUUCCUGUGGUUA-5'(SEQIDNO:1062)
CKAP5-1125靶:5'-AAGAAGGTTGTTGGAAAGGACACCAAT-3'(SEQIDNO:1638)
5'-GGAAGAAAUUUGGACAAUAUGCAGG-3'(SEQIDNO:2215)
3'-UUCCUUCUUUAAACCUGUUAUACGUCC-5'(SEQIDNO:1063)
CKAP5-1205靶:5'-AAGGAAGAAATTTGGACAATATGCAGG-3'(SEQIDNO:1639)
5'-GUGAGGAUGUUUUAGCAGUAAUGGA-3'(SEQIDNO:2216)
3'-GUCACUCCUACAAAAUCGUCAUUACCU-5'(SEQIDNO:1064)
CKAP5-1343靶:5'-CAGTGAGGATGTTTTAGCAGTAATGGA-3'(SEQIDNO:1640)
5'-GUUUUAGCAGUAAUGGAUAAUAAAA-3'(SEQIDNO:2217)
3'-UACAAAAUCGUCAUUACCUAUUAUUUU-5'(SEQIDNO:1065)
CKAP5-1351靶:5'-ATGTTTTAGCAGTAATGGATAATAAAA-3'(SEQIDNO:1641)
5'-CAAGCAGCAGACAUCUCUUUUUAUU-3'(SEQIDNO:2218)
3'-UAGUUCGUCGUCUGUAGAGAAAAAUAA-5'(SEQIDNO:1066)
CKAP5-1386靶:5'-ATCAAGCAGCAGACATCTCTTTTTATT-3'(SEQIDNO:1642)
5'-GACAUCUCUUUUUAUUGCAAGAAGU-3'(SEQIDNO:2219)
3'-GUCUGUAGAGAAAAAUAACGUUCUUCA-5'(SEQIDNO:1067)
CKAP5-1395靶:5'-CAGACATCTCTTTTTATTGCAAGAAGT-3'(SEQIDNO:1643)
5'-UCAGAGAUGCCGCAUUUGAAGCAUU-3'(SEQIDNO:2220)
3'-UCAGUCUCUACGGCGUAAACUUCGUAA-5'(SEQIDNO:1068)
CKAP5-1514靶:5'-AGTCAGAGATGCCGCATTTGAAGCATT-3'(SEQIDNO:1644)
5'-CAUUGGGUACUGCUUUGAAGGUGGU-3'(SEQIDNO:2221)
3'-UCGUAACCCAUGACGAAACUUCCACCA-5'(SEQIDNO:1069)
CKAP5-1535靶:5'-AGCATTGGGTACTGCTTTGAAGGTGGT-3'(SEQIDNO:1645)
5'-GUGGACAAACUCAAGCUUGAUAAGA-3'(SEQIDNO:2222)
3'-UACACCUGUUUGAGUUCGAACUAUUCU-5'(SEQIDNO:1070)
CKAP5-1594靶:5'-ATGTGGACAAACTCAAGCTTGATAAGA-3'(SEQIDNO:1646)
5'-AAGAAUGUUCAGAAAAGGUAGAACU-3'(SEQIDNO:2223)
3'-GUUUCUUACAAGUCUUUUCCAUCUUGA-5'(SEQIDNO:1071)
CKAP5-1622靶:5'-CAAAGAATGTTCAGAAAAGGTAGAACT-3'(SEQIDNO:1647)
5'-UCAGAAAAGGUAGAACUGAUACAUG-3'(SEQIDNO:2224)
3'-CAAGUCUUUUCCAUCUUGACUAUGUAC-5'(SEQIDNO:1072)
CKAP5-1630靶:5'-GTTCAGAAAAGGTAGAACTGATACATG-3'(SEQIDNO:1648)
5'-GGUAGAACUGAUACAUGGUAAGAAA-3'(SEQIDNO:2225)
3'-UUCCAUCUUGACUAUGUACCAUUCUUU-5'(SEQIDNO:1073)
CKAP5-1638靶:5'-AAGGTAGAACTGATACATGGTAAGAAA-3'(SEQIDNO:1649)
5'-CAGGGAAUACUGGAACCAAGAACAA-3'(SEQIDNO:2226)
3'-GCGUCCCUUAUGACCUUGGUUCUUGUU-5'(SEQIDNO:1074)
CKAP5-1847靶:5'-CGCAGGGAATACTGGAACCAAGAACAA-3'(SEQIDNO:1650)
5'-CCUGAGCUCUCGAUAGAAGUAUGUG-3'(SEQIDNO:2227)
3'-UCGGACUCGAGAGCUAUCUUCAUACAC-5'(SEQIDNO:1075)
CKAP5-1903靶:5'-AGCCTGAGCTCTCGATAGAAGTATGTG-3'(SEQIDNO:1651)
5'-CGAUAGAAGUAUGUGAAGAAAAAGC-3'(SEQIDNO:2228)
3'-GAGCUAUCUUCAUACACUUCUUUUUCG-5'(SEQIDNO:1076)
CKAP5-1913靶:5'-CTCGATAGAAGTATGTGAAGAAAAAGC-3'(SEQIDNO:1652)
5'-CUUGACAGCAGUAACUGGAAAGAAA-3'(SEQIDNO:2229)
3'-AAGAACUGUCGUCAUUGACCUUUCUUU-5'(SEQIDNO:1077)
CKAP5-1972靶:5'-TTCTTGACAGCAGTAACTGGAAAGAAA-3'(SEQIDNO:1653)
5'-GCUAAUGGACCGAACUGAAAUGCCA-3'(SEQIDNO:2230)
3'-CUCGAUUACCUGGCUUGACUUUACGGU-5'(SEQIDNO:1078)
CKAP5-2034靶:5'-GAGCTAATGGACCGAACTGAAATGCCA-3'(SEQIDNO:1654)
5'-UUAGUGAGGAUGCUAGCCAAGAAAC-3'(SEQIDNO:2231)
3'-GUAAUCACUCCUACGAUCGGUUCUUUG-5'(SEQIDNO:1079)
CKAP5-2068靶:5'-CATTAGTGAGGATGCTAGCCAAGAAAC-3'(SEQIDNO:1655)
5'-GCCAAGAAACCUGGAUGGAAAGAAA-3'(SEQIDNO:2232)
3'-AUCGGUUCUUUGGACCUACCUUUCUUU-5'(SEQIDNO:1080)
CKAP5-2083靶:5'-TAGCCAAGAAACCTGGATGGAAAGAAA-3'(SEQIDNO:1656)
5'-GAAACCUGGAUGGAAAGAAACUAAU-3'(SEQIDNO:2233)
3'-UUCUUUGGACCUACCUUUCUUUGAUUA-5'(SEQIDNO:1081)
CKAP5-2088靶:5'-AAGAAACCTGGATGGAAAGAAACTAAT-3'(SEQIDNO:1657)
5'-GUGAUGCAAAUGAAGCUUCAUAUAG-3'(SEQIDNO:2234)
3'-UCCACUACGUUUACUUCGAAGUAUAUC-5'(SEQIDNO:1082)
CKAP5-2119靶:5'-AGGTGATGCAAATGAAGCTTCATATAG-3'(SEQIDNO:1658)
5'-AAACGUCAGCUCAGGUUGUAUUAGA-3'(SEQIDNO:2235)
3'-GUUUUGCAGUCGAGUCCAACAUAAUCU-5'(SEQIDNO:1083)
CKAP5-2177靶:5'-CAAAACGTCAGCTCAGGTTGTATTAGA-3'(SEQIDNO:1659)
5'-CAAAAGAAGCUAUGACAGCAAUAGC-3'(SEQIDNO:2236)
3'-ACGUUUUCUUCGAUACUGUCGUUAUCG-5'(SEQIDNO:1084)
CKAP5-2246靶:5'-TGCAAAAGAAGCTATGACAGCAATAGC-3'(SEQIDNO:1660)
5'-CAGCAAUAGCCGAAGCCUGUAUGUU-3'(SEQIDNO:2237)
3'-CUGUCGUUAUCGGCUUCGGACAUACAA-5'(SEQIDNO:1085)
CKAP5-2261靶:5'-GACAGCAATAGCCGAAGCCTGTATGTT-3'(SEQIDNO:1661)
5'-GAAGCCUGUAUGUUACCAUGGACUG-3'(SEQIDNO:2238)
3'-GGCUUCGGACAUACAAUGGUACCUGAC-5'(SEQIDNO:1086)
CKAP5-2272靶:5'-CCGAAGCCTGTATGTTACCATGGACTG-3'(SEQIDNO:1662)
5'-AAAAUCAGUCAGAAACUCUGAAUUG-3'(SEQIDNO:2239)
3'-GUUUUUAGUCAGUCUUUGAGACUUAAC-5'(SEQIDNO:1087)
CKAP5-2339靶:5'-CAAAAATCAGTCAGAAACTCTGAATTG-3'(SEQIDNO:1663)
5'-AGCUUUCAUUAGCAAUGUGAAGACA-3'(SEQIDNO:2240)
3'-UUUCGAAAGUAAUCGUUACACUUCUGU-5'(SEQIDNO:1088)
CKAP5-2412靶:5'-AAAGCTTTCATTAGCAATGTGAAGACA-3'(SEQIDNO:1664)
5'-GAGAAGAUGCAGGGACAAAGUCCAC-3'(SEQIDNO:2241)
3'-AACUCUUCUACGUCCCUGUUUCAGGUG-5'(SEQIDNO:1089)
CKAP5-2578靶:5'-TTGAGAAGATGCAGGGACAAAGTCCAC-3'(SEQIDNO:1665)
5'-GCAAUGAUGUCGUUGAUCUUUUGCC-3'(SEQIDNO:2242)
3'-CUCGUUACUACAGCAACUAGAAAACGG-5'(SEQIDNO:1090)
CKAP5-2684靶:5'-GAGCAATGATGTCGTTGATCTTTTGCC-3'(SEQIDNO:1666)
5'-GAAGUGGCAGGUAUUAUUAAUGACG-3'(SEQIDNO:2243)
3'-UACUUCACCGUCCAUAAUAAUUACUGC-5'(SEQIDNO:1091)
CKAP5-2797靶:5'-ATGAAGTGGCAGGTATTATTAATGACG-3'(SEQIDNO:1667)
5'-GCCUUGAAGGGUCGACUCAAUGAUU-3'(SEQIDNO:2244)
3'-GACGGAACUUCCCAGCUGAGUUACUAA-5'(SEQIDNO:1092)
CKAP5-2860靶:5'-CTGCCTTGAAGGGTCGACTCAATGATT-3'(SEQIDNO:1668)
5'-GAAGGGUCGACUCAAUGAUUCAAAU-3'(SEQIDNO:2245)
3'-AACUUCCCAGCUGAGUUACUAAGUUUA-5'(SEQIDNO:1093)
CKAP5-2865靶:5'-TTGAAGGGTCGACTCAATGATTCAAAT-3'(SEQIDNO:1669)
5'-GACUCAAUGAUUCAAAUAAAAUCUU-3'(SEQIDNO:2246)
3'-AGCUGAGUUACUAAGUUUAUUUUAGAA-5'(SEQIDNO:1094)
CKAP5-2873靶:5'-TCGACTCAATGATTCAAATAAAATCTT-3'(SEQIDNO:1670)
5'-AUGAUUCAAAUAAAAUCUUGGUACA-3'(SEQIDNO:2247)
3'-GUUACUAAGUUUAUUUUAGAACCAUGU-5'(SEQIDNO:1095)
CKAP5-2879靶:5'-CAATGATTCAAATAAAATCTTGGTACA-3'(SEQIDNO:1671)
5'-AGCCAUGGGCCCAAAUAUUAAGCAA-3'(SEQIDNO:2248)
3'-CAUCGGUACCCGGGUUUAUAAUUCGUU-5'(SEQIDNO:1096)
CKAP5-2937靶:5'-GTAGCCATGGGCCCAAATATTAAGCAA-3'(SEQIDNO:1672)
5'-AAAUAUUAAGCAACAUGUAAAAAAU-3'(SEQIDNO:2249)
3'-GGUUUAUAAUUCGUUGUACAUUUUUUA-5'(SEQIDNO:1097)
CKAP5-2949靶:5'-CCAAATATTAAGCAACATGTAAAAAAT-3'(SEQIDNO:1673)
5'-CCUUGGAGACAGCAAGAACAAUGUU-3'(SEQIDNO:2250)
3'-CAGGAACCUCUGUCGUUCUUGUUACAA-5'(SEQIDNO:1098)
CKAP5-2997靶:5'-GTCCTTGGAGACAGCAAGAACAATGTT-3'(SEQIDNO:1674)
5'-GAGACAGCAAGAACAAUGUUCGAGC-3'(SEQIDNO:2251)
3'-ACCUCUGUCGUUCUUGUUACAAGCUCG-5'(SEQIDNO:1099)
CKAP5-3002靶:5'-TGGAGACAGCAAGAACAATGTTCGAGC-3'(SEQIDNO:1675)
5'-CAUGAUGCAUUUAGGAUAUGAAAAA-3'(SEQIDNO:2252)
3'-AAGUACUACGUAAAUCCUAUACUUUUU-5'(SEQIDNO:1100)
CKAP5-3285靶:5'-TTCATGATGCATTTAGGATATGAAAAA-3'(SEQIDNO:1676)
5'-CUAGAGAAAGCCAAAGUUAACAUGC-3'(SEQIDNO:2253)
3'-ACGAUCUCUUUCGGUUUCAAUUGUACG-5'(SEQIDNO:1101)
CKAP5-3367靶:5'-TGCTAGAGAAAGCCAAAGTTAACATGC-3'(SEQIDNO:1677)
5'-GGGAAGAAGAUGCCAAGCAAAACCA-3'(SEQIDNO:2254)
3'-UUCCCUUCUUCUACGGUUCGUUUUGGU-5'(SEQIDNO:1102)
CKAP5-3571靶:5'-AAGGGAAGAAGATGCCAAGCAAAACCA-3'(SEQIDNO:1678)
5'-GAAAAGAGCAAAGGAUGAAAGAUGA-3'(SEQIDNO:2255)
3'-ACCUUUUCUCGUUUCCUACUUUCUACU-5'(SEQIDNO:1103)
CKAP5-3650靶:5'-TGGAAAAGAGCAAAGGATGAAAGATGA-3'(SEQIDNO:1679)
5'-GAGCAAAGGAUGAAAGAUGAAAAAG-3'(SEQIDNO:2256)
3'-UUCUCGUUUCCUACUUUCUACUUUUUC-5'(SEQIDNO:1104)
CKAP5-3655靶:5'-AAGAGCAAAGGATGAAAGATGAAAAAG-3'(SEQIDNO:1680)
5'-GGGAUGAAUACAUUGAGCAACUAAA-3'(SEQIDNO:2257)
3'-UGCCCUACUUAUGUAACUCGUUGAUUU-5'(SEQIDNO:1105)
CKAP5-3716靶:5'-ACGGGATGAATACATTGAGCAACTAAA-3'(SEQIDNO:1681)
5'-GAAUACAUUGAGCAACUAAAGACUC-3'(SEQIDNO:2258)
3'-UACUUAUGUAACUCGUUGAUUUCUGAG-5'(SEQIDNO:1106)
CKAP5-3721靶:5'-ATGAATACATTGAGCAACTAAAGACTC-3'(SEQIDNO:1682)
5'-AGUGGCUUACCCUGAGGUUUUUUGA-3'(SEQIDNO:2259)
3'-UUUCACCGAAUGGGACUCCAAAAAACU-5'(SEQIDNO:1107)
CKAP5-3890靶:5'-AAAGTGGCTTACCCTGAGGTTTTTTGA-3'(SEQIDNO:1683)
5'-CCUGAGGUUUUUUGACACCAAUACA-3'(SEQIDNO:2260)
3'-UGGGACUCCAAAAAACUGUGGUUAUGU-5'(SEQIDNO:1108)
CKAP5-3900靶:5'-ACCCTGAGGTTTTTTGACACCAATACA-3'(SEQIDNO:1684)
5'-CAAUACAAGCGUCCUGAUGAAAGCA-3'(SEQIDNO:2261)
3'-UGGUUAUGUUCGCAGGACUACUUUCGU-5'(SEQIDNO:1109)
CKAP5-3918靶:5'-ACCAATACAAGCGTCCTGATGAAAGCA-3'(SEQIDNO:1685)
5'-GUCCUGAUGAAAGCACUAGAAUAUU-3'(SEQIDNO:2262)
3'-CGCAGGACUACUUUCGUGAUCUUAUAA-5'(SEQIDNO:1110)
CKAP5-3928靶:5'-GCGTCCTGATGAAAGCACTAGAATATT-3'(SEQIDNO:1686)
5'-AUGAAAGCACUAGAAUAUUUAAAAU-3'(SEQIDNO:2263)
3'-ACUACUUUCGUGAUCUUAUAAAUUUUA-5'(SEQIDNO:1111)
CKAP5-3934靶:5'-TGATGAAAGCACTAGAATATTTAAAAT-3'(SEQIDNO:1687)
5'-GAAAUCUUUCUGAAAAGGAUAUGAG-3'(SEQIDNO:2264)
3'-ACCUUUAGAAAGACUUUUCCUAUACUC-5'(SEQIDNO:1112)
CKAP5-4367靶:5'-TGGAAATCTTTCTGAAAAGGATATGAG-3'(SEQIDNO:1688)
5'-GAAAAGGAUAUGAGCAUGCUCGAGG-3'(SEQIDNO:2265)
3'-GACUUUUCCUAUACUCGUACGAGCUCC-5'(SEQIDNO:1113)
CKAP5-4378靶:5'-CTGAAAAGGATATGAGCATGCTCGAGG-3'(SEQIDNO:1689)
5'-GCUCCAAUGCCAACAUGUUACGCAA-3'(SEQIDNO:2266)
3'-UUCGAGGUUACGGUUGUACAAUGCGUU-5'(SEQIDNO:1114)
CKAP5-4487靶:5'-AAGCTCCAATGCCAACATGTTACGCAA-3'(SEQIDNO:1690)
5'-AAUGCCAACAUGUUACGCAAGGGAC-3'(SEQIDNO:2267)
3'-GGUUACGGUUGUACAAUGCGUUCCCUG-5'(SEQIDNO:1115)
CKAP5-4492靶:5'-CCAATGCCAACATGTTACGCAAGGGAC-3'(SEQIDNO:1691)
5'-GUGAAAUGCCAGAACUUGUUCAGCA-3'(SEQIDNO:2268)
3'-UACACUUUACGGUCUUGAACAAGUCGU-5'(SEQIDNO:1116)
CKAP5-4649靶:5'-ATGTGAAATGCCAGAACTTGTTCAGCA-3'(SEQIDNO:1692)
5'-CAGAACUUGUUCAGCACAAACUGGA-3'(SEQIDNO:2269)
3'-CGGUCUUGAACAAGUCGUGUUUGACCU-5'(SEQIDNO:1117)
CKAP5-4658靶:5'-GCCAGAACTTGTTCAGCACAAACTGGA-3'(SEQIDNO:1693)
5'-ACAAACUGGAUGACAUUUUUGAGCC-3'(SEQIDNO:2270)
3'-CGUGUUUGACCUACUGUAAAAACUCGG-5'(SEQIDNO:1118)
CKAP5-4673靶:5'-GCACAAACTGGATGACATTTTTGAGCC-3'(SEQIDNO:1694)
5'-GAUGACAUUUUUGAGCCAGUCCUUA-3'(SEQIDNO:2271)
3'-ACCUACUGUAAAAACUCGGUCAGGAAU-5'(SEQIDNO:1119)
CKAP5-4681靶:5'-TGGATGACATTTTTGAGCCAGTCCTTA-3'(SEQIDNO:1695)
5'-CAUUUUUGAGCCAGUCCUUAUUCCU-3'(SEQIDNO:2272)
3'-CUGUAAAAACUCGGUCAGGAAUAAGGA-5'(SEQIDNO:1120)
CKAP5-4686靶:5'-GACATTTTTGAGCCAGTCCTTATTCCT-3'(SEQIDNO:1696)
5'-GAGCCAGUCCUUAUUCCUGAACCCA-3'(SEQIDNO:2273)
3'-AACUCGGUCAGGAAUAAGGACUUGGGU-5'(SEQIDNO:1121)
CKAP5-4693靶:5'-TTGAGCCAGTCCTTATTCCTGAACCCA-3'(SEQIDNO:1697)
5'-CUGGAGUACUAAAAGACCUAAUGCA-3'(SEQIDNO:2274)
3'-GUGACCUCAUGAUUUUCUGGAUUACGU-5'(SEQIDNO:1122)
CKAP5-5057靶:5'-CACTGGAGTACTAAAAGACCTAATGCA-3'(SEQIDNO:1698)
5'-GUGAAGGUUCUGGAGAAGUCAGACC-3'(SEQIDNO:2275)
3'-ACCACUUCCAAGACCUCUUCAGUCUGG-5'(SEQIDNO:1123)
CKAP5-5167靶:5'-TGGTGAAGGTTCTGGAGAAGTCAGACC-3'(SEQIDNO:1699)
5'-CCUGAGUGCCCUACUUGUUUUGCUC-3'(SEQIDNO:2276)
3'-UAGGACUCACGGGAUGAACAAAACGAG-5'(SEQIDNO:1124)
CKAP5-5202靶:5'-ATCCTGAGTGCCCTACTTGTTTTGCTC-3'(SEQIDNO:1700)
5'-CAGCCAGUUCUCCCAAAUUCUCAGA-3'(SEQIDNO:2277)
3'-UUGUCGGUCAAGAGGGUUUAAGAGUCU-5'(SEQIDNO:1125)
CKAP5-5246靶:5'-AACAGCCAGTTCTCCCAAATTCTCAGA-3'(SEQIDNO:1701)
5'-GCUUGUUAUGAAGUGUCUCUGGAGA-3'(SEQIDNO:2278)
3'-CUCGAACAAUACUUCACAGAGACCUCU-5'(SEQIDNO:1126)
CKAP5-5271靶:5'-GAGCTTGTTATGAAGTGTCTCTGGAGA-3'(SEQIDNO:1702)
5'-CGACUGUUGCCUGAUACCAUCAAUA-3'(SEQIDNO:2279)
3'-AAGCUGACAACGGACUAUGGUAGUUAU-5'(SEQIDNO:1127)
CKAP5-5302靶:5'-TTCGACTGTTGCCTGATACCATCAATA-3'(SEQIDNO:1703)
5'-GUUGCCUGAUACCAUCAAUAGCAUU-3'(SEQIDNO:2280)
3'-GACAACGGACUAUGGUAGUUAUCGUAA-5'(SEQIDNO:1128)
CKAP5-5307靶:5'-CTGTTGCCTGATACCATCAATAGCATT-3'(SEQIDNO:1704)
5'-CUGAUACCAUCAAUAGCAUUAACCU-3'(SEQIDNO:2281)
3'-CGGACUAUGGUAGUUAUCGUAAUUGGA-5'(SEQIDNO:1129)
CKAP5-5312靶:5'-GCCTGATACCATCAATAGCATTAACCT-3'(SEQIDNO:1705)
5'-AUCAAUAGCAUUAACCUAGACAGAA-3'(SEQIDNO:2282)
3'-GGUAGUUAUCGUAAUUGGAUCUGUCUU-5'(SEQIDNO:1130)
CKAP5-5320靶:5'-CCATCAATAGCATTAACCTAGACAGAA-3'(SEQIDNO:1706)
5'-UAGCAUUAACCUAGACAGAAUUCUU-3'(SEQIDNO:2283)
3'-UUAUCGUAAUUGGAUCUGUCUUAAGAA-5'(SEQIDNO:1131)
CKAP5-5325靶:5'-AATAGCATTAACCTAGACAGAATTCTT-3'(SEQIDNO:1707)
5'-GAAUUCUUCUGGAUAUCCACAUUUU-3'(SEQIDNO:2284)
3'-GUCUUAAGAAGACCUAUAGGUGUAAAA-5'(SEQIDNO:1132)
CKAP5-5342靶:5'-CAGAATTCTTCTGGATATCCACATTTT-3'(SEQIDNO:1708)
5'-CUGGAUAUCCACAUUUUCAUGAAGG-3'(SEQIDNO:2285)
3'-AAGACCUAUAGGUGUAAAAGUACUUCC-5'(SEQIDNO:1133)
CKAP5-5350靶:5'-TTCTGGATATCCACATTTTCATGAAGG-3'(SEQIDNO:1709)
5'-AAAGAGAAACUGAAGCAAUGCAAAA-3'(SEQIDNO:2286)
3'-GGUUUCUCUUUGACUUCGUUACGUUUU-5'(SEQIDNO:1134)
CKAP5-5383靶:5'-CCAAAGAGAAACTGAAGCAATGCAAAA-3'(SEQIDNO:1710)
5'-GAAACUGAAGCAAUGCAAAAGUGAA-3'(SEQIDNO:2287)
3'-CUCUUUGACUUCGUUACGUUUUCACUU-5'(SEQIDNO:1135)
CKAP5-5388靶:5'-GAGAAACTGAAGCAATGCAAAAGTGAA-3'(SEQIDNO:1711)
5'-CGGAUGAUGAAGCACAGUAUGGACC-3'(SEQIDNO:2288)
3'-CGGCCUACUACUUCGUGUCAUACCUGG-5'(SEQIDNO:1136)
CKAP5-5536靶:5'-GCCGGATGATGAAGCACAGTATGGACC-3'(SEQIDNO:1712)
5'-CAGAAAAGGGAGCAUCUCGAAUAGA-3'(SEQIDNO:2289)
3'-UUGUCUUUUCCCUCGUAGAGCUUAUCU-5'(SEQIDNO:1137)
CKAP5-5588靶:5'-AACAGAAAAGGGAGCATCTCGAATAGA-3'(SEQIDNO:1713)
5'-AGGGAGCAUCUCGAAUAGAUGAAAA-3'(SEQIDNO:2290)
3'-UUUCCCUCGUAGAGCUUAUCUACUUUU-5'(SEQIDNO:1138)
CKAP5-5594靶:5'-AAAGGGAGCATCTCGAATAGATGAAAA-3'(SEQIDNO:1714)
5'-GCAUCUCGAAUAGAUGAAAAAUCAU-3'(SEQIDNO:2291)
3'-CUCGUAGAGCUUAUCUACUUUUUAGUA-5'(SEQIDNO:1139)
CKAP5-5599靶:5'-GAGCATCTCGAATAGATGAAAAATCAT-3'(SEQIDNO:1715)
5'-GAGGGACUAGCAGAGUUAUAUGAAU-3'(SEQIDNO:2292)
3'-UUCUCCCUGAUCGUCUCAAUAUACUUA-5'(SEQIDNO:1140)
CKAP5-5692靶:5'-AAGAGGGACTAGCAGAGTTATATGAAT-3'(SEQIDNO:1716)
5'-ACUCAGAUGCUGACAUUGAACCAUU-3'(SEQIDNO:2293)
3'-UAUGAGUCUACGACUGUAACUUGGUAA-5'(SEQIDNO:1141)
CKAP5-5729靶:5'-ATACTCAGATGCTGACATTGAACCATT-3'(SEQIDNO:1717)
5'-CAUUCAGACCUGGAUUCUAACCAGA-3'(SEQIDNO:2294)
3'-UCGUAAGUCUGGACCUAAGAUUGGUCU-5'(SEQIDNO:1142)
CKAP5-6130靶:5'-AGCATTCAGACCTGGATTCTAACCAGA-3'(SEQIDNO:1718)
5'-GACCUGGAUUCUAACCAGACUCACU-3'(SEQIDNO:2295)
3'-GUCUGGACCUAAGAUUGGUCUGAGUGA-5'(SEQIDNO:1143)
CKAP5-6136靶:5'-CAGACCTGGATTCTAACCAGACTCACT-3'(SEQIDNO:1719)
5'-GGAUUCUAACCAGACUCACUCUUCA-3'(SEQIDNO:2296)
3'-GACCUAAGAUUGGUCUGAGUGAGAAGU-5'(SEQIDNO:1144)
CKAP5-6141靶:5'-CTGGATTCTAACCAGACTCACTCTTCA-3'(SEQIDNO:1720)
5'-GCUAACAUAGACGACUUGAAAAAAA-3'(SEQIDNO:2297)
3'-GUCGAUUGUAUCUGCUGAACUUUUUUU-5'(SEQIDNO:1145)
CKAP5-6193靶:5'-CAGCTAACATAGACGACTTGAAAAAAA-3'(SEQIDNO:1721)
5'-CAUAGACGACUUGAAAAAAAGACUG-3'(SEQIDNO:2298)
3'-UUGUAUCUGCUGAACUUUUUUUCUGAC-5'(SEQIDNO:1146)
CKAP5-6198靶:5'-AACATAGACGACTTGAAAAAAAGACTG-3'(SEQIDNO:1722)
5'-CUAGAAGUCCUCAUAGUUUAAAAUG-3'(SEQIDNO:2299)
3'-UUGAUCUUCAGGAGUAUCAAAUUUUAC-5'(SEQIDNO:1147)
CKAP5-6294靶:5'-AACTAGAAGTCCTCATAGTTTAAAATG-3'(SEQIDNO:1723)
5'-GAUGAGUUUAGUGUACAGACUUGUA-3'(SEQIDNO:2300)
3'-ACCUACUCAAAUCACAUGUCUGAACAU-5'(SEQIDNO:1148)
CKAP5-6459靶:5'-TGGATGAGTTTAGTGTACAGACTTGTA-3'(SEQIDNO:1724)
5'-CAGAUCCUUUUCUUUUCUUUUUAAU-3'(SEQIDNO:2301)
3'-GGGUCUAGGAAAAGAAAAGAAAAAUUA-5'(SEQIDNO:1149)
CKAP5-6517靶:5'-CCCAGATCCTTTTCTTTTCTTTTTAAT-3'(SEQIDNO:1725)
5'-UGCUCAUUUGUAAAAUUGUCCUAAU-3'(SEQIDNO:2302)
3'-UAACGAGUAAACAUUUUAACAGGAUUA-5'(SEQIDNO:1150)
CKAP5-6542靶:5'-ATTGCTCATTTGTAAAATTGTCCTAAT-3'(SEQIDNO:1726)
5'-GAAGGGUCACUGUAUUCUGUAUGAA-3'(SEQIDNO:2303)
3'-GACUUCCCAGUGACAUAAGACAUACUU-5'(SEQIDNO:1151)
CKAP5-6648靶:5'-CTGAAGGGTCACTGTATTCTGTATGAA-3'(SEQIDNO:1727)
5'-GUCACUGUAUUCUGUAUGAAUGCAU-3'(SEQIDNO:2304)
3'-CCCAGUGACAUAAGACAUACUUACGUA-5'(SEQIDNO:1152)
CKAP5-6653靶:5'-GGGTCACTGTATTCTGTATGAATGCAT-3'(SEQIDNO:1728)
表4:CKAP5mRNA中的DsiRNA靶序列(21mer)
CKAP5-14321nt靶:5'-UGGAAGCACAAUGGGAGAUGA-3'(SEQIDNO:2305)
CKAP5-14521nt靶:5'-GAAGCACAAUGGGAGAUGACA-3'(SEQIDNO:2306)
CKAP5-14721nt靶:5'-AGCACAAUGGGAGAUGACAGU-3'(SEQIDNO:2307)
CKAP5-14921nt靶:5'-CACAAUGGGAGAUGACAGUGA-3'(SEQIDNO:2308)
CKAP5-15121nt靶:5'-CAAUGGGAGAUGACAGUGAGU-3'(SEQIDNO:2309)
CKAP5-15321nt靶:5'-AUGGGAGAUGACAGUGAGUGG-3'(SEQIDNO:2310)
CKAP5-15521nt靶:5'-GGGAGAUGACAGUGAGUGGUU-3'(SEQIDNO:2311)
CKAP5-15721nt靶:5'-GAGAUGACAGUGAGUGGUUGA-3'(SEQIDNO:2312)
CKAP5-15921nt靶:5'-GAUGACAGUGAGUGGUUGAAA-3'(SEQIDNO:2313)
CKAP5-24621nt靶:5'-CUGAAGAUCUUCCAGAAAAUA-3'(SEQIDNO:2314)
CKAP5-24821nt靶:5'-GAAGAUCUUCCAGAAAAUAAA-3'(SEQIDNO:2315)
CKAP5-25021nt靶:5'-AGAUCUUCCAGAAAAUAAAGG-3'(SEQIDNO:2316)
CKAP5-25221nt靶:5'-AUCUUCCAGAAAAUAAAGGAU-3'(SEQIDNO:2317)
CKAP5-25421nt靶:5'-CUUCCAGAAAAUAAAGGAUGA-3'(SEQIDNO:2318)
CKAP5-25621nt靶:5'-UCCAGAAAAUAAAGGAUGAAA-3'(SEQIDNO:2319)
CKAP5-25821nt靶:5'-CAGAAAAUAAAGGAUGAAAAG-3'(SEQIDNO:2320)
CKAP5-26021nt靶:5'-GAAAAUAAAGGAUGAAAAGAG-3'(SEQIDNO:2321)
CKAP5-30821nt靶:5'-GAUCAAAAAAUUUGUCACUGA-3'(SEQIDNO:2322)
CKAP5-31021nt靶:5'-UCAAAAAAUUUGUCACUGAUU-3'(SEQIDNO:2323)
CKAP5-31221nt靶:5'-AAAAAAUUUGUCACUGAUUCC-3'(SEQIDNO:2324)
CKAP5-31421nt靶:5'-AAAAUUUGUCACUGAUUCCAA-3'(SEQIDNO:2325)
CKAP5-31621nt靶:5'-AAUUUGUCACUGAUUCCAAUG-3'(SEQIDNO:2326)
CKAP5-31821nt靶:5'-UUUGUCACUGAUUCCAAUGCA-3'(SEQIDNO:2327)
CKAP5-32021nt靶:5'-UGUCACUGAUUCCAAUGCAGU-3'(SEQIDNO:2328)
CKAP5-32221nt靶:5'-UCACUGAUUCCAAUGCAGUGG-3'(SEQIDNO:2329)
CKAP5-32421nt靶:5'-ACUGAUUCCAAUGCAGUGGUU-3'(SEQIDNO:2330)
CKAP5-32621nt靶:5'-UGAUUCCAAUGCAGUGGUUCA-3'(SEQIDNO:2331)
CKAP5-32821nt靶:5'-AUUCCAAUGCAGUGGUUCAAU-3'(SEQIDNO:2332)
CKAP5-33021nt靶:5'-UCCAAUGCAGUGGUUCAAUUG-3'(SEQIDNO:2333)
CKAP5-33221nt靶:5'-CAAUGCAGUGGUUCAAUUGAA-3'(SEQIDNO:2334)
CKAP5-33421nt靶:5'-AUGCAGUGGUUCAAUUGAAAG-3'(SEQIDNO:2335)
CKAP5-33621nt靶:5'-GCAGUGGUUCAAUUGAAAGGA-3'(SEQIDNO:2336)
CKAP5-56521nt靶:5'-CCAAGAUCAUAGUGGCCUGUA-3'(SEQIDNO:2337)
CKAP5-56721nt靶:5'-AAGAUCAUAGUGGCCUGUAUA-3'(SEQIDNO:2338)
CKAP5-56921nt靶:5'-GAUCAUAGUGGCCUGUAUAGA-3'(SEQIDNO:2339)
CKAP5-59021nt靶:5'-GACACUGAGGAAAGCCUUAAG-3'(SEQIDNO:2340)
CKAP5-59221nt靶:5'-CACUGAGGAAAGCCUUAAGUG-3'(SEQIDNO:2341)
CKAP5-59421nt靶:5'-CUGAGGAAAGCCUUAAGUGAA-3'(SEQIDNO:2342)
CKAP5-59621nt靶:5'-GAGGAAAGCCUUAAGUGAAUU-3'(SEQIDNO:2343)
CKAP5-59821nt靶:5'-GGAAAGCCUUAAGUGAAUUUG-3'(SEQIDNO:2344)
CKAP5-60021nt靶:5'-AAAGCCUUAAGUGAAUUUGGU-3'(SEQIDNO:2345)
CKAP5-60221nt靶:5'-AGCCUUAAGUGAAUUUGGUUC-3'(SEQIDNO:2346)
CKAP5-60421nt靶:5'-CCUUAAGUGAAUUUGGUUCCA-3'(SEQIDNO:2347)
CKAP5-60621nt靶:5'-UUAAGUGAAUUUGGUUCCAAA-3'(SEQIDNO:2348)
CKAP5-60821nt靶:5'-AAGUGAAUUUGGUUCCAAAAU-3'(SEQIDNO:2349)
CKAP5-61021nt靶:5'-GUGAAUUUGGUUCCAAAAUCA-3'(SEQIDNO:2350)
CKAP5-61221nt靶:5'-GAAUUUGGUUCCAAAAUCAUC-3'(SEQIDNO:2351)
CKAP5-84721nt靶:5'-UUCGUUCCCAACAAGAACUAG-3'(SEQIDNO:2352)
CKAP5-84921nt靶:5'-CGUUCCCAACAAGAACUAGAA-3'(SEQIDNO:2353)
CKAP5-85121nt靶:5'-UUCCCAACAAGAACUAGAAGC-3'(SEQIDNO:2354)
CKAP5-85321nt靶:5'-CCCAACAAGAACUAGAAGCUA-3'(SEQIDNO:2355)
CKAP5-85521nt靶:5'-CAACAAGAACUAGAAGCUAAA-3'(SEQIDNO:2356)
CKAP5-88421nt靶:5'-ACAACAGUCUGCUGGUGGAGA-3'(SEQIDNO:2357)
CKAP5-88621nt靶:5'-AACAGUCUGCUGGUGGAGAUG-3'(SEQIDNO:2358)
CKAP5-91421nt靶:5'-AGGUGGUGAUGAUGGUGAUGA-3'(SEQIDNO:2359)
CKAP5-91621nt靶:5'-GUGGUGAUGAUGGUGAUGAGG-3'(SEQIDNO:2360)
CKAP5-97621nt靶:5'-AAAUCCUUUCCAAACUUCCCA-3'(SEQIDNO:2361)
CKAP5-97821nt靶:5'-AUCCUUUCCAAACUUCCCAAA-3'(SEQIDNO:2362)
CKAP5-98021nt靶:5'-CCUUUCCAAACUUCCCAAAGA-3'(SEQIDNO:2363)
CKAP5-98221nt靶:5'-UUUCCAAACUUCCCAAAGACU-3'(SEQIDNO:2364)
CKAP5-98421nt靶:5'-UCCAAACUUCCCAAAGACUUU-3'(SEQIDNO:2365)
CKAP5-98621nt靶:5'-CAAACUUCCCAAAGACUUUUA-3'(SEQIDNO:2366)
CKAP5-98821nt靶:5'-AACUUCCCAAAGACUUUUAUG-3'(SEQIDNO:2367)
CKAP5-99021nt靶:5'-CUUCCCAAAGACUUUUAUGAC-3'(SEQIDNO:2368)
CKAP5-99221nt靶:5'-UCCCAAAGACUUUUAUGACAA-3'(SEQIDNO:2369)
CKAP5-99421nt靶:5'-CCAAAGACUUUUAUGACAAAA-3'(SEQIDNO:2370)
CKAP5-99621nt靶:5'-AAAGACUUUUAUGACAAAAUU-3'(SEQIDNO:2371)
CKAP5-99821nt靶:5'-AGACUUUUAUGACAAAAUUGA-3'(SEQIDNO:2372)
CKAP5-100021nt靶:5'-ACUUUUAUGACAAAAUUGAGG-3'(SEQIDNO:2373)
CKAP5-100221nt靶:5'-UUUUAUGACAAAAUUGAGGCA-3'(SEQIDNO:2374)
CKAP5-100421nt靶:5'-UUAUGACAAAAUUGAGGCAAA-3'(SEQIDNO:2375)
CKAP5-102521nt靶:5'-AAAAUGGCAAGAGAGAAAAGA-3'(SEQIDNO:2376)
CKAP5-112721nt靶:5'-GAAGGUUGUUGGAAAGGACAC-3'(SEQIDNO:2377)
CKAP5-112921nt靶:5'-AGGUUGUUGGAAAGGACACCA-3'(SEQIDNO:2378)
CKAP5-113121nt靶:5'-GUUGUUGGAAAGGACACCAAU-3'(SEQIDNO:2379)
CKAP5-113321nt靶:5'-UGUUGGAAAGGACACCAAUGU-3'(SEQIDNO:2380)
CKAP5-113521nt靶:5'-UUGGAAAGGACACCAAUGUCA-3'(SEQIDNO:2381)
CKAP5-113721nt靶:5'-GGAAAGGACACCAAUGUCAUG-3'(SEQIDNO:2382)
CKAP5-113921nt靶:5'-AAAGGACACCAAUGUCAUGUU-3'(SEQIDNO:2383)
CKAP5-114121nt靶:5'-AGGACACCAAUGUCAUGUUGG-3'(SEQIDNO:2384)
CKAP5-116221nt靶:5'-UGGCUUUGGCAGCAAAAUGUC-3'(SEQIDNO:2385)
CKAP5-116421nt靶:5'-GCUUUGGCAGCAAAAUGUCUU-3'(SEQIDNO:2386)
CKAP5-116621nt靶:5'-UUUGGCAGCAAAAUGUCUUAC-3'(SEQIDNO:2387)
CKAP5-116821nt靶:5'-UGGCAGCAAAAUGUCUUACUG-3'(SEQIDNO:2388)
CKAP5-117021nt靶:5'-GCAGCAAAAUGUCUUACUGGC-3'(SEQIDNO:2389)
CKAP5-120821nt靶:5'-GAAGAAAUUUGGACAAUAUGC-3'(SEQIDNO:2390)
CKAP5-121021nt靶:5'-AGAAAUUUGGACAAUAUGCAG-3'(SEQIDNO:2391)
CKAP5-121221nt靶:5'-AAAUUUGGACAAUAUGCAGGA-3'(SEQIDNO:2392)
CKAP5-121421nt靶:5'-AUUUGGACAAUAUGCAGGACA-3'(SEQIDNO:2393)
CKAP5-121621nt靶:5'-UUGGACAAUAUGCAGGACAUG-3'(SEQIDNO:2394)
CKAP5-121821nt靶:5'-GGACAAUAUGCAGGACAUGUU-3'(SEQIDNO:2395)
CKAP5-122021nt靶:5'-ACAAUAUGCAGGACAUGUUGU-3'(SEQIDNO:2396)
CKAP5-122221nt靶:5'-AAUAUGCAGGACAUGUUGUGC-3'(SEQIDNO:2397)
CKAP5-122421nt靶:5'-UAUGCAGGACAUGUUGUGCCA-3'(SEQIDNO:2398)
CKAP5-122621nt靶:5'-UGCAGGACAUGUUGUGCCAAC-3'(SEQIDNO:2399)
CKAP5-127421nt靶:5'-ACCUCAAGUGGUACAAGCCCU-3'(SEQIDNO:2400)
CKAP5-127621nt靶:5'-CUCAAGUGGUACAAGCCCUGC-3'(SEQIDNO:2401)
CKAP5-127821nt靶:5'-CAAGUGGUACAAGCCCUGCAG-3'(SEQIDNO:2402)
CKAP5-128021nt靶:5'-AGUGGUACAAGCCCUGCAGGA-3'(SEQIDNO:2403)
CKAP5-128221nt靶:5'-UGGUACAAGCCCUGCAGGAGG-3'(SEQIDNO:2404)
CKAP5-128421nt靶:5'-GUACAAGCCCUGCAGGAGGCA-3'(SEQIDNO:2405)
CKAP5-128621nt靶:5'-ACAAGCCCUGCAGGAGGCAAU-3'(SEQIDNO:2406)
CKAP5-128821nt靶:5'-AAGCCCUGCAGGAGGCAAUUG-3'(SEQIDNO:2407)
CKAP5-129021nt靶:5'-GCCCUGCAGGAGGCAAUUGAU-3'(SEQIDNO:2408)
CKAP5-129221nt靶:5'-CCUGCAGGAGGCAAUUGAUGC-3'(SEQIDNO:2409)
CKAP5-129421nt靶:5'-UGCAGGAGGCAAUUGAUGCAA-3'(SEQIDNO:2410)
CKAP5-129621nt靶:5'-CAGGAGGCAAUUGAUGCAAUC-3'(SEQIDNO:2411)
CKAP5-129821nt靶:5'-GGAGGCAAUUGAUGCAAUCUU-3'(SEQIDNO:2412)
CKAP5-130021nt靶:5'-AGGCAAUUGAUGCAAUCUUCC-3'(SEQIDNO:2413)
CKAP5-132121nt靶:5'-UUACUACCACACUACAGAACA-3'(SEQIDNO:2414)
CKAP5-132321nt靶:5'-ACUACCACACUACAGAACAUC-3'(SEQIDNO:2415)
CKAP5-132521nt靶:5'-UACCACACUACAGAACAUCAG-3'(SEQIDNO:2416)
CKAP5-132721nt靶:5'-CCACACUACAGAACAUCAGUG-3'(SEQIDNO:2417)
CKAP5-132921nt靶:5'-ACACUACAGAACAUCAGUGAG-3'(SEQIDNO:2418)
CKAP5-133121nt靶:5'-ACUACAGAACAUCAGUGAGGA-3'(SEQIDNO:2419)
CKAP5-133321nt靶:5'-UACAGAACAUCAGUGAGGAUG-3'(SEQIDNO:2420)
CKAP5-135421nt靶:5'-UUUUAGCAGUAAUGGAUAAUA-3'(SEQIDNO:2421)
CKAP5-135621nt靶:5'-UUAGCAGUAAUGGAUAAUAAA-3'(SEQIDNO:2422)
CKAP5-135821nt靶:5'-AGCAGUAAUGGAUAAUAAAAA-3'(SEQIDNO:2423)
CKAP5-136021nt靶:5'-CAGUAAUGGAUAAUAAAAAUC-3'(SEQIDNO:2424)
CKAP5-138121nt靶:5'-CAACCAUCAAGCAGCAGACAU-3'(SEQIDNO:2425)
CKAP5-148021nt靶:5'-CACUACUUAAGCACAUCAAUG-3'(SEQIDNO:2426)
CKAP5-148221nt靶:5'-CUACUUAAGCACAUCAAUGAU-3'(SEQIDNO:2427)
CKAP5-148421nt靶:5'-ACUUAAGCACAUCAAUGAUUC-3'(SEQIDNO:2428)
CKAP5-148621nt靶:5'-UUAAGCACAUCAAUGAUUCUG-3'(SEQIDNO:2429)
CKAP5-148821nt靶:5'-AAGCACAUCAAUGAUUCUGCU-3'(SEQIDNO:2430)
CKAP5-149021nt靶:5'-GCACAUCAAUGAUUCUGCUCC-3'(SEQIDNO:2431)
CKAP5-149221nt靶:5'-ACAUCAAUGAUUCUGCUCCUG-3'(SEQIDNO:2432)
CKAP5-149421nt靶:5'-AUCAAUGAUUCUGCUCCUGAA-3'(SEQIDNO:2433)
CKAP5-149621nt靶:5'-CAAUGAUUCUGCUCCUGAAGU-3'(SEQIDNO:2434)
CKAP5-149821nt靶:5'-AUGAUUCUGCUCCUGAAGUCA-3'(SEQIDNO:2435)
CKAP5-150021nt靶:5'-GAUUCUGCUCCUGAAGUCAGA-3'(SEQIDNO:2436)
CKAP5-150221nt靶:5'-UUCUGCUCCUGAAGUCAGAGA-3'(SEQIDNO:2437)
CKAP5-150421nt靶:5'-CUGCUCCUGAAGUCAGAGAUG-3'(SEQIDNO:2438)
CKAP5-161721nt靶:5'-AAGAUCAAAGAAUGUUCAGAA-3'(SEQIDNO:2439)
CKAP5-161921nt靶:5'-GAUCAAAGAAUGUUCAGAAAA-3'(SEQIDNO:2440)
CKAP5-209021nt靶:5'-GAAACCUGGAUGGAAAGAAAC-3'(SEQIDNO:2441)
CKAP5-209221nt靶:5'-AACCUGGAUGGAAAGAAACUA-3'(SEQIDNO:2442)
CKAP5-209421nt靶:5'-CCUGGAUGGAAAGAAACUAAU-3'(SEQIDNO:2443)
CKAP5-209621nt靶:5'-UGGAUGGAAAGAAACUAAUUU-3'(SEQIDNO:2444)
CKAP5-209821nt靶:5'-GAUGGAAAGAAACUAAUUUUC-3'(SEQIDNO:2445)
CKAP5-210021nt靶:5'-UGGAAAGAAACUAAUUUUCAG-3'(SEQIDNO:2446)
CKAP5-210221nt靶:5'-GAAAGAAACUAAUUUUCAGGU-3'(SEQIDNO:2447)
CKAP5-210421nt靶:5'-AAGAAACUAAUUUUCAGGUGA-3'(SEQIDNO:2448)
CKAP5-210621nt靶:5'-GAAACUAAUUUUCAGGUGAUG-3'(SEQIDNO:2449)
CKAP5-210821nt靶:5'-AACUAAUUUUCAGGUGAUGCA-3'(SEQIDNO:2450)
CKAP5-214421nt靶:5'-AGUUGCUUUGAUUGCCCAGAA-3'(SEQIDNO:2451)
CKAP5-214621nt靶:5'-UUGCUUUGAUUGCCCAGAAGG-3'(SEQIDNO:2452)
CKAP5-214821nt靶:5'-GCUUUGAUUGCCCAGAAGGGA-3'(SEQIDNO:2453)
CKAP5-215021nt靶:5'-UUUGAUUGCCCAGAAGGGAAA-3'(SEQIDNO:2454)
CKAP5-215221nt靶:5'-UGAUUGCCCAGAAGGGAAAUU-3'(SEQIDNO:2455)
CKAP5-215421nt靶:5'-AUUGCCCAGAAGGGAAAUUUU-3'(SEQIDNO:2456)
CKAP5-215621nt靶:5'-UGCCCAGAAGGGAAAUUUUUC-3'(SEQIDNO:2457)
CKAP5-221221nt靶:5'-UGGACAAGAUUGGAGAUGUGA-3'(SEQIDNO:2458)
CKAP5-221421nt靶:5'-GACAAGAUUGGAGAUGUGAAA-3'(SEQIDNO:2459)
CKAP5-221621nt靶:5'-CAAGAUUGGAGAUGUGAAAUG-3'(SEQIDNO:2460)
CKAP5-221821nt靶:5'-AGAUUGGAGAUGUGAAAUGUG-3'(SEQIDNO:2461)
CKAP5-222021nt靶:5'-AUUGGAGAUGUGAAAUGUGGG-3'(SEQIDNO:2462)
CKAP5-222221nt靶:5'-UGGAGAUGUGAAAUGUGGGAA-3'(SEQIDNO:2463)
CKAP5-222421nt靶:5'-GAGAUGUGAAAUGUGGGAACA-3'(SEQIDNO:2464)
CKAP5-222621nt靶:5'-GAUGUGAAAUGUGGGAACAAU-3'(SEQIDNO:2465)
CKAP5-222821nt靶:5'-UGUGAAAUGUGGGAACAAUGC-3'(SEQIDNO:2466)
CKAP5-223021nt靶:5'-UGAAAUGUGGGAACAAUGCAA-3'(SEQIDNO:2467)
CKAP5-223221nt靶:5'-AAAUGUGGGAACAAUGCAAAA-3'(SEQIDNO:2468)
CKAP5-223421nt靶:5'-AUGUGGGAACAAUGCAAAAGA-3'(SEQIDNO:2469)
CKAP5-223621nt靶:5'-GUGGGAACAAUGCAAAAGAAG-3'(SEQIDNO:2470)
CKAP5-240021nt靶:5'-GGGUUGAAUGUCAAAGCUUUC-3'(SEQIDNO:2471)
CKAP5-240221nt靶:5'-GUUGAAUGUCAAAGCUUUCAU-3'(SEQIDNO:2472)
CKAP5-240421nt靶:5'-UGAAUGUCAAAGCUUUCAUUA-3'(SEQIDNO:2473)
CKAP5-240621nt靶:5'-AAUGUCAAAGCUUUCAUUAGC-3'(SEQIDNO:2474)
CKAP5-240821nt靶:5'-UGUCAAAGCUUUCAUUAGCAA-3'(SEQIDNO:2475)
CKAP5-248021nt靶:5'-AACCCUGCUUGGCGUGAUGUA-3'(SEQIDNO:2476)
CKAP5-248221nt靶:5'-CCCUGCUUGGCGUGAUGUAUC-3'(SEQIDNO:2477)
CKAP5-252821nt靶:5'-GUUCUUUGAGGAUGAGAAGCC-3'(SEQIDNO:2478)
CKAP5-253021nt靶:5'-UCUUUGAGGAUGAGAAGCCUG-3'(SEQIDNO:2479)
CKAP5-253221nt靶:5'-UUUGAGGAUGAGAAGCCUGCC-3'(SEQIDNO:2480)
CKAP5-253421nt靶:5'-UGAGGAUGAGAAGCCUGCCCU-3'(SEQIDNO:2481)
CKAP5-253621nt靶:5'-AGGAUGAGAAGCCUGCCCUCC-3'(SEQIDNO:2482)
CKAP5-253821nt靶:5'-GAUGAGAAGCCUGCCCUCCUA-3'(SEQIDNO:2483)
CKAP5-254021nt靶:5'-UGAGAAGCCUGCCCUCCUAUC-3'(SEQIDNO:2484)
CKAP5-254221nt靶:5'-AGAAGCCUGCCCUCCUAUCCC-3'(SEQIDNO:2485)
CKAP5-254421nt靶:5'-AAGCCUGCCCUCCUAUCCCAG-3'(SEQIDNO:2486)
CKAP5-254621nt靶:5'-GCCUGCCCUCCUAUCCCAGAU-3'(SEQIDNO:2487)
CKAP5-254821nt靶:5'-CUGCCCUCCUAUCCCAGAUAG-3'(SEQIDNO:2488)
CKAP5-255021nt靶:5'-GCCCUCCUAUCCCAGAUAGAU-3'(SEQIDNO:2489)
CKAP5-255221nt靶:5'-CCUCCUAUCCCAGAUAGAUGC-3'(SEQIDNO:2490)
CKAP5-255421nt靶:5'-UCCUAUCCCAGAUAGAUGCAG-3'(SEQIDNO:2491)
CKAP5-255621nt靶:5'-CUAUCCCAGAUAGAUGCAGAA-3'(SEQIDNO:2492)
CKAP5-255821nt靶:5'-AUCCCAGAUAGAUGCAGAAUU-3'(SEQIDNO:2493)
CKAP5-258121nt靶:5'-AGAAGAUGCAGGGACAAAGUC-3'(SEQIDNO:2494)
CKAP5-264321nt靶:5'-GGUACAGAUGAAGGAGAAGAU-3'(SEQIDNO:2495)
CKAP5-264521nt靶:5'-UACAGAUGAAGGAGAAGAUGG-3'(SEQIDNO:2496)
CKAP5-264721nt靶:5'-CAGAUGAAGGAGAAGAUGGAG-3'(SEQIDNO:2497)
CKAP5-269521nt靶:5'-UCGUUGAUCUUUUGCCGAGGA-3'(SEQIDNO:2498)
CKAP5-278021nt靶:5'-UAGGAAAGAAGGCCUAGAUGA-3'(SEQIDNO:2499)
CKAP5-278221nt靶:5'-GGAAAGAAGGCCUAGAUGAAG-3'(SEQIDNO:2500)
CKAP5-278421nt靶:5'-AAAGAAGGCCUAGAUGAAGUG-3'(SEQIDNO:2501)
CKAP5-278621nt靶:5'-AGAAGGCCUAGAUGAAGUGGC-3'(SEQIDNO:2502)
CKAP5-278821nt靶:5'-AAGGCCUAGAUGAAGUGGCAG-3'(SEQIDNO:2503)
CKAP5-279021nt靶:5'-GGCCUAGAUGAAGUGGCAGGU-3'(SEQIDNO:2504)
CKAP5-279221nt靶:5'-CCUAGAUGAAGUGGCAGGUAU-3'(SEQIDNO:2505)
CKAP5-279421nt靶:5'-UAGAUGAAGUGGCAGGUAUUA-3'(SEQIDNO:2506)
CKAP5-283921nt靶:5'-CGAAUAUAGGUGAACUUCCAA-3'(SEQIDNO:2507)
CKAP5-284121nt靶:5'-AAUAUAGGUGAACUUCCAACU-3'(SEQIDNO:2508)
CKAP5-284321nt靶:5'-UAUAGGUGAACUUCCAACUGC-3'(SEQIDNO:2509)
CKAP5-284521nt靶:5'-UAGGUGAACUUCCAACUGCCU-3'(SEQIDNO:2510)
CKAP5-284721nt靶:5'-GGUGAACUUCCAACUGCCUUG-3'(SEQIDNO:2511)
CKAP5-284921nt靶:5'-UGAACUUCCAACUGCCUUGAA-3'(SEQIDNO:2512)
CKAP5-285121nt靶:5'-AACUUCCAACUGCCUUGAAGG-3'(SEQIDNO:2513)
CKAP5-285321nt靶:5'-CUUCCAACUGCCUUGAAGGGU-3'(SEQIDNO:2514)
CKAP5-285521nt靶:5'-UCCAACUGCCUUGAAGGGUCG-3'(SEQIDNO:2515)
CKAP5-285721nt靶:5'-CAACUGCCUUGAAGGGUCGAC-3'(SEQIDNO:2516)
CKAP5-292621nt靶:5'-AACAACUGGCAGUAGCCAUGG-3'(SEQIDNO:2517)
CKAP5-300721nt靶:5'-ACAGCAAGAACAAUGUUCGAG-3'(SEQIDNO:2518)
CKAP5-300921nt靶:5'-AGCAAGAACAAUGUUCGAGCU-3'(SEQIDNO:2519)
CKAP5-301121nt靶:5'-CAAGAACAAUGUUCGAGCUGC-3'(SEQIDNO:2520)
CKAP5-301321nt靶:5'-AGAACAAUGUUCGAGCUGCUG-3'(SEQIDNO:2521)
CKAP5-301521nt靶:5'-AACAAUGUUCGAGCUGCUGCC-3'(SEQIDNO:2522)
CKAP5-301721nt靶:5'-CAAUGUUCGAGCUGCUGCCCU-3'(SEQIDNO:2523)
CKAP5-301921nt靶:5'-AUGUUCGAGCUGCUGCCCUAG-3'(SEQIDNO:2524)
CKAP5-304021nt靶:5'-CGACUGUGAAUGCUUGGGCAG-3'(SEQIDNO:2525)
CKAP5-304221nt靶:5'-ACUGUGAAUGCUUGGGCAGAA-3'(SEQIDNO:2526)
CKAP5-304421nt靶:5'-UGUGAAUGCUUGGGCAGAACA-3'(SEQIDNO:2527)
CKAP5-308921nt靶:5'-AGGAGAAGAUCUUUCUGAAGA-3'(SEQIDNO:2528)
CKAP5-322921nt靶:5'-GCCUAGAAGAUCGAAAUGGAG-3'(SEQIDNO:2529)
CKAP5-323121nt靶:5'-CUAGAAGAUCGAAAUGGAGAU-3'(SEQIDNO:2530)
CKAP5-323321nt靶:5'-AGAAGAUCGAAAUGGAGAUGU-3'(SEQIDNO:2531)
CKAP5-328721nt靶:5'-CAUGAUGCAUUUAGGAUAUGA-3'(SEQIDNO:2532)
CKAP5-328921nt靶:5'-UGAUGCAUUUAGGAUAUGAAA-3'(SEQIDNO:2533)
CKAP5-329121nt靶:5'-AUGCAUUUAGGAUAUGAAAAA-3'(SEQIDNO:2534)
CKAP5-329321nt靶:5'-GCAUUUAGGAUAUGAAAAAAU-3'(SEQIDNO:2535)
CKAP5-329521nt靶:5'-AUUUAGGAUAUGAAAAAAUGG-3'(SEQIDNO:2536)
CKAP5-331621nt靶:5'-CCAAGGCUACUGGGAAACUAA-3'(SEQIDNO:2537)
CKAP5-331821nt靶:5'-AAGGCUACUGGGAAACUAAAG-3'(SEQIDNO:2538)
CKAP5-332021nt靶:5'-GGCUACUGGGAAACUAAAGCC-3'(SEQIDNO:2539)
CKAP5-332221nt靶:5'-CUACUGGGAAACUAAAGCCAA-3'(SEQIDNO:2540)
CKAP5-332421nt靶:5'-ACUGGGAAACUAAAGCCAACU-3'(SEQIDNO:2541)
CKAP5-332621nt靶:5'-UGGGAAACUAAAGCCAACUUC-3'(SEQIDNO:2542)
CKAP5-332821nt靶:5'-GGAAACUAAAGCCAACUUCUA-3'(SEQIDNO:2543)
CKAP5-333021nt靶:5'-AAACUAAAGCCAACUUCUAAA-3'(SEQIDNO:2544)
CKAP5-333221nt靶:5'-ACUAAAGCCAACUUCUAAAGA-3'(SEQIDNO:2545)
CKAP5-333421nt靶:5'-UAAAGCCAACUUCUAAAGAUC-3'(SEQIDNO:2546)
CKAP5-362521nt靶:5'-GGCCUAUUUUUAUUGUUGUUC-3'(SEQIDNO:2547)
CKAP5-362721nt靶:5'-CCUAUUUUUAUUGUUGUUCCA-3'(SEQIDNO:2548)
CKAP5-362921nt靶:5'-UAUUUUUAUUGUUGUUCCAAA-3'(SEQIDNO:2549)
CKAP5-363121nt靶:5'-UUUUUAUUGUUGUUCCAAAUG-3'(SEQIDNO:2550)
CKAP5-363321nt靶:5'-UUUAUUGUUGUUCCAAAUGGA-3'(SEQIDNO:2551)
CKAP5-363521nt靶:5'-UAUUGUUGUUCCAAAUGGAAA-3'(SEQIDNO:2552)
CKAP5-368621nt靶:5'-GAAGGUGCUAAAGUGGAAUUU-3'(SEQIDNO:2553)
CKAP5-368821nt靶:5'-AGGUGCUAAAGUGGAAUUUUA-3'(SEQIDNO:2554)
CKAP5-398921nt靶:5'-AUAUCAUCUUACUGAGAAUGA-3'(SEQIDNO:2555)
CKAP5-399121nt靶:5'-AUCAUCUUACUGAGAAUGAAG-3'(SEQIDNO:2556)
CKAP5-399321nt靶:5'-CAUCUUACUGAGAAUGAAGCA-3'(SEQIDNO:2557)
CKAP5-399521nt靶:5'-UCUUACUGAGAAUGAAGCAUC-3'(SEQIDNO:2558)
CKAP5-403821nt靶:5'-GUCAAGGUUGGAGAACCAAAG-3'(SEQIDNO:2559)
CKAP5-404021nt靶:5'-CAAGGUUGGAGAACCAAAGGA-3'(SEQIDNO:2560)
CKAP5-404221nt靶:5'-AGGUUGGAGAACCAAAGGAUG-3'(SEQIDNO:2561)
CKAP5-404421nt靶:5'-GUUGGAGAACCAAAGGAUGUC-3'(SEQIDNO:2562)
CKAP5-404621nt靶:5'-UGGAGAACCAAAGGAUGUCAU-3'(SEQIDNO:2563)
CKAP5-404821nt靶:5'-GAGAACCAAAGGAUGUCAUUC-3'(SEQIDNO:2564)
CKAP5-405021nt靶:5'-GAACCAAAGGAUGUCAUUCGU-3'(SEQIDNO:2565)
CKAP5-405221nt靶:5'-ACCAAAGGAUGUCAUUCGUAA-3'(SEQIDNO:2566)
CKAP5-405421nt靶:5'-CAAAGGAUGUCAUUCGUAAAG-3'(SEQIDNO:2567)
CKAP5-405621nt靶:5'-AAGGAUGUCAUUCGUAAAGAU-3'(SEQIDNO:2568)
CKAP5-405821nt靶:5'-GGAUGUCAUUCGUAAAGAUGU-3'(SEQIDNO:2569)
CKAP5-408521nt靶:5'-CAUCCUGAACCGGAUGUGCCU-3'(SEQIDNO:2570)
CKAP5-408721nt靶:5'-UCCUGAACCGGAUGUGCCUUG-3'(SEQIDNO:2571)
CKAP5-408921nt靶:5'-CUGAACCGGAUGUGCCUUGUC-3'(SEQIDNO:2572)
CKAP5-409121nt靶:5'-GAACCGGAUGUGCCUUGUCUA-3'(SEQIDNO:2573)
CKAP5-409321nt靶:5'-ACCGGAUGUGCCUUGUCUACC-3'(SEQIDNO:2574)
CKAP5-409521nt靶:5'-CGGAUGUGCCUUGUCUACCCA-3'(SEQIDNO:2575)
CKAP5-409721nt靶:5'-GAUGUGCCUUGUCUACCCAGC-3'(SEQIDNO:2576)
CKAP5-415421nt靶:5'-AUCCAAAAACUCUAAGCAGAG-3'(SEQIDNO:2577)
CKAP5-415621nt靶:5'-CCAAAAACUCUAAGCAGAGAG-3'(SEQIDNO:2578)
CKAP5-415821nt靶:5'-AAAAACUCUAAGCAGAGAGCA-3'(SEQIDNO:2579)
CKAP5-416021nt靶:5'-AAACUCUAAGCAGAGAGCAGA-3'(SEQIDNO:2580)
CKAP5-416221nt靶:5'-ACUCUAAGCAGAGAGCAGAGU-3'(SEQIDNO:2581)
CKAP5-416421nt靶:5'-UCUAAGCAGAGAGCAGAGUGC-3'(SEQIDNO:2582)
CKAP5-416621nt靶:5'-UAAGCAGAGAGCAGAGUGCCU-3'(SEQIDNO:2583)
CKAP5-416821nt靶:5'-AGCAGAGAGCAGAGUGCCUGG-3'(SEQIDNO:2584)
CKAP5-417021nt靶:5'-CAGAGAGCAGAGUGCCUGGAA-3'(SEQIDNO:2585)
CKAP5-417221nt靶:5'-GAGAGCAGAGUGCCUGGAAGA-3'(SEQIDNO:2586)
CKAP5-417421nt靶:5'-GAGCAGAGUGCCUGGAAGAGC-3'(SEQIDNO:2587)
CKAP5-424121nt靶:5'-CCCAGGAAAAGCCUUAAAGGA-3'(SEQIDNO:2588)
CKAP5-434621nt靶:5'-GGAUCAGGUGUUCAAACUGAU-3'(SEQIDNO:2589)
CKAP5-434821nt靶:5'-AUCAGGUGUUCAAACUGAUUG-3'(SEQIDNO:2590)
CKAP5-435021nt靶:5'-CAGGUGUUCAAACUGAUUGGA-3'(SEQIDNO:2591)
CKAP5-435221nt靶:5'-GGUGUUCAAACUGAUUGGAAA-3'(SEQIDNO:2592)
CKAP5-435421nt靶:5'-UGUUCAAACUGAUUGGAAAUC-3'(SEQIDNO:2593)
CKAP5-435621nt靶:5'-UUCAAACUGAUUGGAAAUCUU-3'(SEQIDNO:2594)
CKAP5-435821nt靶:5'-CAAACUGAUUGGAAAUCUUUC-3'(SEQIDNO:2595)
CKAP5-436021nt靶:5'-AACUGAUUGGAAAUCUUUCUG-3'(SEQIDNO:2596)
CKAP5-441121nt靶:5'-UUAAGCGGUCAGCAAAGAGAC-3'(SEQIDNO:2597)
CKAP5-441321nt靶:5'-AAGCGGUCAGCAAAGAGACCC-3'(SEQIDNO:2598)
CKAP5-441521nt靶:5'-GCGGUCAGCAAAGAGACCCUC-3'(SEQIDNO:2599)
CKAP5-441721nt靶:5'-GGUCAGCAAAGAGACCCUCUG-3'(SEQIDNO:2600)
CKAP5-441921nt靶:5'-UCAGCAAAGAGACCCUCUGCU-3'(SEQIDNO:2601)
CKAP5-442121nt靶:5'-AGCAAAGAGACCCUCUGCUGC-3'(SEQIDNO:2602)
CKAP5-442321nt靶:5'-CAAAGAGACCCUCUGCUGCAC-3'(SEQIDNO:2603)
CKAP5-450521nt靶:5'-GUUACGCAAGGGACCAGCUGA-3'(SEQIDNO:2604)
CKAP5-450721nt靶:5'-UACGCAAGGGACCAGCUGAGG-3'(SEQIDNO:2605)
CKAP5-459121nt靶:5'-UCCGCCGAGAAUUCCAGCUGG-3'(SEQIDNO:2606)
CKAP5-459321nt靶:5'-CGCCGAGAAUUCCAGCUGGAU-3'(SEQIDNO:2607)
CKAP5-471821nt靶:5'-CAAGAUCCGGGCUGUUUCUCC-3'(SEQIDNO:2608)
CKAP5-472021nt靶:5'-AGAUCCGGGCUGUUUCUCCAC-3'(SEQIDNO:2609)
CKAP5-474421nt靶:5'-UCGAUGACAUGCACAGUAAUA-3'(SEQIDNO:2610)
CKAP5-474621nt靶:5'-GAUGACAUGCACAGUAAUACA-3'(SEQIDNO:2611)
CKAP5-474821nt靶:5'-UGACAUGCACAGUAAUACAGC-3'(SEQIDNO:2612)
CKAP5-475021nt靶:5'-ACAUGCACAGUAAUACAGCAU-3'(SEQIDNO:2613)
CKAP5-475221nt靶:5'-AUGCACAGUAAUACAGCAUCC-3'(SEQIDNO:2614)
CKAP5-475421nt靶:5'-GCACAGUAAUACAGCAUCCAC-3'(SEQIDNO:2615)
CKAP5-475621nt靶:5'-ACAGUAAUACAGCAUCCACAA-3'(SEQIDNO:2616)
CKAP5-475821nt靶:5'-AGUAAUACAGCAUCCACAAUC-3'(SEQIDNO:2617)
CKAP5-476021nt靶:5'-UAAUACAGCAUCCACAAUCAA-3'(SEQIDNO:2618)
CKAP5-476221nt靶:5'-AUACAGCAUCCACAAUCAAUU-3'(SEQIDNO:2619)
CKAP5-476421nt靶:5'-ACAGCAUCCACAAUCAAUUUC-3'(SEQIDNO:2620)
CKAP5-476621nt靶:5'-AGCAUCCACAAUCAAUUUCAU-3'(SEQIDNO:2621)
CKAP5-476821nt靶:5'-CAUCCACAAUCAAUUUCAUUA-3'(SEQIDNO:2622)
CKAP5-477021nt靶:5'-UCCACAAUCAAUUUCAUUAUC-3'(SEQIDNO:2623)
CKAP5-477221nt靶:5'-CACAAUCAAUUUCAUUAUCUC-3'(SEQIDNO:2624)
CKAP5-477421nt靶:5'-CAAUCAAUUUCAUUAUCUCCC-3'(SEQIDNO:2625)
CKAP5-477621nt靶:5'-AUCAAUUUCAUUAUCUCCCAA-3'(SEQIDNO:2626)
CKAP5-477821nt靶:5'-CAAUUUCAUUAUCUCCCAAGU-3'(SEQIDNO:2627)
CKAP5-478021nt靶:5'-AUUUCAUUAUCUCCCAAGUAG-3'(SEQIDNO:2628)
CKAP5-478221nt靶:5'-UUCAUUAUCUCCCAAGUAGCC-3'(SEQIDNO:2629)
CKAP5-478421nt靶:5'-CAUUAUCUCCCAAGUAGCCAG-3'(SEQIDNO:2630)
CKAP5-478621nt靶:5'-UUAUCUCCCAAGUAGCCAGUG-3'(SEQIDNO:2631)
CKAP5-478821nt靶:5'-AUCUCCCAAGUAGCCAGUGGU-3'(SEQIDNO:2632)
CKAP5-479021nt靶:5'-CUCCCAAGUAGCCAGUGGUGA-3'(SEQIDNO:2633)
CKAP5-479221nt靶:5'-CCCAAGUAGCCAGUGGUGACA-3'(SEQIDNO:2634)
CKAP5-504121nt靶:5'-UUGCCCGGGAGGCCUCCACUG-3'(SEQIDNO:2635)
CKAP5-504321nt靶:5'-GCCCGGGAGGCCUCCACUGGA-3'(SEQIDNO:2636)
CKAP5-504521nt靶:5'-CCGGGAGGCCUCCACUGGAGU-3'(SEQIDNO:2637)
CKAP5-504721nt靶:5'-GGGAGGCCUCCACUGGAGUAC-3'(SEQIDNO:2638)
CKAP5-508921nt靶:5'-UCAUCACCUUAAUGCUGGAUU-3'(SEQIDNO:2639)
CKAP5-509121nt靶:5'-AUCACCUUAAUGCUGGAUUCU-3'(SEQIDNO:2640)
CKAP5-509321nt靶:5'-CACCUUAAUGCUGGAUUCUCG-3'(SEQIDNO:2641)
CKAP5-509521nt靶:5'-CCUUAAUGCUGGAUUCUCGGA-3'(SEQIDNO:2642)
CKAP5-509721nt靶:5'-UUAAUGCUGGAUUCUCGGAUU-3'(SEQIDNO:2643)
CKAP5-509921nt靶:5'-AAUGCUGGAUUCUCGGAUUGA-3'(SEQIDNO:2644)
CKAP5-510121nt靶:5'-UGCUGGAUUCUCGGAUUGAAG-3'(SEQIDNO:2645)
CKAP5-510321nt靶:5'-CUGGAUUCUCGGAUUGAAGAU-3'(SEQIDNO:2646)
CKAP5-510521nt靶:5'-GGAUUCUCGGAUUGAAGAUCU-3'(SEQIDNO:2647)
CKAP5-515021nt靶:5'-CUCUGUGAACCUCUUGGUGGU-3'(SEQIDNO:2648)
CKAP5-515221nt靶:5'-CUGUGAACCUCUUGGUGGUGA-3'(SEQIDNO:2649)
CKAP5-515421nt靶:5'-GUGAACCUCUUGGUGGUGAAG-3'(SEQIDNO:2650)
CKAP5-515621nt靶:5'-GAACCUCUUGGUGGUGAAGGU-3'(SEQIDNO:2651)
CKAP5-523021nt靶:5'-AAGACAGCCUGCUAGCAACAG-3'(SEQIDNO:2652)
CKAP5-525121nt靶:5'-CCAGUUCUCCCAAAUUCUCAG-3'(SEQIDNO:2653)
CKAP5-525321nt靶:5'-AGUUCUCCCAAAUUCUCAGAG-3'(SEQIDNO:2654)
CKAP5-525521nt靶:5'-UUCUCCCAAAUUCUCAGAGCU-3'(SEQIDNO:2655)
CKAP5-525721nt靶:5'-CUCCCAAAUUCUCAGAGCUUG-3'(SEQIDNO:2656)
CKAP5-525921nt靶:5'-CCCAAAUUCUCAGAGCUUGUU-3'(SEQIDNO:2657)
CKAP5-526121nt靶:5'-CAAAUUCUCAGAGCUUGUUAU-3'(SEQIDNO:2658)
CKAP5-526321nt靶:5'-AAUUCUCAGAGCUUGUUAUGA-3'(SEQIDNO:2659)
CKAP5-526521nt靶:5'-UUCUCAGAGCUUGUUAUGAAG-3'(SEQIDNO:2660)
CKAP5-526721nt靶:5'-CUCAGAGCUUGUUAUGAAGUG-3'(SEQIDNO:2661)
CKAP5-526921nt靶:5'-CAGAGCUUGUUAUGAAGUGUC-3'(SEQIDNO:2662)
CKAP5-532621nt靶:5'-AUAGCAUUAACCUAGACAGAA-3'(SEQIDNO:2663)
CKAP5-532821nt靶:5'-AGCAUUAACCUAGACAGAAUU-3'(SEQIDNO:2664)
CKAP5-533021nt靶:5'-CAUUAACCUAGACAGAAUUCU-3'(SEQIDNO:2665)
CKAP5-533221nt靶:5'-UUAACCUAGACAGAAUUCUUC-3'(SEQIDNO:2666)
CKAP5-533421nt靶:5'-AACCUAGACAGAAUUCUUCUG-3'(SEQIDNO:2667)
CKAP5-533621nt靶:5'-CCUAGACAGAAUUCUUCUGGA-3'(SEQIDNO:2668)
CKAP5-535721nt靶:5'-UAUCCACAUUUUCAUGAAGGU-3'(SEQIDNO:2669)
CKAP5-539421nt靶:5'-CUGAAGCAAUGCAAAAGUGAA-3'(SEQIDNO:2670)
CKAP5-539621nt靶:5'-GAAGCAAUGCAAAAGUGAAUU-3'(SEQIDNO:2671)
CKAP5-539821nt靶:5'-AGCAAUGCAAAAGUGAAUUUC-3'(SEQIDNO:2672)
CKAP5-555121nt靶:5'-ACAGUAUGGACCAGACUGGGA-3'(SEQIDNO:2673)
CKAP5-555321nt靶:5'-AGUAUGGACCAGACUGGGAGC-3'(SEQIDNO:2674)
CKAP5-555521nt靶:5'-UAUGGACCAGACUGGGAGCAA-3'(SEQIDNO:2675)
CKAP5-555721nt靶:5'-UGGACCAGACUGGGAGCAAGU-3'(SEQIDNO:2676)
CKAP5-555921nt靶:5'-GACCAGACUGGGAGCAAGUCU-3'(SEQIDNO:2677)
CKAP5-556121nt靶:5'-CCAGACUGGGAGCAAGUCUGA-3'(SEQIDNO:2678)
CKAP5-556321nt靶:5'-AGACUGGGAGCAAGUCUGAUA-3'(SEQIDNO:2679)
CKAP5-556521nt靶:5'-ACUGGGAGCAAGUCUGAUAAG-3'(SEQIDNO:2680)
CKAP5-556721nt靶:5'-UGGGAGCAAGUCUGAUAAGGA-3'(SEQIDNO:2681)
CKAP5-556921nt靶:5'-GGAGCAAGUCUGAUAAGGAAA-3'(SEQIDNO:2682)
CKAP5-557121nt靶:5'-AGCAAGUCUGAUAAGGAAACA-3'(SEQIDNO:2683)
CKAP5-557321nt靶:5'-CAAGUCUGAUAAGGAAACAGA-3'(SEQIDNO:2684)
CKAP5-557521nt靶:5'-AGUCUGAUAAGGAAACAGAAA-3'(SEQIDNO:2685)
CKAP5-557721nt靶:5'-UCUGAUAAGGAAACAGAAAAG-3'(SEQIDNO:2686)
CKAP5-557921nt靶:5'-UGAUAAGGAAACAGAAAAGGG-3'(SEQIDNO:2687)
CKAP5-558121nt靶:5'-AUAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:2688)
CKAP5-560221nt靶:5'-CAUCUCGAAUAGAUGAAAAAU-3'(SEQIDNO:2689)
CKAP5-560421nt靶:5'-UCUCGAAUAGAUGAAAAAUCA-3'(SEQIDNO:2690)
CKAP5-560621nt靶:5'-UCGAAUAGAUGAAAAAUCAUC-3'(SEQIDNO:2691)
CKAP5-560821nt靶:5'-GAAUAGAUGAAAAAUCAUCAA-3'(SEQIDNO:2692)
CKAP5-561021nt靶:5'-AUAGAUGAAAAAUCAUCAAAG-3'(SEQIDNO:2693)
CKAP5-561221nt靶:5'-AGAUGAAAAAUCAUCAAAGGC-3'(SEQIDNO:2694)
CKAP5-561421nt靶:5'-AUGAAAAAUCAUCAAAGGCCA-3'(SEQIDNO:2695)
CKAP5-561621nt靶:5'-GAAAAAUCAUCAAAGGCCAAA-3'(SEQIDNO:2696)
CKAP5-561821nt靶:5'-AAAAUCAUCAAAGGCCAAAGU-3'(SEQIDNO:2697)
CKAP5-563921nt靶:5'-GAAUGAUUUCUUAGCUGAGAU-3'(SEQIDNO:2698)
CKAP5-564121nt靶:5'-AUGAUUUCUUAGCUGAGAUUU-3'(SEQIDNO:2699)
CKAP5-564321nt靶:5'-GAUUUCUUAGCUGAGAUUUUU-3'(SEQIDNO:2700)
CKAP5-564521nt靶:5'-UUUCUUAGCUGAGAUUUUUAA-3'(SEQIDNO:2701)
CKAP5-564721nt靶:5'-UCUUAGCUGAGAUUUUUAAGA-3'(SEQIDNO:2702)
CKAP5-564921nt靶:5'-UUAGCUGAGAUUUUUAAGAAG-3'(SEQIDNO:2703)
CKAP5-565121nt靶:5'-AGCUGAGAUUUUUAAGAAGAU-3'(SEQIDNO:2704)
CKAP5-565321nt靶:5'-CUGAGAUUUUUAAGAAGAUUG-3'(SEQIDNO:2705)
CKAP5-565521nt靶:5'-GAGAUUUUUAAGAAGAUUGGC-3'(SEQIDNO:2706)
CKAP5-565721nt靶:5'-GAUUUUUAAGAAGAUUGGCUC-3'(SEQIDNO:2707)
CKAP5-569921nt靶:5'-ACUAGCAGAGUUAUAUGAAUA-3'(SEQIDNO:2708)
CKAP5-570121nt靶:5'-UAGCAGAGUUAUAUGAAUAUA-3'(SEQIDNO:2709)
CKAP5-570321nt靶:5'-GCAGAGUUAUAUGAAUAUAAG-3'(SEQIDNO:2710)
CKAP5-570521nt靶:5'-AGAGUUAUAUGAAUAUAAGAA-3'(SEQIDNO:2711)
CKAP5-570721nt靶:5'-AGUUAUAUGAAUAUAAGAAGA-3'(SEQIDNO:2712)
CKAP5-570921nt靶:5'-UUAUAUGAAUAUAAGAAGAAA-3'(SEQIDNO:2713)
CKAP5-571121nt靶:5'-AUAUGAAUAUAAGAAGAAAUA-3'(SEQIDNO:2714)
CKAP5-573921nt靶:5'-GCUGACAUUGAACCAUUUCUG-3'(SEQIDNO:2715)
CKAP5-574121nt靶:5'-UGACAUUGAACCAUUUCUGAA-3'(SEQIDNO:2716)
CKAP5-574321nt靶:5'-ACAUUGAACCAUUUCUGAAAA-3'(SEQIDNO:2717)
CKAP5-574521nt靶:5'-AUUGAACCAUUUCUGAAAAAU-3'(SEQIDNO:2718)
CKAP5-574721nt靶:5'-UGAACCAUUUCUGAAAAAUUC-3'(SEQIDNO:2719)
CKAP5-574921nt靶:5'-AACCAUUUCUGAAAAAUUCCU-3'(SEQIDNO:2720)
CKAP5-579421nt靶:5'-AAAGAGGCCUUCGGGUGAUUG-3'(SEQIDNO:2721)
CKAP5-579621nt靶:5'-AGAGGCCUUCGGGUGAUUGAG-3'(SEQIDNO:2722)
CKAP5-579821nt靶:5'-AGGCCUUCGGGUGAUUGAGAU-3'(SEQIDNO:2723)
CKAP5-580021nt靶:5'-GCCUUCGGGUGAUUGAGAUGG-3'(SEQIDNO:2724)
CKAP5-580221nt靶:5'-CUUCGGGUGAUUGAGAUGGAG-3'(SEQIDNO:2725)
CKAP5-580421nt靶:5'-UCGGGUGAUUGAGAUGGAGAG-3'(SEQIDNO:2726)
CKAP5-594421nt靶:5'-GGCCAUCUGUCUACUUGGAAA-3'(SEQIDNO:2727)
CKAP5-594621nt靶:5'-CCAUCUGUCUACUUGGAAAGG-3'(SEQIDNO:2728)
CKAP5-594821nt靶:5'-AUCUGUCUACUUGGAAAGGCU-3'(SEQIDNO:2729)
CKAP5-595021nt靶:5'-CUGUCUACUUGGAAAGGCUAA-3'(SEQIDNO:2730)
CKAP5-602621nt靶:5'-UUUGACCUCUUUGCUCUCCAA-3'(SEQIDNO:2731)
CKAP5-602821nt靶:5'-UGACCUCUUUGCUCUCCAAAC-3'(SEQIDNO:2732)
CKAP5-603021nt靶:5'-ACCUCUUUGCUCUCCAAACCA-3'(SEQIDNO:2733)
CKAP5-603221nt靶:5'-CUCUUUGCUCUCCAAACCAGC-3'(SEQIDNO:2734)
CKAP5-617321nt靶:5'-UGUGACCUCCUCCUCCUCCAC-3'(SEQIDNO:2735)
CKAP5-621721nt靶:5'-AAAGACUGGAGAGAAUAAAGA-3'(SEQIDNO:2736)
CKAP5-621921nt靶:5'-AGACUGGAGAGAAUAAAGAGC-3'(SEQIDNO:2737)
CKAP5-622121nt靶:5'-ACUGGAGAGAAUAAAGAGCAG-3'(SEQIDNO:2738)
CKAP5-622321nt靶:5'-UGGAGAGAAUAAAGAGCAGUC-3'(SEQIDNO:2739)
CKAP5-622521nt靶:5'-GAGAGAAUAAAGAGCAGUCGC-3'(SEQIDNO:2740)
CKAP5-622721nt靶:5'-GAGAAUAAAGAGCAGUCGCAA-3'(SEQIDNO:2741)
CKAP5-622921nt靶:5'-GAAUAAAGAGCAGUCGCAAAU-3'(SEQIDNO:2742)
CKAP5-623121nt靶:5'-AUAAAGAGCAGUCGCAAAUGA-3'(SEQIDNO:2743)
CKAP5-623321nt靶:5'-AAAGAGCAGUCGCAAAUGAAG-3'(SEQIDNO:2744)
CKAP5-634221nt靶:5'-ACAAACUGGUUGUAUGUAUCA-3'(SEQIDNO:2745)
CKAP5-654421nt靶:5'-UGCUCAUUUGUAAAAUUGUCC-3'(SEQIDNO:2746)
CKAP5-654621nt靶:5'-CUCAUUUGUAAAAUUGUCCUA-3'(SEQIDNO:2747)
CKAP5-654821nt靶:5'-CAUUUGUAAAAUUGUCCUAAU-3'(SEQIDNO:2748)
CKAP5-665621nt靶:5'-UCACUGUAUUCUGUAUGAAUG-3'(SEQIDNO:2749)
CKAP5-665821nt靶:5'-ACUGUAUUCUGUAUGAAUGCA-3'(SEQIDNO:2750)
CKAP5-666021nt靶:5'-UGUAUUCUGUAUGAAUGCAUG-3'(SEQIDNO:2751)
CKAP5-666221nt靶:5'-UAUUCUGUAUGAAUGCAUGGC-3'(SEQIDNO:2752)
CKAP5-666421nt靶:5'-UUCUGUAUGAAUGCAUGGCAU-3'(SEQIDNO:2753)
CKAP5-666621nt靶:5'-CUGUAUGAAUGCAUGGCAUGA-3'(SEQIDNO:2754)
CKAP5-670421nt靶:5'-UCUUUUAUAAAUAAAGUUUGC-3'(SEQIDNO:2755)
CKAP5-670621nt靶:5'-UUUUAUAAAUAAAGUUUGCAU-3'(SEQIDNO:2756)
CKAP5-670821nt靶:5'-UUAUAAAUAAAGUUUGCAUUA-3'(SEQIDNO:2757)
CKAP5-671021nt靶:5'-AUAAAUAAAGUUUGCAUUAAC-3'(SEQIDNO:2758)
CKAP5-671221nt靶:5'-AAAUAAAGUUUGCAUUAACUA-3'(SEQIDNO:2759)
CKAP5-671421nt靶:5'-AUAAAGUUUGCAUUAACUAUA-3'(SEQIDNO:2760)
CKAP5-10621nt靶:5'-CCCAGCUGAGGAAAUACUCUU-3'(SEQIDNO:2761)
CKAP5-17221nt靶:5'-GGUUGAAACUGCCAGUUGAUC-3'(SEQIDNO:2762)
CKAP5-18021nt靶:5'-CUGCCAGUUGAUCAGAAAUGU-3'(SEQIDNO:2763)
CKAP5-21321nt靶:5'-UGGAAAGCAAGGUUAAGUGGG-3'(SEQIDNO:2764)
CKAP5-28121nt靶:5'-CCCAGAGUGGUCCAAAUUUUU-3'(SEQIDNO:2765)
CKAP5-33721nt靶:5'-CAGUGGUUCAAUUGAAAGGAU-3'(SEQIDNO:2766)
CKAP5-35321nt靶:5'-AGGAUUAGAAGCUGCACUUGU-3'(SEQIDNO:2767)
CKAP5-36221nt靶:5'-AGCUGCACUUGUUUAUGUUGA-3'(SEQIDNO:2768)
CKAP5-39521nt靶:5'-AGCAGGAAAAACCACAGGAGA-3'(SEQIDNO:2769)
CKAP5-42221nt靶:5'-GUCAGGUGUUGUAAGUAAGGU-3'(SEQIDNO:2770)
CKAP5-42721nt靶:5'-GUGUUGUAAGUAAGGUGUUCA-3'(SEQIDNO:2771)
CKAP5-44321nt靶:5'-GUUCAAUCAACCUAAAGCUAA-3'(SEQIDNO:2772)
CKAP5-53721nt靶:5'-CUCCUGAAAGGCUUGGACAAU-3'(SEQIDNO:2773)
CKAP5-63721nt靶:5'-UUAAGCCAAUUAUCAAAGUGU-3'(SEQIDNO:2774)
CKAP5-64921nt靶:5'-UCAAAGUGUUGCCAAAACUCU-3'(SEQIDNO:2775)
CKAP5-65921nt靶:5'-GCCAAAACUCUUUGAGUCUCG-3'(SEQIDNO:2776)
CKAP5-68621nt靶:5'-GGCUGUUCGAGAUGAAGCCAA-3'(SEQIDNO:2777)
CKAP5-75521nt靶:5'-CCCAUUACAAAAUAUAAACUC-3'(SEQIDNO:2778)
CKAP5-76121nt靶:5'-ACAAAAUAUAAACUCUGUUCA-3'(SEQIDNO:2779)
CKAP5-76621nt靶:5'-AUAUAAACUCUGUUCAGUUGA-3'(SEQIDNO:2780)
CKAP5-77321nt靶:5'-CUCUGUUCAGUUGAAAGAACU-3'(SEQIDNO:2781)
CKAP5-92821nt靶:5'-GUGAUGAGGUGCCACAAAUAG-3'(SEQIDNO:2782)
CKAP5-94121nt靶:5'-ACAAAUAGAUGCUUAUGAGCU-3'(SEQIDNO:2783)
CKAP5-95321nt靶:5'-UUAUGAGCUUUUAGAAGCUGU-3'(SEQIDNO:2784)
CKAP5-104621nt靶:5'-GGCCCUGGAGUCUGUAGAAGU-3'(SEQIDNO:2785)
CKAP5-105121nt靶:5'-UGGAGUCUGUAGAAGUACUAA-3'(SEQIDNO:2786)
CKAP5-110321nt靶:5'-UGCAGAUUUAGUAAAAGCAUU-3'(SEQIDNO:2787)
CKAP5-111321nt靶:5'-GUAAAAGCAUUAAAGAAGGUU-3'(SEQIDNO:2788)
CKAP5-111821nt靶:5'-AGCAUUAAAGAAGGUUGUUGG-3'(SEQIDNO:2789)
CKAP5-112521nt靶:5'-AAGAAGGUUGUUGGAAAGGAC-3'(SEQIDNO:2790)
CKAP5-120521nt靶:5'-AAGGAAGAAAUUUGGACAAUA-3'(SEQIDNO:2791)
CKAP5-134321nt靶:5'-CAGUGAGGAUGUUUUAGCAGU-3'(SEQIDNO:2792)
CKAP5-135121nt靶:5'-AUGUUUUAGCAGUAAUGGAUA-3'(SEQIDNO:2793)
CKAP5-138621nt靶:5'-AUCAAGCAGCAGACAUCUCUU-3'(SEQIDNO:2794)
CKAP5-139521nt靶:5'-CAGACAUCUCUUUUUAUUGCA-3'(SEQIDNO:2795)
CKAP5-151421nt靶:5'-AGUCAGAGAUGCCGCAUUUGA-3'(SEQIDNO:2796)
CKAP5-153521nt靶:5'-AGCAUUGGGUACUGCUUUGAA-3'(SEQIDNO:2797)
CKAP5-159421nt靶:5'-AUGUGGACAAACUCAAGCUUG-3'(SEQIDNO:2798)
CKAP5-162221nt靶:5'-CAAAGAAUGUUCAGAAAAGGU-3'(SEQIDNO:2799)
CKAP5-163021nt靶:5'-GUUCAGAAAAGGUAGAACUGA-3'(SEQIDNO:2800)
CKAP5-163821nt靶:5'-AAGGUAGAACUGAUACAUGGU-3'(SEQIDNO:2801)
CKAP5-184721nt靶:5'-CGCAGGGAAUACUGGAACCAA-3'(SEQIDNO:2802)
CKAP5-190321nt靶:5'-AGCCUGAGCUCUCGAUAGAAG-3'(SEQIDNO:2803)
CKAP5-191321nt靶:5'-CUCGAUAGAAGUAUGUGAAGA-3'(SEQIDNO:2804)
CKAP5-197221nt靶:5'-UUCUUGACAGCAGUAACUGGA-3'(SEQIDNO:2805)
CKAP5-203421nt靶:5'-GAGCUAAUGGACCGAACUGAA-3'(SEQIDNO:2806)
CKAP5-206821nt靶:5'-CAUUAGUGAGGAUGCUAGCCA-3'(SEQIDNO:2807)
CKAP5-208321nt靶:5'-UAGCCAAGAAACCUGGAUGGA-3'(SEQIDNO:2808)
CKAP5-208821nt靶:5'-AAGAAACCUGGAUGGAAAGAA-3'(SEQIDNO:2809)
CKAP5-211921nt靶:5'-AGGUGAUGCAAAUGAAGCUUC-3'(SEQIDNO:2810)
CKAP5-217721nt靶:5'-CAAAACGUCAGCUCAGGUUGU-3'(SEQIDNO:2811)
CKAP5-224621nt靶:5'-UGCAAAAGAAGCUAUGACAGC-3'(SEQIDNO:2812)
CKAP5-226121nt靶:5'-GACAGCAAUAGCCGAAGCCUG-3'(SEQIDNO:2813)
CKAP5-227221nt靶:5'-CCGAAGCCUGUAUGUUACCAU-3'(SEQIDNO:2814)
CKAP5-233921nt靶:5'-CAAAAAUCAGUCAGAAACUCU-3'(SEQIDNO:2815)
CKAP5-241221nt靶:5'-AAAGCUUUCAUUAGCAAUGUG-3'(SEQIDNO:2816)
CKAP5-257821nt靶:5'-UUGAGAAGAUGCAGGGACAAA-3'(SEQIDNO:2817)
CKAP5-268421nt靶:5'-GAGCAAUGAUGUCGUUGAUCU-3'(SEQIDNO:2818)
CKAP5-279721nt靶:5'-AUGAAGUGGCAGGUAUUAUUA-3'(SEQIDNO:2819)
CKAP5-286021nt靶:5'-CUGCCUUGAAGGGUCGACUCA-3'(SEQIDNO:2820)
CKAP5-286521nt靶:5'-UUGAAGGGUCGACUCAAUGAU-3'(SEQIDNO:2821)
CKAP5-287321nt靶:5'-UCGACUCAAUGAUUCAAAUAA-3'(SEQIDNO:2822)
CKAP5-287921nt靶:5'-CAAUGAUUCAAAUAAAAUCUU-3'(SEQIDNO:2823)
CKAP5-293721nt靶:5'-GUAGCCAUGGGCCCAAAUAUU-3'(SEQIDNO:2824)
CKAP5-294921nt靶:5'-CCAAAUAUUAAGCAACAUGUA-3'(SEQIDNO:2825)
CKAP5-299721nt靶:5'-GUCCUUGGAGACAGCAAGAAC-3'(SEQIDNO:2826)
CKAP5-300221nt靶:5'-UGGAGACAGCAAGAACAAUGU-3'(SEQIDNO:2827)
CKAP5-328521nt靶:5'-UUCAUGAUGCAUUUAGGAUAU-3'(SEQIDNO:2828)
CKAP5-336721nt靶:5'-UGCUAGAGAAAGCCAAAGUUA-3'(SEQIDNO:2829)
CKAP5-357121nt靶:5'-AAGGGAAGAAGAUGCCAAGCA-3'(SEQIDNO:2830)
CKAP5-365021nt靶:5'-UGGAAAAGAGCAAAGGAUGAA-3'(SEQIDNO:2831)
CKAP5-365521nt靶:5'-AAGAGCAAAGGAUGAAAGAUG-3'(SEQIDNO:2832)
CKAP5-371621nt靶:5'-ACGGGAUGAAUACAUUGAGCA-3'(SEQIDNO:2833)
CKAP5-372121nt靶:5'-AUGAAUACAUUGAGCAACUAA-3'(SEQIDNO:2834)
CKAP5-389021nt靶:5'-AAAGUGGCUUACCCUGAGGUU-3'(SEQIDNO:2835)
CKAP5-390021nt靶:5'-ACCCUGAGGUUUUUUGACACC-3'(SEQIDNO:2836)
CKAP5-391821nt靶:5'-ACCAAUACAAGCGUCCUGAUG-3'(SEQIDNO:2837)
CKAP5-392821nt靶:5'-GCGUCCUGAUGAAAGCACUAG-3'(SEQIDNO:2838)
CKAP5-393421nt靶:5'-UGAUGAAAGCACUAGAAUAUU-3'(SEQIDNO:2839)
CKAP5-436721nt靶:5'-UGGAAAUCUUUCUGAAAAGGA-3'(SEQIDNO:2840)
CKAP5-437821nt靶:5'-CUGAAAAGGAUAUGAGCAUGC-3'(SEQIDNO:2841)
CKAP5-448721nt靶:5'-AAGCUCCAAUGCCAACAUGUU-3'(SEQIDNO:2842)
CKAP5-449221nt靶:5'-CCAAUGCCAACAUGUUACGCA-3'(SEQIDNO:2843)
CKAP5-464921nt靶:5'-AUGUGAAAUGCCAGAACUUGU-3'(SEQIDNO:2844)
CKAP5-465821nt靶:5'-GCCAGAACUUGUUCAGCACAA-3'(SEQIDNO:2845)
CKAP5-467321nt靶:5'-GCACAAACUGGAUGACAUUUU-3'(SEQIDNO:2846)
CKAP5-468121nt靶:5'-UGGAUGACAUUUUUGAGCCAG-3'(SEQIDNO:2847)
CKAP5-468621nt靶:5'-GACAUUUUUGAGCCAGUCCUU-3'(SEQIDNO:2848)
CKAP5-469321nt靶:5'-UUGAGCCAGUCCUUAUUCCUG-3'(SEQIDNO:2849)
CKAP5-505721nt靶:5'-CACUGGAGUACUAAAAGACCU-3'(SEQIDNO:2850)
CKAP5-516721nt靶:5'-UGGUGAAGGUUCUGGAGAAGU-3'(SEQIDNO:2851)
CKAP5-520221nt靶:5'-AUCCUGAGUGCCCUACUUGUU-3'(SEQIDNO:2852)
CKAP5-524621nt靶:5'-AACAGCCAGUUCUCCCAAAUU-3'(SEQIDNO:2853)
CKAP5-527121nt靶:5'-GAGCUUGUUAUGAAGUGUCUC-3'(SEQIDNO:2854)
CKAP5-530221nt靶:5'-UUCGACUGUUGCCUGAUACCA-3'(SEQIDNO:2855)
CKAP5-530721nt靶:5'-CUGUUGCCUGAUACCAUCAAU-3'(SEQIDNO:2856)
CKAP5-531221nt靶:5'-GCCUGAUACCAUCAAUAGCAU-3'(SEQIDNO:2857)
CKAP5-532021nt靶:5'-CCAUCAAUAGCAUUAACCUAG-3'(SEQIDNO:2858)
CKAP5-532521nt靶:5'-AAUAGCAUUAACCUAGACAGA-3'(SEQIDNO:2859)
CKAP5-534221nt靶:5'-CAGAAUUCUUCUGGAUAUCCA-3'(SEQIDNO:2860)
CKAP5-535021nt靶:5'-UUCUGGAUAUCCACAUUUUCA-3'(SEQIDNO:2861)
CKAP5-538321nt靶:5'-CCAAAGAGAAACUGAAGCAAU-3'(SEQIDNO:2862)
CKAP5-538821nt靶:5'-GAGAAACUGAAGCAAUGCAAA-3'(SEQIDNO:2863)
CKAP5-553621nt靶:5'-GCCGGAUGAUGAAGCACAGUA-3'(SEQIDNO:2864)
CKAP5-558821nt靶:5'-AACAGAAAAGGGAGCAUCUCG-3'(SEQIDNO:2865)
CKAP5-559421nt靶:5'-AAAGGGAGCAUCUCGAAUAGA-3'(SEQIDNO:2866)
CKAP5-559921nt靶:5'-GAGCAUCUCGAAUAGAUGAAA-3'(SEQIDNO:2867)
CKAP5-569221nt靶:5'-AAGAGGGACUAGCAGAGUUAU-3'(SEQIDNO:2868)
CKAP5-572921nt靶:5'-AUACUCAGAUGCUGACAUUGA-3'(SEQIDNO:2869)
CKAP5-613021nt靶:5'-AGCAUUCAGACCUGGAUUCUA-3'(SEQIDNO:2870)
CKAP5-613621nt靶:5'-CAGACCUGGAUUCUAACCAGA-3'(SEQIDNO:2871)
CKAP5-614121nt靶:5'-CUGGAUUCUAACCAGACUCAC-3'(SEQIDNO:2872)
CKAP5-619321nt靶:5'-CAGCUAACAUAGACGACUUGA-3'(SEQIDNO:2873)
CKAP5-619821nt靶:5'-AACAUAGACGACUUGAAAAAA-3'(SEQIDNO:2874)
CKAP5-629421nt靶:5'-AACUAGAAGUCCUCAUAGUUU-3'(SEQIDNO:2875)
CKAP5-645921nt靶:5'-UGGAUGAGUUUAGUGUACAGA-3'(SEQIDNO:2876)
CKAP5-651721nt靶:5'-CCCAGAUCCUUUUCUUUUCUU-3'(SEQIDNO:2877)
CKAP5-654221nt靶:5'-AUUGCUCAUUUGUAAAAUUGU-3'(SEQIDNO:2878)
CKAP5-664821nt靶:5'-CUGAAGGGUCACUGUAUUCUG-3'(SEQIDNO:2879)
CKAP5-665321nt靶:5'-GGGUCACUGUAUUCUGUAUGA-3'(SEQIDNO:2880)
表5:选择的人抗-CKAP5“平端/磨损”DsiRNA
表6:选择的人抗-CKAP5“平端/磨损”DsiRNA
5'-UGGAAGCACAAUGGGAGAUGACAGUGA-3'(SEQIDNO:3457)
3'-ACCUUCGUGUUACCCUCUACUGUCACU-5'(SEQIDNO:577)
CKAP5-143靶:5'-TGGAAGCACAATGGGAGATGACAGTGA-3'(SEQIDNO:1153)
5'-GAAGCACAAUGGGAGAUGACAGUGAGU-3'(SEQIDNO:3458)
3'-CUUCGUGUUACCCUCUACUGUCACUCA-5'(SEQIDNO:578)
CKAP5-145靶:5'-GAAGCACAATGGGAGATGACAGTGAGT-3'(SEQIDNO:1154)
5'-AGCACAAUGGGAGAUGACAGUGAGUGG-3'(SEQIDNO:3459)
3'-UCGUGUUACCCUCUACUGUCACUCACC-5'(SEQIDNO:579)
CKAP5-147靶:5'-AGCACAATGGGAGATGACAGTGAGTGG-3'(SEQIDNO:1155)
5'-CACAAUGGGAGAUGACAGUGAGUGGUU-3'(SEQIDNO:3460)
3'-GUGUUACCCUCUACUGUCACUCACCAA-5'(SEQIDNO:580)
CKAP5-149靶:5'-CACAATGGGAGATGACAGTGAGTGGTT-3'(SEQIDNO:1156)
5'-CAAUGGGAGAUGACAGUGAGUGGUUGA-3'(SEQIDNO:3461)
3'-GUUACCCUCUACUGUCACUCACCAACU-5'(SEQIDNO:581)
CKAP5-151靶:5'-CAATGGGAGATGACAGTGAGTGGTTGA-3'(SEQIDNO:1157)
5'-AUGGGAGAUGACAGUGAGUGGUUGAAA-3'(SEQIDNO:3462)
3'-UACCCUCUACUGUCACUCACCAACUUU-5'(SEQIDNO:582)
CKAP5-153靶:5'-ATGGGAGATGACAGTGAGTGGTTGAAA-3'(SEQIDNO:1158)
5'-GGGAGAUGACAGUGAGUGGUUGAAACU-3'(SEQIDNO:3463)
3'-CCCUCUACUGUCACUCACCAACUUUGA-5'(SEQIDNO:583)
CKAP5-155靶:5'-GGGAGATGACAGTGAGTGGTTGAAACT-3'(SEQIDNO:1159)
5'-GAGAUGACAGUGAGUGGUUGAAACUGC-3'(SEQIDNO:3464)
3'-CUCUACUGUCACUCACCAACUUUGACG-5'(SEQIDNO:584)
CKAP5-157靶:5'-GAGATGACAGTGAGTGGTTGAAACTGC-3'(SEQIDNO:1160)
5'-GAUGACAGUGAGUGGUUGAAACUGCCA-3'(SEQIDNO:3465)
3'-CUACUGUCACUCACCAACUUUGACGGU-5'(SEQIDNO:585)
CKAP5-159靶:5'-GATGACAGTGAGTGGTTGAAACTGCCA-3'(SEQIDNO:1161)
5'-CUGAAGAUCUUCCAGAAAAUAAAGGAU-3'(SEQIDNO:3466)
3'-GACUUCUAGAAGGUCUUUUAUUUCCUA-5'(SEQIDNO:586)
CKAP5-246靶:5'-CTGAAGATCTTCCAGAAAATAAAGGAT-3'(SEQIDNO:1162)
5'-GAAGAUCUUCCAGAAAAUAAAGGAUGA-3'(SEQIDNO:3467)
3'-CUUCUAGAAGGUCUUUUAUUUCCUACU-5'(SEQIDNO:587)
CKAP5-248靶:5'-GAAGATCTTCCAGAAAATAAAGGATGA-3'(SEQIDNO:1163)
5'-AGAUCUUCCAGAAAAUAAAGGAUGAAA-3'(SEQIDNO:3468)
3'-UCUAGAAGGUCUUUUAUUUCCUACUUU-5'(SEQIDNO:588)
CKAP5-250靶:5'-AGATCTTCCAGAAAATAAAGGATGAAA-3'(SEQIDNO:1164)
5'-AUCUUCCAGAAAAUAAAGGAUGAAAAG-3'(SEQIDNO:3469)
3'-UAGAAGGUCUUUUAUUUCCUACUUUUC-5'(SEQIDNO:589)
CKAP5-252靶:5'-ATCTTCCAGAAAATAAAGGATGAAAAG-3'(SEQIDNO:1165)
5'-CUUCCAGAAAAUAAAGGAUGAAAAGAG-3'(SEQIDNO:3470)
3'-GAAGGUCUUUUAUUUCCUACUUUUCUC-5'(SEQIDNO:590)
CKAP5-254靶:5'-CTTCCAGAAAATAAAGGATGAAAAGAG-3'(SEQIDNO:1166)
5'-UCCAGAAAAUAAAGGAUGAAAAGAGCC-3'(SEQIDNO:3471)
3'-AGGUCUUUUAUUUCCUACUUUUCUCGG-5'(SEQIDNO:591)
CKAP5-256靶:5'-TCCAGAAAATAAAGGATGAAAAGAGCC-3'(SEQIDNO:1167)
5'-CAGAAAAUAAAGGAUGAAAAGAGCCCA-3'(SEQIDNO:3472)
3'-GUCUUUUAUUUCCUACUUUUCUCGGGU-5'(SEQIDNO:592)
CKAP5-258靶:5'-CAGAAAATAAAGGATGAAAAGAGCCCA-3'(SEQIDNO:1168)
5'-GAAAAUAAAGGAUGAAAAGAGCCCAGA-3'(SEQIDNO:3473)
3'-CUUUUAUUUCCUACUUUUCUCGGGUCU-5'(SEQIDNO:593)
CKAP5-260靶:5'-GAAAATAAAGGATGAAAAGAGCCCAGA-3'(SEQIDNO:1169)
5'-GAUCAAAAAAUUUGUCACUGAUUCCAA-3'(SEQIDNO:3474)
3'-CUAGUUUUUUAAACAGUGACUAAGGUU-5'(SEQIDNO:594)
CKAP5-308靶:5'-GATCAAAAAATTTGTCACTGATTCCAA-3'(SEQIDNO:1170)
5'-UCAAAAAAUUUGUCACUGAUUCCAAUG-3'(SEQIDNO:3475)
3'-AGUUUUUUAAACAGUGACUAAGGUUAC-5'(SEQIDNO:595)
CKAP5-310靶:5'-TCAAAAAATTTGTCACTGATTCCAATG-3'(SEQIDNO:1171)
5'-AAAAAAUUUGUCACUGAUUCCAAUGCA-3'(SEQIDNO:3476)
3'-UUUUUUAAACAGUGACUAAGGUUACGU-5'(SEQIDNO:596)
CKAP5-312靶:5'-AAAAAATTTGTCACTGATTCCAATGCA-3'(SEQIDNO:1172)
5'-AAAAUUUGUCACUGAUUCCAAUGCAGU-3'(SEQIDNO:3477)
3'-UUUUAAACAGUGACUAAGGUUACGUCA-5'(SEQIDNO:597)
CKAP5-314靶:5'-AAAATTTGTCACTGATTCCAATGCAGT-3'(SEQIDNO:1173)
5'-AAUUUGUCACUGAUUCCAAUGCAGUGG-3'(SEQIDNO:3478)
3'-UUAAACAGUGACUAAGGUUACGUCACC-5'(SEQIDNO:598)
CKAP5-316靶:5'-AATTTGTCACTGATTCCAATGCAGTGG-3'(SEQIDNO:1174)
5'-UUUGUCACUGAUUCCAAUGCAGUGGUU-3'(SEQIDNO:3479)
3'-AAACAGUGACUAAGGUUACGUCACCAA-5'(SEQIDNO:599)
CKAP5-318靶:5'-TTTGTCACTGATTCCAATGCAGTGGTT-3'(SEQIDNO:1175)
5'-UGUCACUGAUUCCAAUGCAGUGGUUCA-3'(SEQIDNO:3480)
3'-ACAGUGACUAAGGUUACGUCACCAAGU-5'(SEQIDNO:600)
CKAP5-320靶:5'-TGTCACTGATTCCAATGCAGTGGTTCA-3'(SEQIDNO:1176)
5'-UCACUGAUUCCAAUGCAGUGGUUCAAU-3'(SEQIDNO:3481)
3'-AGUGACUAAGGUUACGUCACCAAGUUA-5'(SEQIDNO:601)
CKAP5-322靶:5'-TCACTGATTCCAATGCAGTGGTTCAAT-3'(SEQIDNO:1177)
5'-ACUGAUUCCAAUGCAGUGGUUCAAUUG-3'(SEQIDNO:3482)
3'-UGACUAAGGUUACGUCACCAAGUUAAC-5'(SEQIDNO:602)
CKAP5-324靶:5'-ACTGATTCCAATGCAGTGGTTCAATTG-3'(SEQIDNO:1178)
5'-UGAUUCCAAUGCAGUGGUUCAAUUGAA-3'(SEQIDNO:3483)
3'-ACUAAGGUUACGUCACCAAGUUAACUU-5'(SEQIDNO:603)
CKAP5-326靶:5'-TGATTCCAATGCAGTGGTTCAATTGAA-3'(SEQIDNO:1179)
5'-AUUCCAAUGCAGUGGUUCAAUUGAAAG-3'(SEQIDNO:3484)
3'-UAAGGUUACGUCACCAAGUUAACUUUC-5'(SEQIDNO:604)
CKAP5-328靶:5'-ATTCCAATGCAGTGGTTCAATTGAAAG-3'(SEQIDNO:1180)
5'-UCCAAUGCAGUGGUUCAAUUGAAAGGA-3'(SEQIDNO:3485)
3'-AGGUUACGUCACCAAGUUAACUUUCCU-5'(SEQIDNO:605)
CKAP5-330靶:5'-TCCAATGCAGTGGTTCAATTGAAAGGA-3'(SEQIDNO:1181)
5'-CAAUGCAGUGGUUCAAUUGAAAGGAUU-3'(SEQIDNO:3486)
3'-GUUACGUCACCAAGUUAACUUUCCUAA-5'(SEQIDNO:606)
CKAP5-332靶:5'-CAATGCAGTGGTTCAATTGAAAGGATT-3'(SEQIDNO:1182)
5'-AUGCAGUGGUUCAAUUGAAAGGAUUAG-3'(SEQIDNO:3487)
3'-UACGUCACCAAGUUAACUUUCCUAAUC-5'(SEQIDNO:607)
CKAP5-334靶:5'-ATGCAGTGGTTCAATTGAAAGGATTAG-3'(SEQIDNO:1183)
5'-GCAGUGGUUCAAUUGAAAGGAUUAGAA-3'(SEQIDNO:3488)
3'-CGUCACCAAGUUAACUUUCCUAAUCUU-5'(SEQIDNO:608)
CKAP5-336靶:5'-GCAGTGGTTCAATTGAAAGGATTAGAA-3'(SEQIDNO:1184)
5'-CCAAGAUCAUAGUGGCCUGUAUAGAGA-3'(SEQIDNO:3489)
3'-GGUUCUAGUAUCACCGGACAUAUCUCU-5'(SEQIDNO:609)
CKAP5-565靶:5'-CCAAGATCATAGTGGCCTGTATAGAGA-3'(SEQIDNO:1185)
5'-AAGAUCAUAGUGGCCUGUAUAGAGACA-3'(SEQIDNO:3490)
3'-UUCUAGUAUCACCGGACAUAUCUCUGU-5'(SEQIDNO:610)
CKAP5-567靶:5'-AAGATCATAGTGGCCTGTATAGAGACA-3'(SEQIDNO:1186)
5'-GAUCAUAGUGGCCUGUAUAGAGACACU-3'(SEQIDNO:3491)
3'-CUAGUAUCACCGGACAUAUCUCUGUGA-5'(SEQIDNO:611)
CKAP5-569靶:5'-GATCATAGTGGCCTGTATAGAGACACT-3'(SEQIDNO:1187)
5'-GACACUGAGGAAAGCCUUAAGUGAAUU-3'(SEQIDNO:3492)
3'-CUGUGACUCCUUUCGGAAUUCACUUAA-5'(SEQIDNO:612)
CKAP5-590靶:5'-GACACTGAGGAAAGCCTTAAGTGAATT-3'(SEQIDNO:1188)
5'-CACUGAGGAAAGCCUUAAGUGAAUUUG-3'(SEQIDNO:3493)
3'-GUGACUCCUUUCGGAAUUCACUUAAAC-5'(SEQIDNO:613)
CKAP5-592靶:5'-CACTGAGGAAAGCCTTAAGTGAATTTG-3'(SEQIDNO:1189)
5'-CUGAGGAAAGCCUUAAGUGAAUUUGGU-3'(SEQIDNO:3494)
3'-GACUCCUUUCGGAAUUCACUUAAACCA-5'(SEQIDNO:614)
CKAP5-594靶:5'-CTGAGGAAAGCCTTAAGTGAATTTGGT-3'(SEQIDNO:1190)
5'-GAGGAAAGCCUUAAGUGAAUUUGGUUC-3'(SEQIDNO:3495)
3'-CUCCUUUCGGAAUUCACUUAAACCAAG-5'(SEQIDNO:615)
CKAP5-596靶:5'-GAGGAAAGCCTTAAGTGAATTTGGTTC-3'(SEQIDNO:1191)
5'-GGAAAGCCUUAAGUGAAUUUGGUUCCA-3'(SEQIDNO:3496)
3'-CCUUUCGGAAUUCACUUAAACCAAGGU-5'(SEQIDNO:616)
CKAP5-598靶:5'-GGAAAGCCTTAAGTGAATTTGGTTCCA-3'(SEQIDNO:1192)
5'-AAAGCCUUAAGUGAAUUUGGUUCCAAA-3'(SEQIDNO:3497)
3'-UUUCGGAAUUCACUUAAACCAAGGUUU-5'(SEQIDNO:617)
CKAP5-600靶:5'-AAAGCCTTAAGTGAATTTGGTTCCAAA-3'(SEQIDNO:1193)
5'-AGCCUUAAGUGAAUUUGGUUCCAAAAU-3'(SEQIDNO:3498)
3'-UCGGAAUUCACUUAAACCAAGGUUUUA-5'(SEQIDNO:618)
CKAP5-602靶:5'-AGCCTTAAGTGAATTTGGTTCCAAAAT-3'(SEQIDNO:1194)
5'-CCUUAAGUGAAUUUGGUUCCAAAAUCA-3'(SEQIDNO:3499)
3'-GGAAUUCACUUAAACCAAGGUUUUAGU-5'(SEQIDNO:619)
CKAP5-604靶:5'-CCTTAAGTGAATTTGGTTCCAAAATCA-3'(SEQIDNO:1195)
5'-UUAAGUGAAUUUGGUUCCAAAAUCAUC-3'(SEQIDNO:3500)
3'-AAUUCACUUAAACCAAGGUUUUAGUAG-5'(SEQIDNO:620)
CKAP5-606靶:5'-TTAAGTGAATTTGGTTCCAAAATCATC-3'(SEQIDNO:1196)
5'-AAGUGAAUUUGGUUCCAAAAUCAUCUU-3'(SEQIDNO:3501)
3'-UUCACUUAAACCAAGGUUUUAGUAGAA-5'(SEQIDNO:621)
CKAP5-608靶:5'-AAGTGAATTTGGTTCCAAAATCATCTT-3'(SEQIDNO:1197)
5'-GUGAAUUUGGUUCCAAAAUCAUCUUGC-3'(SEQIDNO:3502)
3'-CACUUAAACCAAGGUUUUAGUAGAACG-5'(SEQIDNO:622)
CKAP5-610靶:5'-GTGAATTTGGTTCCAAAATCATCTTGC-3'(SEQIDNO:1198)
5'-GAAUUUGGUUCCAAAAUCAUCUUGCUU-3'(SEQIDNO:3503)
3'-CUUAAACCAAGGUUUUAGUAGAACGAA-5'(SEQIDNO:623)
CKAP5-612靶:5'-GAATTTGGTTCCAAAATCATCTTGCTT-3'(SEQIDNO:1199)
5'-UUCGUUCCCAACAAGAACUAGAAGCUA-3'(SEQIDNO:3504)
3'-AAGCAAGGGUUGUUCUUGAUCUUCGAU-5'(SEQIDNO:624)
CKAP5-847靶:5'-TTCGTTCCCAACAAGAACTAGAAGCTA-3'(SEQIDNO:1200)
5'-CGUUCCCAACAAGAACUAGAAGCUAAA-3'(SEQIDNO:3505)
3'-GCAAGGGUUGUUCUUGAUCUUCGAUUU-5'(SEQIDNO:625)
CKAP5-849靶:5'-CGTTCCCAACAAGAACTAGAAGCTAAA-3'(SEQIDNO:1201)
5'-UUCCCAACAAGAACUAGAAGCUAAAUU-3'(SEQIDNO:3506)
3'-AAGGGUUGUUCUUGAUCUUCGAUUUAA-5'(SEQIDNO:626)
CKAP5-851靶:5'-TTCCCAACAAGAACTAGAAGCTAAATT-3'(SEQIDNO:1202)
5'-CCCAACAAGAACUAGAAGCUAAAUUGG-3'(SEQIDNO:3507)
3'-GGGUUGUUCUUGAUCUUCGAUUUAACC-5'(SEQIDNO:627)
CKAP5-853靶:5'-CCCAACAAGAACTAGAAGCTAAATTGG-3'(SEQIDNO:1203)
5'-CAACAAGAACUAGAAGCUAAAUUGGAA-3'(SEQIDNO:3508)
3'-GUUGUUCUUGAUCUUCGAUUUAACCUU-5'(SEQIDNO:628)
CKAP5-855靶:5'-CAACAAGAACTAGAAGCTAAATTGGAA-3'(SEQIDNO:1204)
5'-ACAACAGUCUGCUGGUGGAGAUGCUGA-3'(SEQIDNO:3509)
3'-UGUUGUCAGACGACCACCUCUACGACU-5'(SEQIDNO:629)
CKAP5-884靶:5'-ACAACAGTCTGCTGGTGGAGATGCTGA-3'(SEQIDNO:1205)
5'-AACAGUCUGCUGGUGGAGAUGCUGAAG-3'(SEQIDNO:3510)
3'-UUGUCAGACGACCACCUCUACGACUUC-5'(SEQIDNO:630)
CKAP5-886靶:5'-AACAGTCTGCTGGTGGAGATGCTGAAG-3'(SEQIDNO:1206)
5'-AGGUGGUGAUGAUGGUGAUGAGGUGCC-3'(SEQIDNO:3511)
3'-UCCACCACUACUACCACUACUCCACGG-5'(SEQIDNO:631)
CKAP5-914靶:5'-AGGTGGTGATGATGGTGATGAGGTGCC-3'(SEQIDNO:1207)
5'-GUGGUGAUGAUGGUGAUGAGGUGCCAC-3'(SEQIDNO:3512)
3'-CACCACUACUACCACUACUCCACGGUG-5'(SEQIDNO:632)
CKAP5-916靶:5'-GTGGTGATGATGGTGATGAGGTGCCAC-3'(SEQIDNO:1208)
5'-AAAUCCUUUCCAAACUUCCCAAAGACU-3'(SEQIDNO:3513)
3'-UUUAGGAAAGGUUUGAAGGGUUUCUGA-5'(SEQIDNO:633)
CKAP5-976靶:5'-AAATCCTTTCCAAACTTCCCAAAGACT-3'(SEQIDNO:1209)
5'-AUCCUUUCCAAACUUCCCAAAGACUUU-3'(SEQIDNO:3514)
3'-UAGGAAAGGUUUGAAGGGUUUCUGAAA-5'(SEQIDNO:634)
CKAP5-978靶:5'-ATCCTTTCCAAACTTCCCAAAGACTTT-3'(SEQIDNO:1210)
5'-CCUUUCCAAACUUCCCAAAGACUUUUA-3'(SEQIDNO:3515)
3'-GGAAAGGUUUGAAGGGUUUCUGAAAAU-5'(SEQIDNO:635)
CKAP5-980靶:5'-CCTTTCCAAACTTCCCAAAGACTTTTA-3'(SEQIDNO:1211)
5'-UUUCCAAACUUCCCAAAGACUUUUAUG-3'(SEQIDNO:3516)
3'-AAAGGUUUGAAGGGUUUCUGAAAAUAC-5'(SEQIDNO:636)
CKAP5-982靶:5'-TTTCCAAACTTCCCAAAGACTTTTATG-3'(SEQIDNO:1212)
5'-UCCAAACUUCCCAAAGACUUUUAUGAC-3'(SEQIDNO:3517)
3'-AGGUUUGAAGGGUUUCUGAAAAUACUG-5'(SEQIDNO:637)
CKAP5-984靶:5'-TCCAAACTTCCCAAAGACTTTTATGAC-3'(SEQIDNO:1213)
5'-CAAACUUCCCAAAGACUUUUAUGACAA-3'(SEQIDNO:3518)
3'-GUUUGAAGGGUUUCUGAAAAUACUGUU-5'(SEQIDNO:638)
CKAP5-986靶:5'-CAAACTTCCCAAAGACTTTTATGACAA-3'(SEQIDNO:1214)
5'-AACUUCCCAAAGACUUUUAUGACAAAA-3'(SEQIDNO:3519)
3'-UUGAAGGGUUUCUGAAAAUACUGUUUU-5'(SEQIDNO:639)
CKAP5-988靶:5'-AACTTCCCAAAGACTTTTATGACAAAA-3'(SEQIDNO:1215)
5'-CUUCCCAAAGACUUUUAUGACAAAAUU-3'(SEQIDNO:3520)
3'-GAAGGGUUUCUGAAAAUACUGUUUUAA-5'(SEQIDNO:640)
CKAP5-990靶:5'-CTTCCCAAAGACTTTTATGACAAAATT-3'(SEQIDNO:1216)
5'-UCCCAAAGACUUUUAUGACAAAAUUGA-3'(SEQIDNO:3521)
3'-AGGGUUUCUGAAAAUACUGUUUUAACU-5'(SEQIDNO:641)
CKAP5-992靶:5'-TCCCAAAGACTTTTATGACAAAATTGA-3'(SEQIDNO:1217)
5'-CCAAAGACUUUUAUGACAAAAUUGAGG-3'(SEQIDNO:3522)
3'-GGUUUCUGAAAAUACUGUUUUAACUCC-5'(SEQIDNO:642)
CKAP5-994靶:5'-CCAAAGACTTTTATGACAAAATTGAGG-3'(SEQIDNO:1218)
5'-AAAGACUUUUAUGACAAAAUUGAGGCA-3'(SEQIDNO:3523)
3'-UUUCUGAAAAUACUGUUUUAACUCCGU-5'(SEQIDNO:643)
CKAP5-996靶:5'-AAAGACTTTTATGACAAAATTGAGGCA-3'(SEQIDNO:1219)
5'-AGACUUUUAUGACAAAAUUGAGGCAAA-3'(SEQIDNO:3524)
3'-UCUGAAAAUACUGUUUUAACUCCGUUU-5'(SEQIDNO:644)
CKAP5-998靶:5'-AGACTTTTATGACAAAATTGAGGCAAA-3'(SEQIDNO:1220)
5'-ACUUUUAUGACAAAAUUGAGGCAAAAA-3'(SEQIDNO:3525)
3'-UGAAAAUACUGUUUUAACUCCGUUUUU-5'(SEQIDNO:645)
CKAP5-1000靶:5'-ACTTTTATGACAAAATTGAGGCAAAAA-3'(SEQIDNO:1221)
5'-UUUUAUGACAAAAUUGAGGCAAAAAAA-3'(SEQIDNO:3526)
3'-AAAAUACUGUUUUAACUCCGUUUUUUU-5'(SEQIDNO:646)
CKAP5-1002靶:5'-TTTTATGACAAAATTGAGGCAAAAAAA-3'(SEQIDNO:1222)
5'-UUAUGACAAAAUUGAGGCAAAAAAAUG-3'(SEQIDNO:3527)
3'-AAUACUGUUUUAACUCCGUUUUUUUAC-5'(SEQIDNO:647)
CKAP5-1004靶:5'-TTATGACAAAATTGAGGCAAAAAAATG-3'(SEQIDNO:1223)
5'-AAAAUGGCAAGAGAGAAAAGAGGCCCU-3'(SEQIDNO:3528)
3'-UUUUACCGUUCUCUCUUUUCUCCGGGA-5'(SEQIDNO:648)
CKAP5-1025靶:5'-AAAATGGCAAGAGAGAAAAGAGGCCCT-3'(SEQIDNO:1224)
5'-GAAGGUUGUUGGAAAGGACACCAAUGU-3'(SEQIDNO:3529)
3'-CUUCCAACAACCUUUCCUGUGGUUACA-5'(SEQIDNO:649)
CKAP5-1127靶:5'-GAAGGTTGTTGGAAAGGACACCAATGT-3'(SEQIDNO:1225)
5'-AGGUUGUUGGAAAGGACACCAAUGUCA-3'(SEQIDNO:3530)
3'-UCCAACAACCUUUCCUGUGGUUACAGU-5'(SEQIDNO:650)
CKAP5-1129靶:5'-AGGTTGTTGGAAAGGACACCAATGTCA-3'(SEQIDNO:1226)
5'-GUUGUUGGAAAGGACACCAAUGUCAUG-3'(SEQIDNO:3531)
3'-CAACAACCUUUCCUGUGGUUACAGUAC-5'(SEQIDNO:651)
CKAP5-1131靶:5'-GTTGTTGGAAAGGACACCAATGTCATG-3'(SEQIDNO:1227)
5'-UGUUGGAAAGGACACCAAUGUCAUGUU-3'(SEQIDNO:3532)
3'-ACAACCUUUCCUGUGGUUACAGUACAA-5'(SEQIDNO:652)
CKAP5-1133靶:5'-TGTTGGAAAGGACACCAATGTCATGTT-3'(SEQIDNO:1228)
5'-UUGGAAAGGACACCAAUGUCAUGUUGG-3'(SEQIDNO:3533)
3'-AACCUUUCCUGUGGUUACAGUACAACC-5'(SEQIDNO:653)
CKAP5-1135靶:5'-TTGGAAAGGACACCAATGTCATGTTGG-3'(SEQIDNO:1229)
5'-GGAAAGGACACCAAUGUCAUGUUGGUG-3'(SEQIDNO:3534)
3'-CCUUUCCUGUGGUUACAGUACAACCAC-5'(SEQIDNO:654)
CKAP5-1137靶:5'-GGAAAGGACACCAATGTCATGTTGGTG-3'(SEQIDNO:1230)
5'-AAAGGACACCAAUGUCAUGUUGGUGGC-3'(SEQIDNO:3535)
3'-UUUCCUGUGGUUACAGUACAACCACCG-5'(SEQIDNO:655)
CKAP5-1139靶:5'-AAAGGACACCAATGTCATGTTGGTGGC-3'(SEQIDNO:1231)
5'-AGGACACCAAUGUCAUGUUGGUGGCUU-3'(SEQIDNO:3536)
3'-UCCUGUGGUUACAGUACAACCACCGAA-5'(SEQIDNO:656)
CKAP5-1141靶:5'-AGGACACCAATGTCATGTTGGTGGCTT-3'(SEQIDNO:1232)
5'-UGGCUUUGGCAGCAAAAUGUCUUACUG-3'(SEQIDNO:3537)
3'-ACCGAAACCGUCGUUUUACAGAAUGAC-5'(SEQIDNO:657)
CKAP5-1162靶:5'-TGGCTTTGGCAGCAAAATGTCTTACTG-3'(SEQIDNO:1233)
5'-GCUUUGGCAGCAAAAUGUCUUACUGGC-3'(SEQIDNO:3538)
3'-CGAAACCGUCGUUUUACAGAAUGACCG-5'(SEQIDNO:658)
CKAP5-1164靶:5'-GCTTTGGCAGCAAAATGTCTTACTGGC-3'(SEQIDNO:1234)
5'-UUUGGCAGCAAAAUGUCUUACUGGCCU-3'(SEQIDNO:3539)
3'-AAACCGUCGUUUUACAGAAUGACCGGA-5'(SEQIDNO:659)
CKAP5-1166靶:5'-TTTGGCAGCAAAATGTCTTACTGGCCT-3'(SEQIDNO:1235)
5'-UGGCAGCAAAAUGUCUUACUGGCCUGG-3'(SEQIDNO:3540)
3'-ACCGUCGUUUUACAGAAUGACCGGACC-5'(SEQIDNO:660)
CKAP5-1168靶:5'-TGGCAGCAAAATGTCTTACTGGCCTGG-3'(SEQIDNO:1236)
5'-GCAGCAAAAUGUCUUACUGGCCUGGCU-3'(SEQIDNO:3541)
3'-CGUCGUUUUACAGAAUGACCGGACCGA-5'(SEQIDNO:661)
CKAP5-1170靶:5'-GCAGCAAAATGTCTTACTGGCCTGGCT-3'(SEQIDNO:1237)
5'-GAAGAAAUUUGGACAAUAUGCAGGACA-3'(SEQIDNO:3542)
3'-CUUCUUUAAACCUGUUAUACGUCCUGU-5'(SEQIDNO:662)
CKAP5-1208靶:5'-GAAGAAATTTGGACAATATGCAGGACA-3'(SEQIDNO:1238)
5'-AGAAAUUUGGACAAUAUGCAGGACAUG-3'(SEQIDNO:3543)
3'-UCUUUAAACCUGUUAUACGUCCUGUAC-5'(SEQIDNO:663)
CKAP5-1210靶:5'-AGAAATTTGGACAATATGCAGGACATG-3'(SEQIDNO:1239)
5'-AAAUUUGGACAAUAUGCAGGACAUGUU-3'(SEQIDNO:3544)
3'-UUUAAACCUGUUAUACGUCCUGUACAA-5'(SEQIDNO:664)
CKAP5-1212靶:5'-AAATTTGGACAATATGCAGGACATGTT-3'(SEQIDNO:1240)
5'-AUUUGGACAAUAUGCAGGACAUGUUGU-3'(SEQIDNO:3545)
3'-UAAACCUGUUAUACGUCCUGUACAACA-5'(SEQIDNO:665)
CKAP5-1214靶:5'-ATTTGGACAATATGCAGGACATGTTGT-3'(SEQIDNO:1241)
5'-UUGGACAAUAUGCAGGACAUGUUGUGC-3'(SEQIDNO:3546)
3'-AACCUGUUAUACGUCCUGUACAACACG-5'(SEQIDNO:666)
CKAP5-1216靶:5'-TTGGACAATATGCAGGACATGTTGTGC-3'(SEQIDNO:1242)
5'-GGACAAUAUGCAGGACAUGUUGUGCCA-3'(SEQIDNO:3547)
3'-CCUGUUAUACGUCCUGUACAACACGGU-5'(SEQIDNO:667)
CKAP5-1218靶:5'-GGACAATATGCAGGACATGTTGTGCCA-3'(SEQIDNO:1243)
5'-ACAAUAUGCAGGACAUGUUGUGCCAAC-3'(SEQIDNO:3548)
3'-UGUUAUACGUCCUGUACAACACGGUUG-5'(SEQIDNO:668)
CKAP5-1220靶:5'-ACAATATGCAGGACATGTTGTGCCAAC-3'(SEQIDNO:1244)
5'-AAUAUGCAGGACAUGUUGUGCCAACCA-3'(SEQIDNO:3549)
3'-UUAUACGUCCUGUACAACACGGUUGGU-5'(SEQIDNO:669)
CKAP5-1222靶:5'-AATATGCAGGACATGTTGTGCCAACCA-3'(SEQIDNO:1245)
5'-UAUGCAGGACAUGUUGUGCCAACCAUC-3'(SEQIDNO:3550)
3'-AUACGUCCUGUACAACACGGUUGGUAG-5'(SEQIDNO:670)
CKAP5-1224靶:5'-TATGCAGGACATGTTGTGCCAACCATC-3'(SEQIDNO:1246)
5'-UGCAGGACAUGUUGUGCCAACCAUCUU-3'(SEQIDNO:3551)
3'-ACGUCCUGUACAACACGGUUGGUAGAA-5'(SEQIDNO:671)
CKAP5-1226靶:5'-TGCAGGACATGTTGTGCCAACCATCTT-3'(SEQIDNO:1247)
5'-ACCUCAAGUGGUACAAGCCCUGCAGGA-3'(SEQIDNO:3552)
3'-UGGAGUUCACCAUGUUCGGGACGUCCU-5'(SEQIDNO:672)
CKAP5-1274靶:5'-ACCTCAAGTGGTACAAGCCCTGCAGGA-3'(SEQIDNO:1248)
5'-CUCAAGUGGUACAAGCCCUGCAGGAGG-3'(SEQIDNO:3553)
3'-GAGUUCACCAUGUUCGGGACGUCCUCC-5'(SEQIDNO:673)
CKAP5-1276靶:5'-CTCAAGTGGTACAAGCCCTGCAGGAGG-3'(SEQIDNO:1249)
5'-CAAGUGGUACAAGCCCUGCAGGAGGCA-3'(SEQIDNO:3554)
3'-GUUCACCAUGUUCGGGACGUCCUCCGU-5'(SEQIDNO:674)
CKAP5-1278靶:5'-CAAGTGGTACAAGCCCTGCAGGAGGCA-3'(SEQIDNO:1250)
5'-AGUGGUACAAGCCCUGCAGGAGGCAAU-3'(SEQIDNO:3555)
3'-UCACCAUGUUCGGGACGUCCUCCGUUA-5'(SEQIDNO:675)
CKAP5-1280靶:5'-AGTGGTACAAGCCCTGCAGGAGGCAAT-3'(SEQIDNO:1251)
5'-UGGUACAAGCCCUGCAGGAGGCAAUUG-3'(SEQIDNO:3556)
3'-ACCAUGUUCGGGACGUCCUCCGUUAAC-5'(SEQIDNO:676)
CKAP5-1282靶:5'-TGGTACAAGCCCTGCAGGAGGCAATTG-3'(SEQIDNO:1252)
5'-GUACAAGCCCUGCAGGAGGCAAUUGAU-3'(SEQIDNO:3557)
3'-CAUGUUCGGGACGUCCUCCGUUAACUA-5'(SEQIDNO:677)
CKAP5-1284靶:5'-GTACAAGCCCTGCAGGAGGCAATTGAT-3'(SEQIDNO:1253)
5'-ACAAGCCCUGCAGGAGGCAAUUGAUGC-3'(SEQIDNO:3558)
3'-UGUUCGGGACGUCCUCCGUUAACUACG-5'(SEQIDNO:678)
CKAP5-1286靶:5'-ACAAGCCCTGCAGGAGGCAATTGATGC-3'(SEQIDNO:1254)
5'-AAGCCCUGCAGGAGGCAAUUGAUGCAA-3'(SEQIDNO:3559)
3'-UUCGGGACGUCCUCCGUUAACUACGUU-5'(SEQIDNO:679)
CKAP5-1288靶:5'-AAGCCCTGCAGGAGGCAATTGATGCAA-3'(SEQIDNO:1255)
5'-GCCCUGCAGGAGGCAAUUGAUGCAAUC-3'(SEQIDNO:3560)
3'-CGGGACGUCCUCCGUUAACUACGUUAG-5'(SEQIDNO:680)
CKAP5-1290靶:5'-GCCCTGCAGGAGGCAATTGATGCAATC-3'(SEQIDNO:1256)
5'-CCUGCAGGAGGCAAUUGAUGCAAUCUU-3'(SEQIDNO:3561)
3'-GGACGUCCUCCGUUAACUACGUUAGAA-5'(SEQIDNO:681)
CKAP5-1292靶:5'-CCTGCAGGAGGCAATTGATGCAATCTT-3'(SEQIDNO:1257)
5'-UGCAGGAGGCAAUUGAUGCAAUCUUCC-3'(SEQIDNO:3562)
3'-ACGUCCUCCGUUAACUACGUUAGAAGG-5'(SEQIDNO:682)
CKAP5-1294靶:5'-TGCAGGAGGCAATTGATGCAATCTTCC-3'(SEQIDNO:1258)
5'-CAGGAGGCAAUUGAUGCAAUCUUCCUU-3'(SEQIDNO:3563)
3'-GUCCUCCGUUAACUACGUUAGAAGGAA-5'(SEQIDNO:683)
CKAP5-1296靶:5'-CAGGAGGCAATTGATGCAATCTTCCTT-3'(SEQIDNO:1259)
5'-GGAGGCAAUUGAUGCAAUCUUCCUUAC-3'(SEQIDNO:3564)
3'-CCUCCGUUAACUACGUUAGAAGGAAUG-5'(SEQIDNO:684)
CKAP5-1298靶:5'-GGAGGCAATTGATGCAATCTTCCTTAC-3'(SEQIDNO:1260)
5'-AGGCAAUUGAUGCAAUCUUCCUUACUA-3'(SEQIDNO:3565)
3'-UCCGUUAACUACGUUAGAAGGAAUGAU-5'(SEQIDNO:685)
CKAP5-1300靶:5'-AGGCAATTGATGCAATCTTCCTTACTA-3'(SEQIDNO:1261)
5'-UUACUACCACACUACAGAACAUCAGUG-3'(SEQIDNO:3566)
3'-AAUGAUGGUGUGAUGUCUUGUAGUCAC-5'(SEQIDNO:686)
CKAP5-1321靶:5'-TTACTACCACACTACAGAACATCAGTG-3'(SEQIDNO:1262)
5'-ACUACCACACUACAGAACAUCAGUGAG-3'(SEQIDNO:3567)
3'-UGAUGGUGUGAUGUCUUGUAGUCACUC-5'(SEQIDNO:687)
CKAP5-1323靶:5'-ACTACCACACTACAGAACATCAGTGAG-3'(SEQIDNO:1263)
5'-UACCACACUACAGAACAUCAGUGAGGA-3'(SEQIDNO:3568)
3'-AUGGUGUGAUGUCUUGUAGUCACUCCU-5'(SEQIDNO:688)
CKAP5-1325靶:5'-TACCACACTACAGAACATCAGTGAGGA-3'(SEQIDNO:1264)
5'-CCACACUACAGAACAUCAGUGAGGAUG-3'(SEQIDNO:3569)
3'-GGUGUGAUGUCUUGUAGUCACUCCUAC-5'(SEQIDNO:689)
CKAP5-1327靶:5'-CCACACTACAGAACATCAGTGAGGATG-3'(SEQIDNO:1265)
5'-ACACUACAGAACAUCAGUGAGGAUGUU-3'(SEQIDNO:3570)
3'-UGUGAUGUCUUGUAGUCACUCCUACAA-5'(SEQIDNO:690)
CKAP5-1329靶:5'-ACACTACAGAACATCAGTGAGGATGTT-3'(SEQIDNO:1266)
5'-ACUACAGAACAUCAGUGAGGAUGUUUU-3'(SEQIDNO:3571)
3'-UGAUGUCUUGUAGUCACUCCUACAAAA-5'(SEQIDNO:691)
CKAP5-1331靶:5'-ACTACAGAACATCAGTGAGGATGTTTT-3'(SEQIDNO:1267)
5'-UACAGAACAUCAGUGAGGAUGUUUUAG-3'(SEQIDNO:3572)
3'-AUGUCUUGUAGUCACUCCUACAAAAUC-5'(SEQIDNO:692)
CKAP5-1333靶:5'-TACAGAACATCAGTGAGGATGTTTTAG-3'(SEQIDNO:1268)
5'-UUUUAGCAGUAAUGGAUAAUAAAAAUC-3'(SEQIDNO:3573)
3'-AAAAUCGUCAUUACCUAUUAUUUUUAG-5'(SEQIDNO:693)
CKAP5-1354靶:5'-TTTTAGCAGTAATGGATAATAAAAATC-3'(SEQIDNO:1269)
5'-UUAGCAGUAAUGGAUAAUAAAAAUCCA-3'(SEQIDNO:3574)
3'-AAUCGUCAUUACCUAUUAUUUUUAGGU-5'(SEQIDNO:694)
CKAP5-1356靶:5'-TTAGCAGTAATGGATAATAAAAATCCA-3'(SEQIDNO:1270)
5'-AGCAGUAAUGGAUAAUAAAAAUCCAAC-3'(SEQIDNO:3575)
3'-UCGUCAUUACCUAUUAUUUUUAGGUUG-5'(SEQIDNO:695)
CKAP5-1358靶:5'-AGCAGTAATGGATAATAAAAATCCAAC-3'(SEQIDNO:1271)
5'-CAGUAAUGGAUAAUAAAAAUCCAACCA-3'(SEQIDNO:3576)
3'-GUCAUUACCUAUUAUUUUUAGGUUGGU-5'(SEQIDNO:696)
CKAP5-1360靶:5'-CAGTAATGGATAATAAAAATCCAACCA-3'(SEQIDNO:1272)
5'-CAACCAUCAAGCAGCAGACAUCUCUUU-3'(SEQIDNO:3577)
3'-GUUGGUAGUUCGUCGUCUGUAGAGAAA-5'(SEQIDNO:697)
CKAP5-1381靶:5'-CAACCATCAAGCAGCAGACATCTCTTT-3'(SEQIDNO:1273)
5'-CACUACUUAAGCACAUCAAUGAUUCUG-3'(SEQIDNO:3578)
3'-GUGAUGAAUUCGUGUAGUUACUAAGAC-5'(SEQIDNO:698)
CKAP5-1480靶:5'-CACTACTTAAGCACATCAATGATTCTG-3'(SEQIDNO:1274)
5'-CUACUUAAGCACAUCAAUGAUUCUGCU-3'(SEQIDNO:3579)
3'-GAUGAAUUCGUGUAGUUACUAAGACGA-5'(SEQIDNO:699)
CKAP5-1482靶:5'-CTACTTAAGCACATCAATGATTCTGCT-3'(SEQIDNO:1275)
5'-ACUUAAGCACAUCAAUGAUUCUGCUCC-3'(SEQIDNO:3580)
3'-UGAAUUCGUGUAGUUACUAAGACGAGG-5'(SEQIDNO:700)
CKAP5-1484靶:5'-ACTTAAGCACATCAATGATTCTGCTCC-3'(SEQIDNO:1276)
5'-UUAAGCACAUCAAUGAUUCUGCUCCUG-3'(SEQIDNO:3581)
3'-AAUUCGUGUAGUUACUAAGACGAGGAC-5'(SEQIDNO:701)
CKAP5-1486靶:5'-TTAAGCACATCAATGATTCTGCTCCTG-3'(SEQIDNO:1277)
5'-AAGCACAUCAAUGAUUCUGCUCCUGAA-3'(SEQIDNO:3582)
3'-UUCGUGUAGUUACUAAGACGAGGACUU-5'(SEQIDNO:702)
CKAP5-1488靶:5'-AAGCACATCAATGATTCTGCTCCTGAA-3'(SEQIDNO:1278)
5'-GCACAUCAAUGAUUCUGCUCCUGAAGU-3'(SEQIDNO:3583)
3'-CGUGUAGUUACUAAGACGAGGACUUCA-5'(SEQIDNO:703)
CKAP5-1490靶:5'-GCACATCAATGATTCTGCTCCTGAAGT-3'(SEQIDNO:1279)
5'-ACAUCAAUGAUUCUGCUCCUGAAGUCA-3'(SEQIDNO:3584)
3'-UGUAGUUACUAAGACGAGGACUUCAGU-5'(SEQIDNO:704)
CKAP5-1492靶:5'-ACATCAATGATTCTGCTCCTGAAGTCA-3'(SEQIDNO:1280)
5'-AUCAAUGAUUCUGCUCCUGAAGUCAGA-3'(SEQIDNO:3585)
3'-UAGUUACUAAGACGAGGACUUCAGUCU-5'(SEQIDNO:705)
CKAP5-1494靶:5'-ATCAATGATTCTGCTCCTGAAGTCAGA-3'(SEQIDNO:1281)
5'-CAAUGAUUCUGCUCCUGAAGUCAGAGA-3'(SEQIDNO:3586)
3'-GUUACUAAGACGAGGACUUCAGUCUCU-5'(SEQIDNO:706)
CKAP5-1496靶:5'-CAATGATTCTGCTCCTGAAGTCAGAGA-3'(SEQIDNO:1282)
5'-AUGAUUCUGCUCCUGAAGUCAGAGAUG-3'(SEQIDNO:3587)
3'-UACUAAGACGAGGACUUCAGUCUCUAC-5'(SEQIDNO:707)
CKAP5-1498靶:5'-ATGATTCTGCTCCTGAAGTCAGAGATG-3'(SEQIDNO:1283)
5'-GAUUCUGCUCCUGAAGUCAGAGAUGCC-3'(SEQIDNO:3588)
3'-CUAAGACGAGGACUUCAGUCUCUACGG-5'(SEQIDNO:708)
CKAP5-1500靶:5'-GATTCTGCTCCTGAAGTCAGAGATGCC-3'(SEQIDNO:1284)
5'-UUCUGCUCCUGAAGUCAGAGAUGCCGC-3'(SEQIDNO:3589)
3'-AAGACGAGGACUUCAGUCUCUACGGCG-5'(SEQIDNO:709)
CKAP5-1502靶:5'-TTCTGCTCCTGAAGTCAGAGATGCCGC-3'(SEQIDNO:1285)
5'-CUGCUCCUGAAGUCAGAGAUGCCGCAU-3'(SEQIDNO:3590)
3'-GACGAGGACUUCAGUCUCUACGGCGUA-5'(SEQIDNO:710)
CKAP5-1504靶:5'-CTGCTCCTGAAGTCAGAGATGCCGCAT-3'(SEQIDNO:1286)
5'-AAGAUCAAAGAAUGUUCAGAAAAGGUA-3'(SEQIDNO:3591)
3'-UUCUAGUUUCUUACAAGUCUUUUCCAU-5'(SEQIDNO:711)
CKAP5-1617靶:5'-AAGATCAAAGAATGTTCAGAAAAGGTA-3'(SEQIDNO:1287)
5'-GAUCAAAGAAUGUUCAGAAAAGGUAGA-3'(SEQIDNO:3592)
3'-CUAGUUUCUUACAAGUCUUUUCCAUCU-5'(SEQIDNO:712)
CKAP5-1619靶:5'-GATCAAAGAATGTTCAGAAAAGGTAGA-3'(SEQIDNO:1288)
5'-GAAACCUGGAUGGAAAGAAACUAAUUU-3'(SEQIDNO:3593)
3'-CUUUGGACCUACCUUUCUUUGAUUAAA-5'(SEQIDNO:713)
CKAP5-2090靶:5'-GAAACCTGGATGGAAAGAAACTAATTT-3'(SEQIDNO:1289)
5'-AACCUGGAUGGAAAGAAACUAAUUUUC-3'(SEQIDNO:3594)
3'-UUGGACCUACCUUUCUUUGAUUAAAAG-5'(SEQIDNO:714)
CKAP5-2092靶:5'-AACCTGGATGGAAAGAAACTAATTTTC-3'(SEQIDNO:1290)
5'-CCUGGAUGGAAAGAAACUAAUUUUCAG-3'(SEQIDNO:3595)
3'-GGACCUACCUUUCUUUGAUUAAAAGUC-5'(SEQIDNO:715)
CKAP5-2094靶:5'-CCTGGATGGAAAGAAACTAATTTTCAG-3'(SEQIDNO:1291)
5'-UGGAUGGAAAGAAACUAAUUUUCAGGU-3'(SEQIDNO:3596)
3'-ACCUACCUUUCUUUGAUUAAAAGUCCA-5'(SEQIDNO:716)
CKAP5-2096靶:5'-TGGATGGAAAGAAACTAATTTTCAGGT-3'(SEQIDNO:1292)
5'-GAUGGAAAGAAACUAAUUUUCAGGUGA-3'(SEQIDNO:3597)
3'-CUACCUUUCUUUGAUUAAAAGUCCACU-5'(SEQIDNO:717)
CKAP5-2098靶:5'-GATGGAAAGAAACTAATTTTCAGGTGA-3'(SEQIDNO:1293)
5'-UGGAAAGAAACUAAUUUUCAGGUGAUG-3'(SEQIDNO:3598)
3'-ACCUUUCUUUGAUUAAAAGUCCACUAC-5'(SEQIDNO:718)
CKAP5-2100靶:5'-TGGAAAGAAACTAATTTTCAGGTGATG-3'(SEQIDNO:1294)
5'-GAAAGAAACUAAUUUUCAGGUGAUGCA-3'(SEQIDNO:3599)
3'-CUUUCUUUGAUUAAAAGUCCACUACGU-5'(SEQIDNO:719)
CKAP5-2102靶:5'-GAAAGAAACTAATTTTCAGGTGATGCA-3'(SEQIDNO:1295)
5'-AAGAAACUAAUUUUCAGGUGAUGCAAA-3'(SEQIDNO:3600)
3'-UUCUUUGAUUAAAAGUCCACUACGUUU-5'(SEQIDNO:720)
CKAP5-2104靶:5'-AAGAAACTAATTTTCAGGTGATGCAAA-3'(SEQIDNO:1296)
5'-GAAACUAAUUUUCAGGUGAUGCAAAUG-3'(SEQIDNO:3601)
3'-CUUUGAUUAAAAGUCCACUACGUUUAC-5'(SEQIDNO:721)
CKAP5-2106靶:5'-GAAACTAATTTTCAGGTGATGCAAATG-3'(SEQIDNO:1297)
5'-AACUAAUUUUCAGGUGAUGCAAAUGAA-3'(SEQIDNO:3602)
3'-UUGAUUAAAAGUCCACUACGUUUACUU-5'(SEQIDNO:722)
CKAP5-2108靶:5'-AACTAATTTTCAGGTGATGCAAATGAA-3'(SEQIDNO:1298)
5'-AGUUGCUUUGAUUGCCCAGAAGGGAAA-3'(SEQIDNO:3603)
3'-UCAACGAAACUAACGGGUCUUCCCUUU-5'(SEQIDNO:723)
CKAP5-2144靶:5'-AGTTGCTTTGATTGCCCAGAAGGGAAA-3'(SEQIDNO:1299)
5'-UUGCUUUGAUUGCCCAGAAGGGAAAUU-3'(SEQIDNO:3604)
3'-AACGAAACUAACGGGUCUUCCCUUUAA-5'(SEQIDNO:724)
CKAP5-2146靶:5'-TTGCTTTGATTGCCCAGAAGGGAAATT-3'(SEQIDNO:1300)
5'-GCUUUGAUUGCCCAGAAGGGAAAUUUU-3'(SEQIDNO:3605)
3'-CGAAACUAACGGGUCUUCCCUUUAAAA-5'(SEQIDNO:725)
CKAP5-2148靶:5'-GCTTTGATTGCCCAGAAGGGAAATTTT-3'(SEQIDNO:1301)
5'-UUUGAUUGCCCAGAAGGGAAAUUUUUC-3'(SEQIDNO:3606)
3'-AAACUAACGGGUCUUCCCUUUAAAAAG-5'(SEQIDNO:726)
CKAP5-2150靶:5'-TTTGATTGCCCAGAAGGGAAATTTTTC-3'(SEQIDNO:1302)
5'-UGAUUGCCCAGAAGGGAAAUUUUUCCA-3'(SEQIDNO:3607)
3'-ACUAACGGGUCUUCCCUUUAAAAAGGU-5'(SEQIDNO:727)
CKAP5-2152靶:5'-TGATTGCCCAGAAGGGAAATTTTTCCA-3'(SEQIDNO:1303)
5'-AUUGCCCAGAAGGGAAAUUUUUCCAAA-3'(SEQIDNO:3608)
3'-UAACGGGUCUUCCCUUUAAAAAGGUUU-5'(SEQIDNO:728)
CKAP5-2154靶:5'-ATTGCCCAGAAGGGAAATTTTTCCAAA-3'(SEQIDNO:1304)
5'-UGCCCAGAAGGGAAAUUUUUCCAAAAC-3'(SEQIDNO:3609)
3'-ACGGGUCUUCCCUUUAAAAAGGUUUUG-5'(SEQIDNO:729)
CKAP5-2156靶:5'-TGCCCAGAAGGGAAATTTTTCCAAAAC-3'(SEQIDNO:1305)
5'-UGGACAAGAUUGGAGAUGUGAAAUGUG-3'(SEQIDNO:3610)
3'-ACCUGUUCUAACCUCUACACUUUACAC-5'(SEQIDNO:730)
CKAP5-2212靶:5'-TGGACAAGATTGGAGATGTGAAATGTG-3'(SEQIDNO:1306)
5'-GACAAGAUUGGAGAUGUGAAAUGUGGG-3'(SEQIDNO:3611)
3'-CUGUUCUAACCUCUACACUUUACACCC-5'(SEQIDNO:731)
CKAP5-2214靶:5'-GACAAGATTGGAGATGTGAAATGTGGG-3'(SEQIDNO:1307)
5'-CAAGAUUGGAGAUGUGAAAUGUGGGAA-3'(SEQIDNO:3612)
3'-GUUCUAACCUCUACACUUUACACCCUU-5'(SEQIDNO:732)
CKAP5-2216靶:5'-CAAGATTGGAGATGTGAAATGTGGGAA-3'(SEQIDNO:1308)
5'-AGAUUGGAGAUGUGAAAUGUGGGAACA-3'(SEQIDNO:3613)
3'-UCUAACCUCUACACUUUACACCCUUGU-5'(SEQIDNO:733)
CKAP5-2218靶:5'-AGATTGGAGATGTGAAATGTGGGAACA-3'(SEQIDNO:1309)
5'-AUUGGAGAUGUGAAAUGUGGGAACAAU-3'(SEQIDNO:3614)
3'-UAACCUCUACACUUUACACCCUUGUUA-5'(SEQIDNO:734)
CKAP5-2220靶:5'-ATTGGAGATGTGAAATGTGGGAACAAT-3'(SEQIDNO:1310)
5'-UGGAGAUGUGAAAUGUGGGAACAAUGC-3'(SEQIDNO:3615)
3'-ACCUCUACACUUUACACCCUUGUUACG-5'(SEQIDNO:735)
CKAP5-2222靶:5'-TGGAGATGTGAAATGTGGGAACAATGC-3'(SEQIDNO:1311)
5'-GAGAUGUGAAAUGUGGGAACAAUGCAA-3'(SEQIDNO:3616)
3'-CUCUACACUUUACACCCUUGUUACGUU-5'(SEQIDNO:736)
CKAP5-2224靶:5'-GAGATGTGAAATGTGGGAACAATGCAA-3'(SEQIDNO:1312)
5'-GAUGUGAAAUGUGGGAACAAUGCAAAA-3'(SEQIDNO:3617)
3'-CUACACUUUACACCCUUGUUACGUUUU-5'(SEQIDNO:737)
CKAP5-2226靶:5'-GATGTGAAATGTGGGAACAATGCAAAA-3'(SEQIDNO:1313)
5'-UGUGAAAUGUGGGAACAAUGCAAAAGA-3'(SEQIDNO:3618)
3'-ACACUUUACACCCUUGUUACGUUUUCU-5'(SEQIDNO:738)
CKAP5-2228靶:5'-TGTGAAATGTGGGAACAATGCAAAAGA-3'(SEQIDNO:1314)
5'-UGAAAUGUGGGAACAAUGCAAAAGAAG-3'(SEQIDNO:3619)
3'-ACUUUACACCCUUGUUACGUUUUCUUC-5'(SEQIDNO:739)
CKAP5-2230靶:5'-TGAAATGTGGGAACAATGCAAAAGAAG-3'(SEQIDNO:1315)
5'-AAAUGUGGGAACAAUGCAAAAGAAGCU-3'(SEQIDNO:3620)
3'-UUUACACCCUUGUUACGUUUUCUUCGA-5'(SEQIDNO:740)
CKAP5-2232靶:5'-AAATGTGGGAACAATGCAAAAGAAGCT-3'(SEQIDNO:1316)
5'-AUGUGGGAACAAUGCAAAAGAAGCUAU-3'(SEQIDNO:3621)
3'-UACACCCUUGUUACGUUUUCUUCGAUA-5'(SEQIDNO:741)
CKAP5-2234靶:5'-ATGTGGGAACAATGCAAAAGAAGCTAT-3'(SEQIDNO:1317)
5'-GUGGGAACAAUGCAAAAGAAGCUAUGA-3'(SEQIDNO:3622)
3'-CACCCUUGUUACGUUUUCUUCGAUACU-5'(SEQIDNO:742)
CKAP5-2236靶:5'-GTGGGAACAATGCAAAAGAAGCTATGA-3'(SEQIDNO:1318)
5'-GGGUUGAAUGUCAAAGCUUUCAUUAGC-3'(SEQIDNO:3623)
3'-CCCAACUUACAGUUUCGAAAGUAAUCG-5'(SEQIDNO:743)
CKAP5-2400靶:5'-GGGTTGAATGTCAAAGCTTTCATTAGC-3'(SEQIDNO:1319)
5'-GUUGAAUGUCAAAGCUUUCAUUAGCAA-3'(SEQIDNO:3624)
3'-CAACUUACAGUUUCGAAAGUAAUCGUU-5'(SEQIDNO:744)
CKAP5-2402靶:5'-GTTGAATGTCAAAGCTTTCATTAGCAA-3'(SEQIDNO:1320)
5'-UGAAUGUCAAAGCUUUCAUUAGCAAUG-3'(SEQIDNO:3625)
3'-ACUUACAGUUUCGAAAGUAAUCGUUAC-5'(SEQIDNO:745)
CKAP5-2404靶:5'-TGAATGTCAAAGCTTTCATTAGCAATG-3'(SEQIDNO:1321)
5'-AAUGUCAAAGCUUUCAUUAGCAAUGUG-3'(SEQIDNO:3626)
3'-UUACAGUUUCGAAAGUAAUCGUUACAC-5'(SEQIDNO:746)
CKAP5-2406靶:5'-AATGTCAAAGCTTTCATTAGCAATGTG-3'(SEQIDNO:1322)
5'-UGUCAAAGCUUUCAUUAGCAAUGUGAA-3'(SEQIDNO:3627)
3'-ACAGUUUCGAAAGUAAUCGUUACACUU-5'(SEQIDNO:747)
CKAP5-2408靶:5'-TGTCAAAGCTTTCATTAGCAATGTGAA-3'(SEQIDNO:1323)
5'-AACCCUGCUUGGCGUGAUGUAUCUGUA-3'(SEQIDNO:3628)
3'-UUGGGACGAACCGCACUACAUAGACAU-5'(SEQIDNO:748)
CKAP5-2480靶:5'-AACCCTGCTTGGCGTGATGTATCTGTA-3'(SEQIDNO:1324)
5'-CCCUGCUUGGCGUGAUGUAUCUGUAUG-3'(SEQIDNO:3629)
3'-GGGACGAACCGCACUACAUAGACAUAC-5'(SEQIDNO:749)
CKAP5-2482靶:5'-CCCTGCTTGGCGTGATGTATCTGTATG-3'(SEQIDNO:1325)
5'-GUUCUUUGAGGAUGAGAAGCCUGCCCU-3'(SEQIDNO:3630)
3'-CAAGAAACUCCUACUCUUCGGACGGGA-5'(SEQIDNO:750)
CKAP5-2528靶:5'-GTTCTTTGAGGATGAGAAGCCTGCCCT-3'(SEQIDNO:1326)
5'-UCUUUGAGGAUGAGAAGCCUGCCCUCC-3'(SEQIDNO:3631)
3'-AGAAACUCCUACUCUUCGGACGGGAGG-5'(SEQIDNO:751)
CKAP5-2530靶:5'-TCTTTGAGGATGAGAAGCCTGCCCTCC-3'(SEQIDNO:1327)
5'-UUUGAGGAUGAGAAGCCUGCCCUCCUA-3'(SEQIDNO:3632)
3'-AAACUCCUACUCUUCGGACGGGAGGAU-5'(SEQIDNO:752)
CKAP5-2532靶:5'-TTTGAGGATGAGAAGCCTGCCCTCCTA-3'(SEQIDNO:1328)
5'-UGAGGAUGAGAAGCCUGCCCUCCUAUC-3'(SEQIDNO:3633)
3'-ACUCCUACUCUUCGGACGGGAGGAUAG-5'(SEQIDNO:753)
CKAP5-2534靶:5'-TGAGGATGAGAAGCCTGCCCTCCTATC-3'(SEQIDNO:1329)
5'-AGGAUGAGAAGCCUGCCCUCCUAUCCC-3'(SEQIDNO:3634)
3'-UCCUACUCUUCGGACGGGAGGAUAGGG-5'(SEQIDNO:754)
CKAP5-2536靶:5'-AGGATGAGAAGCCTGCCCTCCTATCCC-3'(SEQIDNO:1330)
5'-GAUGAGAAGCCUGCCCUCCUAUCCCAG-3'(SEQIDNO:3635)
3'-CUACUCUUCGGACGGGAGGAUAGGGUC-5'(SEQIDNO:755)
CKAP5-2538靶:5'-GATGAGAAGCCTGCCCTCCTATCCCAG-3'(SEQIDNO:1331)
5'-UGAGAAGCCUGCCCUCCUAUCCCAGAU-3'(SEQIDNO:3636)
3'-ACUCUUCGGACGGGAGGAUAGGGUCUA-5'(SEQIDNO:756)
CKAP5-2540靶:5'-TGAGAAGCCTGCCCTCCTATCCCAGAT-3'(SEQIDNO:1332)
5'-AGAAGCCUGCCCUCCUAUCCCAGAUAG-3'(SEQIDNO:3637)
3'-UCUUCGGACGGGAGGAUAGGGUCUAUC-5'(SEQIDNO:757)
CKAP5-2542靶:5'-AGAAGCCTGCCCTCCTATCCCAGATAG-3'(SEQIDNO:1333)
5'-AAGCCUGCCCUCCUAUCCCAGAUAGAU-3'(SEQIDNO:3638)
3'-UUCGGACGGGAGGAUAGGGUCUAUCUA-5'(SEQIDNO:758)
CKAP5-2544靶:5'-AAGCCTGCCCTCCTATCCCAGATAGAT-3'(SEQIDNO:1334)
5'-GCCUGCCCUCCUAUCCCAGAUAGAUGC-3'(SEQIDNO:3639)
3'-CGGACGGGAGGAUAGGGUCUAUCUACG-5'(SEQIDNO:759)
CKAP5-2546靶:5'-GCCTGCCCTCCTATCCCAGATAGATGC-3'(SEQIDNO:1335)
5'-CUGCCCUCCUAUCCCAGAUAGAUGCAG-3'(SEQIDNO:3640)
3'-GACGGGAGGAUAGGGUCUAUCUACGUC-5'(SEQIDNO:760)
CKAP5-2548靶:5'-CTGCCCTCCTATCCCAGATAGATGCAG-3'(SEQIDNO:1336)
5'-GCCCUCCUAUCCCAGAUAGAUGCAGAA-3'(SEQIDNO:3641)
3'-CGGGAGGAUAGGGUCUAUCUACGUCUU-5'(SEQIDNO:761)
CKAP5-2550靶:5'-GCCCTCCTATCCCAGATAGATGCAGAA-3'(SEQIDNO:1337)
5'-CCUCCUAUCCCAGAUAGAUGCAGAAUU-3'(SEQIDNO:3642)
3'-GGAGGAUAGGGUCUAUCUACGUCUUAA-5'(SEQIDNO:762)
CKAP5-2552靶:5'-CCTCCTATCCCAGATAGATGCAGAATT-3'(SEQIDNO:1338)
5'-UCCUAUCCCAGAUAGAUGCAGAAUUUG-3'(SEQIDNO:3643)
3'-AGGAUAGGGUCUAUCUACGUCUUAAAC-5'(SEQIDNO:763)
CKAP5-2554靶:5'-TCCTATCCCAGATAGATGCAGAATTTG-3'(SEQIDNO:1339)
5'-CUAUCCCAGAUAGAUGCAGAAUUUGAG-3'(SEQIDNO:3644)
3'-GAUAGGGUCUAUCUACGUCUUAAACUC-5'(SEQIDNO:764)
CKAP5-2556靶:5'-CTATCCCAGATAGATGCAGAATTTGAG-3'(SEQIDNO:1340)
5'-AUCCCAGAUAGAUGCAGAAUUUGAGAA-3'(SEQIDNO:3645)
3'-UAGGGUCUAUCUACGUCUUAAACUCUU-5'(SEQIDNO:765)
CKAP5-2558靶:5'-ATCCCAGATAGATGCAGAATTTGAGAA-3'(SEQIDNO:1341)
5'-AGAAGAUGCAGGGACAAAGUCCACCUG-3'(SEQIDNO:3646)
3'-UCUUCUACGUCCCUGUUUCAGGUGGAC-5'(SEQIDNO:766)
CKAP5-2581靶:5'-AGAAGATGCAGGGACAAAGTCCACCTG-3'(SEQIDNO:1342)
5'-GGUACAGAUGAAGGAGAAGAUGGAGAU-3'(SEQIDNO:3647)
3'-CCAUGUCUACUUCCUCUUCUACCUCUA-5'(SEQIDNO:767)
CKAP5-2643靶:5'-GGTACAGATGAAGGAGAAGATGGAGAT-3'(SEQIDNO:1343)
5'-UACAGAUGAAGGAGAAGAUGGAGAUGA-3'(SEQIDNO:3648)
3'-AUGUCUACUUCCUCUUCUACCUCUACU-5'(SEQIDNO:768)
CKAP5-2645靶:5'-TACAGATGAAGGAGAAGATGGAGATGA-3'(SEQIDNO:1344)
5'-CAGAUGAAGGAGAAGAUGGAGAUGAAC-3'(SEQIDNO:3649)
3'-GUCUACUUCCUCUUCUACCUCUACUUG-5'(SEQIDNO:769)
CKAP5-2647靶:5'-CAGATGAAGGAGAAGATGGAGATGAAC-3'(SEQIDNO:1345)
5'-UCGUUGAUCUUUUGCCGAGGACGGAGA-3'(SEQIDNO:3650)
3'-AGCAACUAGAAAACGGCUCCUGCCUCU-5'(SEQIDNO:770)
CKAP5-2695靶:5'-TCGTTGATCTTTTGCCGAGGACGGAGA-3'(SEQIDNO:1346)
5'-UAGGAAAGAAGGCCUAGAUGAAGUGGC-3'(SEQIDNO:3651)
3'-AUCCUUUCUUCCGGAUCUACUUCACCG-5'(SEQIDNO:771)
CKAP5-2780靶:5'-TAGGAAAGAAGGCCTAGATGAAGTGGC-3'(SEQIDNO:1347)
5'-GGAAAGAAGGCCUAGAUGAAGUGGCAG-3'(SEQIDNO:3652)
3'-CCUUUCUUCCGGAUCUACUUCACCGUC-5'(SEQIDNO:772)
CKAP5-2782靶:5'-GGAAAGAAGGCCTAGATGAAGTGGCAG-3'(SEQIDNO:1348)
5'-AAAGAAGGCCUAGAUGAAGUGGCAGGU-3'(SEQIDNO:3653)
3'-UUUCUUCCGGAUCUACUUCACCGUCCA-5'(SEQIDNO:773)
CKAP5-2784靶:5'-AAAGAAGGCCTAGATGAAGTGGCAGGT-3'(SEQIDNO:1349)
5'-AGAAGGCCUAGAUGAAGUGGCAGGUAU-3'(SEQIDNO:3654)
3'-UCUUCCGGAUCUACUUCACCGUCCAUA-5'(SEQIDNO:774)
CKAP5-2786靶:5'-AGAAGGCCTAGATGAAGTGGCAGGTAT-3'(SEQIDNO:1350)
5'-AAGGCCUAGAUGAAGUGGCAGGUAUUA-3'(SEQIDNO:3655)
3'-UUCCGGAUCUACUUCACCGUCCAUAAU-5'(SEQIDNO:775)
CKAP5-2788靶:5'-AAGGCCTAGATGAAGTGGCAGGTATTA-3'(SEQIDNO:1351)
5'-GGCCUAGAUGAAGUGGCAGGUAUUAUU-3'(SEQIDNO:3656)
3'-CCGGAUCUACUUCACCGUCCAUAAUAA-5'(SEQIDNO:776)
CKAP5-2790靶:5'-GGCCTAGATGAAGTGGCAGGTATTATT-3'(SEQIDNO:1352)
5'-CCUAGAUGAAGUGGCAGGUAUUAUUAA-3'(SEQIDNO:3657)
3'-GGAUCUACUUCACCGUCCAUAAUAAUU-5'(SEQIDNO:777)
CKAP5-2792靶:5'-CCTAGATGAAGTGGCAGGTATTATTAA-3'(SEQIDNO:1353)
5'-UAGAUGAAGUGGCAGGUAUUAUUAAUG-3'(SEQIDNO:3658)
3'-AUCUACUUCACCGUCCAUAAUAAUUAC-5'(SEQIDNO:778)
CKAP5-2794靶:5'-TAGATGAAGTGGCAGGTATTATTAATG-3'(SEQIDNO:1354)
5'-CGAAUAUAGGUGAACUUCCAACUGCCU-3'(SEQIDNO:3659)
3'-GCUUAUAUCCACUUGAAGGUUGACGGA-5'(SEQIDNO:779)
CKAP5-2839靶:5'-CGAATATAGGTGAACTTCCAACTGCCT-3'(SEQIDNO:1355)
5'-AAUAUAGGUGAACUUCCAACUGCCUUG-3'(SEQIDNO:3660)
3'-UUAUAUCCACUUGAAGGUUGACGGAAC-5'(SEQIDNO:780)
CKAP5-2841靶:5'-AATATAGGTGAACTTCCAACTGCCTTG-3'(SEQIDNO:1356)
5'-UAUAGGUGAACUUCCAACUGCCUUGAA-3'(SEQIDNO:3661)
3'-AUAUCCACUUGAAGGUUGACGGAACUU-5'(SEQIDNO:781)
CKAP5-2843靶:5'-TATAGGTGAACTTCCAACTGCCTTGAA-3'(SEQIDNO:1357)
5'-UAGGUGAACUUCCAACUGCCUUGAAGG-3'(SEQIDNO:3662)
3'-AUCCACUUGAAGGUUGACGGAACUUCC-5'(SEQIDNO:782)
CKAP5-2845靶:5'-TAGGTGAACTTCCAACTGCCTTGAAGG-3'(SEQIDNO:1358)
5'-GGUGAACUUCCAACUGCCUUGAAGGGU-3'(SEQIDNO:3663)
3'-CCACUUGAAGGUUGACGGAACUUCCCA-5'(SEQIDNO:783)
CKAP5-2847靶:5'-GGTGAACTTCCAACTGCCTTGAAGGGT-3'(SEQIDNO:1359)
5'-UGAACUUCCAACUGCCUUGAAGGGUCG-3'(SEQIDNO:3664)
3'-ACUUGAAGGUUGACGGAACUUCCCAGC-5'(SEQIDNO:784)
CKAP5-2849靶:5'-TGAACTTCCAACTGCCTTGAAGGGTCG-3'(SEQIDNO:1360)
5'-AACUUCCAACUGCCUUGAAGGGUCGAC-3'(SEQIDNO:3665)
3'-UUGAAGGUUGACGGAACUUCCCAGCUG-5'(SEQIDNO:785)
CKAP5-2851靶:5'-AACTTCCAACTGCCTTGAAGGGTCGAC-3'(SEQIDNO:1361)
5'-CUUCCAACUGCCUUGAAGGGUCGACUC-3'(SEQIDNO:3666)
3'-GAAGGUUGACGGAACUUCCCAGCUGAG-5'(SEQIDNO:786)
CKAP5-2853靶:5'-CTTCCAACTGCCTTGAAGGGTCGACTC-3'(SEQIDNO:1362)
5'-UCCAACUGCCUUGAAGGGUCGACUCAA-3'(SEQIDNO:3667)
3'-AGGUUGACGGAACUUCCCAGCUGAGUU-5'(SEQIDNO:787)
CKAP5-2855靶:5'-TCCAACTGCCTTGAAGGGTCGACTCAA-3'(SEQIDNO:1363)
5'-CAACUGCCUUGAAGGGUCGACUCAAUG-3'(SEQIDNO:3668)
3'-GUUGACGGAACUUCCCAGCUGAGUUAC-5'(SEQIDNO:788)
CKAP5-2857靶:5'-CAACTGCCTTGAAGGGTCGACTCAATG-3'(SEQIDNO:1364)
5'-AACAACUGGCAGUAGCCAUGGGCCCAA-3'(SEQIDNO:3669)
3'-UUGUUGACCGUCAUCGGUACCCGGGUU-5'(SEQIDNO:789)
CKAP5-2926靶:5'-AACAACTGGCAGTAGCCATGGGCCCAA-3'(SEQIDNO:1365)
5'-ACAGCAAGAACAAUGUUCGAGCUGCUG-3'(SEQIDNO:3670)
3'-UGUCGUUCUUGUUACAAGCUCGACGAC-5'(SEQIDNO:790)
CKAP5-3007靶:5'-ACAGCAAGAACAATGTTCGAGCTGCTG-3'(SEQIDNO:1366)
5'-AGCAAGAACAAUGUUCGAGCUGCUGCC-3'(SEQIDNO:3671)
3'-UCGUUCUUGUUACAAGCUCGACGACGG-5'(SEQIDNO:791)
CKAP5-3009靶:5'-AGCAAGAACAATGTTCGAGCTGCTGCC-3'(SEQIDNO:1367)
5'-CAAGAACAAUGUUCGAGCUGCUGCCCU-3'(SEQIDNO:3672)
3'-GUUCUUGUUACAAGCUCGACGACGGGA-5'(SEQIDNO:792)
CKAP5-3011靶:5'-CAAGAACAATGTTCGAGCTGCTGCCCT-3'(SEQIDNO:1368)
5'-AGAACAAUGUUCGAGCUGCUGCCCUAG-3'(SEQIDNO:3673)
3'-UCUUGUUACAAGCUCGACGACGGGAUC-5'(SEQIDNO:793)
CKAP5-3013靶:5'-AGAACAATGTTCGAGCTGCTGCCCTAG-3'(SEQIDNO:1369)
5'-AACAAUGUUCGAGCUGCUGCCCUAGCG-3'(SEQIDNO:3674)
3'-UUGUUACAAGCUCGACGACGGGAUCGC-5'(SEQIDNO:794)
CKAP5-3015靶:5'-AACAATGTTCGAGCTGCTGCCCTAGCG-3'(SEQIDNO:1370)
5'-CAAUGUUCGAGCUGCUGCCCUAGCGAC-3'(SEQIDNO:3675)
3'-GUUACAAGCUCGACGACGGGAUCGCUG-5'(SEQIDNO:795)
CKAP5-3017靶:5'-CAATGTTCGAGCTGCTGCCCTAGCGAC-3'(SEQIDNO:1371)
5'-AUGUUCGAGCUGCUGCCCUAGCGACUG-3'(SEQIDNO:3676)
3'-UACAAGCUCGACGACGGGAUCGCUGAC-5'(SEQIDNO:796)
CKAP5-3019靶:5'-ATGTTCGAGCTGCTGCCCTAGCGACTG-3'(SEQIDNO:1372)
5'-CGACUGUGAAUGCUUGGGCAGAACAGA-3'(SEQIDNO:3677)
3'-GCUGACACUUACGAACCCGUCUUGUCU-5'(SEQIDNO:797)
CKAP5-3040靶:5'-CGACTGTGAATGCTTGGGCAGAACAGA-3'(SEQIDNO:1373)
5'-ACUGUGAAUGCUUGGGCAGAACAGACU-3'(SEQIDNO:3678)
3'-UGACACUUACGAACCCGUCUUGUCUGA-5'(SEQIDNO:798)
CKAP5-3042靶:5'-ACTGTGAATGCTTGGGCAGAACAGACT-3'(SEQIDNO:1374)
5'-UGUGAAUGCUUGGGCAGAACAGACUGG-3'(SEQIDNO:3679)
3'-ACACUUACGAACCCGUCUUGUCUGACC-5'(SEQIDNO:799)
CKAP5-3044靶:5'-TGTGAATGCTTGGGCAGAACAGACTGG-3'(SEQIDNO:1375)
5'-AGGAGAAGAUCUUUCUGAAGAGCUCAA-3'(SEQIDNO:3680)
3'-UCCUCUUCUAGAAAGACUUCUCGAGUU-5'(SEQIDNO:800)
CKAP5-3089靶:5'-AGGAGAAGATCTTTCTGAAGAGCTCAA-3'(SEQIDNO:1376)
5'-GCCUAGAAGAUCGAAAUGGAGAUGUGC-3'(SEQIDNO:3681)
3'-CGGAUCUUCUAGCUUUACCUCUACACG-5'(SEQIDNO:801)
CKAP5-3229靶:5'-GCCTAGAAGATCGAAATGGAGATGTGC-3'(SEQIDNO:1377)
5'-CUAGAAGAUCGAAAUGGAGAUGUGCGA-3'(SEQIDNO:3682)
3'-GAUCUUCUAGCUUUACCUCUACACGCU-5'(SEQIDNO:802)
CKAP5-3231靶:5'-CTAGAAGATCGAAATGGAGATGTGCGA-3'(SEQIDNO:1378)
5'-AGAAGAUCGAAAUGGAGAUGUGCGAAA-3'(SEQIDNO:3683)
3'-UCUUCUAGCUUUACCUCUACACGCUUU-5'(SEQIDNO:803)
CKAP5-3233靶:5'-AGAAGATCGAAATGGAGATGTGCGAAA-3'(SEQIDNO:1379)
5'-CAUGAUGCAUUUAGGAUAUGAAAAAAU-3'(SEQIDNO:3684)
3'-GUACUACGUAAAUCCUAUACUUUUUUA-5'(SEQIDNO:804)
CKAP5-3287靶:5'-CATGATGCATTTAGGATATGAAAAAAT-3'(SEQIDNO:1380)
5'-UGAUGCAUUUAGGAUAUGAAAAAAUGG-3'(SEQIDNO:3685)
3'-ACUACGUAAAUCCUAUACUUUUUUACC-5'(SEQIDNO:805)
CKAP5-3289靶:5'-TGATGCATTTAGGATATGAAAAAATGG-3'(SEQIDNO:1381)
5'-AUGCAUUUAGGAUAUGAAAAAAUGGCC-3'(SEQIDNO:3686)
3'-UACGUAAAUCCUAUACUUUUUUACCGG-5'(SEQIDNO:806)
CKAP5-3291靶:5'-ATGCATTTAGGATATGAAAAAATGGCC-3'(SEQIDNO:1382)
5'-GCAUUUAGGAUAUGAAAAAAUGGCCAA-3'(SEQIDNO:3687)
3'-CGUAAAUCCUAUACUUUUUUACCGGUU-5'(SEQIDNO:807)
CKAP5-3293靶:5'-GCATTTAGGATATGAAAAAATGGCCAA-3'(SEQIDNO:1383)
5'-AUUUAGGAUAUGAAAAAAUGGCCAAGG-3'(SEQIDNO:3688)
3'-UAAAUCCUAUACUUUUUUACCGGUUCC-5'(SEQIDNO:808)
CKAP5-3295靶:5'-ATTTAGGATATGAAAAAATGGCCAAGG-3'(SEQIDNO:1384)
5'-CCAAGGCUACUGGGAAACUAAAGCCAA-3'(SEQIDNO:3689)
3'-GGUUCCGAUGACCCUUUGAUUUCGGUU-5'(SEQIDNO:809)
CKAP5-3316靶:5'-CCAAGGCTACTGGGAAACTAAAGCCAA-3'(SEQIDNO:1385)
5'-AAGGCUACUGGGAAACUAAAGCCAACU-3'(SEQIDNO:3690)
3'-UUCCGAUGACCCUUUGAUUUCGGUUGA-5'(SEQIDNO:810)
CKAP5-3318靶:5'-AAGGCTACTGGGAAACTAAAGCCAACT-3'(SEQIDNO:1386)
5'-GGCUACUGGGAAACUAAAGCCAACUUC-3'(SEQIDNO:3691)
3'-CCGAUGACCCUUUGAUUUCGGUUGAAG-5'(SEQIDNO:811)
CKAP5-3320靶:5'-GGCTACTGGGAAACTAAAGCCAACTTC-3'(SEQIDNO:1387)
5'-CUACUGGGAAACUAAAGCCAACUUCUA-3'(SEQIDNO:3692)
3'-GAUGACCCUUUGAUUUCGGUUGAAGAU-5'(SEQIDNO:812)
CKAP5-3322靶:5'-CTACTGGGAAACTAAAGCCAACTTCTA-3'(SEQIDNO:1388)
5'-ACUGGGAAACUAAAGCCAACUUCUAAA-3'(SEQIDNO:3693)
3'-UGACCCUUUGAUUUCGGUUGAAGAUUU-5'(SEQIDNO:813)
CKAP5-3324靶:5'-ACTGGGAAACTAAAGCCAACTTCTAAA-3'(SEQIDNO:1389)
5'-UGGGAAACUAAAGCCAACUUCUAAAGA-3'(SEQIDNO:3694)
3'-ACCCUUUGAUUUCGGUUGAAGAUUUCU-5'(SEQIDNO:814)
CKAP5-3326靶:5'-TGGGAAACTAAAGCCAACTTCTAAAGA-3'(SEQIDNO:1390)
5'-GGAAACUAAAGCCAACUUCUAAAGAUC-3'(SEQIDNO:3695)
3'-CCUUUGAUUUCGGUUGAAGAUUUCUAG-5'(SEQIDNO:815)
CKAP5-3328靶:5'-GGAAACTAAAGCCAACTTCTAAAGATC-3'(SEQIDNO:1391)
5'-AAACUAAAGCCAACUUCUAAAGAUCAG-3'(SEQIDNO:3696)
3'-UUUGAUUUCGGUUGAAGAUUUCUAGUC-5'(SEQIDNO:816)
CKAP5-3330靶:5'-AAACTAAAGCCAACTTCTAAAGATCAG-3'(SEQIDNO:1392)
5'-ACUAAAGCCAACUUCUAAAGAUCAGGU-3'(SEQIDNO:3697)
3'-UGAUUUCGGUUGAAGAUUUCUAGUCCA-5'(SEQIDNO:817)
CKAP5-3332靶:5'-ACTAAAGCCAACTTCTAAAGATCAGGT-3'(SEQIDNO:1393)
5'-UAAAGCCAACUUCUAAAGAUCAGGUAU-3'(SEQIDNO:3698)
3'-AUUUCGGUUGAAGAUUUCUAGUCCAUA-5'(SEQIDNO:818)
CKAP5-3334靶:5'-TAAAGCCAACTTCTAAAGATCAGGTAT-3'(SEQIDNO:1394)
5'-GGCCUAUUUUUAUUGUUGUUCCAAAUG-3'(SEQIDNO:3699)
3'-CCGGAUAAAAAUAACAACAAGGUUUAC-5'(SEQIDNO:819)
CKAP5-3625靶:5'-GGCCTATTTTTATTGTTGTTCCAAATG-3'(SEQIDNO:1395)
5'-CCUAUUUUUAUUGUUGUUCCAAAUGGA-3'(SEQIDNO:3700)
3'-GGAUAAAAAUAACAACAAGGUUUACCU-5'(SEQIDNO:820)
CKAP5-3627靶:5'-CCTATTTTTATTGTTGTTCCAAATGGA-3'(SEQIDNO:1396)
5'-UAUUUUUAUUGUUGUUCCAAAUGGAAA-3'(SEQIDNO:3701)
3'-AUAAAAAUAACAACAAGGUUUACCUUU-5'(SEQIDNO:821)
CKAP5-3629靶:5'-TATTTTTATTGTTGTTCCAAATGGAAA-3'(SEQIDNO:1397)
5'-UUUUUAUUGUUGUUCCAAAUGGAAAAG-3'(SEQIDNO:3702)
3'-AAAAAUAACAACAAGGUUUACCUUUUC-5'(SEQIDNO:822)
CKAP5-3631靶:5'-TTTTTATTGTTGTTCCAAATGGAAAAG-3'(SEQIDNO:1398)
5'-UUUAUUGUUGUUCCAAAUGGAAAAGAG-3'(SEQIDNO:3703)
3'-AAAUAACAACAAGGUUUACCUUUUCUC-5'(SEQIDNO:823)
CKAP5-3633靶:5'-TTTATTGTTGTTCCAAATGGAAAAGAG-3'(SEQIDNO:1399)
5'-UAUUGUUGUUCCAAAUGGAAAAGAGCA-3'(SEQIDNO:3704)
3'-AUAACAACAAGGUUUACCUUUUCUCGU-5'(SEQIDNO:824)
CKAP5-3635靶:5'-TATTGTTGTTCCAAATGGAAAAGAGCA-3'(SEQIDNO:1400)
5'-GAAGGUGCUAAAGUGGAAUUUUACUAC-3'(SEQIDNO:3705)
3'-CUUCCACGAUUUCACCUUAAAAUGAUG-5'(SEQIDNO:825)
CKAP5-3686靶:5'-GAAGGTGCTAAAGTGGAATTTTACTAC-3'(SEQIDNO:1401)
5'-AGGUGCUAAAGUGGAAUUUUACUACCC-3'(SEQIDNO:3706)
3'-UCCACGAUUUCACCUUAAAAUGAUGGG-5'(SEQIDNO:826)
CKAP5-3688靶:5'-AGGTGCTAAAGTGGAATTTTACTACCC-3'(SEQIDNO:1402)
5'-AUAUCAUCUUACUGAGAAUGAAGCAUC-3'(SEQIDNO:3707)
3'-UAUAGUAGAAUGACUCUUACUUCGUAG-5'(SEQIDNO:827)
CKAP5-3989靶:5'-ATATCATCTTACTGAGAATGAAGCATC-3'(SEQIDNO:1403)
5'-AUCAUCUUACUGAGAAUGAAGCAUCUU-3'(SEQIDNO:3708)
3'-UAGUAGAAUGACUCUUACUUCGUAGAA-5'(SEQIDNO:828)
CKAP5-3991靶:5'-ATCATCTTACTGAGAATGAAGCATCTT-3'(SEQIDNO:1404)
5'-CAUCUUACUGAGAAUGAAGCAUCUUCC-3'(SEQIDNO:3709)
3'-GUAGAAUGACUCUUACUUCGUAGAAGG-5'(SEQIDNO:829)
CKAP5-3993靶:5'-CATCTTACTGAGAATGAAGCATCTTCC-3'(SEQIDNO:1405)
5'-UCUUACUGAGAAUGAAGCAUCUUCCUU-3'(SEQIDNO:3710)
3'-AGAAUGACUCUUACUUCGUAGAAGGAA-5'(SEQIDNO:830)
CKAP5-3995靶:5'-TCTTACTGAGAATGAAGCATCTTCCTT-3'(SEQIDNO:1406)
5'-GUCAAGGUUGGAGAACCAAAGGAUGUC-3'(SEQIDNO:3711)
3'-CAGUUCCAACCUCUUGGUUUCCUACAG-5'(SEQIDNO:831)
CKAP5-4038靶:5'-GTCAAGGTTGGAGAACCAAAGGATGTC-3'(SEQIDNO:1407)
5'-CAAGGUUGGAGAACCAAAGGAUGUCAU-3'(SEQIDNO:3712)
3'-GUUCCAACCUCUUGGUUUCCUACAGUA-5'(SEQIDNO:832)
CKAP5-4040靶:5'-CAAGGTTGGAGAACCAAAGGATGTCAT-3'(SEQIDNO:1408)
5'-AGGUUGGAGAACCAAAGGAUGUCAUUC-3'(SEQIDNO:3713)
3'-UCCAACCUCUUGGUUUCCUACAGUAAG-5'(SEQIDNO:833)
CKAP5-4042靶:5'-AGGTTGGAGAACCAAAGGATGTCATTC-3'(SEQIDNO:1409)
5'-GUUGGAGAACCAAAGGAUGUCAUUCGU-3'(SEQIDNO:3714)
3'-CAACCUCUUGGUUUCCUACAGUAAGCA-5'(SEQIDNO:834)
CKAP5-4044靶:5'-GTTGGAGAACCAAAGGATGTCATTCGT-3'(SEQIDNO:1410)
5'-UGGAGAACCAAAGGAUGUCAUUCGUAA-3'(SEQIDNO:3715)
3'-ACCUCUUGGUUUCCUACAGUAAGCAUU-5'(SEQIDNO:835)
CKAP5-4046靶:5'-TGGAGAACCAAAGGATGTCATTCGTAA-3'(SEQIDNO:1411)
5'-GAGAACCAAAGGAUGUCAUUCGUAAAG-3'(SEQIDNO:3716)
3'-CUCUUGGUUUCCUACAGUAAGCAUUUC-5'(SEQIDNO:836)
CKAP5-4048靶:5'-GAGAACCAAAGGATGTCATTCGTAAAG-3'(SEQIDNO:1412)
5'-GAACCAAAGGAUGUCAUUCGUAAAGAU-3'(SEQIDNO:3717)
3'-CUUGGUUUCCUACAGUAAGCAUUUCUA-5'(SEQIDNO:837)
CKAP5-4050靶:5'-GAACCAAAGGATGTCATTCGTAAAGAT-3'(SEQIDNO:1413)
5'-ACCAAAGGAUGUCAUUCGUAAAGAUGU-3'(SEQIDNO:3718)
3'-UGGUUUCCUACAGUAAGCAUUUCUACA-5'(SEQIDNO:838)
CKAP5-4052靶:5'-ACCAAAGGATGTCATTCGTAAAGATGT-3'(SEQIDNO:1414)
5'-CAAAGGAUGUCAUUCGUAAAGAUGUUC-3'(SEQIDNO:3719)
3'-GUUUCCUACAGUAAGCAUUUCUACAAG-5'(SEQIDNO:839)
CKAP5-4054靶:5'-CAAAGGATGTCATTCGTAAAGATGTTC-3'(SEQIDNO:1415)
5'-AAGGAUGUCAUUCGUAAAGAUGUUCGU-3'(SEQIDNO:3720)
3'-UUCCUACAGUAAGCAUUUCUACAAGCA-5'(SEQIDNO:840)
CKAP5-4056靶:5'-AAGGATGTCATTCGTAAAGATGTTCGT-3'(SEQIDNO:1416)
5'-GGAUGUCAUUCGUAAAGAUGUUCGUGC-3'(SEQIDNO:3721)
3'-CCUACAGUAAGCAUUUCUACAAGCACG-5'(SEQIDNO:841)
CKAP5-4058靶:5'-GGATGTCATTCGTAAAGATGTTCGTGC-3'(SEQIDNO:1417)
5'-CAUCCUGAACCGGAUGUGCCUUGUCUA-3'(SEQIDNO:3722)
3'-GUAGGACUUGGCCUACACGGAACAGAU-5'(SEQIDNO:842)
CKAP5-4085靶:5'-CATCCTGAACCGGATGTGCCTTGTCTA-3'(SEQIDNO:1418)
5'-UCCUGAACCGGAUGUGCCUUGUCUACC-3'(SEQIDNO:3723)
3'-AGGACUUGGCCUACACGGAACAGAUGG-5'(SEQIDNO:843)
CKAP5-4087靶:5'-TCCTGAACCGGATGTGCCTTGTCTACC-3'(SEQIDNO:1419)
5'-CUGAACCGGAUGUGCCUUGUCUACCCA-3'(SEQIDNO:3724)
3'-GACUUGGCCUACACGGAACAGAUGGGU-5'(SEQIDNO:844)
CKAP5-4089靶:5'-CTGAACCGGATGTGCCTTGTCTACCCA-3'(SEQIDNO:1420)
5'-GAACCGGAUGUGCCUUGUCUACCCAGC-3'(SEQIDNO:3725)
3'-CUUGGCCUACACGGAACAGAUGGGUCG-5'(SEQIDNO:845)
CKAP5-4091靶:5'-GAACCGGATGTGCCTTGTCTACCCAGC-3'(SEQIDNO:1421)
5'-ACCGGAUGUGCCUUGUCUACCCAGCUA-3'(SEQIDNO:3726)
3'-UGGCCUACACGGAACAGAUGGGUCGAU-5'(SEQIDNO:846)
CKAP5-4093靶:5'-ACCGGATGTGCCTTGTCTACCCAGCTA-3'(SEQIDNO:1422)
5'-CGGAUGUGCCUUGUCUACCCAGCUAGC-3'(SEQIDNO:3727)
3'-GCCUACACGGAACAGAUGGGUCGAUCG-5'(SEQIDNO:847)
CKAP5-4095靶:5'-CGGATGTGCCTTGTCTACCCAGCTAGC-3'(SEQIDNO:1423)
5'-GAUGUGCCUUGUCUACCCAGCUAGCAA-3'(SEQIDNO:3728)
3'-CUACACGGAACAGAUGGGUCGAUCGUU-5'(SEQIDNO:848)
CKAP5-4097靶:5'-GATGTGCCTTGTCTACCCAGCTAGCAA-3'(SEQIDNO:1424)
5'-AUCCAAAAACUCUAAGCAGAGAGCAGA-3'(SEQIDNO:3729)
3'-UAGGUUUUUGAGAUUCGUCUCUCGUCU-5'(SEQIDNO:849)
CKAP5-4154靶:5'-ATCCAAAAACTCTAAGCAGAGAGCAGA-3'(SEQIDNO:1425)
5'-CCAAAAACUCUAAGCAGAGAGCAGAGU-3'(SEQIDNO:3730)
3'-GGUUUUUGAGAUUCGUCUCUCGUCUCA-5'(SEQIDNO:850)
CKAP5-4156靶:5'-CCAAAAACTCTAAGCAGAGAGCAGAGT-3'(SEQIDNO:1426)
5'-AAAAACUCUAAGCAGAGAGCAGAGUGC-3'(SEQIDNO:3731)
3'-UUUUUGAGAUUCGUCUCUCGUCUCACG-5'(SEQIDNO:851)
CKAP5-4158靶:5'-AAAAACTCTAAGCAGAGAGCAGAGTGC-3'(SEQIDNO:1427)
5'-AAACUCUAAGCAGAGAGCAGAGUGCCU-3'(SEQIDNO:3732)
3'-UUUGAGAUUCGUCUCUCGUCUCACGGA-5'(SEQIDNO:852)
CKAP5-4160靶:5'-AAACTCTAAGCAGAGAGCAGAGTGCCT-3'(SEQIDNO:1428)
5'-ACUCUAAGCAGAGAGCAGAGUGCCUGG-3'(SEQIDNO:3733)
3'-UGAGAUUCGUCUCUCGUCUCACGGACC-5'(SEQIDNO:853)
CKAP5-4162靶:5'-ACTCTAAGCAGAGAGCAGAGTGCCTGG-3'(SEQIDNO:1429)
5'-UCUAAGCAGAGAGCAGAGUGCCUGGAA-3'(SEQIDNO:3734)
3'-AGAUUCGUCUCUCGUCUCACGGACCUU-5'(SEQIDNO:854)
CKAP5-4164靶:5'-TCTAAGCAGAGAGCAGAGTGCCTGGAA-3'(SEQIDNO:1430)
5'-UAAGCAGAGAGCAGAGUGCCUGGAAGA-3'(SEQIDNO:3735)
3'-AUUCGUCUCUCGUCUCACGGACCUUCU-5'(SEQIDNO:855)
CKAP5-4166靶:5'-TAAGCAGAGAGCAGAGTGCCTGGAAGA-3'(SEQIDNO:1431)
5'-AGCAGAGAGCAGAGUGCCUGGAAGAGC-3'(SEQIDNO:3736)
3'-UCGUCUCUCGUCUCACGGACCUUCUCG-5'(SEQIDNO:856)
CKAP5-4168靶:5'-AGCAGAGAGCAGAGTGCCTGGAAGAGC-3'(SEQIDNO:1432)
5'-CAGAGAGCAGAGUGCCUGGAAGAGCUG-3'(SEQIDNO:3737)
3'-GUCUCUCGUCUCACGGACCUUCUCGAC-5'(SEQIDNO:857)
CKAP5-4170靶:5'-CAGAGAGCAGAGTGCCTGGAAGAGCTG-3'(SEQIDNO:1433)
5'-GAGAGCAGAGUGCCUGGAAGAGCUGGG-3'(SEQIDNO:3738)
3'-CUCUCGUCUCACGGACCUUCUCGACCC-5'(SEQIDNO:858)
CKAP5-4172靶:5'-GAGAGCAGAGTGCCTGGAAGAGCTGGG-3'(SEQIDNO:1434)
5'-GAGCAGAGUGCCUGGAAGAGCUGGGAU-3'(SEQIDNO:3739)
3'-CUCGUCUCACGGACCUUCUCGACCCUA-5'(SEQIDNO:859)
CKAP5-4174靶:5'-GAGCAGAGTGCCTGGAAGAGCTGGGAT-3'(SEQIDNO:1435)
5'-CCCAGGAAAAGCCUUAAAGGAAAUAGC-3'(SEQIDNO:3740)
3'-GGGUCCUUUUCGGAAUUUCCUUUAUCG-5'(SEQIDNO:860)
CKAP5-4241靶:5'-CCCAGGAAAAGCCTTAAAGGAAATAGC-3'(SEQIDNO:1436)
5'-GGAUCAGGUGUUCAAACUGAUUGGAAA-3'(SEQIDNO:3741)
3'-CCUAGUCCACAAGUUUGACUAACCUUU-5'(SEQIDNO:861)
CKAP5-4346靶:5'-GGATCAGGTGTTCAAACTGATTGGAAA-3'(SEQIDNO:1437)
5'-AUCAGGUGUUCAAACUGAUUGGAAAUC-3'(SEQIDNO:3742)
3'-UAGUCCACAAGUUUGACUAACCUUUAG-5'(SEQIDNO:862)
CKAP5-4348靶:5'-ATCAGGTGTTCAAACTGATTGGAAATC-3'(SEQIDNO:1438)
5'-CAGGUGUUCAAACUGAUUGGAAAUCUU-3'(SEQIDNO:3743)
3'-GUCCACAAGUUUGACUAACCUUUAGAA-5'(SEQIDNO:863)
CKAP5-4350靶:5'-CAGGTGTTCAAACTGATTGGAAATCTT-3'(SEQIDNO:1439)
5'-GGUGUUCAAACUGAUUGGAAAUCUUUC-3'(SEQIDNO:3744)
3'-CCACAAGUUUGACUAACCUUUAGAAAG-5'(SEQIDNO:864)
CKAP5-4352靶:5'-GGTGTTCAAACTGATTGGAAATCTTTC-3'(SEQIDNO:1440)
5'-UGUUCAAACUGAUUGGAAAUCUUUCUG-3'(SEQIDNO:3745)
3'-ACAAGUUUGACUAACCUUUAGAAAGAC-5'(SEQIDNO:865)
CKAP5-4354靶:5'-TGTTCAAACTGATTGGAAATCTTTCTG-3'(SEQIDNO:1441)
5'-UUCAAACUGAUUGGAAAUCUUUCUGAA-3'(SEQIDNO:3746)
3'-AAGUUUGACUAACCUUUAGAAAGACUU-5'(SEQIDNO:866)
CKAP5-4356靶:5'-TTCAAACTGATTGGAAATCTTTCTGAA-3'(SEQIDNO:1442)
5'-CAAACUGAUUGGAAAUCUUUCUGAAAA-3'(SEQIDNO:3747)
3'-GUUUGACUAACCUUUAGAAAGACUUUU-5'(SEQIDNO:867)
CKAP5-4358靶:5'-CAAACTGATTGGAAATCTTTCTGAAAA-3'(SEQIDNO:1443)
5'-AACUGAUUGGAAAUCUUUCUGAAAAGG-3'(SEQIDNO:3748)
3'-UUGACUAACCUUUAGAAAGACUUUUCC-5'(SEQIDNO:868)
CKAP5-4360靶:5'-AACTGATTGGAAATCTTTCTGAAAAGG-3'(SEQIDNO:1444)
5'-UUAAGCGGUCAGCAAAGAGACCCUCUG-3'(SEQIDNO:3749)
3'-AAUUCGCCAGUCGUUUCUCUGGGAGAC-5'(SEQIDNO:869)
CKAP5-4411靶:5'-TTAAGCGGTCAGCAAAGAGACCCTCTG-3'(SEQIDNO:1445)
5'-AAGCGGUCAGCAAAGAGACCCUCUGCU-3'(SEQIDNO:3750)
3'-UUCGCCAGUCGUUUCUCUGGGAGACGA-5'(SEQIDNO:870)
CKAP5-4413靶:5'-AAGCGGTCAGCAAAGAGACCCTCTGCT-3'(SEQIDNO:1446)
5'-GCGGUCAGCAAAGAGACCCUCUGCUGC-3'(SEQIDNO:3751)
3'-CGCCAGUCGUUUCUCUGGGAGACGACG-5'(SEQIDNO:871)
CKAP5-4415靶:5'-GCGGTCAGCAAAGAGACCCTCTGCTGC-3'(SEQIDNO:1447)
5'-GGUCAGCAAAGAGACCCUCUGCUGCAC-3'(SEQIDNO:3752)
3'-CCAGUCGUUUCUCUGGGAGACGACGUG-5'(SEQIDNO:872)
CKAP5-4417靶:5'-GGTCAGCAAAGAGACCCTCTGCTGCAC-3'(SEQIDNO:1448)
5'-UCAGCAAAGAGACCCUCUGCUGCACCA-3'(SEQIDNO:3753)
3'-AGUCGUUUCUCUGGGAGACGACGUGGU-5'(SEQIDNO:873)
CKAP5-4419靶:5'-TCAGCAAAGAGACCCTCTGCTGCACCA-3'(SEQIDNO:1449)
5'-AGCAAAGAGACCCUCUGCUGCACCAAU-3'(SEQIDNO:3754)
3'-UCGUUUCUCUGGGAGACGACGUGGUUA-5'(SEQIDNO:874)
CKAP5-4421靶:5'-AGCAAAGAGACCCTCTGCTGCACCAAT-3'(SEQIDNO:1450)
5'-CAAAGAGACCCUCUGCUGCACCAAUAA-3'(SEQIDNO:3755)
3'-GUUUCUCUGGGAGACGACGUGGUUAUU-5'(SEQIDNO:875)
CKAP5-4423靶:5'-CAAAGAGACCCTCTGCTGCACCAATAA-3'(SEQIDNO:1451)
5'-GUUACGCAAGGGACCAGCUGAGGACAU-3'(SEQIDNO:3756)
3'-CAAUGCGUUCCCUGGUCGACUCCUGUA-5'(SEQIDNO:876)
CKAP5-4505靶:5'-GTTACGCAAGGGACCAGCTGAGGACAT-3'(SEQIDNO:1452)
5'-UACGCAAGGGACCAGCUGAGGACAUGU-3'(SEQIDNO:3757)
3'-AUGCGUUCCCUGGUCGACUCCUGUACA-5'(SEQIDNO:877)
CKAP5-4507靶:5'-TACGCAAGGGACCAGCTGAGGACATGT-3'(SEQIDNO:1453)
5'-UCCGCCGAGAAUUCCAGCUGGAUCUAG-3'(SEQIDNO:3758)
3'-AGGCGGCUCUUAAGGUCGACCUAGAUC-5'(SEQIDNO:878)
CKAP5-4591靶:5'-TCCGCCGAGAATTCCAGCTGGATCTAG-3'(SEQIDNO:1454)
5'-CGCCGAGAAUUCCAGCUGGAUCUAGAU-3'(SEQIDNO:3759)
3'-GCGGCUCUUAAGGUCGACCUAGAUCUA-5'(SEQIDNO:879)
CKAP5-4593靶:5'-CGCCGAGAATTCCAGCTGGATCTAGAT-3'(SEQIDNO:1455)
5'-CAAGAUCCGGGCUGUUUCUCCACACUU-3'(SEQIDNO:3760)
3'-GUUCUAGGCCCGACAAAGAGGUGUGAA-5'(SEQIDNO:880)
CKAP5-4718靶:5'-CAAGATCCGGGCTGTTTCTCCACACTT-3'(SEQIDNO:1456)
5'-AGAUCCGGGCUGUUUCUCCACACUUCG-3'(SEQIDNO:3761)
3'-UCUAGGCCCGACAAAGAGGUGUGAAGC-5'(SEQIDNO:881)
CKAP5-4720靶:5'-AGATCCGGGCTGTTTCTCCACACTTCG-3'(SEQIDNO:1457)
5'-UCGAUGACAUGCACAGUAAUACAGCAU-3'(SEQIDNO:3762)
3'-AGCUACUGUACGUGUCAUUAUGUCGUA-5'(SEQIDNO:882)
CKAP5-4744靶:5'-TCGATGACATGCACAGTAATACAGCAT-3'(SEQIDNO:1458)
5'-GAUGACAUGCACAGUAAUACAGCAUCC-3'(SEQIDNO:3763)
3'-CUACUGUACGUGUCAUUAUGUCGUAGG-5'(SEQIDNO:883)
CKAP5-4746靶:5'-GATGACATGCACAGTAATACAGCATCC-3'(SEQIDNO:1459)
5'-UGACAUGCACAGUAAUACAGCAUCCAC-3'(SEQIDNO:3764)
3'-ACUGUACGUGUCAUUAUGUCGUAGGUG-5'(SEQIDNO:884)
CKAP5-4748靶:5'-TGACATGCACAGTAATACAGCATCCAC-3'(SEQIDNO:1460)
5'-ACAUGCACAGUAAUACAGCAUCCACAA-3'(SEQIDNO:3765)
3'-UGUACGUGUCAUUAUGUCGUAGGUGUU-5'(SEQIDNO:885)
CKAP5-4750靶:5'-ACATGCACAGTAATACAGCATCCACAA-3'(SEQIDNO:1461)
5'-AUGCACAGUAAUACAGCAUCCACAAUC-3'(SEQIDNO:3766)
3'-UACGUGUCAUUAUGUCGUAGGUGUUAG-5'(SEQIDNO:886)
CKAP5-4752靶:5'-ATGCACAGTAATACAGCATCCACAATC-3'(SEQIDNO:1462)
5'-GCACAGUAAUACAGCAUCCACAAUCAA-3'(SEQIDNO:3767)
3'-CGUGUCAUUAUGUCGUAGGUGUUAGUU-5'(SEQIDNO:887)
CKAP5-4754靶:5'-GCACAGTAATACAGCATCCACAATCAA-3'(SEQIDNO:1463)
5'-ACAGUAAUACAGCAUCCACAAUCAAUU-3'(SEQIDNO:3768)
3'-UGUCAUUAUGUCGUAGGUGUUAGUUAA-5'(SEQIDNO:888)
CKAP5-4756靶:5'-ACAGTAATACAGCATCCACAATCAATT-3'(SEQIDNO:1464)
5'-AGUAAUACAGCAUCCACAAUCAAUUUC-3'(SEQIDNO:3769)
3'-UCAUUAUGUCGUAGGUGUUAGUUAAAG-5'(SEQIDNO:889)
CKAP5-4758靶:5'-AGTAATACAGCATCCACAATCAATTTC-3'(SEQIDNO:1465)
5'-UAAUACAGCAUCCACAAUCAAUUUCAU-3'(SEQIDNO:3770)
3'-AUUAUGUCGUAGGUGUUAGUUAAAGUA-5'(SEQIDNO:890)
CKAP5-4760靶:5'-TAATACAGCATCCACAATCAATTTCAT-3'(SEQIDNO:1466)
5'-AUACAGCAUCCACAAUCAAUUUCAUUA-3'(SEQIDNO:3771)
3'-UAUGUCGUAGGUGUUAGUUAAAGUAAU-5'(SEQIDNO:891)
CKAP5-4762靶:5'-ATACAGCATCCACAATCAATTTCATTA-3'(SEQIDNO:1467)
5'-ACAGCAUCCACAAUCAAUUUCAUUAUC-3'(SEQIDNO:3772)
3'-UGUCGUAGGUGUUAGUUAAAGUAAUAG-5'(SEQIDNO:892)
CKAP5-4764靶:5'-ACAGCATCCACAATCAATTTCATTATC-3'(SEQIDNO:1468)
5'-AGCAUCCACAAUCAAUUUCAUUAUCUC-3'(SEQIDNO:3773)
3'-UCGUAGGUGUUAGUUAAAGUAAUAGAG-5'(SEQIDNO:893)
CKAP5-4766靶:5'-AGCATCCACAATCAATTTCATTATCTC-3'(SEQIDNO:1469)
5'-CAUCCACAAUCAAUUUCAUUAUCUCCC-3'(SEQIDNO:3774)
3'-GUAGGUGUUAGUUAAAGUAAUAGAGGG-5'(SEQIDNO:894)
CKAP5-4768靶:5'-CATCCACAATCAATTTCATTATCTCCC-3'(SEQIDNO:1470)
5'-UCCACAAUCAAUUUCAUUAUCUCCCAA-3'(SEQIDNO:3775)
3'-AGGUGUUAGUUAAAGUAAUAGAGGGUU-5'(SEQIDNO:895)
CKAP5-4770靶:5'-TCCACAATCAATTTCATTATCTCCCAA-3'(SEQIDNO:1471)
5'-CACAAUCAAUUUCAUUAUCUCCCAAGU-3'(SEQIDNO:3776)
3'-GUGUUAGUUAAAGUAAUAGAGGGUUCA-5'(SEQIDNO:896)
CKAP5-4772靶:5'-CACAATCAATTTCATTATCTCCCAAGT-3'(SEQIDNO:1472)
5'-CAAUCAAUUUCAUUAUCUCCCAAGUAG-3'(SEQIDNO:3777)
3'-GUUAGUUAAAGUAAUAGAGGGUUCAUC-5'(SEQIDNO:897)
CKAP5-4774靶:5'-CAATCAATTTCATTATCTCCCAAGTAG-3'(SEQIDNO:1473)
5'-AUCAAUUUCAUUAUCUCCCAAGUAGCC-3'(SEQIDNO:3778)
3'-UAGUUAAAGUAAUAGAGGGUUCAUCGG-5'(SEQIDNO:898)
CKAP5-4776靶:5'-ATCAATTTCATTATCTCCCAAGTAGCC-3'(SEQIDNO:1474)
5'-CAAUUUCAUUAUCUCCCAAGUAGCCAG-3'(SEQIDNO:3779)
3'-GUUAAAGUAAUAGAGGGUUCAUCGGUC-5'(SEQIDNO:899)
CKAP5-4778靶:5'-CAATTTCATTATCTCCCAAGTAGCCAG-3'(SEQIDNO:1475)
5'-AUUUCAUUAUCUCCCAAGUAGCCAGUG-3'(SEQIDNO:3780)
3'-UAAAGUAAUAGAGGGUUCAUCGGUCAC-5'(SEQIDNO:900)
CKAP5-4780靶:5'-ATTTCATTATCTCCCAAGTAGCCAGTG-3'(SEQIDNO:1476)
5'-UUCAUUAUCUCCCAAGUAGCCAGUGGU-3'(SEQIDNO:3781)
3'-AAGUAAUAGAGGGUUCAUCGGUCACCA-5'(SEQIDNO:901)
CKAP5-4782靶:5'-TTCATTATCTCCCAAGTAGCCAGTGGT-3'(SEQIDNO:1477)
5'-CAUUAUCUCCCAAGUAGCCAGUGGUGA-3'(SEQIDNO:3782)
3'-GUAAUAGAGGGUUCAUCGGUCACCACU-5'(SEQIDNO:902)
CKAP5-4784靶:5'-CATTATCTCCCAAGTAGCCAGTGGTGA-3'(SEQIDNO:1478)
5'-UUAUCUCCCAAGUAGCCAGUGGUGACA-3'(SEQIDNO:3783)
3'-AAUAGAGGGUUCAUCGGUCACCACUGU-5'(SEQIDNO:903)
CKAP5-4786靶:5'-TTATCTCCCAAGTAGCCAGTGGTGACA-3'(SEQIDNO:1479)
5'-AUCUCCCAAGUAGCCAGUGGUGACAUC-3'(SEQIDNO:3784)
3'-UAGAGGGUUCAUCGGUCACCACUGUAG-5'(SEQIDNO:904)
CKAP5-4788靶:5'-ATCTCCCAAGTAGCCAGTGGTGACATC-3'(SEQIDNO:1480)
5'-CUCCCAAGUAGCCAGUGGUGACAUCAA-3'(SEQIDNO:3785)
3'-GAGGGUUCAUCGGUCACCACUGUAGUU-5'(SEQIDNO:905)
CKAP5-4790靶:5'-CTCCCAAGTAGCCAGTGGTGACATCAA-3'(SEQIDNO:1481)
5'-CCCAAGUAGCCAGUGGUGACAUCAACA-3'(SEQIDNO:3786)
3'-GGGUUCAUCGGUCACCACUGUAGUUGU-5'(SEQIDNO:906)
CKAP5-4792靶:5'-CCCAAGTAGCCAGTGGTGACATCAACA-3'(SEQIDNO:1482)
5'-UUGCCCGGGAGGCCUCCACUGGAGUAC-3'(SEQIDNO:3787)
3'-AACGGGCCCUCCGGAGGUGACCUCAUG-5'(SEQIDNO:907)
CKAP5-5041靶:5'-TTGCCCGGGAGGCCTCCACTGGAGTAC-3'(SEQIDNO:1483)
5'-GCCCGGGAGGCCUCCACUGGAGUACUA-3'(SEQIDNO:3788)
3'-CGGGCCCUCCGGAGGUGACCUCAUGAU-5'(SEQIDNO:908)
CKAP5-5043靶:5'-GCCCGGGAGGCCTCCACTGGAGTACTA-3'(SEQIDNO:1484)
5'-CCGGGAGGCCUCCACUGGAGUACUAAA-3'(SEQIDNO:3789)
3'-GGCCCUCCGGAGGUGACCUCAUGAUUU-5'(SEQIDNO:909)
CKAP5-5045靶:5'-CCGGGAGGCCTCCACTGGAGTACTAAA-3'(SEQIDNO:1485)
5'-GGGAGGCCUCCACUGGAGUACUAAAAG-3'(SEQIDNO:3790)
3'-CCCUCCGGAGGUGACCUCAUGAUUUUC-5'(SEQIDNO:910)
CKAP5-5047靶:5'-GGGAGGCCTCCACTGGAGTACTAAAAG-3'(SEQIDNO:1486)
5'-UCAUCACCUUAAUGCUGGAUUCUCGGA-3'(SEQIDNO:3791)
3'-AGUAGUGGAAUUACGACCUAAGAGCCU-5'(SEQIDNO:911)
CKAP5-5089靶:5'-TCATCACCTTAATGCTGGATTCTCGGA-3'(SEQIDNO:1487)
5'-AUCACCUUAAUGCUGGAUUCUCGGAUU-3'(SEQIDNO:3792)
3'-UAGUGGAAUUACGACCUAAGAGCCUAA-5'(SEQIDNO:912)
CKAP5-5091靶:5'-ATCACCTTAATGCTGGATTCTCGGATT-3'(SEQIDNO:1488)
5'-CACCUUAAUGCUGGAUUCUCGGAUUGA-3'(SEQIDNO:3793)
3'-GUGGAAUUACGACCUAAGAGCCUAACU-5'(SEQIDNO:913)
CKAP5-5093靶:5'-CACCTTAATGCTGGATTCTCGGATTGA-3'(SEQIDNO:1489)
5'-CCUUAAUGCUGGAUUCUCGGAUUGAAG-3'(SEQIDNO:3794)
3'-GGAAUUACGACCUAAGAGCCUAACUUC-5'(SEQIDNO:914)
CKAP5-5095靶:5'-CCTTAATGCTGGATTCTCGGATTGAAG-3'(SEQIDNO:1490)
5'-UUAAUGCUGGAUUCUCGGAUUGAAGAU-3'(SEQIDNO:3795)
3'-AAUUACGACCUAAGAGCCUAACUUCUA-5'(SEQIDNO:915)
CKAP5-5097靶:5'-TTAATGCTGGATTCTCGGATTGAAGAT-3'(SEQIDNO:1491)
5'-AAUGCUGGAUUCUCGGAUUGAAGAUCU-3'(SEQIDNO:3796)
3'-UUACGACCUAAGAGCCUAACUUCUAGA-5'(SEQIDNO:916)
CKAP5-5099靶:5'-AATGCTGGATTCTCGGATTGAAGATCT-3'(SEQIDNO:1492)
5'-UGCUGGAUUCUCGGAUUGAAGAUCUUG-3'(SEQIDNO:3797)
3'-ACGACCUAAGAGCCUAACUUCUAGAAC-5'(SEQIDNO:917)
CKAP5-5101靶:5'-TGCTGGATTCTCGGATTGAAGATCTTG-3'(SEQIDNO:1493)
5'-CUGGAUUCUCGGAUUGAAGAUCUUGAG-3'(SEQIDNO:3798)
3'-GACCUAAGAGCCUAACUUCUAGAACUC-5'(SEQIDNO:918)
CKAP5-5103靶:5'-CTGGATTCTCGGATTGAAGATCTTGAG-3'(SEQIDNO:1494)
5'-GGAUUCUCGGAUUGAAGAUCUUGAGGA-3'(SEQIDNO:3799)
3'-CCUAAGAGCCUAACUUCUAGAACUCCU-5'(SEQIDNO:919)
CKAP5-5105靶:5'-GGATTCTCGGATTGAAGATCTTGAGGA-3'(SEQIDNO:1495)
5'-CUCUGUGAACCUCUUGGUGGUGAAGGU-3'(SEQIDNO:3800)
3'-GAGACACUUGGAGAACCACCACUUCCA-5'(SEQIDNO:920)
CKAP5-5150靶:5'-CTCTGTGAACCTCTTGGTGGTGAAGGT-3'(SEQIDNO:1496)
5'-CUGUGAACCUCUUGGUGGUGAAGGUUC-3'(SEQIDNO:3801)
3'-GACACUUGGAGAACCACCACUUCCAAG-5'(SEQIDNO:921)
CKAP5-5152靶:5'-CTGTGAACCTCTTGGTGGTGAAGGTTC-3'(SEQIDNO:1497)
5'-GUGAACCUCUUGGUGGUGAAGGUUCUG-3'(SEQIDNO:3802)
3'-CACUUGGAGAACCACCACUUCCAAGAC-5'(SEQIDNO:922)
CKAP5-5154靶:5'-GTGAACCTCTTGGTGGTGAAGGTTCTG-3'(SEQIDNO:1498)
5'-GAACCUCUUGGUGGUGAAGGUUCUGGA-3'(SEQIDNO:3803)
3'-CUUGGAGAACCACCACUUCCAAGACCU-5'(SEQIDNO:923)
CKAP5-5156靶:5'-GAACCTCTTGGTGGTGAAGGTTCTGGA-3'(SEQIDNO:1499)
5'-AAGACAGCCUGCUAGCAACAGCCAGUU-3'(SEQIDNO:3804)
3'-UUCUGUCGGACGAUCGUUGUCGGUCAA-5'(SEQIDNO:924)
CKAP5-5230靶:5'-AAGACAGCCTGCTAGCAACAGCCAGTT-3'(SEQIDNO:1500)
5'-CCAGUUCUCCCAAAUUCUCAGAGCUUG-3'(SEQIDNO:3805)
3'-GGUCAAGAGGGUUUAAGAGUCUCGAAC-5'(SEQIDNO:925)
CKAP5-5251靶:5'-CCAGTTCTCCCAAATTCTCAGAGCTTG-3'(SEQIDNO:1501)
5'-AGUUCUCCCAAAUUCUCAGAGCUUGUU-3'(SEQIDNO:3806)
3'-UCAAGAGGGUUUAAGAGUCUCGAACAA-5'(SEQIDNO:926)
CKAP5-5253靶:5'-AGTTCTCCCAAATTCTCAGAGCTTGTT-3'(SEQIDNO:1502)
5'-UUCUCCCAAAUUCUCAGAGCUUGUUAU-3'(SEQIDNO:3807)
3'-AAGAGGGUUUAAGAGUCUCGAACAAUA-5'(SEQIDNO:927)
CKAP5-5255靶:5'-TTCTCCCAAATTCTCAGAGCTTGTTAT-3'(SEQIDNO:1503)
5'-CUCCCAAAUUCUCAGAGCUUGUUAUGA-3'(SEQIDNO:3808)
3'-GAGGGUUUAAGAGUCUCGAACAAUACU-5'(SEQIDNO:928)
CKAP5-5257靶:5'-CTCCCAAATTCTCAGAGCTTGTTATGA-3'(SEQIDNO:1504)
5'-CCCAAAUUCUCAGAGCUUGUUAUGAAG-3'(SEQIDNO:3809)
3'-GGGUUUAAGAGUCUCGAACAAUACUUC-5'(SEQIDNO:929)
CKAP5-5259靶:5'-CCCAAATTCTCAGAGCTTGTTATGAAG-3'(SEQIDNO:1505)
5'-CAAAUUCUCAGAGCUUGUUAUGAAGUG-3'(SEQIDNO:3810)
3'-GUUUAAGAGUCUCGAACAAUACUUCAC-5'(SEQIDNO:930)
CKAP5-5261靶:5'-CAAATTCTCAGAGCTTGTTATGAAGTG-3'(SEQIDNO:1506)
5'-AAUUCUCAGAGCUUGUUAUGAAGUGUC-3'(SEQIDNO:3811)
3'-UUAAGAGUCUCGAACAAUACUUCACAG-5'(SEQIDNO:931)
CKAP5-5263靶:5'-AATTCTCAGAGCTTGTTATGAAGTGTC-3'(SEQIDNO:1507)
5'-UUCUCAGAGCUUGUUAUGAAGUGUCUC-3'(SEQIDNO:3812)
3'-AAGAGUCUCGAACAAUACUUCACAGAG-5'(SEQIDNO:932)
CKAP5-5265靶:5'-TTCTCAGAGCTTGTTATGAAGTGTCTC-3'(SEQIDNO:1508)
5'-CUCAGAGCUUGUUAUGAAGUGUCUCUG-3'(SEQIDNO:3813)
3'-GAGUCUCGAACAAUACUUCACAGAGAC-5'(SEQIDNO:933)
CKAP5-5267靶:5'-CTCAGAGCTTGTTATGAAGTGTCTCTG-3'(SEQIDNO:1509)
5'-CAGAGCUUGUUAUGAAGUGUCUCUGGA-3'(SEQIDNO:3814)
3'-GUCUCGAACAAUACUUCACAGAGACCU-5'(SEQIDNO:934)
CKAP5-5269靶:5'-CAGAGCTTGTTATGAAGTGTCTCTGGA-3'(SEQIDNO:1510)
5'-AUAGCAUUAACCUAGACAGAAUUCUUC-3'(SEQIDNO:3815)
3'-UAUCGUAAUUGGAUCUGUCUUAAGAAG-5'(SEQIDNO:935)
CKAP5-5326靶:5'-ATAGCATTAACCTAGACAGAATTCTTC-3'(SEQIDNO:1511)
5'-AGCAUUAACCUAGACAGAAUUCUUCUG-3'(SEQIDNO:3816)
3'-UCGUAAUUGGAUCUGUCUUAAGAAGAC-5'(SEQIDNO:936)
CKAP5-5328靶:5'-AGCATTAACCTAGACAGAATTCTTCTG-3'(SEQIDNO:1512)
5'-CAUUAACCUAGACAGAAUUCUUCUGGA-3'(SEQIDNO:3817)
3'-GUAAUUGGAUCUGUCUUAAGAAGACCU-5'(SEQIDNO:937)
CKAP5-5330靶:5'-CATTAACCTAGACAGAATTCTTCTGGA-3'(SEQIDNO:1513)
5'-UUAACCUAGACAGAAUUCUUCUGGAUA-3'(SEQIDNO:3818)
3'-AAUUGGAUCUGUCUUAAGAAGACCUAU-5'(SEQIDNO:938)
CKAP5-5332靶:5'-TTAACCTAGACAGAATTCTTCTGGATA-3'(SEQIDNO:1514)
5'-AACCUAGACAGAAUUCUUCUGGAUAUC-3'(SEQIDNO:3819)
3'-UUGGAUCUGUCUUAAGAAGACCUAUAG-5'(SEQIDNO:939)
CKAP5-5334靶:5'-AACCTAGACAGAATTCTTCTGGATATC-3'(SEQIDNO:1515)
5'-CCUAGACAGAAUUCUUCUGGAUAUCCA-3'(SEQIDNO:3820)
3'-GGAUCUGUCUUAAGAAGACCUAUAGGU-5'(SEQIDNO:940)
CKAP5-5336靶:5'-CCTAGACAGAATTCTTCTGGATATCCA-3'(SEQIDNO:1516)
5'-UAUCCACAUUUUCAUGAAGGUCUUCCC-3'(SEQIDNO:3821)
3'-AUAGGUGUAAAAGUACUUCCAGAAGGG-5'(SEQIDNO:941)
CKAP5-5357靶:5'-TATCCACATTTTCATGAAGGTCTTCCC-3'(SEQIDNO:1517)
5'-CUGAAGCAAUGCAAAAGUGAAUUUCCC-3'(SEQIDNO:3822)
3'-GACUUCGUUACGUUUUCACUUAAAGGG-5'(SEQIDNO:942)
CKAP5-5394靶:5'-CTGAAGCAATGCAAAAGTGAATTTCCC-3'(SEQIDNO:1518)
5'-GAAGCAAUGCAAAAGUGAAUUUCCCAU-3'(SEQIDNO:3823)
3'-CUUCGUUACGUUUUCACUUAAAGGGUA-5'(SEQIDNO:943)
CKAP5-5396靶:5'-GAAGCAATGCAAAAGTGAATTTCCCAT-3'(SEQIDNO:1519)
5'-AGCAAUGCAAAAGUGAAUUUCCCAUAA-3'(SEQIDNO:3824)
3'-UCGUUACGUUUUCACUUAAAGGGUAUU-5'(SEQIDNO:944)
CKAP5-5398靶:5'-AGCAATGCAAAAGTGAATTTCCCATAA-3'(SEQIDNO:1520)
5'-ACAGUAUGGACCAGACUGGGAGCAAGU-3'(SEQIDNO:3825)
3'-UGUCAUACCUGGUCUGACCCUCGUUCA-5'(SEQIDNO:945)
CKAP5-5551靶:5'-ACAGTATGGACCAGACTGGGAGCAAGT-3'(SEQIDNO:1521)
5'-AGUAUGGACCAGACUGGGAGCAAGUCU-3'(SEQIDNO:3826)
3'-UCAUACCUGGUCUGACCCUCGUUCAGA-5'(SEQIDNO:946)
CKAP5-5553靶:5'-AGTATGGACCAGACTGGGAGCAAGTCT-3'(SEQIDNO:1522)
5'-UAUGGACCAGACUGGGAGCAAGUCUGA-3'(SEQIDNO:3827)
3'-AUACCUGGUCUGACCCUCGUUCAGACU-5'(SEQIDNO:947)
CKAP5-5555靶:5'-TATGGACCAGACTGGGAGCAAGTCTGA-3'(SEQIDNO:1523)
5'-UGGACCAGACUGGGAGCAAGUCUGAUA-3'(SEQIDNO:3828)
3'-ACCUGGUCUGACCCUCGUUCAGACUAU-5'(SEQIDNO:948)
CKAP5-5557靶:5'-TGGACCAGACTGGGAGCAAGTCTGATA-3'(SEQIDNO:1524)
5'-GACCAGACUGGGAGCAAGUCUGAUAAG-3'(SEQIDNO:3829)
3'-CUGGUCUGACCCUCGUUCAGACUAUUC-5'(SEQIDNO:949)
CKAP5-5559靶:5'-GACCAGACTGGGAGCAAGTCTGATAAG-3'(SEQIDNO:1525)
5'-CCAGACUGGGAGCAAGUCUGAUAAGGA-3'(SEQIDNO:3830)
3'-GGUCUGACCCUCGUUCAGACUAUUCCU-5'(SEQIDNO:950)
CKAP5-5561靶:5'-CCAGACTGGGAGCAAGTCTGATAAGGA-3'(SEQIDNO:1526)
5'-AGACUGGGAGCAAGUCUGAUAAGGAAA-3'(SEQIDNO:3831)
3'-UCUGACCCUCGUUCAGACUAUUCCUUU-5'(SEQIDNO:951)
CKAP5-5563靶:5'-AGACTGGGAGCAAGTCTGATAAGGAAA-3'(SEQIDNO:1527)
5'-ACUGGGAGCAAGUCUGAUAAGGAAACA-3'(SEQIDNO:3832)
3'-UGACCCUCGUUCAGACUAUUCCUUUGU-5'(SEQIDNO:952)
CKAP5-5565靶:5'-ACTGGGAGCAAGTCTGATAAGGAAACA-3'(SEQIDNO:1528)
5'-UGGGAGCAAGUCUGAUAAGGAAACAGA-3'(SEQIDNO:3833)
3'-ACCCUCGUUCAGACUAUUCCUUUGUCU-5'(SEQIDNO:953)
CKAP5-5567靶:5'-TGGGAGCAAGTCTGATAAGGAAACAGA-3'(SEQIDNO:1529)
5'-GGAGCAAGUCUGAUAAGGAAACAGAAA-3'(SEQIDNO:3834)
3'-CCUCGUUCAGACUAUUCCUUUGUCUUU-5'(SEQIDNO:954)
CKAP5-5569靶:5'-GGAGCAAGTCTGATAAGGAAACAGAAA-3'(SEQIDNO:1530)
5'-AGCAAGUCUGAUAAGGAAACAGAAAAG-3'(SEQIDNO:3835)
3'-UCGUUCAGACUAUUCCUUUGUCUUUUC-5'(SEQIDNO:955)
CKAP5-5571靶:5'-AGCAAGTCTGATAAGGAAACAGAAAAG-3'(SEQIDNO:1531)
5'-CAAGUCUGAUAAGGAAACAGAAAAGGG-3'(SEQIDNO:3836)
3'-GUUCAGACUAUUCCUUUGUCUUUUCCC-5'(SEQIDNO:956)
CKAP5-5573靶:5'-CAAGTCTGATAAGGAAACAGAAAAGGG-3'(SEQIDNO:1532)
5'-AGUCUGAUAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:3837)
3'-UCAGACUAUUCCUUUGUCUUUUCCCUC-5'(SEQIDNO:957)
CKAP5-5575靶:5'-AGTCTGATAAGGAAACAGAAAAGGGAG-3'(SEQIDNO:1533)
5'-UCUGAUAAGGAAACAGAAAAGGGAGCA-3'(SEQIDNO:3838)
3'-AGACUAUUCCUUUGUCUUUUCCCUCGU-5'(SEQIDNO:958)
CKAP5-5577靶:5'-TCTGATAAGGAAACAGAAAAGGGAGCA-3'(SEQIDNO:1534)
5'-UGAUAAGGAAACAGAAAAGGGAGCAUC-3'(SEQIDNO:3839)
3'-ACUAUUCCUUUGUCUUUUCCCUCGUAG-5'(SEQIDNO:959)
CKAP5-5579靶:5'-TGATAAGGAAACAGAAAAGGGAGCATC-3'(SEQIDNO:1535)
5'-AUAAGGAAACAGAAAAGGGAGCAUCUC-3'(SEQIDNO:3840)
3'-UAUUCCUUUGUCUUUUCCCUCGUAGAG-5'(SEQIDNO:960)
CKAP5-5581靶:5'-ATAAGGAAACAGAAAAGGGAGCATCTC-3'(SEQIDNO:1536)
5'-CAUCUCGAAUAGAUGAAAAAUCAUCAA-3'(SEQIDNO:3841)
3'-GUAGAGCUUAUCUACUUUUUAGUAGUU-5'(SEQIDNO:961)
CKAP5-5602靶:5'-CATCTCGAATAGATGAAAAATCATCAA-3'(SEQIDNO:1537)
5'-UCUCGAAUAGAUGAAAAAUCAUCAAAG-3'(SEQIDNO:3842)
3'-AGAGCUUAUCUACUUUUUAGUAGUUUC-5'(SEQIDNO:962)
CKAP5-5604靶:5'-TCTCGAATAGATGAAAAATCATCAAAG-3'(SEQIDNO:1538)
5'-UCGAAUAGAUGAAAAAUCAUCAAAGGC-3'(SEQIDNO:3843)
3'-AGCUUAUCUACUUUUUAGUAGUUUCCG-5'(SEQIDNO:963)
CKAP5-5606靶:5'-TCGAATAGATGAAAAATCATCAAAGGC-3'(SEQIDNO:1539)
5'-GAAUAGAUGAAAAAUCAUCAAAGGCCA-3'(SEQIDNO:3844)
3'-CUUAUCUACUUUUUAGUAGUUUCCGGU-5'(SEQIDNO:964)
CKAP5-5608靶:5'-GAATAGATGAAAAATCATCAAAGGCCA-3'(SEQIDNO:1540)
5'-AUAGAUGAAAAAUCAUCAAAGGCCAAA-3'(SEQIDNO:3845)
3'-UAUCUACUUUUUAGUAGUUUCCGGUUU-5'(SEQIDNO:965)
CKAP5-5610靶:5'-ATAGATGAAAAATCATCAAAGGCCAAA-3'(SEQIDNO:1541)
5'-AGAUGAAAAAUCAUCAAAGGCCAAAGU-3'(SEQIDNO:3846)
3'-UCUACUUUUUAGUAGUUUCCGGUUUCA-5'(SEQIDNO:966)
CKAP5-5612靶:5'-AGATGAAAAATCATCAAAGGCCAAAGT-3'(SEQIDNO:1542)
5'-AUGAAAAAUCAUCAAAGGCCAAAGUGA-3'(SEQIDNO:3847)
3'-UACUUUUUAGUAGUUUCCGGUUUCACU-5'(SEQIDNO:967)
CKAP5-5614靶:5'-ATGAAAAATCATCAAAGGCCAAAGTGA-3'(SEQIDNO:1543)
5'-GAAAAAUCAUCAAAGGCCAAAGUGAAU-3'(SEQIDNO:3848)
3'-CUUUUUAGUAGUUUCCGGUUUCACUUA-5'(SEQIDNO:968)
CKAP5-5616靶:5'-GAAAAATCATCAAAGGCCAAAGTGAAT-3'(SEQIDNO:1544)
5'-AAAAUCAUCAAAGGCCAAAGUGAAUGA-3'(SEQIDNO:3849)
3'-UUUUAGUAGUUUCCGGUUUCACUUACU-5'(SEQIDNO:969)
CKAP5-5618靶:5'-AAAATCATCAAAGGCCAAAGTGAATGA-3'(SEQIDNO:1545)
5'-GAAUGAUUUCUUAGCUGAGAUUUUUAA-3'(SEQIDNO:3850)
3'-CUUACUAAAGAAUCGACUCUAAAAAUU-5'(SEQIDNO:970)
CKAP5-5639靶:5'-GAATGATTTCTTAGCTGAGATTTTTAA-3'(SEQIDNO:1546)
5'-AUGAUUUCUUAGCUGAGAUUUUUAAGA-3'(SEQIDNO:3851)
3'-UACUAAAGAAUCGACUCUAAAAAUUCU-5'(SEQIDNO:971)
CKAP5-5641靶:5'-ATGATTTCTTAGCTGAGATTTTTAAGA-3'(SEQIDNO:1547)
5'-GAUUUCUUAGCUGAGAUUUUUAAGAAG-3'(SEQIDNO:3852)
3'-CUAAAGAAUCGACUCUAAAAAUUCUUC-5'(SEQIDNO:972)
CKAP5-5643靶:5'-GATTTCTTAGCTGAGATTTTTAAGAAG-3'(SEQIDNO:1548)
5'-UUUCUUAGCUGAGAUUUUUAAGAAGAU-3'(SEQIDNO:3853)
3'-AAAGAAUCGACUCUAAAAAUUCUUCUA-5'(SEQIDNO:973)
CKAP5-5645靶:5'-TTTCTTAGCTGAGATTTTTAAGAAGAT-3'(SEQIDNO:1549)
5'-UCUUAGCUGAGAUUUUUAAGAAGAUUG-3'(SEQIDNO:3854)
3'-AGAAUCGACUCUAAAAAUUCUUCUAAC-5'(SEQIDNO:974)
CKAP5-5647靶:5'-TCTTAGCTGAGATTTTTAAGAAGATTG-3'(SEQIDNO:1550)
5'-UUAGCUGAGAUUUUUAAGAAGAUUGGC-3'(SEQIDNO:3855)
3'-AAUCGACUCUAAAAAUUCUUCUAACCG-5'(SEQIDNO:975)
CKAP5-5649靶:5'-TTAGCTGAGATTTTTAAGAAGATTGGC-3'(SEQIDNO:1551)
5'-AGCUGAGAUUUUUAAGAAGAUUGGCUC-3'(SEQIDNO:3856)
3'-UCGACUCUAAAAAUUCUUCUAACCGAG-5'(SEQIDNO:976)
CKAP5-5651靶:5'-AGCTGAGATTTTTAAGAAGATTGGCTC-3'(SEQIDNO:1552)
5'-CUGAGAUUUUUAAGAAGAUUGGCUCUA-3'(SEQIDNO:3857)
3'-GACUCUAAAAAUUCUUCUAACCGAGAU-5'(SEQIDNO:977)
CKAP5-5653靶:5'-CTGAGATTTTTAAGAAGATTGGCTCTA-3'(SEQIDNO:1553)
5'-GAGAUUUUUAAGAAGAUUGGCUCUAAA-3'(SEQIDNO:3858)
3'-CUCUAAAAAUUCUUCUAACCGAGAUUU-5'(SEQIDNO:978)
CKAP5-5655靶:5'-GAGATTTTTAAGAAGATTGGCTCTAAA-3'(SEQIDNO:1554)
5'-GAUUUUUAAGAAGAUUGGCUCUAAAGA-3'(SEQIDNO:3859)
3'-CUAAAAAUUCUUCUAACCGAGAUUUCU-5'(SEQIDNO:979)
CKAP5-5657靶:5'-GATTTTTAAGAAGATTGGCTCTAAAGA-3'(SEQIDNO:1555)
5'-ACUAGCAGAGUUAUAUGAAUAUAAGAA-3'(SEQIDNO:3860)
3'-UGAUCGUCUCAAUAUACUUAUAUUCUU-5'(SEQIDNO:980)
CKAP5-5699靶:5'-ACTAGCAGAGTTATATGAATATAAGAA-3'(SEQIDNO:1556)
5'-UAGCAGAGUUAUAUGAAUAUAAGAAGA-3'(SEQIDNO:3861)
3'-AUCGUCUCAAUAUACUUAUAUUCUUCU-5'(SEQIDNO:981)
CKAP5-5701靶:5'-TAGCAGAGTTATATGAATATAAGAAGA-3'(SEQIDNO:1557)
5'-GCAGAGUUAUAUGAAUAUAAGAAGAAA-3'(SEQIDNO:3862)
3'-CGUCUCAAUAUACUUAUAUUCUUCUUU-5'(SEQIDNO:982)
CKAP5-5703靶:5'-GCAGAGTTATATGAATATAAGAAGAAA-3'(SEQIDNO:1558)
5'-AGAGUUAUAUGAAUAUAAGAAGAAAUA-3'(SEQIDNO:3863)
3'-UCUCAAUAUACUUAUAUUCUUCUUUAU-5'(SEQIDNO:983)
CKAP5-5705靶:5'-AGAGTTATATGAATATAAGAAGAAATA-3'(SEQIDNO:1559)
5'-AGUUAUAUGAAUAUAAGAAGAAAUACU-3'(SEQIDNO:3864)
3'-UCAAUAUACUUAUAUUCUUCUUUAUGA-5'(SEQIDNO:984)
CKAP5-5707靶:5'-AGTTATATGAATATAAGAAGAAATACT-3'(SEQIDNO:1560)
5'-UUAUAUGAAUAUAAGAAGAAAUACUCA-3'(SEQIDNO:3865)
3'-AAUAUACUUAUAUUCUUCUUUAUGAGU-5'(SEQIDNO:985)
CKAP5-5709靶:5'-TTATATGAATATAAGAAGAAATACTCA-3'(SEQIDNO:1561)
5'-AUAUGAAUAUAAGAAGAAAUACUCAGA-3'(SEQIDNO:3866)
3'-UAUACUUAUAUUCUUCUUUAUGAGUCU-5'(SEQIDNO:986)
CKAP5-5711靶:5'-ATATGAATATAAGAAGAAATACTCAGA-3'(SEQIDNO:1562)
5'-GCUGACAUUGAACCAUUUCUGAAAAAU-3'(SEQIDNO:3867)
3'-CGACUGUAACUUGGUAAAGACUUUUUA-5'(SEQIDNO:987)
CKAP5-5739靶:5'-GCTGACATTGAACCATTTCTGAAAAAT-3'(SEQIDNO:1563)
5'-UGACAUUGAACCAUUUCUGAAAAAUUC-3'(SEQIDNO:3868)
3'-ACUGUAACUUGGUAAAGACUUUUUAAG-5'(SEQIDNO:988)
CKAP5-5741靶:5'-TGACATTGAACCATTTCTGAAAAATTC-3'(SEQIDNO:1564)
5'-ACAUUGAACCAUUUCUGAAAAAUUCCU-3'(SEQIDNO:3869)
3'-UGUAACUUGGUAAAGACUUUUUAAGGA-5'(SEQIDNO:989)
CKAP5-5743靶:5'-ACATTGAACCATTTCTGAAAAATTCCT-3'(SEQIDNO:1565)
5'-AUUGAACCAUUUCUGAAAAAUUCCUCA-3'(SEQIDNO:3870)
3'-UAACUUGGUAAAGACUUUUUAAGGAGU-5'(SEQIDNO:990)
CKAP5-5745靶:5'-ATTGAACCATTTCTGAAAAATTCCTCA-3'(SEQIDNO:1566)
5'-UGAACCAUUUCUGAAAAAUUCCUCACA-3'(SEQIDNO:3871)
3'-ACUUGGUAAAGACUUUUUAAGGAGUGU-5'(SEQIDNO:991)
CKAP5-5747靶:5'-TGAACCATTTCTGAAAAATTCCTCACA-3'(SEQIDNO:1567)
5'-AACCAUUUCUGAAAAAUUCCUCACAGU-3'(SEQIDNO:3872)
3'-UUGGUAAAGACUUUUUAAGGAGUGUCA-5'(SEQIDNO:992)
CKAP5-5749靶:5'-AACCATTTCTGAAAAATTCCTCACAGT-3'(SEQIDNO:1568)
5'-AAAGAGGCCUUCGGGUGAUUGAGAUGG-3'(SEQIDNO:3873)
3'-UUUCUCCGGAAGCCCACUAACUCUACC-5'(SEQIDNO:993)
CKAP5-5794靶:5'-AAAGAGGCCTTCGGGTGATTGAGATGG-3'(SEQIDNO:1569)
5'-AGAGGCCUUCGGGUGAUUGAGAUGGAG-3'(SEQIDNO:3874)
3'-UCUCCGGAAGCCCACUAACUCUACCUC-5'(SEQIDNO:994)
CKAP5-5796靶:5'-AGAGGCCTTCGGGTGATTGAGATGGAG-3'(SEQIDNO:1570)
5'-AGGCCUUCGGGUGAUUGAGAUGGAGAG-3'(SEQIDNO:3875)
3'-UCCGGAAGCCCACUAACUCUACCUCUC-5'(SEQIDNO:995)
CKAP5-5798靶:5'-AGGCCTTCGGGTGATTGAGATGGAGAG-3'(SEQIDNO:1571)
5'-GCCUUCGGGUGAUUGAGAUGGAGAGGG-3'(SEQIDNO:3876)
3'-CGGAAGCCCACUAACUCUACCUCUCCC-5'(SEQIDNO:996)
CKAP5-5800靶:5'-GCCTTCGGGTGATTGAGATGGAGAGGG-3'(SEQIDNO:1572)
5'-CUUCGGGUGAUUGAGAUGGAGAGGGAG-3'(SEQIDNO:3877)
3'-GAAGCCCACUAACUCUACCUCUCCCUC-5'(SEQIDNO:997)
CKAP5-5802靶:5'-CTTCGGGTGATTGAGATGGAGAGGGAG-3'(SEQIDNO:1573)
5'-UCGGGUGAUUGAGAUGGAGAGGGAGGG-3'(SEQIDNO:3878)
3'-AGCCCACUAACUCUACCUCUCCCUCCC-5'(SEQIDNO:998)
CKAP5-5804靶:5'-TCGGGTGATTGAGATGGAGAGGGAGGG-3'(SEQIDNO:1574)
5'-GGCCAUCUGUCUACUUGGAAAGGCUAA-3'(SEQIDNO:3879)
3'-CCGGUAGACAGAUGAACCUUUCCGAUU-5'(SEQIDNO:999)
CKAP5-5944靶:5'-GGCCATCTGTCTACTTGGAAAGGCTAA-3'(SEQIDNO:1575)
5'-CCAUCUGUCUACUUGGAAAGGCUAAAG-3'(SEQIDNO:3880)
3'-GGUAGACAGAUGAACCUUUCCGAUUUC-5'(SEQIDNO:1000)
CKAP5-5946靶:5'-CCATCTGTCTACTTGGAAAGGCTAAAG-3'(SEQIDNO:1576)
5'-AUCUGUCUACUUGGAAAGGCUAAAGAU-3'(SEQIDNO:3881)
3'-UAGACAGAUGAACCUUUCCGAUUUCUA-5'(SEQIDNO:1001)
CKAP5-5948靶:5'-ATCTGTCTACTTGGAAAGGCTAAAGAT-3'(SEQIDNO:1577)
5'-CUGUCUACUUGGAAAGGCUAAAGAUCC-3'(SEQIDNO:3882)
3'-GACAGAUGAACCUUUCCGAUUUCUAGG-5'(SEQIDNO:1002)
CKAP5-5950靶:5'-CTGTCTACTTGGAAAGGCTAAAGATCC-3'(SEQIDNO:1578)
5'-UUUGACCUCUUUGCUCUCCAAACCAGC-3'(SEQIDNO:3883)
3'-AAACUGGAGAAACGAGAGGUUUGGUCG-5'(SEQIDNO:1003)
CKAP5-6026靶:5'-TTTGACCTCTTTGCTCTCCAAACCAGC-3'(SEQIDNO:1579)
5'-UGACCUCUUUGCUCUCCAAACCAGCAG-3'(SEQIDNO:3884)
3'-ACUGGAGAAACGAGAGGUUUGGUCGUC-5'(SEQIDNO:1004)
CKAP5-6028靶:5'-TGACCTCTTTGCTCTCCAAACCAGCAG-3'(SEQIDNO:1580)
5'-ACCUCUUUGCUCUCCAAACCAGCAGUU-3'(SEQIDNO:3885)
3'-UGGAGAAACGAGAGGUUUGGUCGUCAA-5'(SEQIDNO:1005)
CKAP5-6030靶:5'-ACCTCTTTGCTCTCCAAACCAGCAGTT-3'(SEQIDNO:1581)
5'-CUCUUUGCUCUCCAAACCAGCAGUUCC-3'(SEQIDNO:3886)
3'-GAGAAACGAGAGGUUUGGUCGUCAAGG-5'(SEQIDNO:1006)
CKAP5-6032靶:5'-CTCTTTGCTCTCCAAACCAGCAGTTCC-3'(SEQIDNO:1582)
5'-UGUGACCUCCUCCUCCUCCACAGCUAA-3'(SEQIDNO:3887)
3'-ACACUGGAGGAGGAGGAGGUGUCGAUU-5'(SEQIDNO:1007)
CKAP5-6173靶:5'-TGTGACCTCCTCCTCCTCCACAGCTAA-3'(SEQIDNO:1583)
5'-AAAGACUGGAGAGAAUAAAGAGCAGUC-3'(SEQIDNO:3888)
3'-UUUCUGACCUCUCUUAUUUCUCGUCAG-5'(SEQIDNO:1008)
CKAP5-6217靶:5'-AAAGACTGGAGAGAATAAAGAGCAGTC-3'(SEQIDNO:1584)
5'-AGACUGGAGAGAAUAAAGAGCAGUCGC-3'(SEQIDNO:3889)
3'-UCUGACCUCUCUUAUUUCUCGUCAGCG-5'(SEQIDNO:1009)
CKAP5-6219靶:5'-AGACTGGAGAGAATAAAGAGCAGTCGC-3'(SEQIDNO:1585)
5'-ACUGGAGAGAAUAAAGAGCAGUCGCAA-3'(SEQIDNO:3890)
3'-UGACCUCUCUUAUUUCUCGUCAGCGUU-5'(SEQIDNO:1010)
CKAP5-6221靶:5'-ACTGGAGAGAATAAAGAGCAGTCGCAA-3'(SEQIDNO:1586)
5'-UGGAGAGAAUAAAGAGCAGUCGCAAAU-3'(SEQIDNO:3891)
3'-ACCUCUCUUAUUUCUCGUCAGCGUUUA-5'(SEQIDNO:1011)
CKAP5-6223靶:5'-TGGAGAGAATAAAGAGCAGTCGCAAAT-3'(SEQIDNO:1587)
5'-GAGAGAAUAAAGAGCAGUCGCAAAUGA-3'(SEQIDNO:3892)
3'-CUCUCUUAUUUCUCGUCAGCGUUUACU-5'(SEQIDNO:1012)
CKAP5-6225靶:5'-GAGAGAATAAAGAGCAGTCGCAAATGA-3'(SEQIDNO:1588)
5'-GAGAAUAAAGAGCAGUCGCAAAUGAAG-3'(SEQIDNO:3893)
3'-CUCUUAUUUCUCGUCAGCGUUUACUUC-5'(SEQIDNO:1013)
CKAP5-6227靶:5'-GAGAATAAAGAGCAGTCGCAAATGAAG-3'(SEQIDNO:1589)
5'-GAAUAAAGAGCAGUCGCAAAUGAAGCU-3'(SEQIDNO:3894)
3'-CUUAUUUCUCGUCAGCGUUUACUUCGA-5'(SEQIDNO:1014)
CKAP5-6229靶:5'-GAATAAAGAGCAGTCGCAAATGAAGCT-3'(SEQIDNO:1590)
5'-AUAAAGAGCAGUCGCAAAUGAAGCUGC-3'(SEQIDNO:3895)
3'-UAUUUCUCGUCAGCGUUUACUUCGACG-5'(SEQIDNO:1015)
CKAP5-6231靶:5'-ATAAAGAGCAGTCGCAAATGAAGCTGC-3'(SEQIDNO:1591)
5'-AAAGAGCAGUCGCAAAUGAAGCUGCCC-3'(SEQIDNO:3896)
3'-UUUCUCGUCAGCGUUUACUUCGACGGG-5'(SEQIDNO:1016)
CKAP5-6233靶:5'-AAAGAGCAGTCGCAAATGAAGCTGCCC-3'(SEQIDNO:1592)
5'-ACAAACUGGUUGUAUGUAUCAUGCCGU-3'(SEQIDNO:3897)
3'-UGUUUGACCAACAUACAUAGUACGGCA-5'(SEQIDNO:1017)
CKAP5-6342靶:5'-ACAAACTGGTTGTATGTATCATGCCGT-3'(SEQIDNO:1593)
5'-UGCUCAUUUGUAAAAUUGUCCUAAUCU-3'(SEQIDNO:3898)
3'-ACGAGUAAACAUUUUAACAGGAUUAGA-5'(SEQIDNO:1018)
CKAP5-6544靶:5'-TGCTCATTTGTAAAATTGTCCTAATCT-3'(SEQIDNO:1594)
5'-CUCAUUUGUAAAAUUGUCCUAAUCUUU-3'(SEQIDNO:3899)
3'-GAGUAAACAUUUUAACAGGAUUAGAAA-5'(SEQIDNO:1019)
CKAP5-6546靶:5'-CTCATTTGTAAAATTGTCCTAATCTTT-3'(SEQIDNO:1595)
5'-CAUUUGUAAAAUUGUCCUAAUCUUUCC-3'(SEQIDNO:3900)
3'-GUAAACAUUUUAACAGGAUUAGAAAGG-5'(SEQIDNO:1020)
CKAP5-6548靶:5'-CATTTGTAAAATTGTCCTAATCTTTCC-3'(SEQIDNO:1596)
5'-UCACUGUAUUCUGUAUGAAUGCAUGGC-3'(SEQIDNO:3901)
3'-AGUGACAUAAGACAUACUUACGUACCG-5'(SEQIDNO:1021)
CKAP5-6656靶:5'-TCACTGTATTCTGTATGAATGCATGGC-3'(SEQIDNO:1597)
5'-ACUGUAUUCUGUAUGAAUGCAUGGCAU-3'(SEQIDNO:3902)
3'-UGACAUAAGACAUACUUACGUACCGUA-5'(SEQIDNO:1022)
CKAP5-6658靶:5'-ACTGTATTCTGTATGAATGCATGGCAT-3'(SEQIDNO:1598)
5'-UGUAUUCUGUAUGAAUGCAUGGCAUGA-3'(SEQIDNO:3903)
3'-ACAUAAGACAUACUUACGUACCGUACU-5'(SEQIDNO:1023)
CKAP5-6660靶:5'-TGTATTCTGTATGAATGCATGGCATGA-3'(SEQIDNO:1599)
5'-UAUUCUGUAUGAAUGCAUGGCAUGAUA-3'(SEQIDNO:3904)
3'-AUAAGACAUACUUACGUACCGUACUAU-5'(SEQIDNO:1024)
CKAP5-6662靶:5'-TATTCTGTATGAATGCATGGCATGATA-3'(SEQIDNO:1600)
5'-UUCUGUAUGAAUGCAUGGCAUGAUACA-3'(SEQIDNO:3905)
3'-AAGACAUACUUACGUACCGUACUAUGU-5'(SEQIDNO:1025)
CKAP5-6664靶:5'-TTCTGTATGAATGCATGGCATGATACA-3'(SEQIDNO:1601)
5'-CUGUAUGAAUGCAUGGCAUGAUACAAC-3'(SEQIDNO:3906)
3'-GACAUACUUACGUACCGUACUAUGUUG-5'(SEQIDNO:1026)
CKAP5-6666靶:5'-CTGTATGAATGCATGGCATGATACAAC-3'(SEQIDNO:1602)
5'-UCUUUUAUAAAUAAAGUUUGCAUUAAC-3'(SEQIDNO:3907)
3'-AGAAAAUAUUUAUUUCAAACGUAAUUG-5'(SEQIDNO:1027)
CKAP5-6704靶:5'-TCTTTTATAAATAAAGTTTGCATTAAC-3'(SEQIDNO:1603)
5'-UUUUAUAAAUAAAGUUUGCAUUAACUA-3'(SEQIDNO:3908)
3'-AAAAUAUUUAUUUCAAACGUAAUUGAU-5'(SEQIDNO:1028)
CKAP5-6706靶:5'-TTTTATAAATAAAGTTTGCATTAACTA-3'(SEQIDNO:1604)
5'-UUAUAAAUAAAGUUUGCAUUAACUAUA-3'(SEQIDNO:3909)
3'-AAUAUUUAUUUCAAACGUAAUUGAUAU-5'(SEQIDNO:1029)
CKAP5-6708靶:5'-TTATAAATAAAGTTTGCATTAACTATA-3'(SEQIDNO:1605)
5'-AUAAAUAAAGUUUGCAUUAACUAUACC-3'(SEQIDNO:3910)
3'-UAUUUAUUUCAAACGUAAUUGAUAUGG-5'(SEQIDNO:1030)
CKAP5-6710靶:5'-ATAAATAAAGTTTGCATTAACTATACC-3'(SEQIDNO:1606)
5'-AAAUAAAGUUUGCAUUAACUAUACCUG-3'(SEQIDNO:3911)
3'-UUUAUUUCAAACGUAAUUGAUAUGGAC-5'(SEQIDNO:1031)
CKAP5-6712靶:5'-AAATAAAGTTTGCATTAACTATACCTG-3'(SEQIDNO:1607)
5'-AUAAAGUUUGCAUUAACUAUACCUGAC-3'(SEQIDNO:3912)
3'-UAUUUCAAACGUAAUUGAUAUGGACUG-5'(SEQIDNO:1032)
CKAP5-6714靶:5'-ATAAAGTTTGCATTAACTATACCTGAC-3'(SEQIDNO:1608)
5'-CCCAGCUGAGGAAAUACUCUUAAUUCU-3'(SEQIDNO:3913)
3'-GGGUCGACUCCUUUAUGAGAAUUAAGA-5'(SEQIDNO:1033)
CKAP5-106靶:5'-CCCAGCTGAGGAAATACTCTTAATTCT-3'(SEQIDNO:1609)
5'-GGUUGAAACUGCCAGUUGAUCAGAAAU-3'(SEQIDNO:3914)
3'-CCAACUUUGACGGUCAACUAGUCUUUA-5'(SEQIDNO:1034)
CKAP5-172靶:5'-GGTTGAAACTGCCAGTTGATCAGAAAT-3'(SEQIDNO:1610)
5'-CUGCCAGUUGAUCAGAAAUGUGAACAC-3'(SEQIDNO:3915)
3'-GACGGUCAACUAGUCUUUACACUUGUG-5'(SEQIDNO:1035)
CKAP5-180靶:5'-CTGCCAGTTGATCAGAAATGTGAACAC-3'(SEQIDNO:1611)
5'-UGGAAAGCAAGGUUAAGUGGGUAUGAA-3'(SEQIDNO:3916)
3'-ACCUUUCGUUCCAAUUCACCCAUACUU-5'(SEQIDNO:1036)
CKAP5-213靶:5'-TGGAAAGCAAGGTTAAGTGGGTATGAA-3'(SEQIDNO:1612)
5'-CCCAGAGUGGUCCAAAUUUUUAGGAUU-3'(SEQIDNO:3917)
3'-GGGUCUCACCAGGUUUAAAAAUCCUAA-5'(SEQIDNO:1037)
CKAP5-281靶:5'-CCCAGAGTGGTCCAAATTTTTAGGATT-3'(SEQIDNO:1613)
5'-CAGUGGUUCAAUUGAAAGGAUUAGAAG-3'(SEQIDNO:3918)
3'-GUCACCAAGUUAACUUUCCUAAUCUUC-5'(SEQIDNO:1038)
CKAP5-337靶:5'-CAGTGGTTCAATTGAAAGGATTAGAAG-3'(SEQIDNO:1614)
5'-AGGAUUAGAAGCUGCACUUGUUUAUGU-3'(SEQIDNO:3919)
3'-UCCUAAUCUUCGACGUGAACAAAUACA-5'(SEQIDNO:1039)
CKAP5-353靶:5'-AGGATTAGAAGCTGCACTTGTTTATGT-3'(SEQIDNO:1615)
5'-AGCUGCACUUGUUUAUGUUGAAAAUGC-3'(SEQIDNO:3920)
3'-UCGACGUGAACAAAUACAACUUUUACG-5'(SEQIDNO:1040)
CKAP5-362靶:5'-AGCTGCACTTGTTTATGTTGAAAATGC-3'(SEQIDNO:1616)
5'-AGCAGGAAAAACCACAGGAGAAGUUGU-3'(SEQIDNO:3921)
3'-UCGUCCUUUUUGGUGUCCUCUUCAACA-5'(SEQIDNO:1041)
CKAP5-395靶:5'-AGCAGGAAAAACCACAGGAGAAGTTGT-3'(SEQIDNO:1617)
5'-GUCAGGUGUUGUAAGUAAGGUGUUCAA-3'(SEQIDNO:3922)
3'-CAGUCCACAACAUUCAUUCCACAAGUU-5'(SEQIDNO:1042)
CKAP5-422靶:5'-GTCAGGTGTTGTAAGTAAGGTGTTCAA-3'(SEQIDNO:1618)
5'-GUGUUGUAAGUAAGGUGUUCAAUCAAC-3'(SEQIDNO:3923)
3'-CACAACAUUCAUUCCACAAGUUAGUUG-5'(SEQIDNO:1043)
CKAP5-427靶:5'-GTGTTGTAAGTAAGGTGTTCAATCAAC-3'(SEQIDNO:1619)
5'-GUUCAAUCAACCUAAAGCUAAAGCCAA-3'(SEQIDNO:3924)
3'-CAAGUUAGUUGGAUUUCGAUUUCGGUU-5'(SEQIDNO:1044)
CKAP5-443靶:5'-GTTCAATCAACCTAAAGCTAAAGCCAA-3'(SEQIDNO:1620)
5'-CUCCUGAAAGGCUUGGACAAUAAGAAU-3'(SEQIDNO:3925)
3'-GAGGACUUUCCGAACCUGUUAUUCUUA-5'(SEQIDNO:1045)
CKAP5-537靶:5'-CTCCTGAAAGGCTTGGACAATAAGAAT-3'(SEQIDNO:1621)
5'-UUAAGCCAAUUAUCAAAGUGUUGCCAA-3'(SEQIDNO:3926)
3'-AAUUCGGUUAAUAGUUUCACAACGGUU-5'(SEQIDNO:1046)
CKAP5-637靶:5'-TTAAGCCAATTATCAAAGTGTTGCCAA-3'(SEQIDNO:1622)
5'-UCAAAGUGUUGCCAAAACUCUUUGAGU-3'(SEQIDNO:3927)
3'-AGUUUCACAACGGUUUUGAGAAACUCA-5'(SEQIDNO:1047)
CKAP5-649靶:5'-TCAAAGTGTTGCCAAAACTCTTTGAGT-3'(SEQIDNO:1623)
5'-GCCAAAACUCUUUGAGUCUCGAGAGAA-3'(SEQIDNO:3928)
3'-CGGUUUUGAGAAACUCAGAGCUCUCUU-5'(SEQIDNO:1048)
CKAP5-659靶:5'-GCCAAAACTCTTTGAGTCTCGAGAGAA-3'(SEQIDNO:1624)
5'-GGCUGUUCGAGAUGAAGCCAAACUAAU-3'(SEQIDNO:3929)
3'-CCGACAAGCUCUACUUCGGUUUGAUUA-5'(SEQIDNO:1049)
CKAP5-686靶:5'-GGCTGTTCGAGATGAAGCCAAACTAAT-3'(SEQIDNO:1625)
5'-CCCAUUACAAAAUAUAAACUCUGUUCA-3'(SEQIDNO:3930)
3'-GGGUAAUGUUUUAUAUUUGAGACAAGU-5'(SEQIDNO:1050)
CKAP5-755靶:5'-CCCATTACAAAATATAAACTCTGTTCA-3'(SEQIDNO:1626)
5'-ACAAAAUAUAAACUCUGUUCAGUUGAA-3'(SEQIDNO:3931)
3'-UGUUUUAUAUUUGAGACAAGUCAACUU-5'(SEQIDNO:1051)
CKAP5-761靶:5'-ACAAAATATAAACTCTGTTCAGTTGAA-3'(SEQIDNO:1627)
5'-AUAUAAACUCUGUUCAGUUGAAAGAAC-3'(SEQIDNO:3932)
3'-UAUAUUUGAGACAAGUCAACUUUCUUG-5'(SEQIDNO:1052)
CKAP5-766靶:5'-ATATAAACTCTGTTCAGTTGAAAGAAC-3'(SEQIDNO:1628)
5'-CUCUGUUCAGUUGAAAGAACUAGAAGA-3'(SEQIDNO:3933)
3'-GAGACAAGUCAACUUUCUUGAUCUUCU-5'(SEQIDNO:1053)
CKAP5-773靶:5'-CTCTGTTCAGTTGAAAGAACTAGAAGA-3'(SEQIDNO:1629)
5'-GUGAUGAGGUGCCACAAAUAGAUGCUU-3'(SEQIDNO:3934)
3'-CACUACUCCACGGUGUUUAUCUACGAA-5'(SEQIDNO:1054)
CKAP5-928靶:5'-GTGATGAGGTGCCACAAATAGATGCTT-3'(SEQIDNO:1630)
5'-ACAAAUAGAUGCUUAUGAGCUUUUAGA-3'(SEQIDNO:3935)
3'-UGUUUAUCUACGAAUACUCGAAAAUCU-5'(SEQIDNO:1055)
CKAP5-941靶:5'-ACAAATAGATGCTTATGAGCTTTTAGA-3'(SEQIDNO:1631)
5'-UUAUGAGCUUUUAGAAGCUGUAGAAAU-3'(SEQIDNO:3936)
3'-AAUACUCGAAAAUCUUCGACAUCUUUA-5'(SEQIDNO:1056)
CKAP5-953靶:5'-TTATGAGCTTTTAGAAGCTGTAGAAAT-3'(SEQIDNO:1632)
5'-GGCCCUGGAGUCUGUAGAAGUACUAAU-3'(SEQIDNO:3937)
3'-CCGGGACCUCAGACAUCUUCAUGAUUA-5'(SEQIDNO:1057)
CKAP5-1046靶:5'-GGCCCTGGAGTCTGTAGAAGTACTAAT-3'(SEQIDNO:1633)
5'-UGGAGUCUGUAGAAGUACUAAUAAAAA-3'(SEQIDNO:3938)
3'-ACCUCAGACAUCUUCAUGAUUAUUUUU-5'(SEQIDNO:1058)
CKAP5-1051靶:5'-TGGAGTCTGTAGAAGTACTAATAAAAA-3'(SEQIDNO:1634)
5'-UGCAGAUUUAGUAAAAGCAUUAAAGAA-3'(SEQIDNO:3939)
3'-ACGUCUAAAUCAUUUUCGUAAUUUCUU-5'(SEQIDNO:1059)
CKAP5-1103靶:5'-TGCAGATTTAGTAAAAGCATTAAAGAA-3'(SEQIDNO:1635)
5'-GUAAAAGCAUUAAAGAAGGUUGUUGGA-3'(SEQIDNO:3940)
3'-CAUUUUCGUAAUUUCUUCCAACAACCU-5'(SEQIDNO:1060)
CKAP5-1113靶:5'-GTAAAAGCATTAAAGAAGGTTGTTGGA-3'(SEQIDNO:1636)
5'-AGCAUUAAAGAAGGUUGUUGGAAAGGA-3'(SEQIDNO:3941)
3'-UCGUAAUUUCUUCCAACAACCUUUCCU-5'(SEQIDNO:1061)
CKAP5-1118靶:5'-AGCATTAAAGAAGGTTGTTGGAAAGGA-3'(SEQIDNO:1637)
5'-AAGAAGGUUGUUGGAAAGGACACCAAU-3'(SEQIDNO:3942)
3'-UUCUUCCAACAACCUUUCCUGUGGUUA-5'(SEQIDNO:1062)
CKAP5-1125靶:5'-AAGAAGGTTGTTGGAAAGGACACCAAT-3'(SEQIDNO:1638)
5'-AAGGAAGAAAUUUGGACAAUAUGCAGG-3'(SEQIDNO:3943)
3'-UUCCUUCUUUAAACCUGUUAUACGUCC-5'(SEQIDNO:1063)
CKAP5-1205靶:5'-AAGGAAGAAATTTGGACAATATGCAGG-3'(SEQIDNO:1639)
5'-CAGUGAGGAUGUUUUAGCAGUAAUGGA-3'(SEQIDNO:3944)
3'-GUCACUCCUACAAAAUCGUCAUUACCU-5'(SEQIDNO:1064)
CKAP5-1343靶:5'-CAGTGAGGATGTTTTAGCAGTAATGGA-3'(SEQIDNO:1640)
5'-AUGUUUUAGCAGUAAUGGAUAAUAAAA-3'(SEQIDNO:3945)
3'-UACAAAAUCGUCAUUACCUAUUAUUUU-5'(SEQIDNO:1065)
CKAP5-1351靶:5'-ATGTTTTAGCAGTAATGGATAATAAAA-3'(SEQIDNO:1641)
5'-AUCAAGCAGCAGACAUCUCUUUUUAUU-3'(SEQIDNO:3946)
3'-UAGUUCGUCGUCUGUAGAGAAAAAUAA-5'(SEQIDNO:1066)
CKAP5-1386靶:5'-ATCAAGCAGCAGACATCTCTTTTTATT-3'(SEQIDNO:1642)
5'-CAGACAUCUCUUUUUAUUGCAAGAAGU-3'(SEQIDNO:3947)
3'-GUCUGUAGAGAAAAAUAACGUUCUUCA-5'(SEQIDNO:1067)
CKAP5-1395靶:5'-CAGACATCTCTTTTTATTGCAAGAAGT-3'(SEQIDNO:1643)
5'-AGUCAGAGAUGCCGCAUUUGAAGCAUU-3'(SEQIDNO:3948)
3'-UCAGUCUCUACGGCGUAAACUUCGUAA-5'(SEQIDNO:1068)
CKAP5-1514靶:5'-AGTCAGAGATGCCGCATTTGAAGCATT-3'(SEQIDNO:1644)
5'-AGCAUUGGGUACUGCUUUGAAGGUGGU-3'(SEQIDNO:3949)
3'-UCGUAACCCAUGACGAAACUUCCACCA-5'(SEQIDNO:1069)
CKAP5-1535靶:5'-AGCATTGGGTACTGCTTTGAAGGTGGT-3'(SEQIDNO:1645)
5'-AUGUGGACAAACUCAAGCUUGAUAAGA-3'(SEQIDNO:3950)
3'-UACACCUGUUUGAGUUCGAACUAUUCU-5'(SEQIDNO:1070)
CKAP5-1594靶:5'-ATGTGGACAAACTCAAGCTTGATAAGA-3'(SEQIDNO:1646)
5'-CAAAGAAUGUUCAGAAAAGGUAGAACU-3'(SEQIDNO:3951)
3'-GUUUCUUACAAGUCUUUUCCAUCUUGA-5'(SEQIDNO:1071)
CKAP5-1622靶:5'-CAAAGAATGTTCAGAAAAGGTAGAACT-3'(SEQIDNO:1647)
5'-GUUCAGAAAAGGUAGAACUGAUACAUG-3'(SEQIDNO:3952)
3'-CAAGUCUUUUCCAUCUUGACUAUGUAC-5'(SEQIDNO:1072)
CKAP5-1630靶:5'-GTTCAGAAAAGGTAGAACTGATACATG-3'(SEQIDNO:1648)
5'-AAGGUAGAACUGAUACAUGGUAAGAAA-3'(SEQIDNO:3953)
3'-UUCCAUCUUGACUAUGUACCAUUCUUU-5'(SEQIDNO:1073)
CKAP5-1638靶:5'-AAGGTAGAACTGATACATGGTAAGAAA-3'(SEQIDNO:1649)
5'-CGCAGGGAAUACUGGAACCAAGAACAA-3'(SEQIDNO:3954)
3'-GCGUCCCUUAUGACCUUGGUUCUUGUU-5'(SEQIDNO:1074)
CKAP5-1847靶:5'-CGCAGGGAATACTGGAACCAAGAACAA-3'(SEQIDNO:1650)
5'-AGCCUGAGCUCUCGAUAGAAGUAUGUG-3'(SEQIDNO:3955)
3'-UCGGACUCGAGAGCUAUCUUCAUACAC-5'(SEQIDNO:1075)
CKAP5-1903靶:5'-AGCCTGAGCTCTCGATAGAAGTATGTG-3'(SEQIDNO:1651)
5'-CUCGAUAGAAGUAUGUGAAGAAAAAGC-3'(SEQIDNO:3956)
3'-GAGCUAUCUUCAUACACUUCUUUUUCG-5'(SEQIDNO:1076)
CKAP5-1913靶:5'-CTCGATAGAAGTATGTGAAGAAAAAGC-3'(SEQIDNO:1652)
5'-UUCUUGACAGCAGUAACUGGAAAGAAA-3'(SEQIDNO:3957)
3'-AAGAACUGUCGUCAUUGACCUUUCUUU-5'(SEQIDNO:1077)
CKAP5-1972靶:5'-TTCTTGACAGCAGTAACTGGAAAGAAA-3'(SEQIDNO:1653)
5'-GAGCUAAUGGACCGAACUGAAAUGCCA-3'(SEQIDNO:3958)
3'-CUCGAUUACCUGGCUUGACUUUACGGU-5'(SEQIDNO:1078)
CKAP5-2034靶:5'-GAGCTAATGGACCGAACTGAAATGCCA-3'(SEQIDNO:1654)
5'-CAUUAGUGAGGAUGCUAGCCAAGAAAC-3'(SEQIDNO:3959)
3'-GUAAUCACUCCUACGAUCGGUUCUUUG-5'(SEQIDNO:1079)
CKAP5-2068靶:5'-CATTAGTGAGGATGCTAGCCAAGAAAC-3'(SEQIDNO:1655)
5'-UAGCCAAGAAACCUGGAUGGAAAGAAA-3'(SEQIDNO:3960)
3'-AUCGGUUCUUUGGACCUACCUUUCUUU-5'(SEQIDNO:1080)
CKAP5-2083靶:5'-TAGCCAAGAAACCTGGATGGAAAGAAA-3'(SEQIDNO:1656)
5'-AAGAAACCUGGAUGGAAAGAAACUAAU-3'(SEQIDNO:3961)
3'-UUCUUUGGACCUACCUUUCUUUGAUUA-5'(SEQIDNO:1081)
CKAP5-2088靶:5'-AAGAAACCTGGATGGAAAGAAACTAAT-3'(SEQIDNO:1657)
5'-AGGUGAUGCAAAUGAAGCUUCAUAUAG-3'(SEQIDNO:3962)
3'-UCCACUACGUUUACUUCGAAGUAUAUC-5'(SEQIDNO:1082)
CKAP5-2119靶:5'-AGGTGATGCAAATGAAGCTTCATATAG-3'(SEQIDNO:1658)
5'-CAAAACGUCAGCUCAGGUUGUAUUAGA-3'(SEQIDNO:3963)
3'-GUUUUGCAGUCGAGUCCAACAUAAUCU-5'(SEQIDNO:1083)
CKAP5-2177靶:5'-CAAAACGTCAGCTCAGGTTGTATTAGA-3'(SEQIDNO:1659)
5'-UGCAAAAGAAGCUAUGACAGCAAUAGC-3'(SEQIDNO:3964)
3'-ACGUUUUCUUCGAUACUGUCGUUAUCG-5'(SEQIDNO:1084)
CKAP5-2246靶:5'-TGCAAAAGAAGCTATGACAGCAATAGC-3'(SEQIDNO:1660)
5'-GACAGCAAUAGCCGAAGCCUGUAUGUU-3'(SEQIDNO:3965)
3'-CUGUCGUUAUCGGCUUCGGACAUACAA-5'(SEQIDNO:1085)
CKAP5-2261靶:5'-GACAGCAATAGCCGAAGCCTGTATGTT-3'(SEQIDNO:1661)
5'-CCGAAGCCUGUAUGUUACCAUGGACUG-3'(SEQIDNO:3966)
3'-GGCUUCGGACAUACAAUGGUACCUGAC-5'(SEQIDNO:1086)
CKAP5-2272靶:5'-CCGAAGCCTGTATGTTACCATGGACTG-3'(SEQIDNO:1662)
5'-CAAAAAUCAGUCAGAAACUCUGAAUUG-3'(SEQIDNO:3967)
3'-GUUUUUAGUCAGUCUUUGAGACUUAAC-5'(SEQIDNO:1087)
CKAP5-2339靶:5'-CAAAAATCAGTCAGAAACTCTGAATTG-3'(SEQIDNO:1663)
5'-AAAGCUUUCAUUAGCAAUGUGAAGACA-3'(SEQIDNO:3968)
3'-UUUCGAAAGUAAUCGUUACACUUCUGU-5'(SEQIDNO:1088)
CKAP5-2412靶:5'-AAAGCTTTCATTAGCAATGTGAAGACA-3'(SEQIDNO:1664)
5'-UUGAGAAGAUGCAGGGACAAAGUCCAC-3'(SEQIDNO:3969)
3'-AACUCUUCUACGUCCCUGUUUCAGGUG-5'(SEQIDNO:1089)
CKAP5-2578靶:5'-TTGAGAAGATGCAGGGACAAAGTCCAC-3'(SEQIDNO:1665)
5'-GAGCAAUGAUGUCGUUGAUCUUUUGCC-3'(SEQIDNO:3970)
3'-CUCGUUACUACAGCAACUAGAAAACGG-5'(SEQIDNO:1090)
CKAP5-2684靶:5'-GAGCAATGATGTCGTTGATCTTTTGCC-3'(SEQIDNO:1666)
5'-AUGAAGUGGCAGGUAUUAUUAAUGACG-3'(SEQIDNO:3971)
3'-UACUUCACCGUCCAUAAUAAUUACUGC-5'(SEQIDNO:1091)
CKAP5-2797靶:5'-ATGAAGTGGCAGGTATTATTAATGACG-3'(SEQIDNO:1667)
5'-CUGCCUUGAAGGGUCGACUCAAUGAUU-3'(SEQIDNO:3972)
3'-GACGGAACUUCCCAGCUGAGUUACUAA-5'(SEQIDNO:1092)
CKAP5-2860靶:5'-CTGCCTTGAAGGGTCGACTCAATGATT-3'(SEQIDNO:1668)
5'-UUGAAGGGUCGACUCAAUGAUUCAAAU-3'(SEQIDNO:3973)
3'-AACUUCCCAGCUGAGUUACUAAGUUUA-5'(SEQIDNO:1093)
CKAP5-2865靶:5'-TTGAAGGGTCGACTCAATGATTCAAAT-3'(SEQIDNO:1669)
5'-UCGACUCAAUGAUUCAAAUAAAAUCUU-3'(SEQIDNO:3974)
3'-AGCUGAGUUACUAAGUUUAUUUUAGAA-5'(SEQIDNO:1094)
CKAP5-2873靶:5'-TCGACTCAATGATTCAAATAAAATCTT-3'(SEQIDNO:1670)
5'-CAAUGAUUCAAAUAAAAUCUUGGUACA-3'(SEQIDNO:3975)
3'-GUUACUAAGUUUAUUUUAGAACCAUGU-5'(SEQIDNO:1095)
CKAP5-2879靶:5'-CAATGATTCAAATAAAATCTTGGTACA-3'(SEQIDNO:1671)
5'-GUAGCCAUGGGCCCAAAUAUUAAGCAA-3'(SEQIDNO:3976)
3'-CAUCGGUACCCGGGUUUAUAAUUCGUU-5'(SEQIDNO:1096)
CKAP5-2937靶:5'-GTAGCCATGGGCCCAAATATTAAGCAA-3'(SEQIDNO:1672)
5'-CCAAAUAUUAAGCAACAUGUAAAAAAU-3'(SEQIDNO:3977)
3'-GGUUUAUAAUUCGUUGUACAUUUUUUA-5'(SEQIDNO:1097)
CKAP5-2949靶:5'-CCAAATATTAAGCAACATGTAAAAAAT-3'(SEQIDNO:1673)
5'-GUCCUUGGAGACAGCAAGAACAAUGUU-3'(SEQIDNO:3978)
3'-CAGGAACCUCUGUCGUUCUUGUUACAA-5'(SEQIDNO:1098)
CKAP5-2997靶:5'-GTCCTTGGAGACAGCAAGAACAATGTT-3'(SEQIDNO:1674)
5'-UGGAGACAGCAAGAACAAUGUUCGAGC-3'(SEQIDNO:3979)
3'-ACCUCUGUCGUUCUUGUUACAAGCUCG-5'(SEQIDNO:1099)
CKAP5-3002靶:5'-TGGAGACAGCAAGAACAATGTTCGAGC-3'(SEQIDNO:1675)
5'-UUCAUGAUGCAUUUAGGAUAUGAAAAA-3'(SEQIDNO:3980)
3'-AAGUACUACGUAAAUCCUAUACUUUUU-5'(SEQIDNO:1100)
CKAP5-3285靶:5'-TTCATGATGCATTTAGGATATGAAAAA-3'(SEQIDNO:1676)
5'-UGCUAGAGAAAGCCAAAGUUAACAUGC-3'(SEQIDNO:3981)
3'-ACGAUCUCUUUCGGUUUCAAUUGUACG-5'(SEQIDNO:1101)
CKAP5-3367靶:5'-TGCTAGAGAAAGCCAAAGTTAACATGC-3'(SEQIDNO:1677)
5'-AAGGGAAGAAGAUGCCAAGCAAAACCA-3'(SEQIDNO:3982)
3'-UUCCCUUCUUCUACGGUUCGUUUUGGU-5'(SEQIDNO:1102)
CKAP5-3571靶:5'-AAGGGAAGAAGATGCCAAGCAAAACCA-3'(SEQIDNO:1678)
5'-UGGAAAAGAGCAAAGGAUGAAAGAUGA-3'(SEQIDNO:3983)
3'-ACCUUUUCUCGUUUCCUACUUUCUACU-5'(SEQIDNO:1103)
CKAP5-3650靶:5'-TGGAAAAGAGCAAAGGATGAAAGATGA-3'(SEQIDNO:1679)
5'-AAGAGCAAAGGAUGAAAGAUGAAAAAG-3'(SEQIDNO:3984)
3'-UUCUCGUUUCCUACUUUCUACUUUUUC-5'(SEQIDNO:1104)
CKAP5-3655靶:5'-AAGAGCAAAGGATGAAAGATGAAAAAG-3'(SEQIDNO:1680)
5'-ACGGGAUGAAUACAUUGAGCAACUAAA-3'(SEQIDNO:3985)
3'-UGCCCUACUUAUGUAACUCGUUGAUUU-5'(SEQIDNO:1105)
CKAP5-3716靶:5'-ACGGGATGAATACATTGAGCAACTAAA-3'(SEQIDNO:1681)
5'-AUGAAUACAUUGAGCAACUAAAGACUC-3'(SEQIDNO:3986)
3'-UACUUAUGUAACUCGUUGAUUUCUGAG-5'(SEQIDNO:1106)
CKAP5-3721靶:5'-ATGAATACATTGAGCAACTAAAGACTC-3'(SEQIDNO:1682)
5'-AAAGUGGCUUACCCUGAGGUUUUUUGA-3'(SEQIDNO:3987)
3'-UUUCACCGAAUGGGACUCCAAAAAACU-5'(SEQIDNO:1107)
CKAP5-3890靶:5'-AAAGTGGCTTACCCTGAGGTTTTTTGA-3'(SEQIDNO:1683)
5'-ACCCUGAGGUUUUUUGACACCAAUACA-3'(SEQIDNO:3988)
3'-UGGGACUCCAAAAAACUGUGGUUAUGU-5'(SEQIDNO:1108)
CKAP5-3900靶:5'-ACCCTGAGGTTTTTTGACACCAATACA-3'(SEQIDNO:1684)
5'-ACCAAUACAAGCGUCCUGAUGAAAGCA-3'(SEQIDNO:3989)
3'-UGGUUAUGUUCGCAGGACUACUUUCGU-5'(SEQIDNO:1109)
CKAP5-3918靶:5'-ACCAATACAAGCGTCCTGATGAAAGCA-3'(SEQIDNO:1685)
5'-GCGUCCUGAUGAAAGCACUAGAAUAUU-3'(SEQIDNO:3990)
3'-CGCAGGACUACUUUCGUGAUCUUAUAA-5'(SEQIDNO:1110)
CKAP5-3928靶:5'-GCGTCCTGATGAAAGCACTAGAATATT-3'(SEQIDNO:1686)
5'-UGAUGAAAGCACUAGAAUAUUUAAAAU-3'(SEQIDNO:3991)
3'-ACUACUUUCGUGAUCUUAUAAAUUUUA-5'(SEQIDNO:1111)
CKAP5-3934靶:5'-TGATGAAAGCACTAGAATATTTAAAAT-3'(SEQIDNO:1687)
5'-UGGAAAUCUUUCUGAAAAGGAUAUGAG-3'(SEQIDNO:3992)
3'-ACCUUUAGAAAGACUUUUCCUAUACUC-5'(SEQIDNO:1112)
CKAP5-4367靶:5'-TGGAAATCTTTCTGAAAAGGATATGAG-3'(SEQIDNO:1688)
5'-CUGAAAAGGAUAUGAGCAUGCUCGAGG-3'(SEQIDNO:3993)
3'-GACUUUUCCUAUACUCGUACGAGCUCC-5'(SEQIDNO:1113)
CKAP5-4378靶:5'-CTGAAAAGGATATGAGCATGCTCGAGG-3'(SEQIDNO:1689)
5'-AAGCUCCAAUGCCAACAUGUUACGCAA-3'(SEQIDNO:3994)
3'-UUCGAGGUUACGGUUGUACAAUGCGUU-5'(SEQIDNO:1114)
CKAP5-4487靶:5'-AAGCTCCAATGCCAACATGTTACGCAA-3'(SEQIDNO:1690)
5'-CCAAUGCCAACAUGUUACGCAAGGGAC-3'(SEQIDNO:3995)
3'-GGUUACGGUUGUACAAUGCGUUCCCUG-5'(SEQIDNO:1115)
CKAP5-4492靶:5'-CCAATGCCAACATGTTACGCAAGGGAC-3'(SEQIDNO:1691)
5'-AUGUGAAAUGCCAGAACUUGUUCAGCA-3'(SEQIDNO:3996)
3'-UACACUUUACGGUCUUGAACAAGUCGU-5'(SEQIDNO:1116)
CKAP5-4649靶:5'-ATGTGAAATGCCAGAACTTGTTCAGCA-3'(SEQIDNO:1692)
5'-GCCAGAACUUGUUCAGCACAAACUGGA-3'(SEQIDNO:3997)
3'-CGGUCUUGAACAAGUCGUGUUUGACCU-5'(SEQIDNO:1117)
CKAP5-4658靶:5'-GCCAGAACTTGTTCAGCACAAACTGGA-3'(SEQIDNO:1693)
5'-GCACAAACUGGAUGACAUUUUUGAGCC-3'(SEQIDNO:3998)
3'-CGUGUUUGACCUACUGUAAAAACUCGG-5'(SEQIDNO:1118)
CKAP5-4673靶:5'-GCACAAACTGGATGACATTTTTGAGCC-3'(SEQIDNO:1694)
5'-UGGAUGACAUUUUUGAGCCAGUCCUUA-3'(SEQIDNO:3999)
3'-ACCUACUGUAAAAACUCGGUCAGGAAU-5'(SEQIDNO:1119)
CKAP5-4681靶:5'-TGGATGACATTTTTGAGCCAGTCCTTA-3'(SEQIDNO:1695)
5'-GACAUUUUUGAGCCAGUCCUUAUUCCU-3'(SEQIDNO:4000)
3'-CUGUAAAAACUCGGUCAGGAAUAAGGA-5'(SEQIDNO:1120)
CKAP5-4686靶:5'-GACATTTTTGAGCCAGTCCTTATTCCT-3'(SEQIDNO:1696)
5'-UUGAGCCAGUCCUUAUUCCUGAACCCA-3'(SEQIDNO:4001)
3'-AACUCGGUCAGGAAUAAGGACUUGGGU-5'(SEQIDNO:1121)
CKAP5-4693靶:5'-TTGAGCCAGTCCTTATTCCTGAACCCA-3'(SEQIDNO:1697)
5'-CACUGGAGUACUAAAAGACCUAAUGCA-3'(SEQIDNO:4002)
3'-GUGACCUCAUGAUUUUCUGGAUUACGU-5'(SEQIDNO:1122)
CKAP5-5057靶:5'-CACTGGAGTACTAAAAGACCTAATGCA-3'(SEQIDNO:1698)
5'-UGGUGAAGGUUCUGGAGAAGUCAGACC-3'(SEQIDNO:4003)
3'-ACCACUUCCAAGACCUCUUCAGUCUGG-5'(SEQIDNO:1123)
CKAP5-5167靶:5'-TGGTGAAGGTTCTGGAGAAGTCAGACC-3'(SEQIDNO:1699)
5'-AUCCUGAGUGCCCUACUUGUUUUGCUC-3'(SEQIDNO:4004)
3'-UAGGACUCACGGGAUGAACAAAACGAG-5'(SEQIDNO:1124)
CKAP5-5202靶:5'-ATCCTGAGTGCCCTACTTGTTTTGCTC-3'(SEQIDNO:1700)
5'-AACAGCCAGUUCUCCCAAAUUCUCAGA-3'(SEQIDNO:4005)
3'-UUGUCGGUCAAGAGGGUUUAAGAGUCU-5'(SEQIDNO:1125)
CKAP5-5246靶:5'-AACAGCCAGTTCTCCCAAATTCTCAGA-3'(SEQIDNO:1701)
5'-GAGCUUGUUAUGAAGUGUCUCUGGAGA-3'(SEQIDNO:4006)
3'-CUCGAACAAUACUUCACAGAGACCUCU-5'(SEQIDNO:1126)
CKAP5-5271靶:5'-GAGCTTGTTATGAAGTGTCTCTGGAGA-3'(SEQIDNO:1702)
5'-UUCGACUGUUGCCUGAUACCAUCAAUA-3'(SEQIDNO:4007)
3'-AAGCUGACAACGGACUAUGGUAGUUAU-5'(SEQIDNO:1127)
CKAP5-5302靶:5'-TTCGACTGTTGCCTGATACCATCAATA-3'(SEQIDNO:1703)
5'-CUGUUGCCUGAUACCAUCAAUAGCAUU-3'(SEQIDNO:4008)
3'-GACAACGGACUAUGGUAGUUAUCGUAA-5'(SEQIDNO:1128)
CKAP5-5307靶:5'-CTGTTGCCTGATACCATCAATAGCATT-3'(SEQIDNO:1704)
5'-GCCUGAUACCAUCAAUAGCAUUAACCU-3'(SEQIDNO:4009)
3'-CGGACUAUGGUAGUUAUCGUAAUUGGA-5'(SEQIDNO:1129)
CKAP5-5312靶:5'-GCCTGATACCATCAATAGCATTAACCT-3'(SEQIDNO:1705)
5'-CCAUCAAUAGCAUUAACCUAGACAGAA-3'(SEQIDNO:4010)
3'-GGUAGUUAUCGUAAUUGGAUCUGUCUU-5'(SEQIDNO:1130)
CKAP5-5320靶:5'-CCATCAATAGCATTAACCTAGACAGAA-3'(SEQIDNO:1706)
5'-AAUAGCAUUAACCUAGACAGAAUUCUU-3'(SEQIDNO:4011)
3'-UUAUCGUAAUUGGAUCUGUCUUAAGAA-5'(SEQIDNO:1131)
CKAP5-5325靶:5'-AATAGCATTAACCTAGACAGAATTCTT-3'(SEQIDNO:1707)
5'-CAGAAUUCUUCUGGAUAUCCACAUUUU-3'(SEQIDNO:4012)
3'-GUCUUAAGAAGACCUAUAGGUGUAAAA-5'(SEQIDNO:1132)
CKAP5-5342靶:5'-CAGAATTCTTCTGGATATCCACATTTT-3'(SEQIDNO:1708)
5'-UUCUGGAUAUCCACAUUUUCAUGAAGG-3'(SEQIDNO:4013)
3'-AAGACCUAUAGGUGUAAAAGUACUUCC-5'(SEQIDNO:1133)
CKAP5-5350靶:5'-TTCTGGATATCCACATTTTCATGAAGG-3'(SEQIDNO:1709)
5'-CCAAAGAGAAACUGAAGCAAUGCAAAA-3'(SEQIDNO:4014)
3'-GGUUUCUCUUUGACUUCGUUACGUUUU-5'(SEQIDNO:1134)
CKAP5-5383靶:5'-CCAAAGAGAAACTGAAGCAATGCAAAA-3'(SEQIDNO:1710)
5'-GAGAAACUGAAGCAAUGCAAAAGUGAA-3'(SEQIDNO:4015)
3'-CUCUUUGACUUCGUUACGUUUUCACUU-5'(SEQIDNO:1135)
CKAP5-5388靶:5'-GAGAAACTGAAGCAATGCAAAAGTGAA-3'(SEQIDNO:1711)
5'-GCCGGAUGAUGAAGCACAGUAUGGACC-3'(SEQIDNO:4016)
3'-CGGCCUACUACUUCGUGUCAUACCUGG-5'(SEQIDNO:1136)
CKAP5-5536靶:5'-GCCGGATGATGAAGCACAGTATGGACC-3'(SEQIDNO:1712)
5'-AACAGAAAAGGGAGCAUCUCGAAUAGA-3'(SEQIDNO:4017)
3'-UUGUCUUUUCCCUCGUAGAGCUUAUCU-5'(SEQIDNO:1137)
CKAP5-5588靶:5'-AACAGAAAAGGGAGCATCTCGAATAGA-3'(SEQIDNO:1713)
5'-AAAGGGAGCAUCUCGAAUAGAUGAAAA-3'(SEQIDNO:4018)
3'-UUUCCCUCGUAGAGCUUAUCUACUUUU-5'(SEQIDNO:1138)
CKAP5-5594靶:5'-AAAGGGAGCATCTCGAATAGATGAAAA-3'(SEQIDNO:1714)
5'-GAGCAUCUCGAAUAGAUGAAAAAUCAU-3'(SEQIDNO:4019)
3'-CUCGUAGAGCUUAUCUACUUUUUAGUA-5'(SEQIDNO:1139)
CKAP5-5599靶:5'-GAGCATCTCGAATAGATGAAAAATCAT-3'(SEQIDNO:1715)
5'-AAGAGGGACUAGCAGAGUUAUAUGAAU-3'(SEQIDNO:4020)
3'-UUCUCCCUGAUCGUCUCAAUAUACUUA-5'(SEQIDNO:1140)
CKAP5-5692靶:5'-AAGAGGGACTAGCAGAGTTATATGAAT-3'(SEQIDNO:1716)
5'-AUACUCAGAUGCUGACAUUGAACCAUU-3'(SEQIDNO:4021)
3'-UAUGAGUCUACGACUGUAACUUGGUAA-5'(SEQIDNO:1141)
CKAP5-5729靶:5'-ATACTCAGATGCTGACATTGAACCATT-3'(SEQIDNO:1717)
5'-AGCAUUCAGACCUGGAUUCUAACCAGA-3'(SEQIDNO:4022)
3'-UCGUAAGUCUGGACCUAAGAUUGGUCU-5'(SEQIDNO:1142)
CKAP5-6130靶:5'-AGCATTCAGACCTGGATTCTAACCAGA-3'(SEQIDNO:1718)
5'-CAGACCUGGAUUCUAACCAGACUCACU-3'(SEQIDNO:4023)
3'-GUCUGGACCUAAGAUUGGUCUGAGUGA-5'(SEQIDNO:1143)
CKAP5-6136靶:5'-CAGACCTGGATTCTAACCAGACTCACT-3'(SEQIDNO:1719)
5'-CUGGAUUCUAACCAGACUCACUCUUCA-3'(SEQIDNO:4024)
3'-GACCUAAGAUUGGUCUGAGUGAGAAGU-5'(SEQIDNO:1144)
CKAP5-6141靶:5'-CTGGATTCTAACCAGACTCACTCTTCA-3'(SEQIDNO:1720)
5'-CAGCUAACAUAGACGACUUGAAAAAAA-3'(SEQIDNO:4025)
3'-GUCGAUUGUAUCUGCUGAACUUUUUUU-5'(SEQIDNO:1145)
CKAP5-6193靶:5'-CAGCTAACATAGACGACTTGAAAAAAA-3'(SEQIDNO:1721)
5'-AACAUAGACGACUUGAAAAAAAGACUG-3'(SEQIDNO:4026)
3'-UUGUAUCUGCUGAACUUUUUUUCUGAC-5'(SEQIDNO:1146)
CKAP5-6198靶:5'-AACATAGACGACTTGAAAAAAAGACTG-3'(SEQIDNO:1722)
5'-AACUAGAAGUCCUCAUAGUUUAAAAUG-3'(SEQIDNO:4027)
3'-UUGAUCUUCAGGAGUAUCAAAUUUUAC-5'(SEQIDNO:1147)
CKAP5-6294靶:5'-AACTAGAAGTCCTCATAGTTTAAAATG-3'(SEQIDNO:1723)
5'-UGGAUGAGUUUAGUGUACAGACUUGUA-3'(SEQIDNO:4028)
3'-ACCUACUCAAAUCACAUGUCUGAACAU-5'(SEQIDNO:1148)
CKAP5-6459靶:5'-TGGATGAGTTTAGTGTACAGACTTGTA-3'(SEQIDNO:1724)
5'-CCCAGAUCCUUUUCUUUUCUUUUUAAU-3'(SEQIDNO:4029)
3'-GGGUCUAGGAAAAGAAAAGAAAAAUUA-5'(SEQIDNO:1149)
CKAP5-6517靶:5'-CCCAGATCCTTTTCTTTTCTTTTTAAT-3'(SEQIDNO:1725)
5'-AUUGCUCAUUUGUAAAAUUGUCCUAAU-3'(SEQIDNO:4030)
3'-UAACGAGUAAACAUUUUAACAGGAUUA-5'(SEQIDNO:1150)
CKAP5-6542靶:5'-ATTGCTCATTTGTAAAATTGTCCTAAT-3'(SEQIDNO:1726)
5'-CUGAAGGGUCACUGUAUUCUGUAUGAA-3'(SEQIDNO:4031)
3'-GACUUCCCAGUGACAUAAGACAUACUU-5'(SEQIDNO:1151)
CKAP5-6648靶:5'-CTGAAGGGTCACTGTATTCTGTATGAA-3'(SEQIDNO:1727)
5'-GGGUCACUGUAUUCUGUAUGAAUGCAU-3'(SEQIDNO:4032)
3'-CCCAGUGACAUAAGACAUACUUACGUA-5'(SEQIDNO:1152)
CKAP5-6653靶:5'-GGGTCACTGTATTCTGTATGAATGCAT-3'(SEQIDNO:1728)
表7:CKAP5mRNA中的DsiRNA组分19个核苷酸的靶序列
CKAP5-14319nt靶#1:5'-GAAGCACAAUGGGAGAUGA-3'(SEQIDNO:4033)
CKAP5-14319nt靶#2:5'-GGAAGCACAAUGGGAGAUG-3'(SEQIDNO:4609)
CKAP5-14319nt靶#3:5'-UGGAAGCACAAUGGGAGAU-3'(SEQIDNO:5185)
CKAP5-14519nt靶#1:5'-AGCACAAUGGGAGAUGACA-3'(SEQIDNO:4034)
CKAP5-14519nt靶#2:5'-AAGCACAAUGGGAGAUGAC-3'(SEQIDNO:4610)
CKAP5-14519nt靶#3:5'-GAAGCACAAUGGGAGAUGA-3'(SEQIDNO:5186)
CKAP5-14719nt靶#1:5'-CACAAUGGGAGAUGACAGU-3'(SEQIDNO:4035)
CKAP5-14719nt靶#2:5'-GCACAAUGGGAGAUGACAG-3'(SEQIDNO:4611)
CKAP5-14719nt靶#3:5'-AGCACAAUGGGAGAUGACA-3'(SEQIDNO:5187)
CKAP5-14919nt靶#1:5'-CAAUGGGAGAUGACAGUGA-3'(SEQIDNO:4036)
CKAP5-14919nt靶#2:5'-ACAAUGGGAGAUGACAGUG-3'(SEQIDNO:4612)
CKAP5-14919nt靶#3:5'-CACAAUGGGAGAUGACAGU-3'(SEQIDNO:5188)
CKAP5-15119nt靶#1:5'-AUGGGAGAUGACAGUGAGU-3'(SEQIDNO:4037)
CKAP5-15119nt靶#2:5'-AAUGGGAGAUGACAGUGAG-3'(SEQIDNO:4613)
CKAP5-15119nt靶#3:5'-CAAUGGGAGAUGACAGUGA-3'(SEQIDNO:5189)
CKAP5-15319nt靶#1:5'-GGGAGAUGACAGUGAGUGG-3'(SEQIDNO:4038)
CKAP5-15319nt靶#2:5'-UGGGAGAUGACAGUGAGUG-3'(SEQIDNO:4614)
CKAP5-15319nt靶#3:5'-AUGGGAGAUGACAGUGAGU-3'(SEQIDNO:5190)
CKAP5-15519nt靶#1:5'-GAGAUGACAGUGAGUGGUU-3'(SEQIDNO:4039)
CKAP5-15519nt靶#2:5'-GGAGAUGACAGUGAGUGGU-3'(SEQIDNO:4615)
CKAP5-15519nt靶#3:5'-GGGAGAUGACAGUGAGUGG-3'(SEQIDNO:5191)
CKAP5-15719nt靶#1:5'-GAUGACAGUGAGUGGUUGA-3'(SEQIDNO:4040)
CKAP5-15719nt靶#2:5'-AGAUGACAGUGAGUGGUUG-3'(SEQIDNO:4616)
CKAP5-15719nt靶#3:5'-GAGAUGACAGUGAGUGGUU-3'(SEQIDNO:5192)
CKAP5-15919nt靶#1:5'-UGACAGUGAGUGGUUGAAA-3'(SEQIDNO:4041)
CKAP5-15919nt靶#2:5'-AUGACAGUGAGUGGUUGAA-3'(SEQIDNO:4617)
CKAP5-15919nt靶#3:5'-GAUGACAGUGAGUGGUUGA-3'(SEQIDNO:5193)
CKAP5-24619nt靶#1:5'-GAAGAUCUUCCAGAAAAUA-3'(SEQIDNO:4042)
CKAP5-24619nt靶#2:5'-UGAAGAUCUUCCAGAAAAU-3'(SEQIDNO:4618)
CKAP5-24619nt靶#3:5'-CUGAAGAUCUUCCAGAAAA-3'(SEQIDNO:5194)
CKAP5-24819nt靶#1:5'-AGAUCUUCCAGAAAAUAAA-3'(SEQIDNO:4043)
CKAP5-24819nt靶#2:5'-AAGAUCUUCCAGAAAAUAA-3'(SEQIDNO:4619)
CKAP5-24819nt靶#3:5'-GAAGAUCUUCCAGAAAAUA-3'(SEQIDNO:5195)
CKAP5-25019nt靶#1:5'-AUCUUCCAGAAAAUAAAGG-3'(SEQIDNO:4044)
CKAP5-25019nt靶#2:5'-GAUCUUCCAGAAAAUAAAG-3'(SEQIDNO:4620)
CKAP5-25019nt靶#3:5'-AGAUCUUCCAGAAAAUAAA-3'(SEQIDNO:5196)
CKAP5-25219nt靶#1:5'-CUUCCAGAAAAUAAAGGAU-3'(SEQIDNO:4045)
CKAP5-25219nt靶#2:5'-UCUUCCAGAAAAUAAAGGA-3'(SEQIDNO:4621)
CKAP5-25219nt靶#3:5'-AUCUUCCAGAAAAUAAAGG-3'(SEQIDNO:5197)
CKAP5-25419nt靶#1:5'-UCCAGAAAAUAAAGGAUGA-3'(SEQIDNO:4046)
CKAP5-25419nt靶#2:5'-UUCCAGAAAAUAAAGGAUG-3'(SEQIDNO:4622)
CKAP5-25419nt靶#3:5'-CUUCCAGAAAAUAAAGGAU-3'(SEQIDNO:5198)
CKAP5-25619nt靶#1:5'-CAGAAAAUAAAGGAUGAAA-3'(SEQIDNO:4047)
CKAP5-25619nt靶#2:5'-CCAGAAAAUAAAGGAUGAA-3'(SEQIDNO:4623)
CKAP5-25619nt靶#3:5'-UCCAGAAAAUAAAGGAUGA-3'(SEQIDNO:5199)
CKAP5-25819nt靶#1:5'-GAAAAUAAAGGAUGAAAAG-3'(SEQIDNO:4048)
CKAP5-25819nt靶#2:5'-AGAAAAUAAAGGAUGAAAA-3'(SEQIDNO:4624)
CKAP5-25819nt靶#3:5'-CAGAAAAUAAAGGAUGAAA-3'(SEQIDNO:5200)
CKAP5-26019nt靶#1:5'-AAAUAAAGGAUGAAAAGAG-3'(SEQIDNO:4049)
CKAP5-26019nt靶#2:5'-AAAAUAAAGGAUGAAAAGA-3'(SEQIDNO:4625)
CKAP5-26019nt靶#3:5'-GAAAAUAAAGGAUGAAAAG-3'(SEQIDNO:5201)
CKAP5-30819nt靶#1:5'-UCAAAAAAUUUGUCACUGA-3'(SEQIDNO:4050)
CKAP5-30819nt靶#2:5'-AUCAAAAAAUUUGUCACUG-3'(SEQIDNO:4626)
CKAP5-30819nt靶#3:5'-GAUCAAAAAAUUUGUCACU-3'(SEQIDNO:5202)
CKAP5-31019nt靶#1:5'-AAAAAAUUUGUCACUGAUU-3'(SEQIDNO:4051)
CKAP5-31019nt靶#2:5'-CAAAAAAUUUGUCACUGAU-3'(SEQIDNO:4627)
CKAP5-31019nt靶#3:5'-UCAAAAAAUUUGUCACUGA-3'(SEQIDNO:5203)
CKAP5-31219nt靶#1:5'-AAAAUUUGUCACUGAUUCC-3'(SEQIDNO:4052)
CKAP5-31219nt靶#2:5'-AAAAAUUUGUCACUGAUUC-3'(SEQIDNO:4628)
CKAP5-31219nt靶#3:5'-AAAAAAUUUGUCACUGAUU-3'(SEQIDNO:5204)
CKAP5-31419nt靶#1:5'-AAUUUGUCACUGAUUCCAA-3'(SEQIDNO:4053)
CKAP5-31419nt靶#2:5'-AAAUUUGUCACUGAUUCCA-3'(SEQIDNO:4629)
CKAP5-31419nt靶#3:5'-AAAAUUUGUCACUGAUUCC-3'(SEQIDNO:5205)
CKAP5-31619nt靶#1:5'-UUUGUCACUGAUUCCAAUG-3'(SEQIDNO:4054)
CKAP5-31619nt靶#2:5'-AUUUGUCACUGAUUCCAAU-3'(SEQIDNO:4630)
CKAP5-31619nt靶#3:5'-AAUUUGUCACUGAUUCCAA-3'(SEQIDNO:5206)
CKAP5-31819nt靶#1:5'-UGUCACUGAUUCCAAUGCA-3'(SEQIDNO:4055)
CKAP5-31819nt靶#2:5'-UUGUCACUGAUUCCAAUGC-3'(SEQIDNO:4631)
CKAP5-31819nt靶#3:5'-UUUGUCACUGAUUCCAAUG-3'(SEQIDNO:5207)
CKAP5-32019nt靶#1:5'-UCACUGAUUCCAAUGCAGU-3'(SEQIDNO:4056)
CKAP5-32019nt靶#2:5'-GUCACUGAUUCCAAUGCAG-3'(SEQIDNO:4632)
CKAP5-32019nt靶#3:5'-UGUCACUGAUUCCAAUGCA-3'(SEQIDNO:5208)
CKAP5-32219nt靶#1:5'-ACUGAUUCCAAUGCAGUGG-3'(SEQIDNO:4057)
CKAP5-32219nt靶#2:5'-CACUGAUUCCAAUGCAGUG-3'(SEQIDNO:4633)
CKAP5-32219nt靶#3:5'-UCACUGAUUCCAAUGCAGU-3'(SEQIDNO:5209)
CKAP5-32419nt靶#1:5'-UGAUUCCAAUGCAGUGGUU-3'(SEQIDNO:4058)
CKAP5-32419nt靶#2:5'-CUGAUUCCAAUGCAGUGGU-3'(SEQIDNO:4634)
CKAP5-32419nt靶#3:5'-ACUGAUUCCAAUGCAGUGG-3'(SEQIDNO:5210)
CKAP5-32619nt靶#1:5'-AUUCCAAUGCAGUGGUUCA-3'(SEQIDNO:4059)
CKAP5-32619nt靶#2:5'-GAUUCCAAUGCAGUGGUUC-3'(SEQIDNO:4635)
CKAP5-32619nt靶#3:5'-UGAUUCCAAUGCAGUGGUU-3'(SEQIDNO:5211)
CKAP5-32819nt靶#1:5'-UCCAAUGCAGUGGUUCAAU-3'(SEQIDNO:4060)
CKAP5-32819nt靶#2:5'-UUCCAAUGCAGUGGUUCAA-3'(SEQIDNO:4636)
CKAP5-32819nt靶#3:5'-AUUCCAAUGCAGUGGUUCA-3'(SEQIDNO:5212)
CKAP5-33019nt靶#1:5'-CAAUGCAGUGGUUCAAUUG-3'(SEQIDNO:4061)
CKAP5-33019nt靶#2:5'-CCAAUGCAGUGGUUCAAUU-3'(SEQIDNO:4637)
CKAP5-33019nt靶#3:5'-UCCAAUGCAGUGGUUCAAU-3'(SEQIDNO:5213)
CKAP5-33219nt靶#1:5'-AUGCAGUGGUUCAAUUGAA-3'(SEQIDNO:4062)
CKAP5-33219nt靶#2:5'-AAUGCAGUGGUUCAAUUGA-3'(SEQIDNO:4638)
CKAP5-33219nt靶#3:5'-CAAUGCAGUGGUUCAAUUG-3'(SEQIDNO:5214)
CKAP5-33419nt靶#1:5'-GCAGUGGUUCAAUUGAAAG-3'(SEQIDNO:4063)
CKAP5-33419nt靶#2:5'-UGCAGUGGUUCAAUUGAAA-3'(SEQIDNO:4639)
CKAP5-33419nt靶#3:5'-AUGCAGUGGUUCAAUUGAA-3'(SEQIDNO:5215)
CKAP5-33619nt靶#1:5'-AGUGGUUCAAUUGAAAGGA-3'(SEQIDNO:4064)
CKAP5-33619nt靶#2:5'-CAGUGGUUCAAUUGAAAGG-3'(SEQIDNO:4640)
CKAP5-33619nt靶#3:5'-GCAGUGGUUCAAUUGAAAG-3'(SEQIDNO:5216)
CKAP5-56519nt靶#1:5'-AAGAUCAUAGUGGCCUGUA-3'(SEQIDNO:4065)
CKAP5-56519nt靶#2:5'-CAAGAUCAUAGUGGCCUGU-3'(SEQIDNO:4641)
CKAP5-56519nt靶#3:5'-CCAAGAUCAUAGUGGCCUG-3'(SEQIDNO:5217)
CKAP5-56719nt靶#1:5'-GAUCAUAGUGGCCUGUAUA-3'(SEQIDNO:4066)
CKAP5-56719nt靶#2:5'-AGAUCAUAGUGGCCUGUAU-3'(SEQIDNO:4642)
CKAP5-56719nt靶#3:5'-AAGAUCAUAGUGGCCUGUA-3'(SEQIDNO:5218)
CKAP5-56919nt靶#1:5'-UCAUAGUGGCCUGUAUAGA-3'(SEQIDNO:4067)
CKAP5-56919nt靶#2:5'-AUCAUAGUGGCCUGUAUAG-3'(SEQIDNO:4643)
CKAP5-56919nt靶#3:5'-GAUCAUAGUGGCCUGUAUA-3'(SEQIDNO:5219)
CKAP5-59019nt靶#1:5'-CACUGAGGAAAGCCUUAAG-3'(SEQIDNO:4068)
CKAP5-59019nt靶#2:5'-ACACUGAGGAAAGCCUUAA-3'(SEQIDNO:4644)
CKAP5-59019nt靶#3:5'-GACACUGAGGAAAGCCUUA-3'(SEQIDNO:5220)
CKAP5-59219nt靶#1:5'-CUGAGGAAAGCCUUAAGUG-3'(SEQIDNO:4069)
CKAP5-59219nt靶#2:5'-ACUGAGGAAAGCCUUAAGU-3'(SEQIDNO:4645)
CKAP5-59219nt靶#3:5'-CACUGAGGAAAGCCUUAAG-3'(SEQIDNO:5221)
CKAP5-59419nt靶#1:5'-GAGGAAAGCCUUAAGUGAA-3'(SEQIDNO:4070)
CKAP5-59419nt靶#2:5'-UGAGGAAAGCCUUAAGUGA-3'(SEQIDNO:4646)
CKAP5-59419nt靶#3:5'-CUGAGGAAAGCCUUAAGUG-3'(SEQIDNO:5222)
CKAP5-59619nt靶#1:5'-GGAAAGCCUUAAGUGAAUU-3'(SEQIDNO:4071)
CKAP5-59619nt靶#2:5'-AGGAAAGCCUUAAGUGAAU-3'(SEQIDNO:4647)
CKAP5-59619nt靶#3:5'-GAGGAAAGCCUUAAGUGAA-3'(SEQIDNO:5223)
CKAP5-59819nt靶#1:5'-AAAGCCUUAAGUGAAUUUG-3'(SEQIDNO:4072)
CKAP5-59819nt靶#2:5'-GAAAGCCUUAAGUGAAUUU-3'(SEQIDNO:4648)
CKAP5-59819nt靶#3:5'-GGAAAGCCUUAAGUGAAUU-3'(SEQIDNO:5224)
CKAP5-60019nt靶#1:5'-AGCCUUAAGUGAAUUUGGU-3'(SEQIDNO:4073)
CKAP5-60019nt靶#2:5'-AAGCCUUAAGUGAAUUUGG-3'(SEQIDNO:4649)
CKAP5-60019nt靶#3:5'-AAAGCCUUAAGUGAAUUUG-3'(SEQIDNO:5225)
CKAP5-60219nt靶#1:5'-CCUUAAGUGAAUUUGGUUC-3'(SEQIDNO:4074)
CKAP5-60219nt靶#2:5'-GCCUUAAGUGAAUUUGGUU-3'(SEQIDNO:4650)
CKAP5-60219nt靶#3:5'-AGCCUUAAGUGAAUUUGGU-3'(SEQIDNO:5226)
CKAP5-60419nt靶#1:5'-UUAAGUGAAUUUGGUUCCA-3'(SEQIDNO:4075)
CKAP5-60419nt靶#2:5'-CUUAAGUGAAUUUGGUUCC-3'(SEQIDNO:4651)
CKAP5-60419nt靶#3:5'-CCUUAAGUGAAUUUGGUUC-3'(SEQIDNO:5227)
CKAP5-60619nt靶#1:5'-AAGUGAAUUUGGUUCCAAA-3'(SEQIDNO:4076)
CKAP5-60619nt靶#2:5'-UAAGUGAAUUUGGUUCCAA-3'(SEQIDNO:4652)
CKAP5-60619nt靶#3:5'-UUAAGUGAAUUUGGUUCCA-3'(SEQIDNO:5228)
CKAP5-60819nt靶#1:5'-GUGAAUUUGGUUCCAAAAU-3'(SEQIDNO:4077)
CKAP5-60819nt靶#2:5'-AGUGAAUUUGGUUCCAAAA-3'(SEQIDNO:4653)
CKAP5-60819nt靶#3:5'-AAGUGAAUUUGGUUCCAAA-3'(SEQIDNO:5229)
CKAP5-61019nt靶#1:5'-GAAUUUGGUUCCAAAAUCA-3'(SEQIDNO:4078)
CKAP5-61019nt靶#2:5'-UGAAUUUGGUUCCAAAAUC-3'(SEQIDNO:4654)
CKAP5-61019nt靶#3:5'-GUGAAUUUGGUUCCAAAAU-3'(SEQIDNO:5230)
CKAP5-61219nt靶#1:5'-AUUUGGUUCCAAAAUCAUC-3'(SEQIDNO:4079)
CKAP5-61219nt靶#2:5'-AAUUUGGUUCCAAAAUCAU-3'(SEQIDNO:4655)
CKAP5-61219nt靶#3:5'-GAAUUUGGUUCCAAAAUCA-3'(SEQIDNO:5231)
CKAP5-84719nt靶#1:5'-CGUUCCCAACAAGAACUAG-3'(SEQIDNO:4080)
CKAP5-84719nt靶#2:5'-UCGUUCCCAACAAGAACUA-3'(SEQIDNO:4656)
CKAP5-84719nt靶#3:5'-UUCGUUCCCAACAAGAACU-3'(SEQIDNO:5232)
CKAP5-84919nt靶#1:5'-UUCCCAACAAGAACUAGAA-3'(SEQIDNO:4081)
CKAP5-84919nt靶#2:5'-GUUCCCAACAAGAACUAGA-3'(SEQIDNO:4657)
CKAP5-84919nt靶#3:5'-CGUUCCCAACAAGAACUAG-3'(SEQIDNO:5233)
CKAP5-85119nt靶#1:5'-CCCAACAAGAACUAGAAGC-3'(SEQIDNO:4082)
CKAP5-85119nt靶#2:5'-UCCCAACAAGAACUAGAAG-3'(SEQIDNO:4658)
CKAP5-85119nt靶#3:5'-UUCCCAACAAGAACUAGAA-3'(SEQIDNO:5234)
CKAP5-85319nt靶#1:5'-CAACAAGAACUAGAAGCUA-3'(SEQIDNO:4083)
CKAP5-85319nt靶#2:5'-CCAACAAGAACUAGAAGCU-3'(SEQIDNO:4659)
CKAP5-85319nt靶#3:5'-CCCAACAAGAACUAGAAGC-3'(SEQIDNO:5235)
CKAP5-85519nt靶#1:5'-ACAAGAACUAGAAGCUAAA-3'(SEQIDNO:4084)
CKAP5-85519nt靶#2:5'-AACAAGAACUAGAAGCUAA-3'(SEQIDNO:4660)
CKAP5-85519nt靶#3:5'-CAACAAGAACUAGAAGCUA-3'(SEQIDNO:5236)
CKAP5-88419nt靶#1:5'-AACAGUCUGCUGGUGGAGA-3'(SEQIDNO:4085)
CKAP5-88419nt靶#2:5'-CAACAGUCUGCUGGUGGAG-3'(SEQIDNO:4661)
CKAP5-88419nt靶#3:5'-ACAACAGUCUGCUGGUGGA-3'(SEQIDNO:5237)
CKAP5-88619nt靶#1:5'-CAGUCUGCUGGUGGAGAUG-3'(SEQIDNO:4086)
CKAP5-88619nt靶#2:5'-ACAGUCUGCUGGUGGAGAU-3'(SEQIDNO:4662)
CKAP5-88619nt靶#3:5'-AACAGUCUGCUGGUGGAGA-3'(SEQIDNO:5238)
CKAP5-91419nt靶#1:5'-GUGGUGAUGAUGGUGAUGA-3'(SEQIDNO:4087)
CKAP5-91419nt靶#2:5'-GGUGGUGAUGAUGGUGAUG-3'(SEQIDNO:4663)
CKAP5-91419nt靶#3:5'-AGGUGGUGAUGAUGGUGAU-3'(SEQIDNO:5239)
CKAP5-91619nt靶#1:5'-GGUGAUGAUGGUGAUGAGG-3'(SEQIDNO:4088)
CKAP5-91619nt靶#2:5'-UGGUGAUGAUGGUGAUGAG-3'(SEQIDNO:4664)
CKAP5-91619nt靶#3:5'-GUGGUGAUGAUGGUGAUGA-3'(SEQIDNO:5240)
CKAP5-97619nt靶#1:5'-AUCCUUUCCAAACUUCCCA-3'(SEQIDNO:4089)
CKAP5-97619nt靶#2:5'-AAUCCUUUCCAAACUUCCC-3'(SEQIDNO:4665)
CKAP5-97619nt靶#3:5'-AAAUCCUUUCCAAACUUCC-3'(SEQIDNO:5241)
CKAP5-97819nt靶#1:5'-CCUUUCCAAACUUCCCAAA-3'(SEQIDNO:4090)
CKAP5-97819nt靶#2:5'-UCCUUUCCAAACUUCCCAA-3'(SEQIDNO:4666)
CKAP5-97819nt靶#3:5'-AUCCUUUCCAAACUUCCCA-3'(SEQIDNO:5242)
CKAP5-98019nt靶#1:5'-UUUCCAAACUUCCCAAAGA-3'(SEQIDNO:4091)
CKAP5-98019nt靶#2:5'-CUUUCCAAACUUCCCAAAG-3'(SEQIDNO:4667)
CKAP5-98019nt靶#3:5'-CCUUUCCAAACUUCCCAAA-3'(SEQIDNO:5243)
CKAP5-98219nt靶#1:5'-UCCAAACUUCCCAAAGACU-3'(SEQIDNO:4092)
CKAP5-98219nt靶#2:5'-UUCCAAACUUCCCAAAGAC-3'(SEQIDNO:4668)
CKAP5-98219nt靶#3:5'-UUUCCAAACUUCCCAAAGA-3'(SEQIDNO:5244)
CKAP5-98419nt靶#1:5'-CAAACUUCCCAAAGACUUU-3'(SEQIDNO:4093)
CKAP5-98419nt靶#2:5'-CCAAACUUCCCAAAGACUU-3'(SEQIDNO:4669)
CKAP5-98419nt靶#3:5'-UCCAAACUUCCCAAAGACU-3'(SEQIDNO:5245)
CKAP5-98619nt靶#1:5'-AACUUCCCAAAGACUUUUA-3'(SEQIDNO:4094)
CKAP5-98619nt靶#2:5'-AAACUUCCCAAAGACUUUU-3'(SEQIDNO:4670)
CKAP5-98619nt靶#3:5'-CAAACUUCCCAAAGACUUU-3'(SEQIDNO:5246)
CKAP5-98819nt靶#1:5'-CUUCCCAAAGACUUUUAUG-3'(SEQIDNO:4095)
CKAP5-98819nt靶#2:5'-ACUUCCCAAAGACUUUUAU-3'(SEQIDNO:4671)
CKAP5-98819nt靶#3:5'-AACUUCCCAAAGACUUUUA-3'(SEQIDNO:5247)
CKAP5-99019nt靶#1:5'-UCCCAAAGACUUUUAUGAC-3'(SEQIDNO:4096)
CKAP5-99019nt靶#2:5'-UUCCCAAAGACUUUUAUGA-3'(SEQIDNO:4672)
CKAP5-99019nt靶#3:5'-CUUCCCAAAGACUUUUAUG-3'(SEQIDNO:5248)
CKAP5-99219nt靶#1:5'-CCAAAGACUUUUAUGACAA-3'(SEQIDNO:4097)
CKAP5-99219nt靶#2:5'-CCCAAAGACUUUUAUGACA-3'(SEQIDNO:4673)
CKAP5-99219nt靶#3:5'-UCCCAAAGACUUUUAUGAC-3'(SEQIDNO:5249)
CKAP5-99419nt靶#1:5'-AAAGACUUUUAUGACAAAA-3'(SEQIDNO:4098)
CKAP5-99419nt靶#2:5'-CAAAGACUUUUAUGACAAA-3'(SEQIDNO:4674)
CKAP5-99419nt靶#3:5'-CCAAAGACUUUUAUGACAA-3'(SEQIDNO:5250)
CKAP5-99619nt靶#1:5'-AGACUUUUAUGACAAAAUU-3'(SEQIDNO:4099)
CKAP5-99619nt靶#2:5'-AAGACUUUUAUGACAAAAU-3'(SEQIDNO:4675)
CKAP5-99619nt靶#3:5'-AAAGACUUUUAUGACAAAA-3'(SEQIDNO:5251)
CKAP5-99819nt靶#1:5'-ACUUUUAUGACAAAAUUGA-3'(SEQIDNO:4100)
CKAP5-99819nt靶#2:5'-GACUUUUAUGACAAAAUUG-3'(SEQIDNO:4676)
CKAP5-99819nt靶#3:5'-AGACUUUUAUGACAAAAUU-3'(SEQIDNO:5252)
CKAP5-100019nt靶#1:5'-UUUUAUGACAAAAUUGAGG-3'(SEQIDNO:4101)
CKAP5-100019nt靶#2:5'-CUUUUAUGACAAAAUUGAG-3'(SEQIDNO:4677)
CKAP5-100019nt靶#3:5'-ACUUUUAUGACAAAAUUGA-3'(SEQIDNO:5253)
CKAP5-100219nt靶#1:5'-UUAUGACAAAAUUGAGGCA-3'(SEQIDNO:4102)
CKAP5-100219nt靶#2:5'-UUUAUGACAAAAUUGAGGC-3'(SEQIDNO:4678)
CKAP5-100219nt靶#3:5'-UUUUAUGACAAAAUUGAGG-3'(SEQIDNO:5254)
CKAP5-100419nt靶#1:5'-AUGACAAAAUUGAGGCAAA-3'(SEQIDNO:4103)
CKAP5-100419nt靶#2:5'-UAUGACAAAAUUGAGGCAA-3'(SEQIDNO:4679)
CKAP5-100419nt靶#3:5'-UUAUGACAAAAUUGAGGCA-3'(SEQIDNO:5255)
CKAP5-102519nt靶#1:5'-AAUGGCAAGAGAGAAAAGA-3'(SEQIDNO:4104)
CKAP5-102519nt靶#2:5'-AAAUGGCAAGAGAGAAAAG-3'(SEQIDNO:4680)
CKAP5-102519nt靶#3:5'-AAAAUGGCAAGAGAGAAAA-3'(SEQIDNO:5256)
CKAP5-112719nt靶#1:5'-AGGUUGUUGGAAAGGACAC-3'(SEQIDNO:4105)
CKAP5-112719nt靶#2:5'-AAGGUUGUUGGAAAGGACA-3'(SEQIDNO:4681)
CKAP5-112719nt靶#3:5'-GAAGGUUGUUGGAAAGGAC-3'(SEQIDNO:5257)
CKAP5-112919nt靶#1:5'-GUUGUUGGAAAGGACACCA-3'(SEQIDNO:4106)
CKAP5-112919nt靶#2:5'-GGUUGUUGGAAAGGACACC-3'(SEQIDNO:4682)
CKAP5-112919nt靶#3:5'-AGGUUGUUGGAAAGGACAC-3'(SEQIDNO:5258)
CKAP5-113119nt靶#1:5'-UGUUGGAAAGGACACCAAU-3'(SEQIDNO:4107)
CKAP5-113119nt靶#2:5'-UUGUUGGAAAGGACACCAA-3'(SEQIDNO:4683)
CKAP5-113119nt靶#3:5'-GUUGUUGGAAAGGACACCA-3'(SEQIDNO:5259)
CKAP5-113319nt靶#1:5'-UUGGAAAGGACACCAAUGU-3'(SEQIDNO:4108)
CKAP5-113319nt靶#2:5'-GUUGGAAAGGACACCAAUG-3'(SEQIDNO:4684)
CKAP5-113319nt靶#3:5'-UGUUGGAAAGGACACCAAU-3'(SEQIDNO:5260)
CKAP5-113519nt靶#1:5'-GGAAAGGACACCAAUGUCA-3'(SEQIDNO:4109)
CKAP5-113519nt靶#2:5'-UGGAAAGGACACCAAUGUC-3'(SEQIDNO:4685)
CKAP5-113519nt靶#3:5'-UUGGAAAGGACACCAAUGU-3'(SEQIDNO:5261)
CKAP5-113719nt靶#1:5'-AAAGGACACCAAUGUCAUG-3'(SEQIDNO:4110)
CKAP5-113719nt靶#2:5'-GAAAGGACACCAAUGUCAU-3'(SEQIDNO:4686)
CKAP5-113719nt靶#3:5'-GGAAAGGACACCAAUGUCA-3'(SEQIDNO:5262)
CKAP5-113919nt靶#1:5'-AGGACACCAAUGUCAUGUU-3'(SEQIDNO:4111)
CKAP5-113919nt靶#2:5'-AAGGACACCAAUGUCAUGU-3'(SEQIDNO:4687)
CKAP5-113919nt靶#3:5'-AAAGGACACCAAUGUCAUG-3'(SEQIDNO:5263)
CKAP5-114119nt靶#1:5'-GACACCAAUGUCAUGUUGG-3'(SEQIDNO:4112)
CKAP5-114119nt靶#2:5'-GGACACCAAUGUCAUGUUG-3'(SEQIDNO:4688)
CKAP5-114119nt靶#3:5'-AGGACACCAAUGUCAUGUU-3'(SEQIDNO:5264)
CKAP5-116219nt靶#1:5'-GCUUUGGCAGCAAAAUGUC-3'(SEQIDNO:4113)
CKAP5-116219nt靶#2:5'-GGCUUUGGCAGCAAAAUGU-3'(SEQIDNO:4689)
CKAP5-116219nt靶#3:5'-UGGCUUUGGCAGCAAAAUG-3'(SEQIDNO:5265)
CKAP5-116419nt靶#1:5'-UUUGGCAGCAAAAUGUCUU-3'(SEQIDNO:4114)
CKAP5-116419nt靶#2:5'-CUUUGGCAGCAAAAUGUCU-3'(SEQIDNO:4690)
CKAP5-116419nt靶#3:5'-GCUUUGGCAGCAAAAUGUC-3'(SEQIDNO:5266)
CKAP5-116619nt靶#1:5'-UGGCAGCAAAAUGUCUUAC-3'(SEQIDNO:4115)
CKAP5-116619nt靶#2:5'-UUGGCAGCAAAAUGUCUUA-3'(SEQIDNO:4691)
CKAP5-116619nt靶#3:5'-UUUGGCAGCAAAAUGUCUU-3'(SEQIDNO:5267)
CKAP5-116819nt靶#1:5'-GCAGCAAAAUGUCUUACUG-3'(SEQIDNO:4116)
CKAP5-116819nt靶#2:5'-GGCAGCAAAAUGUCUUACU-3'(SEQIDNO:4692)
CKAP5-116819nt靶#3:5'-UGGCAGCAAAAUGUCUUAC-3'(SEQIDNO:5268)
CKAP5-117019nt靶#1:5'-AGCAAAAUGUCUUACUGGC-3'(SEQIDNO:4117)
CKAP5-117019nt靶#2:5'-CAGCAAAAUGUCUUACUGG-3'(SEQIDNO:4693)
CKAP5-117019nt靶#3:5'-GCAGCAAAAUGUCUUACUG-3'(SEQIDNO:5269)
CKAP5-120819nt靶#1:5'-AGAAAUUUGGACAAUAUGC-3'(SEQIDNO:4118)
CKAP5-120819nt靶#2:5'-AAGAAAUUUGGACAAUAUG-3'(SEQIDNO:4694)
CKAP5-120819nt靶#3:5'-GAAGAAAUUUGGACAAUAU-3'(SEQIDNO:5270)
CKAP5-121019nt靶#1:5'-AAAUUUGGACAAUAUGCAG-3'(SEQIDNO:4119)
CKAP5-121019nt靶#2:5'-GAAAUUUGGACAAUAUGCA-3'(SEQIDNO:4695)
CKAP5-121019nt靶#3:5'-AGAAAUUUGGACAAUAUGC-3'(SEQIDNO:5271)
CKAP5-121219nt靶#1:5'-AUUUGGACAAUAUGCAGGA-3'(SEQIDNO:4120)
CKAP5-121219nt靶#2:5'-AAUUUGGACAAUAUGCAGG-3'(SEQIDNO:4696)
CKAP5-121219nt靶#3:5'-AAAUUUGGACAAUAUGCAG-3'(SEQIDNO:5272)
CKAP5-121419nt靶#1:5'-UUGGACAAUAUGCAGGACA-3'(SEQIDNO:4121)
CKAP5-121419nt靶#2:5'-UUUGGACAAUAUGCAGGAC-3'(SEQIDNO:4697)
CKAP5-121419nt靶#3:5'-AUUUGGACAAUAUGCAGGA-3'(SEQIDNO:5273)
CKAP5-121619nt靶#1:5'-GGACAAUAUGCAGGACAUG-3'(SEQIDNO:4122)
CKAP5-121619nt靶#2:5'-UGGACAAUAUGCAGGACAU-3'(SEQIDNO:4698)
CKAP5-121619nt靶#3:5'-UUGGACAAUAUGCAGGACA-3'(SEQIDNO:5274)
CKAP5-121819nt靶#1:5'-ACAAUAUGCAGGACAUGUU-3'(SEQIDNO:4123)
CKAP5-121819nt靶#2:5'-GACAAUAUGCAGGACAUGU-3'(SEQIDNO:4699)
CKAP5-121819nt靶#3:5'-GGACAAUAUGCAGGACAUG-3'(SEQIDNO:5275)
CKAP5-122019nt靶#1:5'-AAUAUGCAGGACAUGUUGU-3'(SEQIDNO:4124)
CKAP5-122019nt靶#2:5'-CAAUAUGCAGGACAUGUUG-3'(SEQIDNO:4700)
CKAP5-122019nt靶#3:5'-ACAAUAUGCAGGACAUGUU-3'(SEQIDNO:5276)
CKAP5-122219nt靶#1:5'-UAUGCAGGACAUGUUGUGC-3'(SEQIDNO:4125)
CKAP5-122219nt靶#2:5'-AUAUGCAGGACAUGUUGUG-3'(SEQIDNO:4701)
CKAP5-122219nt靶#3:5'-AAUAUGCAGGACAUGUUGU-3'(SEQIDNO:5277)
CKAP5-122419nt靶#1:5'-UGCAGGACAUGUUGUGCCA-3'(SEQIDNO:4126)
CKAP5-122419nt靶#2:5'-AUGCAGGACAUGUUGUGCC-3'(SEQIDNO:4702)
CKAP5-122419nt靶#3:5'-UAUGCAGGACAUGUUGUGC-3'(SEQIDNO:5278)
CKAP5-122619nt靶#1:5'-CAGGACAUGUUGUGCCAAC-3'(SEQIDNO:4127)
CKAP5-122619nt靶#2:5'-GCAGGACAUGUUGUGCCAA-3'(SEQIDNO:4703)
CKAP5-122619nt靶#3:5'-UGCAGGACAUGUUGUGCCA-3'(SEQIDNO:5279)
CKAP5-127419nt靶#1:5'-CUCAAGUGGUACAAGCCCU-3'(SEQIDNO:4128)
CKAP5-127419nt靶#2:5'-CCUCAAGUGGUACAAGCCC-3'(SEQIDNO:4704)
CKAP5-127419nt靶#3:5'-ACCUCAAGUGGUACAAGCC-3'(SEQIDNO:5280)
CKAP5-127619nt靶#1:5'-CAAGUGGUACAAGCCCUGC-3'(SEQIDNO:4129)
CKAP5-127619nt靶#2:5'-UCAAGUGGUACAAGCCCUG-3'(SEQIDNO:4705)
CKAP5-127619nt靶#3:5'-CUCAAGUGGUACAAGCCCU-3'(SEQIDNO:5281)
CKAP5-127819nt靶#1:5'-AGUGGUACAAGCCCUGCAG-3'(SEQIDNO:4130)
CKAP5-127819nt靶#2:5'-AAGUGGUACAAGCCCUGCA-3'(SEQIDNO:4706)
CKAP5-127819nt靶#3:5'-CAAGUGGUACAAGCCCUGC-3'(SEQIDNO:5282)
CKAP5-128019nt靶#1:5'-UGGUACAAGCCCUGCAGGA-3'(SEQIDNO:4131)
CKAP5-128019nt靶#2:5'-GUGGUACAAGCCCUGCAGG-3'(SEQIDNO:4707)
CKAP5-128019nt靶#3:5'-AGUGGUACAAGCCCUGCAG-3'(SEQIDNO:5283)
CKAP5-128219nt靶#1:5'-GUACAAGCCCUGCAGGAGG-3'(SEQIDNO:4132)
CKAP5-128219nt靶#2:5'-GGUACAAGCCCUGCAGGAG-3'(SEQIDNO:4708)
CKAP5-128219nt靶#3:5'-UGGUACAAGCCCUGCAGGA-3'(SEQIDNO:5284)
CKAP5-128419nt靶#1:5'-ACAAGCCCUGCAGGAGGCA-3'(SEQIDNO:4133)
CKAP5-128419nt靶#2:5'-UACAAGCCCUGCAGGAGGC-3'(SEQIDNO:4709)
CKAP5-128419nt靶#3:5'-GUACAAGCCCUGCAGGAGG-3'(SEQIDNO:5285)
CKAP5-128619nt靶#1:5'-AAGCCCUGCAGGAGGCAAU-3'(SEQIDNO:4134)
CKAP5-128619nt靶#2:5'-CAAGCCCUGCAGGAGGCAA-3'(SEQIDNO:4710)
CKAP5-128619nt靶#3:5'-ACAAGCCCUGCAGGAGGCA-3'(SEQIDNO:5286)
CKAP5-128819nt靶#1:5'-GCCCUGCAGGAGGCAAUUG-3'(SEQIDNO:4135)
CKAP5-128819nt靶#2:5'-AGCCCUGCAGGAGGCAAUU-3'(SEQIDNO:4711)
CKAP5-128819nt靶#3:5'-AAGCCCUGCAGGAGGCAAU-3'(SEQIDNO:5287)
CKAP5-129019nt靶#1:5'-CCUGCAGGAGGCAAUUGAU-3'(SEQIDNO:4136)
CKAP5-129019nt靶#2:5'-CCCUGCAGGAGGCAAUUGA-3'(SEQIDNO:4712)
CKAP5-129019nt靶#3:5'-GCCCUGCAGGAGGCAAUUG-3'(SEQIDNO:5288)
CKAP5-129219nt靶#1:5'-UGCAGGAGGCAAUUGAUGC-3'(SEQIDNO:4137)
CKAP5-129219nt靶#2:5'-CUGCAGGAGGCAAUUGAUG-3'(SEQIDNO:4713)
CKAP5-129219nt靶#3:5'-CCUGCAGGAGGCAAUUGAU-3'(SEQIDNO:5289)
CKAP5-129419nt靶#1:5'-CAGGAGGCAAUUGAUGCAA-3'(SEQIDNO:4138)
CKAP5-129419nt靶#2:5'-GCAGGAGGCAAUUGAUGCA-3'(SEQIDNO:4714)
CKAP5-129419nt靶#3:5'-UGCAGGAGGCAAUUGAUGC-3'(SEQIDNO:5290)
CKAP5-129619nt靶#1:5'-GGAGGCAAUUGAUGCAAUC-3'(SEQIDNO:4139)
CKAP5-129619nt靶#2:5'-AGGAGGCAAUUGAUGCAAU-3'(SEQIDNO:4715)
CKAP5-129619nt靶#3:5'-CAGGAGGCAAUUGAUGCAA-3'(SEQIDNO:5291)
CKAP5-129819nt靶#1:5'-AGGCAAUUGAUGCAAUCUU-3'(SEQIDNO:4140)
CKAP5-129819nt靶#2:5'-GAGGCAAUUGAUGCAAUCU-3'(SEQIDNO:4716)
CKAP5-129819nt靶#3:5'-GGAGGCAAUUGAUGCAAUC-3'(SEQIDNO:5292)
CKAP5-130019nt靶#1:5'-GCAAUUGAUGCAAUCUUCC-3'(SEQIDNO:4141)
CKAP5-130019nt靶#2:5'-GGCAAUUGAUGCAAUCUUC-3'(SEQIDNO:4717)
CKAP5-130019nt靶#3:5'-AGGCAAUUGAUGCAAUCUU-3'(SEQIDNO:5293)
CKAP5-132119nt靶#1:5'-ACUACCACACUACAGAACA-3'(SEQIDNO:4142)
CKAP5-132119nt靶#2:5'-UACUACCACACUACAGAAC-3'(SEQIDNO:4718)
CKAP5-132119nt靶#3:5'-UUACUACCACACUACAGAA-3'(SEQIDNO:5294)
CKAP5-132319nt靶#1:5'-UACCACACUACAGAACAUC-3'(SEQIDNO:4143)
CKAP5-132319nt靶#2:5'-CUACCACACUACAGAACAU-3'(SEQIDNO:4719)
CKAP5-132319nt靶#3:5'-ACUACCACACUACAGAACA-3'(SEQIDNO:5295)
CKAP5-132519nt靶#1:5'-CCACACUACAGAACAUCAG-3'(SEQIDNO:4144)
CKAP5-132519nt靶#2:5'-ACCACACUACAGAACAUCA-3'(SEQIDNO:4720)
CKAP5-132519nt靶#3:5'-UACCACACUACAGAACAUC-3'(SEQIDNO:5296)
CKAP5-132719nt靶#1:5'-ACACUACAGAACAUCAGUG-3'(SEQIDNO:4145)
CKAP5-132719nt靶#2:5'-CACACUACAGAACAUCAGU-3'(SEQIDNO:4721)
CKAP5-132719nt靶#3:5'-CCACACUACAGAACAUCAG-3'(SEQIDNO:5297)
CKAP5-132919nt靶#1:5'-ACUACAGAACAUCAGUGAG-3'(SEQIDNO:4146)
CKAP5-132919nt靶#2:5'-CACUACAGAACAUCAGUGA-3'(SEQIDNO:4722)
CKAP5-132919nt靶#3:5'-ACACUACAGAACAUCAGUG-3'(SEQIDNO:5298)
CKAP5-133119nt靶#1:5'-UACAGAACAUCAGUGAGGA-3'(SEQIDNO:4147)
CKAP5-133119nt靶#2:5'-CUACAGAACAUCAGUGAGG-3'(SEQIDNO:4723)
CKAP5-133119nt靶#3:5'-ACUACAGAACAUCAGUGAG-3'(SEQIDNO:5299)
CKAP5-133319nt靶#1:5'-CAGAACAUCAGUGAGGAUG-3'(SEQIDNO:4148)
CKAP5-133319nt靶#2:5'-ACAGAACAUCAGUGAGGAU-3'(SEQIDNO:4724)
CKAP5-133319nt靶#3:5'-UACAGAACAUCAGUGAGGA-3'(SEQIDNO:5300)
CKAP5-135419nt靶#1:5'-UUAGCAGUAAUGGAUAAUA-3'(SEQIDNO:4149)
CKAP5-135419nt靶#2:5'-UUUAGCAGUAAUGGAUAAU-3'(SEQIDNO:4725)
CKAP5-135419nt靶#3:5'-UUUUAGCAGUAAUGGAUAA-3'(SEQIDNO:5301)
CKAP5-135619nt靶#1:5'-AGCAGUAAUGGAUAAUAAA-3'(SEQIDNO:4150)
CKAP5-135619nt靶#2:5'-UAGCAGUAAUGGAUAAUAA-3'(SEQIDNO:4726)
CKAP5-135619nt靶#3:5'-UUAGCAGUAAUGGAUAAUA-3'(SEQIDNO:5302)
CKAP5-135819nt靶#1:5'-CAGUAAUGGAUAAUAAAAA-3'(SEQIDNO:4151)
CKAP5-135819nt靶#2:5'-GCAGUAAUGGAUAAUAAAA-3'(SEQIDNO:4727)
CKAP5-135819nt靶#3:5'-AGCAGUAAUGGAUAAUAAA-3'(SEQIDNO:5303)
CKAP5-136019nt靶#1:5'-GUAAUGGAUAAUAAAAAUC-3'(SEQIDNO:4152)
CKAP5-136019nt靶#2:5'-AGUAAUGGAUAAUAAAAAU-3'(SEQIDNO:4728)
CKAP5-136019nt靶#3:5'-CAGUAAUGGAUAAUAAAAA-3'(SEQIDNO:5304)
CKAP5-138119nt靶#1:5'-ACCAUCAAGCAGCAGACAU-3'(SEQIDNO:4153)
CKAP5-138119nt靶#2:5'-AACCAUCAAGCAGCAGACA-3'(SEQIDNO:4729)
CKAP5-138119nt靶#3:5'-CAACCAUCAAGCAGCAGAC-3'(SEQIDNO:5305)
CKAP5-148019nt靶#1:5'-CUACUUAAGCACAUCAAUG-3'(SEQIDNO:4154)
CKAP5-148019nt靶#2:5'-ACUACUUAAGCACAUCAAU-3'(SEQIDNO:4730)
CKAP5-148019nt靶#3:5'-CACUACUUAAGCACAUCAA-3'(SEQIDNO:5306)
CKAP5-148219nt靶#1:5'-ACUUAAGCACAUCAAUGAU-3'(SEQIDNO:4155)
CKAP5-148219nt靶#2:5'-UACUUAAGCACAUCAAUGA-3'(SEQIDNO:4731)
CKAP5-148219nt靶#3:5'-CUACUUAAGCACAUCAAUG-3'(SEQIDNO:5307)
CKAP5-148419nt靶#1:5'-UUAAGCACAUCAAUGAUUC-3'(SEQIDNO:4156)
CKAP5-148419nt靶#2:5'-CUUAAGCACAUCAAUGAUU-3'(SEQIDNO:4732)
CKAP5-148419nt靶#3:5'-ACUUAAGCACAUCAAUGAU-3'(SEQIDNO:5308)
CKAP5-148619nt靶#1:5'-AAGCACAUCAAUGAUUCUG-3'(SEQIDNO:4157)
CKAP5-148619nt靶#2:5'-UAAGCACAUCAAUGAUUCU-3'(SEQIDNO:4733)
CKAP5-148619nt靶#3:5'-UUAAGCACAUCAAUGAUUC-3'(SEQIDNO:5309)
CKAP5-148819nt靶#1:5'-GCACAUCAAUGAUUCUGCU-3'(SEQIDNO:4158)
CKAP5-148819nt靶#2:5'-AGCACAUCAAUGAUUCUGC-3'(SEQIDNO:4734)
CKAP5-148819nt靶#3:5'-AAGCACAUCAAUGAUUCUG-3'(SEQIDNO:5310)
CKAP5-149019nt靶#1:5'-ACAUCAAUGAUUCUGCUCC-3'(SEQIDNO:4159)
CKAP5-149019nt靶#2:5'-CACAUCAAUGAUUCUGCUC-3'(SEQIDNO:4735)
CKAP5-149019nt靶#3:5'-GCACAUCAAUGAUUCUGCU-3'(SEQIDNO:5311)
CKAP5-149219nt靶#1:5'-AUCAAUGAUUCUGCUCCUG-3'(SEQIDNO:4160)
CKAP5-149219nt靶#2:5'-CAUCAAUGAUUCUGCUCCU-3'(SEQIDNO:4736)
CKAP5-149219nt靶#3:5'-ACAUCAAUGAUUCUGCUCC-3'(SEQIDNO:5312)
CKAP5-149419nt靶#1:5'-CAAUGAUUCUGCUCCUGAA-3'(SEQIDNO:4161)
CKAP5-149419nt靶#2:5'-UCAAUGAUUCUGCUCCUGA-3'(SEQIDNO:4737)
CKAP5-149419nt靶#3:5'-AUCAAUGAUUCUGCUCCUG-3'(SEQIDNO:5313)
CKAP5-149619nt靶#1:5'-AUGAUUCUGCUCCUGAAGU-3'(SEQIDNO:4162)
CKAP5-149619nt靶#2:5'-AAUGAUUCUGCUCCUGAAG-3'(SEQIDNO:4738)
CKAP5-149619nt靶#3:5'-CAAUGAUUCUGCUCCUGAA-3'(SEQIDNO:5314)
CKAP5-149819nt靶#1:5'-GAUUCUGCUCCUGAAGUCA-3'(SEQIDNO:4163)
CKAP5-149819nt靶#2:5'-UGAUUCUGCUCCUGAAGUC-3'(SEQIDNO:4739)
CKAP5-149819nt靶#3:5'-AUGAUUCUGCUCCUGAAGU-3'(SEQIDNO:5315)
CKAP5-150019nt靶#1:5'-UUCUGCUCCUGAAGUCAGA-3'(SEQIDNO:4164)
CKAP5-150019nt靶#2:5'-AUUCUGCUCCUGAAGUCAG-3'(SEQIDNO:4740)
CKAP5-150019nt靶#3:5'-GAUUCUGCUCCUGAAGUCA-3'(SEQIDNO:5316)
CKAP5-150219nt靶#1:5'-CUGCUCCUGAAGUCAGAGA-3'(SEQIDNO:4165)
CKAP5-150219nt靶#2:5'-UCUGCUCCUGAAGUCAGAG-3'(SEQIDNO:4741)
CKAP5-150219nt靶#3:5'-UUCUGCUCCUGAAGUCAGA-3'(SEQIDNO:5317)
CKAP5-150419nt靶#1:5'-GCUCCUGAAGUCAGAGAUG-3'(SEQIDNO:4166)
CKAP5-150419nt靶#2:5'-UGCUCCUGAAGUCAGAGAU-3'(SEQIDNO:4742)
CKAP5-150419nt靶#3:5'-CUGCUCCUGAAGUCAGAGA-3'(SEQIDNO:5318)
CKAP5-161719nt靶#1:5'-GAUCAAAGAAUGUUCAGAA-3'(SEQIDNO:4167)
CKAP5-161719nt靶#2:5'-AGAUCAAAGAAUGUUCAGA-3'(SEQIDNO:4743)
CKAP5-161719nt靶#3:5'-AAGAUCAAAGAAUGUUCAG-3'(SEQIDNO:5319)
CKAP5-161919nt靶#1:5'-UCAAAGAAUGUUCAGAAAA-3'(SEQIDNO:4168)
CKAP5-161919nt靶#2:5'-AUCAAAGAAUGUUCAGAAA-3'(SEQIDNO:4744)
CKAP5-161919nt靶#3:5'-GAUCAAAGAAUGUUCAGAA-3'(SEQIDNO:5320)
CKAP5-209019nt靶#1:5'-AACCUGGAUGGAAAGAAAC-3'(SEQIDNO:4169)
CKAP5-209019nt靶#2:5'-AAACCUGGAUGGAAAGAAA-3'(SEQIDNO:4745)
CKAP5-209019nt靶#3:5'-GAAACCUGGAUGGAAAGAA-3'(SEQIDNO:5321)
CKAP5-209219nt靶#1:5'-CCUGGAUGGAAAGAAACUA-3'(SEQIDNO:4170)
CKAP5-209219nt靶#2:5'-ACCUGGAUGGAAAGAAACU-3'(SEQIDNO:4746)
CKAP5-209219nt靶#3:5'-AACCUGGAUGGAAAGAAAC-3'(SEQIDNO:5322)
CKAP5-209419nt靶#1:5'-UGGAUGGAAAGAAACUAAU-3'(SEQIDNO:4171)
CKAP5-209419nt靶#2:5'-CUGGAUGGAAAGAAACUAA-3'(SEQIDNO:4747)
CKAP5-209419nt靶#3:5'-CCUGGAUGGAAAGAAACUA-3'(SEQIDNO:5323)
CKAP5-209619nt靶#1:5'-GAUGGAAAGAAACUAAUUU-3'(SEQIDNO:4172)
CKAP5-209619nt靶#2:5'-GGAUGGAAAGAAACUAAUU-3'(SEQIDNO:4748)
CKAP5-209619nt靶#3:5'-UGGAUGGAAAGAAACUAAU-3'(SEQIDNO:5324)
CKAP5-209819nt靶#1:5'-UGGAAAGAAACUAAUUUUC-3'(SEQIDNO:4173)
CKAP5-209819nt靶#2:5'-AUGGAAAGAAACUAAUUUU-3'(SEQIDNO:4749)
CKAP5-209819nt靶#3:5'-GAUGGAAAGAAACUAAUUU-3'(SEQIDNO:5325)
CKAP5-210019nt靶#1:5'-GAAAGAAACUAAUUUUCAG-3'(SEQIDNO:4174)
CKAP5-210019nt靶#2:5'-GGAAAGAAACUAAUUUUCA-3'(SEQIDNO:4750)
CKAP5-210019nt靶#3:5'-UGGAAAGAAACUAAUUUUC-3'(SEQIDNO:5326)
CKAP5-210219nt靶#1:5'-AAGAAACUAAUUUUCAGGU-3'(SEQIDNO:4175)
CKAP5-210219nt靶#2:5'-AAAGAAACUAAUUUUCAGG-3'(SEQIDNO:4751)
CKAP5-210219nt靶#3:5'-GAAAGAAACUAAUUUUCAG-3'(SEQIDNO:5327)
CKAP5-210419nt靶#1:5'-GAAACUAAUUUUCAGGUGA-3'(SEQIDNO:4176)
CKAP5-210419nt靶#2:5'-AGAAACUAAUUUUCAGGUG-3'(SEQIDNO:4752)
CKAP5-210419nt靶#3:5'-AAGAAACUAAUUUUCAGGU-3'(SEQIDNO:5328)
CKAP5-210619nt靶#1:5'-AACUAAUUUUCAGGUGAUG-3'(SEQIDNO:4177)
CKAP5-210619nt靶#2:5'-AAACUAAUUUUCAGGUGAU-3'(SEQIDNO:4753)
CKAP5-210619nt靶#3:5'-GAAACUAAUUUUCAGGUGA-3'(SEQIDNO:5329)
CKAP5-210819nt靶#1:5'-CUAAUUUUCAGGUGAUGCA-3'(SEQIDNO:4178)
CKAP5-210819nt靶#2:5'-ACUAAUUUUCAGGUGAUGC-3'(SEQIDNO:4754)
CKAP5-210819nt靶#3:5'-AACUAAUUUUCAGGUGAUG-3'(SEQIDNO:5330)
CKAP5-214419nt靶#1:5'-UUGCUUUGAUUGCCCAGAA-3'(SEQIDNO:4179)
CKAP5-214419nt靶#2:5'-GUUGCUUUGAUUGCCCAGA-3'(SEQIDNO:4755)
CKAP5-214419nt靶#3:5'-AGUUGCUUUGAUUGCCCAG-3'(SEQIDNO:5331)
CKAP5-214619nt靶#1:5'-GCUUUGAUUGCCCAGAAGG-3'(SEQIDNO:4180)
CKAP5-214619nt靶#2:5'-UGCUUUGAUUGCCCAGAAG-3'(SEQIDNO:4756)
CKAP5-214619nt靶#3:5'-UUGCUUUGAUUGCCCAGAA-3'(SEQIDNO:5332)
CKAP5-214819nt靶#1:5'-UUUGAUUGCCCAGAAGGGA-3'(SEQIDNO:4181)
CKAP5-214819nt靶#2:5'-CUUUGAUUGCCCAGAAGGG-3'(SEQIDNO:4757)
CKAP5-214819nt靶#3:5'-GCUUUGAUUGCCCAGAAGG-3'(SEQIDNO:5333)
CKAP5-215019nt靶#1:5'-UGAUUGCCCAGAAGGGAAA-3'(SEQIDNO:4182)
CKAP5-215019nt靶#2:5'-UUGAUUGCCCAGAAGGGAA-3'(SEQIDNO:4758)
CKAP5-215019nt靶#3:5'-UUUGAUUGCCCAGAAGGGA-3'(SEQIDNO:5334)
CKAP5-215219nt靶#1:5'-AUUGCCCAGAAGGGAAAUU-3'(SEQIDNO:4183)
CKAP5-215219nt靶#2:5'-GAUUGCCCAGAAGGGAAAU-3'(SEQIDNO:4759)
CKAP5-215219nt靶#3:5'-UGAUUGCCCAGAAGGGAAA-3'(SEQIDNO:5335)
CKAP5-215419nt靶#1:5'-UGCCCAGAAGGGAAAUUUU-3'(SEQIDNO:4184)
CKAP5-215419nt靶#2:5'-UUGCCCAGAAGGGAAAUUU-3'(SEQIDNO:4760)
CKAP5-215419nt靶#3:5'-AUUGCCCAGAAGGGAAAUU-3'(SEQIDNO:5336)
CKAP5-215619nt靶#1:5'-CCCAGAAGGGAAAUUUUUC-3'(SEQIDNO:4185)
CKAP5-215619nt靶#2:5'-GCCCAGAAGGGAAAUUUUU-3'(SEQIDNO:4761)
CKAP5-215619nt靶#3:5'-UGCCCAGAAGGGAAAUUUU-3'(SEQIDNO:5337)
CKAP5-221219nt靶#1:5'-GACAAGAUUGGAGAUGUGA-3'(SEQIDNO:4186)
CKAP5-221219nt靶#2:5'-GGACAAGAUUGGAGAUGUG-3'(SEQIDNO:4762)
CKAP5-221219nt靶#3:5'-UGGACAAGAUUGGAGAUGU-3'(SEQIDNO:5338)
CKAP5-221419nt靶#1:5'-CAAGAUUGGAGAUGUGAAA-3'(SEQIDNO:4187)
CKAP5-221419nt靶#2:5'-ACAAGAUUGGAGAUGUGAA-3'(SEQIDNO:4763)
CKAP5-221419nt靶#3:5'-GACAAGAUUGGAGAUGUGA-3'(SEQIDNO:5339)
CKAP5-221619nt靶#1:5'-AGAUUGGAGAUGUGAAAUG-3'(SEQIDNO:4188)
CKAP5-221619nt靶#2:5'-AAGAUUGGAGAUGUGAAAU-3'(SEQIDNO:4764)
CKAP5-221619nt靶#3:5'-CAAGAUUGGAGAUGUGAAA-3'(SEQIDNO:5340)
CKAP5-221819nt靶#1:5'-AUUGGAGAUGUGAAAUGUG-3'(SEQIDNO:4189)
CKAP5-221819nt靶#2:5'-GAUUGGAGAUGUGAAAUGU-3'(SEQIDNO:4765)
CKAP5-221819nt靶#3:5'-AGAUUGGAGAUGUGAAAUG-3'(SEQIDNO:5341)
CKAP5-222019nt靶#1:5'-UGGAGAUGUGAAAUGUGGG-3'(SEQIDNO:4190)
CKAP5-222019nt靶#2:5'-UUGGAGAUGUGAAAUGUGG-3'(SEQIDNO:4766)
CKAP5-222019nt靶#3:5'-AUUGGAGAUGUGAAAUGUG-3'(SEQIDNO:5342)
CKAP5-222219nt靶#1:5'-GAGAUGUGAAAUGUGGGAA-3'(SEQIDNO:4191)
CKAP5-222219nt靶#2:5'-GGAGAUGUGAAAUGUGGGA-3'(SEQIDNO:4767)
CKAP5-222219nt靶#3:5'-UGGAGAUGUGAAAUGUGGG-3'(SEQIDNO:5343)
CKAP5-222419nt靶#1:5'-GAUGUGAAAUGUGGGAACA-3'(SEQIDNO:4192)
CKAP5-222419nt靶#2:5'-AGAUGUGAAAUGUGGGAAC-3'(SEQIDNO:4768)
CKAP5-222419nt靶#3:5'-GAGAUGUGAAAUGUGGGAA-3'(SEQIDNO:5344)
CKAP5-222619nt靶#1:5'-UGUGAAAUGUGGGAACAAU-3'(SEQIDNO:4193)
CKAP5-222619nt靶#2:5'-AUGUGAAAUGUGGGAACAA-3'(SEQIDNO:4769)
CKAP5-222619nt靶#3:5'-GAUGUGAAAUGUGGGAACA-3'(SEQIDNO:5345)
CKAP5-222819nt靶#1:5'-UGAAAUGUGGGAACAAUGC-3'(SEQIDNO:4194)
CKAP5-222819nt靶#2:5'-GUGAAAUGUGGGAACAAUG-3'(SEQIDNO:4770)
CKAP5-222819nt靶#3:5'-UGUGAAAUGUGGGAACAAU-3'(SEQIDNO:5346)
CKAP5-223019nt靶#1:5'-AAAUGUGGGAACAAUGCAA-3'(SEQIDNO:4195)
CKAP5-223019nt靶#2:5'-GAAAUGUGGGAACAAUGCA-3'(SEQIDNO:4771)
CKAP5-223019nt靶#3:5'-UGAAAUGUGGGAACAAUGC-3'(SEQIDNO:5347)
CKAP5-223219nt靶#1:5'-AUGUGGGAACAAUGCAAAA-3'(SEQIDNO:4196)
CKAP5-223219nt靶#2:5'-AAUGUGGGAACAAUGCAAA-3'(SEQIDNO:4772)
CKAP5-223219nt靶#3:5'-AAAUGUGGGAACAAUGCAA-3'(SEQIDNO:5348)
CKAP5-223419nt靶#1:5'-GUGGGAACAAUGCAAAAGA-3'(SEQIDNO:4197)
CKAP5-223419nt靶#2:5'-UGUGGGAACAAUGCAAAAG-3'(SEQIDNO:4773)
CKAP5-223419nt靶#3:5'-AUGUGGGAACAAUGCAAAA-3'(SEQIDNO:5349)
CKAP5-223619nt靶#1:5'-GGGAACAAUGCAAAAGAAG-3'(SEQIDNO:4198)
CKAP5-223619nt靶#2:5'-UGGGAACAAUGCAAAAGAA-3'(SEQIDNO:4774)
CKAP5-223619nt靶#3:5'-GUGGGAACAAUGCAAAAGA-3'(SEQIDNO:5350)
CKAP5-240019nt靶#1:5'-GUUGAAUGUCAAAGCUUUC-3'(SEQIDNO:4199)
CKAP5-240019nt靶#2:5'-GGUUGAAUGUCAAAGCUUU-3'(SEQIDNO:4775)
CKAP5-240019nt靶#3:5'-GGGUUGAAUGUCAAAGCUU-3'(SEQIDNO:5351)
CKAP5-240219nt靶#1:5'-UGAAUGUCAAAGCUUUCAU-3'(SEQIDNO:4200)
CKAP5-240219nt靶#2:5'-UUGAAUGUCAAAGCUUUCA-3'(SEQIDNO:4776)
CKAP5-240219nt靶#3:5'-GUUGAAUGUCAAAGCUUUC-3'(SEQIDNO:5352)
CKAP5-240419nt靶#1:5'-AAUGUCAAAGCUUUCAUUA-3'(SEQIDNO:4201)
CKAP5-240419nt靶#2:5'-GAAUGUCAAAGCUUUCAUU-3'(SEQIDNO:4777)
CKAP5-240419nt靶#3:5'-UGAAUGUCAAAGCUUUCAU-3'(SEQIDNO:5353)
CKAP5-240619nt靶#1:5'-UGUCAAAGCUUUCAUUAGC-3'(SEQIDNO:4202)
CKAP5-240619nt靶#2:5'-AUGUCAAAGCUUUCAUUAG-3'(SEQIDNO:4778)
CKAP5-240619nt靶#3:5'-AAUGUCAAAGCUUUCAUUA-3'(SEQIDNO:5354)
CKAP5-240819nt靶#1:5'-UCAAAGCUUUCAUUAGCAA-3'(SEQIDNO:4203)
CKAP5-240819nt靶#2:5'-GUCAAAGCUUUCAUUAGCA-3'(SEQIDNO:4779)
CKAP5-240819nt靶#3:5'-UGUCAAAGCUUUCAUUAGC-3'(SEQIDNO:5355)
CKAP5-248019nt靶#1:5'-CCCUGCUUGGCGUGAUGUA-3'(SEQIDNO:4204)
CKAP5-248019nt靶#2:5'-ACCCUGCUUGGCGUGAUGU-3'(SEQIDNO:4780)
CKAP5-248019nt靶#3:5'-AACCCUGCUUGGCGUGAUG-3'(SEQIDNO:5356)
CKAP5-248219nt靶#1:5'-CUGCUUGGCGUGAUGUAUC-3'(SEQIDNO:4205)
CKAP5-248219nt靶#2:5'-CCUGCUUGGCGUGAUGUAU-3'(SEQIDNO:4781)
CKAP5-248219nt靶#3:5'-CCCUGCUUGGCGUGAUGUA-3'(SEQIDNO:5357)
CKAP5-252819nt靶#1:5'-UCUUUGAGGAUGAGAAGCC-3'(SEQIDNO:4206)
CKAP5-252819nt靶#2:5'-UUCUUUGAGGAUGAGAAGC-3'(SEQIDNO:4782)
CKAP5-252819nt靶#3:5'-GUUCUUUGAGGAUGAGAAG-3'(SEQIDNO:5358)
CKAP5-253019nt靶#1:5'-UUUGAGGAUGAGAAGCCUG-3'(SEQIDNO:4207)
CKAP5-253019nt靶#2:5'-CUUUGAGGAUGAGAAGCCU-3'(SEQIDNO:4783)
CKAP5-253019nt靶#3:5'-UCUUUGAGGAUGAGAAGCC-3'(SEQIDNO:5359)
CKAP5-253219nt靶#1:5'-UGAGGAUGAGAAGCCUGCC-3'(SEQIDNO:4208)
CKAP5-253219nt靶#2:5'-UUGAGGAUGAGAAGCCUGC-3'(SEQIDNO:4784)
CKAP5-253219nt靶#3:5'-UUUGAGGAUGAGAAGCCUG-3'(SEQIDNO:5360)
CKAP5-253419nt靶#1:5'-AGGAUGAGAAGCCUGCCCU-3'(SEQIDNO:4209)
CKAP5-253419nt靶#2:5'-GAGGAUGAGAAGCCUGCCC-3'(SEQIDNO:4785)
CKAP5-253419nt靶#3:5'-UGAGGAUGAGAAGCCUGCC-3'(SEQIDNO:5361)
CKAP5-253619nt靶#1:5'-GAUGAGAAGCCUGCCCUCC-3'(SEQIDNO:4210)
CKAP5-253619nt靶#2:5'-GGAUGAGAAGCCUGCCCUC-3'(SEQIDNO:4786)
CKAP5-253619nt靶#3:5'-AGGAUGAGAAGCCUGCCCU-3'(SEQIDNO:5362)
CKAP5-253819nt靶#1:5'-UGAGAAGCCUGCCCUCCUA-3'(SEQIDNO:4211)
CKAP5-253819nt靶#2:5'-AUGAGAAGCCUGCCCUCCU-3'(SEQIDNO:4787)
CKAP5-253819nt靶#3:5'-GAUGAGAAGCCUGCCCUCC-3'(SEQIDNO:5363)
CKAP5-254019nt靶#1:5'-AGAAGCCUGCCCUCCUAUC-3'(SEQIDNO:4212)
CKAP5-254019nt靶#2:5'-GAGAAGCCUGCCCUCCUAU-3'(SEQIDNO:4788)
CKAP5-254019nt靶#3:5'-UGAGAAGCCUGCCCUCCUA-3'(SEQIDNO:5364)
CKAP5-254219nt靶#1:5'-AAGCCUGCCCUCCUAUCCC-3'(SEQIDNO:4213)
CKAP5-254219nt靶#2:5'-GAAGCCUGCCCUCCUAUCC-3'(SEQIDNO:4789)
CKAP5-254219nt靶#3:5'-AGAAGCCUGCCCUCCUAUC-3'(SEQIDNO:5365)
CKAP5-254419nt靶#1:5'-GCCUGCCCUCCUAUCCCAG-3'(SEQIDNO:4214)
CKAP5-254419nt靶#2:5'-AGCCUGCCCUCCUAUCCCA-3'(SEQIDNO:4790)
CKAP5-254419nt靶#3:5'-AAGCCUGCCCUCCUAUCCC-3'(SEQIDNO:5366)
CKAP5-254619nt靶#1:5'-CUGCCCUCCUAUCCCAGAU-3'(SEQIDNO:4215)
CKAP5-254619nt靶#2:5'-CCUGCCCUCCUAUCCCAGA-3'(SEQIDNO:4791)
CKAP5-254619nt靶#3:5'-GCCUGCCCUCCUAUCCCAG-3'(SEQIDNO:5367)
CKAP5-254819nt靶#1:5'-GCCCUCCUAUCCCAGAUAG-3'(SEQIDNO:4216)
CKAP5-254819nt靶#2:5'-UGCCCUCCUAUCCCAGAUA-3'(SEQIDNO:4792)
CKAP5-254819nt靶#3:5'-CUGCCCUCCUAUCCCAGAU-3'(SEQIDNO:5368)
CKAP5-255019nt靶#1:5'-CCUCCUAUCCCAGAUAGAU-3'(SEQIDNO:4217)
CKAP5-255019nt靶#2:5'-CCCUCCUAUCCCAGAUAGA-3'(SEQIDNO:4793)
CKAP5-255019nt靶#3:5'-GCCCUCCUAUCCCAGAUAG-3'(SEQIDNO:5369)
CKAP5-255219nt靶#1:5'-UCCUAUCCCAGAUAGAUGC-3'(SEQIDNO:4218)
CKAP5-255219nt靶#2:5'-CUCCUAUCCCAGAUAGAUG-3'(SEQIDNO:4794)
CKAP5-255219nt靶#3:5'-CCUCCUAUCCCAGAUAGAU-3'(SEQIDNO:5370)
CKAP5-255419nt靶#1:5'-CUAUCCCAGAUAGAUGCAG-3'(SEQIDNO:4219)
CKAP5-255419nt靶#2:5'-CCUAUCCCAGAUAGAUGCA-3'(SEQIDNO:4795)
CKAP5-255419nt靶#3:5'-UCCUAUCCCAGAUAGAUGC-3'(SEQIDNO:5371)
CKAP5-255619nt靶#1:5'-AUCCCAGAUAGAUGCAGAA-3'(SEQIDNO:4220)
CKAP5-255619nt靶#2:5'-UAUCCCAGAUAGAUGCAGA-3'(SEQIDNO:4796)
CKAP5-255619nt靶#3:5'-CUAUCCCAGAUAGAUGCAG-3'(SEQIDNO:5372)
CKAP5-255819nt靶#1:5'-CCCAGAUAGAUGCAGAAUU-3'(SEQIDNO:4221)
CKAP5-255819nt靶#2:5'-UCCCAGAUAGAUGCAGAAU-3'(SEQIDNO:4797)
CKAP5-255819nt靶#3:5'-AUCCCAGAUAGAUGCAGAA-3'(SEQIDNO:5373)
CKAP5-258119nt靶#1:5'-AAGAUGCAGGGACAAAGUC-3'(SEQIDNO:4222)
CKAP5-258119nt靶#2:5'-GAAGAUGCAGGGACAAAGU-3'(SEQIDNO:4798)
CKAP5-258119nt靶#3:5'-AGAAGAUGCAGGGACAAAG-3'(SEQIDNO:5374)
CKAP5-264319nt靶#1:5'-UACAGAUGAAGGAGAAGAU-3'(SEQIDNO:4223)
CKAP5-264319nt靶#2:5'-GUACAGAUGAAGGAGAAGA-3'(SEQIDNO:4799)
CKAP5-264319nt靶#3:5'-GGUACAGAUGAAGGAGAAG-3'(SEQIDNO:5375)
CKAP5-264519nt靶#1:5'-CAGAUGAAGGAGAAGAUGG-3'(SEQIDNO:4224)
CKAP5-264519nt靶#2:5'-ACAGAUGAAGGAGAAGAUG-3'(SEQIDNO:4800)
CKAP5-264519nt靶#3:5'-UACAGAUGAAGGAGAAGAU-3'(SEQIDNO:5376)
CKAP5-264719nt靶#1:5'-GAUGAAGGAGAAGAUGGAG-3'(SEQIDNO:4225)
CKAP5-264719nt靶#2:5'-AGAUGAAGGAGAAGAUGGA-3'(SEQIDNO:4801)
CKAP5-264719nt靶#3:5'-CAGAUGAAGGAGAAGAUGG-3'(SEQIDNO:5377)
CKAP5-269519nt靶#1:5'-GUUGAUCUUUUGCCGAGGA-3'(SEQIDNO:4226)
CKAP5-269519nt靶#2:5'-CGUUGAUCUUUUGCCGAGG-3'(SEQIDNO:4802)
CKAP5-269519nt靶#3:5'-UCGUUGAUCUUUUGCCGAG-3'(SEQIDNO:5378)
CKAP5-278019nt靶#1:5'-GGAAAGAAGGCCUAGAUGA-3'(SEQIDNO:4227)
CKAP5-278019nt靶#2:5'-AGGAAAGAAGGCCUAGAUG-3'(SEQIDNO:4803)
CKAP5-278019nt靶#3:5'-UAGGAAAGAAGGCCUAGAU-3'(SEQIDNO:5379)
CKAP5-278219nt靶#1:5'-AAAGAAGGCCUAGAUGAAG-3'(SEQIDNO:4228)
CKAP5-278219nt靶#2:5'-GAAAGAAGGCCUAGAUGAA-3'(SEQIDNO:4804)
CKAP5-278219nt靶#3:5'-GGAAAGAAGGCCUAGAUGA-3'(SEQIDNO:5380)
CKAP5-278419nt靶#1:5'-AGAAGGCCUAGAUGAAGUG-3'(SEQIDNO:4229)
CKAP5-278419nt靶#2:5'-AAGAAGGCCUAGAUGAAGU-3'(SEQIDNO:4805)
CKAP5-278419nt靶#3:5'-AAAGAAGGCCUAGAUGAAG-3'(SEQIDNO:5381)
CKAP5-278619nt靶#1:5'-AAGGCCUAGAUGAAGUGGC-3'(SEQIDNO:4230)
CKAP5-278619nt靶#2:5'-GAAGGCCUAGAUGAAGUGG-3'(SEQIDNO:4806)
CKAP5-278619nt靶#3:5'-AGAAGGCCUAGAUGAAGUG-3'(SEQIDNO:5382)
CKAP5-278819nt靶#1:5'-GGCCUAGAUGAAGUGGCAG-3'(SEQIDNO:4231)
CKAP5-278819nt靶#2:5'-AGGCCUAGAUGAAGUGGCA-3'(SEQIDNO:4807)
CKAP5-278819nt靶#3:5'-AAGGCCUAGAUGAAGUGGC-3'(SEQIDNO:5383)
CKAP5-279019nt靶#1:5'-CCUAGAUGAAGUGGCAGGU-3'(SEQIDNO:4232)
CKAP5-279019nt靶#2:5'-GCCUAGAUGAAGUGGCAGG-3'(SEQIDNO:4808)
CKAP5-279019nt靶#3:5'-GGCCUAGAUGAAGUGGCAG-3'(SEQIDNO:5384)
CKAP5-279219nt靶#1:5'-UAGAUGAAGUGGCAGGUAU-3'(SEQIDNO:4233)
CKAP5-279219nt靶#2:5'-CUAGAUGAAGUGGCAGGUA-3'(SEQIDNO:4809)
CKAP5-279219nt靶#3:5'-CCUAGAUGAAGUGGCAGGU-3'(SEQIDNO:5385)
CKAP5-279419nt靶#1:5'-GAUGAAGUGGCAGGUAUUA-3'(SEQIDNO:4234)
CKAP5-279419nt靶#2:5'-AGAUGAAGUGGCAGGUAUU-3'(SEQIDNO:4810)
CKAP5-279419nt靶#3:5'-UAGAUGAAGUGGCAGGUAU-3'(SEQIDNO:5386)
CKAP5-283919nt靶#1:5'-AAUAUAGGUGAACUUCCAA-3'(SEQIDNO:4235)
CKAP5-283919nt靶#2:5'-GAAUAUAGGUGAACUUCCA-3'(SEQIDNO:4811)
CKAP5-283919nt靶#3:5'-CGAAUAUAGGUGAACUUCC-3'(SEQIDNO:5387)
CKAP5-284119nt靶#1:5'-UAUAGGUGAACUUCCAACU-3'(SEQIDNO:4236)
CKAP5-284119nt靶#2:5'-AUAUAGGUGAACUUCCAAC-3'(SEQIDNO:4812)
CKAP5-284119nt靶#3:5'-AAUAUAGGUGAACUUCCAA-3'(SEQIDNO:5388)
CKAP5-284319nt靶#1:5'-UAGGUGAACUUCCAACUGC-3'(SEQIDNO:4237)
CKAP5-284319nt靶#2:5'-AUAGGUGAACUUCCAACUG-3'(SEQIDNO:4813)
CKAP5-284319nt靶#3:5'-UAUAGGUGAACUUCCAACU-3'(SEQIDNO:5389)
CKAP5-284519nt靶#1:5'-GGUGAACUUCCAACUGCCU-3'(SEQIDNO:4238)
CKAP5-284519nt靶#2:5'-AGGUGAACUUCCAACUGCC-3'(SEQIDNO:4814)
CKAP5-284519nt靶#3:5'-UAGGUGAACUUCCAACUGC-3'(SEQIDNO:5390)
CKAP5-284719nt靶#1:5'-UGAACUUCCAACUGCCUUG-3'(SEQIDNO:4239)
CKAP5-284719nt靶#2:5'-GUGAACUUCCAACUGCCUU-3'(SEQIDNO:4815)
CKAP5-284719nt靶#3:5'-GGUGAACUUCCAACUGCCU-3'(SEQIDNO:5391)
CKAP5-284919nt靶#1:5'-AACUUCCAACUGCCUUGAA-3'(SEQIDNO:4240)
CKAP5-284919nt靶#2:5'-GAACUUCCAACUGCCUUGA-3'(SEQIDNO:4816)
CKAP5-284919nt靶#3:5'-UGAACUUCCAACUGCCUUG-3'(SEQIDNO:5392)
CKAP5-285119nt靶#1:5'-CUUCCAACUGCCUUGAAGG-3'(SEQIDNO:4241)
CKAP5-285119nt靶#2:5'-ACUUCCAACUGCCUUGAAG-3'(SEQIDNO:4817)
CKAP5-285119nt靶#3:5'-AACUUCCAACUGCCUUGAA-3'(SEQIDNO:5393)
CKAP5-285319nt靶#1:5'-UCCAACUGCCUUGAAGGGU-3'(SEQIDNO:4242)
CKAP5-285319nt靶#2:5'-UUCCAACUGCCUUGAAGGG-3'(SEQIDNO:4818)
CKAP5-285319nt靶#3:5'-CUUCCAACUGCCUUGAAGG-3'(SEQIDNO:5394)
CKAP5-285519nt靶#1:5'-CAACUGCCUUGAAGGGUCG-3'(SEQIDNO:4243)
CKAP5-285519nt靶#2:5'-CCAACUGCCUUGAAGGGUC-3'(SEQIDNO:4819)
CKAP5-285519nt靶#3:5'-UCCAACUGCCUUGAAGGGU-3'(SEQIDNO:5395)
CKAP5-285719nt靶#1:5'-ACUGCCUUGAAGGGUCGAC-3'(SEQIDNO:4244)
CKAP5-285719nt靶#2:5'-AACUGCCUUGAAGGGUCGA-3'(SEQIDNO:4820)
CKAP5-285719nt靶#3:5'-CAACUGCCUUGAAGGGUCG-3'(SEQIDNO:5396)
CKAP5-292619nt靶#1:5'-CAACUGGCAGUAGCCAUGG-3'(SEQIDNO:4245)
CKAP5-292619nt靶#2:5'-ACAACUGGCAGUAGCCAUG-3'(SEQIDNO:4821)
CKAP5-292619nt靶#3:5'-AACAACUGGCAGUAGCCAU-3'(SEQIDNO:5397)
CKAP5-300719nt靶#1:5'-AGCAAGAACAAUGUUCGAG-3'(SEQIDNO:4246)
CKAP5-300719nt靶#2:5'-CAGCAAGAACAAUGUUCGA-3'(SEQIDNO:4822)
CKAP5-300719nt靶#3:5'-ACAGCAAGAACAAUGUUCG-3'(SEQIDNO:5398)
CKAP5-300919nt靶#1:5'-CAAGAACAAUGUUCGAGCU-3'(SEQIDNO:4247)
CKAP5-300919nt靶#2:5'-GCAAGAACAAUGUUCGAGC-3'(SEQIDNO:4823)
CKAP5-300919nt靶#3:5'-AGCAAGAACAAUGUUCGAG-3'(SEQIDNO:5399)
CKAP5-301119nt靶#1:5'-AGAACAAUGUUCGAGCUGC-3'(SEQIDNO:4248)
CKAP5-301119nt靶#2:5'-AAGAACAAUGUUCGAGCUG-3'(SEQIDNO:4824)
CKAP5-301119nt靶#3:5'-CAAGAACAAUGUUCGAGCU-3'(SEQIDNO:5400)
CKAP5-301319nt靶#1:5'-AACAAUGUUCGAGCUGCUG-3'(SEQIDNO:4249)
CKAP5-301319nt靶#2:5'-GAACAAUGUUCGAGCUGCU-3'(SEQIDNO:4825)
CKAP5-301319nt靶#3:5'-AGAACAAUGUUCGAGCUGC-3'(SEQIDNO:5401)
CKAP5-301519nt靶#1:5'-CAAUGUUCGAGCUGCUGCC-3'(SEQIDNO:4250)
CKAP5-301519nt靶#2:5'-ACAAUGUUCGAGCUGCUGC-3'(SEQIDNO:4826)
CKAP5-301519nt靶#3:5'-AACAAUGUUCGAGCUGCUG-3'(SEQIDNO:5402)
CKAP5-301719nt靶#1:5'-AUGUUCGAGCUGCUGCCCU-3'(SEQIDNO:4251)
CKAP5-301719nt靶#2:5'-AAUGUUCGAGCUGCUGCCC-3'(SEQIDNO:4827)
CKAP5-301719nt靶#3:5'-CAAUGUUCGAGCUGCUGCC-3'(SEQIDNO:5403)
CKAP5-301919nt靶#1:5'-GUUCGAGCUGCUGCCCUAG-3'(SEQIDNO:4252)
CKAP5-301919nt靶#2:5'-UGUUCGAGCUGCUGCCCUA-3'(SEQIDNO:4828)
CKAP5-301919nt靶#3:5'-AUGUUCGAGCUGCUGCCCU-3'(SEQIDNO:5404)
CKAP5-304019nt靶#1:5'-ACUGUGAAUGCUUGGGCAG-3'(SEQIDNO:4253)
CKAP5-304019nt靶#2:5'-GACUGUGAAUGCUUGGGCA-3'(SEQIDNO:4829)
CKAP5-304019nt靶#3:5'-CGACUGUGAAUGCUUGGGC-3'(SEQIDNO:5405)
CKAP5-304219nt靶#1:5'-UGUGAAUGCUUGGGCAGAA-3'(SEQIDNO:4254)
CKAP5-304219nt靶#2:5'-CUGUGAAUGCUUGGGCAGA-3'(SEQIDNO:4830)
CKAP5-304219nt靶#3:5'-ACUGUGAAUGCUUGGGCAG-3'(SEQIDNO:5406)
CKAP5-304419nt靶#1:5'-UGAAUGCUUGGGCAGAACA-3'(SEQIDNO:4255)
CKAP5-304419nt靶#2:5'-GUGAAUGCUUGGGCAGAAC-3'(SEQIDNO:4831)
CKAP5-304419nt靶#3:5'-UGUGAAUGCUUGGGCAGAA-3'(SEQIDNO:5407)
CKAP5-308919nt靶#1:5'-GAGAAGAUCUUUCUGAAGA-3'(SEQIDNO:4256)
CKAP5-308919nt靶#2:5'-GGAGAAGAUCUUUCUGAAG-3'(SEQIDNO:4832)
CKAP5-308919nt靶#3:5'-AGGAGAAGAUCUUUCUGAA-3'(SEQIDNO:5408)
CKAP5-322919nt靶#1:5'-CUAGAAGAUCGAAAUGGAG-3'(SEQIDNO:4257)
CKAP5-322919nt靶#2:5'-CCUAGAAGAUCGAAAUGGA-3'(SEQIDNO:4833)
CKAP5-322919nt靶#3:5'-GCCUAGAAGAUCGAAAUGG-3'(SEQIDNO:5409)
CKAP5-323119nt靶#1:5'-AGAAGAUCGAAAUGGAGAU-3'(SEQIDNO:4258)
CKAP5-323119nt靶#2:5'-UAGAAGAUCGAAAUGGAGA-3'(SEQIDNO:4834)
CKAP5-323119nt靶#3:5'-CUAGAAGAUCGAAAUGGAG-3'(SEQIDNO:5410)
CKAP5-323319nt靶#1:5'-AAGAUCGAAAUGGAGAUGU-3'(SEQIDNO:4259)
CKAP5-323319nt靶#2:5'-GAAGAUCGAAAUGGAGAUG-3'(SEQIDNO:4835)
CKAP5-323319nt靶#3:5'-AGAAGAUCGAAAUGGAGAU-3'(SEQIDNO:5411)
CKAP5-328719nt靶#1:5'-UGAUGCAUUUAGGAUAUGA-3'(SEQIDNO:4260)
CKAP5-328719nt靶#2:5'-AUGAUGCAUUUAGGAUAUG-3'(SEQIDNO:4836)
CKAP5-328719nt靶#3:5'-CAUGAUGCAUUUAGGAUAU-3'(SEQIDNO:5412)
CKAP5-328919nt靶#1:5'-AUGCAUUUAGGAUAUGAAA-3'(SEQIDNO:4261)
CKAP5-328919nt靶#2:5'-GAUGCAUUUAGGAUAUGAA-3'(SEQIDNO:4837)
CKAP5-328919nt靶#3:5'-UGAUGCAUUUAGGAUAUGA-3'(SEQIDNO:5413)
CKAP5-329119nt靶#1:5'-GCAUUUAGGAUAUGAAAAA-3'(SEQIDNO:4262)
CKAP5-329119nt靶#2:5'-UGCAUUUAGGAUAUGAAAA-3'(SEQIDNO:4838)
CKAP5-329119nt靶#3:5'-AUGCAUUUAGGAUAUGAAA-3'(SEQIDNO:5414)
CKAP5-329319nt靶#1:5'-AUUUAGGAUAUGAAAAAAU-3'(SEQIDNO:4263)
CKAP5-329319nt靶#2:5'-CAUUUAGGAUAUGAAAAAA-3'(SEQIDNO:4839)
CKAP5-329319nt靶#3:5'-GCAUUUAGGAUAUGAAAAA-3'(SEQIDNO:5415)
CKAP5-329519nt靶#1:5'-UUAGGAUAUGAAAAAAUGG-3'(SEQIDNO:4264)
CKAP5-329519nt靶#2:5'-UUUAGGAUAUGAAAAAAUG-3'(SEQIDNO:4840)
CKAP5-329519nt靶#3:5'-AUUUAGGAUAUGAAAAAAU-3'(SEQIDNO:5416)
CKAP5-331619nt靶#1:5'-AAGGCUACUGGGAAACUAA-3'(SEQIDNO:4265)
CKAP5-331619nt靶#2:5'-CAAGGCUACUGGGAAACUA-3'(SEQIDNO:4841)
CKAP5-331619nt靶#3:5'-CCAAGGCUACUGGGAAACU-3'(SEQIDNO:5417)
CKAP5-331819nt靶#1:5'-GGCUACUGGGAAACUAAAG-3'(SEQIDNO:4266)
CKAP5-331819nt靶#2:5'-AGGCUACUGGGAAACUAAA-3'(SEQIDNO:4842)
CKAP5-331819nt靶#3:5'-AAGGCUACUGGGAAACUAA-3'(SEQIDNO:5418)
CKAP5-332019nt靶#1:5'-CUACUGGGAAACUAAAGCC-3'(SEQIDNO:4267)
CKAP5-332019nt靶#2:5'-GCUACUGGGAAACUAAAGC-3'(SEQIDNO:4843)
CKAP5-332019nt靶#3:5'-GGCUACUGGGAAACUAAAG-3'(SEQIDNO:5419)
CKAP5-332219nt靶#1:5'-ACUGGGAAACUAAAGCCAA-3'(SEQIDNO:4268)
CKAP5-332219nt靶#2:5'-UACUGGGAAACUAAAGCCA-3'(SEQIDNO:4844)
CKAP5-332219nt靶#3:5'-CUACUGGGAAACUAAAGCC-3'(SEQIDNO:5420)
CKAP5-332419nt靶#1:5'-UGGGAAACUAAAGCCAACU-3'(SEQIDNO:4269)
CKAP5-332419nt靶#2:5'-CUGGGAAACUAAAGCCAAC-3'(SEQIDNO:4845)
CKAP5-332419nt靶#3:5'-ACUGGGAAACUAAAGCCAA-3'(SEQIDNO:5421)
CKAP5-332619nt靶#1:5'-GGAAACUAAAGCCAACUUC-3'(SEQIDNO:4270)
CKAP5-332619nt靶#2:5'-GGGAAACUAAAGCCAACUU-3'(SEQIDNO:4846)
CKAP5-332619nt靶#3:5'-UGGGAAACUAAAGCCAACU-3'(SEQIDNO:5422)
CKAP5-332819nt靶#1:5'-AAACUAAAGCCAACUUCUA-3'(SEQIDNO:4271)
CKAP5-332819nt靶#2:5'-GAAACUAAAGCCAACUUCU-3'(SEQIDNO:4847)
CKAP5-332819nt靶#3:5'-GGAAACUAAAGCCAACUUC-3'(SEQIDNO:5423)
CKAP5-333019nt靶#1:5'-ACUAAAGCCAACUUCUAAA-3'(SEQIDNO:4272)
CKAP5-333019nt靶#2:5'-AACUAAAGCCAACUUCUAA-3'(SEQIDNO:4848)
CKAP5-333019nt靶#3:5'-AAACUAAAGCCAACUUCUA-3'(SEQIDNO:5424)
CKAP5-333219nt靶#1:5'-UAAAGCCAACUUCUAAAGA-3'(SEQIDNO:4273)
CKAP5-333219nt靶#2:5'-CUAAAGCCAACUUCUAAAG-3'(SEQIDNO:4849)
CKAP5-333219nt靶#3:5'-ACUAAAGCCAACUUCUAAA-3'(SEQIDNO:5425)
CKAP5-333419nt靶#1:5'-AAGCCAACUUCUAAAGAUC-3'(SEQIDNO:4274)
CKAP5-333419nt靶#2:5'-AAAGCCAACUUCUAAAGAU-3'(SEQIDNO:4850)
CKAP5-333419nt靶#3:5'-UAAAGCCAACUUCUAAAGA-3'(SEQIDNO:5426)
CKAP5-362519nt靶#1:5'-CCUAUUUUUAUUGUUGUUC-3'(SEQIDNO:4275)
CKAP5-362519nt靶#2:5'-GCCUAUUUUUAUUGUUGUU-3'(SEQIDNO:4851)
CKAP5-362519nt靶#3:5'-GGCCUAUUUUUAUUGUUGU-3'(SEQIDNO:5427)
CKAP5-362719nt靶#1:5'-UAUUUUUAUUGUUGUUCCA-3'(SEQIDNO:4276)
CKAP5-362719nt靶#2:5'-CUAUUUUUAUUGUUGUUCC-3'(SEQIDNO:4852)
CKAP5-362719nt靶#3:5'-CCUAUUUUUAUUGUUGUUC-3'(SEQIDNO:5428)
CKAP5-362919nt靶#1:5'-UUUUUAUUGUUGUUCCAAA-3'(SEQIDNO:4277)
CKAP5-362919nt靶#2:5'-AUUUUUAUUGUUGUUCCAA-3'(SEQIDNO:4853)
CKAP5-362919nt靶#3:5'-UAUUUUUAUUGUUGUUCCA-3'(SEQIDNO:5429)
CKAP5-363119nt靶#1:5'-UUUAUUGUUGUUCCAAAUG-3'(SEQIDNO:4278)
CKAP5-363119nt靶#2:5'-UUUUAUUGUUGUUCCAAAU-3'(SEQIDNO:4854)
CKAP5-363119nt靶#3:5'-UUUUUAUUGUUGUUCCAAA-3'(SEQIDNO:5430)
CKAP5-363319nt靶#1:5'-UAUUGUUGUUCCAAAUGGA-3'(SEQIDNO:4279)
CKAP5-363319nt靶#2:5'-UUAUUGUUGUUCCAAAUGG-3'(SEQIDNO:4855)
CKAP5-363319nt靶#3:5'-UUUAUUGUUGUUCCAAAUG-3'(SEQIDNO:5431)
CKAP5-363519nt靶#1:5'-UUGUUGUUCCAAAUGGAAA-3'(SEQIDNO:4280)
CKAP5-363519nt靶#2:5'-AUUGUUGUUCCAAAUGGAA-3'(SEQIDNO:4856)
CKAP5-363519nt靶#3:5'-UAUUGUUGUUCCAAAUGGA-3'(SEQIDNO:5432)
CKAP5-368619nt靶#1:5'-AGGUGCUAAAGUGGAAUUU-3'(SEQIDNO:4281)
CKAP5-368619nt靶#2:5'-AAGGUGCUAAAGUGGAAUU-3'(SEQIDNO:4857)
CKAP5-368619nt靶#3:5'-GAAGGUGCUAAAGUGGAAU-3'(SEQIDNO:5433)
CKAP5-368819nt靶#1:5'-GUGCUAAAGUGGAAUUUUA-3'(SEQIDNO:4282)
CKAP5-368819nt靶#2:5'-GGUGCUAAAGUGGAAUUUU-3'(SEQIDNO:4858)
CKAP5-368819nt靶#3:5'-AGGUGCUAAAGUGGAAUUU-3'(SEQIDNO:5434)
CKAP5-398919nt靶#1:5'-AUCAUCUUACUGAGAAUGA-3'(SEQIDNO:4283)
CKAP5-398919nt靶#2:5'-UAUCAUCUUACUGAGAAUG-3'(SEQIDNO:4859)
CKAP5-398919nt靶#3:5'-AUAUCAUCUUACUGAGAAU-3'(SEQIDNO:5435)
CKAP5-399119nt靶#1:5'-CAUCUUACUGAGAAUGAAG-3'(SEQIDNO:4284)
CKAP5-399119nt靶#2:5'-UCAUCUUACUGAGAAUGAA-3'(SEQIDNO:4860)
CKAP5-399119nt靶#3:5'-AUCAUCUUACUGAGAAUGA-3'(SEQIDNO:5436)
CKAP5-399319nt靶#1:5'-UCUUACUGAGAAUGAAGCA-3'(SEQIDNO:4285)
CKAP5-399319nt靶#2:5'-AUCUUACUGAGAAUGAAGC-3'(SEQIDNO:4861)
CKAP5-399319nt靶#3:5'-CAUCUUACUGAGAAUGAAG-3'(SEQIDNO:5437)
CKAP5-399519nt靶#1:5'-UUACUGAGAAUGAAGCAUC-3'(SEQIDNO:4286)
CKAP5-399519nt靶#2:5'-CUUACUGAGAAUGAAGCAU-3'(SEQIDNO:4862)
CKAP5-399519nt靶#3:5'-UCUUACUGAGAAUGAAGCA-3'(SEQIDNO:5438)
CKAP5-403819nt靶#1:5'-CAAGGUUGGAGAACCAAAG-3'(SEQIDNO:4287)
CKAP5-403819nt靶#2:5'-UCAAGGUUGGAGAACCAAA-3'(SEQIDNO:4863)
CKAP5-403819nt靶#3:5'-GUCAAGGUUGGAGAACCAA-3'(SEQIDNO:5439)
CKAP5-404019nt靶#1:5'-AGGUUGGAGAACCAAAGGA-3'(SEQIDNO:4288)
CKAP5-404019nt靶#2:5'-AAGGUUGGAGAACCAAAGG-3'(SEQIDNO:4864)
CKAP5-404019nt靶#3:5'-CAAGGUUGGAGAACCAAAG-3'(SEQIDNO:5440)
CKAP5-404219nt靶#1:5'-GUUGGAGAACCAAAGGAUG-3'(SEQIDNO:4289)
CKAP5-404219nt靶#2:5'-GGUUGGAGAACCAAAGGAU-3'(SEQIDNO:4865)
CKAP5-404219nt靶#3:5'-AGGUUGGAGAACCAAAGGA-3'(SEQIDNO:5441)
CKAP5-404419nt靶#1:5'-UGGAGAACCAAAGGAUGUC-3'(SEQIDNO:4290)
CKAP5-404419nt靶#2:5'-UUGGAGAACCAAAGGAUGU-3'(SEQIDNO:4866)
CKAP5-404419nt靶#3:5'-GUUGGAGAACCAAAGGAUG-3'(SEQIDNO:5442)
CKAP5-404619nt靶#1:5'-GAGAACCAAAGGAUGUCAU-3'(SEQIDNO:4291)
CKAP5-404619nt靶#2:5'-GGAGAACCAAAGGAUGUCA-3'(SEQIDNO:4867)
CKAP5-404619nt靶#3:5'-UGGAGAACCAAAGGAUGUC-3'(SEQIDNO:5443)
CKAP5-404819nt靶#1:5'-GAACCAAAGGAUGUCAUUC-3'(SEQIDNO:4292)
CKAP5-404819nt靶#2:5'-AGAACCAAAGGAUGUCAUU-3'(SEQIDNO:4868)
CKAP5-404819nt靶#3:5'-GAGAACCAAAGGAUGUCAU-3'(SEQIDNO:5444)
CKAP5-405019nt靶#1:5'-ACCAAAGGAUGUCAUUCGU-3'(SEQIDNO:4293)
CKAP5-405019nt靶#2:5'-AACCAAAGGAUGUCAUUCG-3'(SEQIDNO:4869)
CKAP5-405019nt靶#3:5'-GAACCAAAGGAUGUCAUUC-3'(SEQIDNO:5445)
CKAP5-405219nt靶#1:5'-CAAAGGAUGUCAUUCGUAA-3'(SEQIDNO:4294)
CKAP5-405219nt靶#2:5'-CCAAAGGAUGUCAUUCGUA-3'(SEQIDNO:4870)
CKAP5-405219nt靶#3:5'-ACCAAAGGAUGUCAUUCGU-3'(SEQIDNO:5446)
CKAP5-405419nt靶#1:5'-AAGGAUGUCAUUCGUAAAG-3'(SEQIDNO:4295)
CKAP5-405419nt靶#2:5'-AAAGGAUGUCAUUCGUAAA-3'(SEQIDNO:4871)
CKAP5-405419nt靶#3:5'-CAAAGGAUGUCAUUCGUAA-3'(SEQIDNO:5447)
CKAP5-405619nt靶#1:5'-GGAUGUCAUUCGUAAAGAU-3'(SEQIDNO:4296)
CKAP5-405619nt靶#2:5'-AGGAUGUCAUUCGUAAAGA-3'(SEQIDNO:4872)
CKAP5-405619nt靶#3:5'-AAGGAUGUCAUUCGUAAAG-3'(SEQIDNO:5448)
CKAP5-405819nt靶#1:5'-AUGUCAUUCGUAAAGAUGU-3'(SEQIDNO:4297)
CKAP5-405819nt靶#2:5'-GAUGUCAUUCGUAAAGAUG-3'(SEQIDNO:4873)
CKAP5-405819nt靶#3:5'-GGAUGUCAUUCGUAAAGAU-3'(SEQIDNO:5449)
CKAP5-408519nt靶#1:5'-UCCUGAACCGGAUGUGCCU-3'(SEQIDNO:4298)
CKAP5-408519nt靶#2:5'-AUCCUGAACCGGAUGUGCC-3'(SEQIDNO:4874)
CKAP5-408519nt靶#3:5'-CAUCCUGAACCGGAUGUGC-3'(SEQIDNO:5450)
CKAP5-408719nt靶#1:5'-CUGAACCGGAUGUGCCUUG-3'(SEQIDNO:4299)
CKAP5-408719nt靶#2:5'-CCUGAACCGGAUGUGCCUU-3'(SEQIDNO:4875)
CKAP5-408719nt靶#3:5'-UCCUGAACCGGAUGUGCCU-3'(SEQIDNO:5451)
CKAP5-408919nt靶#1:5'-GAACCGGAUGUGCCUUGUC-3'(SEQIDNO:4300)
CKAP5-408919nt靶#2:5'-UGAACCGGAUGUGCCUUGU-3'(SEQIDNO:4876)
CKAP5-408919nt靶#3:5'-CUGAACCGGAUGUGCCUUG-3'(SEQIDNO:5452)
CKAP5-409119nt靶#1:5'-ACCGGAUGUGCCUUGUCUA-3'(SEQIDNO:4301)
CKAP5-409119nt靶#2:5'-AACCGGAUGUGCCUUGUCU-3'(SEQIDNO:4877)
CKAP5-409119nt靶#3:5'-GAACCGGAUGUGCCUUGUC-3'(SEQIDNO:5453)
CKAP5-409319nt靶#1:5'-CGGAUGUGCCUUGUCUACC-3'(SEQIDNO:4302)
CKAP5-409319nt靶#2:5'-CCGGAUGUGCCUUGUCUAC-3'(SEQIDNO:4878)
CKAP5-409319nt靶#3:5'-ACCGGAUGUGCCUUGUCUA-3'(SEQIDNO:5454)
CKAP5-409519nt靶#1:5'-GAUGUGCCUUGUCUACCCA-3'(SEQIDNO:4303)
CKAP5-409519nt靶#2:5'-GGAUGUGCCUUGUCUACCC-3'(SEQIDNO:4879)
CKAP5-409519nt靶#3:5'-CGGAUGUGCCUUGUCUACC-3'(SEQIDNO:5455)
CKAP5-409719nt靶#1:5'-UGUGCCUUGUCUACCCAGC-3'(SEQIDNO:4304)
CKAP5-409719nt靶#2:5'-AUGUGCCUUGUCUACCCAG-3'(SEQIDNO:4880)
CKAP5-409719nt靶#3:5'-GAUGUGCCUUGUCUACCCA-3'(SEQIDNO:5456)
CKAP5-415419nt靶#1:5'-CCAAAAACUCUAAGCAGAG-3'(SEQIDNO:4305)
CKAP5-415419nt靶#2:5'-UCCAAAAACUCUAAGCAGA-3'(SEQIDNO:4881)
CKAP5-415419nt靶#3:5'-AUCCAAAAACUCUAAGCAG-3'(SEQIDNO:5457)
CKAP5-415619nt靶#1:5'-AAAAACUCUAAGCAGAGAG-3'(SEQIDNO:4306)
CKAP5-415619nt靶#2:5'-CAAAAACUCUAAGCAGAGA-3'(SEQIDNO:4882)
CKAP5-415619nt靶#3:5'-CCAAAAACUCUAAGCAGAG-3'(SEQIDNO:5458)
CKAP5-415819nt靶#1:5'-AAACUCUAAGCAGAGAGCA-3'(SEQIDNO:4307)
CKAP5-415819nt靶#2:5'-AAAACUCUAAGCAGAGAGC-3'(SEQIDNO:4883)
CKAP5-415819nt靶#3:5'-AAAAACUCUAAGCAGAGAG-3'(SEQIDNO:5459)
CKAP5-416019nt靶#1:5'-ACUCUAAGCAGAGAGCAGA-3'(SEQIDNO:4308)
CKAP5-416019nt靶#2:5'-AACUCUAAGCAGAGAGCAG-3'(SEQIDNO:4884)
CKAP5-416019nt靶#3:5'-AAACUCUAAGCAGAGAGCA-3'(SEQIDNO:5460)
CKAP5-416219nt靶#1:5'-UCUAAGCAGAGAGCAGAGU-3'(SEQIDNO:4309)
CKAP5-416219nt靶#2:5'-CUCUAAGCAGAGAGCAGAG-3'(SEQIDNO:4885)
CKAP5-416219nt靶#3:5'-ACUCUAAGCAGAGAGCAGA-3'(SEQIDNO:5461)
CKAP5-416419nt靶#1:5'-UAAGCAGAGAGCAGAGUGC-3'(SEQIDNO:4310)
CKAP5-416419nt靶#2:5'-CUAAGCAGAGAGCAGAGUG-3'(SEQIDNO:4886)
CKAP5-416419nt靶#3:5'-UCUAAGCAGAGAGCAGAGU-3'(SEQIDNO:5462)
CKAP5-416619nt靶#1:5'-AGCAGAGAGCAGAGUGCCU-3'(SEQIDNO:4311)
CKAP5-416619nt靶#2:5'-AAGCAGAGAGCAGAGUGCC-3'(SEQIDNO:4887)
CKAP5-416619nt靶#3:5'-UAAGCAGAGAGCAGAGUGC-3'(SEQIDNO:5463)
CKAP5-416819nt靶#1:5'-CAGAGAGCAGAGUGCCUGG-3'(SEQIDNO:4312)
CKAP5-416819nt靶#2:5'-GCAGAGAGCAGAGUGCCUG-3'(SEQIDNO:4888)
CKAP5-416819nt靶#3:5'-AGCAGAGAGCAGAGUGCCU-3'(SEQIDNO:5464)
CKAP5-417019nt靶#1:5'-GAGAGCAGAGUGCCUGGAA-3'(SEQIDNO:4313)
CKAP5-417019nt靶#2:5'-AGAGAGCAGAGUGCCUGGA-3'(SEQIDNO:4889)
CKAP5-417019nt靶#3:5'-CAGAGAGCAGAGUGCCUGG-3'(SEQIDNO:5465)
CKAP5-417219nt靶#1:5'-GAGCAGAGUGCCUGGAAGA-3'(SEQIDNO:4314)
CKAP5-417219nt靶#2:5'-AGAGCAGAGUGCCUGGAAG-3'(SEQIDNO:4890)
CKAP5-417219nt靶#3:5'-GAGAGCAGAGUGCCUGGAA-3'(SEQIDNO:5466)
CKAP5-417419nt靶#1:5'-GCAGAGUGCCUGGAAGAGC-3'(SEQIDNO:4315)
CKAP5-417419nt靶#2:5'-AGCAGAGUGCCUGGAAGAG-3'(SEQIDNO:4891)
CKAP5-417419nt靶#3:5'-GAGCAGAGUGCCUGGAAGA-3'(SEQIDNO:5467)
CKAP5-424119nt靶#1:5'-CAGGAAAAGCCUUAAAGGA-3'(SEQIDNO:4316)
CKAP5-424119nt靶#2:5'-CCAGGAAAAGCCUUAAAGG-3'(SEQIDNO:4892)
CKAP5-424119nt靶#3:5'-CCCAGGAAAAGCCUUAAAG-3'(SEQIDNO:5468)
CKAP5-434619nt靶#1:5'-AUCAGGUGUUCAAACUGAU-3'(SEQIDNO:4317)
CKAP5-434619nt靶#2:5'-GAUCAGGUGUUCAAACUGA-3'(SEQIDNO:4893)
CKAP5-434619nt靶#3:5'-GGAUCAGGUGUUCAAACUG-3'(SEQIDNO:5469)
CKAP5-434819nt靶#1:5'-CAGGUGUUCAAACUGAUUG-3'(SEQIDNO:4318)
CKAP5-434819nt靶#2:5'-UCAGGUGUUCAAACUGAUU-3'(SEQIDNO:4894)
CKAP5-434819nt靶#3:5'-AUCAGGUGUUCAAACUGAU-3'(SEQIDNO:5470)
CKAP5-435019nt靶#1:5'-GGUGUUCAAACUGAUUGGA-3'(SEQIDNO:4319)
CKAP5-435019nt靶#2:5'-AGGUGUUCAAACUGAUUGG-3'(SEQIDNO:4895)
CKAP5-435019nt靶#3:5'-CAGGUGUUCAAACUGAUUG-3'(SEQIDNO:5471)
CKAP5-435219nt靶#1:5'-UGUUCAAACUGAUUGGAAA-3'(SEQIDNO:4320)
CKAP5-435219nt靶#2:5'-GUGUUCAAACUGAUUGGAA-3'(SEQIDNO:4896)
CKAP5-435219nt靶#3:5'-GGUGUUCAAACUGAUUGGA-3'(SEQIDNO:5472)
CKAP5-435419nt靶#1:5'-UUCAAACUGAUUGGAAAUC-3'(SEQIDNO:4321)
CKAP5-435419nt靶#2:5'-GUUCAAACUGAUUGGAAAU-3'(SEQIDNO:4897)
CKAP5-435419nt靶#3:5'-UGUUCAAACUGAUUGGAAA-3'(SEQIDNO:5473)
CKAP5-435619nt靶#1:5'-CAAACUGAUUGGAAAUCUU-3'(SEQIDNO:4322)
CKAP5-435619nt靶#2:5'-UCAAACUGAUUGGAAAUCU-3'(SEQIDNO:4898)
CKAP5-435619nt靶#3:5'-UUCAAACUGAUUGGAAAUC-3'(SEQIDNO:5474)
CKAP5-435819nt靶#1:5'-AACUGAUUGGAAAUCUUUC-3'(SEQIDNO:4323)
CKAP5-435819nt靶#2:5'-AAACUGAUUGGAAAUCUUU-3'(SEQIDNO:4899)
CKAP5-435819nt靶#3:5'-CAAACUGAUUGGAAAUCUU-3'(SEQIDNO:5475)
CKAP5-436019nt靶#1:5'-CUGAUUGGAAAUCUUUCUG-3'(SEQIDNO:4324)
CKAP5-436019nt靶#2:5'-ACUGAUUGGAAAUCUUUCU-3'(SEQIDNO:4900)
CKAP5-436019nt靶#3:5'-AACUGAUUGGAAAUCUUUC-3'(SEQIDNO:5476)
CKAP5-441119nt靶#1:5'-AAGCGGUCAGCAAAGAGAC-3'(SEQIDNO:4325)
CKAP5-441119nt靶#2:5'-UAAGCGGUCAGCAAAGAGA-3'(SEQIDNO:4901)
CKAP5-441119nt靶#3:5'-UUAAGCGGUCAGCAAAGAG-3'(SEQIDNO:5477)
CKAP5-441319nt靶#1:5'-GCGGUCAGCAAAGAGACCC-3'(SEQIDNO:4326)
CKAP5-441319nt靶#2:5'-AGCGGUCAGCAAAGAGACC-3'(SEQIDNO:4902)
CKAP5-441319nt靶#3:5'-AAGCGGUCAGCAAAGAGAC-3'(SEQIDNO:5478)
CKAP5-441519nt靶#1:5'-GGUCAGCAAAGAGACCCUC-3'(SEQIDNO:4327)
CKAP5-441519nt靶#2:5'-CGGUCAGCAAAGAGACCCU-3'(SEQIDNO:4903)
CKAP5-441519nt靶#3:5'-GCGGUCAGCAAAGAGACCC-3'(SEQIDNO:5479)
CKAP5-441719nt靶#1:5'-UCAGCAAAGAGACCCUCUG-3'(SEQIDNO:4328)
CKAP5-441719nt靶#2:5'-GUCAGCAAAGAGACCCUCU-3'(SEQIDNO:4904)
CKAP5-441719nt靶#3:5'-GGUCAGCAAAGAGACCCUC-3'(SEQIDNO:5480)
CKAP5-441919nt靶#1:5'-AGCAAAGAGACCCUCUGCU-3'(SEQIDNO:4329)
CKAP5-441919nt靶#2:5'-CAGCAAAGAGACCCUCUGC-3'(SEQIDNO:4905)
CKAP5-441919nt靶#3:5'-UCAGCAAAGAGACCCUCUG-3'(SEQIDNO:5481)
CKAP5-442119nt靶#1:5'-CAAAGAGACCCUCUGCUGC-3'(SEQIDNO:4330)
CKAP5-442119nt靶#2:5'-GCAAAGAGACCCUCUGCUG-3'(SEQIDNO:4906)
CKAP5-442119nt靶#3:5'-AGCAAAGAGACCCUCUGCU-3'(SEQIDNO:5482)
CKAP5-442319nt靶#1:5'-AAGAGACCCUCUGCUGCAC-3'(SEQIDNO:4331)
CKAP5-442319nt靶#2:5'-AAAGAGACCCUCUGCUGCA-3'(SEQIDNO:4907)
CKAP5-442319nt靶#3:5'-CAAAGAGACCCUCUGCUGC-3'(SEQIDNO:5483)
CKAP5-450519nt靶#1:5'-UACGCAAGGGACCAGCUGA-3'(SEQIDNO:4332)
CKAP5-450519nt靶#2:5'-UUACGCAAGGGACCAGCUG-3'(SEQIDNO:4908)
CKAP5-450519nt靶#3:5'-GUUACGCAAGGGACCAGCU-3'(SEQIDNO:5484)
CKAP5-450719nt靶#1:5'-CGCAAGGGACCAGCUGAGG-3'(SEQIDNO:4333)
CKAP5-450719nt靶#2:5'-ACGCAAGGGACCAGCUGAG-3'(SEQIDNO:4909)
CKAP5-450719nt靶#3:5'-UACGCAAGGGACCAGCUGA-3'(SEQIDNO:5485)
CKAP5-459119nt靶#1:5'-CGCCGAGAAUUCCAGCUGG-3'(SEQIDNO:4334)
CKAP5-459119nt靶#2:5'-CCGCCGAGAAUUCCAGCUG-3'(SEQIDNO:4910)
CKAP5-459119nt靶#3:5'-UCCGCCGAGAAUUCCAGCU-3'(SEQIDNO:5486)
CKAP5-459319nt靶#1:5'-CCGAGAAUUCCAGCUGGAU-3'(SEQIDNO:4335)
CKAP5-459319nt靶#2:5'-GCCGAGAAUUCCAGCUGGA-3'(SEQIDNO:4911)
CKAP5-459319nt靶#3:5'-CGCCGAGAAUUCCAGCUGG-3'(SEQIDNO:5487)
CKAP5-471819nt靶#1:5'-AGAUCCGGGCUGUUUCUCC-3'(SEQIDNO:4336)
CKAP5-471819nt靶#2:5'-AAGAUCCGGGCUGUUUCUC-3'(SEQIDNO:4912)
CKAP5-471819nt靶#3:5'-CAAGAUCCGGGCUGUUUCU-3'(SEQIDNO:5488)
CKAP5-472019nt靶#1:5'-AUCCGGGCUGUUUCUCCAC-3'(SEQIDNO:4337)
CKAP5-472019nt靶#2:5'-GAUCCGGGCUGUUUCUCCA-3'(SEQIDNO:4913)
CKAP5-472019nt靶#3:5'-AGAUCCGGGCUGUUUCUCC-3'(SEQIDNO:5489)
CKAP5-474419nt靶#1:5'-GAUGACAUGCACAGUAAUA-3'(SEQIDNO:4338)
CKAP5-474419nt靶#2:5'-CGAUGACAUGCACAGUAAU-3'(SEQIDNO:4914)
CKAP5-474419nt靶#3:5'-UCGAUGACAUGCACAGUAA-3'(SEQIDNO:5490)
CKAP5-474619nt靶#1:5'-UGACAUGCACAGUAAUACA-3'(SEQIDNO:4339)
CKAP5-474619nt靶#2:5'-AUGACAUGCACAGUAAUAC-3'(SEQIDNO:4915)
CKAP5-474619nt靶#3:5'-GAUGACAUGCACAGUAAUA-3'(SEQIDNO:5491)
CKAP5-474819nt靶#1:5'-ACAUGCACAGUAAUACAGC-3'(SEQIDNO:4340)
CKAP5-474819nt靶#2:5'-GACAUGCACAGUAAUACAG-3'(SEQIDNO:4916)
CKAP5-474819nt靶#3:5'-UGACAUGCACAGUAAUACA-3'(SEQIDNO:5492)
CKAP5-475019nt靶#1:5'-AUGCACAGUAAUACAGCAU-3'(SEQIDNO:4341)
CKAP5-475019nt靶#2:5'-CAUGCACAGUAAUACAGCA-3'(SEQIDNO:4917)
CKAP5-475019nt靶#3:5'-ACAUGCACAGUAAUACAGC-3'(SEQIDNO:5493)
CKAP5-475219nt靶#1:5'-GCACAGUAAUACAGCAUCC-3'(SEQIDNO:4342)
CKAP5-475219nt靶#2:5'-UGCACAGUAAUACAGCAUC-3'(SEQIDNO:4918)
CKAP5-475219nt靶#3:5'-AUGCACAGUAAUACAGCAU-3'(SEQIDNO:5494)
CKAP5-475419nt靶#1:5'-ACAGUAAUACAGCAUCCAC-3'(SEQIDNO:4343)
CKAP5-475419nt靶#2:5'-CACAGUAAUACAGCAUCCA-3'(SEQIDNO:4919)
CKAP5-475419nt靶#3:5'-GCACAGUAAUACAGCAUCC-3'(SEQIDNO:5495)
CKAP5-475619nt靶#1:5'-AGUAAUACAGCAUCCACAA-3'(SEQIDNO:4344)
CKAP5-475619nt靶#2:5'-CAGUAAUACAGCAUCCACA-3'(SEQIDNO:4920)
CKAP5-475619nt靶#3:5'-ACAGUAAUACAGCAUCCAC-3'(SEQIDNO:5496)
CKAP5-475819nt靶#1:5'-UAAUACAGCAUCCACAAUC-3'(SEQIDNO:4345)
CKAP5-475819nt靶#2:5'-GUAAUACAGCAUCCACAAU-3'(SEQIDNO:4921)
CKAP5-475819nt靶#3:5'-AGUAAUACAGCAUCCACAA-3'(SEQIDNO:5497)
CKAP5-476019nt靶#1:5'-AUACAGCAUCCACAAUCAA-3'(SEQIDNO:4346)
CKAP5-476019nt靶#2:5'-AAUACAGCAUCCACAAUCA-3'(SEQIDNO:4922)
CKAP5-476019nt靶#3:5'-UAAUACAGCAUCCACAAUC-3'(SEQIDNO:5498)
CKAP5-476219nt靶#1:5'-ACAGCAUCCACAAUCAAUU-3'(SEQIDNO:4347)
CKAP5-476219nt靶#2:5'-UACAGCAUCCACAAUCAAU-3'(SEQIDNO:4923)
CKAP5-476219nt靶#3:5'-AUACAGCAUCCACAAUCAA-3'(SEQIDNO:5499)
CKAP5-476419nt靶#1:5'-AGCAUCCACAAUCAAUUUC-3'(SEQIDNO:4348)
CKAP5-476419nt靶#2:5'-CAGCAUCCACAAUCAAUUU-3'(SEQIDNO:4924)
CKAP5-476419nt靶#3:5'-ACAGCAUCCACAAUCAAUU-3'(SEQIDNO:5500)
CKAP5-476619nt靶#1:5'-CAUCCACAAUCAAUUUCAU-3'(SEQIDNO:4349)
CKAP5-476619nt靶#2:5'-GCAUCCACAAUCAAUUUCA-3'(SEQIDNO:4925)
CKAP5-476619nt靶#3:5'-AGCAUCCACAAUCAAUUUC-3'(SEQIDNO:5501)
CKAP5-476819nt靶#1:5'-UCCACAAUCAAUUUCAUUA-3'(SEQIDNO:4350)
CKAP5-476819nt靶#2:5'-AUCCACAAUCAAUUUCAUU-3'(SEQIDNO:4926)
CKAP5-476819nt靶#3:5'-CAUCCACAAUCAAUUUCAU-3'(SEQIDNO:5502)
CKAP5-477019nt靶#1:5'-CACAAUCAAUUUCAUUAUC-3'(SEQIDNO:4351)
CKAP5-477019nt靶#2:5'-CCACAAUCAAUUUCAUUAU-3'(SEQIDNO:4927)
CKAP5-477019nt靶#3:5'-UCCACAAUCAAUUUCAUUA-3'(SEQIDNO:5503)
CKAP5-477219nt靶#1:5'-CAAUCAAUUUCAUUAUCUC-3'(SEQIDNO:4352)
CKAP5-477219nt靶#2:5'-ACAAUCAAUUUCAUUAUCU-3'(SEQIDNO:4928)
CKAP5-477219nt靶#3:5'-CACAAUCAAUUUCAUUAUC-3'(SEQIDNO:5504)
CKAP5-477419nt靶#1:5'-AUCAAUUUCAUUAUCUCCC-3'(SEQIDNO:4353)
CKAP5-477419nt靶#2:5'-AAUCAAUUUCAUUAUCUCC-3'(SEQIDNO:4929)
CKAP5-477419nt靶#3:5'-CAAUCAAUUUCAUUAUCUC-3'(SEQIDNO:5505)
CKAP5-477619nt靶#1:5'-CAAUUUCAUUAUCUCCCAA-3'(SEQIDNO:4354)
CKAP5-477619nt靶#2:5'-UCAAUUUCAUUAUCUCCCA-3'(SEQIDNO:4930)
CKAP5-477619nt靶#3:5'-AUCAAUUUCAUUAUCUCCC-3'(SEQIDNO:5506)
CKAP5-477819nt靶#1:5'-AUUUCAUUAUCUCCCAAGU-3'(SEQIDNO:4355)
CKAP5-477819nt靶#2:5'-AAUUUCAUUAUCUCCCAAG-3'(SEQIDNO:4931)
CKAP5-477819nt靶#3:5'-CAAUUUCAUUAUCUCCCAA-3'(SEQIDNO:5507)
CKAP5-478019nt靶#1:5'-UUCAUUAUCUCCCAAGUAG-3'(SEQIDNO:4356)
CKAP5-478019nt靶#2:5'-UUUCAUUAUCUCCCAAGUA-3'(SEQIDNO:4932)
CKAP5-478019nt靶#3:5'-AUUUCAUUAUCUCCCAAGU-3'(SEQIDNO:5508)
CKAP5-478219nt靶#1:5'-CAUUAUCUCCCAAGUAGCC-3'(SEQIDNO:4357)
CKAP5-478219nt靶#2:5'-UCAUUAUCUCCCAAGUAGC-3'(SEQIDNO:4933)
CKAP5-478219nt靶#3:5'-UUCAUUAUCUCCCAAGUAG-3'(SEQIDNO:5509)
CKAP5-478419nt靶#1:5'-UUAUCUCCCAAGUAGCCAG-3'(SEQIDNO:4358)
CKAP5-478419nt靶#2:5'-AUUAUCUCCCAAGUAGCCA-3'(SEQIDNO:4934)
CKAP5-478419nt靶#3:5'-CAUUAUCUCCCAAGUAGCC-3'(SEQIDNO:5510)
CKAP5-478619nt靶#1:5'-AUCUCCCAAGUAGCCAGUG-3'(SEQIDNO:4359)
CKAP5-478619nt靶#2:5'-UAUCUCCCAAGUAGCCAGU-3'(SEQIDNO:4935)
CKAP5-478619nt靶#3:5'-UUAUCUCCCAAGUAGCCAG-3'(SEQIDNO:5511)
CKAP5-478819nt靶#1:5'-CUCCCAAGUAGCCAGUGGU-3'(SEQIDNO:4360)
CKAP5-478819nt靶#2:5'-UCUCCCAAGUAGCCAGUGG-3'(SEQIDNO:4936)
CKAP5-478819nt靶#3:5'-AUCUCCCAAGUAGCCAGUG-3'(SEQIDNO:5512)
CKAP5-479019nt靶#1:5'-CCCAAGUAGCCAGUGGUGA-3'(SEQIDNO:4361)
CKAP5-479019nt靶#2:5'-UCCCAAGUAGCCAGUGGUG-3'(SEQIDNO:4937)
CKAP5-479019nt靶#3:5'-CUCCCAAGUAGCCAGUGGU-3'(SEQIDNO:5513)
CKAP5-479219nt靶#1:5'-CAAGUAGCCAGUGGUGACA-3'(SEQIDNO:4362)
CKAP5-479219nt靶#2:5'-CCAAGUAGCCAGUGGUGAC-3'(SEQIDNO:4938)
CKAP5-479219nt靶#3:5'-CCCAAGUAGCCAGUGGUGA-3'(SEQIDNO:5514)
CKAP5-504119nt靶#1:5'-GCCCGGGAGGCCUCCACUG-3'(SEQIDNO:4363)
CKAP5-504119nt靶#2:5'-UGCCCGGGAGGCCUCCACU-3'(SEQIDNO:4939)
CKAP5-504119nt靶#3:5'-UUGCCCGGGAGGCCUCCAC-3'(SEQIDNO:5515)
CKAP5-504319nt靶#1:5'-CCGGGAGGCCUCCACUGGA-3'(SEQIDNO:4364)
CKAP5-504319nt靶#2:5'-CCCGGGAGGCCUCCACUGG-3'(SEQIDNO:4940)
CKAP5-504319nt靶#3:5'-GCCCGGGAGGCCUCCACUG-3'(SEQIDNO:5516)
CKAP5-504519nt靶#1:5'-GGGAGGCCUCCACUGGAGU-3'(SEQIDNO:4365)
CKAP5-504519nt靶#2:5'-CGGGAGGCCUCCACUGGAG-3'(SEQIDNO:4941)
CKAP5-504519nt靶#3:5'-CCGGGAGGCCUCCACUGGA-3'(SEQIDNO:5517)
CKAP5-504719nt靶#1:5'-GAGGCCUCCACUGGAGUAC-3'(SEQIDNO:4366)
CKAP5-504719nt靶#2:5'-GGAGGCCUCCACUGGAGUA-3'(SEQIDNO:4942)
CKAP5-504719nt靶#3:5'-GGGAGGCCUCCACUGGAGU-3'(SEQIDNO:5518)
CKAP5-508919nt靶#1:5'-AUCACCUUAAUGCUGGAUU-3'(SEQIDNO:4367)
CKAP5-508919nt靶#2:5'-CAUCACCUUAAUGCUGGAU-3'(SEQIDNO:4943)
CKAP5-508919nt靶#3:5'-UCAUCACCUUAAUGCUGGA-3'(SEQIDNO:5519)
CKAP5-509119nt靶#1:5'-CACCUUAAUGCUGGAUUCU-3'(SEQIDNO:4368)
CKAP5-509119nt靶#2:5'-UCACCUUAAUGCUGGAUUC-3'(SEQIDNO:4944)
CKAP5-509119nt靶#3:5'-AUCACCUUAAUGCUGGAUU-3'(SEQIDNO:5520)
CKAP5-509319nt靶#1:5'-CCUUAAUGCUGGAUUCUCG-3'(SEQIDNO:4369)
CKAP5-509319nt靶#2:5'-ACCUUAAUGCUGGAUUCUC-3'(SEQIDNO:4945)
CKAP5-509319nt靶#3:5'-CACCUUAAUGCUGGAUUCU-3'(SEQIDNO:5521)
CKAP5-509519nt靶#1:5'-UUAAUGCUGGAUUCUCGGA-3'(SEQIDNO:4370)
CKAP5-509519nt靶#2:5'-CUUAAUGCUGGAUUCUCGG-3'(SEQIDNO:4946)
CKAP5-509519nt靶#3:5'-CCUUAAUGCUGGAUUCUCG-3'(SEQIDNO:5522)
CKAP5-509719nt靶#1:5'-AAUGCUGGAUUCUCGGAUU-3'(SEQIDNO:4371)
CKAP5-509719nt靶#2:5'-UAAUGCUGGAUUCUCGGAU-3'(SEQIDNO:4947)
CKAP5-509719nt靶#3:5'-UUAAUGCUGGAUUCUCGGA-3'(SEQIDNO:5523)
CKAP5-509919nt靶#1:5'-UGCUGGAUUCUCGGAUUGA-3'(SEQIDNO:4372)
CKAP5-509919nt靶#2:5'-AUGCUGGAUUCUCGGAUUG-3'(SEQIDNO:4948)
CKAP5-509919nt靶#3:5'-AAUGCUGGAUUCUCGGAUU-3'(SEQIDNO:5524)
CKAP5-510119nt靶#1:5'-CUGGAUUCUCGGAUUGAAG-3'(SEQIDNO:4373)
CKAP5-510119nt靶#2:5'-GCUGGAUUCUCGGAUUGAA-3'(SEQIDNO:4949)
CKAP5-510119nt靶#3:5'-UGCUGGAUUCUCGGAUUGA-3'(SEQIDNO:5525)
CKAP5-510319nt靶#1:5'-GGAUUCUCGGAUUGAAGAU-3'(SEQIDNO:4374)
CKAP5-510319nt靶#2:5'-UGGAUUCUCGGAUUGAAGA-3'(SEQIDNO:4950)
CKAP5-510319nt靶#3:5'-CUGGAUUCUCGGAUUGAAG-3'(SEQIDNO:5526)
CKAP5-510519nt靶#1:5'-AUUCUCGGAUUGAAGAUCU-3'(SEQIDNO:4375)
CKAP5-510519nt靶#2:5'-GAUUCUCGGAUUGAAGAUC-3'(SEQIDNO:4951)
CKAP5-510519nt靶#3:5'-GGAUUCUCGGAUUGAAGAU-3'(SEQIDNO:5527)
CKAP5-515019nt靶#1:5'-CUGUGAACCUCUUGGUGGU-3'(SEQIDNO:4376)
CKAP5-515019nt靶#2:5'-UCUGUGAACCUCUUGGUGG-3'(SEQIDNO:4952)
CKAP5-515019nt靶#3:5'-CUCUGUGAACCUCUUGGUG-3'(SEQIDNO:5528)
CKAP5-515219nt靶#1:5'-GUGAACCUCUUGGUGGUGA-3'(SEQIDNO:4377)
CKAP5-515219nt靶#2:5'-UGUGAACCUCUUGGUGGUG-3'(SEQIDNO:4953)
CKAP5-515219nt靶#3:5'-CUGUGAACCUCUUGGUGGU-3'(SEQIDNO:5529)
CKAP5-515419nt靶#1:5'-GAACCUCUUGGUGGUGAAG-3'(SEQIDNO:4378)
CKAP5-515419nt靶#2:5'-UGAACCUCUUGGUGGUGAA-3'(SEQIDNO:4954)
CKAP5-515419nt靶#3:5'-GUGAACCUCUUGGUGGUGA-3'(SEQIDNO:5530)
CKAP5-515619nt靶#1:5'-ACCUCUUGGUGGUGAAGGU-3'(SEQIDNO:4379)
CKAP5-515619nt靶#2:5'-AACCUCUUGGUGGUGAAGG-3'(SEQIDNO:4955)
CKAP5-515619nt靶#3:5'-GAACCUCUUGGUGGUGAAG-3'(SEQIDNO:5531)
CKAP5-523019nt靶#1:5'-GACAGCCUGCUAGCAACAG-3'(SEQIDNO:4380)
CKAP5-523019nt靶#2:5'-AGACAGCCUGCUAGCAACA-3'(SEQIDNO:4956)
CKAP5-523019nt靶#3:5'-AAGACAGCCUGCUAGCAAC-3'(SEQIDNO:5532)
CKAP5-525119nt靶#1:5'-AGUUCUCCCAAAUUCUCAG-3'(SEQIDNO:4381)
CKAP5-525119nt靶#2:5'-CAGUUCUCCCAAAUUCUCA-3'(SEQIDNO:4957)
CKAP5-525119nt靶#3:5'-CCAGUUCUCCCAAAUUCUC-3'(SEQIDNO:5533)
CKAP5-525319nt靶#1:5'-UUCUCCCAAAUUCUCAGAG-3'(SEQIDNO:4382)
CKAP5-525319nt靶#2:5'-GUUCUCCCAAAUUCUCAGA-3'(SEQIDNO:4958)
CKAP5-525319nt靶#3:5'-AGUUCUCCCAAAUUCUCAG-3'(SEQIDNO:5534)
CKAP5-525519nt靶#1:5'-CUCCCAAAUUCUCAGAGCU-3'(SEQIDNO:4383)
CKAP5-525519nt靶#2:5'-UCUCCCAAAUUCUCAGAGC-3'(SEQIDNO:4959)
CKAP5-525519nt靶#3:5'-UUCUCCCAAAUUCUCAGAG-3'(SEQIDNO:5535)
CKAP5-525719nt靶#1:5'-CCCAAAUUCUCAGAGCUUG-3'(SEQIDNO:4384)
CKAP5-525719nt靶#2:5'-UCCCAAAUUCUCAGAGCUU-3'(SEQIDNO:4960)
CKAP5-525719nt靶#3:5'-CUCCCAAAUUCUCAGAGCU-3'(SEQIDNO:5536)
CKAP5-525919nt靶#1:5'-CAAAUUCUCAGAGCUUGUU-3'(SEQIDNO:4385)
CKAP5-525919nt靶#2:5'-CCAAAUUCUCAGAGCUUGU-3'(SEQIDNO:4961)
CKAP5-525919nt靶#3:5'-CCCAAAUUCUCAGAGCUUG-3'(SEQIDNO:5537)
CKAP5-526119nt靶#1:5'-AAUUCUCAGAGCUUGUUAU-3'(SEQIDNO:4386)
CKAP5-526119nt靶#2:5'-AAAUUCUCAGAGCUUGUUA-3'(SEQIDNO:4962)
CKAP5-526119nt靶#3:5'-CAAAUUCUCAGAGCUUGUU-3'(SEQIDNO:5538)
CKAP5-526319nt靶#1:5'-UUCUCAGAGCUUGUUAUGA-3'(SEQIDNO:4387)
CKAP5-526319nt靶#2:5'-AUUCUCAGAGCUUGUUAUG-3'(SEQIDNO:4963)
CKAP5-526319nt靶#3:5'-AAUUCUCAGAGCUUGUUAU-3'(SEQIDNO:5539)
CKAP5-526519nt靶#1:5'-CUCAGAGCUUGUUAUGAAG-3'(SEQIDNO:4388)
CKAP5-526519nt靶#2:5'-UCUCAGAGCUUGUUAUGAA-3'(SEQIDNO:4964)
CKAP5-526519nt靶#3:5'-UUCUCAGAGCUUGUUAUGA-3'(SEQIDNO:5540)
CKAP5-526719nt靶#1:5'-CAGAGCUUGUUAUGAAGUG-3'(SEQIDNO:4389)
CKAP5-526719nt靶#2:5'-UCAGAGCUUGUUAUGAAGU-3'(SEQIDNO:4965)
CKAP5-526719nt靶#3:5'-CUCAGAGCUUGUUAUGAAG-3'(SEQIDNO:5541)
CKAP5-526919nt靶#1:5'-GAGCUUGUUAUGAAGUGUC-3'(SEQIDNO:4390)
CKAP5-526919nt靶#2:5'-AGAGCUUGUUAUGAAGUGU-3'(SEQIDNO:4966)
CKAP5-526919nt靶#3:5'-CAGAGCUUGUUAUGAAGUG-3'(SEQIDNO:5542)
CKAP5-532619nt靶#1:5'-AGCAUUAACCUAGACAGAA-3'(SEQIDNO:4391)
CKAP5-532619nt靶#2:5'-UAGCAUUAACCUAGACAGA-3'(SEQIDNO:4967)
CKAP5-532619nt靶#3:5'-AUAGCAUUAACCUAGACAG-3'(SEQIDNO:5543)
CKAP5-532819nt靶#1:5'-CAUUAACCUAGACAGAAUU-3'(SEQIDNO:4392)
CKAP5-532819nt靶#2:5'-GCAUUAACCUAGACAGAAU-3'(SEQIDNO:4968)
CKAP5-532819nt靶#3:5'-AGCAUUAACCUAGACAGAA-3'(SEQIDNO:5544)
CKAP5-533019nt靶#1:5'-UUAACCUAGACAGAAUUCU-3'(SEQIDNO:4393)
CKAP5-533019nt靶#2:5'-AUUAACCUAGACAGAAUUC-3'(SEQIDNO:4969)
CKAP5-533019nt靶#3:5'-CAUUAACCUAGACAGAAUU-3'(SEQIDNO:5545)
CKAP5-533219nt靶#1:5'-AACCUAGACAGAAUUCUUC-3'(SEQIDNO:4394)
CKAP5-533219nt靶#2:5'-UAACCUAGACAGAAUUCUU-3'(SEQIDNO:4970)
CKAP5-533219nt靶#3:5'-UUAACCUAGACAGAAUUCU-3'(SEQIDNO:5546)
CKAP5-533419nt靶#1:5'-CCUAGACAGAAUUCUUCUG-3'(SEQIDNO:4395)
CKAP5-533419nt靶#2:5'-ACCUAGACAGAAUUCUUCU-3'(SEQIDNO:4971)
CKAP5-533419nt靶#3:5'-AACCUAGACAGAAUUCUUC-3'(SEQIDNO:5547)
CKAP5-533619nt靶#1:5'-UAGACAGAAUUCUUCUGGA-3'(SEQIDNO:4396)
CKAP5-533619nt靶#2:5'-CUAGACAGAAUUCUUCUGG-3'(SEQIDNO:4972)
CKAP5-533619nt靶#3:5'-CCUAGACAGAAUUCUUCUG-3'(SEQIDNO:5548)
CKAP5-535719nt靶#1:5'-UCCACAUUUUCAUGAAGGU-3'(SEQIDNO:4397)
CKAP5-535719nt靶#2:5'-AUCCACAUUUUCAUGAAGG-3'(SEQIDNO:4973)
CKAP5-535719nt靶#3:5'-UAUCCACAUUUUCAUGAAG-3'(SEQIDNO:5549)
CKAP5-539419nt靶#1:5'-GAAGCAAUGCAAAAGUGAA-3'(SEQIDNO:4398)
CKAP5-539419nt靶#2:5'-UGAAGCAAUGCAAAAGUGA-3'(SEQIDNO:4974)
CKAP5-539419nt靶#3:5'-CUGAAGCAAUGCAAAAGUG-3'(SEQIDNO:5550)
CKAP5-539619nt靶#1:5'-AGCAAUGCAAAAGUGAAUU-3'(SEQIDNO:4399)
CKAP5-539619nt靶#2:5'-AAGCAAUGCAAAAGUGAAU-3'(SEQIDNO:4975)
CKAP5-539619nt靶#3:5'-GAAGCAAUGCAAAAGUGAA-3'(SEQIDNO:5551)
CKAP5-539819nt靶#1:5'-CAAUGCAAAAGUGAAUUUC-3'(SEQIDNO:4400)
CKAP5-539819nt靶#2:5'-GCAAUGCAAAAGUGAAUUU-3'(SEQIDNO:4976)
CKAP5-539819nt靶#3:5'-AGCAAUGCAAAAGUGAAUU-3'(SEQIDNO:5552)
CKAP5-555119nt靶#1:5'-AGUAUGGACCAGACUGGGA-3'(SEQIDNO:4401)
CKAP5-555119nt靶#2:5'-CAGUAUGGACCAGACUGGG-3'(SEQIDNO:4977)
CKAP5-555119nt靶#3:5'-ACAGUAUGGACCAGACUGG-3'(SEQIDNO:5553)
CKAP5-555319nt靶#1:5'-UAUGGACCAGACUGGGAGC-3'(SEQIDNO:4402)
CKAP5-555319nt靶#2:5'-GUAUGGACCAGACUGGGAG-3'(SEQIDNO:4978)
CKAP5-555319nt靶#3:5'-AGUAUGGACCAGACUGGGA-3'(SEQIDNO:5554)
CKAP5-555519nt靶#1:5'-UGGACCAGACUGGGAGCAA-3'(SEQIDNO:4403)
CKAP5-555519nt靶#2:5'-AUGGACCAGACUGGGAGCA-3'(SEQIDNO:4979)
CKAP5-555519nt靶#3:5'-UAUGGACCAGACUGGGAGC-3'(SEQIDNO:5555)
CKAP5-555719nt靶#1:5'-GACCAGACUGGGAGCAAGU-3'(SEQIDNO:4404)
CKAP5-555719nt靶#2:5'-GGACCAGACUGGGAGCAAG-3'(SEQIDNO:4980)
CKAP5-555719nt靶#3:5'-UGGACCAGACUGGGAGCAA-3'(SEQIDNO:5556)
CKAP5-555919nt靶#1:5'-CCAGACUGGGAGCAAGUCU-3'(SEQIDNO:4405)
CKAP5-555919nt靶#2:5'-ACCAGACUGGGAGCAAGUC-3'(SEQIDNO:4981)
CKAP5-555919nt靶#3:5'-GACCAGACUGGGAGCAAGU-3'(SEQIDNO:5557)
CKAP5-556119nt靶#1:5'-AGACUGGGAGCAAGUCUGA-3'(SEQIDNO:4406)
CKAP5-556119nt靶#2:5'-CAGACUGGGAGCAAGUCUG-3'(SEQIDNO:4982)
CKAP5-556119nt靶#3:5'-CCAGACUGGGAGCAAGUCU-3'(SEQIDNO:5558)
CKAP5-556319nt靶#1:5'-ACUGGGAGCAAGUCUGAUA-3'(SEQIDNO:4407)
CKAP5-556319nt靶#2:5'-GACUGGGAGCAAGUCUGAU-3'(SEQIDNO:4983)
CKAP5-556319nt靶#3:5'-AGACUGGGAGCAAGUCUGA-3'(SEQIDNO:5559)
CKAP5-556519nt靶#1:5'-UGGGAGCAAGUCUGAUAAG-3'(SEQIDNO:4408)
CKAP5-556519nt靶#2:5'-CUGGGAGCAAGUCUGAUAA-3'(SEQIDNO:4984)
CKAP5-556519nt靶#3:5'-ACUGGGAGCAAGUCUGAUA-3'(SEQIDNO:5560)
CKAP5-556719nt靶#1:5'-GGAGCAAGUCUGAUAAGGA-3'(SEQIDNO:4409)
CKAP5-556719nt靶#2:5'-GGGAGCAAGUCUGAUAAGG-3'(SEQIDNO:4985)
CKAP5-556719nt靶#3:5'-UGGGAGCAAGUCUGAUAAG-3'(SEQIDNO:5561)
CKAP5-556919nt靶#1:5'-AGCAAGUCUGAUAAGGAAA-3'(SEQIDNO:4410)
CKAP5-556919nt靶#2:5'-GAGCAAGUCUGAUAAGGAA-3'(SEQIDNO:4986)
CKAP5-556919nt靶#3:5'-GGAGCAAGUCUGAUAAGGA-3'(SEQIDNO:5562)
CKAP5-557119nt靶#1:5'-CAAGUCUGAUAAGGAAACA-3'(SEQIDNO:4411)
CKAP5-557119nt靶#2:5'-GCAAGUCUGAUAAGGAAAC-3'(SEQIDNO:4987)
CKAP5-557119nt靶#3:5'-AGCAAGUCUGAUAAGGAAA-3'(SEQIDNO:5563)
CKAP5-557319nt靶#1:5'-AGUCUGAUAAGGAAACAGA-3'(SEQIDNO:4412)
CKAP5-557319nt靶#2:5'-AAGUCUGAUAAGGAAACAG-3'(SEQIDNO:4988)
CKAP5-557319nt靶#3:5'-CAAGUCUGAUAAGGAAACA-3'(SEQIDNO:5564)
CKAP5-557519nt靶#1:5'-UCUGAUAAGGAAACAGAAA-3'(SEQIDNO:4413)
CKAP5-557519nt靶#2:5'-GUCUGAUAAGGAAACAGAA-3'(SEQIDNO:4989)
CKAP5-557519nt靶#3:5'-AGUCUGAUAAGGAAACAGA-3'(SEQIDNO:5565)
CKAP5-557719nt靶#1:5'-UGAUAAGGAAACAGAAAAG-3'(SEQIDNO:4414)
CKAP5-557719nt靶#2:5'-CUGAUAAGGAAACAGAAAA-3'(SEQIDNO:4990)
CKAP5-557719nt靶#3:5'-UCUGAUAAGGAAACAGAAA-3'(SEQIDNO:5566)
CKAP5-557919nt靶#1:5'-AUAAGGAAACAGAAAAGGG-3'(SEQIDNO:4415)
CKAP5-557919nt靶#2:5'-GAUAAGGAAACAGAAAAGG-3'(SEQIDNO:4991)
CKAP5-557919nt靶#3:5'-UGAUAAGGAAACAGAAAAG-3'(SEQIDNO:5567)
CKAP5-558119nt靶#1:5'-AAGGAAACAGAAAAGGGAG-3'(SEQIDNO:4416)
CKAP5-558119nt靶#2:5'-UAAGGAAACAGAAAAGGGA-3'(SEQIDNO:4992)
CKAP5-558119nt靶#3:5'-AUAAGGAAACAGAAAAGGG-3'(SEQIDNO:5568)
CKAP5-560219nt靶#1:5'-UCUCGAAUAGAUGAAAAAU-3'(SEQIDNO:4417)
CKAP5-560219nt靶#2:5'-AUCUCGAAUAGAUGAAAAA-3'(SEQIDNO:4993)
CKAP5-560219nt靶#3:5'-CAUCUCGAAUAGAUGAAAA-3'(SEQIDNO:5569)
CKAP5-560419nt靶#1:5'-UCGAAUAGAUGAAAAAUCA-3'(SEQIDNO:4418)
CKAP5-560419nt靶#2:5'-CUCGAAUAGAUGAAAAAUC-3'(SEQIDNO:4994)
CKAP5-560419nt靶#3:5'-UCUCGAAUAGAUGAAAAAU-3'(SEQIDNO:5570)
CKAP5-560619nt靶#1:5'-GAAUAGAUGAAAAAUCAUC-3'(SEQIDNO:4419)
CKAP5-560619nt靶#2:5'-CGAAUAGAUGAAAAAUCAU-3'(SEQIDNO:4995)
CKAP5-560619nt靶#3:5'-UCGAAUAGAUGAAAAAUCA-3'(SEQIDNO:5571)
CKAP5-560819nt靶#1:5'-AUAGAUGAAAAAUCAUCAA-3'(SEQIDNO:4420)
CKAP5-560819nt靶#2:5'-AAUAGAUGAAAAAUCAUCA-3'(SEQIDNO:4996)
CKAP5-560819nt靶#3:5'-GAAUAGAUGAAAAAUCAUC-3'(SEQIDNO:5572)
CKAP5-561019nt靶#1:5'-AGAUGAAAAAUCAUCAAAG-3'(SEQIDNO:4421)
CKAP5-561019nt靶#2:5'-UAGAUGAAAAAUCAUCAAA-3'(SEQIDNO:4997)
CKAP5-561019nt靶#3:5'-AUAGAUGAAAAAUCAUCAA-3'(SEQIDNO:5573)
CKAP5-561219nt靶#1:5'-AUGAAAAAUCAUCAAAGGC-3'(SEQIDNO:4422)
CKAP5-561219nt靶#2:5'-GAUGAAAAAUCAUCAAAGG-3'(SEQIDNO:4998)
CKAP5-561219nt靶#3:5'-AGAUGAAAAAUCAUCAAAG-3'(SEQIDNO:5574)
CKAP5-561419nt靶#1:5'-GAAAAAUCAUCAAAGGCCA-3'(SEQIDNO:4423)
CKAP5-561419nt靶#2:5'-UGAAAAAUCAUCAAAGGCC-3'(SEQIDNO:4999)
CKAP5-561419nt靶#3:5'-AUGAAAAAUCAUCAAAGGC-3'(SEQIDNO:5575)
CKAP5-561619nt靶#1:5'-AAAAUCAUCAAAGGCCAAA-3'(SEQIDNO:4424)
CKAP5-561619nt靶#2:5'-AAAAAUCAUCAAAGGCCAA-3'(SEQIDNO:5000)
CKAP5-561619nt靶#3:5'-GAAAAAUCAUCAAAGGCCA-3'(SEQIDNO:5576)
CKAP5-561819nt靶#1:5'-AAUCAUCAAAGGCCAAAGU-3'(SEQIDNO:4425)
CKAP5-561819nt靶#2:5'-AAAUCAUCAAAGGCCAAAG-3'(SEQIDNO:5001)
CKAP5-561819nt靶#3:5'-AAAAUCAUCAAAGGCCAAA-3'(SEQIDNO:5577)
CKAP5-563919nt靶#1:5'-AUGAUUUCUUAGCUGAGAU-3'(SEQIDNO:4426)
CKAP5-563919nt靶#2:5'-AAUGAUUUCUUAGCUGAGA-3'(SEQIDNO:5002)
CKAP5-563919nt靶#3:5'-GAAUGAUUUCUUAGCUGAG-3'(SEQIDNO:5578)
CKAP5-564119nt靶#1:5'-GAUUUCUUAGCUGAGAUUU-3'(SEQIDNO:4427)
CKAP5-564119nt靶#2:5'-UGAUUUCUUAGCUGAGAUU-3'(SEQIDNO:5003)
CKAP5-564119nt靶#3:5'-AUGAUUUCUUAGCUGAGAU-3'(SEQIDNO:5579)
CKAP5-564319nt靶#1:5'-UUUCUUAGCUGAGAUUUUU-3'(SEQIDNO:4428)
CKAP5-564319nt靶#2:5'-AUUUCUUAGCUGAGAUUUU-3'(SEQIDNO:5004)
CKAP5-564319nt靶#3:5'-GAUUUCUUAGCUGAGAUUU-3'(SEQIDNO:5580)
CKAP5-564519nt靶#1:5'-UCUUAGCUGAGAUUUUUAA-3'(SEQIDNO:4429)
CKAP5-564519nt靶#2:5'-UUCUUAGCUGAGAUUUUUA-3'(SEQIDNO:5005)
CKAP5-564519nt靶#3:5'-UUUCUUAGCUGAGAUUUUU-3'(SEQIDNO:5581)
CKAP5-564719nt靶#1:5'-UUAGCUGAGAUUUUUAAGA-3'(SEQIDNO:4430)
CKAP5-564719nt靶#2:5'-CUUAGCUGAGAUUUUUAAG-3'(SEQIDNO:5006)
CKAP5-564719nt靶#3:5'-UCUUAGCUGAGAUUUUUAA-3'(SEQIDNO:5582)
CKAP5-564919nt靶#1:5'-AGCUGAGAUUUUUAAGAAG-3'(SEQIDNO:4431)
CKAP5-564919nt靶#2:5'-UAGCUGAGAUUUUUAAGAA-3'(SEQIDNO:5007)
CKAP5-564919nt靶#3:5'-UUAGCUGAGAUUUUUAAGA-3'(SEQIDNO:5583)
CKAP5-565119nt靶#1:5'-CUGAGAUUUUUAAGAAGAU-3'(SEQIDNO:4432)
CKAP5-565119nt靶#2:5'-GCUGAGAUUUUUAAGAAGA-3'(SEQIDNO:5008)
CKAP5-565119nt靶#3:5'-AGCUGAGAUUUUUAAGAAG-3'(SEQIDNO:5584)
CKAP5-565319nt靶#1:5'-GAGAUUUUUAAGAAGAUUG-3'(SEQIDNO:4433)
CKAP5-565319nt靶#2:5'-UGAGAUUUUUAAGAAGAUU-3'(SEQIDNO:5009)
CKAP5-565319nt靶#3:5'-CUGAGAUUUUUAAGAAGAU-3'(SEQIDNO:5585)
CKAP5-565519nt靶#1:5'-GAUUUUUAAGAAGAUUGGC-3'(SEQIDNO:4434)
CKAP5-565519nt靶#2:5'-AGAUUUUUAAGAAGAUUGG-3'(SEQIDNO:5010)
CKAP5-565519nt靶#3:5'-GAGAUUUUUAAGAAGAUUG-3'(SEQIDNO:5586)
CKAP5-565719nt靶#1:5'-UUUUUAAGAAGAUUGGCUC-3'(SEQIDNO:4435)
CKAP5-565719nt靶#2:5'-AUUUUUAAGAAGAUUGGCU-3'(SEQIDNO:5011)
CKAP5-565719nt靶#3:5'-GAUUUUUAAGAAGAUUGGC-3'(SEQIDNO:5587)
CKAP5-569919nt靶#1:5'-UAGCAGAGUUAUAUGAAUA-3'(SEQIDNO:4436)
CKAP5-569919nt靶#2:5'-CUAGCAGAGUUAUAUGAAU-3'(SEQIDNO:5012)
CKAP5-569919nt靶#3:5'-ACUAGCAGAGUUAUAUGAA-3'(SEQIDNO:5588)
CKAP5-570119nt靶#1:5'-GCAGAGUUAUAUGAAUAUA-3'(SEQIDNO:4437)
CKAP5-570119nt靶#2:5'-AGCAGAGUUAUAUGAAUAU-3'(SEQIDNO:5013)
CKAP5-570119nt靶#3:5'-UAGCAGAGUUAUAUGAAUA-3'(SEQIDNO:5589)
CKAP5-570319nt靶#1:5'-AGAGUUAUAUGAAUAUAAG-3'(SEQIDNO:4438)
CKAP5-570319nt靶#2:5'-CAGAGUUAUAUGAAUAUAA-3'(SEQIDNO:5014)
CKAP5-570319nt靶#3:5'-GCAGAGUUAUAUGAAUAUA-3'(SEQIDNO:5590)
CKAP5-570519nt靶#1:5'-AGUUAUAUGAAUAUAAGAA-3'(SEQIDNO:4439)
CKAP5-570519nt靶#2:5'-GAGUUAUAUGAAUAUAAGA-3'(SEQIDNO:5015)
CKAP5-570519nt靶#3:5'-AGAGUUAUAUGAAUAUAAG-3'(SEQIDNO:5591)
CKAP5-570719nt靶#1:5'-UUAUAUGAAUAUAAGAAGA-3'(SEQIDNO:4440)
CKAP5-570719nt靶#2:5'-GUUAUAUGAAUAUAAGAAG-3'(SEQIDNO:5016)
CKAP5-570719nt靶#3:5'-AGUUAUAUGAAUAUAAGAA-3'(SEQIDNO:5592)
CKAP5-570919nt靶#1:5'-AUAUGAAUAUAAGAAGAAA-3'(SEQIDNO:4441)
CKAP5-570919nt靶#2:5'-UAUAUGAAUAUAAGAAGAA-3'(SEQIDNO:5017)
CKAP5-570919nt靶#3:5'-UUAUAUGAAUAUAAGAAGA-3'(SEQIDNO:5593)
CKAP5-571119nt靶#1:5'-AUGAAUAUAAGAAGAAAUA-3'(SEQIDNO:4442)
CKAP5-571119nt靶#2:5'-UAUGAAUAUAAGAAGAAAU-3'(SEQIDNO:5018)
CKAP5-571119nt靶#3:5'-AUAUGAAUAUAAGAAGAAA-3'(SEQIDNO:5594)
CKAP5-573919nt靶#1:5'-UGACAUUGAACCAUUUCUG-3'(SEQIDNO:4443)
CKAP5-573919nt靶#2:5'-CUGACAUUGAACCAUUUCU-3'(SEQIDNO:5019)
CKAP5-573919nt靶#3:5'-GCUGACAUUGAACCAUUUC-3'(SEQIDNO:5595)
CKAP5-574119nt靶#1:5'-ACAUUGAACCAUUUCUGAA-3'(SEQIDNO:4444)
CKAP5-574119nt靶#2:5'-GACAUUGAACCAUUUCUGA-3'(SEQIDNO:5020)
CKAP5-574119nt靶#3:5'-UGACAUUGAACCAUUUCUG-3'(SEQIDNO:5596)
CKAP5-574319nt靶#1:5'-AUUGAACCAUUUCUGAAAA-3'(SEQIDNO:4445)
CKAP5-574319nt靶#2:5'-CAUUGAACCAUUUCUGAAA-3'(SEQIDNO:5021)
CKAP5-574319nt靶#3:5'-ACAUUGAACCAUUUCUGAA-3'(SEQIDNO:5597)
CKAP5-574519nt靶#1:5'-UGAACCAUUUCUGAAAAAU-3'(SEQIDNO:4446)
CKAP5-574519nt靶#2:5'-UUGAACCAUUUCUGAAAAA-3'(SEQIDNO:5022)
CKAP5-574519nt靶#3:5'-AUUGAACCAUUUCUGAAAA-3'(SEQIDNO:5598)
CKAP5-574719nt靶#1:5'-AACCAUUUCUGAAAAAUUC-3'(SEQIDNO:4447)
CKAP5-574719nt靶#2:5'-GAACCAUUUCUGAAAAAUU-3'(SEQIDNO:5023)
CKAP5-574719nt靶#3:5'-UGAACCAUUUCUGAAAAAU-3'(SEQIDNO:5599)
CKAP5-574919nt靶#1:5'-CCAUUUCUGAAAAAUUCCU-3'(SEQIDNO:4448)
CKAP5-574919nt靶#2:5'-ACCAUUUCUGAAAAAUUCC-3'(SEQIDNO:5024)
CKAP5-574919nt靶#3:5'-AACCAUUUCUGAAAAAUUC-3'(SEQIDNO:5600)
CKAP5-579419nt靶#1:5'-AGAGGCCUUCGGGUGAUUG-3'(SEQIDNO:4449)
CKAP5-579419nt靶#2:5'-AAGAGGCCUUCGGGUGAUU-3'(SEQIDNO:5025)
CKAP5-579419nt靶#3:5'-AAAGAGGCCUUCGGGUGAU-3'(SEQIDNO:5601)
CKAP5-579619nt靶#1:5'-AGGCCUUCGGGUGAUUGAG-3'(SEQIDNO:4450)
CKAP5-579619nt靶#2:5'-GAGGCCUUCGGGUGAUUGA-3'(SEQIDNO:5026)
CKAP5-579619nt靶#3:5'-AGAGGCCUUCGGGUGAUUG-3'(SEQIDNO:5602)
CKAP5-579819nt靶#1:5'-GCCUUCGGGUGAUUGAGAU-3'(SEQIDNO:4451)
CKAP5-579819nt靶#2:5'-GGCCUUCGGGUGAUUGAGA-3'(SEQIDNO:5027)
CKAP5-579819nt靶#3:5'-AGGCCUUCGGGUGAUUGAG-3'(SEQIDNO:5603)
CKAP5-580019nt靶#1:5'-CUUCGGGUGAUUGAGAUGG-3'(SEQIDNO:4452)
CKAP5-580019nt靶#2:5'-CCUUCGGGUGAUUGAGAUG-3'(SEQIDNO:5028)
CKAP5-580019nt靶#3:5'-GCCUUCGGGUGAUUGAGAU-3'(SEQIDNO:5604)
CKAP5-580219nt靶#1:5'-UCGGGUGAUUGAGAUGGAG-3'(SEQIDNO:4453)
CKAP5-580219nt靶#2:5'-UUCGGGUGAUUGAGAUGGA-3'(SEQIDNO:5029)
CKAP5-580219nt靶#3:5'-CUUCGGGUGAUUGAGAUGG-3'(SEQIDNO:5605)
CKAP5-580419nt靶#1:5'-GGGUGAUUGAGAUGGAGAG-3'(SEQIDNO:4454)
CKAP5-580419nt靶#2:5'-CGGGUGAUUGAGAUGGAGA-3'(SEQIDNO:5030)
CKAP5-580419nt靶#3:5'-UCGGGUGAUUGAGAUGGAG-3'(SEQIDNO:5606)
CKAP5-594419nt靶#1:5'-CCAUCUGUCUACUUGGAAA-3'(SEQIDNO:4455)
CKAP5-594419nt靶#2:5'-GCCAUCUGUCUACUUGGAA-3'(SEQIDNO:5031)
CKAP5-594419nt靶#3:5'-GGCCAUCUGUCUACUUGGA-3'(SEQIDNO:5607)
CKAP5-594619nt靶#1:5'-AUCUGUCUACUUGGAAAGG-3'(SEQIDNO:4456)
CKAP5-594619nt靶#2:5'-CAUCUGUCUACUUGGAAAG-3'(SEQIDNO:5032)
CKAP5-594619nt靶#3:5'-CCAUCUGUCUACUUGGAAA-3'(SEQIDNO:5608)
CKAP5-594819nt靶#1:5'-CUGUCUACUUGGAAAGGCU-3'(SEQIDNO:4457)
CKAP5-594819nt靶#2:5'-UCUGUCUACUUGGAAAGGC-3'(SEQIDNO:5033)
CKAP5-594819nt靶#3:5'-AUCUGUCUACUUGGAAAGG-3'(SEQIDNO:5609)
CKAP5-595019nt靶#1:5'-GUCUACUUGGAAAGGCUAA-3'(SEQIDNO:4458)
CKAP5-595019nt靶#2:5'-UGUCUACUUGGAAAGGCUA-3'(SEQIDNO:5034)
CKAP5-595019nt靶#3:5'-CUGUCUACUUGGAAAGGCU-3'(SEQIDNO:5610)
CKAP5-602619nt靶#1:5'-UGACCUCUUUGCUCUCCAA-3'(SEQIDNO:4459)
CKAP5-602619nt靶#2:5'-UUGACCUCUUUGCUCUCCA-3'(SEQIDNO:5035)
CKAP5-602619nt靶#3:5'-UUUGACCUCUUUGCUCUCC-3'(SEQIDNO:5611)
CKAP5-602819nt靶#1:5'-ACCUCUUUGCUCUCCAAAC-3'(SEQIDNO:4460)
CKAP5-602819nt靶#2:5'-GACCUCUUUGCUCUCCAAA-3'(SEQIDNO:5036)
CKAP5-602819nt靶#3:5'-UGACCUCUUUGCUCUCCAA-3'(SEQIDNO:5612)
CKAP5-603019nt靶#1:5'-CUCUUUGCUCUCCAAACCA-3'(SEQIDNO:4461)
CKAP5-603019nt靶#2:5'-CCUCUUUGCUCUCCAAACC-3'(SEQIDNO:5037)
CKAP5-603019nt靶#3:5'-ACCUCUUUGCUCUCCAAAC-3'(SEQIDNO:5613)
CKAP5-603219nt靶#1:5'-CUUUGCUCUCCAAACCAGC-3'(SEQIDNO:4462)
CKAP5-603219nt靶#2:5'-UCUUUGCUCUCCAAACCAG-3'(SEQIDNO:5038)
CKAP5-603219nt靶#3:5'-CUCUUUGCUCUCCAAACCA-3'(SEQIDNO:5614)
CKAP5-617319nt靶#1:5'-UGACCUCCUCCUCCUCCAC-3'(SEQIDNO:4463)
CKAP5-617319nt靶#2:5'-GUGACCUCCUCCUCCUCCA-3'(SEQIDNO:5039)
CKAP5-617319nt靶#3:5'-UGUGACCUCCUCCUCCUCC-3'(SEQIDNO:5615)
CKAP5-621719nt靶#1:5'-AGACUGGAGAGAAUAAAGA-3'(SEQIDNO:4464)
CKAP5-621719nt靶#2:5'-AAGACUGGAGAGAAUAAAG-3'(SEQIDNO:5040)
CKAP5-621719nt靶#3:5'-AAAGACUGGAGAGAAUAAA-3'(SEQIDNO:5616)
CKAP5-621919nt靶#1:5'-ACUGGAGAGAAUAAAGAGC-3'(SEQIDNO:4465)
CKAP5-621919nt靶#2:5'-GACUGGAGAGAAUAAAGAG-3'(SEQIDNO:5041)
CKAP5-621919nt靶#3:5'-AGACUGGAGAGAAUAAAGA-3'(SEQIDNO:5617)
CKAP5-622119nt靶#1:5'-UGGAGAGAAUAAAGAGCAG-3'(SEQIDNO:4466)
CKAP5-622119nt靶#2:5'-CUGGAGAGAAUAAAGAGCA-3'(SEQIDNO:5042)
CKAP5-622119nt靶#3:5'-ACUGGAGAGAAUAAAGAGC-3'(SEQIDNO:5618)
CKAP5-622319nt靶#1:5'-GAGAGAAUAAAGAGCAGUC-3'(SEQIDNO:4467)
CKAP5-622319nt靶#2:5'-GGAGAGAAUAAAGAGCAGU-3'(SEQIDNO:5043)
CKAP5-622319nt靶#3:5'-UGGAGAGAAUAAAGAGCAG-3'(SEQIDNO:5619)
CKAP5-622519nt靶#1:5'-GAGAAUAAAGAGCAGUCGC-3'(SEQIDNO:4468)
CKAP5-622519nt靶#2:5'-AGAGAAUAAAGAGCAGUCG-3'(SEQIDNO:5044)
CKAP5-622519nt靶#3:5'-GAGAGAAUAAAGAGCAGUC-3'(SEQIDNO:5620)
CKAP5-622719nt靶#1:5'-GAAUAAAGAGCAGUCGCAA-3'(SEQIDNO:4469)
CKAP5-622719nt靶#2:5'-AGAAUAAAGAGCAGUCGCA-3'(SEQIDNO:5045)
CKAP5-622719nt靶#3:5'-GAGAAUAAAGAGCAGUCGC-3'(SEQIDNO:5621)
CKAP5-622919nt靶#1:5'-AUAAAGAGCAGUCGCAAAU-3'(SEQIDNO:4470)
CKAP5-622919nt靶#2:5'-AAUAAAGAGCAGUCGCAAA-3'(SEQIDNO:5046)
CKAP5-622919nt靶#3:5'-GAAUAAAGAGCAGUCGCAA-3'(SEQIDNO:5622)
CKAP5-623119nt靶#1:5'-AAAGAGCAGUCGCAAAUGA-3'(SEQIDNO:4471)
CKAP5-623119nt靶#2:5'-UAAAGAGCAGUCGCAAAUG-3'(SEQIDNO:5047)
CKAP5-623119nt靶#3:5'-AUAAAGAGCAGUCGCAAAU-3'(SEQIDNO:5623)
CKAP5-623319nt靶#1:5'-AGAGCAGUCGCAAAUGAAG-3'(SEQIDNO:4472)
CKAP5-623319nt靶#2:5'-AAGAGCAGUCGCAAAUGAA-3'(SEQIDNO:5048)
CKAP5-623319nt靶#3:5'-AAAGAGCAGUCGCAAAUGA-3'(SEQIDNO:5624)
CKAP5-634219nt靶#1:5'-AAACUGGUUGUAUGUAUCA-3'(SEQIDNO:4473)
CKAP5-634219nt靶#2:5'-CAAACUGGUUGUAUGUAUC-3'(SEQIDNO:5049)
CKAP5-634219nt靶#3:5'-ACAAACUGGUUGUAUGUAU-3'(SEQIDNO:5625)
CKAP5-654419nt靶#1:5'-CUCAUUUGUAAAAUUGUCC-3'(SEQIDNO:4474)
CKAP5-654419nt靶#2:5'-GCUCAUUUGUAAAAUUGUC-3'(SEQIDNO:5050)
CKAP5-654419nt靶#3:5'-UGCUCAUUUGUAAAAUUGU-3'(SEQIDNO:5626)
CKAP5-654619nt靶#1:5'-CAUUUGUAAAAUUGUCCUA-3'(SEQIDNO:4475)
CKAP5-654619nt靶#2:5'-UCAUUUGUAAAAUUGUCCU-3'(SEQIDNO:5051)
CKAP5-654619nt靶#3:5'-CUCAUUUGUAAAAUUGUCC-3'(SEQIDNO:5627)
CKAP5-654819nt靶#1:5'-UUUGUAAAAUUGUCCUAAU-3'(SEQIDNO:4476)
CKAP5-654819nt靶#2:5'-AUUUGUAAAAUUGUCCUAA-3'(SEQIDNO:5052)
CKAP5-654819nt靶#3:5'-CAUUUGUAAAAUUGUCCUA-3'(SEQIDNO:5628)
CKAP5-665619nt靶#1:5'-ACUGUAUUCUGUAUGAAUG-3'(SEQIDNO:4477)
CKAP5-665619nt靶#2:5'-CACUGUAUUCUGUAUGAAU-3'(SEQIDNO:5053)
CKAP5-665619nt靶#3:5'-UCACUGUAUUCUGUAUGAA-3'(SEQIDNO:5629)
CKAP5-665819nt靶#1:5'-UGUAUUCUGUAUGAAUGCA-3'(SEQIDNO:4478)
CKAP5-665819nt靶#2:5'-CUGUAUUCUGUAUGAAUGC-3'(SEQIDNO:5054)
CKAP5-665819nt靶#3:5'-ACUGUAUUCUGUAUGAAUG-3'(SEQIDNO:5630)
CKAP5-666019nt靶#1:5'-UAUUCUGUAUGAAUGCAUG-3'(SEQIDNO:4479)
CKAP5-666019nt靶#2:5'-GUAUUCUGUAUGAAUGCAU-3'(SEQIDNO:5055)
CKAP5-666019nt靶#3:5'-UGUAUUCUGUAUGAAUGCA-3'(SEQIDNO:5631)
CKAP5-666219nt靶#1:5'-UUCUGUAUGAAUGCAUGGC-3'(SEQIDNO:4480)
CKAP5-666219nt靶#2:5'-AUUCUGUAUGAAUGCAUGG-3'(SEQIDNO:5056)
CKAP5-666219nt靶#3:5'-UAUUCUGUAUGAAUGCAUG-3'(SEQIDNO:5632)
CKAP5-666419nt靶#1:5'-CUGUAUGAAUGCAUGGCAU-3'(SEQIDNO:4481)
CKAP5-666419nt靶#2:5'-UCUGUAUGAAUGCAUGGCA-3'(SEQIDNO:5057)
CKAP5-666419nt靶#3:5'-UUCUGUAUGAAUGCAUGGC-3'(SEQIDNO:5633)
CKAP5-666619nt靶#1:5'-GUAUGAAUGCAUGGCAUGA-3'(SEQIDNO:4482)
CKAP5-666619nt靶#2:5'-UGUAUGAAUGCAUGGCAUG-3'(SEQIDNO:5058)
CKAP5-666619nt靶#3:5'-CUGUAUGAAUGCAUGGCAU-3'(SEQIDNO:5634)
CKAP5-670419nt靶#1:5'-UUUUAUAAAUAAAGUUUGC-3'(SEQIDNO:4483)
CKAP5-670419nt靶#2:5'-CUUUUAUAAAUAAAGUUUG-3'(SEQIDNO:5059)
CKAP5-670419nt靶#3:5'-UCUUUUAUAAAUAAAGUUU-3'(SEQIDNO:5635)
CKAP5-670619nt靶#1:5'-UUAUAAAUAAAGUUUGCAU-3'(SEQIDNO:4484)
CKAP5-670619nt靶#2:5'-UUUAUAAAUAAAGUUUGCA-3'(SEQIDNO:5060)
CKAP5-670619nt靶#3:5'-UUUUAUAAAUAAAGUUUGC-3'(SEQIDNO:5636)
CKAP5-670819nt靶#1:5'-AUAAAUAAAGUUUGCAUUA-3'(SEQIDNO:4485)
CKAP5-670819nt靶#2:5'-UAUAAAUAAAGUUUGCAUU-3'(SEQIDNO:5061)
CKAP5-670819nt靶#3:5'-UUAUAAAUAAAGUUUGCAU-3'(SEQIDNO:5637)
CKAP5-671019nt靶#1:5'-AAAUAAAGUUUGCAUUAAC-3'(SEQIDNO:4486)
CKAP5-671019nt靶#2:5'-UAAAUAAAGUUUGCAUUAA-3'(SEQIDNO:5062)
CKAP5-671019nt靶#3:5'-AUAAAUAAAGUUUGCAUUA-3'(SEQIDNO:5638)
CKAP5-671219nt靶#1:5'-AUAAAGUUUGCAUUAACUA-3'(SEQIDNO:4487)
CKAP5-671219nt靶#2:5'-AAUAAAGUUUGCAUUAACU-3'(SEQIDNO:5063)
CKAP5-671219nt靶#3:5'-AAAUAAAGUUUGCAUUAAC-3'(SEQIDNO:5639)
CKAP5-671419nt靶#1:5'-AAAGUUUGCAUUAACUAUA-3'(SEQIDNO:4488)
CKAP5-671419nt靶#2:5'-UAAAGUUUGCAUUAACUAU-3'(SEQIDNO:5064)
CKAP5-671419nt靶#3:5'-AUAAAGUUUGCAUUAACUA-3'(SEQIDNO:5640)
CKAP5-10619nt靶#1:5'-CAGCUGAGGAAAUACUCUU-3'(SEQIDNO:4489)
CKAP5-10619nt靶#2:5'-CCAGCUGAGGAAAUACUCU-3'(SEQIDNO:5065)
CKAP5-10619nt靶#3:5'-CCCAGCUGAGGAAAUACUC-3'(SEQIDNO:5641)
CKAP5-17219nt靶#1:5'-UUGAAACUGCCAGUUGAUC-3'(SEQIDNO:4490)
CKAP5-17219nt靶#2:5'-GUUGAAACUGCCAGUUGAU-3'(SEQIDNO:5066)
CKAP5-17219nt靶#3:5'-GGUUGAAACUGCCAGUUGA-3'(SEQIDNO:5642)
CKAP5-18019nt靶#1:5'-GCCAGUUGAUCAGAAAUGU-3'(SEQIDNO:4491)
CKAP5-18019nt靶#2:5'-UGCCAGUUGAUCAGAAAUG-3'(SEQIDNO:5067)
CKAP5-18019nt靶#3:5'-CUGCCAGUUGAUCAGAAAU-3'(SEQIDNO:5643)
CKAP5-21319nt靶#1:5'-GAAAGCAAGGUUAAGUGGG-3'(SEQIDNO:4492)
CKAP5-21319nt靶#2:5'-GGAAAGCAAGGUUAAGUGG-3'(SEQIDNO:5068)
CKAP5-21319nt靶#3:5'-UGGAAAGCAAGGUUAAGUG-3'(SEQIDNO:5644)
CKAP5-28119nt靶#1:5'-CAGAGUGGUCCAAAUUUUU-3'(SEQIDNO:4493)
CKAP5-28119nt靶#2:5'-CCAGAGUGGUCCAAAUUUU-3'(SEQIDNO:5069)
CKAP5-28119nt靶#3:5'-CCCAGAGUGGUCCAAAUUU-3'(SEQIDNO:5645)
CKAP5-33719nt靶#1:5'-GUGGUUCAAUUGAAAGGAU-3'(SEQIDNO:4494)
CKAP5-33719nt靶#2:5'-AGUGGUUCAAUUGAAAGGA-3'(SEQIDNO:5070)
CKAP5-33719nt靶#3:5'-CAGUGGUUCAAUUGAAAGG-3'(SEQIDNO:5646)
CKAP5-35319nt靶#1:5'-GAUUAGAAGCUGCACUUGU-3'(SEQIDNO:4495)
CKAP5-35319nt靶#2:5'-GGAUUAGAAGCUGCACUUG-3'(SEQIDNO:5071)
CKAP5-35319nt靶#3:5'-AGGAUUAGAAGCUGCACUU-3'(SEQIDNO:5647)
CKAP5-36219nt靶#1:5'-CUGCACUUGUUUAUGUUGA-3'(SEQIDNO:4496)
CKAP5-36219nt靶#2:5'-GCUGCACUUGUUUAUGUUG-3'(SEQIDNO:5072)
CKAP5-36219nt靶#3:5'-AGCUGCACUUGUUUAUGUU-3'(SEQIDNO:5648)
CKAP5-39519nt靶#1:5'-CAGGAAAAACCACAGGAGA-3'(SEQIDNO:4497)
CKAP5-39519nt靶#2:5'-GCAGGAAAAACCACAGGAG-3'(SEQIDNO:5073)
CKAP5-39519nt靶#3:5'-AGCAGGAAAAACCACAGGA-3'(SEQIDNO:5649)
CKAP5-42219nt靶#1:5'-CAGGUGUUGUAAGUAAGGU-3'(SEQIDNO:4498)
CKAP5-42219nt靶#2:5'-UCAGGUGUUGUAAGUAAGG-3'(SEQIDNO:5074)
CKAP5-42219nt靶#3:5'-GUCAGGUGUUGUAAGUAAG-3'(SEQIDNO:5650)
CKAP5-42719nt靶#1:5'-GUUGUAAGUAAGGUGUUCA-3'(SEQIDNO:4499)
CKAP5-42719nt靶#2:5'-UGUUGUAAGUAAGGUGUUC-3'(SEQIDNO:5075)
CKAP5-42719nt靶#3:5'-GUGUUGUAAGUAAGGUGUU-3'(SEQIDNO:5651)
CKAP5-44319nt靶#1:5'-UCAAUCAACCUAAAGCUAA-3'(SEQIDNO:4500)
CKAP5-44319nt靶#2:5'-UUCAAUCAACCUAAAGCUA-3'(SEQIDNO:5076)
CKAP5-44319nt靶#3:5'-GUUCAAUCAACCUAAAGCU-3'(SEQIDNO:5652)
CKAP5-53719nt靶#1:5'-CCUGAAAGGCUUGGACAAU-3'(SEQIDNO:4501)
CKAP5-53719nt靶#2:5'-UCCUGAAAGGCUUGGACAA-3'(SEQIDNO:5077)
CKAP5-53719nt靶#3:5'-CUCCUGAAAGGCUUGGACA-3'(SEQIDNO:5653)
CKAP5-63719nt靶#1:5'-AAGCCAAUUAUCAAAGUGU-3'(SEQIDNO:4502)
CKAP5-63719nt靶#2:5'-UAAGCCAAUUAUCAAAGUG-3'(SEQIDNO:5078)
CKAP5-63719nt靶#3:5'-UUAAGCCAAUUAUCAAAGU-3'(SEQIDNO:5654)
CKAP5-64919nt靶#1:5'-AAAGUGUUGCCAAAACUCU-3'(SEQIDNO:4503)
CKAP5-64919nt靶#2:5'-CAAAGUGUUGCCAAAACUC-3'(SEQIDNO:5079)
CKAP5-64919nt靶#3:5'-UCAAAGUGUUGCCAAAACU-3'(SEQIDNO:5655)
CKAP5-65919nt靶#1:5'-CAAAACUCUUUGAGUCUCG-3'(SEQIDNO:4504)
CKAP5-65919nt靶#2:5'-CCAAAACUCUUUGAGUCUC-3'(SEQIDNO:5080)
CKAP5-65919nt靶#3:5'-GCCAAAACUCUUUGAGUCU-3'(SEQIDNO:5656)
CKAP5-68619nt靶#1:5'-CUGUUCGAGAUGAAGCCAA-3'(SEQIDNO:4505)
CKAP5-68619nt靶#2:5'-GCUGUUCGAGAUGAAGCCA-3'(SEQIDNO:5081)
CKAP5-68619nt靶#3:5'-GGCUGUUCGAGAUGAAGCC-3'(SEQIDNO:5657)
CKAP5-75519nt靶#1:5'-CAUUACAAAAUAUAAACUC-3'(SEQIDNO:4506)
CKAP5-75519nt靶#2:5'-CCAUUACAAAAUAUAAACU-3'(SEQIDNO:5082)
CKAP5-75519nt靶#3:5'-CCCAUUACAAAAUAUAAAC-3'(SEQIDNO:5658)
CKAP5-76119nt靶#1:5'-AAAAUAUAAACUCUGUUCA-3'(SEQIDNO:4507)
CKAP5-76119nt靶#2:5'-CAAAAUAUAAACUCUGUUC-3'(SEQIDNO:5083)
CKAP5-76119nt靶#3:5'-ACAAAAUAUAAACUCUGUU-3'(SEQIDNO:5659)
CKAP5-76619nt靶#1:5'-AUAAACUCUGUUCAGUUGA-3'(SEQIDNO:4508)
CKAP5-76619nt靶#2:5'-UAUAAACUCUGUUCAGUUG-3'(SEQIDNO:5084)
CKAP5-76619nt靶#3:5'-AUAUAAACUCUGUUCAGUU-3'(SEQIDNO:5660)
CKAP5-77319nt靶#1:5'-CUGUUCAGUUGAAAGAACU-3'(SEQIDNO:4509)
CKAP5-77319nt靶#2:5'-UCUGUUCAGUUGAAAGAAC-3'(SEQIDNO:5085)
CKAP5-77319nt靶#3:5'-CUCUGUUCAGUUGAAAGAA-3'(SEQIDNO:5661)
CKAP5-92819nt靶#1:5'-GAUGAGGUGCCACAAAUAG-3'(SEQIDNO:4510)
CKAP5-92819nt靶#2:5'-UGAUGAGGUGCCACAAAUA-3'(SEQIDNO:5086)
CKAP5-92819nt靶#3:5'-GUGAUGAGGUGCCACAAAU-3'(SEQIDNO:5662)
CKAP5-94119nt靶#1:5'-AAAUAGAUGCUUAUGAGCU-3'(SEQIDNO:4511)
CKAP5-94119nt靶#2:5'-CAAAUAGAUGCUUAUGAGC-3'(SEQIDNO:5087)
CKAP5-94119nt靶#3:5'-ACAAAUAGAUGCUUAUGAG-3'(SEQIDNO:5663)
CKAP5-95319nt靶#1:5'-AUGAGCUUUUAGAAGCUGU-3'(SEQIDNO:4512)
CKAP5-95319nt靶#2:5'-UAUGAGCUUUUAGAAGCUG-3'(SEQIDNO:5088)
CKAP5-95319nt靶#3:5'-UUAUGAGCUUUUAGAAGCU-3'(SEQIDNO:5664)
CKAP5-104619nt靶#1:5'-CCCUGGAGUCUGUAGAAGU-3'(SEQIDNO:4513)
CKAP5-104619nt靶#2:5'-GCCCUGGAGUCUGUAGAAG-3'(SEQIDNO:5089)
CKAP5-104619nt靶#3:5'-GGCCCUGGAGUCUGUAGAA-3'(SEQIDNO:5665)
CKAP5-105119nt靶#1:5'-GAGUCUGUAGAAGUACUAA-3'(SEQIDNO:4514)
CKAP5-105119nt靶#2:5'-GGAGUCUGUAGAAGUACUA-3'(SEQIDNO:5090)
CKAP5-105119nt靶#3:5'-UGGAGUCUGUAGAAGUACU-3'(SEQIDNO:5666)
CKAP5-110319nt靶#1:5'-CAGAUUUAGUAAAAGCAUU-3'(SEQIDNO:4515)
CKAP5-110319nt靶#2:5'-GCAGAUUUAGUAAAAGCAU-3'(SEQIDNO:5091)
CKAP5-110319nt靶#3:5'-UGCAGAUUUAGUAAAAGCA-3'(SEQIDNO:5667)
CKAP5-111319nt靶#1:5'-AAAAGCAUUAAAGAAGGUU-3'(SEQIDNO:4516)
CKAP5-111319nt靶#2:5'-UAAAAGCAUUAAAGAAGGU-3'(SEQIDNO:5092)
CKAP5-111319nt靶#3:5'-GUAAAAGCAUUAAAGAAGG-3'(SEQIDNO:5668)
CKAP5-111819nt靶#1:5'-CAUUAAAGAAGGUUGUUGG-3'(SEQIDNO:4517)
CKAP5-111819nt靶#2:5'-GCAUUAAAGAAGGUUGUUG-3'(SEQIDNO:5093)
CKAP5-111819nt靶#3:5'-AGCAUUAAAGAAGGUUGUU-3'(SEQIDNO:5669)
CKAP5-112519nt靶#1:5'-GAAGGUUGUUGGAAAGGAC-3'(SEQIDNO:4518)
CKAP5-112519nt靶#2:5'-AGAAGGUUGUUGGAAAGGA-3'(SEQIDNO:5094)
CKAP5-112519nt靶#3:5'-AAGAAGGUUGUUGGAAAGG-3'(SEQIDNO:5670)
CKAP5-120519nt靶#1:5'-GGAAGAAAUUUGGACAAUA-3'(SEQIDNO:4519)
CKAP5-120519nt靶#2:5'-AGGAAGAAAUUUGGACAAU-3'(SEQIDNO:5095)
CKAP5-120519nt靶#3:5'-AAGGAAGAAAUUUGGACAA-3'(SEQIDNO:5671)
CKAP5-134319nt靶#1:5'-GUGAGGAUGUUUUAGCAGU-3'(SEQIDNO:4520)
CKAP5-134319nt靶#2:5'-AGUGAGGAUGUUUUAGCAG-3'(SEQIDNO:5096)
CKAP5-134319nt靶#3:5'-CAGUGAGGAUGUUUUAGCA-3'(SEQIDNO:5672)
CKAP5-135119nt靶#1:5'-GUUUUAGCAGUAAUGGAUA-3'(SEQIDNO:4521)
CKAP5-135119nt靶#2:5'-UGUUUUAGCAGUAAUGGAU-3'(SEQIDNO:5097)
CKAP5-135119nt靶#3:5'-AUGUUUUAGCAGUAAUGGA-3'(SEQIDNO:5673)
CKAP5-138619nt靶#1:5'-CAAGCAGCAGACAUCUCUU-3'(SEQIDNO:4522)
CKAP5-138619nt靶#2:5'-UCAAGCAGCAGACAUCUCU-3'(SEQIDNO:5098)
CKAP5-138619nt靶#3:5'-AUCAAGCAGCAGACAUCUC-3'(SEQIDNO:5674)
CKAP5-139519nt靶#1:5'-GACAUCUCUUUUUAUUGCA-3'(SEQIDNO:4523)
CKAP5-139519nt靶#2:5'-AGACAUCUCUUUUUAUUGC-3'(SEQIDNO:5099)
CKAP5-139519nt靶#3:5'-CAGACAUCUCUUUUUAUUG-3'(SEQIDNO:5675)
CKAP5-151419nt靶#1:5'-UCAGAGAUGCCGCAUUUGA-3'(SEQIDNO:4524)
CKAP5-151419nt靶#2:5'-GUCAGAGAUGCCGCAUUUG-3'(SEQIDNO:5100)
CKAP5-151419nt靶#3:5'-AGUCAGAGAUGCCGCAUUU-3'(SEQIDNO:5676)
CKAP5-153519nt靶#1:5'-CAUUGGGUACUGCUUUGAA-3'(SEQIDNO:4525)
CKAP5-153519nt靶#2:5'-GCAUUGGGUACUGCUUUGA-3'(SEQIDNO:5101)
CKAP5-153519nt靶#3:5'-AGCAUUGGGUACUGCUUUG-3'(SEQIDNO:5677)
CKAP5-159419nt靶#1:5'-GUGGACAAACUCAAGCUUG-3'(SEQIDNO:4526)
CKAP5-159419nt靶#2:5'-UGUGGACAAACUCAAGCUU-3'(SEQIDNO:5102)
CKAP5-159419nt靶#3:5'-AUGUGGACAAACUCAAGCU-3'(SEQIDNO:5678)
CKAP5-162219nt靶#1:5'-AAGAAUGUUCAGAAAAGGU-3'(SEQIDNO:4527)
CKAP5-162219nt靶#2:5'-AAAGAAUGUUCAGAAAAGG-3'(SEQIDNO:5103)
CKAP5-162219nt靶#3:5'-CAAAGAAUGUUCAGAAAAG-3'(SEQIDNO:5679)
CKAP5-163019nt靶#1:5'-UCAGAAAAGGUAGAACUGA-3'(SEQIDNO:4528)
CKAP5-163019nt靶#2:5'-UUCAGAAAAGGUAGAACUG-3'(SEQIDNO:5104)
CKAP5-163019nt靶#3:5'-GUUCAGAAAAGGUAGAACU-3'(SEQIDNO:5680)
CKAP5-163819nt靶#1:5'-GGUAGAACUGAUACAUGGU-3'(SEQIDNO:4529)
CKAP5-163819nt靶#2:5'-AGGUAGAACUGAUACAUGG-3'(SEQIDNO:5105)
CKAP5-163819nt靶#3:5'-AAGGUAGAACUGAUACAUG-3'(SEQIDNO:5681)
CKAP5-184719nt靶#1:5'-CAGGGAAUACUGGAACCAA-3'(SEQIDNO:4530)
CKAP5-184719nt靶#2:5'-GCAGGGAAUACUGGAACCA-3'(SEQIDNO:5106)
CKAP5-184719nt靶#3:5'-CGCAGGGAAUACUGGAACC-3'(SEQIDNO:5682)
CKAP5-190319nt靶#1:5'-CCUGAGCUCUCGAUAGAAG-3'(SEQIDNO:4531)
CKAP5-190319nt靶#2:5'-GCCUGAGCUCUCGAUAGAA-3'(SEQIDNO:5107)
CKAP5-190319nt靶#3:5'-AGCCUGAGCUCUCGAUAGA-3'(SEQIDNO:5683)
CKAP5-191319nt靶#1:5'-CGAUAGAAGUAUGUGAAGA-3'(SEQIDNO:4532)
CKAP5-191319nt靶#2:5'-UCGAUAGAAGUAUGUGAAG-3'(SEQIDNO:5108)
CKAP5-191319nt靶#3:5'-CUCGAUAGAAGUAUGUGAA-3'(SEQIDNO:5684)
CKAP5-197219nt靶#1:5'-CUUGACAGCAGUAACUGGA-3'(SEQIDNO:4533)
CKAP5-197219nt靶#2:5'-UCUUGACAGCAGUAACUGG-3'(SEQIDNO:5109)
CKAP5-197219nt靶#3:5'-UUCUUGACAGCAGUAACUG-3'(SEQIDNO:5685)
CKAP5-203419nt靶#1:5'-GCUAAUGGACCGAACUGAA-3'(SEQIDNO:4534)
CKAP5-203419nt靶#2:5'-AGCUAAUGGACCGAACUGA-3'(SEQIDNO:5110)
CKAP5-203419nt靶#3:5'-GAGCUAAUGGACCGAACUG-3'(SEQIDNO:5686)
CKAP5-206819nt靶#1:5'-UUAGUGAGGAUGCUAGCCA-3'(SEQIDNO:4535)
CKAP5-206819nt靶#2:5'-AUUAGUGAGGAUGCUAGCC-3'(SEQIDNO:5111)
CKAP5-206819nt靶#3:5'-CAUUAGUGAGGAUGCUAGC-3'(SEQIDNO:5687)
CKAP5-208319nt靶#1:5'-GCCAAGAAACCUGGAUGGA-3'(SEQIDNO:4536)
CKAP5-208319nt靶#2:5'-AGCCAAGAAACCUGGAUGG-3'(SEQIDNO:5112)
CKAP5-208319nt靶#3:5'-UAGCCAAGAAACCUGGAUG-3'(SEQIDNO:5688)
CKAP5-208819nt靶#1:5'-GAAACCUGGAUGGAAAGAA-3'(SEQIDNO:4537)
CKAP5-208819nt靶#2:5'-AGAAACCUGGAUGGAAAGA-3'(SEQIDNO:5113)
CKAP5-208819nt靶#3:5'-AAGAAACCUGGAUGGAAAG-3'(SEQIDNO:5689)
CKAP5-211919nt靶#1:5'-GUGAUGCAAAUGAAGCUUC-3'(SEQIDNO:4538)
CKAP5-211919nt靶#2:5'-GGUGAUGCAAAUGAAGCUU-3'(SEQIDNO:5114)
CKAP5-211919nt靶#3:5'-AGGUGAUGCAAAUGAAGCU-3'(SEQIDNO:5690)
CKAP5-217719nt靶#1:5'-AAACGUCAGCUCAGGUUGU-3'(SEQIDNO:4539)
CKAP5-217719nt靶#2:5'-AAAACGUCAGCUCAGGUUG-3'(SEQIDNO:5115)
CKAP5-217719nt靶#3:5'-CAAAACGUCAGCUCAGGUU-3'(SEQIDNO:5691)
CKAP5-224619nt靶#1:5'-CAAAAGAAGCUAUGACAGC-3'(SEQIDNO:4540)
CKAP5-224619nt靶#2:5'-GCAAAAGAAGCUAUGACAG-3'(SEQIDNO:5116)
CKAP5-224619nt靶#3:5'-UGCAAAAGAAGCUAUGACA-3'(SEQIDNO:5692)
CKAP5-226119nt靶#1:5'-CAGCAAUAGCCGAAGCCUG-3'(SEQIDNO:4541)
CKAP5-226119nt靶#2:5'-ACAGCAAUAGCCGAAGCCU-3'(SEQIDNO:5117)
CKAP5-226119nt靶#3:5'-GACAGCAAUAGCCGAAGCC-3'(SEQIDNO:5693)
CKAP5-227219nt靶#1:5'-GAAGCCUGUAUGUUACCAU-3'(SEQIDNO:4542)
CKAP5-227219nt靶#2:5'-CGAAGCCUGUAUGUUACCA-3'(SEQIDNO:5118)
CKAP5-227219nt靶#3:5'-CCGAAGCCUGUAUGUUACC-3'(SEQIDNO:5694)
CKAP5-233919nt靶#1:5'-AAAAUCAGUCAGAAACUCU-3'(SEQIDNO:4543)
CKAP5-233919nt靶#2:5'-AAAAAUCAGUCAGAAACUC-3'(SEQIDNO:5119)
CKAP5-233919nt靶#3:5'-CAAAAAUCAGUCAGAAACU-3'(SEQIDNO:5695)
CKAP5-241219nt靶#1:5'-AGCUUUCAUUAGCAAUGUG-3'(SEQIDNO:4544)
CKAP5-241219nt靶#2:5'-AAGCUUUCAUUAGCAAUGU-3'(SEQIDNO:5120)
CKAP5-241219nt靶#3:5'-AAAGCUUUCAUUAGCAAUG-3'(SEQIDNO:5696)
CKAP5-257819nt靶#1:5'-GAGAAGAUGCAGGGACAAA-3'(SEQIDNO:4545)
CKAP5-257819nt靶#2:5'-UGAGAAGAUGCAGGGACAA-3'(SEQIDNO:5121)
CKAP5-257819nt靶#3:5'-UUGAGAAGAUGCAGGGACA-3'(SEQIDNO:5697)
CKAP5-268419nt靶#1:5'-GCAAUGAUGUCGUUGAUCU-3'(SEQIDNO:4546)
CKAP5-268419nt靶#2:5'-AGCAAUGAUGUCGUUGAUC-3'(SEQIDNO:5122)
CKAP5-268419nt靶#3:5'-GAGCAAUGAUGUCGUUGAU-3'(SEQIDNO:5698)
CKAP5-279719nt靶#1:5'-GAAGUGGCAGGUAUUAUUA-3'(SEQIDNO:4547)
CKAP5-279719nt靶#2:5'-UGAAGUGGCAGGUAUUAUU-3'(SEQIDNO:5123)
CKAP5-279719nt靶#3:5'-AUGAAGUGGCAGGUAUUAU-3'(SEQIDNO:5699)
CKAP5-286019nt靶#1:5'-GCCUUGAAGGGUCGACUCA-3'(SEQIDNO:4548)
CKAP5-286019nt靶#2:5'-UGCCUUGAAGGGUCGACUC-3'(SEQIDNO:5124)
CKAP5-286019nt靶#3:5'-CUGCCUUGAAGGGUCGACU-3'(SEQIDNO:5700)
CKAP5-286519nt靶#1:5'-GAAGGGUCGACUCAAUGAU-3'(SEQIDNO:4549)
CKAP5-286519nt靶#2:5'-UGAAGGGUCGACUCAAUGA-3'(SEQIDNO:5125)
CKAP5-286519nt靶#3:5'-UUGAAGGGUCGACUCAAUG-3'(SEQIDNO:5701)
CKAP5-287319nt靶#1:5'-GACUCAAUGAUUCAAAUAA-3'(SEQIDNO:4550)
CKAP5-287319nt靶#2:5'-CGACUCAAUGAUUCAAAUA-3'(SEQIDNO:5126)
CKAP5-287319nt靶#3:5'-UCGACUCAAUGAUUCAAAU-3'(SEQIDNO:5702)
CKAP5-287919nt靶#1:5'-AUGAUUCAAAUAAAAUCUU-3'(SEQIDNO:4551)
CKAP5-287919nt靶#2:5'-AAUGAUUCAAAUAAAAUCU-3'(SEQIDNO:5127)
CKAP5-287919nt靶#3:5'-CAAUGAUUCAAAUAAAAUC-3'(SEQIDNO:5703)
CKAP5-293719nt靶#1:5'-AGCCAUGGGCCCAAAUAUU-3'(SEQIDNO:4552)
CKAP5-293719nt靶#2:5'-UAGCCAUGGGCCCAAAUAU-3'(SEQIDNO:5128)
CKAP5-293719nt靶#3:5'-GUAGCCAUGGGCCCAAAUA-3'(SEQIDNO:5704)
CKAP5-294919nt靶#1:5'-AAAUAUUAAGCAACAUGUA-3'(SEQIDNO:4553)
CKAP5-294919nt靶#2:5'-CAAAUAUUAAGCAACAUGU-3'(SEQIDNO:5129)
CKAP5-294919nt靶#3:5'-CCAAAUAUUAAGCAACAUG-3'(SEQIDNO:5705)
CKAP5-299719nt靶#1:5'-CCUUGGAGACAGCAAGAAC-3'(SEQIDNO:4554)
CKAP5-299719nt靶#2:5'-UCCUUGGAGACAGCAAGAA-3'(SEQIDNO:5130)
CKAP5-299719nt靶#3:5'-GUCCUUGGAGACAGCAAGA-3'(SEQIDNO:5706)
CKAP5-300219nt靶#1:5'-GAGACAGCAAGAACAAUGU-3'(SEQIDNO:4555)
CKAP5-300219nt靶#2:5'-GGAGACAGCAAGAACAAUG-3'(SEQIDNO:5131)
CKAP5-300219nt靶#3:5'-UGGAGACAGCAAGAACAAU-3'(SEQIDNO:5707)
CKAP5-328519nt靶#1:5'-CAUGAUGCAUUUAGGAUAU-3'(SEQIDNO:4556)
CKAP5-328519nt靶#2:5'-UCAUGAUGCAUUUAGGAUA-3'(SEQIDNO:5132)
CKAP5-328519nt靶#3:5'-UUCAUGAUGCAUUUAGGAU-3'(SEQIDNO:5708)
CKAP5-336719nt靶#1:5'-CUAGAGAAAGCCAAAGUUA-3'(SEQIDNO:4557)
CKAP5-336719nt靶#2:5'-GCUAGAGAAAGCCAAAGUU-3'(SEQIDNO:5133)
CKAP5-336719nt靶#3:5'-UGCUAGAGAAAGCCAAAGU-3'(SEQIDNO:5709)
CKAP5-357119nt靶#1:5'-GGGAAGAAGAUGCCAAGCA-3'(SEQIDNO:4558)
CKAP5-357119nt靶#2:5'-AGGGAAGAAGAUGCCAAGC-3'(SEQIDNO:5134)
CKAP5-357119nt靶#3:5'-AAGGGAAGAAGAUGCCAAG-3'(SEQIDNO:5710)
CKAP5-365019nt靶#1:5'-GAAAAGAGCAAAGGAUGAA-3'(SEQIDNO:4559)
CKAP5-365019nt靶#2:5'-GGAAAAGAGCAAAGGAUGA-3'(SEQIDNO:5135)
CKAP5-365019nt靶#3:5'-UGGAAAAGAGCAAAGGAUG-3'(SEQIDNO:5711)
CKAP5-365519nt靶#1:5'-GAGCAAAGGAUGAAAGAUG-3'(SEQIDNO:4560)
CKAP5-365519nt靶#2:5'-AGAGCAAAGGAUGAAAGAU-3'(SEQIDNO:5136)
CKAP5-365519nt靶#3:5'-AAGAGCAAAGGAUGAAAGA-3'(SEQIDNO:5712)
CKAP5-371619nt靶#1:5'-GGGAUGAAUACAUUGAGCA-3'(SEQIDNO:4561)
CKAP5-371619nt靶#2:5'-CGGGAUGAAUACAUUGAGC-3'(SEQIDNO:5137)
CKAP5-371619nt靶#3:5'-ACGGGAUGAAUACAUUGAG-3'(SEQIDNO:5713)
CKAP5-372119nt靶#1:5'-GAAUACAUUGAGCAACUAA-3'(SEQIDNO:4562)
CKAP5-372119nt靶#2:5'-UGAAUACAUUGAGCAACUA-3'(SEQIDNO:5138)
CKAP5-372119nt靶#3:5'-AUGAAUACAUUGAGCAACU-3'(SEQIDNO:5714)
CKAP5-389019nt靶#1:5'-AGUGGCUUACCCUGAGGUU-3'(SEQIDNO:4563)
CKAP5-389019nt靶#2:5'-AAGUGGCUUACCCUGAGGU-3'(SEQIDNO:5139)
CKAP5-389019nt靶#3:5'-AAAGUGGCUUACCCUGAGG-3'(SEQIDNO:5715)
CKAP5-390019nt靶#1:5'-CCUGAGGUUUUUUGACACC-3'(SEQIDNO:4564)
CKAP5-390019nt靶#2:5'-CCCUGAGGUUUUUUGACAC-3'(SEQIDNO:5140)
CKAP5-390019nt靶#3:5'-ACCCUGAGGUUUUUUGACA-3'(SEQIDNO:5716)
CKAP5-391819nt靶#1:5'-CAAUACAAGCGUCCUGAUG-3'(SEQIDNO:4565)
CKAP5-391819nt靶#2:5'-CCAAUACAAGCGUCCUGAU-3'(SEQIDNO:5141)
CKAP5-391819nt靶#3:5'-ACCAAUACAAGCGUCCUGA-3'(SEQIDNO:5717)
CKAP5-392819nt靶#1:5'-GUCCUGAUGAAAGCACUAG-3'(SEQIDNO:4566)
CKAP5-392819nt靶#2:5'-CGUCCUGAUGAAAGCACUA-3'(SEQIDNO:5142)
CKAP5-392819nt靶#3:5'-GCGUCCUGAUGAAAGCACU-3'(SEQIDNO:5718)
CKAP5-393419nt靶#1:5'-AUGAAAGCACUAGAAUAUU-3'(SEQIDNO:4567)
CKAP5-393419nt靶#2:5'-GAUGAAAGCACUAGAAUAU-3'(SEQIDNO:5143)
CKAP5-393419nt靶#3:5'-UGAUGAAAGCACUAGAAUA-3'(SEQIDNO:5719)
CKAP5-436719nt靶#1:5'-GAAAUCUUUCUGAAAAGGA-3'(SEQIDNO:4568)
CKAP5-436719nt靶#2:5'-GGAAAUCUUUCUGAAAAGG-3'(SEQIDNO:5144)
CKAP5-436719nt靶#3:5'-UGGAAAUCUUUCUGAAAAG-3'(SEQIDNO:5720)
CKAP5-437819nt靶#1:5'-GAAAAGGAUAUGAGCAUGC-3'(SEQIDNO:4569)
CKAP5-437819nt靶#2:5'-UGAAAAGGAUAUGAGCAUG-3'(SEQIDNO:5145)
CKAP5-437819nt靶#3:5'-CUGAAAAGGAUAUGAGCAU-3'(SEQIDNO:5721)
CKAP5-448719nt靶#1:5'-GCUCCAAUGCCAACAUGUU-3'(SEQIDNO:4570)
CKAP5-448719nt靶#2:5'-AGCUCCAAUGCCAACAUGU-3'(SEQIDNO:5146)
CKAP5-448719nt靶#3:5'-AAGCUCCAAUGCCAACAUG-3'(SEQIDNO:5722)
CKAP5-449219nt靶#1:5'-AAUGCCAACAUGUUACGCA-3'(SEQIDNO:4571)
CKAP5-449219nt靶#2:5'-CAAUGCCAACAUGUUACGC-3'(SEQIDNO:5147)
CKAP5-449219nt靶#3:5'-CCAAUGCCAACAUGUUACG-3'(SEQIDNO:5723)
CKAP5-464919nt靶#1:5'-GUGAAAUGCCAGAACUUGU-3'(SEQIDNO:4572)
CKAP5-464919nt靶#2:5'-UGUGAAAUGCCAGAACUUG-3'(SEQIDNO:5148)
CKAP5-464919nt靶#3:5'-AUGUGAAAUGCCAGAACUU-3'(SEQIDNO:5724)
CKAP5-465819nt靶#1:5'-CAGAACUUGUUCAGCACAA-3'(SEQIDNO:4573)
CKAP5-465819nt靶#2:5'-CCAGAACUUGUUCAGCACA-3'(SEQIDNO:5149)
CKAP5-465819nt靶#3:5'-GCCAGAACUUGUUCAGCAC-3'(SEQIDNO:5725)
CKAP5-467319nt靶#1:5'-ACAAACUGGAUGACAUUUU-3'(SEQIDNO:4574)
CKAP5-467319nt靶#2:5'-CACAAACUGGAUGACAUUU-3'(SEQIDNO:5150)
CKAP5-467319nt靶#3:5'-GCACAAACUGGAUGACAUU-3'(SEQIDNO:5726)
CKAP5-468119nt靶#1:5'-GAUGACAUUUUUGAGCCAG-3'(SEQIDNO:4575)
CKAP5-468119nt靶#2:5'-GGAUGACAUUUUUGAGCCA-3'(SEQIDNO:5151)
CKAP5-468119nt靶#3:5'-UGGAUGACAUUUUUGAGCC-3'(SEQIDNO:5727)
CKAP5-468619nt靶#1:5'-CAUUUUUGAGCCAGUCCUU-3'(SEQIDNO:4576)
CKAP5-468619nt靶#2:5'-ACAUUUUUGAGCCAGUCCU-3'(SEQIDNO:5152)
CKAP5-468619nt靶#3:5'-GACAUUUUUGAGCCAGUCC-3'(SEQIDNO:5728)
CKAP5-469319nt靶#1:5'-GAGCCAGUCCUUAUUCCUG-3'(SEQIDNO:4577)
CKAP5-469319nt靶#2:5'-UGAGCCAGUCCUUAUUCCU-3'(SEQIDNO:5153)
CKAP5-469319nt靶#3:5'-UUGAGCCAGUCCUUAUUCC-3'(SEQIDNO:5729)
CKAP5-505719nt靶#1:5'-CUGGAGUACUAAAAGACCU-3'(SEQIDNO:4578)
CKAP5-505719nt靶#2:5'-ACUGGAGUACUAAAAGACC-3'(SEQIDNO:5154)
CKAP5-505719nt靶#3:5'-CACUGGAGUACUAAAAGAC-3'(SEQIDNO:5730)
CKAP5-516719nt靶#1:5'-GUGAAGGUUCUGGAGAAGU-3'(SEQIDNO:4579)
CKAP5-516719nt靶#2:5'-GGUGAAGGUUCUGGAGAAG-3'(SEQIDNO:5155)
CKAP5-516719nt靶#3:5'-UGGUGAAGGUUCUGGAGAA-3'(SEQIDNO:5731)
CKAP5-520219nt靶#1:5'-CCUGAGUGCCCUACUUGUU-3'(SEQIDNO:4580)
CKAP5-520219nt靶#2:5'-UCCUGAGUGCCCUACUUGU-3'(SEQIDNO:5156)
CKAP5-520219nt靶#3:5'-AUCCUGAGUGCCCUACUUG-3'(SEQIDNO:5732)
CKAP5-524619nt靶#1:5'-CAGCCAGUUCUCCCAAAUU-3'(SEQIDNO:4581)
CKAP5-524619nt靶#2:5'-ACAGCCAGUUCUCCCAAAU-3'(SEQIDNO:5157)
CKAP5-524619nt靶#3:5'-AACAGCCAGUUCUCCCAAA-3'(SEQIDNO:5733)
CKAP5-527119nt靶#1:5'-GCUUGUUAUGAAGUGUCUC-3'(SEQIDNO:4582)
CKAP5-527119nt靶#2:5'-AGCUUGUUAUGAAGUGUCU-3'(SEQIDNO:5158)
CKAP5-527119nt靶#3:5'-GAGCUUGUUAUGAAGUGUC-3'(SEQIDNO:5734)
CKAP5-530219nt靶#1:5'-CGACUGUUGCCUGAUACCA-3'(SEQIDNO:4583)
CKAP5-530219nt靶#2:5'-UCGACUGUUGCCUGAUACC-3'(SEQIDNO:5159)
CKAP5-530219nt靶#3:5'-UUCGACUGUUGCCUGAUAC-3'(SEQIDNO:5735)
CKAP5-530719nt靶#1:5'-GUUGCCUGAUACCAUCAAU-3'(SEQIDNO:4584)
CKAP5-530719nt靶#2:5'-UGUUGCCUGAUACCAUCAA-3'(SEQIDNO:5160)
CKAP5-530719nt靶#3:5'-CUGUUGCCUGAUACCAUCA-3'(SEQIDNO:5736)
CKAP5-531219nt靶#1:5'-CUGAUACCAUCAAUAGCAU-3'(SEQIDNO:4585)
CKAP5-531219nt靶#2:5'-CCUGAUACCAUCAAUAGCA-3'(SEQIDNO:5161)
CKAP5-531219nt靶#3:5'-GCCUGAUACCAUCAAUAGC-3'(SEQIDNO:5737)
CKAP5-532019nt靶#1:5'-AUCAAUAGCAUUAACCUAG-3'(SEQIDNO:4586)
CKAP5-532019nt靶#2:5'-CAUCAAUAGCAUUAACCUA-3'(SEQIDNO:5162)
CKAP5-532019nt靶#3:5'-CCAUCAAUAGCAUUAACCU-3'(SEQIDNO:5738)
CKAP5-532519nt靶#1:5'-UAGCAUUAACCUAGACAGA-3'(SEQIDNO:4587)
CKAP5-532519nt靶#2:5'-AUAGCAUUAACCUAGACAG-3'(SEQIDNO:5163)
CKAP5-532519nt靶#3:5'-AAUAGCAUUAACCUAGACA-3'(SEQIDNO:5739)
CKAP5-534219nt靶#1:5'-GAAUUCUUCUGGAUAUCCA-3'(SEQIDNO:4588)
CKAP5-534219nt靶#2:5'-AGAAUUCUUCUGGAUAUCC-3'(SEQIDNO:5164)
CKAP5-534219nt靶#3:5'-CAGAAUUCUUCUGGAUAUC-3'(SEQIDNO:5740)
CKAP5-535019nt靶#1:5'-CUGGAUAUCCACAUUUUCA-3'(SEQIDNO:4589)
CKAP5-535019nt靶#2:5'-UCUGGAUAUCCACAUUUUC-3'(SEQIDNO:5165)
CKAP5-535019nt靶#3:5'-UUCUGGAUAUCCACAUUUU-3'(SEQIDNO:5741)
CKAP5-538319nt靶#1:5'-AAAGAGAAACUGAAGCAAU-3'(SEQIDNO:4590)
CKAP5-538319nt靶#2:5'-CAAAGAGAAACUGAAGCAA-3'(SEQIDNO:5166)
CKAP5-538319nt靶#3:5'-CCAAAGAGAAACUGAAGCA-3'(SEQIDNO:5742)
CKAP5-538819nt靶#1:5'-GAAACUGAAGCAAUGCAAA-3'(SEQIDNO:4591)
CKAP5-538819nt靶#2:5'-AGAAACUGAAGCAAUGCAA-3'(SEQIDNO:5167)
CKAP5-538819nt靶#3:5'-GAGAAACUGAAGCAAUGCA-3'(SEQIDNO:5743)
CKAP5-553619nt靶#1:5'-CGGAUGAUGAAGCACAGUA-3'(SEQIDNO:4592)
CKAP5-553619nt靶#2:5'-CCGGAUGAUGAAGCACAGU-3'(SEQIDNO:5168)
CKAP5-553619nt靶#3:5'-GCCGGAUGAUGAAGCACAG-3'(SEQIDNO:5744)
CKAP5-558819nt靶#1:5'-CAGAAAAGGGAGCAUCUCG-3'(SEQIDNO:4593)
CKAP5-558819nt靶#2:5'-ACAGAAAAGGGAGCAUCUC-3'(SEQIDNO:5169)
CKAP5-558819nt靶#3:5'-AACAGAAAAGGGAGCAUCU-3'(SEQIDNO:5745)
CKAP5-559419nt靶#1:5'-AGGGAGCAUCUCGAAUAGA-3'(SEQIDNO:4594)
CKAP5-559419nt靶#2:5'-AAGGGAGCAUCUCGAAUAG-3'(SEQIDNO:5170)
CKAP5-559419nt靶#3:5'-AAAGGGAGCAUCUCGAAUA-3'(SEQIDNO:5746)
CKAP5-559919nt靶#1:5'-GCAUCUCGAAUAGAUGAAA-3'(SEQIDNO:4595)
CKAP5-559919nt靶#2:5'-AGCAUCUCGAAUAGAUGAA-3'(SEQIDNO:5171)
CKAP5-559919nt靶#3:5'-GAGCAUCUCGAAUAGAUGA-3'(SEQIDNO:5747)
CKAP5-569219nt靶#1:5'-GAGGGACUAGCAGAGUUAU-3'(SEQIDNO:4596)
CKAP5-569219nt靶#2:5'-AGAGGGACUAGCAGAGUUA-3'(SEQIDNO:5172)
CKAP5-569219nt靶#3:5'-AAGAGGGACUAGCAGAGUU-3'(SEQIDNO:5748)
CKAP5-572919nt靶#1:5'-ACUCAGAUGCUGACAUUGA-3'(SEQIDNO:4597)
CKAP5-572919nt靶#2:5'-UACUCAGAUGCUGACAUUG-3'(SEQIDNO:5173)
CKAP5-572919nt靶#3:5'-AUACUCAGAUGCUGACAUU-3'(SEQIDNO:5749)
CKAP5-613019nt靶#1:5'-CAUUCAGACCUGGAUUCUA-3'(SEQIDNO:4598)
CKAP5-613019nt靶#2:5'-GCAUUCAGACCUGGAUUCU-3'(SEQIDNO:5174)
CKAP5-613019nt靶#3:5'-AGCAUUCAGACCUGGAUUC-3'(SEQIDNO:5750)
CKAP5-613619nt靶#1:5'-GACCUGGAUUCUAACCAGA-3'(SEQIDNO:4599)
CKAP5-613619nt靶#2:5'-AGACCUGGAUUCUAACCAG-3'(SEQIDNO:5175)
CKAP5-613619nt靶#3:5'-CAGACCUGGAUUCUAACCA-3'(SEQIDNO:5751)
CKAP5-614119nt靶#1:5'-GGAUUCUAACCAGACUCAC-3'(SEQIDNO:4600)
CKAP5-614119nt靶#2:5'-UGGAUUCUAACCAGACUCA-3'(SEQIDNO:5176)
CKAP5-614119nt靶#3:5'-CUGGAUUCUAACCAGACUC-3'(SEQIDNO:5752)
CKAP5-619319nt靶#1:5'-GCUAACAUAGACGACUUGA-3'(SEQIDNO:4601)
CKAP5-619319nt靶#2:5'-AGCUAACAUAGACGACUUG-3'(SEQIDNO:5177)
CKAP5-619319nt靶#3:5'-CAGCUAACAUAGACGACUU-3'(SEQIDNO:5753)
CKAP5-619819nt靶#1:5'-CAUAGACGACUUGAAAAAA-3'(SEQIDNO:4602)
CKAP5-619819nt靶#2:5'-ACAUAGACGACUUGAAAAA-3'(SEQIDNO:5178)
CKAP5-619819nt靶#3:5'-AACAUAGACGACUUGAAAA-3'(SEQIDNO:5754)
CKAP5-629419nt靶#1:5'-CUAGAAGUCCUCAUAGUUU-3'(SEQIDNO:4603)
CKAP5-629419nt靶#2:5'-ACUAGAAGUCCUCAUAGUU-3'(SEQIDNO:5179)
CKAP5-629419nt靶#3:5'-AACUAGAAGUCCUCAUAGU-3'(SEQIDNO:5755)
CKAP5-645919nt靶#1:5'-GAUGAGUUUAGUGUACAGA-3'(SEQIDNO:4604)
CKAP5-645919nt靶#2:5'-GGAUGAGUUUAGUGUACAG-3'(SEQIDNO:5180)
CKAP5-645919nt靶#3:5'-UGGAUGAGUUUAGUGUACA-3'(SEQIDNO:5756)
CKAP5-651719nt靶#1:5'-CAGAUCCUUUUCUUUUCUU-3'(SEQIDNO:4605)
CKAP5-651719nt靶#2:5'-CCAGAUCCUUUUCUUUUCU-3'(SEQIDNO:5181)
CKAP5-651719nt靶#3:5'-CCCAGAUCCUUUUCUUUUC-3'(SEQIDNO:5757)
CKAP5-654219nt靶#1:5'-UGCUCAUUUGUAAAAUUGU-3'(SEQIDNO:4606)
CKAP5-654219nt靶#2:5'-UUGCUCAUUUGUAAAAUUG-3'(SEQIDNO:5182)
CKAP5-654219nt靶#3:5'-AUUGCUCAUUUGUAAAAUU-3'(SEQIDNO:5758)
CKAP5-664819nt靶#1:5'-GAAGGGUCACUGUAUUCUG-3'(SEQIDNO:4607)
CKAP5-664819nt靶#2:5'-UGAAGGGUCACUGUAUUCU-3'(SEQIDNO:5183)
CKAP5-664819nt靶#3:5'-CUGAAGGGUCACUGUAUUC-3'(SEQIDNO:5759)
CKAP5-665319nt靶#1:5'-GUCACUGUAUUCUGUAUGA-3'(SEQIDNO:4608)
CKAP5-665319nt靶#2:5'-GGUCACUGUAUUCUGUAUG-3'(SEQIDNO:5184)
CKAP5-665319nt靶#3:5'-GGGUCACUGUAUUCUGUAU-3'(SEQIDNO:5760)
在上述表2-7内,加下划线的残基表示2’-O-甲基残基,大写字母表示核糖核苷酸,小写字母表示脱氧核糖核苷酸。上述表2-3的DsiRNA试剂为具有平端的25/27mer试剂。上述表2-3的试剂的结构和/或修饰模式可容易地适用于上述通用序列结构,例如,可延伸或缩短第二链的3′悬突,可将第二链的2’-O-甲基化向第二链的5′末端扩展,任选地在交替位点处等。这样的进一步修饰是任选的,因为具有这样的修饰的25/27merDsiRNA也可从上述DsiRNA试剂容易地设计,并且也预期是CKAP5表达的功能性抑制剂。类似地,27mer“平端/磨损”和“平端/平端”DsiRNA结构和/或上述表5-6的试剂的修饰模式还可容易地适用上述通用序列结构,例如,以将反义链的修饰模式应用于这样的结构和/或使这样的序列适用上述通用结构。
在某些实施方案中,设计和合成具有各自为27个核苷酸的独立链长度的27merDsiRNA,以用于靶向CKAP5转录物内与本文中表2-3中显示的不对称“25/27”结构相同的位点。任选地设计具有针对上述表5的DsiRNA显示的“平端/磨损”结构,或具有针对上述表6的DsiRNA显示的“平端/平端”结构的示例性“27/27”DsiRNA。
在某些实施方案中,本发明的dsRNA试剂需要例如与第二链的对应的残基互补的第一链的至少19、至少20、至少21、至少22、至少23、至少24、至少25或至少26个残基。在某些相关实施方案中,这些与第二链的对应的残基互补的第一链残基任选地是连续残基。
根据定义,“充分互补”(与之相比,例如,“100%的互补性”)允许一个或多个错配存在于本发明的dsRNA与靶RNA或cDNA序列(例如,CKAP5mRNA)之间,只要所述dsRNA具有足以触发通过RNAi机制(例如,RISC复合物)或过程进行的靶RNA的破坏。在某些实施方案中,本发明的“充分互补”的dsRNA可在dsRNA序列与靶RNA或cDNA序列之间具有1、2、3或甚至4或更多个错配(例如,在某些这样的实施方案中,当与靶RNA或cDNA序列对齐时,dsRNA的反义链具有1、2、3、4、5或甚至6或更多个错配)。本发明的某些dsRNA内的这样的错配的优选位置的另外的考虑在下文中进行更详细地考虑。
如本文中所用,“DsiRNAmm”是指具有含有由DsiRNA的有义与反义链形成的双链体的1、2、3或4个错配碱基对的“错配耐受区”的DisRNA,其中这样的错配被定位在DsiRNA内的位于DsiRNA的任一末端的两个末端碱基对之间(从而不包括所述两个末端碱基对)的位置上。错配碱基对位于在本文中关于对应的靶核酸的预测的Ago2切割位点的位置定义的“错配耐受区”内。错配耐受区位于靶链的预测的Ago2切割位点的“上游”。在本说明书中“上游”被理解为DsiRNAmm双链体的最5′部分,其中5′是指DsiRNA双链体的有义链的取向。因此,错配耐受区在对应于靶核酸的预测的Ago2切割位点的有义(随从)链上的碱基的上游(参见图1);或者,当指DsiRNAmm的反义(引导)链时,错配耐受区还可被描述为定位在与靶核酸的预测的Ago2切割位点互补的碱基的下游,即DsiRNAmm的反义链的最3′部分(其中反义链的位置1是反义链的5′末端核苷酸,参见图1)。
在一个实施方案中,例如按照图1中描述的编号,错配耐受区被定位在碱基对3-9(当从始于双链体的有义链的5′末端的核苷酸编号时)之间并且包括所述碱基对。因此,本发明的DsiRNAmm在右手延伸的DsiRNA的有义链的位置3、4、5、6、7、8或9的任一个上具有单个错配碱基(其中位置1是有义链的5′末端核苷酸,位置9是紧接对应于有义链序列的靶CKAP5RNA序列的预测的Ago2切割位点5′的有义链的核苷酸残基)。在某些实施方案中,对于在有义链的位置3、4、5、6、7、8或9的任一个上具有错配碱基对核苷酸的DsiRNAmm,反义链的对应错配碱基对核苷酸不仅与DsiRNAmm有义链序列形成错配碱基对,而且还与DsiRNAmm靶CKAP5RNA序列形成错配碱基对(从而,反义链序列与有义链序列之间的互补性在DsiRNAmm内的错配碱基对上被中断,并且互补性在DsiRNAmm的反义链序列与靶CKAP5RNA序列之间被类似地中断)。在可选择的实施方案中,DsiRNAmm的反义链的错配碱基对核苷酸只能与所述DsiRNAmm的有义链的对应的核苷酸形成错配碱基对,然而仍与其对应的靶CKAP5RNA序列核苷酸碱基配对(因此,反义链序列与有义链序列之间的互补性在DsiRNAmm内的错配碱基对上被中断,然而互补性在DsiRNAmm的反义链序列与靶CKAP5RNA序列之间仍得以维持)。
在上述错配耐受区域(错配区域)内具有单个错配碱基对的本发明的DsiRNAmm(例如,在有义链的位置3、4、5、6、7、8或9的任一个上具有错配核苷酸残基的DsiRNAmm)还可包括1、2或甚至3个另外的错配碱基对。在优选实施方案中,DsiRNAmm的这1、2或3个额外错配碱基对存在于有义链的位置3、4、5、6、7、8和/或9上(和反义链的对应残基上)。在其中一个额外错配碱基对存在于DsiRNAmm内的一个实施方案中,有义链的两个错配碱基对可以存在于例如有义链的位置4和位置6的核苷酸上(错配也在反义链的对应核苷酸残基上发生)。
在具有两个错配碱基对的DsiRNAmm试剂中,错配可连续存在(例如,在沿有义链核苷酸序列的连续位置上)。或者,与反义链序列形成错配碱基对的有义链的核苷酸可被与反义链序列碱基配对的核苷酸分散(例如,对于在位置3和6上而非位置4和5上具有错配核苷酸的DsiRNAmm,有义链位置3和6的错配残基可被与反义链的对应残基形成匹配碱基对的2个核苷酸分散)。例如,与对应的反义链序列形成错配碱基对的有义链的2个残基(位于有义链的错配耐受区内)可与位于这些错配碱基对之间的0、1、2、3、4或5个匹配碱基对共同存在。
对于某些具有3个错配碱基对的DsiRNAmm试剂,错配可连续存在(例如,以沿有义链核苷酸序列的三联体形式存在)。或者,与反义链序列形成错配碱基对的有义链的核苷酸可被与反义链序列形成匹配碱基对的核苷酸分散(例如,对于在位置3、4和8而非位置5、6和7上具有错配核苷酸的DsiRNAmm,有义链位置3和4的错配残基彼此相邻,而有义链位置4和8的错配残基可被与反义链的对应残基形成匹配碱基对的3个核苷酸分散)。例如,与对应的反义链序列形成错配碱基对的有义链的3个残基(位于有义链的错配耐受区内)可与位于这些错配碱基对的任意两个之间的0、1、2、3或4个匹配碱基对共同存在。
对于某些具有4个错配碱基对的DsiRNAmm试剂,错配可连续存在(例如,以沿有义链核苷酸序列的四联体形式存在)。或者,与反义链序列形成错配碱基对的有义链的核苷酸可被与反义链序列形成匹配碱基对的核苷酸分散(例如,对于在位置3、5、7和8而非位置4和6上具有错配核苷酸的DsiRNAmm,有义链位置7和8的错配残基彼此相邻,而有义链位置3和5的错配残基可被与反义链的对应残基形成匹配碱基对的1个核苷酸分散-类似地,有义链位置5和7的错配残基也可被与反义链的对应残基形成匹配碱基对的1个核苷酸分散)。例如,与对应的反义链序列形成错配碱基对的有义链的4个残基(位于有义链的错配耐受区内)可与位于这些错配碱基对的任意两个之间的0、1、2或3个匹配碱基对共同存在。
在另一个实施方案中,例如按照图1中描述的编号,本发明的DsiRNAmm包含错配耐受区,所述区域在DsiRNA的反义链的位置17、18、19、20、21、22或23的任一个上具有单个错配碱基对(其中位置1是有义链的5′末端核苷酸,位置17是紧接与反义链序列充分互补的靶CKAP5RNA序列的预测的Ago2切割位点的反义链中的3′(下游)的反义链的核苷酸残基)。在某些实施方案中,对于在有义链的位置17、18、19、20、21、22或23的任一个上具有相对于所述DsiRNAmm的反义链的错配碱基对核苷酸的DsiRNAmm,反义链的错配碱基对核苷酸不仅与DsiRNAmm有义链序列形成错配碱基对,而且还与DsiRNAmm靶CKAP5RNA序列形成错配碱基对(从而,反义链序列与有义链序列之间的互补性在DsiRNAmm内的错配碱基对上被中断,并且互补性在DsiRNAmm的反义链序列与靶CKAP5RNA序列之间被类似地中断)。在可选择的实施方案中,DsiRNAmm的反义链的错配碱基对核苷酸只能与所述DsiRNAmm的有义链的对应的核苷酸形成错配碱基对,然而仍与其对应的靶CKAP5RNA序列核苷酸碱基配对(因此,反义链序列与有义链序列之间的互补性在DsiRNAmm内的错配碱基对上被中断,然而互补性在DsiRNAmm的反义链序列与靶CKAP5RNA序列之间仍得以维持)。
在上述错配耐受区域内具有单个错配碱基对的本发明的DsiRNAmm(例如,在反义链的位置17、18、19、20、21、22或23上具有错配核苷酸残基的DsiRNAmm)还可包括1、2或甚至3个另外的错配碱基对。在优选实施方案中,DsiRNAmm的这1、2或3个额外错配碱基对存在于反义链的位置17、18、19、20、21、22和/或23上(和有义链的对应残基上)。在其中一个额外错配碱基对存在于DsiRNAmm内的一个实施方案中,反义链的两个错配碱基对可存在于例如反义链的位置18和位置20的核苷酸上(错配也在有义链的对应核苷酸残基上发生)。
在具有两个错配碱基对的DsiRNAmm试剂中,错配可连续存在(例如,在沿反义链核苷酸序列的连续位置上)。或者,与有义链序列形成错配碱基对的反义链的核苷酸可被与有义链序列碱基配对的核苷酸分散(例如,对于在位置17和20上而非位置18和19上具有错配核苷酸的DsiRNAmm,反义链位置17和20的错配残基可被与有义链的对应残基形成匹配碱基对的2个核苷酸分散)。例如,与对应的有义链序列形成错配碱基对的反义链的2个残基(位于有义链的错配耐受区内)可与位于这些错配碱基对之间的0、1、2、3、4、5、6或7个匹配碱基对共同存在。
对于某些具有3个错配碱基对的DsiRNAmm试剂,错配可连续存在(例如,以沿反义链核苷酸序列的三联体形式存在)。或者,与有义链序列形成错配碱基对的反义链的核苷酸可被与有义链序列形成匹配碱基对的核苷酸分散(例如,对于在位置17、18和22而非位置19、20和21上具有错配核苷酸的DsiRNAmm,反义链位置17和18的错配残基彼此相邻,而反义链位置18和122的错配残基可被与有义链的对应残基形成匹配碱基对的3个核苷酸分散)。例如,与对应的有义链序列形成错配碱基对的反义链的3个残基(位于反义链的错配耐受区内)可与位于这些错配碱基对的任意两个之间的0、1、2、3、4、5或6个匹配碱基对共同存在。
对于某些具有4个错配碱基对的DsiRNAmm试剂,错配可连续存在(例如,以沿反义链核苷酸序列的四联体形式存在)。或者,与有义链序列形成错配碱基对的反义链的核苷酸可被与有义链序列形成匹配碱基对的核苷酸分散(例如,对于在位置18、20、22和23而非位置19和21上具有错配核苷酸的DsiRNAmm,反义链位置22和23的错配残基彼此相邻,而反义链位置18和20的错配残基可被与有义链的对应残基形成匹配碱基对的1个核苷酸分散-类似地,反义链位置20和22的错配残基也可被与有义链的对应残基形成匹配碱基对的1个核苷酸分散)。例如,与对应的有义链序列形成错配碱基对的反义链的4个残基(位于反义链的错配耐受区内)可与位于这些错配碱基对的任意两个之间的0、1、2、3、4或5个匹配碱基对共同存在。
为方便起见,错配核苷酸在上述DsiRNAmm试剂内的位置参照所述DsiRNAmm的有义或反义链的5′末端残基进行编号。位于反义链的错配耐受区(错配区)内的位置的编号可随有义或反义链的5′末端附近的变化而移向预测的Ago2切割位点。因此,优选错配位点在反义链或有义链内的位置还可被鉴定为这样的错配至预测的Ago2切割位点的可允许接近度。因此,在一个优选实施方案中,DsiRNAmm的有义链的错配核苷酸的位置是紧邻对应的靶CKAP5RNA序列的预测的Ago2切割位点的5′(上游)的有义链的核苷酸残基。在其它优选实施方案中,DsiRNAmm的有义链的错配核苷酸定位在位于预测的Ago2切割位点的5′(上游)2个核苷酸、预测的Ago2切割位点的5′(上游)3个核苷酸、预测的Ago2切割位点的5′(上游)4个核苷酸、预测的Ago2切割位点的5′(上游)5个核苷酸、预测的Ago2切割位点的5′(上游)6个核苷酸、预测的Ago2切割位点的5′(上游)7个核苷酸、预测的Ago2切割位点的5′(上游)8个核苷酸或预测的Ago2切割位点的5′(上游)9个核苷酸的有义链的核苷酸残基上。
示例性含有单个错配的25/27merDsiRNA(DsiRNAmm)包括下列结构(还可将这样的含有错配的结构掺入本文中显示的其它示例性DsiRNA结构)。
5′-XXMXXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXMXXXXXXXXXXXXXXXXXXXXXX-5′
5′-XXXMXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXMXXXXXXXXXXXXXXXXXXXXXX-5′
5′-XXXMXXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXMXXXXXXXXXXXXXXXXXXXXX-5′
5′-XXXXMXXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXMXXXXXXXXXXXXXXXXXXXX-5′
5′-XXXXXMXXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXMXXXXXXXXXXXXXXXXXXX-5′
5′-XXXXXXMXXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXMXXXXXXXXXXXXXXXXXX-5′
5′-XXXXXXXMXXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXMXXXXXXXXXXXXXXXXX-5′
5′-XXXXXXXXMXXXXXXXXXXXXXXDD-3′
3′-XXXXXXXXXXMXXXXXXXXXXXXXXXX-5′
其中“X”=RNA,″D″=DNA和“M”=当链退火时不与另外的互补链的对应的“M”残基碱基配对(氢键)的核酸残基(RNA、DNA或非天然或经修饰的核酸)。这样的试剂的任何残基可任选地是2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位,如上文中显示的,也可用于上述DsiRNAmm试剂。对于上述错配结构,顶链为有义链,底链为反义链。
在某些实施方案中,本发明的DsiRNA可包含针对靶CKAP5RNA序列存在,但不必作为DsiRNA的两条链内的错配碱基对存在的错配-因此,DsiRNA可在DsiRNA的第一链与第二链之间具有完全互补性,然而仍然具有针对靶CKAP5RNA存在的错配残基(这在某些实施方案中在促进效率和/或效力和/或效应持续时间中可以是有利的)。在某些实施方案中,当错配存在于反义链与靶CKAP5RNA序列之间时,错配的位置位于反义链内的对应于位于靶区域的预测的Ago2切割位点的5′的有义链的序列的位置上-例如,定位在反义链内与靶序列的预测的Ago2切割位点互补的反义链的3′的反义链残基。
具有针对靶序列的单个错配残基的示例性25/27merDsiRNA包括下列结构。
靶RNA序列:5′-...AXXXXXXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-EXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XAXXXXXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XEXXXXXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...AXXXXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-BXXXXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXEXXXXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XAXXXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XBXXXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXEXXXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXAXXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXBXXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXEXXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXAXXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXBXXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXEXXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXXAXXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXBXXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXXEXXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXXXAXXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXBXXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXXXEXXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXXXXAXXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXXBXXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXXXXEXXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXXXXXAXXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXXXBXXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXXXXXEXXXXXXXXXXXXXXXXX-5′
靶RNA序列:5′-...XXXXXXXXAXXXXXXXXXX...-3′
DsiRNAmm有义链:5′-XXXXXXXXBXXXXXXXXXXXXXXDD-3′
DsiRNAmm反义链:3′-XXXXXXXXXXEXXXXXXXXXXXXXXXX-5′
其中“X”=RNA,“D”=DNA和“E”=当链退火时不与另外的互补链(靶)的对应的“A”RNA残基碱基配对(氢键),然而任选地仍与对应的“B”残基(“B”残基也是RNA、DNA或非天然或经修饰的核酸)碱基配对的核酸残基(RNA、DNA或非天然或经修饰的核酸)。这样的试剂的任何残基可任选地是2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位,如上文中显示的,也可用于上述DsiRNA试剂。
在某些实施方案中,与沿靶基因序列的至少19个核苷酸的靶RNA(例如,mRNA)充分互补以减少靶基因表达的本发明的dsRNA的引导链与沿靶基因序列的至少19个核苷酸不完全互补。相反地,应理解,与沿靶RNA序列的至少19个核苷酸的靶mRNA充分互补以减少靶基因表达的本发明的dsRNA的引导链可具有与所述19个核苷酸或更长的靶链序列错配的1、2、3或甚至4或更多个残基。因此,对于19个核苷酸的靶RNA序列,本发明的dsRNA的引导链可与靶RNA序列充分互补以降低靶基因水平,同时在引导链与靶RNA序列之间具有例如仅15/19、16/19、17/19或18/19的错配核苷酸残基。
除上文例举的结构以外,本发明的dsRNA还可具有1、2或3个与靶CKAP5RNA序列形成另外的错配的额外残基。这样的错配可以是连续的,或可被与靶CKAP5RNA序列形成匹配碱基对的核苷酸分散。当被形成匹配碱基对的核苷酸分散时,错配的残基可在单链内以在形成这样的错配的碱基之间1、2、3、4、5、6、7或甚至8个碱基配对的核苷酸的间隔彼此分隔。
关于上述DsiRNAmm试剂,与靶CKAP5RNA序列形成错配碱基对的反义链核苷酸(仍然可以与或可以不与对应的有义链核苷酸形成错配)在dsRNA(例如,DsiRNA)内的优选位置在反义链区域内,所述区域位于与DsiRNA的预测的Ago2切割位点互补的反义链序列的3′(下游)(例如,在图1中,处于预测的Ago2切割位点的3′的反义链的区域对于形成错配的碱基是优选的,并且恰好位于图1中显示的25/27mer试剂的反义链的位置17-23上)。因此,在一个实施方案中,DsiRNAmm的反义链的错配核苷酸的位置(相对于靶CKAP5RNA序列)是位于紧接对应的靶CKAP5RNA序列的预测的Ago2切割位点的反义链序列内的3′(下游)的反义链的核苷酸残基。在其它优选实施方案中,DsiRNAmm的反义链的错配核苷酸(相对于靶CKAP5RNA序列)被定位在位于对应的预测的Ago2切割位点的3′(下游)2个核苷酸、对应的预测的Ago2切割位点的3′(下游)3个核苷酸、对应的预测的Ago2切割位点的3′(下游)4个核苷酸、对应的预测的Ago2切割位点的3′(下游)5个核苷酸、对应的预测的Ago2切割位点的3′(下游)6个核苷酸、对应的预测的Ago2切割位点的3′(下游)7个核苷酸、对应的预测的Ago2切割位点的3′(下游)8个核苷酸或对应的预测的Ago2切割位点的3′(下游)9个核苷酸的反义链的核苷酸残基上。
在具有反义链的2个形成错配的核苷酸的dsRNA试剂(其中形成错配的碱基相对于靶CKAP5RNA序列形成错配)中,错配可连续存在(例如,在沿反义链核苷酸序列的连续位置上)。或者,与靶CKAP5RNA序列形成错配碱基对的反义链的核苷酸可被与靶CKAP5RNA序列碱基配对的核苷酸分散(例如,对于在位置17和20(始于图1中显示的25/27mer试剂的反义链的5′末端(位置1)但非位置18和19上具有形成错配的核苷酸的DsiRNA,有义链位置17和20的错配残基可被与靶CKAP5RNA序列的对应残基形成错配碱基对的两个核苷酸分散)。例如,与对应的靶CKAP5RNA序列形成错配碱基对的反义链的2个残基(位于反义链的错配耐受区内)可与位于这些形成错配的碱基对之间的0、1、2、3、4或5个匹配碱基对(针对靶CKAP5RNA序列)共同存在。
对于某些具有3个形成错配的碱基对(针对靶CKAP5RNA序列的错配形成)的dsRNA,形成错配的核苷酸可连续存在(例如,以沿反义链核苷酸序列的三联体形式存在)。或者,与靶CKAP5RNA序列形成错配碱基对的反义链的核苷酸可被与靶CKAP5RNA序列形成匹配碱基对的核苷酸分散(例如,对于在位置17、18和22但非位置19、20和21上具有错配核苷酸的DsiRNA,反义链位置17和18的形成错配的残基彼此相邻,然而反义链位置18和22的形成错配的残基被与靶CKAP5RNA的对应残基形成匹配碱基对的3个核苷酸分散)。例如,与对应的靶CKAP5RNA序列形成错配碱基对的反义链的3个残基(位于反义链的错配耐受区内)可与位于这些形成错配的碱基对的任意两个之间的0、1、2、3或4个匹配碱基对共同存在。
对于某些具有4个形成错配的碱基对(针对靶CKAP5RNA序列的错配形成)的dsRNA,形成错配的核苷酸可连续存在(例如,以沿有义链核苷酸序列的四联体形式存在)。或者,与靶CKAP5RNA序列形成错配碱基对的反义链的核苷酸可被与靶CKAP5RNA序列形成匹配碱基对的核苷酸分散(例如,对于在位置17、19、21和22但非位置18和20上具有形成错配的核苷酸的DsiRNA,反义链位置21和22的形成错配的残基彼此相邻,然而反义链位置17和19的形成错配的残基被与靶CKAP5RNA的对应残基形成匹配碱基对的1个核苷酸分散-类似地,反义链位置19和21的形成错配的残基被与靶CKAP5RNA的对应残基形成匹配碱基对的1个核苷酸分散)。例如,与对应的靶CKAP5RNA序列形成错配碱基对的反义链的4个残基(位于反义链的错配耐受区内)可与位于这些形成错配的碱基对的任意两个之间的0、1、2或3个匹配碱基对共同存在。
描述上述DsiRNAmm和其它dsRNA结构以举例说明DsiRNAmm和dsRNA试剂的某些结构。上述DsiRNAmm和dsRNA结构的设计可适于产生例如下文中显示的其它DsiRNA结构的DsiRNAmm形式。如上文中举例说明的,还可设计在dsRNA的反义链与靶序列之间具有单个错配(或2、3或4个错配),但仍然任选地可在dsRNA的有义与反义链序列之间保留完全互补性的dsRNA。
要进一步指出的是,下文中举例说明的dsRNA试剂还可在它们的双链和/或靶CKAP5RNA-对齐结构内具有插入/缺失(in/del)结构。因此,本发明的dsRNA可被设计来在例如反义链序列中相较于靶CKAP5RNA序列和/或反义链序列中相较于有义链具有in/del变异,放置这样的in/del核苷酸的优选位置对应于的上文中针对错配碱基和/或形成错配的碱基对的定位描述的那些位置。
还应指出,本发明的DsiRNA可耐受有义链的3′末端区域/反义链的/5′末端区域内的错配,因为该区域被构建来被切丁酶加工并从加载至RISC的引导链序列释放。具有这样的错配的本发明的示例性DsiRNA结构包括下列序列:
靶RNA序列:5′-...XXXXXXXXXXXXXXXXXXXXXHXXX...-3′
DsiRNA有义链:5′-XXXXXXXXXXXXXXXXXXXXXIXDD-3′
DsiRNA反义链:3′-XXXXXXXXXXXXXXXXXXXXXXXJXXX-5′
靶RNA序列:5′-...XXXXXXXXXXXXXXXXXXXXXXHXX...-3′
DsiRNA有义链:5′-XXXXXXXXXXXXXXXXXXXXXXIDD-3′
DsiRNA反义链:3′-XXXXXXXXXXXXXXXXXXXXXXXXJXX-5′
靶RNA序列:5′-...XXXXXXXXXXXXXXXXXXXXXXXHX...-3′
DsiRNA有义链:5′-XXXXXXXXXXXXXXXXXXXXXXXID-3′
DsiRNA反义链:3′-XXXXXXXXXXXXXXXXXXXXXXXXXJX-5′
靶RNA序列:5′-...XXXXXXXXXXXXXXXXXXXXXXXXH...-3′
DsiRNA有义链:5′-XXXXXXXXXXXXXXXXXXXXXXXDI-3′
DsiRNA反义链:3′-XXXXXXXXXXXXXXXXXXXXXXXXXXJ-5′
其中“X”=RNA,“D”=DNA并且“I”和“J”=彼此不碱基配对(氢键)的核酸残基(RNA、DNA或非天然或经修饰的核酸),然而任选地“J”与靶RNA序列核苷酸“H”互补。这样的试剂的任何残基可任选地为2′-O-甲基RNA单体-从底(第二)链的3′末端残基开始的2′-O-甲基RNA单体的交替定位(如上文中显示的)-或任何上述甲基化模式-也可用于上述DsiRNA试剂。还可将上述错配组合在本发明的DsiRNA内。
在下列结构中,在不对称的CKAP5-604DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAUca-3′(SEQIDNO:5763)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置19的错配′U′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAUca-3′(SEQIDNO:5764)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置20的错配′U′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAUca-3′(SEQIDNO:5765)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置21的错配′U′残基可选择地是′G′或′C′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAUca-3′(SEQIDNO:5766)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置22的错配′G′残基可选择地是′U′或′C′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAca-3′(SEQIDNO:5767)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置23的错配′A′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUa-3′(SEQIDNO:5768)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置24的错配′t′残基可选择地是′a′或′g′。
CKAP5-60425/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUc-3′(SEQIDNO:5769)
3′-GGAAUUCACUUAAACCAAGGUUUUAGU-5′(SEQIDNO:619)
任选地,有义链的位置25的错配′t′残基可选择地是′c′或′g′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUUAG-5′(SEQIDNO:5770)
任选地,反义链的位置1的错配′A′残基可选择地是′G′或′C′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUCa-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUUAU-5′(SEQIDNO:5771)
任选地,反义链的位置2的错配′A′残基可选择地是′U′或′C′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUUGU-5′(SEQIDNO:5772)
任选地,反义链的位置3的错配′U′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUAGU-5′(SEQIDNO:5773)
任选地,反义链的位置4的错配′C′残基可选择地是′A′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置5(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUAGU-5′(SEQIDNO:5774)
任选地,反义链的位置5的错配′A′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUAGU-5′(SEQIDNO:5775)
任选地,反义链的位置6的错配′A′残基可选择地是′C′或′G′。
CKAP5-60425/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-UUAAGUGAAUUUGGUUCCAAAAUca-3′(SEQIDNO:43)
3′-GGAAUUCACUUAAACCAAGGUUUAGU-5′(SEQIDNO:5776)
任选地,反义链的位置7的错配′A′残基可选择地是′C′或′G′。
作为另一个实例,在下列结构中,在不对称的CKAP5-853DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAUUgg-3′(SEQIDNO:5777)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置19的错配′U′残基可选择地是′C′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAUUgg-3′(SEQIDNO:5778)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置20的错配′G′残基可选择地是′C′或′U′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAUUgg-3′(SEQIDNO:5779)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置21的错配′U′残基可选择地是′G′或′C′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUgg-3′(SEQIDNO:5780)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置22的错配′G′残基可选择地是′A′或′C′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUgg-3′(SEQIDNO:5781)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置23的错配′A′残基可选择地是′C′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUg-3′(SEQIDNO:5782)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置24的错配′t′残基可选择地是′a′或′c′。
CKAP5-85325/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUg-3′(SEQIDNO:5783)
3′-GGGUUGUUCUUGAUCUUCGAUUUAACC-5′(SEQIDNO:627)
任选地,有义链的位置25的错配′a′残基可选择地是′t′或′c′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUUAAC-5′(SEQIDNO:5784)
任选地,反义链的位置1的错配′U′残基可选择地是′A′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUUAAC-5′(SEQIDNO:5785)
任选地,反义链的位置2的错配′A′残基可选择地是′U′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUUACC-5′(SEQIDNO:5786)
任选地,反义链的位置3的错配′U′残基可选择地是′C′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUUACC-5′(SEQIDNO:5787)
任选地,反义链的位置4的错配′C′残基可选择地是′U′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置5(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUAACC-5′(SEQIDNO:5788)
任选地,反义链的位置5的错配′A′残基可选择地是′C′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUAACC-5′(SEQIDNO:5789)
任选地,反义链的位置6的错配′C′残基可选择地是′A′或′G′。
CKAP5-85325/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-CAACAAGAACUAGAAGCUAAAUUgg-3′(SEQIDNO:51)
3′-GGGUUGUUCUUGAUCUUCGAUUAACC-5′(SEQIDNO:5790)
任选地,反义链的位置7的错配′A′残基可选择地是′C′或′G′。
作为另外的实例,在下列结构中,在不对称的CKAP5-1358DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAUCCAac-3′(SEQIDNO:5791)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置19的错配′U′残基可选择地是′C′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAACCAac-3′(SEQIDNO:5792)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置20的错配′A′残基可选择地是′C′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCAac-3′(SEQIDNO:5793)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置21的错配′A′残基可选择地是′U′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCAac-3′(SEQIDNO:5794)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置22的错配′U′残基可选择地是′A′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCac-3′(SEQIDNO:5795)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置23的错配′U′残基可选择地是′C′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAc-3′(SEQIDNO:5796)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置24的错配′g′残基可选择地是′t′或′c′。
CKAP5-135825/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAa-3′(SEQIDNO:5797)
3′-UCGUCAUUACCUAUUAUUUUUAGGUUG-5′(SEQIDNO:695)
任选地,有义链的位置25的错配′a′残基可选择地是′t′或′g′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAaC-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUAGGUU-5′(SEQIDNO:5798)
任选地,反义链的位置1的错配′U′残基可选择地是′A′或′C′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUAGGUG-5′(SEQIDNO:5799)
任选地,反义链的位置2的错配′C′残基可选择地是′A′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUAGGUG-5′(SEQIDNO:5800)
任选地,反义链的位置3的错配′A′残基可选择地是′C′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUAGUUG-5′(SEQIDNO:5801)
任选地,反义链的位置4的错配′A′残基可选择地是′U′或′C′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置5(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUAGUUG-5′(SEQIDNO:5802)
任选地,反义链的位置5的错配′U′残基可选择地是′A′或′C′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUUGGUUG-5′(SEQIDNO:5803)
任选地,反义链的位置6的错配′U′残基可选择地是′C′或′G′。
CKAP5-135825/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-CAGUAAUGGAUAAUAAAAAUCCAac-3′(SEQIDNO:119)
3′-UCGUCAUUACCUAUUAUUUUAGGUUG-5′(SEQIDNO:5804)
任选地,反义链的位置7的错配′A′残基可选择地是′C′或′G′。
作为其它实例,在下列结构中,在不对称的CKAP5-2096DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUCAGgt-3′(SEQIDNO:5805)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置19的错配′A′残基可选择地是′C′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUCAGgt-3′(SEQIDNO:5806)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置20的错配′A′残基可选择地是′C′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUAGgt-3′(SEQIDNO:5807)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置21的错配′A′残基可选择地是′U′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCGgt-3′(SEQIDNO:5808)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置22的错配′G′残基可选择地是′U′或′C′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAgt-3′(SEQIDNO:5809)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置23的错配′A′残基可选择地是′U′或′C′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGt-3′(SEQIDNO:5810)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置24的错配′t′残基可选择地是′a′或′c′。
CKAP5-209625/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGg-3′(SEQIDNO:5811)
3′-ACCUACCUUUCUUUGAUUAAAAGUCCA-5′(SEQIDNO:716)
任选地,有义链的位置25的错配′a′残基可选择地是′c′或′g′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAAGUCC-5′(SEQIDNO:5812)
任选地,反义链的位置1的错配′U′残基可选择地是′G′或′C′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAAGUCA-5′(SEQIDNO:5813)
任选地,反义链的位置2的错配′A′残基可选择地是′U′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAAGUCA-5′(SEQIDNO:5814)
任选地,反义链的位置3的错配′U′残基可选择地是′A′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAAGCCA-5′(SEQIDNO:5815)
任选地,反义链的位置4的错配′C′残基可选择地是′A′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位5置(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAAUCCA-5′(SEQIDNO:5816)
任选地,反义链的位置5的错配′U′残基可选择地是′A′或′C′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAGUCCA-5′(SEQIDNO:5817)
任选地,反义链的位置6的错配′U′残基可选择地是′C′或′G′。
CKAP5-209625/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-GAUGGAAAGAAACUAAUUUUCAGgt-3′(SEQIDNO:140)
3′-ACCUACCUUUCUUUGAUUAAAGUCCA-5′(SEQIDNO:5818)
任选地,反义链的位置7的错配′U′残基可选择地是′C′或′G′。
作为另一个实例,在下列结构中,在不对称的CKAP5-1711DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAGUUCgt-3′(SEQIDNO:5819)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置19的错配′A′残基可选择地是′C′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUUUCgt-3′(SEQIDNO:5820)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置20的错配′U′残基可选择地是′A′或′C′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUCgt-3′(SEQIDNO:5821)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置21的错配′A′残基可选择地是′C′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUCgt-3′(SEQIDNO:5822)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置22的错配′G′残基可选择地是′A′或′C′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUgt-3′(SEQIDNO:5823)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置23的错配′A′残基可选择地是′U′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCt-3′(SEQIDNO:5824)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置24的错配′t′残基可选择地是′a′或′c′。
CKAP5-405625/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCg-3′(SEQIDNO:5825)
3′-UUCCUACAGUAAGCAUUUCUACAAGCA-5′(SEQIDNO:840)
任选地,有义链的位置25的错配′a′残基可选择地是′c′或′g′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUACAAGC-5′(SEQIDNO:5826)
任选地,反义链的位置1的错配′U′残基可选择地是′G′或′C′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUACAAGA-5′(SEQIDNO:5827)
任选地,反义链的位置2的错配′A′残基可选择地是′U′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUACAACA-5′(SEQIDNO:5828)
任选地,反义链的位置3的错配′U′残基可选择地是′A′或′C′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUACAGCA-5′(SEQIDNO:5829)
任选地,反义链的位置4的错配′C′残基可选择地是′U′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置5(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUACAGCA-5′(SEQIDNO:5830)
任选地,反义链的位置5的错配′U′残基可选择地是′C′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUAAAGCA-5′(SEQIDNO:5831)
任选地,反义链的位置6的错配′A′残基可选择地是′U′或′G′。
CKAP5-405625/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-GGAUGUCAUUCGUAAAGAUGUUCgt-3′(SEQIDNO:264)
3′-UUCCUACAGUAAGCAUUUCUCAAGCA-5′(SEQIDNO:5832)
任选地,反义链的位置7的错配′U′残基可选择地是′C′或′G′。
作为另外的实例,在下列结构中,在不对称的CKAP5-1769DsiRNA内引入这样的错配(新引入的错配残基以斜体字显示):
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置19(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAUtc-3′(SEQIDNO:5833)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置19的错配′U′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置20(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAUtc-3′(SEQIDNO:5834)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置20的错配′U′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置21(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAUtc-3′(SEQIDNO:5835)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置21的错配′U′残基可选择地是′G′或′C′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置22(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAUtc-3′(SEQIDNO:5836)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置22的错配′G′残基可选择地是′U′或′C′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置23(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAtc-3′(SEQIDNO:5837)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置23的错配′A′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置24(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUc-3′(SEQIDNO:5838)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置24的错配′g′残基可选择地是′a′或′c′。
CKAP5-574125/27merDsiRNA,错配位置=有义链的位置25(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUt-3′(SEQIDNO:5839)
3′-ACUGUAACUUGGUAAAGACUUUUUAAG-5′(SEQIDNO:988)
任选地,有义链的位置25的错配′a′残基可选择地是′t′或′g′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置1(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtC-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUUAA-5′(SEQIDNO:5840)
任选地,有义链的位置1的错配′U′残基可选择地是′A′或′C′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置2(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUUAG-5′(SEQIDNO:5841)
任选地,反义链的位置2的错配′C′残基可选择地是′U′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置3(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUUAG-5′(SEQIDNO:5842)
任选地,反义链的位置3的错配′U′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置4(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUAAG-5′(SEQIDNO:5843)
任选地,反义链的位置4的错配′C′残基可选择地是′A′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置5(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUAAG-5′(SEQIDNO:5844)
任选地,反义链的位置5的错配′A′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置6(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUAAG-5′(SEQIDNO:5845)
任选地,反义链的位置6的错配′A′残基可选择地是′C′或′G′。
CKAP5-574125/27merDsiRNA,错配位置=反义链的位置7(从5′-末端开始)
5′-ACAUUGAACCAUUUCUGAAAAAUtc-3′(SEQIDNO:412)
3′-ACUGUAACUUGGUAAAGACUUUUAAG-5′(SEQIDNO:5846)
任选地,反义链的位置7的错配′A′残基可选择地是′C′或′G′。
对于上述寡核苷酸链序列,预期可将一个描述的双链体的有义链序列与另一个描述的双链体的反义链组合,从而形成不同的双链体-在某些情况下,这样的双链体含有针对CKAP5靶转录物序列的错配碱基,然而这样的有义和反义链序列在该残基上不呈现针对彼此的错配(例如,包含SEQIDNO:5777和5790、SEQIDNO:5778和5789、SEQIDNO:5779和5788等的双链体被考虑为这样的双链体的示例)。
如上文中指出的,可对本文中描述的任何DsiRNA进行这样的错配的引入。
可将这样的DsiRNA结构的错配组合以产生在有义链的3′末端4个核苷酸/反义链的5′末端4个核苷酸内具有例如2、3或甚至4个错配的DsiRNA。
事实上,鉴于可在有义链的3′末端残基/反义链的5′末端残基上被掺入DsiRNA的序列的柔性,在某些实施方案中,本发明的不对称DsiRNA的序列要求可表示为下列(最低必需限度的)结构(针对示例性CKAP5-604DsiRNA序列显示的):
5′-UUAAGUGAAUUUGGUUCCAAAXXX[X]n-3′(SEQIDNO:5847)
3′-GGAAUUCACUUAAACCAAGGUXXXXX[X]n-5′(SEQIDNO:5848)
其中n=1至5、1至10、1至20、1至30、1至50或1至80或更多。
CKAP5-604靶:5’-CCTTAAGTGAATTTGGTTCCAXXXXXX-3’(SEQIDNO:5849)
CKAP5靶位点还可以是被几个其互补靶位点与所述靶位点重叠的寡核苷酸的一个或多个靶向的位点。例如,对于示例性CKAP5-604DsiRNA,应指出,某些靶向重叠并且仅略微偏移的CKAP5序列的DsiRNA可展现与CKAP5-604的活性水平相似的活性水平(具体地,CKAP5-600至CKAP5-606在初步筛选过程中显示这样的作用)。因此,在某些实施方案中,指定的靶序列区域可被一系列具有很大程度重叠的序列的DsiRNA有效地靶向。(例如,如果考虑围绕CKAP5-604位点的DsiRNA,更具包容性的CKAP5转录物靶序列可被引述为例如5'-AAAGCCTTAAGTGAATTTGGTTCCAAAATCATC-3′(SEQIDNO:5850),其中任何给定的DsiRNA(例如,选自CKAP5-600至CKAP5-606的DsiRNA)仅靶向这样的序列区域内的子序列,然而整个序列可被当作这样的一系列DsiRNA的可行的靶)。
此外和/或可选择地,可将有义链的3′末端4至7个核苷酸/反义链的5′末端4至7个核苷酸内的错配与定位在其它错配耐受性位点上的错配组合,如上文中描述的。
鉴于上述切丁酶底物试剂(DsiRNA)目前被鉴定为通过靶向特定CKAP5序列起作用的CKAP5水平的抑制剂,还应了解,还可合成具有与本文中描述的那些结构相似的结构的dsRNA,所述dsRNA靶向NM_001008938.3,NM_014756.3或NM_001165989.1的CKAP5序列内或其变体内的其它序列(例如,具有与NM_001008938.3、NM_014756.3和/或NM_001165989.1的序列具有80%同一性、90%同一性、95%同一性、96%同一性、97%同一性、98%同一性、99%或更高同一性的靶序列)。
抗-CKAP5DsiRNA设计/合成
已凭经验发现,具有25至35个核苷酸(DsiRNA),特别地25至30个核苷酸的更长的dsRNA种类在作用的效力和持续时间方面,相较于19-23mersiRNA试剂产生了预料之外的有效结果。不希望受dsRNA加工机制的基础理论束缚,据认为更长的dsRNA种类用作细胞的细胞质中的切丁酶的底物。除了将本发明的dsRNA切割成更短的区段以外,切丁酶还被认为有利于来源于切割的dsRNA的单链切割产物至RISC复合物中的掺入,所述RISC复合物负责靶基因CKAP5(或与CKAP5相关疾病或病症相关的其它基因)的细胞质RNA(例如,CKAP5RNA)或来源于所述基因的细胞质RNA的破坏。先前的研究(Rossi等人,美国专利申请No.2007/0265220)已显示,dsRNA种类(特别地,DsiRNA试剂)被切丁酶切割的可切割性与dsRNA种类的作用的增加的效力和持续时间相一致。
某些优选的抗-CKAP5DsiRNA试剂选自预筛的群体。DsiRNA的设计可任选地牵涉进行许多可能的横跨序列的区域的DsiRNA试剂的预测的活性/效率的芯片评估的预测评分算法的使用。关于这样的评分算法的设计的信息可见于例如Gong等人,(BMCBioinformatics2006,7:516)中,尽管更近以来“v3”和“v4”算法代表相对于本领域中先前可获得的siRNA评分算法理论上改进的算法。(例如,“v3”和“v4”评分算法是不依赖于人序列中的任何偏倚性的机器学习算法。此外,“v3”和“v4”算法来源于数据集组,所述数据集组比更老的“v2”算法(诸如Gong等人,derives中描述的所述算法)所源自的数据集组大许多倍。)
不要求本发明的DsiRNA试剂的第一和第二寡核苷酸是完全互补的。事实上,在一个实施方案中,有义链的3′末端含有一个或多个错配。在一个方面,在有义链的3′末端掺入2个错配。在另一个实施方案中,本发明的DsiRNA是含有两个RNA寡核苷酸的双链RNA分子,所述RNA寡核苷酸各自长度为27个核苷酸并且,当彼此退火时,具有平端以及在有义链的3′末端(反义链的5'末端)上具有2个核苷酸错配。已有人提出错配或降低的热力学稳定性(特别地在3′有义/5'反义位置)的使用有助于或有利于反义链进入RISC(Schwarz等人,2003,Cell115:199-208;Khvorova等人,2003,Cell115:209-216),假定地通过影响一些因siRNA进入RISC而发生的限速解链步骤来实现。因此,末端碱基组成已被包括在用于选择活性21mersiRNA双链体的设计算法中(Ui-Tei等人,2004,NucleicAcidsRes32:936-948;Reynolds等人,2004,NatBiotechnol22:326-330)。通过本发明的dsRNA的切丁酶切割,含有错配的小的末端序列将保持不与反义链配对(成为3′悬突的部分)或被完全切离最终的21-mersiRNA。这些“错配”从而不作为错配保持在RISC的最终RNA组分中。碱基错配或区段在切丁酶底物的有义链的3′末端上的去稳定作用在RNAi中提高合成双链体的效力(假定地通过促进切丁酶的加工作用来进行)的发现,是过去描述25-30merdsRNA(在本文中也称为“DsiRNA”;Rossi等人,美国专利申请No.2005/0277610、2005/0244858和2007/0265220)的设计和用途的工作的令人惊讶发现。
抗-CKAP5dsRNA的修饰
抑制双链RNA(“dsRNA”)的作用的一个主要因素核酸酶对dsRNA(例如,siRNA和DsiRNA)的降解。3′外切核苷酸酶是存在于血清中的主要核酸酶活性,反义DNA寡核苷酸的3′末端的修饰对于阻止降解是至关重要的(Eder等人,1991,AntisenseResDev,1:141-151)。RNA酶-T家族核酸酶已被鉴定称为ERI-1,其具有参与siRNA的调控和降解的3′至5'外切核酸酶活性(Kennedy等人,2004,Nature427:645-649;Hong等人,2005,BiochemJ,390:675-679)。该基因在在小鼠中也称为Thex1(NM_02067)或在人中称为THEX1(NM_153332),并且参与组蛋白mRNA的降解;其还介导siRNA中的3′悬突降解,但不降解双链体RNA(Yang等人,2006,JBiolChem,281:30447-30454)。因此合理地预期dsRNA(包括本发明的DsiRNA)的3′末端稳定化作用将提高稳定性。
XRN1(NM_019001)是存在于P体中的5'至3′外切核酸酶,其牵涉被miRNA靶向的mRNA的降解(Rehwinkel等人,2005,RNA11:1640-1647)并且还可能负责通过内部切割(如由siRNA指导的)起始的完全降解。XRN2(NM_012255)是参与细胞核RNA加工的不同的5'至3′外切核酸酶。
RNA酶A是哺乳动物中降解RNA的主要内切核酸酶活性。其对于ssRNA是特异性,并且在嘧啶碱基的3′末端进行切割。与RNA酶A切割一致的SiRNA的降解产物可在于血清中孵育后通过质谱法来检测(Turner等人,2007,MolBiosyst3:43-50)。3′悬突增强siRNA对RNA酶降解的易感性。RNA酶A从血清的耗尽减少siRNA的降解;该降解显示一定的序列偏好,并且对于在末端具有多聚A/U序列的序列更加不利(Haupenthal等人,2006BiochemPharmacol71:702-710)。这表明双链体的更低的稳定性区域可"呼吸"并且提供可用于被RNA酶A降解的瞬时单链种类的可能性。可将RNA酶A抑制剂添加至血清,从而延伸siRNA的寿命和增强效力(Haupenthal等人,2007,IntJ.Cancer121:206-210)。
在21mer中,硫代磷酸酯或硼烷化磷酸酯(boranophosphate)修饰直接稳定核苷间磷酸键。作为沉默剂,硼烷化磷酸酯修饰的RNA是高度抗核酸酶的强效的,并且是相对无毒的。硼烷化磷酸酯修饰的RNA不能使用标准化学合成法来制造,取而代之地通过体外转录(IVT)来制造(Hall等人,2004,NucleicAcidsRes32:5991-6000;Hall等人,2006,NucleicAcidsRes34:2773-2781)。硫代磷酸酯(PS)修饰可被容易地置于RNA双链中的任何想要的位置,并且可使用标准化学合成法来制造。PS修饰显示剂量依赖性毒性,因此大多数研究人员建议有限地掺入siRNA,从而有利于其中免受核酸降解的保护是最重要的3′末端(Harborth等人,2003,AntisenseNucleicAcidDrugDev13:83-105;Chiu和Rana,2003,MolCell10:549-561;Braasch等人,2003,Biochemistry42:7967-7975;Amarzguioui等人,2003,NucleicAcidsResearch31:589-595)。更广泛的PS修饰可与强效的RNAi活性相容;然而糖修饰(诸如2'-O-甲基RNA)的使用可以是更优的(Choung等人,2006,BiochemBiophysResCommun342:919-927)。
可将各种各样的置换置于核糖的2'位置,这通常增强双链体的稳定性(Tm)并且可极大地增强核酸酶抗性。2'-O-甲基RNA是在哺乳动物核糖RNA和转运RNA中发现的天然存在的修饰。siRNA中的2'-O-甲基修饰是已知的,但双链体内经修饰的碱基的精确位置对于保持效力是非常重要的,2'-O-甲基RNA对RNA的完全取代将使siRNA失活。例如,应用交替的2'-O-甲基碱基的模式可具有等同于未修饰RNA的效力并且在血清中相当稳定(Choung等人,2006,BiochemBiophysResCommun342:919-927;Czauderna等人,2003,NucleicAcidsResearch31:2705-2716)。
2'-氟(2'-F)修饰也与dsRNA(例如,siRNA和DsiRNA)功能相容;其最常见地被置于嘧啶位点(因试剂成本和可用度的原因)并且可在嘌呤位置上与2'-O-甲基修饰组合;2'-F嘌呤是可获得的,并且也可被使用。该类型的高度修饰的双链体可以是RNAi的体外强效触发剂(Allerson等人,2005,JMedChem48:901-904;Prakash等人,2005,JMedChem48:4247-4253;Kraynack和Baker,2006,RNA12:163-176),并且可改善性能,当在体内使用时延长作用持续时间(Morrissey等人,2005,Hepatology41:1349-1356;Morrissey等人,2005,NatBiotechnol23:1002-1007)。含有交替的2'-F和2'-O-Me碱基的高度强效的核酸酶稳定的平端19mer双链体由Allerson教导。在该设计中,以与由Czauderna使用的模式相同的模式定位交替的2'-O-Me残基,然而剩余的RNA残基被转换成2'-F修饰的碱基。由Morrissey使用的高度强效的抗核酸酶siRNA使用在体内高度强效的抗核酸酶siRNA。除了2'-O-MeRNA和2'-FRNA以外,该双链体还包括DNA、RNA、倒置的无碱基残基和3′末端PS核苷间键。虽然广泛的修饰具有一定益处,但双链体的更有限的修饰还可改善体内性能,并且对于制造来说更加简单以及成本更低。Soutschek等人,(2004,Nature432:173-178)在体内使用双链体,并且主要是具有2个2'-O-MeRNA碱基和有限的3′末端PS核苷间键的RNA。
锁核酸(LNA)是可用于稳定dsRNA(例如,siRNA和DsiRNA)的不同种类的2'修饰。保持效力的LNA掺入的模式比2'-O-甲基或2'-F碱基更受限制,因此有限的修饰是优选的(Braasch等人,2003,Biochemistry42:7967-7975;Grunweller等人,2003,NucleicAcidsRes31:3185-3193;Elmen等人,2005,NucleicAcidsRes33:439-447)。即使具有有限的掺入,LNA修饰的使用仍可在体内改善dsRNA的性能,并且还可改变或改善脱靶效应特征(Mook等人,2007,MolCancerTher6:833-843)。
被引入细胞或活动物的合成核酸可被识别为“外来物”并且触发免疫反应。免疫刺激构成一大类可显著改变实验结果,甚至导致细胞死亡的脱靶效应。先天免疫系统包括与介导这些反应的DNA和RNA特异性相互作用的受体分子的集合,其中一些受体位于细胞质中,其中一些受体存在于内体中(Marques和Williams,2005,NatBiotechnol23:1399-1405;Schlee等人,2006,MolTher14:463-470)。通过阳离子脂质或脂质体进行的siRNA的递送使siRNA暴露于细胞质和内体区室,从而使在体外和体内触发1型干扰素(IFN)反应的风险最大化(Morrissey等人,2005,NatBiotechnol23:1002-1007;Sioud和Sorensen,2003,BiochemBiophysResCommun312:1220-1225;Sioud,2005,JMolBiol348:1079-1090;Ma等人,2005,BiochemBiophysResCommun330:755-759)。在细胞内转录的RNA具有较低的免疫原性(Robbins等人,2006,NatBiotechnol24:566-571),当使用基于脂质的方法递送时具有免疫原性的合成RNA,当通过机械方式引入细胞,甚体内时,可逃避免疫刺激(Heidel等人,2004,NatBiotechnol22:1579-1582)。然而,基于脂质的递送法是方便有效的,并且被广泛使用。需要一些防止免疫反应的一般策略,尤其是对于其中所有细胞类型存在并且产生免疫反应的风险最高的体内应用。化学修饰的RNA的使用可解决大部分或甚至所有这些问题。
在某些实施方案中,可在本发明的抗-CKAP5dsRNA试剂中包含修饰,只要修饰不妨碍dsRNA试剂具有CKAP5抑制活性。在一个实施方案中,可产生一个或多个修饰,所述修饰增强DsiRNA试剂的切丁酶加工(用于测定DsiRNA的切丁酶加工的测定在本文中的其它地方进行了描述)。在第二实施方案中,产生一个或多个修饰,所述修饰导致更有效的CKAP5抑制(如本文中描述的,可通过本领域公认的用于测定RNA水平的或用于测定CKAP5多肽水平的方法测定dsRNA的CKAP5抑制/CKAP5抑制活性,应当替代例如CKAP5mRNA水平而评估这样的水平,或除了评估CKAP5mRNA水平以外,还评估这样的水平)。在第三实施方案中,产生一个或多个修饰,所述修饰支持更强的CKAP5抑制活性(测定CKAP5抑制活性的方法描述于上文中)。在第四实施方案中,产生一个或多个修饰,所述修饰导致更大效力的CKAP5抑制活性每每一种待递送至细胞的dsRNA试剂分子(CKAP5抑制活性的效力描述于上文中)。可将修饰掺入3′末端区域、5'末端区域、3′末端区域和5'末端区域或在一些情况下序列内的不同位置。将上文中指出的限制熟记于心,可将修饰的数目和组合掺入dsRNA试剂。当存在多个修饰时,它们可以相同或不同。设想了对碱基、糖部分、磷酸主链及其组合的修饰。可对任一5'末端进行磷酸化。
被考虑用于磷酸主链的修饰的实例包括磷酸酯,包括甲基磷酸酯、硫代磷酸酯和磷酸三酯修饰诸如烷基磷酸三酯等。被考虑用于糖部分的修饰的实例包括2'-烷基嘧啶诸如2'-O-甲基、2'-氟、氨基和脱氧修饰等(参见,例如,Amarzguioui等人,2003,NucleicAcidsResearch31:589-595)。被考虑用于碱基基团的修饰的实例包括无碱基糖、2-O-烷基修饰的嘧啶、4-硫尿嘧啶、5-溴尿嘧啶、5-碘尿嘧啶和5-(3-氨基烯丙基)-尿嘧啶等。还可掺入锁核酸或LNA。许多其它修饰是已知的并且可被使用,只要满足上述标准。修饰的实例也公开于美国专利No.5,684,143、5,858,988和6,291,438中,以及美国公开专利申请No.2004/0203145A1中。其它修饰公开于Herdewijn(2000,AntisenseNucleicAcidDrugDev10:297-310)、Eckstein(2000,AntisenseNucleicAcidDrugDev10:117-21)、Rusckowski等人,(2000,AntisenseNucleicAcidDrugDev10:333-345)、Stein等人,(2001,AntisenseNucleicAcidDrugDev11:317-25);Vorobjev等人,(2001,AntisenseNucleicAcidDrugDev11:77-85)中。
可将被考虑的一个或多个修饰掺入任一条链。将修饰置于dsRNA试剂中可极大地影响所述dsRNA试剂的特征,包括赋予更大的效力和稳定性,降低毒性,增强切丁酶加工,以及使免疫反应降至最低。在一个实施方案中,反义链或有义链或两条链具有一个或多个2'-O-甲基修饰的核苷酸。在另一个实施方案中,反义链含有2'-O-甲基修饰的核苷酸。在另一个实施方案中,反义链含有由2'-O-甲基修饰的核苷酸组成的3′悬突。反义链还可包含额外的2'-O-甲基修饰的核苷酸。
在某些实施方案中,本发明的抗-CKAP5DsiRNA试剂具有几个增强其被切丁酶加工的性质。根据这样的实施方案,DsiRNA试剂具有充足的长度,以便其被切丁酶加工以产生siRNA和下列性质的至少一个性质:(i)所述DsiRNA试剂是不对称的,例如,在有义链上具有3′悬突,和(ii)所述DsiRNA试剂在反义链上具有指导切丁酶结合dsRNA并将其加工成活性siRNA的方向的修饰的3′末端。根据这些实施方案,DsiRNA试剂中最长的链包含25-30个核苷酸。在一个实施方案中,有义链包含25-30个核苷酸,并且反义链包含25-28个核苷酸。因此,所得的dsRNA在有义链的3′末端上具有悬突。悬突为1-4个核苷酸,诸如2个核苷酸。反义链也可具有5'磷酸。
在某些实施方案中,DsiRNA试剂的有义链被位于有义链的3′末端上的适当的修饰剂修饰以用于进行切丁酶加工,即,DsiRNA试剂被设计来指导切丁酶结合和加工的方向。适当的修饰剂包括核苷酸诸如脱氧核糖核苷酸、二脱氧核糖核苷酸、无环核苷酸等,以及空间位阻分子,诸如荧光分子等。无环核苷酸用2-羟基乙氧基甲基基团替代通常存在于dNMP中的2'-脱氧呋喃核糖苷。其它核苷酸修饰剂可包括3′-脱氧腺苷(虫草素)、3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-双脱氧肌苷(ddI)、2',3′-二脱氧-3′-硫代胞苷(3TC)、2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)以及3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-二脱氧-3′-硫代胞苷(3TC)和2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)的单磷酸核苷酸。在一个实施方案中,脱氧核苷酸用作修饰剂。当使用核苷酸修饰剂时,1-3个核苷酸修饰剂或2个核苷酸修饰剂替代有义链的3′末端上的核糖核苷酸。当使用空间位阻分子时,将它们附接于反义链的3′末端上的核糖核苷酸。因此,链的长度不随修饰剂的掺入而改变。在另一个实施方案中,本发明考虑替代dsRNA中的两个DNA碱基以指导切丁酶加工的方向。在其它发明中,两个末端DNA碱基位于有义链的3′末端,替代了在反义链的5'末端和有义链的3′末端上形成双链体的平端的2个核糖核苷酸,并且二核苷酸RNA悬突位于反义链的3′末端。这是在平端上具有DNA并且在悬突末端具有RNA碱基的不对称组合物。
在某些其它实施方案中,DsiRNA试剂的反义链被位于反义链的3′末端上的适当的修饰剂修饰以用于进行切丁酶加工,即,DsiRNA试剂被设计来指导切丁酶结合和加工的方向。适当的修饰剂包括核苷酸诸如脱氧核糖核苷酸、二脱氧核糖核苷酸、无环核苷酸等,以及空间位阻分子,诸如荧光分子等。无环核苷酸用2-羟基乙氧基甲基基团替代通常存在于dNMP中的2'-脱氧呋喃核糖苷。其它核苷酸修饰剂可包括3′-脱氧腺苷(虫草素)、3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-双脱氧肌苷(ddI)、2',3′-二脱氧-3′-硫代胞苷(3TC)、2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)以及3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-二脱氧-3′-硫代胞苷(3TC)和2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)的单磷酸核苷酸。在一个实施方案中,脱氧核苷酸用作修饰剂。当使用核苷酸修饰剂时,1-3个核苷酸修饰剂或2个核苷酸修饰剂替代反义链的3′末端上的核糖核苷酸。当使用空间位阻分子时,将它们附接于反义链的3′末端上的核糖核苷酸。因此,链的长度不随修饰剂的掺入而改变。在另一个实施方案中,本发明考虑替代dsRNA中的两个DNA碱基以指导切丁酶加工的方向。在其它发明中,两个末端DNA碱基位于反义链的3′末端,替代了在有义链的5'末端和反义链的3′末端上形成双链体的平端的2个核糖核苷酸,并且二核苷酸RNA悬突位于反义链的3′末端。这是在平端上具有DNA并且在悬突末端具有RNA碱基的不对称组合物。
有义链与反义链在生物条件,诸如存在于细胞的细胞质中的条件下退火。此外,序列,特别地dsRNA的反义链的序列之一的区域具有长度为至少19个核苷酸的序列,其中这些核苷酸与反义链的3′末端相邻,并且与靶CKAP5RNA的核苷酸序列充分互补。
此外,可优化DsiRNA试剂结构,以确保从切丁酶的切割产生的寡核苷酸区段可为在抑制基因表达中最有效的寡核苷酸的部分。例如,在本发明的一个实施方案中,合成27-bp寡核苷酸的DsiRNA试剂结构,其中可抑制基因表达的预期的21至22-bp的区段位于反义链的3′末端。位于反义链的5'末端的其余碱基将被切丁酶切割并将被弃去。该切割的部分可以是同源的(即,基于靶序列的序列)或非同源的,并且被添加来延伸核酸链。
US2007/0265220公开了,27merDsiRNA在血清中显示优于可比较的21mersiRNA组合物的增强的稳定性,即使在化学修饰不存在的情况下亦如此。DsiRNA试剂的修饰(诸如以诸如上述模式在反义链中包含2'-O-甲基RNA),当与5′磷酸的添加偶联时,可增强DsiRNA试剂的稳定性。5'磷酸至合成RNA双链体的所有链的添加可以是提供一定有限程度的核酸酶稳定性的廉价生理学方法。
本发明的dsRNA试剂的化学修饰模式被设计来增强这样的试剂的效率。因此,这样的修饰被设计来避免降低dsRNA试剂的效力;避免干扰DsiRNA试剂的切丁酶加工;增强dsRNA试剂在生物液体中的稳定性(减小核酸酶敏感性);或阻断或逃避先天免疫系统的检测。这样的修饰还被设计来避免具有毒性和避免增加生产本发明的即时dsRNA试剂的成本或影响所述生产的容易性。
在本发明的某些实施方案中,抗-CKAP5DsiRNA试剂具有以下性质的一个或多个性质:(i)所述DsiRNA试剂是不对称的,例如,在反义链上具有3′悬突,和(ii)所述DsiRNA试剂在有义链上具有指导切丁酶结合dsRNA并将其加工成活性siRNA的方向的3′末端。根据该实施方案,dsRNA中最长的链包含25-35个核苷酸(例如,25、26、27、28、29、30、31、32、33、34或35个核苷酸)。在某些这样的实施方案中,DsiRNA试剂是不对称的,以便有义链包含25-34个核苷酸并且有义链的3′末端与反义链的5′末端形成平端,而反义链包含26-35个核苷酸并在反义链的3′末端上形成悬突。在一个实施方案中,DsiRNA试剂是不对称的,以便有义链包含25-28个核苷酸并且反义链包含25-30个核苷酸。因此,所得的dsRNA在反义链的3′末端具有悬突。所述悬突为1-4个核苷酸,例如2个核苷酸。有义链还可具有5'磷酸。
DsiRNA试剂还可具有下列额外性质的一个或多个性质:(a)反义链具有从典型的21mer的右迁移(例如,DsiRNA包含一段延伸至DsiRNA内的预测的切丁酶切割位点的5′的反义链核苷酸,这样的反义链核苷酸与有义链的对应核苷酸碱基配对,从而延伸有义链中的预测的切丁酶切割位点的3′),(b)所述链可以不是完全互补的,即,所述链可含有简单的错配碱基对(在某些实施方案中,本发明的DsiRNA具有1、2、3、4或甚至5或更多个错配碱基对,只要具有错配碱基对的DsiRNA的CKAP5抑制活性以充足的水平得以保持(例如,相较于不具有错配碱基对的对应的DsiRNA保持至少50%的CKAP5抑制活性或更多、至少60%的CKAP5抑制活性更多、至少70%的CKAP5抑制活性更多、至少80%的CKAP5抑制活性更多、至少90%的CKAP5抑制活性更多或至少95%的CKAP5抑制活性或更多。在某些实施方案中,错配碱基对存在于DsiRNA的反义链与有义链之间。在一些实施方案中,错配碱基对存在(或经预测存在)于反义链与靶RNA之间。在某些实施方案中,反义链残基与靶RNA内的对应残基(位于预测的Ago2切割位点的靶RNA序列的3′)之间的错配碱基对的存在保持本发明的DsiRNA的CKAP5抑制活性,甚至可增强所述CKAP5抑制活性活性),和(c)可在有义链的5'末端中包含碱基修饰诸如锁核酸。使用常规技术来设计“典型的”21mersiRNA。在一个技术中,通常平行地或在含有数种不同的对于相同靶是特异性的siRNA双链体的混合物中测试各种位点,希望试剂的一种会是有效的(Ji等人,2003,FEBSLett552:247-252)。其它技术使用设计规则和算法来增加获得活性RNAi效应分子的概率(Schwarz等人,2003,Cell115:199-208;Khvorova等人,2003,Cell115:209-216;Ui-Tei等人,2004,NucleicAcidsRes32:936-948;Reynolds等人,2004,NatBiotechnol22:326-330;Krol等人,2004,JBiolChem279:42230-42239;Yuan等人,2004,NuclAcidsRes32(网络服用器发布):W130-134;Boese等人,2005,MethodsEnzymol392:73-96)。siRNA的高通量选择也已被开发(美国公开专利申请No.2005/0042641A1)。潜在的靶位点还可通过二级结构预测来分析(Heale等人,2005,NucleicAcidsRes33(3):e30)。随后将该21mer用于设计右迁移以在21mer的5'端上包含3-9个额外核苷酸。这些额外的核苷酸的序列不受限制。在一个实施方案中,添加的核糖核苷酸基于靶基因的序列。即使在该实施方案中,靶序列与反义siRNA之间的完全互补性是不需要的。
本发明的DsiRNA试剂的第一和第二寡核苷酸不是完全互补所需的。它们仅需充分互补以在生物条件下退火,以及提供产生与靶序列充分互补的siRNA的切丁酶的底物。锁核酸或LNA对于本领域普通技术人员来说是公知的(Elmen等人,2005,NucleicAcidsRes33:439-447;Kurreck等人,2002,NucleicAcidsRes30:1911-1918;Crinelli等人,2002,NucleicAcidsRes30:2435-2443;Braasch和Corey,2001,ChemBiol8:1-7;Bondensgaard等人,2000,Chemistry6:2687-2695;Wahlestedt等人,2000,ProcNatlAcadSciUSA97:5633-5638)。在一个实施方案中,在有义链的5'末端掺入LNA。在另一个实施方案中,在被设计来在反义链上包含3′悬突的双链体中的有义链的5'末端上掺入LNA。
在某些实施方案中,本发明的DsiRNA试剂具有不对称的结构,有义链具有25-碱基对长度,反义链具有拥有2碱基3′悬突的27-碱基对长度。在其它实施方案中,具有不对称结构的该DsiRNA试剂还在有义链的3′末端上含有2个脱氧核苷酸,替代2个核糖核苷酸。
某些含有两个分开的寡核苷酸的DsiRNA试剂组合物可通过第三结构连接。所述第三结构不会阻断DsiRNA试剂上的切丁酶活性,并且不会干扰从靶基因转录的RNA的直接破坏。在一个实施方案中,第三结构可以是化学连接基团。许多适当的化学连接基团在本领域中是已知的,并且可被使用。或者,第三结构可以是以使发夹结构在组成dsRNA组合物的两个寡核苷酸退火后产生的方式连接DsiRNA试剂的两个寡核苷酸的多核苷酸。发夹结构不会阻断DsiRNA试剂上的切丁酶活性,并且不会干扰CKAP5RNA的直接破坏。
CKAP5cDNA和多肽序列
已知的人和小鼠CKAP5cDNA和多肽序列包括下列序列:人CKAP5转录物变体1(NM_001008938.3)和2(NM_014756.3);对应的人CKAP5多肽序列GenBank登录号NP_001008938.1(转录物变体1)和NP_055571.2(转录物变体2);小鼠野生型CKAP5序列GenBank登录号NM_001165989.1(小家鼠C57BL/6CKAP5转录物)和对应的小鼠CKAP5多肽序列GenBank登录号NP_001159461.1。
评估dsRNACKAP5抑制活性的体外测定
在无细胞系统中概括RNAi的体外测定可用于评价靶向CKAP5RNA序列的dsRNA构建体,从而可用于评估dsRNA的CKAP5特异性基因抑制活性(在本文中也称为CKAP5抑制活性)。所述测定包含由Tuschl等人,1999,GenesandDevelopment,13,3191-3197和Zamore等人,2000,Cell,101,25-33描述的适用于与针对CKAP5RNA的dsRNA(例如,DsiRNA)试剂一起使用的系统。从合胞体胚层衍生的果蝇提取物被用于体外重构RNAi活性。靶RNA通过使用T7RNA聚合酶从选择的CKAP5表达质粒体外转录或通过化学合成来产生。通过在90℃于缓冲液(诸如100mM醋酸钾,30mM的HEPES-KOH,pH7.4,2mM醋酸镁)中孵育1分钟,随后在37℃孵育1小时来使有义和反义dsRNA链(例如,各自20uM)退火,随后在裂解缓冲液(例如100mM醋酸钾,30mMHEPES-KOH,pH7.4,2mM醋酸镁)中进行稀释。退火可通过在琼脂糖凝胶上于TBE缓冲液中凝胶电泳,并用溴化乙锭进行染色来监测。使用来自在酵母菌糖蜜琼脂上收集的OregonR果蝇的被除去卵膜和裂解的0至2小时龄胚胎来制备果蝇裂解物。将裂解物离心,分离上清液。所述测定包含含有50%裂解物[体积/体积]、RNA(10-50pM的终浓度)和10%[体积/体积]含有dsRNA的裂解缓冲液(10nM的终浓度)的反应混合物。所述反应混合物还含有10mM肌酸磷酸盐、10ug/ml肌酸磷酸激酶、100umGTP、100uMUTP、100uMCTP、500uMATP、5mMDTT、0.1U/uLRNasin(Promega)和100uM的每一种氨基酸。将醋酸钾的终浓度调节至100mM。将所述反应在冰上预先装配,在添加RNA之前在25℃预孵育10分钟,随后在25℃再孵育另外60分钟。用4倍体积的1.25xPassive裂解缓冲液(Promega)淬灭反应。通过RT-PCR分析或本领域中已知的其它方法来测定靶RNA切割,并将其与其中从反应物中省去dsRNA的对照反应相比较。
或者,通过在[α-32P]CTP存在的情况下,通过体外转录制备用于测定的内部标记的靶RNA,将旋转层析将其在G50Sephadex柱上通过,随后用作靶RNA而无需进一步纯化。任选地,使用T4多核苷酸激酶对靶RNA进行5'-32P-末端标记。如上所述进行测定,在凝胶的放射自显影照片上显现靶RNA和通过RNAi生成的特定RNA切割产物。通过代表完整对照RNA或来自无dsRNA的对照反应的RNA和通过测定生成的切割产物的条带的PHOSPHOR(放射自显影术)定量测定切割的百分比。
在一个实施方案中,该测定用于测定CKAP5RNA靶中用于dsRNA介导的RNAi切割的靶位点,其中例如通过分析测定反应(通过标记的靶RNA的电泳或通过northern印迹,以及通过本领域中公知的其它方法)来筛选多个dsRNA构建体的RNAi介导的CKAP5RNA靶的切割。
在某些实施方案中,如果例如相对于适当的对照在系统、细胞、组织或生物体中观察到CKAP5RNA水平的50%降低,则本发明的dsRNA被认为具有CKAP5抑制活性。在上文中描述了用于测定本发明的dsRNA的CKAP5抑制活性的另外的界限。
抗-CKAP5dsRNA试剂的缀合和递送
在某些实施方案中,本发明涉及用于治疗患有CKAP5相关疾病或病症或处于发展CKAP5相关疾病或病症的风险中的受试者的方法。在这样的实施方案中,dsRNA可用作用于控制CKAP5相关疾病或病症的新型治疗剂。所述方法包括向患者(例如,人)施用本发明的药物组合物,使得CKAP5RNA的表达、水平和/或活性降低。由CKAP5RNA编码的多肽的表达水平和/或活性还可通过本发明的dsRNA来降低,甚至在所述dsRNA针对CKAP5转录物的非编码区(例如,被靶向的5′UTR或3′UTR序列)的情况下亦如此。由于它们的高度特异性,因此本发明的dsRNA可特异性靶向细胞和组织的CKAP5序列,任选地当多态型等位基因存在于个体和/或群体中时以等位基因特异性的方式进行靶向。
在CKAP5相关疾病或病症的治疗中,可将dsRNA与受试者的细胞或组织,例如展现CKAP5的失调和/或另外地被靶向以降低CKAP5水平的受试者的细胞或组织接触。例如,可将大体上与全部或部分CKAP5RNA序列相同的dsRNA在体内或体内与这样的细胞接触或引入所述细胞。类似地,可向患有CKAP5相关疾病或病症或处于发展CKAP5相关疾病或病症的风险中的受试者直接施用与全部或部分CKAP5RNA序列大体上相同的dsRNA。
本发明的dsRNA试剂的治疗性使用可包括包含多种不同dsRNA试剂序列的dsRNA试剂的制剂的使用。例如,可将2种或更多种、3种或更多种、4种或更多种、5种或更多种等的目前描述的试剂组合以产生这样的制剂,所述制剂例如靶向CKAP5RNA的多个不同区域,或不仅靶向CKAP5RNA而且还靶向例如与CKAP5相关疾病或病症相关的细胞靶基因。还可构建本发明的dsRNA试剂,使得dsRNA试剂的任一条链可独立地靶向CKAP5RNA的两个或更多个区域,或使得dsRNA试剂的一条链靶向本领域中已知的CKAP5的细胞靶基因。
靶向靶核酸分子的多于一个区域的多功能dsRNA分子的使用还可提供CKAP5RNA水平和表达的强效抑制。例如,本发明的单个多功能dsRNA构建体可同时靶向CKAP5-604和CKAP5-853位点;此外和/或可选择地,本发明的单功能或多功能试剂可被设计来选择性靶向CKAP5的一种剪接变体而非另一种剪接变体。
因此,可将本发明的dsRNA试剂单独地或与其它药物组合或联合地用于治疗、抑制、减轻或预防CKAP5相关疾病或病症。例如,在适合于治疗的条件下可向受试者或可向对于本领域普通技术人员来说显而易见的其它适当的细胞单独地或与一种或多种药物组合地施用述dsRNA分子。
还可将dsRNA分子与其它已知的治疗组合用于治疗、抑制、减轻或预防受试者或生物体的CKAP5相关疾病或病症。例如,可将所述分子与一种或多种已知的化合物、治疗或方法组合以治疗、抑制、减轻或预防本领域中是已知的受试者或生物体的CKAP5相关疾病或病症。
可将本发明的dsRNA试剂与另一个部分(例如非核酸部分诸如肽)、有机化合物质(例如,染料、胆固醇等)缀合(例如,在其有义或反义链的5′或3′)或不缀合。以该方式修饰dsRNA试剂可改善细胞吸收或相较于对应的未缀合的dsRNA试剂增强所得的dsRNA试剂衍生物的细胞靶向活性,用于追踪细胞中的dsRNA试剂衍生物或相较于对应的未缀合的dsRNA试剂改善dsRNA试剂衍生物的稳定性。
引入核酸、载体和宿主细胞的方法
可将本发明的dsRNA试剂直接引入细胞(即,细胞内地);或细胞外地引入腔、间质间隙,引入生物体的循环,口服引入,或可通过将细胞或生物体在含有所述核酸的溶液中浸浴来引入。血管或血管外循环、血液或淋巴系统以及脑脊髓液是可将核酸引入其中的部位。
可使用本领域已知的核酸递送法引入本发明的dsRNA试剂,所述方法包括含有核酸的溶液的注射、利用涂覆有核酸的颗粒的微粒轰击、在所述核酸的溶液中浸泡细胞或生物体,或在核酸存在的情况下进行的细胞膜的电穿孔。可使用本领域中已知的用于将核酸引入细胞的其它方法,诸如脂质介导的载体转运、化学制品介导的转运和阳离子脂质体转染诸如磷酸钙等。可将核酸与进行下列活性的一个或多个活性的其它组分一起引入:增强细胞对核酸的吸收或另外地增强靶CKAP5RNA的抑制。
具有靶CKAP5RNA的细胞可来自种系细胞或体细胞、全能细胞或多能细胞、正在分裂的细胞或非分裂的细胞、实质细胞或上皮细胞、永生化细胞或转化细胞等。细胞可以是干细胞或分化细胞。分化的细胞类型包括脂肪细胞、成纤维细胞、肌细胞、心肌细胞、内皮细胞、神经细胞、神经胶质细胞、血细胞、巨核细胞、淋巴细胞、巨噬细胞、中性粒细胞、嗜酸性粒细胞、嗜碱性粒细胞、肥大细胞、白细胞、粒细胞、角化细胞、软骨细胞、成骨细胞、破骨细胞、肝细胞和内分泌或外分泌腺的细胞。
取决于特定靶CKAP5RNA序列和递送的dsRNA试剂材料的剂量,该方法可为CKAP5RNA提供功能的部分或完全丧失。至少50%、60%、70%、80%、90%、95%或99%或更多的靶细胞中的RNA水平或表达(CKAP5RNA的表达或编码的多肽的表达)的降低或丧失是示例性的。CKAP5RNA水平或表达的抑制是指CKAP5RNA或CKAP5RNA编码的蛋白质的水平的不存在(或可观察的降低)。特异性是指抑制CKAP5RNA而不表现对细胞的其它基因的影响的能力。抑制的结果可通过细胞或生物体的外向性质的研究或通过生物化学技术诸如RNA溶液杂交、核酸酶保护、Northern杂交、反转录、利用微阵列的基因表达监测、抗体结合、酶联免疫吸附测定(ELISA)、Western印迹、放射免疫测定(RIA)、其它免疫测定和荧光激活细胞分析(FACS)来确认。本发明的dsRNA试剂对靶CKAP5RNA序列的抑制也可基于这样的dsRNA试剂的施用在体内或体外对CKAP5相关疾病或病症的发展/进展(例如肿瘤形成、生长、转移等)的影响来测量。治疗和/或肿瘤或癌症细胞水平的降低可包括肿瘤的生长或癌细胞水平的停止或降低,或例如10%、20%、30%、40%、50%、60%、70%、80%、90%、95%或99%或更多的降低,并且还可以对数项来测量,例如,癌细胞水平的10倍、100倍、1000倍、105倍、106倍、107倍降低可通过向细胞、组织或受试者施用本发骨的dsRNA试剂来实现。
对于细胞系或整个生物体中的RNA介导的抑制,可测量其蛋白质产物容易被测定的受体或抗药基因的表达。这样的报告基因包括乙酰羟酸合酶(AHAS)、碱性磷酸酶(AP)、β-半乳糖苷酶(LacZ)、β-葡萄糖苷酸(GUS)、氯霉素乙酰转移酶(CAT)、绿色荧光蛋白(GFP)、辣根过氧化物酶(HRP)、荧光素酶(Luc)、胭脂碱合酶(NOS)、章鱼碱合酶(OCS)及其衍生物。赋予对氨苄青霉素、博来霉素、氯霉素、庆大霉素、潮霉素、卡那霉素、林可霉素、甲氨蝶呤、草丁膦、嘌呤霉素和四环素的多个可选择标记是可获得的。取决于测定,基因表达的量的定量允许测定相较于未按照本发明处理的细胞大于10%、33%、50%、90%、95%或99%的抑制程度。
更低剂量注射材料和施用RNA沉默剂后更长的时间可在更小部分的细胞(例如,至少10%、20%、50%、75%、90%或95%的被靶向的细胞)中导致抑制。细胞中基因表达的定量可在靶CKAP5RNA的积累或靶蛋白的翻译的水平上显示相似量的抑制。作为实例,抑制的效率可通过评估细胞中基因产物的量来测定;RNA可利用具有用于抑制性dsRNA的区域外的核苷酸序列的杂交探针来检测,或翻译的多肽可利用针对该区域的多肽序列产生的抗体来检测。
可以以允许每细胞至少一个拷贝的递送的量引入dsRNA试剂。更高剂量(例如,至少5、10、100、500或1000个拷贝/细胞)的材料可产生更有效的抑制;更低的剂量也可用于特殊应用。
CKAP5生物学和CKAP5-靶向治疗剂
CKAP5是在人中由CKAP5基因编码的微管相关蛋白(Nagase等人,DNARes.2:37–43;Charrasse等人EurJBiochem234:406–13;"EntrezGene:CKAP5cytoskeletonassociatedprotein5")。CKAP5也被称为ch-TOG,并且非洲爪蟾CKAP5同源物为XMAP215(Cassimeris和Morabito.MolecularBiologyoftheCell15:1580–1590)。
CKAP5蛋白在纺锤体形成中起着至少两种不同的作用:其保护动粒微管免于被MCAK(KIF2C)解聚,同时CKAP5蛋白还在中心体微管装配中起着必需的作用(一种不依赖于MCAK活性的功能)(Barr和Gergely.MolecularandCellularBiology28:7199–7211)。还已显示其与TACC1相互作用,所述TACC1是候选乳腺癌基因(Conte等人Oncogene22:8102–16;Lauffart等人Biochem.J.363:195–200;"EntrezGene:TACC1transforming,acidiccoiled-coilcontainingprotein1")。
可将本发明的CKAP5抑制性双链核酸单独使用,或与任何本领域公认的CKAP5-靶向治疗剂组合使用。
药物组合物
在某些实施方案中,本发明提供了包含本发明的dsRNA试剂的药物组合物。可适当地配制dsRNA试剂样,通过允许充足部分的样品进入细胞以诱导基因沉默(如果其将发生的话)的任何方法将其引入细胞的环境。用于dsRNA的许多制剂在本领域中是已知的,并且可被使用,只要dsRNA获得进入靶细胞,以便其可起作用。参见,例如,美国公开专利申请No.2004/0203145A1和2005/0054598A1。例如,可在缓冲液诸如磷酸缓冲盐溶液、脂质体、胶束结构和衣壳中配制本发明的dsRNA试剂。利用阳离子脂质的dsRNA试剂的配制可用于促进dsRNA试剂至细胞内的转染。例如,可使用阳离脂质诸如lipofectin(美国专利No.5,705,188)、阳离子甘油衍生物和多聚阳离子分子诸如多聚赖氨酸(公开的PCT国际申请WO97/30731)。适当的脂质包括Oligofectamine、Lipofectamine(LifeTechnologies)、NC388(RibozymePharmaceuticals,Inc.,Boulder,Colo.)或FuGene6(Roche),其全部可按照制造商的说明书来进行使用。
这样的组合物通常包括核酸分子和药学上可接受的载体。如本文中所用,专门用语“药学上可接受的载体”包括与药物施用相容的盐水、溶液、分散介质、包衣、抗菌剂和抗真菌剂、等渗剂和吸收延迟剂等。还可将补充活性化合物掺入组合物。
配制药物组合物以与其期望的施用途径相容。施用途径的实例包括胃肠外,例如,静脉内、真皮内、皮下、口服(例如,吸入),经皮(局部)、经粘膜和直肠施用。用于肠胃外、真皮内或皮下施用的溶液或悬浮液可包括下列组分:无菌稀释剂诸如注射用水、盐水溶液、不挥发油、聚乙二醇、甘油、丙二醇或其它合成溶剂;抗菌剂诸如苯甲醇或对羟基苯甲酸甲酯;抗氧化剂诸如抗坏血酸或亚硫酸氢钠;螯合剂诸如乙二胺四乙酸;缓冲剂诸如醋酸盐、柠檬酸盐或磷酸盐和用于渗透压的调节的试剂诸如氯化钠或葡萄糖。pH可用酸或碱,诸如盐酸或氢氧化钠来调节。可将胃肠外制剂封装在安瓿、一次性注射器或由玻璃或塑料制成的多剂量小瓶中。
适用于注射的药物组合物包括无菌水溶液(当为水溶性时)或分散体和用于无菌可注射液或分散体的临时配制的无菌粉剂。对于静脉内施用,适当的载体包括生理盐水、抑菌水、CremophorEL.TM.(BASF,Parsippany,N.J.)或磷酸盐缓冲盐水(PBS)。在所有情况下,组合物必须是无菌的并且应当是流体以达到容易注射的程度。其在制造和贮存的条件下应当是稳定的,并且必须预防微生物诸如细菌和真菌的污染作用。载体可以是含有例如水、乙醇、多元醇(例如,甘油、丙二醇和液体聚乙醇等)及其适当的混合物的溶剂或分散介质。可以例如通过使用包衣诸如卵磷脂,通过维持所需粒度(在分散体的情况下)和通过使用表面活性剂维持恰当的流动性。微生物作用的预防可通过各种抗菌和抗真菌试剂例如对羟基苯甲酸酯、氯丁醇、苯酚、抗坏血酸、硫柳汞等来实现。在许多情况下,其优选在组合物中包含等渗剂,例如糖、多元醇诸如甘露醇、山梨醇、氯化钠。可注射组合物的延长吸收可通过在组合物中包含延迟吸收的试剂例如单硬脂酸铝和明胶来实现。
无菌可注射溶液可通过以所需量将活性化合物与上文中列举的成分的一种或组合(按需要)掺入选择的溶剂,随后通过过滤灭菌来制备。通常地,通过将活性化合物掺入无菌媒介物来制备分散体,所述分散体含有基本分散介质和来自上文中列举的成份的所需其它成分。在用于制备无菌可注射溶液的无菌粉剂的情况下,制备的优选方法是真空干燥和冷冻干燥,这产生活性成分加来自其先前无菌过滤的溶液的任何另外的所需成分。
口服组合物通常包括惰性稀释剂和可食用载体。为了口服治疗施用,可将赋形剂掺入活性化合物,并以片剂、锭剂或胶囊例如明胶胶囊的形式使用。还可使用液体载体用作漱口水来制备口服组合物。可包含在药学上相容的粘合剂和/或佐剂材料作为组合物的部分。片剂、丸剂、胶囊、锭剂等可含有下列具有相似性质的成分或化合物的任一种:粘合剂诸如微晶纤维素、黄蓍胶或明胶;赋形剂诸如淀粉或乳糖、崩解剂诸如海藻酸、Primogel或玉米淀粉;润滑剂诸如硬脂酸镁或Sterotes;助流剂诸如胶体二氧化硅;甜味剂诸如蔗糖或糖精;或调味剂诸如薄荷、水杨酸甲酯或橙调味剂。
对于通过吸入的施用,以气溶胶喷雾剂的形式从含有适当的助推剂例如气体诸如二氧化碳的加压容器或分配器,或喷雾器递送组合物。这样的方法包括美国专利No.6,468,798中描述的那些方法。
全身性施用还可通过经粘膜或经皮方式来进行。对于经粘膜或经皮施用,在配制中使用适合于待渗透的屏障的穿透剂。这样的穿透剂在本领域中是公知的,包括例如,对于经粘膜施用,去垢剂、胆汁酸盐和夫西地酸衍生物。经粘膜施用可通过使用鼻喷雾剂或栓剂来实现。对于经皮施用,将活性化合物配制成本领域中通常已知的软膏剂、油膏剂、凝胶或乳膏剂。
还可以以栓剂(例如,利用常规栓剂基质诸如可可脂和其它甘油酯类)或用于直肠递送的保留灌肠剂的形式来制备化合物。
还可使用本领域中已知的方法通过转染或感染施用所述化合物,所述方法包括但不限于McCaffrey等人,(2002),Nature,418(6893),38-9(hydrodynamictransfection);Xia等人,(2002),NatureBiotechnol.,20(10),1006-10(viral-mediateddelivery);或Putnam(1996),Am.J.HealthSyst.Pharm.53(2),151-160,erratumatAm.J.HealthSyst.Pharm.53(3),325(1996)中描述的方法。
所述化合物还可通过适合于施用核酸试剂诸如DNA疫苗的方法来施用。这些方法包括基因枪、生物注射器和皮肤贴剂以及无针法诸如美国专利No.6,194,389中公开的微粒DNA疫苗技术,和美国专利No.6,168,587中公开的利用粉末形式疫苗的哺乳动物经皮无针接种。此外,鼻内递送是可能,如在尤其地Hamajima等人,(1998),Clin.Immunol.Immunopathol.,88(2),205-10中描述的。还可使用脂质体(例如,如在美国专利No.6,472,375中描述的)和微胶囊封装。还可使用生物可降解的可靶向微粒递送系统(例如,如美国专利No.6,471,996中描述的)。
在一个实施方案中,利用载体诸如受控释放制剂(包括埋植剂和微胶囊化递送系统)制备活性化合物,所述载体可保护化合物免于从身体快速清除。可使用生物可降解的生物相容性聚合物,诸如乙烯乙酸乙烯酯、聚酐、聚乙醇酸、胶原、聚原酸酯和聚乳酸。这样的制剂可使用标准技术来制备。所述材料还可从AlzaCorporation和NovaPharmaceuticals,Inc.商购获得。脂质体悬浮液(包括通过针对病毒抗原的单克隆抗体靶向感染的细胞的脂质体)也可用作药学上可接受的载体。这些制剂可按照对于本领域普通技术人员来说是已知的方法,例如如在美国专利No.4,522,811中描述的方法来制备。
这样的化合物的毒性和治疗功效可在细胞培养物或实验动物中通过标准药学方法来测定,所述方法例如用以测定LD50(使50%的群体致死的剂量)和ED50(在50%的群体中具有疗效的剂量)。毒性效应与疗效之间的剂量比率是治疗指数,其可表示为比率LD50/ED50。显示高治疗指数的化合物是优选的。虽然可使用显示毒副作用的化合物,但应当小心地设计递送系统,所述递送系统将这样的化合物靶向患病组织的部位以使对未感染的细胞的潜在损害降至最低,从而减小副作用。
从细胞培养测定和动物研究获得的数据可用于制定用于人中使用的剂量的范围。这样的化合物的剂量优选在包括ED50的几乎没有毒性或无毒性的循环浓度的范围内。剂量可取决于使用的剂型和利用的施用途径而在该范围内变化。对于本发明的方法中使用的化合物,可从细胞培养测定初步估计治疗有效剂量。可在动物模型中制定剂量以获得包括如在细胞培养中测定的IC50(即,实现症状的半最大抑制的测试化合物的浓度)的化合物的循环血浆浓度范围。这样的信息可用于精确地测定在人中有用的剂量。可以例如通过高效液相色谱测量血浆中的水平。
如本文中定义的,核酸分子的治疗有效量(即,有效剂量)取决于选择的核酸。例如,可施用在约1pg至1000mg的范围内的dsRNA(或,例如,编码这样的dsRNA)的单次剂量量;在一些实施方案中,可施用10、30、100或1000pg,或10、30、100或1000ng,或10、30、100或1000μg,或10、30、100或1000mg。在一些实施方案中,可施用1-5g的组合物。可从每天一次或多次至每周一次或多次施用组合物;包括每隔一天一次。本领域普通技术人员将理解,某些因素可影响有效治疗受试者所需的剂量和时间安排,包括但不限于疾病或病症的严重度、先前的治疗、受试者的一般健康状况或年龄以及存在的其它疾病。此外,利用治疗有效量的核酸(例如,dsRNA)、蛋白质、多肽或抗体治疗受试者可包括单次治疗或,优选地可包括一系列治疗。
可以例如使用本领域已知的方法将本发明的核酸分子插入表达构建体,例如病毒载体、逆转录病毒载体、表达盒或质粒病毒载体,所述方法包括但不限于Xia等人,(2002),同上中描述的方法。可以例如通过吸入、口服、静脉内注射、局部施用(参见美国专利No.5,328,470)或通过立体定位注射(参见例如,Chen等人,(1994),Proc.Natl.Acad.Sci.USA,91,3054-3057)将表达构建体递送至受试者。递送载体的药物制剂可包括可接受的稀释剂中的载体,或可包含其中包埋递送媒介物的缓慢释放基质。或者,当可从重组细胞完整地产生完整递送载体例如逆转录病毒载体时,药物制剂可包括一个或多个产生基因递送系统的细胞。
表达构建体可以是适合用于适当的表达系统的构建体,包括但不限于逆转录病毒载体、线性表达载体、质粒和病毒或病毒衍生的载体,如本领域中已知的。这样的表达构建体可包括一个或多个诱导型启动子、RNAPolIII启动子系统诸如U6snRNA启动子或H1RNA聚合酶III启动子,或本领域中已知的其它启动子。构建体可包括siRNA的一条或两条链。表达两条链的表达构建体还可包括连接两条链的环结构,或每一条链可从相同构建体内单独的启动子单独转录。每一条链还可从单独的表达构建体例如Tuschl(2002,NatureBiotechnol20:500-505)转录。
可理解,将dsRNA试剂引入细胞的环境的方法将取决于细胞的类型和其环境的组成。例如,当在脂质体内发现细胞时,一种优选制剂是利用脂质制剂(诸如在lipofectamine中),可将dsRNA试剂直接添加至细胞的液体环境。还可诸如通过静脉内、肌内或腹膜内注射,或口服,或通过吸入或本领域中已知的其它方法向动物施用脂质制剂。当制剂适合用于施用至动物诸如哺乳动物,更具体地人中时,制剂也是在药学上可接受的。用于施用寡核苷酸的药学上可接受的制剂是已知的并且可被使用。在一些情况下,可以优选地在缓冲液或盐溶液中配制dsRNA试剂,将配制的dsRNA试剂直接注射进细胞,如在利用卵母细胞的研究中一样。也可进行dsRNA试剂双链体的直接注射。关于引入dsRNA(例如,DsiRNA试剂)的合适方法,参见美国公开专利申请No.2004/0203145A1。
必须引入合适量的dsRNA试剂,这些量可使用标准方法来凭经验测定。通常地,单独的dsRNA试剂种类在细胞环境中的有效浓度为50纳摩尔或更低,10纳摩尔或更低,或其中可使用1纳摩尔或更低的浓度的组合物。在另一个实施方案中,使用200皮摩尔或更低、100皮摩尔或更低、50皮摩尔或更低、20皮摩尔或更低的浓度以及甚至10皮摩尔或更低、5皮摩尔或更低、2皮摩尔或更低或1皮摩尔或更低的浓度的方法可用于许多情况。
可通过将dsRNA试剂组合物添加至细胞可在其中生活的细胞外基质来进行所述方法,只要这样配制所述dsRNA试剂组合物,以使得充足量的dsRNA试剂可以进入细胞以发挥其作用。例如,所述方法适合于与存在于液体诸如液体培养物或细胞生长培养基中、组织外植体中或整个生物体(包括动物,诸如哺乳动物,尤其是人)中的细胞一起使用。
CKAP5RNA的水平或活性可通过本领域中现在已知的或以后开发的合适方法来测定。可理解,用于测量靶RNA和/或靶RNA的表达的方法可取决于靶RNA的性质。例如,当靶CKAP5RNA序列编码蛋白质时,术语“表达”可指来源于CKAP5基因(基因组或外源来源)的蛋白质或CKAP5RNA/转录物。在此类情况下,可通过直接测量CKAP5RNA/转录物的量或通过测量CKAP5蛋白的量来测定靶CKAP5RNA的表达。可在蛋白质测定中诸如通过染色或免疫印迹,或者如果蛋白质催化可测量的反应,通过测量反应速率来测量蛋白质。所有这样的方法在本领域中是已知的并且可被使用。当将测量靶CKAP5RNA水平时,可使用用于检测RNA水平的本领域公认的方法(例如,RT-PCR、Northern印迹等)。在用本发明的dsRNA试剂靶向CKAP5RNA中,还预期dsRNA试剂在降低受试者、组织中、细胞中(体内或体外)或细胞提取物中的CKAP5RNA或蛋白质的水平中的效率的测量还可用于测定CKAP5相关表型(例如,疾病或病症,例如癌症或肿瘤形成、生长、转移、扩散等)的减轻的程度。可对细胞、细胞提取物、组织、组织提取物或其它合适的来源材料进行上述测量。
CKAP5RNA的表达是否已被减少的确定可通过能够可靠地检测RNA水平的变化的适当方法来进行。通常地,通过将未消化的dsRNA引入细胞的环境(使得至少一部分该dsRNA试剂进入细胞质),随后测量靶RNA的水平来进行所述测定。对相同的未处理细胞进行相同测量,比较获自每一个测量的结果。
可将dsRNA试剂配制为包含药理学有效量的dsRNA试剂和药学上可接受的载体的药物组合物。药理学或治疗有效量是指对于产生期望的病理学、治疗或预防结果是有效的dsRNA试剂的那个量。短语“药理学有效量”和“治疗有效量”或简称“有效量”是指对于产生期望的病理学、治疗或预防结果是有效的RNA试剂的那个量。例如,如果当与疾病或病症相关的可测量的参数存在至少20%的减小时给定的临床治疗被认为是有效的,则用于治疗该疾病或病症的药物的治疗有效量是实现该参数至少20%的减小所必需的量。
可通过本领域已知的方法诸如通过胃肠外途径,包括静脉内、肌内、腹膜内、皮下、经皮、气道(气溶胶)、直肠、阴道和局部(包括口腔和舌下)施用来施用本发明的适当配制的药物组合物。在一些实施方案中,通过静脉内或非肠道内(intraparenteral)输注或注射施用药物组合物。
一般地,dsRNA的合适的剂量单位在每天0.001至0.25毫克/千克的接受者的体重的范围内,或在每天0.01至20微克/千克的体重的范围内,或在每天0.001至5微克/千克的体重的范围内,或在每天1至500纳克/千克的体重的范围内,或在每天0.01至10微克/千克的体重的范围内,或在每天0.10至5微克/千克的体重的范围内,或在每天0.1至2.5微克/千克的体重的范围内。可每天一次施用包含dsRNA的药物组合物。然而,还可以以含有在一天中以适当的间隔施用的2、3、4、5、6或更多个亚剂量的剂量单位施用治疗剂。在该情况下,每一个亚剂量中含有的dsRNA必须相应地更小,以实现总的日剂量单位。还可例如使用常规持续释放制剂将剂量单位混合以用于在数天中施用的单次剂量,所述持续释放制剂在数天的时期中提供dsRNA的持续和恒定释放。持续释放制剂在本领域中是公知的。在该实施方案中,剂量单位包含对应的多个日剂量。无论制剂是何类型,药物组合物必须以足以抑制靶基因在待治疗的动物或人中表达的量含有dsRNA。可以以这样的方法混合组合物,以便多个单位的dsRNA的总和一起含有充足的剂量。
数据可获自细胞培养测定和为人制定合适的剂量范围的动物研究。本发明的组合物的剂量在包括ED50(如通过已知的方法测定的)的几乎没有毒性或无毒性的循环浓度的范围内。剂量可取决于使用的剂型和利用的施用途径而在该范围内变化。对于本发明的方法中使用的化合物,可从细胞培养测定初步估计治疗有效剂量。可在动物模型中制定剂量以获得包括如在细胞培养中测定的IC50(即,实现症状的半最大抑制的测试化合物的浓度)的化合物的循环血浆浓度范围。这样的信息可用于更精确地测定在人中有用的剂量。可通过标准方法,例如通过高效液相色谱测量血浆中的dsRNA水平。
可将药物组合物与施用说明书一起包含在试剂盒、容器、包装或分配器。
治疗方法
本发明提供了治疗处于完全或部分由CKAP5(例如,CKAP5转录物和/或CKAP5蛋白水平的失调和/或升高)引发的或可通过CKAP5的选择性靶向可治疗的疾病或病症的风险中的(或对所述疾病或病症易感的)受试剂者的预防性和治疗性方法。
如本文中所用,“治疗(treatment)”或“治疗(treating)”定义为治疗剂(例如,dsRNA试剂或载体或编码其的转基因)至患者的应用或施用,或治疗剂至来自患者的分离的组织或细胞系的应用或施用,所述患者具有疾病或病症、疾病或病症的症状或对疾病或病症易感,目的是治愈、愈合、缓解、解除、改变、补救、减轻、改善或影响疾病或病症、疾病或病症的症状或对疾病的易感性。
在一个方面,本发明提供了用于通过向受试者施用治疗剂(例如,dsRNA试剂或编码其的载体或转基因),预防受试者的上述疾病或病症(包括,例如,通过抑制CKAP5表达对受试者内的转化事件的开始的抑制)的方法。处于发生疾病的风险中的受试者可通过例如本文中描述的诊断或预后测定的一种或组合来鉴定。预防药物的施用可在例如受试者的癌症的检测、表征疾病或病症的症状表现之前进行,以便预防所述疾病或病症,或可选择地迟延其进展。
本发明的另一个方面涉及治疗性(即,改变疾病或病症的症状的发作)治疗受试者的方法。可在体外(例如,通过用dsRNA试剂培养细胞)或可选择地,体内(例如,通过向受试者施用dsRNA试剂)进行这些方法。
关于治疗的预防性和治疗性方法,可基于获自药物基因组学领域的知识,专门地定制或改进这样的方法。如本文中所用,“药物基因组学”是指基因组学技术诸如基因测序、统计遗传学以及对临床开发和出售中的药物的基因表达分析。更具体地,该术语是指患者的基因是如何决定他或她对药物的反应(例如,患者的“药物反应表型”或“药物反应基因型”)的研究。因此,本发明的另一个方面提供了用于根据个体的药物反应基因型,利用本发明的靶CKAP5RNA分子或靶CKAP5RNA调节剂定制个体的预防性或治疗性治疗的方法。药物基因组学允许临床医生或内科医生将预防性或治疗性治疗靶向最受益于所述治疗的患者,并且避免会经历毒性药物相关副作用的患者的治疗。
可在选择的动物模型中测试治疗剂。例如,可动物模型中使用本文中所述的dsRNA试剂(或编码其的表达载体或转基因)以测定利用所述试剂的治疗的功效、毒性或副作用。或者,可将试剂(例如,治疗剂)在动物模型中用于确定这样的试剂的作用机制。
用于评价CKAP5mRNA水平和表达的下调的模型
细胞培养
可以例如使用下列方法测试本发明的dsRNA试剂的体内切割活性。被本发明的dsRNA试剂靶向的CKAP5cDNA内的核苷酸序列示于上述CKAP5序列中。
可使用HeLa或其它哺乳动物细胞在细胞培养物中测试本发明的dsRNA试剂以测定CKAP5RNA和CKAP5蛋白的抑制的程度。在某些实施方案中,选择针对本文中描述的CKAP5靶的DsiRNA试剂(例如,参见图1,和上文中引述的结构)。在利用适当的转染剂将这些试剂递送至例如培养的HeLa细胞或其它培养的转化的或非转化的哺乳动物细胞后,测量CKAP5RNA的抑制。使用扩增的实时PCR监测(例如,ABI7700)测量靶CKAP5RNA相对肌动蛋白或其它合适的对照的相对量。将寡核苷酸序列的活性与无关靶或与具有相同总长度和化学性质的随机化的DsiRNA对照进行比较,或仅与适当的媒介物处理的或未处理的对照进行比较。初级和次级前导试剂被选择用于靶,并进行最优化。
(扩增的实时PCR监测)和mRNA的Lightcycler定量
在DsiRNA递送后,例如,使用用于大规模提取的AmbionRnaqueous4-PCR纯化试剂盒或用于96孔测定的PromegaSV96,从细胞制备总RNA。对于Taqman分析,利用例如在5'末端共价连接的报告染料FAM或VIC和缀合3′末端的淬灭染料TAMCKAP5A合成双重标记探针。使用50uL由10uL总RNA、100nM正向引物、100mM反向引物、100nM探针、1xTaqManPCR反应缓冲液(PE-AppliedBiosystems)、5.5mMMgCl2、各自100uM的dATP、dCTP、dGTP和dTTP、0.2URNA酶抑制剂(Promega)、0.025UAmpliTaqGold(PE-AppliedBiosystems)和0.2UM-MLV逆转录酶(Promega)组成的反应物,在例如ABIPRISM7700Sequence检测器上进行PCR扩增。热循环条件可由如下步骤组成:在48℃进行30分钟、在95℃进行10分钟,随后进行40个循环(在95℃进行15秒和在60℃进行1分钟)。相对于从系列稀释的总细胞RNA(300、100、30、10ng/rxn)生成的标准确定靶CKAP5mRNA水平的定量,将其在平行或相同管的TaqMan反应中针对例如HPRT1mRNA进行标准化。
Western印迹
可使用标准微量制备技术(例如使用RIPA缓冲液)或优选地,通过利用方法诸如NE-PERNuclearandCytoplasmicExtraction试剂盒(Thermo-FisherScientific)提取细胞核蛋白质来制备细胞蛋白质提取物。将细胞蛋白质提取物在Tris-甘氨酸聚丙烯酰胺凝胶上电泳,随后转移至膜上。可通过例如用5%脱脂乳孵育1小时,随后在4℃用一抗孵育16小时来封闭非特异性结合。洗涤后,在室温下施用二抗例如(1:10,000的稀释度),进行1小时,随后在VersaDoc成像系统上检测信号
在几个细胞培养系统中,已显示阳离子脂质增强寡核苷酸至培养细胞的生物可用度(Bennet,等人,1992,Mol.Pharmacology,41,1023-1033)。在一个实施方案中,将本发明的dsRNA分子与阳离子脂质复合以进行细胞培养实验。在无血清OptimMEM(InVitrogen)中制备dsRNA和阳离子脂质混合物,随后立即将其添加至细胞。将OptiMEM加温至室温(约20-25℃),将阳离子脂质添加至期望的终浓度。将dsRNA分子添加至OptiMEM达到期望的浓度,随后将溶液添加至稀释的dsRNA,并在室温孵育15分钟。在剂量反应实验中,在添加阳离子脂质之前,将RNA复合物系列稀释至OptiMEM中。
动物模型
可在动物模型中评价抗-CKAP5dsRNA试剂的效率。如本领域中已知的癌症和/或增生性疾病、病况或病症的动物模型可用于抗-CKAP5dsRNA的效率、效力、毒性等的评价。增生性疾病的合适的动物模型包括例如具有原癌基因(例如,Myc、Src)的功能的获得和/或肿瘤抑制蛋白(例如,p53、Rb)的功能的丢失的转基因啮齿类动物(例如,小鼠、大鼠)或已被暴露于诱导DNA改变(其有利于致瘤性转化)的辐照或化学诱变剂的啮齿类动物。许多这样的动物模型是可商购获得的,例如获自TheJacksonLaboratory,BarHarbor,ME,USA。这些动物模型可用作用于本发明的组合物的测定的源细胞或组织。这样的模型还可用于或适用于针对治疗用途临床前评价本发明的dsRNA组合物在调节CKAP5基因表达中的效率。
与在细胞培养模型中一样,与CKAP5最相关的小鼠肿瘤异种移植物是来源于表达CKAP5蛋白的癌细胞的那些肿瘤异种移植物。与调节有丝分裂功能基因样CKAP5的抗肿瘤效应的研究相关的癌症的异种移植小鼠模型已由不同的研究小组进行了描述(例如,Judge等人,JCI2009年3月;119(3):661;Seth等人,2011年5月;19(5):928;)。这些模型的使用已证明诸如siRNA介导的基因沉默对有丝分裂功能基因的表达的的抑制在动物中引起肿瘤生长的抑制。
这样的模型可用于评价本发明的dsRNA分子抑制CKAP5水平、表达、肿瘤/癌症形成、生长、扩散、其它CKAP5相关表型、疾病或病症等的发展的效率。这些模型和其它模型可类似地用于评价本发明的dsRNA分子在临床前背景中的安全/毒性和效率。
用于本发明的CKAP5-靶向dsRNA的评价的动物模型系统的具体实例包括野生型小鼠以及常位或皮下MHCC97、A549、H1299、HepG2、Hep3B、SNU398、HuH7、NCI-H196、NCI-H1975、HT29、MKN-45、MDA-MB-231、NCI-H441、Panc-1、MiaPaCa、BxPC3、DU-145、M2182、VCaP、OvCar-3、ES-2、SKOV3、PC3、HCT116、A431、MCF-7、U937、KU-7、K562、HeLa、或T98G肿瘤模型小鼠。在示例性体内实验中,将本发明的dsRNA以1至10mg/kg范围的剂量经尾静脉注射至这样的小鼠模型或者,可选择地,以单剂量IC50水平施用重复剂量,在施用终剂量后24小时收获器官(例如,前列腺、肝、肾、肺、胰腺、结肠、皮肤、脾、骨髓、淋巴结、乳房脂肪垫等)。随后取决于使用的模型,评价此类器官的小鼠和/或人CKAP5水平。还可在例如终dsRNA施用后1、4、7、14、21或更多天研究作用持续时间。
除非另有所指,否则本发明的实践使用化学、分子生物学、微生物学、重组DNA、遗传学、免疫学、细胞生物学、细胞培养和转基因生物学的常规技术,这些都在本领域普通技术人员的能力范围内。参见,例如,Maniatis等人,1982,MolecularCloning(ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.);Sambrook等人,1989,MolecularCloning,第2版(ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.);Sambrook和Russell,2001,MolecularCloning,第3版(ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.);Ausubel等人,1992),CurrentProtocolsinMolecularBiology(JohnWiley&Sons,包括定期更新资料);Glover,1985,DNACloning(IRLPress,Oxford);Anand,1992;Guthrie和Fink,1991;Harlow和Lane,1988,Antibodies,(ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.);Jakoby和Pastan,1979;NucleicAcidHybridization(B.D.Hames&S.J.Higgins编辑1984);TranscriptionAndTranslation(B.D.Hames&S.J.Higgins编辑1984);CultureOfAnimalCells(R.I.Freshney,AlanR.Liss,Inc.,1987);ImmobilizedCellsAndEnzymes(IRLPress,1986);B.Perbal,APracticalGuideToMolecularCloning(1984);论文,MethodsInEnzymology(AcademicPress,Inc.,N.Y.);GeneTransferVectorsForMammalianCells(J.H.Miller和M.P.Caloseds.,1987,ColdSpringHarborLaboratory);MethodsInEnzymology,第154和155卷(Wu等人,编辑),ImmunochemicalMethodsInCellAndMolecularBiology(Mayer和Walker,编辑,AcademicPress,London,1987);HandbookOfExperimentalImmunology,第I-IV卷(D.M.Weir和C.C.Blackwell,编辑,1986);Riott,EssentialImmunology,第6版,BlackwellScientificPublications,Oxford,1988;Hogan等人,ManipulatingtheMouseEmbryo,(ColdSpringHarborLaboratoryPress,ColdSpringHarbor,N.Y.,1986);Westerfield,M.,Thezebrafishbook.Aguideforthelaboratoryuseofzebrafish(Daniorerio),(第4版,Univ.ofOregonPress,Eugene,2000)。
除非另有定义,否则本文使用的所有技术和科学术语具有与本发明所属领域内的普通技术人员通常理解的含义相同的含义。尽管与本文中描述的方法和材料类似或等同的方法和材料可以用于本发明的实践或测试,但合适的方法和材料描述于下文中。本文中提及的所有出版物、专利申请、专利和其它参考资料都通过引用整体并入。在冲突的情况下,以本说明书(包括定义)为准。此外,材料、方法和实施例仅是说明性的并且不旨在进行限制。
实施例
本发明通过参考以下实施例进行描述,所述实施例通过举例说明的方式提供,并且不旨在以任何方式限制本发明。使用本领域公知的标准技术或下文中明确描述的技术中。
实施例1:双链RNA寡核苷酸的制备
寡核苷酸的合成和纯化
DsiRNA分子可被设计来与RNA信使中的各种位点,例如本文中描述的RNA序列内的靶序列相互作用。在目前例举的试剂中,在第一筛选中,576个人靶CKAP5序列被选择来用于评价(576个人靶CKAP5位点中的456个与小鼠CKAP5转录物序列中的对应位点经预测是保守的)。DsiRNA分子的一条链的序列与上述靶CKAP5位点序列互补。使用本文中描述的方法化学合成DsiRNA分子。一般地,使用如针对19-23mersiRNA描述的固相寡核苷酸合成法(参见例如Usman等人,美国专利No.5,804,683、5,831,071、5,998,203、6,117,657、6,353,098、6,362,323、6,437,117、6,469,158;Scaringe等人,美国专利No.6,111,086、6,008,400、6,111,086)合成DsiRNA构建体。
合成个别RNA链,按照标准方法(IntegratedDNATechnologies,Coralville,Iowa)对其进行HPLC纯化。例如,使用固相亚磷酰胺化学法合成RNA寡核苷酸,使用标准技术(Damha和Olgivie,1993,MethodsMolBiol20:81-114;Wincott等人,1995,NucleicAcidsRes23:2677-84)将其去保护,并在NAP-5柱(AmershamPharmaciaBiotech,Piscataway,N.J.)上进行脱盐。使用15分钟的阶梯线性梯度在AmershamSource15Q柱(1.0cmx25cm;AmershamPharmaciaBiotech,Piscataway,N.J.)上,使用离子交换高效液相色谱(IE-HPLC)纯化所述寡聚物。梯度从90:10缓冲液A:B变化至52:48缓冲液A:B,其中缓冲液A为100mMTrispH8.5,缓冲液B为100mMTrispH8.5,1MNaCl。在260nm处监测样品,并且收集对应于全长寡核苷酸种类的峰,将其混合,在NAP-5柱上脱盐,随后冻干。
通过在BeckmanPACE5000(BeckmanCoulter,Inc.,Fullerton,Calif.)上进行毛细管电泳(CE)来测定每一种寡聚物的纯度。CE毛细管具有100μm的内径并且含有ssDNA100R凝胶(Beckman-Coulter)。通常地,将约0.6纳摩尔的寡核苷酸注射至毛细管中,在444V/cm的电场中电泳,通过260nm处的紫外光吸光度进行检测。变性Tris-Borate-7M-尿素电泳缓冲液购自Beckman-Coulter。获得通过纯度至少90%(通过CE评估的)的寡核糖核苷酸以用于下文中描述的实验。按照制造商推荐的方案,在VoyagerDE.TMBiospectometry工作站(AppliedBiosystems,FosterCity,Calif.)上通过基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱验证化合物的身份。获得所有寡聚物的相对分子质量,通常在0.2%的预期分子质量内。
双链体的制备
将单链RNA(ssRNA)寡聚物例如以100μM的浓度悬浮于由100mM醋酸钾、30mMHEPES,pH7.5组成的双链体缓冲液中。将互补有义与反义链以等摩尔量混合以产生例如50μM双链体的终溶液。将样品在RNA缓冲液(IDT)中加热至100℃,持续5分钟,在使用前使其冷却至室温。将双链RNA(dsRNA)寡聚物于-20℃下贮存。将单链RNA寡聚物冻干贮存或于不含核酸酶的水中于-80℃下贮存。
命名法
为了一致起见,下列命名法已被用于本说明书。给予双链体的名称指示寡聚物的长度以及悬突的存在或不存在。“25/27”是具有25个碱基的有义链和拥有2-碱基3′悬突的27个碱基的反义链的不对称双链体。“27/25”是具有27个碱基的有义链和25个碱基的反义链的不对称双链体。
细胞培养和RNA转染
HeLa细胞获自ATCC并且在5%CO2下于37℃维持在补充有10%胎牛血清(HyClone)的DMEM(HyClone)中。Hepa1-6细胞获自ATCC并且在5%CO2下于37℃维持在补充有10%胎牛血清(HyClone)的DMEM(HyClone)中。关于RNA转染,使用LipofectamineTMRNAiMAX(Invitrogen)并按照制造商的说明书,以1nM、0.3nM或0.1nM的终浓度用指定的DsiRNA转染细胞。简言之,对于0.1nM的转染,例如下文中某些实施例的转染,将每一种DsiRNA的原液的等分与Opti-MEMI(Invitrogen)和LipofectamineTMRNAiMAX混合以达到150μL(含有0.3nMDsiRNA)的体积。将所得的150μL混合物在室温下孵育20分钟以使DsiRNA:LipofectamineTMRNAiMAX复合物形成。同时,使靶细胞接受胰蛋白酶作用,并重悬浮于培养基中。在20分钟的复合结束时,将50uL的DsiRNA:RNAiMAX混合物每孔添加96孔板的一式三份孔中。最后,将100μL的细胞悬浮液添加至每一个孔(终体积150μL),并将板置于培养箱中进行24小时。
CKAP5抑制的评估
通过qRT-PCR测定CKAP5靶基因敲低,将值针对HPRT和SFRS9管家基因(在人HeLa细胞中)和RPL23管家基因(在小鼠Hepa1-6细胞中)以及针对利用对照DsiRNA的转染和/或模拟转染对照进行标准化。
RNA分离和分析
抽吸培养基,使用SV96试剂盒(Promega)提取总RNA。按照制造商的说明书,使用SuperscriptII、寡聚dT和随机六聚体反转录总RNA。通常地,使用对于CKAP5基因以及对于人基因HPRT-1和SFRS9(或在小鼠Hepa1-6细胞中RPL23)都是特异性的引物和探针通过qPCR分析所得的cDNA。将ABI7700用于扩增反应。以一式三份测试每一个样品。将相对CKAP5RNA水平针对HPRT1和SFRS9(或RPL23)RNA水平进行标准化,将其与在转染对照样品中获得的RNA水平进行比较。
实施例2:CKAP5-初步筛选的DsiRNA抑制
如上所述设计和合成靶向CKAP5的DsiRNA分子,并在人HeLa细胞中测试其抑制效率。对于转染,将退火的DsiRNA与转染剂(LipofectamineTMRNAiMAX,Invitrogen)混合,在室温下孵育20分钟。使HeLa(人)细胞接受胰蛋白酶处理,重悬浮于培养基中,随后添加至孔(100uL/孔)以在150μl的体积中产生1nM的终DsiRNA浓度。将每一种DsiRNA转染混合物添加至3个孔中以进行一式三份的DsiRNA处理。在DsiRNA转染混合物连续存在的情况下将细胞在37℃孵育24小时。在第24小时,从每一个孔的处理的细胞制备RNA。首先取出具有转染混合物的上清液并弃去,随后将细胞裂解,从每一个孔制备RNA。通过靶qRT-PCR评价CKAP5靶基因的处理后靶CKAP5RNA水平,将值针对对于对照获得的那些值进行标准化。将一式三份数据求平均值,测定每一个处理的百分比误差。将标准化的数据作图,测定活性DsiRNA相较于对照产生的靶mRNA的减少。
就测试的初始期中CKAP5抑制效率研究CKAP5靶向DsiRNA。在本实施例中,构建了576个不对称DsiRNA(测试的DsiRNA具有25/27mer结构),并于在浓度为1nM的这样的DsiRNA存在的情况下孵育的人HeLa细胞中测试其CKAP5抑制效率。初始初步筛选中测试的576个不对称DsiRNA包括选自上面表2的DsiRNA,其中加下划线的核苷酸残基指示2’-O-甲基修饰的残基,核糖核苷酸残基以大写字母显示,脱氧核糖核苷酸残基以小写字母显示。具有“M0-M48”修饰模式的这样的双链体,是指具有不具有经2’-O-甲基修饰的核苷酸(“M0”)的随从链和具有经2’-O-甲基修饰的核苷酸的“M48”修饰模式的引导链的双链体。
在人HeLa细胞中以1nM进行的576个CKAP5靶向DsiRNA(456个靶向人和小鼠CKAP5序列,而120个DsiRNA经预测为人特异性的)的测定显示它们的CKAP5抑制效率。使用定位在CKAP5转录物内的2个位置的qPCR测定来测定CKAP5水平(对于人HeLa细胞实验,进行成对qPCR测定,并且在其它地方指示为“HsCKAP5798-913”(HEX)和“HsCKAP55921-6017”(FAM)。
在人HeLa细胞中研究的576个测定的不对称DsiRNA中有255个可显示在1nM于所述细胞中平均大于70%的人CKAP5水平的降低。在这255个DsiRNA中,61个在对活性CKAP5靶向DsiRNA的该初步筛选中在人HeLa细胞在1nM上展现80%或更大的人CKAP5水平的降低。
实施例3:CKAP5靶向DsiRNA的修饰形式在体外-初步筛选中降低CKAP5水平
在初步修饰评估中,从上述初步筛选选择4种DsiRNA(CKAP5-604、-853、-1004和-1356)用于研究不同的2’-O-甲基修饰模式对所述DsiRNA的体外活性的影响。该初步修饰评估中使用的修饰模式示于图2-1和2-2中,有义链修饰模式-反义链修饰模式指示每一个测试的DsiRNA。图2-3至2-6显示这样的试验的结果,将双链体CKAP5-604、-853、-1004和-1356的标识符分别缩写成C-604、C-853、C-1004和C-1356。如图2-3和2-4中显示的,DsiRNACKAP-604和-853耐受宽范围的修饰模式而不影响在人HeLa细胞中的体外活性,然而DsiRNACKAP-1004和-1356有些不太耐受广泛的2’-O-甲基修饰,尽管也鉴定了这些更后的序列的每一种的活性修饰形式。如图2-5和2-6中显示的,小鼠Hepa1-6细胞中CKAP5敲低的程度对于每一种DsiRNA序列低于在人HeLa细胞中观察到的。然而,对于每一种检查的双链体序列,至少一种在有义和反义链上都具有广泛修饰的DsiRNA经鉴定具有显著的小鼠CKAP5体外抑制活性。
实施例4:CKAP5-二次筛选的DsiRNA抑制
随后在二次测定(“2期”)中研究上述初步筛选实验的96个不对称DsiRNA(22个经预测对于人(Hs)CKAP5是特异性,而其余74个经预测靶向人和小鼠(Mm)CKAP5),这样的测定的结果以直方图形式示于图3-1至3-8中。具体地,在人HeLa细胞(图3-1至3-4)的环境中(以一式二份)在1nM和0.1nM下评价选自上文中测试的576个DsiRNA的96个不对称DsiRNA对人CKAP5的抑制作用。还在小鼠Hepa1-6细胞(图3-5至3-8)的环境中(以一式二份)在1nM和0.1nM下评价这96个不对称DsiRNA对小鼠CKAP5的抑制作用。如图3-1至3-4中所示,当在HeLa细胞的环境中测定时,非常多的不对称DsiRNA在亚纳摩尔浓度下可重现地显示强劲的人CKAP5抑制效率。此外,如图3-5至3-8中所示,当在小鼠Hepa1-6细胞的环境中测定时,许多这类不对称DsiRNA在亚纳摩尔浓度下也显示强劲的的小鼠CKAP5抑制效率(参见,例如,CKAP5-992和CKAP5-1358,作为在人HeLa细胞中和小鼠Hepa1-6细胞中具有高度活性的DsiRNA的实例)。同时,还鉴定了人CKAP5特异性抑制不对称DsiRNA(参见,例如,CKAP5-395、427、637和4367双链体)。
实施例5:CKAP5-靶向DsiRNA的引导链修饰形式在体外降低CKAP5水平
利用图4-1的示意图中所示的2’-O-甲基引导链修饰模式(包括未修饰的随从链和上述引导链修饰模式“M8”、“M17”、“M35”和“M48”)制备上述初步筛选的24个CKAP5-靶向DsiRNA(CKAP5-281、-427、-600、-853、-988、-1046、-1294、-1343、-1358、-1514、-2096、-2098、-2214、-2220、-2230、-3287、-3328、-4056、-4350、-4756、-5396、-5699、-5703和-5741)。对于24个DsiRNA序列中的每一个,在HeLa细胞的环境中在1.0nM和0.1nM(以一式二份)浓度下测试具有4个引导链修饰模式M8、M17、M35和M48的每一个的DsiRNA的人HeLa细胞中的CKAP5抑制作用。将这些实验的结果以直方图形式示于图4-2至4-5中。还在小鼠Hepa1-6细胞中测定这些相同的双链体,对应的结果示于图4-6至4-9中。一般地,随着引导链的2’-O-甲基修饰的程度增加,24个DsiRNA序列显示朝向降低的CKAP5抑制的效率的倾向。然而,对于所有研究的DsiRNA序列,可鉴定允许DsiRNA在体外保持显著的CKAP5抑制效率的修饰模式。还值得注意的是,许多这类DsiRNA(例如,CKAP5-1046、CKAP5-1343、CKAP5-1358、CKAP5-2096、CKAP5-2214、CKAP5-4056、CKAP5-4350和CKAP5-5741)在甚至研究的最高度修饰状态中展现强劲的CKAP5抑制效率的明显降低。因此,这样的高活性修饰的DsiRNA序列具有据信当向受试者体内治疗性施用时,能够稳定这样的DsiRNA和/或减小这样的DsiRNA的免疫原性的修饰模式。
实施例6:在引导链和随从链上具有修饰的CKAP5-靶向DsiRNA的另外修饰形式在体外降低CKAP5水平
利用如上文中和图5-1及5-2中所示的2’-O-甲基随从链和引导链修饰模式(包括上述随从链修饰模式“SM14”、“SM24”、“SM31”和“SM12”以及引导链修饰模式“M48”、“M8”、“M35”和“M17”)制备上述实验的16个CKAP5-靶向DsiRNA(CKAP5-604、CKAP5-853、CKAP5-1004、CKAP5-1294、CKAP5-1343、CKAP5-1358、CKAP5-2096、CKAP5-2098、CKAP5-2214、CKAP5-3287、CKAP5-4056、CKAP5-4350、CKAP5-4756、CKAP5-5396、CKAP5-5703和CKAP5-5741)。对于该16个DsiRNA序列的每一个,在HeLa细胞的环境中在1.0nM和0.1nM(以一式二份)的浓度下测定具有4种随从链修饰模式M14、M24、M31和M12的每一个和至少一个优选引导链修饰模式(选自引导链修饰模式M48、M8、M35和M17)的DsiRNA在人HeLa细胞中的CKAP5抑制作用。将这些实验的结果以直方图形式示于图5-3至5-6中。对于所有研究的DsiRNA序列,可鉴定至少一个允许DsiRNA在体外保持显著的CKAP5抑制效率的具有广泛的引导链和随从链修饰的双链体。值得注意的是,大部分这类DsiRNA(例如,CKAP5-604、CKAP5-1343、CKAP5-2096、CKAP5-2214、CKAP5-4056、CKAP5-4350和CKAP5-5741)在所有研究的经修饰的状态中展现强劲的CKAP5抑制效率。这样的高度活性修饰的DsiRNA序列具有据信当向受试者体内治疗性施用时,能够稳定这样的DsiRNA和/或减小这样的DsiRNA的免疫原性的修饰模式。
为了进一步评估经修饰的CKAP5靶向DsiRNA的效力,在人HeLa细胞的环境中以3nM、1nM、0.1nM和0.03nM的浓度测试5种经修饰的DsiRNA(CKAP5-853M14-M8、CKAP5-1358M12-M17、CKAP5-2096M12-M17、CKAP5-4056M31-M17和CKAP5-5741M14-17)的CKAP5敲低。令人吃惊地,在转染后1天甚至在最低的测试浓度0.03nM(30皮摩尔)上对于所有5种测定的双链体观察到大于90%的CKAP5水平的敲低。
CKAP5-85321核苷酸mRNA靶序列在小鼠与人之间是保守的,然而发现“G”残基在对应于CKAP5-85325/27merDsiRNA的随从链的5’开始的位置9(当位置1为随从链的5’-末端残基时)的位置上替代猕猴序列中的“A”残基。研究该多态性残基对CKAP5-853DsiRNA在猕猴细胞系中抑制CKAP5的能力的影响。2个猕猴细胞系(CMMT乳腺细胞系和LLC-MK2衍生肾细胞系)被鉴定,并且不仅用CKAP5-853M14-M8DsiRNA而且还用CKAP5-2096M12-M17DsiRNA和CKAP5-604M24-M8DsiRNA进行转染。所有DsiRNA难以置信地是CKAP5表达的强效抑制剂,在猕猴CMMT细胞系中CKAP5-853M14-M8DsiRNA观察到3.1pM的IC50值,在猕猴CMMT细胞系中对于CKAP5-2096M12-M17DsiRNA观察到2.3pM的IC50值,以及在猕猴CMMT细胞系中对于CKAP5-604M24-M8DsiRNA观察到5.8pM的IC50值。
实施例7:其它经修饰的CKAP5DsiRNA
研究CKAP5-853和CKAP5-604DsiRNA的对多种其它引导链和随从链修饰模式的抑制活性的影响。本实施例中使用的修饰模式示于图6-1至6-16中,随从链修饰模式示于图6-1中,引导链修饰模式示于图6-2中,组合的双链体修饰模式示于图6-3至6-14,并且如用于特定CKAP5-853随从链和引导链的修饰模式示于图6-15。如图6-16至6-19中显示的,鉴定了许多不同的具有异常高的抑制活性和效力的高度2’-O-甲基修饰的CKAP5-853双链体。在图6-19中,还测定了针对CKAP5mRNA靶序列具有错配的CKAP5靶向双链体(“853-764_mm”,其由SEQIDNO:5778随从链和SEQIDNO:5789引导链组成)的活性,所述活性相对于其它经修饰的不含错配的双链体略有降低。在图6-20中,测试了CKAP5-604双链体的6种其它经修饰的形式,并且所有这样的形式显示强劲的抑制活性。
实施例8:CKAP5靶向DsiRNA在体外减缓癌细胞系的生长
研究CKAP5靶向DsiRNACKAP5-604M24-M8和CKAP5-853M14-M8的抑制培养中的哺乳动物癌细胞的生长的性质。观察到两种DsiRNA显著减缓培养中的人HeLa细胞和培养中的人Hep3B细胞的生长(相较于非特异性对照DsiRNA,2至10倍或更大的细胞生长的减缓)。甚至当以皮摩尔范围的浓度(30皮摩尔或更低)施用双链体时,观察到这些显著的生长抑制作用。因此,活性DsiRNA靶向CKAP5能够甚至在极低的浓度上显著地减缓培养中的HeLa和Hep3B癌细胞系的生长。
对于针对Hep3B生长抑制研究的4种其它DsiRNA(CKAP5-1358M12-M17、CKAP5-2096M12-M17、CKAP5-4056M31-M17和CKAP5-5741M14-17)也观察到类似结果。在这样的实验中,在转染后第4天分析单层Hep3B培养的细胞,在低至30皮摩尔或更低的浓度上观察到Hep3B细胞生长的显著抑制(相较于非特异性对照DsiRNA,2至10倍或更多倍的细胞生长的减缓)。
在某些实施方案中,选择靶向CKAP5mRNA中的下列靶序列的双链核酸:
表8:选择的dsRNA的CKAP527个核苷酸的mRNA靶序列
对应于表8的上述双链核酸的21个核苷酸的选择的CKAP5mRNA靶序列包括:
表9:选择的dsRNA的CKAP5的21个核苷酸的mRNA靶序列
对应于表9的上述双链核酸的19个核苷酸的CKAP5mRNA靶序列包括:
表10:选择的dsRNA的CKAP5的19个核苷酸的mRNA靶序列
27个核苷酸的CKAP5mRNA靶序列的某些选择包括下列序列:
表11:另外选择的dsRNA的CKAP5的27个核苷酸的mRNA靶序列
21个核苷酸的CKAP5mRNA靶的某些选择包括下列序列:
表12:另外选择的dsRNA的CKAP5的21个核苷酸的mRNA靶序列
19个核苷酸的CKAP5mRNA靶的某些另外的选择包括下列序列:
表13:另外选择的dsRNA的CKAP5的19个核苷酸的mRNA靶序列
27个核苷酸的CKAP5mRNA靶的进一步选择包括下列序列:
表14:进一步选择的dsRNA的CKAP5的27个核苷酸的mRNA靶序列
21个核苷酸的CKAP5mRNA靶的进一步选择包括下列序列:
表15:进一步选择的dsRNA的CKAP5的21个核苷酸的mRNA靶序列
19个核苷酸的CKAP5mRNA靶序列的进一步选择包括下列序列:
表16:进一步选择的dsRNA的CKAP5的19个核苷酸的mRNA靶序列
27个核苷酸的CKAP5mRNA靶的更多选择包括下列序列:
表17:更多选择的dsRNA的CKAP5的27个核苷酸的mRNA靶序列
21个核苷酸的CKAP5mRNA靶的更多选择包括下列序列:
表18:更多选择的dsRNA的CKAP5的21个核苷酸的mRNA靶序列
19个核苷酸的CKAP5mRNA靶的更多选择包括下列序列:
表19:更多选择的dsRNA的CKAP5的19个核苷酸的mRNA靶序列
本说明书中提及的所有专利和出版物表明本发明所属的领域内的普通技术人员的能力水平。本公开内容中引用的所有参考资料通过引用并入,其引用程度就如同每一参考资料已单独地以通过引用整体并入。
本领域普通技术人员可容易地理解,本发明非常适用于进行所述目的,以及获得提及目的和有利方面,以及其中固有的所述目的和有利方面。本文中描述的作为优选实施方案的目前代表的方法和组合物是示例性,并且无意作为对本发明的范围的限制。其中的变化及其它用途对于本领域普通技术人员来说将会想到,这包括在本发明的精神范围内,由权利要求的范围来界定。
对于本领域普通技术人员来部显而易见的是,在不背离本发明的范围和精神的情况下,可对本文中公开的本发明进行不同的替代和变动。因此,这样的另外的实施方案在本发明和下列权利要求的范围内。本发明教导本领域普通技术人员针对产生具有增强的介导RNAi活性的活性的核酸构建体测试本文中描述的化学修饰的组合和/或替代。这样的增强的活性可包括增强的稳定性、增加的生物可用度和/或增强的介导RNAi的细胞反应的活化。因此,本文中描述的具体实施方案不是限制性的,本领域普通技术人员可容易地理解,可测试本文中描述的修饰的特定组合而无需针对鉴定具有增强的RNAi活性的DsiRNA分子的过度实验。
适当地可在任何本文中未明确公开的任何组件、限制不存在的情况的情况下实施本文中举例说明性描述的本发明。因此,例如,在本文中的每一种情况下,术语“包含”、“基本上由……组成”和“由……组成”的任一个可用另外两个术语的任一个替代。已使用的术语和表达用作描述而非限制的术语,在这样的术语和表达的使用,无意排除显示和描述的任何等同物或其部分,但应了解,各种修饰可能在所述发明的范围内。因此,应理解,尽管已通过优选实施方案明确地公开本发明,但本文中公开的任何性质、概念的变动和变化可求助于本领域普通技术人员,并且这样的变动和变化在由说明书和所附权利要求定义的本发明的范围内。
此外,当本发明的特性或方面根据Markush组或其它替代分组进行描述时,本领域普通技术人员应了解,本发明也由此根据Markush组或其它组的任何个别成员或成员的亚组来进行描述。
描述本发明的上下文中(尤其在下列权利要求的上下文中)术语“一个(a)”和“一种(an)”以及“所述(the)”和类似的指示物的使用,除非在本文中另有所指或根据上下文发现明显地矛盾,否则将被解释为包括单数和复数。术语“包含”、“具有”、“包括”和“含有”,除非另有所指,否则应被解释为开放式术语(即,意指"包括,但不限于")。其中的值的范围的引用,除非本文中另有所指,否则仅意欲用作个别地提及落在所述范围内的每一个离散值的速记法,并且每一个离散值并入本说明书,就如同其个别地在本文中被引用。除非本文中另有所指或另外地通过上下文发现明确地矛盾,否则可以以任何适当的顺序进行本文中描述的所有方法。除非另外声明,否则本文中提供的任何和所有实例或示例性专门用语(例如,“诸如”)的使用仅意欲更好地说明本发明,并不对本发明的范围施加限制。本说明书没有专门用语应当被解释为将任何非声明的组件指定为实施本发明所必需的。
本文中描述了本发明的实施方案,包括对于本发明人来说是已知的进行本发明的最好模式。在阅读前述说明后,这些实施方案的变型对于本领域普通技术人员来说是显而易见的。
本发明人预期本领域普通技术人员视情况而定使用这样的变化,本发明人希望不按本文中明确描述的方式来实施本发明。因此,本发明包括其所附权利要求中引用的主题的所有变动和等同物(在适用法律允许的情况下)。此外,除非在本文中另有所指或另外地根据上下文明显地出现矛盾,否则所有其可能的变型中的上述组件的任意组合包括在本发明内。本领域普通技术人员将了解或能够仅使用常规实验来确定本文中描述的本发明的特定实施方案的许多等同物。这样的等同物意欲包括在下列权利要求中。
Claims (70)
1.一种分离的核酸,其包含长度为15-35个核苷酸的寡核苷酸链,其中所述寡核苷酸链与选自表11-13的靶CKAP5mRNA序列沿所述寡核苷酸链长度的至少15个核苷酸充分互补,从而使当所述核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
2.一种分离的核酸,其包含长度为19-35个核苷酸的寡核苷酸链,其中所述寡核苷酸链与选自表14-16的靶CKAP5mRNA序列沿所述寡核苷酸链长度的至少19个核苷酸充分互补,从而使当所述核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
3.一种分离的双链核酸(dsNA),其包含含有RNA的第一和第二核酸链,其中所述第一链的长度为15-35个核苷酸,并且所述dsNA的所述第二链的长度为19-35个核苷酸,其中所述第二寡核苷酸链与选自表11-13的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少15个核苷酸充分互补,从而使当所述双链核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
4.一种分离的双链核酸(dsNA),其包含第一和第二核酸链,其中所述第一链的长度为15-35个核苷酸,并且所述dsNA的所述第二链的长度为19-35个核苷酸,其中所述第二寡核苷酸链与选自表14-16的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少19个核苷酸充分互补,从而使当所述双链核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
5.一种分离的双链核酸(dsNA),其包含第一和第二核酸链,其中所述第一链的长度为15-35个核苷酸,并且所述dsNA的所述第二链的长度为19-35个核苷酸,其中所述第二寡核苷酸链与选自表17-19的靶CKAP5mRNA序列沿所述第二寡核苷酸链长度的至少19个核苷酸充分互补,从而使当所述双链核酸被引入哺乳动物细胞时,减少CKAP5靶mRNA表达,并且其中,从选自表17-19的CKAP5mRNA序列的5'端(位置1)开始,哺乳动物Ago2在所述序列的位置9与10之间的位点上切割所述mRNA。
6.一种分离的dsNA分子,其由如下区域组成:(a)有义区和反义区,其中所述有义区和反义区一起形成由25-35个碱基对组成的双链体区域,并且所述反义区包含选自表8-10的序列的互补序列的序列;和(b)0至2个3′悬突区域,其中每一个悬突区域的长度为6个或更少的核苷酸。
7.一种分离的双链核酸(dsNA),其包含第一和第二核酸链以及至少25个碱基对的双链体区域,其中所述第一链的长度为25-34个核苷酸,并且所述dsNA的所述第二链的长度为26-35个核苷酸,并且在其3′末端上包含1-5个单链核苷酸,其中所述第二寡核苷酸链与选自表8-10的靶CKAP5mRNA序列沿所述第二寡核苷酸长度的至少19个核苷酸充分互补,从而使当所述双链核酸被引入哺乳动物细胞时减少CKAP5靶基因表达。
8.一种分离的双链核酸(dsNA),其包含第一和第二核酸链以及至少25个碱基对的双链体区域,其中所述第一链的长度为25-34个核苷酸,并且所述dsNA的所述第二链的长度为26-35个核苷酸,并且在其3′末端上包含1-5个单链核苷酸,其中所述第一寡核苷酸链的3′末端与所述第二寡核苷酸链的5′末端形成平端,并且所述第二寡核苷酸链与选自SEQIDNO:3457-4032、2305-2880和4033-5760的靶CKAP5序列沿所述第二寡核苷酸长度的至少19个核苷酸充分互补,从而使当所述双链核酸被引入哺乳动物细胞时减少CKAP5mRNA表达。
9.根据权利要求3-5任一项所述的分离的dsNA,其包含双链体区域,所述双链体区域选自由至少25个碱基对、19-21个碱基对和21-25个碱基对组成的组。
10.根据权利要求3-6任一项所述的分离的dsNA,其中所述第二寡核苷酸链在其3′末端上包含1-5个单链核苷酸。
11.根据权利要求3-6任一项所述的分离的dsNA,其中所述第一链的长度为25-35个核苷酸。
12.根据权利要求3-6任一项所述的分离的dsNA,其中所述第二链的长度为25-35个核苷酸。
13.根据权利要求3-12任一项所述的分离的dsNA,其中所述第二寡核苷酸链与靶CKAP5cDNA序列沿所述第二寡核苷酸链长度的至多27个核苷酸互补,所述靶CKAP5cDNA序列选自由GenBank登录号NM_001008938.3和NM_014756.3组成的组。
14.根据权利要求3-12任一项所述的分离的dsNA,其中从所述第一寡核苷酸链的3′末端上的第一核苷酸(位置1)开始,用经修饰的核苷酸置换位置1、2和/或3。
15.根据权利要求3-12任一项所述的分离的dsNA,其中所述第一链的所述3′末端与所述第二链的所述5′末端形成平端。
16.根据权利要求3-12任一项所述的分离的dsNA,其中所述第一链的长度为25个核苷酸并且所述第二链的长度为27个核苷酸。
17.根据权利要求3-4或6-16任一项所述的分离的dsNA,其中,从选自表8的CKAP5mRNA序列的5′端(位置1)开始,哺乳动物Ago2在所述序列的位置9与10之间的位点上切割所述mRNA,从而当所述双链核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
18.根据权利要求8-17任一项所述的分离的dsNA,其中,从选自SEQIDNO:3457-4032、2305-2880和4033-5760的CKAP5mRNA序列的5′端开始,哺乳动物Ago2在所述mRNA序列的位置9与10之间的位点上切割所述cDNA,从而当所述双链核酸被引入哺乳动物细胞时减少CKAP5靶mRNA表达。
19.根据权利要求3-18任一项所述的分离的dsNA,其中所述第二链包含选自由SEQIDNO:577-1152组成的组的序列。
20.根据权利要求3-19任一项所述的分离的dsNA,其中所述第一链包含选自由SEQIDNO:1-576和1729-2304组成的组的序列。
21.根据权利要求3-20任一项所述的分离的dsNA,其包含一对选自表2的第一链/第二链序列。
22.根据权利要求3-21任一项所述的分离的dsNA,其中所述第一链和第二链中的每一个具有为至少26个核苷酸的长度。
23.根据权利要求14所述的分离的dsNA,其中所述第一链的所述3′末端的所述经修饰的核苷酸残基选自由脱氧核糖核苷酸、无环核苷酸和荧光分子组成的组。
24.根据权利要求23所述的分离的dsNA,其中所述第一寡核苷酸链的所述3′末端的位置1为脱氧核糖核苷酸。
25.根据权利要求6、7或10所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的所述核苷酸包含经修饰的核苷酸。
26.根据权利要求25所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的所述经修饰的核苷酸为2’-O-甲基核糖核苷酸。
27.根据权利要求25或26所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的所有核苷酸为经修饰的核苷酸。
28.根据权利要求3-27任一项所述的分离的dsNA,其中所述dsNA包含经修饰的核苷酸。
29.根据权利要求28所述的分离的dsNA,其中所述经修饰的核苷酸残基选自由2’-O-甲基、2’-甲氧基乙氧基、2’-氟、2’-烯丙基、2’-O-[2-(甲氨基)-2-氧代乙基]、4’-硫代、4’-CH2-O-2’-桥、4’-(CH2)2-O-2’-桥、2’-LNA、2’-氨基或2’-O-(N-甲基氨基甲酸酯)组成的组。
30.根据权利要求6、7或10所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的长度为1-3个核苷酸。
31.根据权利要求6、7或10所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的长度为1-2个核苷酸。
32.根据权利要求6、7或10所述的分离的dsNA,其中所述第二链的所述3′末端的所述1-5个单链核苷酸的长度为2个核苷酸,并且包含2’-O-甲基修饰的核糖核苷酸。
33.根据权利要求3-32中任一项所述的分离的dsNA,其中所述第二寡核苷酸链包含选自由AS-M1至AS-M52和AS-M1*至AS-M52*组成的组的修饰模式。
34.根据权利要求3-33中任一项所述的分离的dsNA,其中所述第一寡核苷酸链包含选自SM1至SM31的修饰模式。
35.根据权利要求3-34中任一项所述的分离的dsNA,其中所述第一链和所述第二链中的每一个具有为至少26个核苷酸和至多30个核苷酸的长度。
36.根据权利要求3-35中任一项所述的分离的dsNA,其中所述dsNA在所述细胞内被切丁酶内源性切割。
37.根据前述权利要求中任一项所述的分离的dsNA,其中足以减少靶基因的表达的所述分离的核酸的量选自由以下量组成的组,所述细胞的环境中的1纳摩尔或更低、200皮摩尔或更低、100皮摩尔或更低、50皮摩尔或更低、20皮摩尔或更低、10皮摩尔或更低、5皮摩尔或更低、2皮摩尔或更低和1皮摩尔或更低。
38.根据权利要求6-37中任一项所述的分离的dsNA,其中当在细胞环境中以1纳摩尔或更低的有效浓度在哺乳动物细胞中进行体外测定时,所述分离的dsNA在减少靶CKAP5mRNA表达中具有比针对所述靶CKAP5mRNA相同的至少19个核苷酸的分离的21mersiRNA更大的效力。
39.根据权利要求3-38中任一项所述的分离的dsNA,其中所述分离的dsNA与所述靶CKAP5mRNA序列充分互补,从而使当所述双链核酸被引入哺乳动物细胞时,使CKAP5靶mRNA表达减少选自至少10%、至少50%、至少80-90%、至少95%、至少98%和至少99%的量(以%表示)。
40.根据权利要求3-39中任一项所述的分离的dsNA,其中所述第一链与第二链通过化学的接头连接。
41.根据权利要求3-40中任一项所述的分离的双链核酸,其中所述第一链的所述3′末端与所述第二链的所述5′末端通过化学的接头连接。
42.根据权利要求3-41中任一项所述的分离的双链核酸,其中所述第二链或所述第一链的核苷酸被指导切丁酶切割的方向的经修饰的核苷酸置换。
43.根据前述权利要求中任一项所述的分离的核酸,其包含经修饰的核苷酸,所述经修饰的核苷酸选自由脱氧核糖核苷酸、二脱氧核糖核苷酸、无环核苷酸、3′-脱氧腺苷(虫草素)、3′-叠氮基-3′-脱氧胸苷(AZT)、2',3′-双脱氧肌苷(ddI)、2',3′-二脱氧-3′-硫代胞苷(3TC)、2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)、3′-叠氮基-3′-脱氧胸苷(AZT)的单磷酸核苷酸、2',3′-二脱氧-3′-硫代胞苷(3TC)和2',3′-二脱氢-2',3′-二脱氧胸苷(d4T)的单磷酸核苷酸、4-硫尿嘧啶、5-溴尿嘧啶、5-碘尿嘧啶、5-(3-氨基烯丙基)-尿嘧啶、2’-O-烷基核糖核苷酸、2’-O-甲基核糖核苷酸、2’-氨基核糖核苷酸、2’-氟代核糖核苷酸和锁核酸组成的组。
44.根据前述权利要求中任一项所述的分离的核酸,其包含选自膦酸酯、硫代磷酸酯或磷酸三酯的磷酸主链修饰。
45.根据前述权利要求中任一项所述的分离的核酸,其包含选自吗啉代核酸或肽核酸(PNA)的修饰。
46.一种用于减少哺乳动物细胞中的靶CKAP5基因的表达的方法,其包括将哺乳动物细胞在体外与以足以减少所述细胞中的靶CKAP5mRNA表达的量的根据权利要求3-45中任一项所述的分离的dsNA接触。
47.根据权利要求46所述的方法,其中使靶CKAP5mRNA表达减少的量(以%表示)选自由至少10%、至少50%和至少80-90%组成的组。
48.根据权利要求46或47所述的方法,其中CKAP5mRNA水平在将所述细胞与所述dsNA接触后至少8天降低至少90%的量(以%表示)。
49.根据权利要求46-48中任一项所述的方法,其中CKAP5mRNA水平在将所述细胞与所述dsNA接触后至少10天降低至少70%的量(以%表示)。
50.一种用于减少哺乳动物中的靶CKAP5mRNA表达的方法,其包括以足以减少所述哺乳动物中的靶CKAP5mRNA的表达的量将根据权利要求1-45中任一项所述的分离的核酸给予哺乳动物施用。
51.根据权利要求50所述的方法,其中以如下剂量给予所述分离的核酸,所述剂量选自每天1微克至5毫克/千克所述哺乳动物、100微克至0.5毫克/千克、0.001至0.25毫克/千克、0.01至20微克/千克、0.01至10微克/千克、0.10至5微克/千克和0.1至2.5微克/千克的剂量组。
52.根据权利要求50或51所述的方法,其中当在细胞环境中以1纳摩尔或更低的有效浓度在哺乳动物细胞中进行体外测定时,所述分离的核酸在减少靶CKAP5mRNA表达中具有比针对所述靶CKAP5mRNA的相同的至少19个核苷酸的分离的21mersiRNA更大的效力。
53.根据权利要求50-52中任一项所述的方法,其中在向所述哺乳动物施用所述分离的dsNA后至少3天,CKAP5mRNA水平在所述哺乳动物的组织中降低至少70%的量(以%表示)。
54.根据权利要求53所述的方法,其中所述组织选自肝、胰腺和卵巢组织。
55.根据权利要求50-54中任一项所述的方法,其中所述施用步骤包括选自静脉内注射、肌内注射、腹膜内注射、输注、皮下注射、经皮、气溶胶、直肠、阴道、局部、口服或吸入递送的模式。
56.一种选择性抑制细胞生长的方法,其包括将细胞与足以抑制所述细胞生长的量的根据权利要求1-45中任一项所述的分离的核酸接触。
57.根据权利要求56所述的方法,其中所述细胞是受试者的肿瘤细胞。
58.根据权利要求56或57所述的方法,其中所述细胞是体外肿瘤细胞。
59.根据权利要求56-58中任一项所述的方法,其中所述细胞是人细胞。
60.一种包含根据权利要求1-45中任一项所述的分离的核酸的制剂,其中当所述核酸在体外被引入哺乳动物细胞时,所述核酸以有效地将靶CKAP5mRNA水平降低选自以下的量存在,至少10%、至少50%和至少80-90%的量(以%表示)。
61.根据权利要求60所述的制剂,其中所述有效的量选自所述细胞的环境中的1纳摩尔或更低、200皮摩尔或更低、100皮摩尔或更低、50皮摩尔或更低、20皮摩尔或更低、10皮摩尔或更低、5皮摩尔或更低、2皮摩尔或更低和1皮摩尔或更低。
62.一种包含根据权利要求6-45中任一项所述的分离的dsNA的制剂,其中当所述dsNA被引入哺乳动物受试者的细胞时,所述dsNA以有效地将靶CKAP5mRNA水平降低选自以下的量存在,至少10%、至少50%和至少80-90%的量(以%表示)。
63.根据权利要求62所述的制剂,其中所述有效量的剂量如下,所述剂量选自由每天1微克至5毫克/千克所述受试者、100微克至0.5毫克/千克、0.001至0.25毫克/千克、0.01至20微克/千克、0.01至10微克/千克、0.10至5微克/千克和0.1至2.5微克/千克组成的剂量组。
64.根据权利要求60-63中任一项所述的制剂,其中当在细胞环境中以1纳摩尔或更低的有效浓度在哺乳动物细胞中进行体外测定时,所述dsNA在降低靶CKAP5mRNA水平中具有比针对所述靶CKAP5mRNA的相同的至少19个核苷酸的分离的21mersiRNA更大的效力。
65.一种哺乳动物细胞,其包含根据权利要求1-45中任一项所述的分离的核酸。
66.一种药物组合物,其包含根据权利要求1-45中任一项所述的分离的核酸和药学上可接受的载体。
67.一种试剂盒,其包含根据权利要求1-45中任一项所述的分离的核酸和其使用说明书。
68.一种用于治疗或预防受试者的CKAP5相关疾病或病症的方法,其包括以足以治疗或预防所述受试者的所述CKAP5相关疾病或病症的量向所述受试者施用根据权利要求1-45中任一项所述的分离的核酸和药学上可接受的载体,从而治疗或预防所述受试者的所述CKAP5相关疾病或病症。
69.根据权利要求68所述的方法,其中所述CKAP5相关疾病或病症选自肾癌、乳腺癌、肺癌、卵巢癌、肝癌、宫颈癌、食道癌、口咽癌和胰腺癌。
70.一种具有CKAP5抑制活性的组合物,其基本上由根据权利要求1-45中任一项所述的分离的核酸组成。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737404P | 2012-12-14 | 2012-12-14 | |
US61/737404 | 2012-12-14 | ||
PCT/US2013/074880 WO2014093746A2 (en) | 2012-12-14 | 2013-12-13 | Methods and compositions for the specific inhibition of ckap5 by double-stranded rna |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105189541A true CN105189541A (zh) | 2015-12-23 |
Family
ID=50935084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380070277.5A Pending CN105189541A (zh) | 2012-12-14 | 2013-12-13 | 用于通过双链rna特异性抑制ckap5的方法和组合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9850486B2 (zh) |
EP (1) | EP2931746A4 (zh) |
JP (1) | JP2016501533A (zh) |
KR (1) | KR20150095763A (zh) |
CN (1) | CN105189541A (zh) |
CA (1) | CA2893824A1 (zh) |
TW (1) | TW201437368A (zh) |
WO (1) | WO2014093746A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108467010A (zh) * | 2018-03-14 | 2018-08-31 | 国家纳米科学中心 | 一种基于dna纳米结构的金属图案及其制备方法和应用 |
CN111372593A (zh) * | 2017-10-20 | 2020-07-03 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
CN117187246A (zh) * | 2023-09-07 | 2023-12-08 | 东莞市中医院 | 抑制CKAP5基因表达的siRNA及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170012366A (ko) * | 2014-06-04 | 2017-02-02 | 교와 핫꼬 기린 가부시키가이샤 | CKAP5 유전자 발현 억제 RNAi 의약 조성물 |
JP6715325B2 (ja) * | 2015-06-26 | 2020-07-01 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用 |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
US20060223099A1 (en) | 2005-03-30 | 2006-10-05 | Baylor College Of Medicine | TEX14 compositions and modulators thereof to alter intercellular bridge development and function |
BR112012007137A2 (pt) | 2009-09-30 | 2015-09-15 | Harvard College | metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia |
CA2804210A1 (en) | 2010-07-06 | 2012-01-12 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna |
WO2012018754A2 (en) * | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
-
2013
- 2013-12-13 CA CA2893824A patent/CA2893824A1/en not_active Abandoned
- 2013-12-13 CN CN201380070277.5A patent/CN105189541A/zh active Pending
- 2013-12-13 JP JP2015547968A patent/JP2016501533A/ja active Pending
- 2013-12-13 WO PCT/US2013/074880 patent/WO2014093746A2/en active Application Filing
- 2013-12-13 US US14/651,087 patent/US9850486B2/en active Active
- 2013-12-13 EP EP13862599.1A patent/EP2931746A4/en not_active Withdrawn
- 2013-12-13 KR KR1020157018170A patent/KR20150095763A/ko not_active Application Discontinuation
- 2013-12-13 TW TW102146027A patent/TW201437368A/zh unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111372593A (zh) * | 2017-10-20 | 2020-07-03 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
CN111372593B (zh) * | 2017-10-20 | 2024-03-19 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
CN108467010A (zh) * | 2018-03-14 | 2018-08-31 | 国家纳米科学中心 | 一种基于dna纳米结构的金属图案及其制备方法和应用 |
CN108467010B (zh) * | 2018-03-14 | 2020-07-07 | 国家纳米科学中心 | 一种基于dna纳米结构的金属图案及其制备方法和应用 |
CN117187246A (zh) * | 2023-09-07 | 2023-12-08 | 东莞市中医院 | 抑制CKAP5基因表达的siRNA及其应用 |
CN117187246B (zh) * | 2023-09-07 | 2024-05-28 | 东莞市中医院 | 抑制CKAP5基因表达的siRNA及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2931746A4 (en) | 2016-08-24 |
KR20150095763A (ko) | 2015-08-21 |
CA2893824A1 (en) | 2014-06-19 |
TW201437368A (zh) | 2014-10-01 |
WO2014093746A3 (en) | 2014-10-02 |
US20150315583A1 (en) | 2015-11-05 |
JP2016501533A (ja) | 2016-01-21 |
WO2014093746A2 (en) | 2014-06-19 |
EP2931746A2 (en) | 2015-10-21 |
US9850486B2 (en) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11851658B2 (en) | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | |
CN102575254B (zh) | 利用不对称双链rna特异性抑制kras的方法和组合物 | |
CN104968785A (zh) | 用于通过双链RNA特异性抑制myc的方法和组合物 | |
US10072263B2 (en) | Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA | |
CN105189541A (zh) | 用于通过双链rna特异性抑制ckap5的方法和组合物 | |
US9708605B2 (en) | Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA | |
US10011834B2 (en) | Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151223 |